Clustering O 0 0.0003486248606350273
of O 0 9.882373888103757e-06
missense O 0 0.0036536443512886763
mutations O 0 0.0002593216486275196
in O 0 2.54945075539581e-06
the O 0 8.613270620116964e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 0.9999998807907104
gene O 0 1.3932577530795243e-05
in O 0 8.587740580878744e-07
a O 0 5.828734174428973e-06
sporadic B-Disease 0 0.02376062050461769
T I-Disease 1 0.9249034523963928
- I-Disease 0 0.03814185410737991
cell I-Disease 0 0.001239023171365261
leukaemia I-Disease 0 0.061097752302885056
. O 0 1.2906990377814509e-05

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.040662527084350586
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 3.3851765124381927e-07
is O 0 6.524523854523068e-08
a O 0 1.1117356280010426e-06
recessive B-Disease 0 0.0015634075971320271
multi I-Disease 0 0.02953174337744713
- I-Disease 1 0.9990033507347107
system I-Disease 0 0.12278717011213303
disorder I-Disease 1 0.664359986782074
caused O 0 1.6617235814919695e-05
by O 0 7.159775918808009e-07
mutations O 0 5.577694992098259e-06
in O 0 4.661862362809188e-08
the O 0 9.891795116345747e-08
ATM O 0 3.6455753615882713e-06
gene O 0 8.170265459739312e-07
at O 0 2.5551241833454696e-07
11q22 O 0 6.39726931694895e-06
- O 0 1.857180177466944e-05
q23 O 0 1.6420508472947404e-05
( O 0 5.175361934561806e-07
ref O 0 1.4679673768114299e-05
. O 0 1.074086313224143e-07
3 O 0 6.85499628616526e-07
) O 0 4.249636447184457e-07
. O 0 1.16070816602587e-06

The O 0 1.7212292732438073e-05
risk O 0 2.100343772326596e-05
of O 0 1.0043187330666115e-06
cancer B-Disease 0 0.0005826301057823002
, O 0 4.267042186256731e-07
especially O 0 2.2688540468607243e-07
lymphoid B-Disease 0 2.4071254301816225e-05
neoplasias I-Disease 0 0.00011299298057565466
, O 0 3.5919524066230224e-07
is O 0 1.2316480990648415e-07
substantially O 0 7.747819836367853e-06
elevated O 0 8.945913577917963e-05
in O 0 1.0217981980531476e-06
A B-Disease 1 0.9999972581863403
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 1.0916540304606315e-05
and O 0 5.159778879715304e-07
has O 0 1.42907765621203e-06
long O 0 1.6823203168314649e-06
been O 0 5.720718831980776e-07
associated O 0 6.832792109889851e-07
with O 0 7.3358069130335934e-06
chromosomal O 1 1.0
instability O 1 0.9999971389770508
. O 0 5.344752935343422e-05

By O 0 3.885626210831106e-05
analysing O 0 0.0001984835835173726
tumour B-Disease 1 0.9999983310699463
DNA O 0 0.00013474380830302835
from O 0 1.0615855217110948e-06
patients O 0 1.930342477862723e-06
with O 0 1.9309302956571628e-07
sporadic B-Disease 0 0.0035949277225881815
T I-Disease 1 0.7988646626472473
- I-Disease 0 0.001025203033350408
cell I-Disease 0 0.0002725903468672186
prolymphocytic I-Disease 0 0.0013744954485446215
leukaemia I-Disease 1 0.6677939295768738
( O 0 8.521735253452789e-06
T B-Disease 0 0.0005020466051064432
- I-Disease 0 0.00010487206600373611
PLL I-Disease 0 0.00020247201609890908
) O 0 2.0593907379407028e-07
, O 0 3.303845730329158e-08
a O 0 2.0092711849883926e-07
rare O 0 1.3880888900530408e-06
clonal B-Disease 0 4.949787398800254e-05
malignancy I-Disease 0 0.00034095195587724447
with O 0 2.388274538134283e-07
similarities O 0 7.911284001238528e-07
to O 0 8.289659803040195e-08
a O 0 1.99390024135937e-06
mature B-Disease 0 6.9147990870988e-06
T I-Disease 0 0.0004460484778974205
- I-Disease 0 4.6365410526050255e-05
cell I-Disease 0 5.823009632877074e-05
leukaemia I-Disease 0 0.00034246742143295705
seen O 0 1.7710932525005774e-06
in O 0 3.3807825161602523e-07
A B-Disease 1 0.9990884065628052
- I-Disease 1 0.9995087385177612
T I-Disease 1 0.9999988079071045
, O 0 1.8057650663649838e-07
we O 0 1.7671062835233897e-08
demonstrate O 0 3.3879985039675375e-08
a O 0 3.9470794632734396e-08
high O 0 2.7689412718245876e-07
frequency O 0 2.397503067186335e-07
of O 0 3.629748235312036e-08
ATM O 0 1.1423847354308236e-05
mutations O 0 4.253473434800981e-06
in O 0 9.929864290825208e-07
T B-Disease 0 0.005369564518332481
- I-Disease 0 0.0004255408712197095
PLL I-Disease 0 0.000880303792655468
. O 0 1.0537538400967605e-05

In O 0 1.5687573977629654e-05
marked O 0 1.7184458556585014e-05
contrast O 0 2.5005092538776807e-06
to O 0 6.200254176746967e-08
the O 0 1.1420402756812109e-07
ATM O 0 3.7139852793188766e-05
mutation O 0 6.131472673587268e-06
pattern O 0 6.773067070753314e-06
in O 0 1.1010534990418819e-06
A B-Disease 1 0.9999912977218628
- I-Disease 1 0.9999991655349731
T I-Disease 1 0.9999998807907104
, O 0 8.669711348829878e-08
the O 0 2.0233208886111242e-08
most O 0 1.2496957246810325e-08
frequent O 0 1.8465613038642914e-07
nucleotide O 0 6.616420478167129e-07
changes O 0 9.741948048258564e-08
in O 0 7.657387612880484e-08
this O 0 3.01313605177711e-07
leukaemia B-Disease 0 0.01959002949297428
were O 0 1.3762633898295462e-05
missense O 0 0.0006423324812203646
mutations O 0 5.391300146584399e-05
. O 0 3.956599357479718e-06

These O 0 5.231906925473595e-06
clustered O 0 1.605056968401186e-05
in O 0 2.593382077975548e-07
the O 0 1.6356476351120364e-07
region O 0 4.85275961636944e-07
corresponding O 0 1.1748232253694368e-07
to O 0 2.566645918022914e-08
the O 0 8.565144327121743e-08
kinase O 0 3.2176030799746513e-06
domain O 0 2.70027300075526e-07
, O 0 7.576235105943852e-08
which O 0 7.204516094816427e-08
is O 0 2.9646281873851876e-08
highly O 0 3.7150172715882945e-08
conserved O 0 9.29590342479969e-08
in O 0 1.6417855519534896e-08
ATM O 0 2.485384356987197e-06
- O 0 6.673468760709511e-06
related O 0 9.840440640118686e-08
proteins O 0 7.750222152935748e-08
in O 0 6.48490967591897e-08
mouse O 0 7.330975222430425e-06
, O 0 1.3270407350773894e-07
yeast O 0 2.618078042360139e-06
and O 0 4.2441075720489607e-07
Drosophila O 0 7.224672572192503e-06
. O 0 2.8428719360817922e-06

The O 0 1.3146224773663562e-05
resulting O 0 1.917534609674476e-05
amino O 0 4.678333425545134e-06
- O 0 2.0944189600413665e-05
acid O 0 3.216372761016828e-06
substitutions O 0 4.256552017523063e-07
are O 0 2.9108660370980033e-08
predicted O 0 6.258957228055806e-07
to O 0 2.1188011345429913e-08
interfere O 0 2.998939976350812e-07
with O 0 1.322781315593602e-07
ATP O 0 4.760433512274176e-06
binding O 0 2.6317914034734713e-06
or O 0 8.051041504586465e-07
substrate O 0 1.001303371594986e-05
recognition O 0 2.941949787782505e-06
. O 0 5.150637662154622e-06

Two O 0 7.99128338258015e-06
of O 0 7.459928497155488e-07
seventeen O 0 5.733024863729952e-06
mutated O 0 5.0769231165759265e-05
T B-Disease 0 0.0005624627228826284
- I-Disease 0 3.0585269996663556e-05
PLL I-Disease 0 5.950571357971057e-05
samples O 0 8.661774586471438e-07
had O 0 8.095327075352543e-07
a O 0 4.179432835371699e-07
previously O 0 4.771150543092517e-06
reported O 0 2.400358789600432e-05
A B-Disease 1 0.9969733953475952
- I-Disease 1 0.999980092048645
T I-Disease 1 0.9999994039535522
allele O 0 8.269832324003801e-05
. O 0 5.423532911663642e-06

In O 0 2.1128818843862973e-05
contrast O 0 2.0803054212592542e-05
, O 0 7.045843517516914e-07
no O 0 6.526310016852221e-07
mutations O 0 4.672581781051122e-06
were O 0 4.694909989666485e-07
detected O 0 5.031440082348126e-07
in O 0 2.3318461828125692e-08
the O 0 8.031243936557075e-08
p53 O 0 9.065937547347858e-07
gene O 0 3.6327998031993047e-07
, O 0 5.877958031419439e-08
suggesting O 0 3.0195596423254756e-07
that O 0 5.521377843820119e-08
this O 0 3.439515126046899e-07
tumour B-Disease 1 0.9999983310699463
suppressor O 0 0.0009496412822045386
is O 0 4.411675718074548e-07
not O 0 1.2971111118531553e-07
frequently O 0 4.959252919434221e-07
altered O 0 7.0864034569240175e-06
in O 0 9.512843917036662e-07
this O 0 2.5855340481939493e-06
leukaemia B-Disease 0 0.046016354113817215
. O 0 1.0863077477551997e-05

Occasional O 0 0.0013417673762887716
missense O 0 0.03451951965689659
mutations O 0 0.00030421800329349935
in O 0 7.259595236064342e-07
ATM O 0 1.36675453177304e-05
were O 0 5.54601865587756e-06
also O 0 6.966785690565303e-07
found O 0 4.6244986151577905e-07
in O 0 1.1408802720325184e-06
tumour B-Disease 1 0.9999986886978149
DNA O 0 1.891257124952972e-05
from O 0 2.5835177552835376e-07
patients O 0 6.46300350126694e-07
with O 0 1.6305766337154637e-07
B B-Disease 0 2.0714032871183008e-05
- I-Disease 0 3.220010330551304e-05
cell I-Disease 0 0.00011761105270124972
non I-Disease 0 1.5046372027427424e-05
- I-Disease 1 0.565823495388031
Hodgkins I-Disease 1 0.9994198083877563
lymphomas I-Disease 0 0.4484619200229645
( O 0 1.6419255643995712e-06
B B-Disease 0 5.046937076258473e-06
- I-Disease 0 1.0814082997967489e-05
NHL I-Disease 0 2.3814588985260343e-06
) O 0 1.044682207407277e-07
and O 0 8.142420426793251e-08
a O 0 1.063716808857862e-06
B B-Disease 0 1.778961086529307e-05
- I-Disease 0 2.7664977096719667e-05
NHL I-Disease 0 1.0416969416837674e-05
cell O 0 1.9690176486619748e-05
line O 0 3.4588603739393875e-05
. O 0 4.120702215004712e-06

The O 0 6.117851626186166e-06
evidence O 0 5.045465627517842e-07
of O 0 5.191328256159977e-08
a O 0 3.957921137498488e-07
significant O 0 1.3516664409962686e-07
proportion O 0 1.691861655217508e-07
of O 0 2.646822316876296e-08
loss O 0 2.3812292511138367e-06
- O 0 7.904022822913248e-06
of O 0 6.578380862265476e-08
- O 0 0.00024623519857414067
function O 0 8.376646860597248e-07
mutations O 0 1.0488964790056343e-06
and O 0 6.380157913099538e-08
a O 0 2.619479175791639e-07
complete O 0 1.102026203625428e-06
absence O 0 2.661412565885257e-07
of O 0 1.1717747661066369e-08
the O 0 7.180536698569995e-08
normal O 0 1.388901722521041e-07
copy O 0 2.1187167931202566e-07
of O 0 1.1577123260053668e-08
ATM O 0 4.803437718692294e-07
in O 0 3.597972408897476e-08
the O 0 7.576581850798902e-08
majority O 0 2.12632357943221e-07
of O 0 1.4302963791124057e-07
mutated O 0 0.0022378030698746443
tumours B-Disease 1 0.9999991655349731
establishes O 0 1.0397942787676584e-05
somatic O 0 1.0515634130570106e-05
inactivation O 0 2.6927666112896986e-05
of O 0 2.1129089589067007e-08
this O 0 1.7450002331997894e-08
gene O 0 1.1181007408822552e-07
in O 0 3.411765092664609e-08
the O 0 9.243039755801874e-08
pathogenesis O 0 1.819773274291947e-06
of O 0 8.862890865657391e-08
sporadic B-Disease 0 0.002969837747514248
T I-Disease 1 0.6414312124252319
- I-Disease 0 0.00022901005286257714
PLL I-Disease 0 9.510415839031339e-05
and O 0 2.5401431003047037e-07
suggests O 0 1.2231990353939182e-07
that O 0 1.668123594811277e-08
ATM O 0 9.435412380298658e-07
acts O 0 3.7122558183000365e-07
as O 0 1.5615677284586127e-07
a O 0 1.0903067959588952e-05
tumour B-Disease 1 0.9999994039535522
suppressor O 0 0.0038247632328420877
. O 0 1.0009415746026207e-05

As O 0 1.1503556379466318e-05
constitutional O 0 4.590051958075492e-06
DNA O 0 8.380662620766088e-06
was O 0 3.4937902455567382e-06
not O 0 2.6898218763449222e-08
available O 0 2.3003314808534014e-08
, O 0 5.202281272431719e-08
a O 0 6.02972306751326e-07
putative O 0 0.0001665833406150341
hereditary O 0 0.04776135832071304
predisposition O 0 5.904215504415333e-05
to O 0 1.5282087133527966e-06
T B-Disease 0 0.010373466648161411
- I-Disease 0 7.087285484885797e-05
PLL I-Disease 0 3.157770697725937e-05
will O 0 1.1332068794445149e-07
require O 0 9.65620401416345e-08
further O 0 1.585928970371242e-07
investigation O 0 1.1538675153133227e-06
. O 0 7.35263370188477e-07
. O 0 2.559919721534243e-06

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.00259181740693748
kinase O 0 0.001362767186947167
is O 0 2.080176955132629e-06
involved O 0 2.085992605316278e-07
in O 0 7.111663791192768e-08
the O 0 7.81166349383966e-08
modulation O 0 1.2810745602109819e-06
of O 0 2.707714585881149e-08
the O 0 5.292314995131164e-07
Ca2 O 0 0.00010018793545896187
+ O 0 2.5635165002313443e-05
homeostasis O 0 8.2786449638661e-05
in O 0 2.0447030237846775e-06
skeletal O 0 0.026010099798440933
muscle O 0 0.0011315897572785616
cells O 0 4.649070979212411e-05
. O 0 6.035745627741562e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9954113364219666
DM B-Disease 1 1.0
) O 0 4.357500438345596e-05
, O 0 3.634619361037039e-07
the O 0 1.2955781869550265e-07
most O 0 4.1424701180403645e-07
prevalent O 0 0.0001303030294366181
muscular B-Disease 1 0.9960440397262573
disorder I-Disease 1 0.6294131278991699
in O 0 3.1887691420706687e-06
adults O 0 2.2609821826335974e-05
, O 0 3.05071324646633e-07
is O 0 2.5960693506021926e-07
caused O 0 1.1303806104479008e-06
by O 0 7.179002636803489e-08
( O 0 2.8635142257371626e-07
CTG O 0 7.815812750777695e-06
) O 0 8.579794297247645e-08
n O 0 1.2470335377656738e-06
- O 0 1.9135807178827235e-06
repeat O 0 4.552694008452818e-07
expansion O 0 1.5607488990099228e-07
in O 0 2.1215106116301286e-08
a O 0 7.007928104485472e-08
gene O 0 3.293779116120277e-07
encoding O 0 4.555764974156773e-07
a O 0 1.0246027386529022e-06
protein O 0 6.754373771400424e-06
kinase O 0 0.00012830049672629684
( O 0 3.5933576327806804e-06
DM B-Disease 1 0.9999651908874512
protein O 0 7.194826594059123e-06
kinase O 0 2.6199508283752948e-05
; O 0 1.3008366295252927e-06
DMPK O 0 8.331779827130958e-05
) O 0 8.279373275854596e-08
and O 0 3.664991155005737e-08
involves O 0 7.460896966904329e-08
changes O 0 8.434749787511464e-08
in O 0 1.3591636616183678e-07
cytoarchitecture O 0 1.2212867659400217e-05
and O 0 5.609015829577402e-07
ion O 0 2.8953540095244534e-05
homeostasis O 0 0.00033803112455643713
. O 0 8.082127351372037e-06

To O 0 7.550810551038012e-06
obtain O 0 1.7793192910176003e-06
clues O 0 1.9280410015198868e-06
to O 0 1.0567364938651735e-07
the O 0 9.278225121533978e-08
normal O 0 5.081547556073929e-07
biological O 0 1.658552690741999e-07
role O 0 6.575320554702557e-08
of O 0 3.2767847102377345e-08
DMPK O 0 2.168897663068492e-05
in O 0 8.310112775689049e-08
cellular O 0 1.6566476688240073e-06
ion O 0 1.7735018218445475e-06
homeostasis O 0 9.97524239210179e-06
, O 0 1.5241494111251086e-07
we O 0 3.187729902265346e-08
have O 0 3.3990342984679955e-08
compared O 0 1.5854571699946973e-07
the O 0 4.501992734162741e-08
resting O 0 1.5268246897903737e-06
[ O 0 3.0740949341634405e-07
Ca2 O 0 2.8532913347589783e-06
+ O 0 2.3744694317429094e-06
] O 0 8.615081128482416e-07
i O 0 1.067255368525366e-07
, O 0 1.291698836780597e-08
the O 0 2.1686746620730446e-08
amplitude O 0 3.688772949317354e-07
and O 0 6.033518928916237e-08
shape O 0 5.035669232711371e-07
of O 0 1.1520187825908579e-07
depolarization O 0 5.627191967505496e-06
- O 0 4.5793462049914524e-05
induced O 0 0.00018199121404904872
Ca2 O 0 7.159821689128876e-05
+ O 0 1.5347637599916197e-05
transients O 0 2.2532181901624426e-05
, O 0 9.445768966998003e-08
and O 0 2.048393810127891e-08
the O 0 1.4003084025659973e-08
content O 0 6.481706549266164e-08
of O 0 8.635347548135996e-09
ATP O 0 1.0374637895438354e-06
- O 0 5.863373644388048e-06
driven O 0 3.141973820675048e-06
ion O 0 3.7068889469082933e-06
pumps O 0 2.986657818837557e-06
in O 0 1.7232804339073482e-07
cultured O 0 5.319428055372555e-06
skeletal O 0 8.44065798446536e-05
muscle O 0 1.504222473158734e-05
cells O 0 4.979019081474689e-07
of O 0 2.8721725442437673e-08
wild O 0 4.5463548303814605e-07
- O 0 1.0795915841299575e-05
type O 0 5.400381724030012e-07
and O 0 1.911138838295301e-07
DMPK O 0 3.8989997847238556e-05
[ O 0 1.3386206774157472e-06
- O 0 1.2057215826644097e-05
/ O 0 2.3328097086050548e-05
- O 0 7.035718590486795e-05
] O 0 1.1272037227172405e-05
knockout O 0 0.00014229514636099339
mice O 0 0.0004266288015060127
. O 0 6.813980235165218e-06

In O 0 2.800696347549092e-05
vitro O 0 0.0003052644897252321
- O 0 0.00030073444941081107
differentiated O 0 5.2673716709250584e-05
DMPK O 0 0.00022882892517372966
[ O 0 5.586809038504725e-06
- O 0 2.8500107873696834e-05
/ O 0 1.595788125996478e-05
- O 0 2.1350611859816127e-05
] O 0 2.1110997749929084e-06
myotubes O 0 2.479134536770289e-06
exhibit O 0 2.5489131871836435e-07
a O 0 2.2108073949311802e-07
higher O 0 4.284040926449961e-07
resting O 0 2.124713319062721e-06
[ O 0 1.42222665999725e-06
Ca2 O 0 1.248097851203056e-05
+ O 0 6.840630248916568e-06
] O 0 1.006001070891216e-06
i O 0 9.14977604793421e-08
than O 0 1.4981454299345387e-08
do O 0 1.8543572011253673e-08
wild O 0 1.0380362880368921e-07
- O 0 8.811699444777332e-06
type O 0 7.298532409549807e-07
myotubes O 0 1.1154237654409371e-05
because O 0 2.5453463337044013e-08
of O 0 6.73529232386727e-09
an O 0 2.9991394256967396e-08
altered O 0 5.089722890261328e-06
open O 0 3.5527233421817073e-07
probability O 0 6.170570543417853e-08
of O 0 2.6919979134731875e-08
voltage O 0 5.3702155128121376e-05
- O 0 5.126697942614555e-06
dependent O 0 7.924430178718467e-07
l O 0 5.940504706813954e-06
- O 0 3.114857236141688e-06
type O 0 1.3747724096901948e-06
Ca2 O 0 9.880320249067154e-06
+ O 0 2.9141381219233153e-06
and O 0 5.126200903760036e-07
Na O 0 1.7211505110026337e-05
+ O 0 1.0111612937180325e-05
channels O 0 6.574306098627858e-06
. O 0 3.969003046222497e-06

The O 0 2.164197212550789e-05
mutant O 0 7.9318844655063e-05
myotubes O 0 6.512075196951628e-05
exhibit O 0 2.4119653971865773e-06
smaller O 0 5.2861707899865e-07
and O 0 2.391469990925543e-07
slower O 0 1.0110494258697145e-05
Ca2 O 0 4.005429218523204e-05
+ O 0 6.422889327950543e-06
responses O 0 4.4936069798495737e-07
upon O 0 4.810635090279902e-08
triggering O 0 1.1478322221591952e-06
by O 0 8.061446266083294e-08
acetylcholine O 0 2.8876058422611095e-05
or O 0 4.610689074979746e-07
high O 0 1.7450939822083456e-06
external O 0 4.502960109675769e-06
K O 0 1.0177584954362828e-05
+ O 0 9.067935025086626e-06
. O 0 1.3045424793745042e-06

In O 0 6.641994787059957e-06
addition O 0 1.3270323506731074e-06
, O 0 2.561623944075109e-07
we O 0 6.513445072187096e-08
observed O 0 9.629314234871345e-08
that O 0 1.2081594391588624e-08
these O 0 3.54891298570692e-08
Ca2 O 0 2.9229806386865675e-05
+ O 0 2.6301822799723595e-05
transients O 0 0.00012206489918753505
partially O 0 3.072261097258888e-05
result O 0 1.1194941862413543e-07
from O 0 1.2690462902753552e-08
an O 0 1.0334487043905938e-08
influx O 0 6.874611102603012e-08
of O 0 1.3367546181086709e-08
extracellular O 0 4.069745784818224e-07
Ca2 O 0 5.431058070826111e-06
+ O 0 6.634928126914019e-07
through O 0 4.183787538636352e-08
the O 0 8.806171791775341e-08
l O 0 9.49894092627801e-06
- O 0 3.757106924240361e-06
type O 0 1.5059715678944485e-06
Ca2 O 0 2.7809643142973073e-05
+ O 0 1.5347226508310996e-05
channel O 0 1.3957898772787303e-05
. O 0 2.7853031951963203e-06

Neither O 0 4.928530688630417e-05
the O 0 7.863534392527072e-07
content O 0 1.1158801953570219e-06
nor O 0 3.157817900500959e-07
the O 0 3.417203231492749e-08
activity O 0 1.2460748166631674e-07
of O 0 3.394939795953178e-08
Na O 0 9.327939551440068e-06
+ O 0 4.7742732931510545e-06
/ O 0 5.6335866247536615e-06
K O 0 3.1570821192872245e-06
+ O 0 3.6451060623221565e-06
ATPase O 0 1.3661042430612724e-05
and O 0 1.355462018182152e-06
sarcoplasmic O 0 0.00016107667761389166
reticulum O 0 0.00019462949421722442
Ca2 O 0 0.00019136503397021443
+ O 0 2.798296009132173e-05
- O 0 3.811393253272399e-05
ATPase O 0 1.5039428035379387e-05
are O 0 8.00045114601744e-08
affected O 0 2.445516997795494e-07
by O 0 1.7917739114636788e-07
DMPK O 0 0.00023118108219932765
absence O 0 1.3418412891041953e-05
. O 0 6.5205199462070595e-06

In O 0 6.663637122983346e-06
conclusion O 0 1.8137714050681097e-06
, O 0 1.790554193803473e-07
our O 0 5.429922111943597e-08
data O 0 1.642202960283612e-07
suggest O 0 1.3322804193194315e-07
that O 0 2.821523281681948e-08
DMPK O 0 2.7064319510827772e-05
is O 0 3.5263898467974286e-08
involved O 0 3.9318265976362454e-08
in O 0 3.607771503766344e-08
modulating O 0 1.4134781167740584e-06
the O 0 7.155748704690268e-08
initial O 0 2.7869032237504143e-07
events O 0 4.778928541782079e-08
of O 0 4.4590411363287785e-08
excitation O 0 3.663709321699571e-06
- O 0 0.0002114211965817958
contraction O 0 6.7062173911836e-05
coupling O 0 8.706008884473704e-06
in O 0 7.460867550435069e-07
skeletal O 0 0.001260987133719027
muscle O 0 0.0001747135102050379
. O 0 1.3091125765640754e-06
. O 0 2.7420114747656044e-06

Constitutional O 0 0.0009951977990567684
RB1 O 0 0.02109706774353981
- O 0 0.0019501482602208853
gene O 0 8.794804307399318e-05
mutations O 0 5.4977335821604356e-05
in O 0 1.685279812591034e-06
patients O 0 1.07689456854132e-05
with O 0 1.3083063095109537e-06
isolated O 0 0.00016836835129652172
unilateral B-Disease 0 0.0005430463352240622
retinoblastoma I-Disease 0 0.007939500734210014
. O 0 2.051369665423408e-05

In O 0 1.9706840248545632e-05
most O 0 1.8502327066016733e-06
patients O 0 2.9245338737382554e-06
with O 0 2.4428177880508883e-07
isolated O 0 3.9411228499375284e-05
unilateral B-Disease 0 0.00012930628145113587
retinoblastoma I-Disease 0 0.006517053581774235
, O 0 2.941158754765638e-06
tumor B-Disease 0 6.226199184311554e-05
development O 0 1.839179759599574e-07
is O 0 6.9119778345339e-08
initiated O 0 3.500276193335594e-07
by O 0 5.215654041990092e-08
somatic O 0 2.2051863197702914e-06
inactivation O 0 1.531687485112343e-05
of O 0 2.832091006155224e-08
both O 0 9.004504164522587e-08
alleles O 0 4.956218049301242e-07
of O 0 6.480470915448677e-08
the O 0 3.123912392766215e-06
RB1 O 0 0.0007267554174177349
gene O 0 1.5452702427865006e-05
. O 0 5.83136397835915e-06

However O 0 4.250746496836655e-05
, O 0 3.3380379704794905e-07
some O 0 2.5136490222621433e-08
of O 0 1.7247462125169477e-08
these O 0 9.645344078990092e-08
patients O 0 1.7874730247058324e-06
can O 0 4.4596623638426536e-07
transmit O 0 2.4878860131138936e-05
retinoblastoma B-Disease 0 0.00019398477161303163
predisposition O 0 3.8353813579306006e-05
to O 0 3.427236379138776e-07
their O 0 9.768916697794339e-07
offspring O 0 4.7223427827702835e-05
. O 0 2.7278279048914555e-06

To O 0 6.906995622557588e-06
determine O 0 1.3937063840785413e-06
the O 0 2.0598544381300599e-07
frequency O 0 6.080254024709575e-06
and O 0 3.9820611164032016e-07
nature O 0 1.5042878942495008e-07
of O 0 3.6581887741249375e-08
constitutional O 0 5.091587354399962e-06
RB1 O 0 0.0006562445778399706
- O 0 6.343907443806529e-05
gene O 0 5.821096237923484e-06
mutations O 0 6.0111715356470086e-06
in O 0 4.4557259570865426e-07
patients O 0 1.9681463072629413e-06
with O 0 2.2264265453486587e-07
isolated O 0 1.8311240637558512e-05
unilateral B-Disease 0 5.97419602854643e-05
retinoblastoma I-Disease 0 0.00020313682034611702
, O 0 4.4443351043810253e-07
we O 0 5.11950766224345e-08
analyzed O 0 3.0632315883849515e-07
DNA O 0 7.105596182555018e-07
from O 0 7.602769613868077e-08
peripheral O 0 2.156989648938179e-05
blood O 0 8.954764780355617e-06
and O 0 6.441547384383739e-07
from O 0 9.022449489748396e-07
tumor B-Disease 0 0.0005626161000691354
tissue O 0 0.00010877589375013486
. O 0 6.32680485068704e-06

The O 0 3.494970087558613e-06
analysis O 0 1.8389866909274133e-06
of O 0 8.723035875846108e-07
tumors B-Disease 1 0.9999990463256836
from O 0 4.862103537561779e-07
54 O 0 5.898864856135333e-06
( O 0 1.9333018030920357e-07
71 O 0 1.436935690435348e-06
% O 0 7.657693856799597e-08
) O 0 8.50871995083935e-09
of O 0 1.5731814073660644e-08
76 O 0 1.3728569001614233e-06
informative O 0 1.98912948690122e-06
patients O 0 9.922046046995092e-06
showed O 0 2.14769988815533e-05
loss O 0 1.4902772136338172e-06
of O 0 9.571524373086504e-08
constitutional O 0 1.8599648683448322e-05
heterozygosity O 0 0.0044623855501413345
( O 0 1.4625594303652178e-05
LOH O 1 0.997649610042572
) O 0 5.992267233523307e-07
at O 0 8.367296686628833e-07
intragenic O 0 6.473378743976355e-05
loci O 0 1.7993692381423898e-05
. O 0 2.9940126751171192e-06

Three O 0 9.651629625295755e-06
of O 0 2.079419346046052e-06
13 O 0 9.50154208112508e-06
uninformative O 0 0.001331429579295218
patients O 0 6.88712825649418e-05
had O 0 9.15350847208174e-06
constitutional O 0 1.1099326002295129e-05
deletions O 0 0.00030473529477603734
. O 0 1.0247385034745093e-05

For O 0 1.615411565580871e-05
39 O 0 2.9949556846986525e-05
randomly O 0 5.473278633871814e-06
selected O 0 9.326303370471578e-06
tumors B-Disease 1 0.9999967813491821
, O 0 1.008365984489501e-06
SSCP O 0 7.665807061130181e-05
, O 0 3.588295953704801e-07
hetero O 0 1.5408206309075467e-05
- O 0 4.311388238420477e-06
duplex O 0 2.7844536816701293e-05
analysis O 0 1.1927892273888574e-07
, O 0 3.2389795734388827e-08
sequencing O 0 2.0255457400253363e-07
, O 0 2.5303648953922675e-08
and O 0 4.467724679102503e-08
Southern O 0 3.450527685799898e-07
blot O 0 1.778862497303635e-05
analysis O 0 3.827663306310569e-07
were O 0 1.5367598393822846e-07
used O 0 1.515932979145873e-07
to O 0 1.8766782261536719e-07
identify O 0 7.71842405811185e-06
mutations O 0 2.543262053222861e-05
. O 0 3.940711849281797e-06

Mutations O 0 0.033669613301754
were O 0 1.1537945283635054e-05
detected O 0 1.6207271755774855e-06
in O 0 1.2320474240823387e-07
21 O 0 1.4659882481282693e-06
( O 0 1.8453675920682144e-07
91 O 0 6.999578090471914e-07
% O 0 1.5988950963219395e-07
) O 0 2.6436284272790544e-08
of O 0 8.29502155852424e-08
23 O 0 0.0007130647427402437
tumors B-Disease 1 0.9999997615814209
with O 0 2.5122284569079056e-05
LOH O 1 0.9999805688858032
. O 0 1.91202198038809e-05

In O 0 1.0201069926552009e-05
6 O 0 1.8790518879541196e-05
( O 0 5.301175178828998e-07
38 O 0 1.7204441746798693e-06
% O 0 2.1556805052114214e-07
) O 0 2.554558342637847e-08
of O 0 5.7961297983410986e-08
16 O 0 9.388160106027499e-05
tumors B-Disease 1 1.0
without O 0 2.6267739485774655e-06
LOH O 1 0.9898687601089478
, O 0 3.22521458429037e-07
one O 0 1.3516999786133965e-07
mutation O 0 1.2860737115261145e-06
was O 0 3.43877809427795e-06
detected O 0 1.2134291864640545e-06
, O 0 3.6287307381144274e-08
and O 0 2.461553805233052e-08
in O 0 3.204940668410927e-08
9 O 0 8.402256526096608e-07
( O 0 8.313775623491892e-08
56 O 0 3.849239078590472e-07
% O 0 7.650015731996973e-08
) O 0 1.0062600530602595e-08
of O 0 2.322392056441913e-08
the O 0 8.3534287114162e-06
tumors B-Disease 1 1.0
without O 0 6.771620064682793e-06
LOH O 1 0.9986048340797424
, O 0 5.264557785267243e-07
both O 0 2.4194844172598096e-07
mutations O 0 3.831296908174409e-06
were O 0 4.815675538338837e-07
found O 0 1.3423343716567615e-06
. O 0 3.7745862755400594e-06

Thus O 0 3.777567690121941e-05
, O 0 4.735664731470024e-07
a O 0 1.5011293896805e-07
total O 0 3.9942616325561175e-08
of O 0 3.2888191725533034e-08
45 O 0 1.0587505130388308e-06
mutations O 0 1.3144167496648151e-06
were O 0 3.47894399510551e-07
identified O 0 2.8953013497812208e-06
in O 0 3.027170805580681e-06
tumors B-Disease 1 0.9999979734420776
of O 0 5.637196522911836e-07
36 O 0 2.3850201614550315e-05
patients O 0 1.1945874575758353e-05
. O 0 2.1643147647409933e-06

Thirty O 0 0.00016695434169378132
- O 0 0.00012064182374160737
nine O 0 8.4442859815681e-07
of O 0 3.100575440839748e-08
the O 0 2.3724112452327972e-07
mutations O 0 4.389091827761149e-06
- O 0 2.6613108730089152e-06
including O 0 9.489776431337305e-08
34 O 0 5.712344659514201e-07
small O 0 1.7746019409514702e-07
mutations O 0 2.1808900783071294e-06
, O 0 5.224883992127616e-08
2 O 0 2.2976378488692717e-07
large O 0 9.826505475984959e-08
structural O 0 1.1351185094099492e-05
alterations O 0 3.365111115272157e-05
, O 0 2.822888802711532e-07
and O 0 3.042490845928114e-07
hypermethylation O 0 4.9841750296764076e-05
in O 0 5.948635362074128e-07
3 O 0 6.784138531656936e-05
tumors O 1 0.9999996423721313
- O 0 0.002766313962638378
were O 0 3.2247762646875344e-06
not O 0 4.896579852697869e-08
detected O 0 1.1868932148217937e-07
in O 0 1.291405737902096e-08
the O 0 1.0540672690240172e-07
corresponding O 0 1.1700917639245745e-06
peripheral O 0 7.903954247012734e-05
blood O 0 3.07552982121706e-05
DNA O 0 2.1592702978523448e-05
. O 0 2.778437192318961e-06

In O 0 1.0207989362243097e-05
6 O 0 1.3347554158826824e-05
( O 0 8.258206207756302e-07
17 O 0 1.2202028756291838e-06
% O 0 1.286224176055839e-07
) O 0 7.580988281574719e-09
of O 0 3.2851936726530084e-09
the O 0 1.2147869199452543e-07
36 O 0 2.8143508643552195e-06
patients O 0 3.644486810117087e-07
, O 0 3.5899862638189006e-08
a O 0 3.059156199469726e-07
mutation O 0 2.8460920020734193e-06
was O 0 5.449382570077432e-06
detected O 0 4.5135226400816464e-07
in O 0 1.4670348491563345e-08
constitutional O 0 3.090582652021112e-07
DNA O 0 2.4039418349275365e-06
, O 0 5.307153827516231e-08
and O 0 4.001544340326291e-08
1 O 0 4.1926544014359024e-08
of O 0 6.039423627868246e-09
these O 0 4.523234764519657e-08
mutations O 0 5.668426297233964e-07
is O 0 3.2822139672816775e-08
known O 0 1.4914873247562355e-07
to O 0 5.241923162202511e-08
be O 0 1.1749643391567588e-07
associated O 0 1.7783358430278895e-07
with O 0 2.7393090817895427e-07
reduced O 0 3.7776688259327784e-05
expressivity O 0 0.0007463390356861055
. O 0 5.907911599933868e-06

The O 0 3.5373677746974863e-06
presence O 0 6.719018870171567e-07
of O 0 9.679604318080237e-08
a O 0 7.180508418969112e-07
constitutional O 0 8.93406195245916e-06
mutation O 0 1.205357057187939e-05
was O 0 7.725066097918898e-06
not O 0 5.546700165837137e-08
associated O 0 4.8343942182782484e-08
with O 0 1.5927671626059237e-08
an O 0 1.3987860825181997e-07
early O 0 4.484840246732347e-06
age O 0 9.741230542203994e-07
at O 0 7.790985705469211e-07
treatment O 0 1.0505149475648068e-05
. O 0 2.974077688122634e-06

In O 0 1.9696750314324163e-05
1 O 0 9.942221367964521e-06
patient O 0 2.190864870499354e-05
, O 0 6.217662757990183e-07
somatic O 0 2.1037876649643295e-05
mosaicism O 0 0.002455152338370681
was O 0 0.00011396981426514685
demonstrated O 0 1.202487624141213e-06
by O 0 2.522236108859488e-08
molecular O 0 1.6195824059650477e-07
analysis O 0 7.428138815157581e-08
of O 0 2.6196309121928607e-08
DNA O 0 2.3589116153743817e-06
and O 0 2.1149072892967524e-07
RNA O 0 1.610616209291038e-06
from O 0 2.371601510731125e-07
peripheral O 0 8.583293674746528e-05
blood O 0 2.1968442524666898e-05
. O 0 3.6950968933524564e-06

In O 0 1.835766488511581e-05
2 O 0 3.9231497794389725e-05
patients O 0 1.308997980231652e-05
without O 0 2.8790896067221183e-07
a O 0 1.919034048114554e-06
detectable O 0 7.356972491834313e-05
mutation O 0 3.629662842286052e-06
in O 0 1.6424831983385957e-07
peripheral O 0 0.00026316530420444906
blood O 0 5.642927862936631e-05
, O 0 1.633893589314539e-06
mosaicism O 0 0.00021976511925458908
was O 0 1.771363167790696e-05
suggested O 0 1.194253400171874e-06
because O 0 4.385592333733257e-08
1 O 0 6.113915418382021e-08
of O 0 1.0923745463742307e-08
the O 0 9.374699061481806e-07
patients O 0 2.9830067433067597e-05
showed O 0 0.015341155230998993
multifocal O 1 0.9999808073043823
tumors B-Disease 1 1.0
and O 0 4.036341124447063e-06
the O 0 1.5570353184557462e-07
other O 0 5.793952340127362e-08
later O 0 1.5664019201722112e-06
developed O 0 3.4522633995948127e-06
bilateral B-Disease 0 3.681080670503434e-06
retinoblastoma I-Disease 0 0.00045010747271589935
. O 0 1.098572010960197e-05

In O 0 8.921571861719713e-06
conclusion O 0 2.5389520033058943e-06
, O 0 4.2669930166994163e-07
our O 0 6.946353181547238e-08
results O 0 1.5019169552488165e-07
emphasize O 0 3.8097527976788115e-07
that O 0 1.869735477555423e-08
the O 0 5.8435730920791684e-08
manifestation O 0 2.0001584744022693e-06
and O 0 4.726225881768187e-07
transmissibility O 0 9.32984403334558e-06
of O 0 8.9917520540439e-08
retinoblastoma B-Disease 0 1.590061219758354e-05
depend O 0 1.4174128182276036e-07
on O 0 5.213853455643402e-07
the O 0 1.0898921942725792e-07
nature O 0 5.6082736676899e-08
of O 0 9.316170057616091e-09
the O 0 8.50929211537732e-08
first O 0 2.1780281258543255e-06
mutation O 0 6.289370730883093e-07
, O 0 8.868399348216371e-09
its O 0 8.073260282515093e-09
time O 0 1.5564822319902305e-08
in O 0 1.1873660277217368e-08
development O 0 2.83295555902896e-08
, O 0 2.1922010873254294e-08
and O 0 2.764270590205342e-08
the O 0 1.5458018864933365e-08
number O 0 1.3169240808963423e-08
and O 0 1.9896701175525777e-08
types O 0 1.8276706370556894e-08
of O 0 1.7121534412467554e-08
cells O 0 2.9163854264879774e-07
that O 0 2.4696097611354162e-08
are O 0 3.075414056752379e-08
affected O 0 1.7673833951903362e-07
. O 0 1.360138810468925e-07
. O 0 1.6152355328813428e-06

Hereditary B-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9991206526756287
of I-Disease 0 9.848362196862581e-07
the I-Disease 0 1.2249258816154907e-06
fifth I-Disease 0 1.828721178753767e-05
component I-Disease 0 9.963824822989409e-07
of I-Disease 0 6.365122118268118e-08
complement I-Disease 0 1.1308615057714633e-06
in O 0 7.26398639017134e-07
man O 0 3.462008680799045e-05
. O 0 4.267666554369498e-06

I O 0 0.0020544668659567833
. O 0 0.0001391722762491554

Clinical O 0 0.0027426406741142273
, O 0 1.965464252862148e-05
immunochemical O 0 0.000253181962762028
, O 0 8.178060966201883e-07
and O 0 3.7848448641852883e-07
family O 0 1.6371097899536835e-06
studies O 0 1.8609513290357427e-06
. O 0 2.3213262920762645e-06

The O 0 5.168642019270919e-06
first O 0 1.878208536254533e-06
recognized O 0 1.1156822665725485e-06
human O 0 9.905631941364845e-07
kindred O 0 0.00023914880875963718
with O 0 0.00035007993574254215
hereditary B-Disease 1 0.9999980926513672
deficiency I-Disease 0 0.3281472623348236
of I-Disease 0 3.638669454630872e-08
the I-Disease 0 3.510686781282857e-07
fifth I-Disease 0 2.5056533559109084e-05
component I-Disease 0 6.679636612716422e-07
of I-Disease 0 4.3154425810598696e-08
complement I-Disease 0 1.6785110119599267e-06
( O 0 1.02310491456592e-06
C5 O 0 0.00010086633847095072
) O 0 2.703050370200799e-07
is O 0 3.307755491732678e-07
described O 0 1.072485429176595e-05
. O 0 6.45378031549626e-06

The O 0 1.2909711585962214e-05
proband O 0 7.26442740415223e-05
, O 0 4.248132938755589e-07
a O 0 3.426089278946165e-07
20 O 0 3.7665529362129746e-07
- O 0 5.1727542995649856e-06
year O 0 2.536526721996779e-07
- O 0 7.821703547961079e-06
old O 0 9.106352081289515e-06
black O 0 1.7271386241191067e-05
female O 0 1.3562283129431307e-05
with O 0 6.794076034566388e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999996423721313
erythematosus I-Disease 1 1.0
since O 0 0.00011044285929528996
age O 0 4.038204679090995e-06
11 O 0 1.3582156270786072e-06
, O 0 4.935990887133812e-07
lacked O 0 2.8630756787606515e-05
serum O 0 0.00019372878887224942
hemolytic O 0 0.0007504218956455588
complement O 0 1.6897248542591115e-06
activity O 0 9.426022415937041e-07
, O 0 1.707484074131571e-07
even O 0 2.8375043825690227e-07
during O 0 2.134502210537903e-06
remission O 0 4.9290480092167854e-05
. O 0 3.970320449298015e-06

C5 O 0 0.276245653629303
was O 0 0.0001383171183988452
undetectable O 0 4.0818566048983485e-05
in O 0 3.366934038240288e-07
her O 0 2.3239620077220025e-06
serum O 0 1.3379632036958355e-05
by O 0 8.761172409776918e-08
both O 0 2.579497788701701e-07
immunodiffusion O 0 9.24812484299764e-05
and O 0 5.007394520362141e-06
hemolytic O 0 0.011844093911349773
assays O 0 0.0001697996776783839
. O 0 9.113944543059915e-06

Other O 0 7.2639354584680405e-06
complement O 0 5.6542176025686786e-06
components O 0 3.175307483616052e-06
were O 0 3.5770480621977185e-07
normal O 0 9.64578134698968e-07
during O 0 1.1547217582119629e-06
remission O 0 1.128577241615858e-05
of O 0 4.747308537389472e-07
lupus O 0 0.08339075744152069
, O 0 3.5190868175050127e-07
but O 0 1.644138194478728e-07
C1 O 0 3.1878891604719684e-05
, O 0 1.7258905415928893e-07
C4 O 0 1.8003613149630837e-05
, O 0 2.945055541658803e-07
C2 O 0 1.7922056940733455e-05
, O 0 1.095759714075939e-07
and O 0 3.7239780681375123e-07
C3 O 0 8.129932393785566e-05
levels O 0 1.2262396467122016e-06
fell O 0 3.555913644959219e-05
during O 0 4.210560291539878e-06
exacerbations O 0 0.0014816983602941036
. O 0 1.175989837065572e-05

A O 0 6.188728002598509e-05
younger O 0 3.2163457944989204e-05
half O 0 5.706318461307092e-06
- O 0 2.2686888769385405e-05
sister O 0 1.206435808853712e-05
, O 0 4.835878826270346e-07
who O 0 1.3264451581562753e-06
had O 0 9.348957064503338e-06
no O 0 3.0561370749637717e-06
underlying O 0 0.0017843046225607395
disease O 0 0.00027199069154448807
, O 0 7.30693159312068e-07
was O 0 6.6029338086082134e-06
also O 0 7.26954453966755e-07
found O 0 8.771589676825897e-08
to O 0 1.228705741596059e-07
lack O 0 1.9464177967165597e-06
immunochemically O 0 0.00023307139053940773
detectable O 0 0.00011225090565858409
C5 O 0 0.00046235870104283094
. O 0 6.111763468652498e-06

By O 0 5.940547271165997e-05
hemolytic O 0 0.3773442804813385
assay O 0 0.0002249229873996228
, O 0 2.7726036933017895e-06
she O 0 1.2813017065127497e-06
exhibited O 0 7.719652330706595e-07
1 O 0 2.605916904485639e-07
- O 0 7.176824055932229e-06
2 O 0 8.61117939621181e-07
% O 0 4.449313806276223e-08
of O 0 4.6430033151523276e-09
the O 0 4.577225709567756e-08
normal O 0 8.304613174914266e-07
serum O 0 1.7477790606790222e-05
C5 O 0 3.704575647134334e-05
level O 0 7.963075887573723e-08
and O 0 6.443396927124923e-08
normal O 0 1.1668629440464429e-07
concentrations O 0 1.387531369800854e-07
of O 0 9.807907375147806e-09
other O 0 1.9741976942100337e-08
complement O 0 7.197003810688329e-07
components O 0 3.6445915156946285e-06
. O 0 3.2796879168017767e-06

C5 O 0 0.050329726189374924
levels O 0 1.8799320969264954e-05
of O 0 1.2437062935077847e-07
other O 0 6.956828002557813e-08
family O 0 1.7086765069507237e-07
members O 0 3.5094807060431776e-08
were O 0 1.2456411013772595e-07
either O 0 9.226693720165713e-08
normal O 0 1.772668554167467e-07
or O 0 5.08986026659386e-08
approximately O 0 4.836432410115776e-08
half O 0 1.8562722914339247e-07
- O 0 2.1434370864881203e-06
normal O 0 2.157455298856803e-07
, O 0 5.40168016982534e-08
consistent O 0 5.482559686242894e-07
with O 0 7.195712896646e-07
autosomal O 0 0.0009294566698372364
codominant O 0 0.00010000696056522429
inheritance O 0 3.4517893254815135e-06
of O 0 1.1397075638797105e-07
the O 0 1.6347415794371045e-06
gene O 0 5.643191980198026e-05
determining O 0 0.0012713619507849216
C5 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
. O 0 2.037070044025313e-05

Normal O 0 0.008921202272176743
hemolytic O 1 0.9768486618995667
titers O 0 0.021574031561613083
were O 0 2.451302316330839e-05
restored O 0 1.3965981452201959e-05
to O 0 4.005381981642131e-07
both O 0 1.923623813127051e-06
homozygous O 1 0.8070814609527588
C5 B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
deficient I-Disease 1 1.0
( O 0 4.520183210843243e-05
C5D B-Disease 1 0.9999983310699463
) O 0 1.5883007336014998e-06
sera O 0 4.541299404081656e-06
by O 0 3.69134838251739e-08
addition O 0 6.831020726849601e-08
of O 0 6.103277883084957e-08
highly O 0 1.0503719067855855e-06
purified O 0 9.515289093542378e-06
human O 0 3.684013108795625e-06
C5 O 0 0.0006512036779895425
. O 0 5.996353138471022e-06

In O 0 7.534913947893074e-06
specific O 0 3.235132226109272e-06
C5 O 0 0.000706266553606838
titrations O 0 0.00036963311140425503
, O 0 1.1055083177780034e-06
however O 0 2.6956544729728193e-07
, O 0 1.0778686032608675e-07
it O 0 7.909385146831482e-08
was O 0 3.4049405712721637e-06
noted O 0 2.088854955673014e-07
that O 0 1.141018746153577e-08
when O 0 1.4077746968155225e-08
limited O 0 1.487624068374771e-08
amounts O 0 1.558847095850524e-08
of O 0 1.923957704264012e-08
C5 O 0 4.412750058691017e-05
were O 0 2.0595952321400546e-07
assayed O 0 7.254778893184266e-07
in O 0 2.159293011061436e-08
the O 0 1.6337294184154416e-08
presence O 0 3.445699903181776e-08
of O 0 1.3825934175315524e-08
low O 0 1.6140775187523104e-06
dilutions O 0 1.4698935046908446e-05
of O 0 1.6357506638087216e-07
either O 0 3.6553090012603207e-06
C5D B-Disease 1 0.9999985694885254
serum O 0 4.0138336771633476e-05
, O 0 6.278428088535293e-08
curving O 0 1.0010236337620881e-06
rather O 0 4.8902982996423816e-08
than O 0 2.356414618986946e-08
linear O 0 4.6548302634619176e-07
dose O 0 1.9977317151642637e-06
- O 0 3.1501558623858728e-06
response O 0 2.627147068778868e-07
plots O 0 7.787160143379879e-07
were O 0 1.0130360124094295e-06
consistently O 0 3.0668436465930426e-06
obtained O 0 1.1867052762681851e-07
, O 0 4.274849985108631e-08
suggesting O 0 1.6287364701383922e-07
some O 0 3.390804081959686e-08
inhibitory O 0 4.1520193008182105e-06
effect O 0 1.48483968587243e-06
. O 0 1.4833026398264337e-06

Further O 0 3.1114850571611896e-05
studies O 0 5.72664248466026e-06
suggested O 0 3.3768712910386967e-06
that O 0 2.1693371365927305e-07
low O 0 6.204469627846265e-06
dilutions O 0 0.00025768164778128266
of O 0 1.530171630292898e-06
C5D B-Disease 1 0.9999996423721313
serum O 0 6.955624849069864e-05
contain O 0 2.616385756937234e-07
a O 0 3.6446155604608066e-07
factor O 0 4.858548550146224e-07
( O 0 1.8521255640280287e-07
or O 0 8.881522006731757e-08
factors O 0 7.746822916487872e-08
) O 0 2.4987587110558707e-08
interfering O 0 4.4068563909149816e-08
at O 0 2.5877287868070198e-08
some O 0 5.6623563615687544e-09
step O 0 6.798836693633348e-08
in O 0 3.8586840389598365e-08
the O 0 2.424986860205536e-07
hemolytic O 0 0.00014079097309149802
assay O 0 8.288936442113481e-06
of O 0 2.5068985110010544e-07
C5 O 0 0.00019670053734444082
, O 0 1.1000966537721979e-07
rather O 0 3.714499996476661e-08
than O 0 1.1564213586723326e-08
a O 0 2.0509924070211127e-07
true O 0 1.517364808023558e-06
C5 O 0 0.00014934329374227673
inhibitor O 0 1.1499531865410972e-05
or O 0 1.6976766801235499e-06
inactivator O 0 9.19020822038874e-05
. O 0 4.445752892934252e-06

Of O 0 5.385869826568523e-06
clinical O 0 2.7940564905293286e-05
interest O 0 1.2093707937310683e-06
are O 0 9.974646530963582e-08
( O 0 1.8319221339879732e-07
a O 0 5.219863510319556e-07
) O 0 1.030475047514301e-07
the O 0 7.640828414423595e-08
documentation O 0 6.642620746788452e-07
of O 0 7.404981943182065e-07
membranous O 1 0.9945427179336548
glomerulonephritis B-Disease 1 1.0
, O 0 0.00828749779611826
vasculitis B-Disease 1 0.9999998807907104
, O 0 0.00013580720406025648
and O 0 0.04429604485630989
arthritis B-Disease 1 1.0
in O 0 2.3833467821532395e-06
an O 0 3.953092857500451e-07
individual O 0 6.177660907269455e-07
lacking O 0 1.1587037079152651e-05
C5 O 0 0.011689258739352226
( O 0 2.832408085851057e-07
and O 0 3.156582906171934e-08
its O 0 4.2539138433994594e-08
biologic O 0 3.219444579372066e-06
functions O 0 8.694617292803741e-08
) O 0 5.877262765352498e-08
, O 0 2.1667025507099424e-08
and O 0 8.659514350028985e-08
( O 0 1.446609871891269e-07
b O 0 1.8457372163993568e-07
) O 0 1.6266216817939494e-08
a O 0 8.516565941363297e-08
remarkable O 0 6.01512340381305e-07
propensity O 0 1.9395138224354014e-05
to O 0 6.083630069042556e-06
bacterial B-Disease 1 0.9999996423721313
infections I-Disease 1 0.9999974966049194
in O 0 4.088858815975982e-07
the O 0 2.4417090571660083e-07
proband O 0 2.413179936411325e-05
, O 0 6.684626896458212e-08
even O 0 3.871275211508873e-08
during O 0 6.833822396856704e-08
periods O 0 7.324870665570415e-08
of O 0 1.3898299400239011e-08
low O 0 2.5411975457245717e-06
- O 0 6.71356883685803e-06
dose O 0 1.18345667488029e-06
or O 0 5.184372042776886e-08
alternate O 0 6.161809551485931e-07
- O 0 2.6519965103943832e-05
day O 0 3.9766223380865995e-06
corticosteroid O 0 0.00019576482009142637
therapy O 0 8.876717765815556e-05
. O 0 3.662692733996664e-06

Other O 0 3.0018979941814905e-06
observations O 0 6.093838237575255e-06
indicate O 0 1.8560168655312737e-06
that O 0 5.3253145892995235e-08
the O 0 3.7378009665189893e-07
C5D B-Disease 1 0.9999988079071045
state O 0 1.2319287634454668e-07
is O 0 3.73501762851447e-08
compatible O 0 2.064371642518381e-07
with O 0 1.5630995164883643e-07
normal O 0 1.4694301171402913e-06
coagulation O 0 8.394220458285417e-06
function O 0 1.2862831511029071e-07
and O 0 9.74179954482679e-08
the O 0 4.7031964101051926e-08
capacity O 0 6.34615133776606e-08
to O 0 4.8144812581085716e-08
mount O 0 7.730113793513738e-06
a O 0 1.567465551488567e-05
neutrophilic O 0 0.08435067534446716
leukocytosis O 0 0.07771116495132446
during O 0 7.047154213069007e-05
pyogenic B-Disease 0 0.4821605682373047
infection I-Disease 0 0.0032879547215998173
. O 0 2.5781378099054564e-06
. O 0 6.025456514180405e-06

Susceptibility O 1 0.9759100079536438
to O 0 0.0076711284928023815
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.10922723263502121
twins O 0 0.0924912691116333
: O 0 3.878785435063037e-07
the O 0 5.657102519762702e-08
role O 0 1.4300644579634536e-07
of O 0 4.4279627076093675e-08
genes O 0 6.901582878526824e-07
, O 0 2.4112057417369215e-07
HLA O 0 2.004786983889062e-05
, O 0 5.43826566001826e-08
and O 0 9.825792801620992e-08
the O 0 2.598903279249498e-07
environment O 0 6.7281439442012925e-06
. O 0 4.279004315321799e-06

OBJECTIVE O 0 6.887863855808973e-05
To O 0 1.56714895638288e-06
determine O 0 6.403566317203513e-07
the O 0 1.8036102744645177e-07
relative O 0 1.8869664017984178e-06
effects O 0 4.274554612493375e-06
of O 0 1.0727780619390614e-07
genetic O 0 5.756791779276682e-06
and O 0 2.839780961494398e-07
environmental O 0 5.222492518441868e-07
factors O 0 2.162434071806274e-07
in O 0 6.257793074837537e-07
susceptibility O 0 0.00868864357471466
to O 0 0.0006188735133036971
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.010085800662636757
AS B-Disease 1 0.9829154014587402
) O 0 3.846816980512813e-06
. O 0 4.64309960079845e-06

METHODS O 0 0.00022479907784145325
Twins O 0 0.003036101348698139
with O 0 5.894017249374883e-06
AS B-Disease 1 0.9702969193458557
were O 0 3.0943037927499972e-06
identified O 0 3.744176808595512e-07
from O 0 2.7445327788200302e-08
the O 0 1.6484133880112495e-07
Royal O 0 3.2702216685720487e-06
National O 0 4.6958192001511634e-07
Hospital O 0 2.9329798053367995e-05
for O 0 6.027709332556697e-06
Rheumatic B-Disease 1 0.9991495609283447
Diseases I-Disease 0 0.000554403814021498
database O 0 6.8403169279918075e-06
. O 0 5.434580998553429e-06

Clinical O 0 0.001708021154627204
and O 0 2.1725309125031345e-05
radiographic O 0 0.0012086533242836595
examinations O 0 4.248817640473135e-05
were O 0 2.75397223958862e-06
performed O 0 9.775533271749737e-07
to O 0 9.479121843014582e-08
establish O 0 9.321751122115529e-07
diagnoses O 0 0.009195709601044655
, O 0 9.906500508805038e-07
and O 0 2.043489075731486e-05
disease O 0 0.0007404586649499834
severity O 0 0.000310818461002782
was O 0 6.296439096331596e-05
assessed O 0 9.860992804533453e-07
using O 0 1.577307244815529e-07
a O 0 4.6087367877589713e-07
combination O 0 9.316117370872234e-07
of O 0 6.175751821047015e-08
validated O 0 2.039267656073207e-06
scoring O 0 1.2996906662010588e-06
systems O 0 1.1675474524963647e-05
. O 0 4.170536612946307e-06

HLA O 0 0.00750246737152338
typing O 0 0.00016590551240369678
for O 0 4.210523911751807e-06
HLA O 0 0.0002397186472080648
- O 0 5.5975593568291515e-05
B27 O 0 1.3932337424193975e-05
, O 0 4.02889298811715e-07
HLA O 0 2.1568499505519867e-05
- O 0 6.82159407006111e-06
B60 O 0 4.087115030415589e-06
, O 0 1.0923853466238143e-07
and O 0 3.4320444797231175e-07
HLA O 0 0.00011951693886658177
- O 0 0.0002613741671666503
DR1 O 0 0.012033144012093544
was O 0 4.32375782111194e-06
performed O 0 3.0677279028168414e-07
by O 0 3.843802076630709e-08
polymerase O 0 1.0679360684662242e-06
chain O 0 1.261190391232958e-06
reaction O 0 1.2863739584645373e-07
with O 0 2.5586007978972702e-08
sequence O 0 2.1934940264145553e-07
- O 0 1.155672407548991e-06
specific O 0 6.000318109045111e-08
primers O 0 5.864407739863964e-06
, O 0 1.1380089404156024e-07
and O 0 2.0192388205941825e-07
zygosity O 0 1.2526938007795252e-05
was O 0 2.427579147479264e-06
assessed O 0 8.849577284308907e-07
using O 0 1.084014115804166e-06
microsatellite O 0 0.0003001275472342968
markers O 0 9.828376641962677e-05
. O 0 1.0731115253292955e-05

Genetic O 0 0.0008071524789556861
and O 0 4.156452632742003e-06
environmental O 0 1.0503689509278047e-06
variance O 0 6.324883088382194e-07
components O 0 3.31502951667062e-06
were O 0 1.635767603147542e-06
assessed O 0 7.368448677880224e-07
with O 0 4.3995498799631605e-08
the O 0 1.371201392430521e-07
program O 0 3.227085016987985e-07
Mx O 0 2.6146396976400865e-06
, O 0 1.4546663429371165e-08
using O 0 1.710015773426221e-08
data O 0 4.055437230476855e-08
from O 0 5.732622376797281e-09
this O 0 6.123308082806034e-09
and O 0 5.738095154583789e-08
previous O 0 3.1127527222452045e-07
studies O 0 5.414936055103681e-08
of O 0 3.054124420032167e-08
twins O 0 2.1775878849439323e-05
with O 0 1.2665975646086736e-06
AS B-Disease 1 0.9875853061676025
. O 0 5.516447799891466e-06

RESULTS O 0 0.00017189969366881996
Six O 0 2.618492544570472e-06
of O 0 4.3705364305424155e-07
8 O 0 9.548441994411405e-06
monozygotic O 0 0.000667269341647625
( O 0 1.0055492566607427e-05
MZ O 1 0.9385203123092651
) O 0 2.207685838584439e-06
twin O 0 0.0029209251515567303
pairs O 0 4.983248436474241e-05
were O 0 2.3413414965034463e-05
disease O 0 4.3069750972790644e-05
concordant O 0 7.254887168528512e-05
, O 0 8.567412237425742e-07
compared O 0 9.356969030704931e-07
with O 0 3.652290914146761e-08
4 O 0 3.6463609376369277e-07
of O 0 3.066481468749771e-08
15 O 0 3.0377705684259126e-07
B27 O 0 5.921217507420806e-06
- O 0 3.365843076608144e-05
positive O 0 1.0518294857320143e-06
dizygotic O 0 1.6472471543238498e-05
( O 0 5.082381449028617e-07
DZ O 0 0.00045915445662103593
) O 0 3.479189558674989e-07
twin O 0 3.2522817491553724e-05
pairs O 0 1.899804601634969e-06
( O 0 2.695184093681746e-07
27 O 0 3.1785491501068464e-06
% O 0 1.6759985044245695e-07
) O 0 2.015901934271369e-08
and O 0 3.0543922946435487e-08
4 O 0 1.879074318367202e-07
of O 0 4.104102302449064e-08
32 O 0 2.5399401692993706e-06
DZ O 0 0.0030154669657349586
twin O 0 0.0002225862699560821
pairs O 0 3.50322238773515e-06
overall O 0 1.7474356354796328e-05
( O 0 2.2626826989835536e-07
12 O 0 2.3219939748742036e-07
. O 0 5.5402395560122386e-08
5 O 0 6.150091280687775e-07
% O 0 2.8141744223830756e-07
) O 0 2.889327390676044e-07
. O 0 9.962113836081699e-07

Nonsignificant O 0 0.01014433428645134
increases O 0 0.00023835778119973838
in O 0 3.7773733652102237e-07
similarity O 0 4.865290179623116e-07
with O 0 1.0041379994163435e-07
regard O 0 2.052741763236554e-07
to O 0 9.624595520563162e-08
age O 0 6.996201591391582e-07
at O 0 7.775553854116879e-07
disease O 0 1.185359087685356e-05
onset O 0 2.931975723186042e-05
and O 0 4.5035687890049303e-07
all O 0 8.188360212102452e-09
of O 0 1.9659722738651908e-08
the O 0 1.2454789839466684e-06
disease O 0 3.40592632710468e-05
severity O 0 3.953793930122629e-05
scores O 0 3.699218495967216e-06
assessed O 0 4.370859187474707e-06
were O 0 1.4795757579122437e-06
noted O 0 1.3516320223061484e-06
in O 0 4.004570655524731e-06
disease O 0 0.00014207186177372932
- O 0 0.0005591470398940146
concordant O 0 0.014642724767327309
MZ O 1 0.9988129138946533
twins O 0 0.0005082398420199752
compared O 0 8.167139640136156e-06
with O 0 2.0555285118462052e-06
concordant O 0 0.06227586418390274
DZ O 1 0.9958564639091492
twins O 0 0.014048784971237183
. O 0 2.9045273549854755e-05

HLA O 0 0.034061528742313385
- O 0 0.001470681163482368
B27 O 0 8.558904664823785e-05
and O 0 2.067115246973117e-06
B60 O 0 1.0563094292592723e-05
were O 0 5.919078489569074e-07
associated O 0 1.299433876056355e-07
with O 0 1.0075395096009743e-07
the O 0 3.4131790016544983e-06
disease O 0 1.517598229838768e-05
in O 0 1.5525216667811037e-07
probands O 0 7.253739022416994e-05
, O 0 1.4432337991365785e-07
and O 0 7.483914998829277e-08
the O 0 6.844871336397773e-08
rate O 0 3.082916236962774e-06
of O 0 1.3299319334691972e-07
disease O 0 9.264233085559681e-06
concordance O 0 1.3694121662410907e-05
was O 0 1.2649747986870352e-05
significantly O 0 6.980752004892565e-06
increased O 0 3.867722170980414e-06
among O 0 2.2388888964997022e-07
DZ O 0 0.005770999472588301
twin O 0 0.0001427775132469833
pairs O 0 1.8163678987548337e-06
in O 0 8.513090676842694e-08
which O 0 9.370438647238188e-08
the O 0 1.0986560994297179e-07
co O 0 1.487772988184588e-05
- O 0 0.00010888030374189839
twin O 0 0.0005634647677652538
was O 0 9.55725226958748e-06
positive O 0 6.638998684138642e-08
for O 0 3.62043479640306e-08
both O 0 1.4175844853525632e-07
B27 O 0 1.3819818377669435e-05
and O 0 3.03339265883551e-06
DR1 O 0 0.003008411731570959
. O 0 7.1572894739801995e-06

Additive O 0 0.0006445395410992205
genetic O 0 0.00012882494775112718
effects O 0 6.592214049305767e-05
were O 0 1.3281160136102699e-06
estimated O 0 2.2852711367704615e-07
to O 0 5.4801972737550386e-08
contribute O 0 1.330048462477862e-07
97 O 0 1.1894715044036275e-06
% O 0 1.114468375362776e-07
of O 0 1.508824531981645e-08
the O 0 1.7430851073640952e-07
population O 0 3.6920249613103806e-07
variance O 0 2.747262215052615e-06
. O 0 4.511182396527147e-06

CONCLUSION O 0 0.00016654745559208095
Susceptibility O 0 0.0012796804076060653
to O 0 2.9528080176532967e-06
AS B-Disease 1 0.8102137446403503
is O 0 3.6651070445259393e-07
largely O 0 4.759280614052841e-07
genetically O 0 1.3719406979362248e-06
determined O 0 2.4607898012618534e-06
, O 0 1.10624498006473e-07
and O 0 1.3387480635174143e-07
the O 0 7.974977478397705e-08
environmental O 0 4.905881496597431e-07
trigger O 0 9.674114153312985e-06
for O 0 1.8190878847690328e-07
the O 0 4.306293249101145e-06
disease O 0 4.430771878105588e-05
is O 0 5.407204639595875e-07
probably O 0 1.638028038541961e-06
ubiquitous O 0 1.508773766545346e-05
. O 0 3.3533419809828047e-06

HLA O 0 0.02912895381450653
- O 0 0.0005630591767840087
B27 O 0 3.891960295732133e-05
accounts O 0 5.215007377046277e-07
for O 0 4.9158003889715474e-08
a O 0 3.240123476189183e-07
minority O 0 7.882695740590862e-07
of O 0 1.5538423880911978e-08
the O 0 1.81563208911939e-07
overall O 0 3.597965041990392e-05
genetic O 0 2.6852123482967727e-05
susceptibility O 0 6.005417162668891e-05
to O 0 1.5196659433058812e-06
AS B-Disease 1 0.9458871483802795
. O 0 1.5116643226065207e-05

Cell O 0 0.0032764950301498175
cycle O 0 0.00027049874188378453
- O 0 5.844845873070881e-05
dependent O 0 3.885592832375551e-06
colocalization O 0 8.389978574996348e-06
of O 0 1.3621585992495966e-07
BARD1 O 0 0.00017133171786554158
and O 0 1.4353784081322374e-06
BRCA1 O 0 2.139863499905914e-05
proteins O 0 4.3374595293244056e-07
in O 0 1.15322571048182e-07
discrete O 0 2.2291235381999286e-06
nuclear O 0 7.2851717050070874e-06
domains O 0 6.925999059603782e-06
. O 0 2.8199526695971144e-06

Germ O 0 0.03426933288574219
- O 1 0.5138623714447021
line O 0 0.0007332669920288026
mutations O 0 7.853245733713266e-06
of O 0 6.680611619458432e-08
the O 0 2.3178965591341694e-07
BRCA1 O 0 9.764163405634463e-05
gene O 0 2.7096161829831544e-06
predispose O 0 6.0068623497500084e-06
women O 0 4.212630244637694e-07
to O 0 1.0720416554477197e-07
early O 0 6.154483799036825e-06
- O 0 0.1534484475851059
onset O 1 0.8434146642684937
breast B-Disease 1 0.9999582767486572
and I-Disease 1 0.9911013841629028
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 4.679162373122381e-07
compromising O 0 6.737929197697667e-06
the O 0 4.2679820921875944e-07
genes O 0 3.7733550470875343e-06
presumptive O 0 0.00010089000716106966
function O 0 5.400587497206288e-07
as O 0 4.4174521462991834e-07
a O 0 8.006838470464572e-06
tumor B-Disease 0 0.0011115538654848933
suppressor O 0 0.0015529777156189084
. O 0 1.394720129610505e-05

Although O 0 1.9481916751828976e-05
the O 0 1.0831771533048595e-06
biochemical O 0 1.299668747378746e-05
properties O 0 2.651964678079821e-06
of O 0 2.4916491270232655e-07
BRCA1 O 0 8.579553832532838e-05
polypeptides O 0 9.300057172367815e-06
are O 0 1.348055604921683e-07
not O 0 8.019824093707939e-08
understood O 0 1.6882255238215294e-07
, O 0 2.8488319259167838e-08
their O 0 4.5793829173135236e-08
expression O 0 3.526666318975913e-07
pattern O 0 1.5996957927200128e-06
and O 0 1.4149034655019932e-07
subcellular O 0 9.293168659496587e-06
localization O 0 5.1924644139944576e-06
suggest O 0 3.8889265852048993e-07
a O 0 7.649884281590857e-08
role O 0 1.592925968907366e-07
in O 0 3.7988036183378426e-07
cell O 0 2.9184406230342574e-05
- O 0 8.472195622744039e-05
cycle O 0 2.7739688448491506e-05
regulation O 0 5.48680918655009e-06
. O 0 2.7281737402518047e-06

When O 0 7.127171556930989e-05
resting O 0 0.0001751942909322679
cells O 0 7.973150786710903e-06
are O 0 1.187615623621241e-07
induced O 0 1.6962130757747218e-05
to O 0 1.0926229521146524e-07
proliferate O 0 1.1573081337701296e-06
, O 0 3.1460821503515035e-08
the O 0 1.828326112729428e-08
steady O 0 3.4878380574809853e-06
- O 0 3.879139512719121e-06
state O 0 1.7995754220123672e-08
levels O 0 2.7822709469660367e-08
of O 0 1.209768996091043e-08
BRCA1 O 0 1.8991524939337978e-06
increase O 0 8.886384961215299e-08
in O 0 3.917297064504055e-08
late O 0 8.569398346480739e-07
G1 O 0 8.682643965585157e-06
and O 0 6.73212241508736e-08
reach O 0 1.2365794077595638e-07
a O 0 2.055948868928681e-07
maximum O 0 6.441602522500034e-07
during O 0 1.731771135382587e-06
S O 0 6.908913928782567e-05
phase O 0 6.321124146779766e-06
. O 0 1.8412417830404593e-06

Moreover O 0 5.725225491914898e-05
, O 0 1.1252329841227038e-06
in O 0 5.36812478912907e-07
S O 0 0.00013317546108737588
phase O 0 5.247327408142155e-06
cells O 0 3.0988012440502644e-06
, O 0 2.4255558628283325e-07
BRCA1 O 0 1.3204262359067798e-05
polypeptides O 0 2.2726185306964908e-06
are O 0 8.677221785546863e-08
hyperphosphorylated O 0 7.880555131123401e-06
and O 0 1.805957907663469e-07
accumulate O 0 5.931792657065671e-07
into O 0 9.464650929658092e-08
discrete O 0 1.7315268223683233e-06
subnuclear O 0 3.367207682458684e-05
foci O 0 6.1086866480764e-05
termed O 0 2.407557076367084e-05
" O 0 9.54389906837605e-06
BRCA1 O 0 0.00013031309936195612
nuclear O 0 1.1540475497895386e-05
dots O 0 0.000747071928344667
. O 0 6.388855581462849e-06

" O 0 0.0010622694389894605
BRCA1 O 0 0.0034743058495223522
associates O 0 0.00028727445169351995
in O 0 8.972484693003935e-07
vivo O 0 2.2776677724323235e-05
with O 0 2.0947598500242748e-07
a O 0 4.495695975492708e-06
structurally O 0 0.004550684709101915
related O 0 3.417012521822471e-06
protein O 0 1.07817186290049e-05
termed O 0 4.622885171556845e-05
BARD1 O 0 0.0014681601896882057
. O 0 1.0328701137041207e-05

Here O 0 2.0735002181027085e-05
we O 0 4.6669515540997963e-07
show O 0 5.487340217769088e-07
that O 0 1.809436334099246e-08
the O 0 4.8731283897041067e-08
steady O 0 6.148160082375398e-06
- O 0 4.784784323419444e-06
state O 0 2.8049269573671154e-08
levels O 0 3.113542135224634e-08
of O 0 9.260559430401827e-09
BARD1 O 0 9.12380619411124e-06
, O 0 3.685439153855441e-08
unlike O 0 3.559080852255647e-08
those O 0 9.575501280778553e-09
of O 0 3.052697650218761e-08
BRCA1 O 0 1.789454290701542e-05
, O 0 1.1872622707187475e-07
remain O 0 1.8964470882565365e-07
relatively O 0 1.1346494943609287e-07
constant O 0 4.083917701791506e-07
during O 0 7.525216574322258e-07
cell O 0 2.6310326575185172e-05
cycle O 0 3.937404108000919e-05
progression O 0 4.551516758510843e-05
. O 0 4.284672286303248e-06

However O 0 4.257871114532463e-05
, O 0 2.3363775198959047e-06
immunostaining O 0 5.4481519327964634e-05
revealed O 0 1.0877508429985028e-05
that O 0 2.805687699947157e-07
BARD1 O 0 0.00014024240954313427
resides O 0 6.188603038026486e-06
within O 0 4.521742766883108e-07
BRCA1 O 0 2.4270433641504496e-05
nuclear O 0 1.4079621450946433e-06
dots O 0 5.217851867200807e-05
during O 0 1.1863154441016377e-06
S O 0 2.7098825739813037e-05
phase O 0 2.014096054381298e-07
of O 0 1.0329245014872868e-08
the O 0 3.9309945520926703e-08
cell O 0 6.925609341124073e-06
cycle O 0 4.5448045966622885e-06
, O 0 3.2392019733151756e-08
but O 0 1.4980511053863665e-08
not O 0 1.2928080828089605e-08
during O 0 7.13572703148202e-08
the O 0 3.0212851243049954e-07
G1 O 0 9.859457350103185e-05
phase O 0 8.329167030751705e-06
. O 0 3.01664886137587e-06

Nevertheless O 0 0.0005318329785950482
, O 0 7.802758773323148e-06
BARD1 O 0 0.00014120209380052984
polypeptides O 0 1.8263683159602806e-05
are O 0 9.069468376310397e-08
found O 0 1.0614655820972985e-07
exclusively O 0 4.606109271776404e-08
in O 0 2.390155984244302e-08
the O 0 2.8734985946243796e-08
nuclear O 0 1.3306269863733178e-07
fractions O 0 1.2319581799147272e-07
of O 0 8.979682775134279e-09
both O 0 5.9289767762038537e-08
G1 O 0 1.6844165656948462e-05
- O 0 6.024215508659836e-06
and O 0 8.015325647647842e-07
S O 0 7.3456802056171e-05
- O 0 2.9075230486341752e-05
phase O 0 6.63580976834055e-06
cells O 0 8.027451258385554e-06
. O 0 2.316487552889157e-06

Therefore O 0 2.9710148737649433e-05
, O 0 1.1509824844324612e-06
progression O 0 5.948912530584494e-06
to O 0 3.34762091824814e-07
S O 0 0.00016282300930470228
phase O 0 2.236847421954735e-06
is O 0 1.2384606407067622e-07
accompanied O 0 3.0588120125685236e-07
by O 0 2.6946436193497902e-08
the O 0 3.026094219649167e-08
aggregation O 0 3.130483605673362e-07
of O 0 4.597490033120266e-08
nuclear O 0 3.0097467060841154e-06
BARD1 O 0 2.9904835173510946e-05
polypeptides O 0 5.81344011152396e-06
into O 0 5.519018486666027e-07
BRCA1 O 0 6.658920756308362e-05
nuclear O 0 1.5524832633673213e-05
dots O 0 0.00031278334790840745
. O 0 1.0631655641191173e-05

This O 0 7.813487172825262e-06
cell O 0 5.707176751457155e-05
cycle O 0 2.5443707272643223e-05
- O 0 9.376448360853828e-06
dependent O 0 6.712466529279482e-07
colocalization O 0 4.39676659880206e-06
of O 0 1.0696050622982511e-07
BARD1 O 0 0.000158872950123623
and O 0 3.6408396226761397e-06
BRCA1 O 0 4.561215246212669e-05
indicates O 0 5.619842227133631e-07
a O 0 1.5338373771101033e-07
role O 0 2.1047844711574726e-07
for O 0 9.936876210758783e-08
BARD1 O 0 7.335963164223358e-05
in O 0 6.131480176918558e-07
BRCA1 O 0 0.00023526388395112008
- O 0 0.00025844070478342474
mediated O 0 0.0008898671367205679
tumor B-Disease 0 0.00429125502705574
suppression O 0 6.356612720992416e-05
. O 0 1.3118223250785377e-05

Ethnic O 0 0.0001913737942231819
differences O 0 6.188858242239803e-05
in O 0 1.7367279951940873e-06
the O 0 1.747377041283471e-06
HFE O 0 0.0017616759287193418
codon O 0 6.97070499882102e-05
282 O 0 5.323495133779943e-05
( O 0 8.780727512203157e-06
Cys O 0 0.01959819346666336
/ O 0 0.0005070014158263803
Tyr O 0 0.0009133295970968902
) O 0 8.207131941162515e-06
polymorphism O 0 0.00012222914665471762
. O 0 9.61504611041164e-06

Recent O 0 3.8324418710544705e-05
studies O 0 5.55464703211328e-06
have O 0 1.0489364967725123e-06
shown O 0 1.1687071491905954e-05
that O 0 1.970975245058071e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.06181450933218002
HH B-Disease 1 0.9738417863845825
) O 0 7.656955745005689e-07
is O 0 1.2482978206662665e-07
likely O 0 5.48804166555783e-07
to O 0 7.219372832878435e-08
be O 0 2.697858576539147e-07
caused O 0 8.689673904882511e-07
by O 0 3.775716450604705e-08
homozygosity O 0 4.552526206680341e-06
for O 0 2.900778994785469e-08
a O 0 1.1184723689439124e-06
Cys282Tyr O 0 6.939354352653027e-05
mutation O 0 1.405844841428916e-06
in O 0 4.480816073737515e-08
the O 0 3.984059162576159e-07
HFE O 0 0.0002632636751513928
gene O 0 2.8027961889165454e-06
located O 0 1.9191768387827324e-06
4 O 0 4.420993718667887e-06
. O 0 3.0506337225233437e-06

5 O 0 0.000423125340603292
Mb O 0 0.0021911372896283865
telomeric O 0 0.0013218120438978076
to O 0 1.5467297998839058e-05
HLA O 0 0.001241733436472714
- O 0 0.00010577355715213344
A O 0 2.5805858967942186e-05
. O 0 9.82898836809909e-06

Population O 0 2.578799831098877e-05
studies O 0 1.4421057130675763e-06
of O 0 7.39586383247115e-08
this O 0 7.152665659759805e-08
polymorphism O 0 2.630744165799115e-05
are O 0 2.1392144944343272e-08
facilitated O 0 2.8761039061464544e-07
by O 0 5.407504843901734e-08
the O 0 6.017016573878209e-08
fact O 0 4.851325385857308e-08
that O 0 3.9018765107812214e-08
the O 0 1.7970823762425425e-07
Cys282Tyr O 0 0.00011583646119106561
mutation O 0 2.332081294298405e-06
creates O 0 6.745663085894194e-07
a O 0 5.527794542103948e-07
Rsal O 0 1.7926295186043717e-05
restriction O 0 2.11841074815311e-06
site O 0 3.7437946502905106e-06
. O 0 3.638617954493384e-06

We O 0 2.0121728084632196e-05
have O 0 9.505752132099587e-07
studied O 0 8.930442163546104e-07
the O 0 3.3284948131040437e-07
codon O 0 1.4220734556147363e-05
282 O 0 1.650655030971393e-05
( O 0 4.345945399109041e-06
Cys O 0 0.0038150267209857702
/ O 0 0.00019826603238470852
Tyr O 0 0.0002515102969482541
) O 0 7.49068306049594e-07
polymorphism O 0 3.992254278273322e-06
in O 0 9.249689014723117e-08
different O 0 2.0197396111143462e-07
ethnic O 0 3.4601473544171313e-06
groups O 0 2.3085524389898637e-06
. O 0 3.704803930304479e-06

In O 0 5.590199180005584e-06
agreement O 0 1.2162166740381508e-06
with O 0 2.24426102590769e-07
previous O 0 8.583891712987679e-07
observations O 0 7.93136337051692e-07
the O 0 2.2021001200300816e-07
Tyr O 0 3.5307770303916186e-05
allele O 0 3.518151061143726e-06
appeared O 0 2.016042117247707e-06
to O 0 3.790732350239523e-08
be O 0 4.457952940128962e-08
rare O 0 2.9574738391602295e-07
or O 0 4.577788956794393e-07
absent O 0 9.83543714028201e-07
in O 0 1.6339639330453792e-07
Asiatic O 0 6.11326777288923e-06
( O 0 5.0070514845401703e-08
Indian O 0 4.120275320929068e-08
, O 0 3.205044407650348e-08
Chinese O 0 3.802340486913636e-08
) O 0 1.4882817822581274e-07
populations O 0 1.3899116311222315e-06
. O 0 1.157781753136078e-06

The O 0 1.2780536962964106e-05
highest O 0 8.846877790347207e-06
allele O 0 1.2703761058219243e-05
frequency O 0 5.243325631454354e-06
( O 0 2.7451093842500995e-07
7 O 0 4.447964840892382e-07
. O 0 3.7487851045625575e-08
5 O 0 5.336407866707304e-07
% O 0 1.9674509132983076e-07
) O 0 3.3790925613175204e-08
was O 0 1.357315682071203e-06
found O 0 1.7562923915193096e-07
in O 0 2.9425291359075345e-07
Swedes O 0 0.000151476648170501
. O 0 5.44214299225132e-06

Saamis O 0 0.003339915070682764
( O 0 1.3547030903282575e-05
2 O 0 7.66517041483894e-06
% O 0 1.055956317941309e-06
) O 0 6.789868223222584e-08
and O 0 8.928910943950541e-08
Mordvinians O 0 9.808996765059419e-06
( O 0 7.589830630649885e-08
1 O 0 8.049831023981824e-08
. O 0 1.630411006203758e-08
8 O 0 3.321632675579167e-07
% O 0 7.388715062006668e-08
) O 0 1.8536075785391404e-08
had O 0 8.379554969906167e-07
significantly O 0 3.2802320220071124e-06
lower O 0 9.713020290291752e-07
frequencies O 0 1.3123609221565857e-07
of O 0 2.1568478558720017e-08
the O 0 5.039128154749051e-07
Tyr O 0 0.0002501552808098495
allele O 0 3.7915637221885845e-05
. O 0 3.9944702621141914e-06

Comparisons O 0 3.215137985534966e-05
with O 0 1.8431585431244457e-06
allele O 0 8.79286108101951e-06
frequencies O 0 1.4848667433398077e-06
based O 0 2.968091905586334e-07
on O 0 8.233654398281942e-07
prevalence O 0 1.4662770809081849e-05
estimates O 0 1.8188761714554857e-06
of O 0 1.6920841972023482e-07
HH B-Disease 0 0.19720955193042755
showed O 0 5.596722985501401e-06
some O 0 1.756128931162948e-08
disagreements O 0 4.586555348851107e-07
with O 0 7.846696092883576e-08
the O 0 4.6177120793799986e-07
RFLP O 0 3.8813632272649556e-05
data O 0 8.23855600629031e-07
, O 0 8.089725866966546e-08
particularly O 0 1.0453558729750512e-07
in O 0 2.688601909994759e-07
Finns O 0 3.8895006582606584e-05
. O 0 3.0157862056512386e-06

The O 0 1.1278370948275551e-05
newly O 0 1.8831620764103718e-05
described O 0 1.4545225894835312e-05
HFE O 0 0.0007051400607451797
marker O 0 1.2659812455240171e-05
provides O 0 3.8165458704497723e-07
a O 0 2.0511663478828268e-07
new O 0 9.3993115513058e-08
approach O 0 2.1177733344757144e-07
to O 0 2.181302605208657e-08
the O 0 2.1206608025181595e-08
screening O 0 2.514306629564089e-07
of O 0 5.975910255529016e-08
HH B-Disease 0 0.0011664462508633733
as O 0 1.0653131710114394e-07
well O 0 4.889589177992093e-08
as O 0 2.143053379199955e-08
studies O 0 8.264523287948577e-09
of O 0 3.1888778284638875e-09
the O 0 2.934709186774853e-08
relationship O 0 1.1670732646962279e-07
between O 0 1.7580335054390162e-07
the O 0 1.1121215948151075e-06
HFE O 0 0.004562224727123976
Tyr O 0 0.00020540409605018795
allele O 0 1.0862342605832964e-05
and O 0 4.000201556664251e-07
different O 0 2.842926278390223e-06
disorders O 0 0.13499948382377625
including O 0 2.487902565917466e-05
cancer B-Disease 0 0.2051805704832077

Autosomal B-Disease 1 0.9999560117721558
dominant I-Disease 1 0.9709429144859314
neurohypophyseal I-Disease 1 0.9997852444648743
diabetes I-Disease 1 0.9999990463256836
insipidus I-Disease 1 0.9998146891593933
associated O 0 7.048034603940323e-05
with O 0 1.4333634226204595e-06
a O 0 1.572394285176415e-05
missense O 0 0.0005399032961577177
mutation O 0 1.6913008948904462e-05
encoding O 0 4.260582500137389e-06
Gly23 O 0 0.00018923485185950994
- O 0 0.0006698587676510215
- O 0 0.0002544400922488421
> O 0 1.685436836851295e-05
Val O 0 9.74200083874166e-05
in O 0 1.5308285128412535e-06
neurophysin O 0 0.00013598160876426846
II O 0 0.00024763273540884256
. O 0 9.182868780044373e-06

Autosomal B-Disease 1 0.9999706745147705
dominant I-Disease 1 0.9830974340438843
neurohypophyseal I-Disease 1 0.9999072551727295
diabetes I-Disease 1 0.9999996423721313
insipidus I-Disease 1 0.9999678134918213
( O 0 0.00045794734614901245
ADNDI B-Disease 0 0.31707918643951416
) O 0 3.509944235702278e-06
is O 0 1.078645595953276e-06
an O 0 3.158978506689891e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.015499578788876534
by O 0 9.647064871387556e-06
progressive O 1 0.6564803123474121
degeneration O 0 0.30961984395980835
of O 0 8.191817357783293e-08
the O 0 6.8690405896632e-07
magnocellular O 0 0.00016625391435809433
neurons O 0 2.9779007491015363e-06
of O 0 3.371592427470205e-08
the O 0 1.321816682775534e-07
hypothalamus O 0 5.7813185776467435e-06
leading O 0 6.002991312925587e-07
to O 0 1.127560267377703e-07
decreased O 0 8.193477697204798e-06
ability O 0 1.1448733516772336e-07
to O 0 2.932577380931889e-08
produce O 0 1.3864784875750047e-07
the O 0 4.5439148266268603e-07
hormone O 0 9.483002941124141e-06
arginine O 0 1.4499355529551394e-05
vasopressin O 0 3.637647387222387e-05
( O 0 2.5475042093603406e-06
AVP O 0 7.69875114201568e-05
) O 0 4.213818101561628e-06
. O 0 4.519553840509616e-06

Affected O 0 0.00015343051927629858
individuals O 0 1.602025577085442e-06
are O 0 9.646208809499512e-08
not O 0 1.5728041091733758e-07
symptomatic O 0 1.5530236851191148e-05
at O 0 1.0375498504799907e-06
birth O 0 1.2407330359565094e-05
, O 0 1.8771346788071241e-07
but O 0 1.504173070543402e-07
usually O 0 1.2583250281750225e-06
develop O 0 3.246047754146275e-06
diabetes B-Disease 0 0.013074937276542187
insipidus I-Disease 0 0.0005384118994697928
at O 0 7.61330340992572e-07
1 O 0 1.4693446246383246e-06
- O 0 7.819919846951962e-05
6 O 0 5.291958586894907e-06
yr O 0 0.00016077698091976345
of O 0 2.5192989028255397e-07
age O 0 1.8780508526106132e-06
. O 0 2.356478717047139e-06

The O 0 1.4311343875306193e-05
genetic O 0 5.570997382164933e-05
locus O 0 2.7398251404520124e-05
of O 0 3.6550301274473895e-07
the O 0 7.343905963352881e-06
disease O 0 7.446647941833362e-05
is O 0 1.7994868528603547e-07
the O 0 2.2733505034011614e-07
AVP O 0 9.34483323362656e-05
- O 0 0.0008103426080197096
neurophysin O 0 0.0001401753252139315
II O 0 6.938943261047825e-05
( O 0 2.920109238857549e-07
NPII O 0 7.994935003807768e-06
) O 0 6.603031721397201e-08
gene O 0 1.960397355560417e-07
, O 0 8.64652562881929e-08
and O 0 1.0422396599096828e-06
mutations O 0 3.509569296511472e-06
that O 0 1.3502170759238652e-07
cause O 0 2.604041583254002e-06
ADNDI B-Disease 0 0.0004073208256158978
have O 0 7.520746407863044e-07
been O 0 3.649429345387034e-07
found O 0 8.042556487453112e-08
in O 0 3.223074074298893e-08
both O 0 5.076190490171939e-08
the O 0 1.1046614645238151e-07
signal O 0 3.511601562422584e-06
peptide O 0 9.499864006556891e-08
of O 0 9.39036581826258e-09
the O 0 7.77141977437168e-08
prepro O 0 1.235339732374996e-05
- O 0 1.0153687071579043e-05
AVP O 0 2.460455107211601e-05
- O 0 5.4590422223554924e-05
NPII O 0 1.9005923604709096e-05
precursor O 0 1.2626272791749216e-06
and O 0 2.1990737764099322e-07
within O 0 2.68103832468114e-07
NPII O 0 7.476911559933797e-05
itself O 0 6.595601917069871e-06
. O 0 2.4936725822044536e-06

An O 0 7.259759058797499e-06
affected O 0 7.6146852734382264e-06
girl O 0 8.555061504011974e-05
who O 0 1.9614760731201386e-06
presented O 0 3.1381119924844825e-07
at O 0 1.2373791946629353e-07
9 O 0 4.055862916629849e-07
months O 0 7.713678229492871e-08
of O 0 7.481228081474e-09
age O 0 1.3373468732424953e-07
and O 0 1.1031370661385154e-07
her O 0 2.5023748548846925e-06
similarly O 0 1.0359044608776458e-05
affected O 0 3.889868480655423e-07
younger O 0 6.394851084223774e-07
brother O 0 2.2144736249174457e-06
and O 0 2.928257742951246e-07
father O 0 1.548130626360944e-06
were O 0 1.5936369379687676e-07
all O 0 3.1841067560378633e-09
found O 0 2.6226855354138934e-08
to O 0 1.3491752604011253e-08
have O 0 5.032317673681064e-08
a O 0 2.0970585978830059e-07
novel O 0 6.142111942608608e-06
missense O 0 7.24844285286963e-05
mutation O 0 3.00744568448863e-06
( O 0 2.3558041561955179e-07
G1758 O 0 2.908041551563656e-06
- O 0 2.144034624507185e-05
- O 0 7.118864596122876e-05
> O 0 1.051576418831246e-05
T O 0 1.3004572792851832e-05
) O 0 4.1698061892248006e-08
encoding O 0 1.124058073287415e-07
the O 0 8.172698784392196e-08
amino O 0 4.417106822529604e-07
acid O 0 8.29242537747632e-07
substitution O 0 7.688426535423787e-07
Gly23 O 0 1.73610733327223e-05
- O 0 3.873568493872881e-05
- O 0 7.166953582782298e-05
> O 0 1.721416447253432e-05
Val O 0 6.727965228492394e-05
within O 0 2.9383636501734145e-06
NPII O 0 0.00017153899534605443
. O 0 7.78834419179475e-06

The O 0 3.728521187440492e-05
mutation O 0 0.00016356153355445713
was O 0 1.4480370737146586e-05
confirmed O 0 1.999678033826058e-06
by O 0 1.788168617622432e-07
restriction O 0 2.94471738016e-06
endonuclease O 0 5.3669908083975315e-05
analysis O 0 6.92971207172377e-06
. O 0 6.557030701515032e-06

A O 0 0.00022772650117985904
T1 O 0 0.025579197332262993
- O 0 0.0001298950082855299
weighted O 0 1.3223958376329392e-05
magnetic O 0 5.940737082710257e-06
resonance O 0 6.146846317278687e-06
imaging O 0 1.7447729987907223e-05
of O 0 1.7908857330439787e-07
the O 0 1.3026825627093785e-06
fathers O 0 4.2252049752278253e-05
pituitary O 0 0.0001482465595472604
gland O 0 7.569752051495016e-05
demonstrates O 0 3.057848516618833e-06
an O 0 6.881149943183118e-07
attenuated O 0 0.0007003599894233048
posterior O 0 0.031197577714920044
pituitary O 0 0.006279794033616781
bright O 0 0.000468883547000587
spot O 0 0.00016157720529008657
. O 0 1.6334779502358288e-05

This O 0 3.0403023629332893e-05
mutation O 0 0.0002013676567003131
may O 0 7.455955710611306e-06
be O 0 4.036422396325179e-08
valuable O 0 3.4354822986415456e-08
for O 0 3.048438301789247e-08
developing O 0 1.410306964544361e-07
models O 0 1.0893752460106043e-06
of O 0 1.9857544941714877e-07
dominantly B-Disease 0 0.07279618829488754
inherited I-Disease 1 0.9348224997520447
neurodegeneration I-Disease 1 1.0
, O 0 1.5621844795532525e-06
as O 0 5.3057870985639966e-08
the O 0 5.659929769308292e-08
early O 0 5.206341029406758e-07
age O 0 4.767148098494545e-08
of O 0 1.5712172896087395e-08
onset O 0 2.273138852615375e-05
of O 0 6.636383318436856e-07
symptoms O 0 0.0001333151012659073
suggests O 0 3.339632996812725e-07
that O 0 1.951506511943535e-08
this O 0 4.077596571505637e-08
mutation O 0 4.883568180957809e-06
may O 0 1.1107352975159301e-06
be O 0 4.170449940943399e-08
particularly O 0 9.458280203489267e-08
deleterious O 0 3.320446694488055e-06
to O 0 1.0965688801434226e-07
the O 0 4.6856774815751123e-07
magnocellular O 0 6.960011523915455e-05
neuron O 0 3.8107064028736204e-05
. O 0 4.440047973730543e-07
. O 0 2.224154513896792e-06

Frequent O 0 0.0015592774143442512
inactivation O 0 0.0019215185893699527
of O 0 2.696557203307748e-05
PTEN O 0 0.029112325981259346
/ O 0 0.0020211846567690372
MMAC1 O 0 0.0025572022423148155
in O 0 3.5645713069243357e-05
primary O 1 0.5055545568466187
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 3.911394014721736e-05

Sporadic B-Disease 1 0.9999805688858032
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.562810030009132e-05
the O 0 5.296540734889277e-07
most O 0 2.118231918757374e-07
common O 0 3.91382764064474e-06
male B-Disease 0 0.0004334004770498723
cancer I-Disease 0 4.261998037691228e-05
in O 0 1.1893009599361903e-07
the O 0 8.403068108009393e-08
Western O 0 3.5893361882699537e-07
world O 0 2.088285526724576e-07
, O 0 1.2349553912827105e-07
yet O 0 2.444565083692396e-08
many O 0 1.6522521129047618e-09
of O 0 2.71558509012948e-09
the O 0 2.5530676239782224e-08
major O 0 6.073734937217523e-08
genetic O 0 2.1182277976095065e-07
events O 0 2.6622394955211348e-08
involved O 0 2.7241098266017616e-08
in O 0 1.5131300656889834e-08
the O 0 8.233280368585838e-08
progression O 0 1.6425332205471932e-06
of O 0 1.591027398717415e-08
this O 0 9.547255785946618e-08
often O 0 1.0292379556631204e-05
fatal O 0 0.012224197387695312
cancer B-Disease 0 0.0026986533775925636
remain O 0 1.8139079429602134e-06
to O 0 3.383736952855543e-07
be O 0 1.5183043160504894e-06
elucidated O 0 0.00017256200953852385
. O 0 6.505786586785689e-06

Numerous O 0 7.139830995583907e-05
cytogenetic O 0 0.001633081934414804
and O 0 1.2223691555846017e-05
allelotype O 0 0.0002252481208415702
studies O 0 1.8592553487906116e-06
have O 0 7.54018685711344e-07
reported O 0 7.917315997474361e-06
frequent O 0 4.332772732595913e-06
loss O 0 1.0980818842654116e-05
of O 0 2.919936434864212e-07
heterozygosity O 0 0.0003146808594465256
on O 0 3.7857971619814634e-05
chromosomal O 1 0.6999093294143677
arm O 0 0.005188546143472195
10q O 0 3.996417217422277e-05
in O 0 6.608502644667169e-06
sporadic B-Disease 1 0.9934984445571899
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.9690942028537393e-05

Deletion O 0 0.001842989819124341
mapping O 0 0.00010805080091813579
studies O 0 6.670350558124483e-06
have O 0 1.0876240139623405e-06
unambiguously O 0 2.2746980903320946e-05
identified O 0 1.335345132247312e-06
a O 0 1.752435849766698e-07
region O 0 3.968753787830792e-07
of O 0 5.4571039243000996e-08
chromosome O 0 2.951005444629118e-05
10q23 O 0 3.8009739000699483e-06
to O 0 6.977504796168432e-08
be O 0 2.640534368936187e-08
the O 0 4.1044387444344466e-08
minimal O 0 9.073150977201294e-07
area O 0 8.060152936195664e-07
of O 0 1.864017491470804e-07
loss O 0 2.6537698431639e-05
. O 0 6.17447221884504e-06

A O 0 9.916540147969499e-05
new O 0 1.1099664334324189e-05
tumor B-Disease 0 0.00013017970195505768
suppressor O 0 0.0001806513173505664
gene O 0 1.5619489204254933e-05
, O 0 1.067476773641829e-06
PTEN O 0 0.0008506645099259913
/ O 0 0.00016159725782927126
MMAC1 O 0 0.0011289825197309256
, O 0 9.996365406550467e-07
was O 0 2.5527670004521497e-06
isolated O 0 2.491217173883342e-06
recently O 0 3.625349108915543e-06
at O 0 4.848846302252241e-08
this O 0 9.673749801208942e-09
region O 0 1.0926666504929017e-07
of O 0 4.0891702468570656e-08
chromosome O 0 2.452464286761824e-05
10q23 O 0 3.854686838167254e-06
and O 0 1.8965845072216325e-07
found O 0 9.594737093721051e-08
to O 0 3.441568452444699e-08
be O 0 5.982867889997578e-08
inactivated O 0 1.1687188816722482e-06
by O 0 5.300760008708494e-08
mutation O 0 7.989393679963541e-07
in O 0 3.3144371514026716e-07
three O 0 0.00542061310261488
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cell O 0 0.0008469658205285668
lines O 0 0.00014378388004843146
. O 0 9.39065921556903e-06

We O 0 6.541565380757675e-05
screened O 0 0.0002938120160251856
80 O 0 8.278495079139248e-05
prostate B-Disease 1 0.9993329644203186
tumors I-Disease 1 0.9999998807907104
by O 0 4.5144349769543624e-07
microsatellite O 0 0.00011390275903977454
analysis O 0 4.672817226492043e-07
and O 0 2.680910426988703e-07
found O 0 3.118374252153444e-07
chromosome O 0 2.051891897281166e-05
10q23 O 0 1.5458748521268717e-06
to O 0 4.595043989752412e-08
be O 0 7.295422932429574e-08
deleted O 0 2.065706212306395e-06
in O 0 5.832059741806006e-07
23 O 0 4.162728600931587e-06
cases O 0 1.567298454574484e-06
. O 0 3.719162123161368e-06

We O 0 7.683665899094194e-06
then O 0 8.571940384172194e-07
proceeded O 0 4.870647671850747e-07
with O 0 2.2966622381659363e-08
sequence O 0 1.0483729795396357e-07
analysis O 0 4.268901676596215e-08
of O 0 1.0608073530704587e-08
the O 0 6.911120919994573e-08
entire O 0 1.5408469380417955e-06
PTEN O 0 0.0003251114394515753
/ O 0 3.964190909755416e-05
MMAC1 O 0 5.2945360948797315e-05
coding O 0 1.1744678886316251e-05
region O 0 2.3054590201354586e-06
and O 0 8.748513096179522e-07
tested O 0 1.0584224128251662e-06
for O 0 4.3206227928749286e-08
homozygous O 0 4.5726415009994525e-06
deletion O 0 1.4565787296305643e-06
with O 0 8.373149995577478e-08
new O 0 6.439919388867565e-07
intragenic O 0 2.580971886345651e-05
markers O 0 3.7645886550308205e-06
in O 0 6.561239018765264e-08
these O 0 3.398703896095867e-08
23 O 0 7.101010055521328e-07
cases O 0 1.0009790685217013e-07
with O 0 1.9270063944532012e-07
10q23 O 0 3.965219366364181e-05
loss O 0 8.33120066090487e-06
of O 0 1.4664930176877533e-06
heterozygosity O 0 0.001476346980780363
. O 0 2.1085719708935358e-05

The O 0 4.456505394045962e-06
identification O 0 1.0890521480177995e-06
of O 0 7.957261516366998e-08
the O 0 1.1208295092046683e-07
second O 0 3.0415355922741583e-06
mutational O 0 4.633596836356446e-05
event O 0 8.727029694455268e-07
in O 0 1.107458800220229e-07
10 O 0 3.6613164411392063e-07
( O 0 2.8234137516847113e-07
43 O 0 3.4180129659944214e-06
% O 0 1.2497276884460007e-06
) O 0 1.5470458265554043e-06
tumors B-Disease 1 0.9999920129776001
establishes O 0 7.014689617790282e-05
PTEN O 0 0.001202652812935412
/ O 0 4.7022556827869266e-05
MMAC1 O 0 3.2945958082564175e-05
as O 0 1.38769024715657e-07
a O 0 2.366044071777651e-07
main O 0 1.3711807014260557e-06
inactivation O 0 1.2348285963525996e-05
target O 0 2.9373475740612776e-07
of O 0 7.182043049169806e-08
10q O 0 7.80117443355266e-06
loss O 0 4.428466581885004e-06
in O 0 6.827321612945525e-06
sporadic B-Disease 1 0.9992332458496094
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.543332918023225e-06
. O 0 4.953428287990391e-06

Risk O 0 0.0010570004815235734
reversals O 0 0.0002268430107505992
in O 0 3.1687732189311646e-06
predictive O 0 2.8765432944055647e-05
testing O 0 1.0563860087131616e-05
for O 0 2.8493393983808346e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.999993085861206
. O 0 2.5744382583070546e-05

The O 0 6.400875918188831e-06
first O 0 2.4541197944927262e-06
predictive O 0 1.3658436728292145e-05
testing O 0 3.1160070648184046e-06
for O 0 9.65558774623787e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999399185180664
( O 0 1.777336706254573e-06
HD B-Disease 0 0.002981276251375675
) O 0 6.634871283495158e-07
was O 0 3.2595853554084897e-06
based O 0 2.0362679720165033e-07
on O 0 2.3122709080780623e-07
analysis O 0 9.495280295368502e-08
of O 0 2.0427014746360328e-08
linked O 0 4.343579348642379e-06
polymorphic O 0 6.386504082911415e-06
DNA O 0 2.536198053348926e-06
markers O 0 1.8911855477199424e-06
to O 0 5.1174087190020145e-08
estimate O 0 1.1241110087212292e-06
the O 0 3.8298683335824535e-08
likelihood O 0 1.683225860915627e-07
of O 0 3.3441104108078434e-08
inheriting O 0 1.0194933111051796e-06
the O 0 2.690299822916131e-07
mutation O 0 2.191203520851559e-06
for O 0 2.725555532379076e-07
HD B-Disease 0 0.00028246085275895894
. O 0 5.678198704117676e-06

Limits O 0 3.524946077959612e-05
to O 0 6.020282512508857e-07
accuracy O 0 3.954528438043781e-06
included O 0 4.080297060227167e-07
recombination O 0 1.6971700915746624e-06
between O 0 1.3568067913638515e-07
the O 0 1.5422891408434225e-07
DNA O 0 3.6306114452600013e-06
markers O 0 9.260274964617565e-06
and O 0 4.20469916662114e-07
the O 0 4.537440929652803e-07
mutation O 0 4.2234737520630006e-06
, O 0 1.822647845983738e-07
pedigree O 0 2.105520252371207e-06
structure O 0 3.949106144318648e-07
, O 0 6.374963845701132e-08
and O 0 4.2862392746201294e-08
whether O 0 3.151565763914732e-08
DNA O 0 3.3171565405609726e-07
samples O 0 6.459565327077144e-08
were O 0 4.1503973591261456e-08
available O 0 1.9182779809057138e-08
from O 0 2.540762800151697e-08
family O 0 2.5607056386434124e-07
members O 0 2.7170119665242964e-07
. O 0 1.2082283546988037e-06

With O 0 4.526706106844358e-06
direct O 0 1.6158318203451927e-06
tests O 0 4.6372267092920083e-07
for O 0 4.194734160023472e-08
the O 0 1.337303530135614e-07
HD B-Disease 0 0.0006086032371968031
mutation O 0 1.386382223245164e-06
, O 0 3.496758793630761e-08
we O 0 9.555286339946178e-09
have O 0 1.4926463620668073e-08
assessed O 0 9.50747747197056e-08
the O 0 2.9052529271211824e-08
accuracy O 0 3.0954931844462408e-06
of O 0 6.374379779572337e-08
results O 0 3.758895559258235e-07
obtained O 0 6.654681072859603e-08
by O 0 1.842166952314983e-08
linkage O 0 1.2303536323088338e-06
approaches O 0 6.874662972222723e-07
when O 0 6.185878476117068e-08
requested O 0 7.844705862680712e-08
to O 0 1.861948817349912e-08
do O 0 1.883861067142334e-08
so O 0 8.563130649008599e-09
by O 0 9.693531310972503e-09
the O 0 5.95970242045496e-08
test O 0 8.046888524404494e-07
individuals O 0 2.8427996312530013e-07
. O 0 1.6589717688475503e-06

For O 0 2.051529691016185e-06
six O 0 1.0365776006437954e-06
such O 0 5.8323266216575576e-08
individuals O 0 4.610943449279148e-08
, O 0 4.719974100453328e-08
there O 0 3.5945838305906364e-08
was O 0 1.3310095710039604e-06
significant O 0 1.664497943920651e-07
disparity O 0 1.4030655393071356e-06
between O 0 1.1466501348422753e-07
the O 0 2.799556284571736e-07
tests O 0 1.7443436490793829e-06
. O 0 1.5549265981462668e-06

Three O 0 2.4227145331678912e-05
went O 0 4.342291049397318e-06
from O 0 1.3925104269674193e-07
a O 0 4.5490526190405944e-07
decreased O 0 2.6461582820047624e-05
risk O 0 5.386134489526739e-07
to O 0 1.540386307397057e-08
an O 0 4.95901666397458e-08
increased O 0 3.0822634471405763e-06
risk O 0 1.0110150014952524e-06
, O 0 3.7625603965807386e-08
while O 0 1.237971325451781e-08
in O 0 1.114465852936064e-08
another O 0 4.475161929917704e-08
three O 0 7.561438053471647e-08
the O 0 4.4557557998814445e-07
risk O 0 3.2269820167130092e-06
was O 0 2.71941717073787e-05
decreased O 0 1.788080953701865e-05
. O 0 2.3997224616323365e-06

Knowledge O 0 9.382119060319383e-06
of O 0 3.0380198268176173e-07
the O 0 2.1206592748512776e-07
potential O 0 2.540213586144091e-07
reasons O 0 6.903268712221688e-08
for O 0 1.137811000972988e-08
these O 0 9.853170723772564e-09
changes O 0 4.874801717846822e-08
in O 0 5.375707701205101e-08
results O 0 3.2479567835252965e-07
and O 0 1.4557160454842233e-07
impact O 0 5.410589665189036e-08
of O 0 1.154435658179409e-08
these O 0 3.3845239499896707e-08
risk O 0 2.317834599807611e-07
reversals O 0 1.2049304132233374e-06
on O 0 1.4082548887017765e-06
both O 0 5.907737659072154e-07
patients O 0 4.649621700991702e-07
and O 0 7.623897602115903e-08
the O 0 4.640880746364928e-08
counseling O 0 1.592853067222677e-07
team O 0 2.8406171637129773e-08
can O 0 1.7795464657410776e-08
assist O 0 1.8943389079595363e-08
in O 0 1.0645104353557144e-08
the O 0 1.2456525588788736e-08
development O 0 1.054201614891781e-08
of O 0 5.120872170749635e-09
strategies O 0 7.796109002811136e-08
for O 0 7.69782992904311e-09
the O 0 4.5570160978058993e-08
prevention O 0 1.2077146038791398e-06
and O 0 3.156125956138567e-07
, O 0 4.5692182482071075e-08
where O 0 3.855851815615097e-08
necessary O 0 3.763335598705453e-08
, O 0 2.0660392507920733e-08
management O 0 1.5832958055739255e-08
of O 0 5.767652577759463e-09
a O 0 6.283202083068318e-07
risk O 0 7.842197646823479e-07
reversal O 0 1.1979343526036246e-06
in O 0 5.434169736417971e-08
any O 0 4.84242299592097e-08
predictive O 0 1.8634891603142023e-06
testing O 0 6.141715971352824e-07
program O 0 8.562151947444363e-07
. O 0 3.0190386723916163e-07
. O 0 2.2129472654341953e-06

A O 0 9.765914728632197e-05
novel O 0 3.995235965703614e-05
common O 0 1.1930892469536047e-05
missense O 0 0.00030119557050056756
mutation O 0 2.69318788923556e-05
G301C O 0 6.808011221437482e-06
in O 0 1.5604840086780314e-07
the O 0 1.932369144697077e-07
N O 0 3.568849933799356e-05
- O 0 2.2488560716737993e-05
acetylgalactosamine O 0 2.2813634132035077e-05
- O 0 2.3884322217782028e-05
6 O 0 1.9730305211851373e-06
- O 0 1.854415677371435e-05
sulfate O 0 2.0507650333456695e-05
sulfatase O 0 4.916110265185125e-05
gene O 0 4.461259322852129e-06
in O 0 7.663347787456587e-07
mucopolysaccharidosis B-Disease 0 0.00023131117632146925
IVA I-Disease 0 0.2068728655576706
. O 0 2.7401256375014782e-05

Mucopolysaccharidosis B-Disease 0 0.45346689224243164
IVA I-Disease 1 0.9997801184654236
( O 0 0.02569732815027237
MPS B-Disease 1 0.9999963045120239
IVA I-Disease 1 1.0
) O 0 1.1081810953328386e-05
is O 0 1.1238881825192948e-06
an O 0 7.829622518329415e-06
autosomal B-Disease 1 0.9998606443405151
recessive I-Disease 1 0.9999752044677734
lysosomal I-Disease 1 0.9999508857727051
storage I-Disease 1 0.9999895095825195
disorder I-Disease 1 0.9999978542327881
caused O 0 0.000780259317252785
by O 0 1.7108758356698672e-06
a O 0 0.002414451679214835
genetic B-Disease 1 0.9999996423721313
defect I-Disease 1 0.9999508857727051
in O 0 2.089740746669122e-06
N O 0 7.700425339862704e-05
- O 0 2.543914524721913e-05
acetylgalactosamine O 0 6.660845247097313e-05
- O 0 8.032295590965077e-05
6 O 0 1.3420780305750668e-05
- O 0 0.00014279411698225886
sulfate O 0 0.00021664130326826125
sulfatase O 0 0.00018599028408061713
( O 0 2.183427113777725e-06
GALNS O 0 6.764313002349809e-05
) O 0 2.111379671987379e-06
. O 0 3.544986611814238e-06

In O 0 4.6011837184778415e-06
previous O 0 2.95060385724355e-06
studies O 0 5.259183808448142e-07
, O 0 1.2653477199364715e-07
we O 0 3.0645519899508145e-08
have O 0 2.769246698619554e-08
found O 0 6.566170895894174e-08
two O 0 8.743844404079937e-08
common O 0 2.2208967038750416e-06
mutations O 0 5.150470769876847e-06
in O 0 1.3585287206296925e-07
Caucasians O 0 5.268282166071003e-06
and O 0 8.145626111399906e-07
Japanese O 0 8.111710485536605e-07
, O 0 1.971103671394303e-07
respectively O 0 1.9524431991158053e-06
. O 0 1.401979488946381e-06

To O 0 8.104766493488569e-06
characterize O 0 2.9600138077512383e-05
the O 0 2.0620550458261278e-06
mutational O 0 0.0005504856817424297
spectrum O 0 3.2593266951153055e-05
in O 0 9.093926678360731e-08
various O 0 3.65131569424193e-08
ethnic O 0 4.402765227951022e-07
groups O 0 1.1672035782339663e-07
, O 0 8.995302636094493e-08
mutations O 0 4.814605745195877e-07
in O 0 2.147750777226065e-08
the O 0 8.104613868908928e-08
GALNS O 0 2.0482279069256037e-05
gene O 0 5.486660370479512e-07
in O 0 1.9032815146147186e-07
Colombian O 0 6.976776785450056e-05
MPS B-Disease 1 0.9997158646583557
IVA I-Disease 1 1.0
patients O 0 0.0007197767845354974
were O 0 2.8804870453313924e-06
investigated O 0 1.921528109960491e-06
, O 0 9.373280107638493e-08
and O 0 2.577149302851467e-07
genetic O 0 1.2050315945089096e-06
backgrounds O 0 4.040428507323668e-07
were O 0 9.739142825537783e-08
extensively O 0 2.5046716700671823e-07
analyzed O 0 3.639023873347469e-07
to O 0 3.580453622475943e-08
identify O 0 2.1618402001877257e-07
racial O 0 1.0636933893692913e-06
origin O 0 1.057238492307988e-07
, O 0 2.9254263012035153e-08
based O 0 7.146842051497515e-08
on O 0 2.5967281658267893e-07
mitochondrial O 0 5.5713476285745855e-06
DNA O 0 8.254511158156674e-06
( O 0 6.327983896881051e-07
mtDNA O 0 4.376151991891675e-06
) O 0 7.191844133558334e-07
lineages O 0 6.69187420498929e-06
. O 0 2.4181520075217122e-06

Three O 0 2.666700675035827e-05
novel O 0 5.523577783606015e-05
missense O 0 0.002232298953458667
mutations O 0 0.0002903927525039762
never O 0 9.9050184871885e-06
identified O 0 2.601795131340623e-06
previously O 0 1.1337446039760835e-06
in O 0 6.448117773061313e-08
other O 0 3.479162202779662e-08
populations O 0 2.1352158796617005e-07
and O 0 1.6208062447731209e-07
found O 0 1.5215933046874852e-07
in O 0 7.41672820936401e-08
16 O 0 1.7289299591993768e-07
out O 0 3.191331643392914e-08
of O 0 3.097643386240634e-08
19 O 0 3.6072874536330346e-06
Colombian O 0 1.7961614503292367e-05
MPS B-Disease 1 0.9573455452919006
IVA I-Disease 1 0.9999746084213257
unrelated O 0 2.9353976060519926e-05
alleles O 0 3.5874581953976303e-06
account O 0 5.273698207020061e-07
for O 0 2.783471302336693e-07
84 O 0 1.527872336737346e-05
. O 0 4.1705879993969575e-06

2 O 0 0.00026652083033695817
% O 0 5.695618710888084e-06
of O 0 9.574153381208816e-08
the O 0 1.8204990226422524e-07
alleles O 0 5.215017608861672e-07
in O 0 8.718679822550257e-08
this O 0 1.5276040699063742e-07
study O 0 8.491318226333533e-07
. O 0 2.9750933663308388e-06

The O 0 1.6897098248591647e-05
G301C O 0 0.00012526105274446309
and O 0 2.283661842739093e-06
S162F O 0 4.372252442408353e-05
mutations O 0 7.947778613015544e-06
account O 0 4.020924109227053e-07
for O 0 2.6406937081446813e-07
68 O 0 2.0934485291945748e-05
. O 0 4.5354563553701155e-06

4 O 0 0.0009564579231664538
% O 0 2.326415960851591e-05
and O 0 1.4035755384611548e-06
10 O 0 3.2765026389824925e-06
. O 0 3.051020712518948e-06

5 O 0 0.00023838004563003778
% O 0 5.577806859946577e-06
of O 0 1.9762893543884275e-07
mutations O 0 7.783562068652827e-06
, O 0 2.1868039823402796e-07
respectively O 0 1.2513867204688722e-06
, O 0 4.435333167407407e-08
whereas O 0 1.1660230825327744e-07
the O 0 5.98564113829525e-08
remaining O 0 1.8202904357167426e-06
F69V O 0 6.275733903748915e-05
is O 0 1.0120039206640286e-07
limited O 0 4.097492833921024e-08
to O 0 2.182043346010687e-08
a O 0 2.8669353469013004e-07
single O 0 5.3058952289575245e-06
allele O 0 1.478221111028688e-05
. O 0 2.903629820139031e-06

The O 0 1.6671170669724233e-05
skewed O 0 8.064760913839564e-05
prevalence O 0 8.068930765148252e-05
of O 0 1.7318970435553638e-07
G301C O 0 7.122107945178868e-06
in O 0 1.7045051947661705e-07
only O 0 8.594715694698607e-08
Colombian O 0 4.327057467889972e-06
patients O 0 1.174607405118877e-06
and O 0 1.9871032463925076e-07
haplotype O 0 1.3844671229890082e-05
analysis O 0 7.507346566626438e-08
by O 0 3.140141302537813e-08
restriction O 0 5.57057546757278e-07
fragment O 0 3.5950956771557685e-06
length O 0 9.95021855487721e-06
polymorphisms O 0 2.6608022380969487e-05
in O 0 3.8244660771624694e-08
the O 0 1.0718739673620803e-07
GALNS O 0 2.6537571102380753e-05
gene O 0 4.827087423109333e-07
suggest O 0 2.1793944426917733e-07
that O 0 3.1602457539747775e-08
G301C O 0 2.199941263825167e-06
originated O 0 3.167239981394232e-07
from O 0 2.6262446439773157e-08
a O 0 2.570776871380076e-07
common O 0 8.901217825041385e-07
ancestor O 0 5.668956873705611e-06
. O 0 4.740129043057095e-06

Investigation O 0 4.319932122598402e-05
of O 0 7.922956797301595e-07
the O 0 7.953207727950939e-07
genetic O 0 4.365264430816751e-06
background O 0 2.1747819118900225e-06
by O 0 4.70368952676381e-08
means O 0 6.227573123851471e-08
of O 0 1.6230234933800602e-08
mtDNA O 0 1.0212595498160226e-06
lineages O 0 4.835823688154051e-07
indicate O 0 2.0089281349555677e-07
that O 0 1.037200636488933e-08
all O 0 8.28720558843088e-09
our O 0 1.1217042583666625e-07
patients O 0 2.9106587362548453e-07
are O 0 1.4617782539971813e-08
probably O 0 6.484056314093323e-08
of O 0 2.8378444483223575e-08
native O 0 1.5564799014100572e-06
American O 0 1.003468696580967e-05
descent O 0 0.00033313583116978407

Low O 0 0.0004583526460919529
frequency O 0 6.93028123350814e-05
of O 0 3.171850949001964e-06
BRCA1 O 0 0.0019178020302206278
germline O 0 0.0004720240249298513
mutations O 0 1.8249456843477674e-05
in O 0 8.270232569884683e-07
45 O 0 1.1661064490908757e-05
German O 0 0.12948910892009735
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.1104885895038024e-05
. O 0 6.2361946220335085e-06

In O 0 7.593358077429002e-06
this O 0 2.73514274340414e-07
study O 0 1.8363614628924552e-07
we O 0 6.240986039074414e-08
investigated O 0 5.715843371945084e-07
45 O 0 1.6661510926496703e-06
German O 0 0.030757751315832138
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.775544319571054e-06
for O 0 3.114867013209732e-07
germline O 0 0.00016713159857317805
mutations O 0 4.679114226746606e-06
in O 0 1.541925911396902e-07
the O 0 1.1091526630480075e-06
BRCA1 O 0 0.00017153621593024582
gene O 0 2.5419283701921813e-05
. O 0 8.259960850409698e-06

We O 0 1.3973121895105578e-05
identified O 0 1.1525715308380313e-05
four O 0 1.6183824982363149e-06
germline O 0 0.00017997308168560266
mutations O 0 1.788711961125955e-05
in O 0 3.475538505881559e-07
three O 0 4.3615666072582826e-05
breast B-Disease 1 0.9999910593032837
cancer I-Disease 0 0.3841291069984436
families O 0 9.058418868335139e-07
and O 0 2.6011500153799716e-07
in O 0 3.1157020430327975e-07
one O 0 2.2556154362973757e-05
breast B-Disease 1 0.999998927116394
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.654811047861585e-06
. O 0 1.22087968179585e-07
among O 0 3.220413091753471e-08
these O 0 1.502403357278581e-08
were O 0 2.1559435481321998e-07
one O 0 3.798912189267867e-07
frameshift O 0 0.0002996925904881209
mutation O 0 4.439041731529869e-06
, O 0 5.5949925581444404e-08
one O 0 1.486252045879155e-07
nonsense O 0 1.5557598089799285e-05
mutation O 0 5.066158792033093e-06
, O 0 6.46392805947471e-08
one O 0 3.945988069631312e-08
novel O 0 9.38460061661317e-07
splice O 0 6.43397870589979e-05
site O 0 1.758485632308293e-05
mutation O 0 4.082946361450013e-06
, O 0 1.0893102597719917e-07
and O 0 2.6577754397294484e-07
one O 0 9.302595458393625e-07
missense O 0 0.00026725264615379274
mutation O 0 4.163011544733308e-05
. O 0 5.060610419604927e-06

The O 0 2.3885120754130185e-05
missense O 0 0.0034970794804394245
mutation O 0 0.00018300082592759281
was O 0 1.6625479474896565e-05
also O 0 1.2917785170429852e-06
found O 0 2.4865835257514846e-07
in O 0 2.9036695536888146e-07
2 O 0 1.0163375009142328e-05
. O 0 4.663540039473446e-06

8 O 0 0.0006538236048072577
% O 0 6.585225037269993e-06
of O 0 5.204007536008248e-08
the O 0 7.053751005514641e-08
general O 0 1.397448698980952e-07
population O 0 7.529473577960744e-08
, O 0 3.376425183887477e-08
suggesting O 0 1.3394949860412453e-07
that O 0 1.6856249729357842e-08
it O 0 4.838702238885162e-08
is O 0 2.698357661756745e-07
not O 0 9.439309565095755e-07
disease O 0 2.5309514967375435e-05
associated O 0 2.8584115625562845e-06
. O 0 4.290004198992392e-06

The O 0 1.5804791473783553e-05
average O 0 3.0115041226963513e-05
age O 0 1.6121837234095437e-06
of O 0 3.695181192142627e-07
disease O 0 0.00010708619811339304
onset O 0 0.0002725193917285651
in O 0 7.878757060097996e-07
those O 0 4.0283626390191785e-07
families O 0 1.650897388572048e-06
harbouring O 0 0.00021243681840132922
causative O 0 0.0001552555477246642
mutations O 0 5.051891639595851e-05
was O 0 4.51607274953858e-06
between O 0 1.028848373607616e-06
32 O 0 8.021788744372316e-06
. O 0 3.3353821891068947e-06

3 O 0 0.00028054940048605204
and O 0 1.3030918125878088e-05
37 O 0 5.264158244244754e-05
. O 0 9.055318514583632e-06

4 O 0 0.0002236006985185668
years O 0 3.0245823836594354e-06
, O 0 1.7681453812201653e-07
whereas O 0 1.9012080088032235e-07
the O 0 6.76761686690952e-08
family O 0 3.621609323545272e-07
harbouring O 0 8.394725227844901e-06
the O 0 3.7823699017280887e-07
missense O 0 4.721694131148979e-05
mutation O 0 2.4967946501419647e-06
had O 0 8.359281196135271e-07
an O 0 1.1780880981859809e-07
average O 0 2.0095253603358287e-06
age O 0 1.5879479065006308e-07
of O 0 3.376096913143556e-08
onset O 0 1.7824388123699464e-05
of O 0 2.8664268825195904e-07
51 O 0 1.78538521140581e-05
. O 0 2.124536877090577e-06

2 O 0 0.0006752904155291617
years O 0 5.397411223384552e-05
. O 0 2.5738734620972537e-05

These O 0 6.5377307691960596e-06
findings O 0 5.798075562779559e-06
show O 0 3.171373236909858e-06
that O 0 2.9703002724090766e-07
BRCA1 O 0 5.845492341904901e-05
is O 0 2.803504912662902e-07
implicated O 0 1.3541583712139982e-06
in O 0 9.309619031228067e-08
a O 0 2.3979603724910703e-07
small O 0 1.1562078583438051e-07
fraction O 0 3.590825770061201e-07
of O 0 9.603376156519516e-07
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.174589664922678e-06
suggesting O 0 5.403667842074356e-07
the O 0 5.037820827169526e-08
involvement O 0 2.47634119432405e-07
of O 0 6.047148559673587e-08
another O 0 1.3783234180664294e-06
susceptibility O 0 0.0002735573216341436
gene O 0 1.1913439266209025e-05
( O 0 3.7812767459399765e-06
s O 0 0.00019330640498083085
) O 0 1.0278862646373454e-05

Paternal O 1 0.5462242960929871
transmission O 1 0.9620203971862793
of O 0 0.001788581837899983
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0008959851111285388

We O 0 1.140776657848619e-05
report O 0 1.1074076837758184e-06
a O 0 5.534910769711132e-07
rare O 0 1.3373536376093398e-06
case O 0 2.5556801119819283e-06
of O 0 2.6939942472381517e-06
paternally O 1 0.9995424747467041
transmitted O 1 0.9999959468841553
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.3782850503921509
DM B-Disease 1 1.0
) O 0 4.627062298823148e-05
. O 0 1.3853176824341062e-05

The O 0 1.307788807025645e-05
proband O 0 9.337822848465294e-05
is O 0 3.2020756179917953e-07
a O 0 5.98313079080981e-07
23 O 0 3.883470071741613e-06
year O 0 2.165789965147269e-07
old O 0 2.6099707611138e-05
, O 0 2.0427505660336465e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.05667370557785034
who O 0 0.0013997536152601242
suffers O 1 0.9951850771903992
severe O 1 0.9953058362007141
muscular B-Disease 1 0.9999902248382568
weakness I-Disease 1 0.960128128528595
. O 0 2.1125049897818826e-05

He O 0 7.673903019167483e-05
presented O 0 9.504487024969421e-06
with O 0 9.190262062475085e-06
respiratory O 1 0.9340505599975586
and O 0 1.6571120795561e-05
feeding O 0 2.6278357836417854e-05
difficulties O 0 7.44695989851607e-06
at O 0 1.3020393225815496e-06
birth O 0 3.096689761150628e-05
. O 0 4.534946128842421e-06

His O 0 0.00012854898523073643
two O 0 4.86255157738924e-05
sibs O 1 0.6121803522109985
suffer O 0 0.0007564169936813414
from O 0 4.3361005737097e-06
childhood O 0 0.0006892671808600426
onset O 1 0.9948764443397522
DM B-Disease 1 0.9999998807907104
. O 0 0.0001265234313905239

Their O 0 2.2959604393690825e-05
late O 0 2.6279611120116897e-05
father O 0 5.32546346221352e-06
had O 0 1.263319745703484e-06
the O 0 6.417333509034506e-08
adult O 0 6.225394031389442e-07
type O 0 4.65888035705575e-07
of O 0 4.2115297560485487e-07
DM B-Disease 1 1.0
, O 0 1.3240678526926786e-06
with O 0 2.1581776366019767e-07
onset O 0 3.24178472510539e-05
around O 0 2.748535905539029e-07
30 O 0 9.131676961260382e-07
years O 0 5.337797119864263e-07
. O 0 1.4240343944038614e-06

Only O 0 4.534638719633222e-06
six O 0 1.190449779642222e-06
other O 0 6.658642348611465e-08
cases O 0 5.6800235626042195e-08
of O 0 4.489413285568844e-08
paternal O 0 0.0003816224343609065
transmission O 0 0.023792415857315063
of O 0 2.5724086299305782e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 4.639761391445063e-05
been O 0 8.223851182265207e-06
reported O 0 1.3711004612559918e-05
recently O 0 1.1191701560164802e-05
. O 0 3.5408443181950133e-06

We O 0 6.08027721682447e-06
review O 0 1.8925820768345147e-06
the O 0 2.2550783285169018e-07
sex O 0 1.6882784166227793e-06
related O 0 1.681568051026261e-06
effects O 0 1.6478128600283526e-05
on O 0 2.4597793526481837e-05
transmission O 0 0.012204021215438843
of O 0 3.5180819395463914e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.00011738898319890723

Decreased O 0 0.0037439814768731594
fertility O 0 7.830186950741336e-05
of O 0 4.424045698669943e-07
males O 0 9.246263630302565e-07
with O 0 2.6479591497263755e-07
adult O 0 7.502931839553639e-05
onset O 1 0.9361253380775452
DM B-Disease 1 1.0
and O 0 1.1207135685253888e-05
contraction O 0 2.9398852348094806e-05
of O 0 2.4024645384201904e-08
the O 0 9.564006120399426e-08
repeat O 0 1.9744932160392636e-06
upon O 0 1.2499346269123635e-07
male O 0 1.458772317164403e-06
transmission O 0 3.0304956908366876e-06
contribute O 0 4.1492814517596344e-08
to O 0 1.417268880032907e-08
the O 0 5.96772125049938e-08
almost O 0 2.004140355893469e-07
absent O 0 9.188204899146513e-07
occurrence O 0 6.943166681594448e-07
of O 0 1.4955594451748766e-07
paternal O 0 0.00017850838776212186
transmission O 0 0.005437639541924
of O 0 5.770451025455259e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 8.046886068768799e-05

Also O 0 3.986368756159209e-05
the O 0 5.246434398031852e-07
fathers O 0 5.80987091325369e-07
of O 0 4.184952828722999e-08
the O 0 4.6227438588175573e-07
reported O 0 3.344896686030552e-05
congenitally O 0 0.0004828154342249036
affected O 0 1.9846538634737954e-06
children O 0 1.3048920664004982e-06
showed O 0 6.427674634323921e-06
, O 0 6.52240856879871e-08
on O 0 4.776222226610116e-07
average O 0 8.414180570071039e-07
, O 0 1.1059326254780899e-07
shorter O 0 4.47182219431852e-06
CTG O 0 1.540460652904585e-05
repeat O 0 3.4767128909152234e-06
lengths O 0 9.001614671433344e-05
and O 0 6.473231337622565e-07
hence O 0 6.873810889373999e-07
less O 0 2.679055057797086e-07
severe O 0 0.0002421658718958497
clinical O 0 0.00013565679546445608
symptoms O 0 0.00031032098922878504
than O 0 5.250437951076492e-08
the O 0 1.2674624372266408e-07
mothers O 0 5.796599111818068e-07
of O 0 3.819538463289973e-08
children O 0 3.878551069647074e-06
with O 0 9.982498158933595e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 5.7215849665226415e-05

We O 0 1.3113194654579274e-05
conclude O 0 6.146682153485017e-06
that O 0 3.5652780638883996e-07
paternal O 0 9.456400584895164e-05
transmission O 0 0.008905204012989998
of O 0 3.9724418456899e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.218404501443729e-05
rare O 0 2.667523631316726e-06
and O 0 1.5461342854905524e-06
preferentially O 0 1.952560523932334e-06
occurs O 0 1.4948065540920652e-07
with O 0 3.326076480902884e-08
onset O 0 1.542098107165657e-05
of O 0 2.392624196545512e-07
DM B-Disease 1 0.9999998807907104
past O 0 5.873278951185057e-06
30 O 0 5.821257218485698e-07
years O 0 4.5585114349933065e-08
in O 0 1.900070856208913e-08
the O 0 1.345493245707985e-07
father O 0 1.2219881000419264e-06
. O 0 2.3448210129117797e-07
. O 0 1.2061423149134498e-06

The O 0 8.56713522807695e-05
RB1 O 0 0.00834593828767538
gene O 0 8.821169467410073e-05
mutation O 0 3.632198422565125e-05
in O 0 4.898233214589709e-07
a O 0 2.0395070805534488e-06
child O 0 7.234148506540805e-05
with O 0 2.6002026061178185e-05
ectopic B-Disease 1 0.9999996423721313
intracranial I-Disease 1 0.9999984502792358
retinoblastoma I-Disease 1 0.9878199100494385
. O 0 0.000111914545414038

The O 0 5.581653749686666e-05
RB1 O 0 0.007940119132399559
gene O 0 9.644282545195892e-05
mutation O 0 5.31173063791357e-05
was O 0 6.974849384278059e-06
investigated O 0 1.8442503915139241e-06
in O 0 1.913064551217758e-07
a O 0 5.021520792070078e-06
child O 0 3.277051291661337e-05
with O 0 7.150583314796677e-06
ectopic B-Disease 1 0.9999982118606567
intracranial I-Disease 1 0.9995796084403992
retinoblastoma I-Disease 0 0.0014924207935109735
using O 0 2.3006116407486843e-06
DNA O 0 4.6010873120394535e-06
obtained O 0 1.5724141633199906e-07
from O 0 2.2469116345291695e-08
both O 0 5.4325948184441586e-08
the O 0 4.341995349932404e-07
pineal B-Disease 0 0.0002738417242653668
and I-Disease 0 7.099204231053591e-05
retinal I-Disease 1 0.9983236193656921
tumours I-Disease 1 1.0
of O 0 4.1018333263309614e-07
the O 0 4.262923994247103e-06
patient O 0 0.0001004186415229924
. O 0 5.28973896507523e-06

A O 0 0.00030132971005514264
nonsense O 0 0.0004809789243154228
mutation O 0 5.448765296023339e-05
in O 0 8.935126629694423e-07
exon O 0 5.1402788812993094e-05
17 O 0 8.646145033708308e-06
( O 0 4.2768235175572045e-07
codon O 0 2.0329125618445687e-06
556 O 0 1.135615548264468e-06
) O 0 5.3775227826236005e-08
of O 0 1.3516660679613324e-08
the O 0 2.2578714720111748e-07
RB1 O 0 8.034035272430629e-05
gene O 0 5.694965921065887e-07
was O 0 3.1023112114780815e-06
found O 0 6.009285868913139e-08
to O 0 3.21246815815357e-08
be O 0 4.942482334513443e-08
present O 0 6.648996730973522e-08
homozygously O 0 3.0772705486015184e-06
in O 0 4.511164064524564e-08
both O 0 7.201769136599978e-08
the O 0 2.2426094403726893e-07
retinal B-Disease 0 0.0003316935617476702
and I-Disease 0 3.2162315619643778e-06
the I-Disease 0 1.5654548406018876e-05
pineal I-Disease 1 0.5696361064910889
tumours I-Disease 1 0.9999996423721313
. O 0 2.494585896783974e-05

The O 0 4.271681518730475e-06
same O 0 2.833017788361758e-06
mutation O 0 7.726171133981552e-06
was O 0 1.3502908586815465e-06
present O 0 9.503814624167717e-08
heterozygously O 0 8.068065653787926e-06
in O 0 6.798732243851191e-08
the O 0 7.377674648978427e-08
DNA O 0 7.049425789773522e-07
from O 0 1.1394919674501125e-08
the O 0 1.8528547585106026e-08
constitutional O 0 2.5182421836689173e-07
cells O 0 9.868220729458699e-08
of O 0 4.361731420488013e-09
the O 0 8.189707756400821e-08
patient O 0 2.1506466509890743e-06
, O 0 9.985382831700917e-08
proving O 0 3.394273164758488e-07
it O 0 1.6156571192027513e-08
to O 0 1.7587401757168664e-08
be O 0 4.0262499112486694e-08
of O 0 1.3330569004210702e-07
germline O 0 2.2751146389055066e-05
origin O 0 1.8996215658262372e-06
. O 0 3.6459925922827097e-06

The O 0 7.1926724558579735e-06
initial O 0 1.5720674127805978e-05
mutation O 0 1.914327913254965e-05
was O 0 7.6770511441282e-06
shown O 0 4.7344227027679153e-07
to O 0 4.1483001922415497e-08
have O 0 2.6518966933508636e-07
occurred O 0 9.50251660469803e-07
in O 0 1.072409787639117e-07
the O 0 8.532286415174895e-07
paternally O 0 0.00010350393131375313
derived O 0 1.0106214176630601e-05
RB1 O 0 0.0005281671765260398
allele O 0 6.86008352204226e-05
. O 0 9.709505320643075e-06

The O 0 2.5959308914025314e-05
mutation O 0 3.8113204936962575e-05
is O 0 2.4208875970543886e-07
in O 0 3.444365859195386e-08
an O 0 7.305420268721718e-08
area O 0 4.458914020233351e-07
of O 0 1.4463829245414672e-08
the O 0 7.597942186521323e-08
gene O 0 2.316000546898067e-07
that O 0 2.111047869846061e-08
encodes O 0 2.2632265483935043e-07
the O 0 6.05053998015137e-08
protein O 0 3.5289943411953573e-07
- O 0 2.4411556296399795e-06
binding O 0 2.3647265834370046e-07
region O 0 3.6398535030457424e-07
known O 0 2.0462019278966181e-07
as O 0 3.663320669033965e-08
the O 0 7.365259335756491e-08
pocket O 0 0.010826769284904003
region O 0 2.5242102310585324e-06
and O 0 3.3023340506588283e-07
has O 0 1.104873831536679e-06
been O 0 6.514899268950103e-07
detected O 0 4.327229419232026e-07
in O 0 1.8696571402188056e-08
other O 0 1.6691387827449944e-08
cases O 0 9.718916516021636e-08
of O 0 1.2051242492816527e-07
retinoblastoma B-Disease 0 0.00010428121458971873
. O 0 6.442216999857919e-07
. O 0 3.353185093146749e-06

Low O 0 0.000539748405572027
levels O 0 7.194627869466785e-06
of O 0 2.1541350747611432e-07
beta O 0 7.067708907015913e-07
hexosaminidase O 0 3.4906795463029994e-06
A O 0 5.119165962241823e-07
in O 0 2.414450079868402e-07
healthy O 0 1.3067027566648903e-06
individuals O 0 6.969125365685613e-08
with O 0 3.594751945001917e-07
apparent O 0 0.0655379667878151
deficiency O 0 0.004437094088643789
of O 0 5.374446843120495e-08
this O 0 3.062390590002906e-07
enzyme O 0 1.2807916391466279e-05
. O 0 3.5606437904789345e-06

Appreciable O 0 0.0005406202981248498
beta O 0 8.30992721603252e-05
hexosaminidase O 0 0.00015620827616658062
A O 0 1.4283227756095584e-05
( O 0 6.416036057999008e-07
hex O 0 1.4439855476666708e-05
A O 0 3.0337080261233496e-06
) O 0 9.774613118906927e-08
activity O 0 1.1324506488108455e-07
has O 0 7.554186964853216e-08
been O 0 1.3799962061966653e-07
detected O 0 5.198818939788907e-07
in O 0 2.2104616448359593e-07
cultured O 0 4.231495040585287e-05
skin O 0 0.10113943368196487
fibroblasts O 0 2.1074805772514082e-05
and O 0 2.519476765883155e-05
melanoma B-Disease 1 0.9738510847091675
tissue O 0 5.238358426140621e-05
from O 0 2.481040439761273e-07
healthy O 0 1.1391430234652944e-06
individuals O 0 5.976423267384234e-08
previously O 0 1.4230203078113846e-06
reported O 0 9.419423804502003e-06
as O 0 2.1334908524295315e-06
having O 0 0.00014467269647866488
deficiency B-Disease 0 4.9890873924596235e-05
of I-Disease 0 1.4375709511682544e-08
hex I-Disease 0 1.7519692846690305e-05
A I-Disease 0 5.354315817385213e-07
activity O 0 2.277225803481997e-07
indistinguishable O 0 1.787903016747805e-07
from O 0 1.1861979842819892e-08
that O 0 1.2390082737567809e-08
of O 0 5.965194560531017e-08
patients O 0 5.798446636617882e-06
with O 0 0.00012544920900836587
Tay B-Disease 1 1.0
- I-Disease 1 0.9999988079071045
Sachs I-Disease 1 1.0
disease I-Disease 0 0.10513558983802795
( O 0 4.815391093870858e-06
TSD B-Disease 0 0.0008047225419431925
) O 0 4.5965616664034314e-06
. O 0 7.200956588349072e-06

Identification O 0 6.595836021006107e-05
and O 0 4.885375346930232e-06
quantitation O 0 0.000227964817895554
of O 0 3.5591426694736583e-07
hex O 0 0.00016960760694928467
A O 0 3.6913208987243706e-06
, O 0 9.91495312518964e-08
amounting O 0 3.32010614556566e-07
to O 0 1.4680571780445462e-07
3 O 0 3.89345677831443e-06
. O 0 2.6159441404161043e-06

5 O 0 0.0006368221365846694
% O 0 4.738437928608619e-05
- O 0 0.00012060868903063238
6 O 0 2.0951181795680895e-05
. O 0 8.005265044630505e-06

9 O 0 0.00024321382807102054
% O 0 4.967639597452944e-06
of O 0 1.234757576185075e-07
total O 0 3.6431907801670604e-07
beta O 0 7.192626299001859e-07
hexosaminidase O 0 3.857643150695367e-06
activity O 0 3.3115495057245425e-07
, O 0 6.572837918383811e-08
has O 0 1.126444644228286e-07
been O 0 1.4163060768623836e-07
obtained O 0 8.637657344934269e-08
by O 0 1.8275876811912894e-07
cellulose O 0 8.486265141982585e-05
acetate O 0 9.814338409341872e-05
gel O 0 0.0003437713021412492
electrophoresis O 0 0.00011063480633310974
, O 0 6.723088858962001e-07
DEAE O 0 3.061503957724199e-05
- O 0 1.2083633009751793e-05
cellulose O 0 1.2155883268860634e-05
ion O 0 2.5380563783983234e-06
- O 0 3.766304871533066e-06
exchange O 0 3.892058089149941e-07
chromatography O 0 2.785791821224848e-06
, O 0 1.9556544827992184e-07
radial O 0 9.410992788616568e-06
immunodiffusion O 0 1.8488166460883804e-05
, O 0 3.2262263971460925e-07
and O 0 5.170803660803358e-07
radioimmunoassay O 0 8.579251152696088e-05
. O 0 5.408244305726839e-06

Previous O 0 0.00024362534168176353
family O 0 1.1077013368776534e-05
studies O 0 7.28447901110485e-07
suggested O 0 5.880469871044625e-07
that O 0 2.803600729350819e-08
these O 0 1.7006675179231934e-08
individuals O 0 3.0188594735136576e-08
may O 0 3.006035456110112e-07
be O 0 2.6256135043922768e-08
compound O 0 8.437322662757651e-07
heterozygotes O 0 1.6674769085511798e-06
for O 0 1.829508633477417e-08
the O 0 1.3890169725527812e-07
common O 0 1.0432639783175546e-06
mutant O 0 2.9764538339804858e-05
TSD B-Disease 0 0.00010198932432103902
gene O 0 1.332833562628366e-06
and O 0 2.064479929231311e-07
a O 0 7.13971587629203e-07
rare O 0 2.605981762826559e-06
( O 0 1.0520592468310497e-06
allelic O 0 1.8806404114002362e-05
) O 0 1.1052511581510771e-06
mutant O 0 2.9824208468198776e-05
gene O 0 2.0962173948646523e-05
. O 0 8.175095899787266e-06

Thus O 0 3.996138912043534e-05
, O 0 4.942232294524729e-07
the O 0 1.6555027571030223e-07
postulated O 0 3.1072349884198047e-06
rate O 0 1.2954362773598405e-06
mutant O 0 4.150994300289312e-06
gene O 0 4.330821070652746e-07
appears O 0 4.317188029290264e-07
to O 0 1.7179859312932422e-08
code O 0 5.065106734036817e-08
for O 0 7.55320428424966e-09
the O 0 2.8036060584213374e-08
expression O 0 1.200895383135503e-07
of O 0 1.5785857954142557e-08
low O 0 1.272948907171667e-06
amounts O 0 7.873622109855205e-08
of O 0 4.0552279756411735e-08
hex O 0 4.5546432374976575e-05
A O 0 5.741363111155806e-06
. O 0 4.5532642616308294e-06

Heterozygotes O 0 0.0028749750927090645
for O 0 2.838919272107887e-06
the O 0 1.0820125453392393e-06
rare O 0 1.8371373471381958e-06
mutant O 0 7.156682113418356e-05
may O 0 3.060993776671239e-06
be O 0 4.4765961604298354e-08
indistinguishable O 0 9.329862677986966e-07
from O 0 8.731743861289942e-08
heterozygotes O 0 2.841088644345291e-06
for O 0 5.067725439289461e-08
the O 0 3.11934996943819e-07
common O 0 4.11676637668279e-06
TSD B-Disease 0 0.000482007279060781
mutant O 0 0.00014065731375012547
. O 0 9.527084330329672e-06

However O 0 1.2534907909866888e-05
, O 0 3.2664453897268686e-07
direct O 0 2.0807354417229362e-07
visualization O 0 5.268256700219354e-06
and O 0 1.8356171267441823e-06
quantitation O 0 0.0001361175673082471
of O 0 1.3399971976468805e-07
hex O 0 5.08830817125272e-05
A O 0 1.3333675497051445e-06
by O 0 2.1976351405328387e-08
the O 0 2.7189292595153347e-08
methods O 0 5.735599302170158e-07
described O 0 5.162287379789632e-06
may O 0 9.555204769640113e-07
prevent O 0 2.863885697479418e-07
false O 0 1.2666579323195037e-06
- O 0 5.190799492993392e-05
positive O 0 1.2332552614680026e-06
prenatal O 0 6.430439680116251e-05
diagnosis O 0 0.00015850829367991537
of O 0 3.023827446213545e-07
TSD B-Disease 0 0.0008630476077087224
in O 0 1.3540137615564163e-06
fetuses O 0 9.778550156624988e-05
having O 0 3.793155940456927e-07
the O 0 1.327804000084143e-07
incomplete O 0 2.8481204026320484e-06
hex B-Disease 0 0.012513588182628155
A I-Disease 0 0.000705441168975085
deficiency I-Disease 0 0.00016880978364497423
of O 0 8.991388078527507e-09
the O 0 1.3128666864758998e-07
type O 0 1.4952898936826386e-06
described O 0 1.971847495951806e-06
in O 0 5.779879330702897e-08
the O 0 1.657480623862284e-07
four O 0 1.482711581957119e-06
healthy O 0 9.621843673812691e-06
individuals O 0 3.491598590699141e-06

The O 0 7.72154307924211e-05
tumor B-Disease 0 0.0013273300137370825
suppressor O 0 0.0006670289440080523
gene O 0 2.9755568903055973e-05
Smad4 O 0 0.0003664469695650041
/ O 0 0.00011075239308411255
Dpc4 O 0 4.9908336222870275e-05
is O 0 2.8263181661714043e-07
required O 0 5.8707090744292145e-08
for O 0 3.0315423060756075e-08
gastrulation O 0 6.444032351282658e-06
and O 0 1.5300840914278524e-06
later O 0 1.2653672456508502e-06
for O 0 7.354815778626289e-08
anterior O 0 8.638086001155898e-06
development O 0 6.681962361199112e-08
of O 0 3.593747521790647e-08
the O 0 3.3078123351515387e-07
mouse O 0 8.366149268113077e-05
embryo O 0 4.015802187495865e-05
. O 0 5.536564913199982e-06

Mutations O 0 0.0025788082275539637
in O 0 2.2028239072824363e-06
the O 0 1.76860021383618e-06
SMAD4 O 0 0.0009303178521804512
/ O 0 0.0002656587748788297
DPC4 O 0 0.0003417114494368434
tumor B-Disease 0 0.00012502894969657063
suppressor O 0 0.00012367231829557568
gene O 0 2.007749571930617e-06
, O 0 1.5919037821277016e-07
a O 0 2.248592920750525e-07
key O 0 1.218510874423373e-06
signal O 0 6.657614903815556e-06
transducer O 0 6.246236353035783e-06
in O 0 1.0911817582837102e-07
most O 0 1.0212922063601582e-07
TGFbeta O 0 4.516218905337155e-05
- O 0 5.973398219794035e-05
related O 0 6.524176114908187e-07
pathways O 0 2.323727358088945e-06
, O 0 4.910805628810522e-08
are O 0 6.465738611183269e-09
involved O 0 1.6161010307769175e-08
in O 0 4.003949172215471e-08
50 O 0 1.5555896482055687e-07
% O 0 1.9923710681268858e-07
of O 0 3.6915920986757556e-07
pancreatic B-Disease 1 0.9974187612533569
cancers I-Disease 1 0.9836003184318542
. O 0 1.228489327331772e-05

Homozygous O 0 0.017843205481767654
Smad4 O 0 0.0036229174584150314
mutant O 0 0.002407254185527563
mice O 0 0.0887843519449234
die O 0 0.00019257092208135873
before O 0 9.305479125032434e-07
day O 0 9.769196367415134e-07
7 O 0 3.140895387332421e-06
. O 0 1.9656069980555912e-06

5 O 0 6.011995719745755e-05
of O 0 6.404869509424316e-06
embryogenesis O 0 0.00040423692553304136
. O 0 3.227157503715716e-05

Mutant O 0 0.00031255173962563276
embryos O 0 5.329102714313194e-05
have O 0 1.6863956489032716e-06
reduced O 0 8.875575758793275e-07
size O 0 4.4261261678002484e-07
, O 0 1.5881690273999993e-07
fail O 0 4.402211004617129e-07
to O 0 8.501439907604436e-08
gastrulate O 0 1.6817137293401174e-05
or O 0 3.880864767324965e-07
express O 0 1.585375599688632e-07
a O 0 1.134933000912497e-07
mesodermal O 0 3.8007999592082342e-06
marker O 0 9.520517778582871e-06
, O 0 1.4936465220216633e-07
and O 0 3.7815328823853633e-07
show O 0 6.788975952076726e-06
abnormal O 0 2.218055487901438e-05
visceral O 0 5.971655264147557e-05
endoderm O 0 0.00017059488163795322
development O 0 5.2720060921274126e-06
. O 0 6.394652245944599e-06

Growth B-Disease 1 0.9999996423721313
retardation I-Disease 1 0.9999997615814209
of O 0 2.887381924665533e-06
the O 0 2.6667478323361138e-06
Smad4 O 0 0.052688032388687134
- O 0 0.22818982601165771
deficient O 0 8.268577948911116e-05
embryos O 0 2.0594432044163113e-06
results O 0 4.605569188242953e-07
from O 0 4.009374876545735e-08
reduced O 0 8.546293202016386e-07
cell O 0 3.585556441976223e-06
proliferation O 0 3.42512549877938e-07
rather O 0 5.363734700836176e-08
than O 0 3.683534544052236e-08
increased O 0 1.5477837678190554e-06
apoptosis O 0 1.666743446548935e-05
. O 0 2.0136210423515877e-06

Aggregation O 0 0.00018275984621141106
of O 0 4.001092747785151e-06
mutant O 0 8.936799713410437e-05
Smad4 O 0 0.000508476747199893
ES O 0 3.636617475422099e-05
cells O 0 3.32586887452635e-06
with O 0 1.4689464933326235e-07
wild O 0 2.156615209969459e-06
- O 0 0.00011548155453056097
type O 0 1.0777626812341623e-05
tetraploid O 0 0.00013190846948418766
morulae O 0 0.00016778211283963174
rescues O 0 0.00011823107342934236
the O 0 3.3143342079711147e-06
gastrulation B-Disease 0 0.0004065690445713699
defect I-Disease 0 0.00036052061477676034
. O 0 1.1227568393223919e-05

These O 0 8.14845316199353e-06
results O 0 5.855226390849566e-06
indicate O 0 1.1900990557478508e-06
that O 0 1.2980490282643586e-07
Smad4 O 0 2.5078146791202016e-05
is O 0 2.4936983322731976e-07
initially O 0 1.441183258066303e-06
required O 0 1.989731046592169e-08
for O 0 3.798083625383697e-09
the O 0 2.4100282658423566e-08
differentiation O 0 1.0216876944468822e-07
of O 0 1.2124208303987416e-08
the O 0 8.586817301647898e-08
visceral O 0 6.933909844519803e-06
endoderm O 0 2.816896630974952e-05
and O 0 3.741399439149973e-07
that O 0 2.0157903790618548e-08
the O 0 1.7389076845120144e-07
gastrulation B-Disease 0 1.946078373293858e-05
defect I-Disease 0 5.894455625821138e-06
in O 0 7.5774202912271e-08
the O 0 4.0567761061538476e-07
epiblast O 0 0.00012361268454696983
is O 0 1.584807165500024e-07
secondary O 0 1.6727983620512532e-07
and O 0 2.1933642813110055e-07
non O 0 9.117345030063007e-07
- O 0 6.719225348206237e-05
cell O 0 3.0185943614924327e-05
autonomous O 0 9.242911801266018e-06
. O 0 4.7763683141965885e-06

Rescued O 0 0.002218686742708087
embryos O 0 0.00040789417107589543
show O 0 0.00033169990638270974
severe O 0 0.002401040866971016
anterior O 0 0.013248504139482975
truncations O 0 0.006008298601955175
, O 0 3.909321549144806e-06
indicating O 0 3.622808662839816e-06
a O 0 5.217683565206244e-07
second O 0 2.397117214059108e-06
important O 0 3.2865681731664154e-08
role O 0 1.0085508250767816e-07
for O 0 8.911301563330198e-08
Smad4 O 0 2.727005266933702e-05
in O 0 6.831592713751888e-07
anterior O 0 0.00014462457329500467
patterning O 0 0.0006064741173759103
during O 0 6.894326816109242e-06
embryogenesis O 0 8.306837116833776e-05
. O 0 9.737564141687471e-06

Prevalence O 0 0.008333507925271988
of O 0 1.1090247426182032e-05
p16 O 0 0.00018819588876795024
and O 0 4.143001660850132e-06
CDK4 O 0 0.0015578342135995626
germline O 0 0.0008586763287894428
mutations O 0 4.2638599552446976e-05
in O 0 1.2623141856238362e-06
48 O 0 0.00010752752132248133
melanoma B-Disease 1 0.9951655864715576
- O 0 0.25831732153892517
prone O 0 0.0016856888541951776
families O 0 1.153321818492259e-06
in O 0 7.810544389030838e-07
France O 0 2.1794161511934362e-05
. O 0 5.000779765396146e-06

The O 0 4.615410580299795e-05
French O 0 0.0010431618429720402
Familial B-Disease 1 0.7436784505844116
Melanoma I-Disease 1 0.9999548196792603
Study O 0 3.294837733847089e-05
Group O 0 2.9071903554722667e-05
. O 0 7.323232694034232e-06

Germline O 1 0.6887516975402832
mutations O 0 0.0024086791090667248
in O 0 1.25350550206349e-06
the O 0 5.665643243446539e-07
p16 O 0 7.704920790274628e-06
and O 0 6.357442430271476e-07
CDK4 O 0 9.042064630193636e-05
genes O 0 1.11007864234125e-06
have O 0 3.0399701245187316e-07
been O 0 1.4740588767381269e-06
reported O 0 1.214191001963627e-06
in O 0 3.2144232164910136e-08
a O 0 2.2908353969341988e-07
subset O 0 4.544499745406938e-07
of O 0 4.1387383475921524e-07
melanoma B-Disease 1 0.8507236242294312
pedigrees O 0 2.1630150513374247e-05
, O 0 1.9637431591945642e-07
but O 0 3.807442539027761e-08
their O 0 1.1323772497462414e-07
prevalence O 0 2.1870240743737668e-05
is O 0 1.2561173434733064e-07
not O 0 5.168535111010897e-08
well O 0 1.6908906275148183e-07
known O 0 1.9590459032770013e-06
. O 0 2.1844246020918945e-06

We O 0 6.381226285157027e-06
searched O 0 4.86078670292045e-06
for O 0 2.097662701316949e-07
such O 0 2.5146903226413997e-07
germline O 0 6.292045145528391e-05
mutations O 0 5.482796950673219e-06
in O 0 1.2306288965646672e-07
48 O 0 3.4689494441408897e-06
French O 0 0.0011001455131918192
melanoma B-Disease 1 0.9993672966957092
- O 1 0.5809548497200012
prone O 0 0.0015805215807631612
families O 0 2.667221110641549e-07
selected O 0 4.0390947475543726e-08
according O 0 1.3930863573818897e-08
to O 0 1.055380494108249e-08
two O 0 3.220707966988812e-08
major O 0 9.633448172507997e-08
criteria O 0 1.805665164056336e-07
families O 0 4.21481622936426e-08
with O 0 1.2187179265765735e-08
at O 0 6.533714014267389e-08
least O 0 3.532832693053933e-08
three O 0 3.2990786991149434e-08
affected O 0 6.079066139363931e-08
members O 0 1.464764576297739e-08
( O 0 3.968208162064002e-08
n O 0 1.4618835848523304e-06
= O 0 2.660465952430968e-06
20 O 0 8.983746369040091e-08
) O 0 2.299112189518837e-08
or O 0 2.521557895818205e-08
families O 0 1.528197834943512e-08
with O 0 2.521125175292127e-08
two O 0 7.551066687483399e-07
affected O 0 2.2298199553461018e-07
members O 0 2.4062616788000923e-08
, O 0 1.5009025133849718e-08
one O 0 5.5843387691822954e-09
of O 0 2.428512058116894e-09
them O 0 5.447740925035305e-09
affected O 0 3.173958162960844e-08
before O 0 1.9184536625971305e-08
the O 0 1.833148388641348e-08
age O 0 2.173341329125833e-08
of O 0 2.926680675585658e-09
50 O 0 3.3370760377238184e-08
( O 0 4.1431288622106877e-08
n O 0 1.4613930261475616e-06
= O 0 5.414746738097165e-06
28 O 0 6.120520197328005e-07
) O 0 3.1249587806314594e-08
, O 0 1.763436152657505e-08
and O 0 3.130142900431565e-08
one O 0 4.602824432708985e-08
additional O 0 2.4090360284390044e-07
minor O 0 2.570563765402767e-06
criterion O 0 1.9971654182882048e-05
. O 0 2.926085016952129e-06

Sixteen O 0 0.000172651547472924
different O 0 1.0224289326288272e-05
p16 O 0 0.0002576308324933052
germline O 0 0.0008934490615502
mutations O 0 0.00013688016042578965
were O 0 1.3684075383935124e-06
found O 0 1.9986777033409453e-07
in O 0 2.3189267039924744e-07
21 O 0 6.080503226257861e-06
families O 0 1.8388149669590348e-07
, O 0 5.1408193257884705e-08
while O 0 8.221541492048345e-08
one O 0 2.1658539139934874e-07
germline O 0 1.3582010069512762e-05
mutation O 0 1.5681027889513643e-06
, O 0 7.502536902848078e-08
Arg24His O 0 1.2869858437625226e-05
, O 0 2.891323163112247e-07
was O 0 2.8710828701150604e-06
detected O 0 4.792474896930798e-07
in O 0 3.1588538007554234e-08
the O 0 3.291411587724724e-07
CDK4 O 0 0.0002429748565191403
gene O 0 1.1906487998203374e-05
. O 0 5.926493940933142e-06

The O 0 6.970042704779189e-06
frequency O 0 7.353366527240723e-06
of O 0 2.039217861238285e-07
p16 O 0 1.1423923751863185e-05
gene O 0 2.48204901254212e-06
mutation O 0 1.4028743180460879e-06
in O 0 5.027021998671444e-08
our O 0 4.816749665792486e-08
sample O 0 1.6149800785569823e-07
( O 0 1.0078374401700785e-07
44 O 0 2.737533293384331e-07
% O 0 1.3144828869826597e-07
) O 0 1.6845675077092892e-08
is O 0 1.1397093047094131e-08
among O 0 1.1382863540632115e-08
the O 0 3.518924884815533e-08
highest O 0 8.125275599013548e-07
rates O 0 1.1400145467632683e-06
yet O 0 1.4391901004273677e-07
reported O 0 4.817333660867007e-07
and O 0 4.556555310841759e-08
the O 0 1.1465878202443491e-07
CDK4 O 0 0.00012721044186037034
mutation O 0 9.135195568887866e-07
is O 0 2.419054645486085e-08
the O 0 4.0159953584861796e-08
second O 0 4.461620846996084e-06
mutation O 0 4.014405476482352e-06
detected O 0 9.437842436454957e-07
in O 0 4.750555504529075e-08
this O 0 7.897958198554988e-08
gene O 0 2.4942767140601063e-06
worldwide O 0 2.113112032020581e-06
. O 0 4.258145509083988e-06

In O 0 1.0883984032261651e-05
summary O 0 9.682808013167232e-06
, O 0 2.7317642548041476e-07
our O 0 1.4203219222963526e-07
results O 0 2.47499542638252e-07
show O 0 4.771687258653401e-07
frequent O 0 3.3716702318997704e-07
involvement O 0 1.5101986150511948e-07
of O 0 1.9564634357038813e-08
the O 0 9.996740146789307e-08
p16 O 0 2.8118586214986863e-06
gene O 0 8.69818109094922e-07
in O 0 6.416819928745099e-07
familial B-Disease 0 0.02505423128604889
melanoma I-Disease 1 0.998768150806427
and O 0 4.786199042428052e-06
confirm O 0 8.773184845267679e-07
the O 0 6.240914274258103e-08
role O 0 1.3405723109372047e-07
of O 0 1.900038348878752e-08
the O 0 9.526064559395309e-08
CDK4 O 0 2.734886402322445e-05
gene O 0 4.815505576516443e-07
as O 0 1.2165781981821056e-07
a O 0 4.904281013295986e-06
melanoma B-Disease 1 0.57655930519104
- O 0 0.00018419754633214325
predisposing O 0 5.619638250209391e-05
gene O 0 1.0791849490487948e-05
. O 0 1.5567516129522119e-06
. O 0 4.96872007715865e-06

Progression O 0 0.0018932420061901212
of O 0 6.845942607469624e-06
somatic O 0 0.00030355656053870916
CTG O 0 0.0007631246116943657
repeat O 0 7.163256668718532e-05
length O 0 1.9740600691875443e-05
heterogeneity O 0 2.0610956198652275e-05
in O 0 8.098678563328576e-07
the O 0 1.4961400438551209e-06
blood O 0 3.619425115175545e-05
cells O 0 3.611164720496163e-05
of O 0 2.2088521291152574e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.08203671872615814
. O 0 2.1480767827597447e-05

The O 0 1.0165052117372397e-05
genetic O 0 2.014991878240835e-05
basis O 0 2.2956958218856016e-06
of O 0 2.3160846467362717e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.4403521418571472
DM B-Disease 1 1.0
) O 0 5.105191121401731e-06
is O 0 4.9375071142776505e-08
the O 0 3.1498348818104205e-08
expansion O 0 1.1240130248779678e-07
of O 0 1.6774912126038544e-08
an O 0 1.5189633018053428e-07
unstable O 0 0.0001506005646660924
CTG O 0 0.00010406129149487242
repeat O 0 3.7497047742363065e-06
in O 0 5.468461239388489e-08
the O 0 1.648831613465518e-07
34 O 0 8.775117521508946e-07
UTR O 0 7.633655513927806e-06
of O 0 7.588354833387712e-08
the O 0 8.837938594297157e-07
DM B-Disease 1 0.9999842643737793
protein O 0 6.6551710915518925e-06
kinase O 0 1.333843101747334e-05
gene O 0 2.1634314180118963e-06
on O 0 5.058588612882886e-06
chromosome O 0 0.000302529166219756
19 O 0 1.1939451724174432e-05
. O 0 5.889297426620033e-06

One O 0 5.7033753364521544e-06
of O 0 1.3900398698751815e-07
the O 0 9.910888110198357e-08
principal O 0 1.7905782101479417e-07
features O 0 2.7566895255404233e-07
of O 0 4.0713874938091976e-08
the O 0 4.408850600157166e-06
DM B-Disease 1 1.0
mutation O 0 2.1486464902409352e-05
is O 0 4.4923858411038964e-08
an O 0 2.4944254661818377e-08
extraordinarily O 0 1.2923995882374584e-06
high O 0 7.925926865937072e-07
level O 0 1.1504202745982184e-07
of O 0 3.144300464441585e-08
somatic O 0 8.008014447113965e-06
mosaicism O 0 0.00010069709969684482
, O 0 3.6730429542330967e-07
due O 0 1.9558558506105328e-07
to O 0 4.096984795864955e-08
an O 0 1.5914652351511904e-07
extremely O 0 1.428899167876807e-06
high O 0 2.4058958842942957e-06
degree O 0 3.234158612031024e-07
of O 0 4.3659451165467544e-08
somatic O 0 8.987550245365128e-06
instability O 0 9.708930519991554e-06
both O 0 1.229324624318906e-07
within O 0 5.888416509947092e-08
and O 0 1.2573926255754486e-07
between O 0 1.510593250486636e-07
different O 0 2.981675208957313e-07
tissues O 0 1.8490669390303083e-05
. O 0 2.7539197162695928e-06

This O 0 1.8183773136115633e-05
instability O 0 0.00012888110359199345
appears O 0 9.487453098699916e-06
to O 0 1.3787017394406575e-07
be O 0 6.531122664910072e-08
biased O 0 6.119913109614572e-07
towards O 0 9.23473990610546e-08
further O 0 5.326350560608262e-08
expansion O 0 1.4941936399281985e-07
and O 0 5.808447411936868e-08
continuous O 0 3.6474668263508647e-07
throughout O 0 8.82286670389476e-08
the O 0 5.907641664748553e-08
life O 0 3.6395022107171826e-08
of O 0 4.582805690489522e-09
an O 0 3.279642157849594e-08
individual O 0 2.1211262080100823e-08
, O 0 2.0958346169663855e-08
features O 0 1.9152186325754883e-07
that O 0 5.306475614474948e-08
could O 0 3.4889450262198807e-07
be O 0 3.937034520617999e-08
associated O 0 4.176978052328195e-08
with O 0 3.268164761038861e-08
the O 0 5.599956125479366e-07
progressive O 0 4.2308412957936525e-05
nature O 0 2.0888113283490384e-07
of O 0 8.52984811672286e-08
the O 0 4.84219617646886e-06
disease O 0 0.00022742901637684554
. O 0 5.997777407173999e-06

Although O 0 1.1850889677589294e-05
increasing O 0 3.75796321350208e-06
measured O 0 5.3329754337028135e-06
allele O 0 2.2309800442599226e-06
size O 0 7.103366783667298e-07
between O 0 1.7477804021837073e-06
patients O 0 8.409451766056009e-06
clearly O 0 1.3684179975825828e-06
correlates O 0 1.5829461972316494e-06
with O 0 4.3759911250162986e-08
an O 0 2.3394468939841317e-07
increased O 0 7.575528343295446e-06
severity O 0 0.00023314074496738613
of O 0 6.929440701242129e-07
symptoms O 0 0.0005922229029238224
and O 0 1.4262889180827187e-07
an O 0 5.250988976968074e-08
earlier O 0 2.0924069303873694e-06
age O 0 1.0729805666187531e-07
of O 0 1.5561498756255787e-08
onset O 0 1.33442072183243e-05
, O 0 6.314312628319385e-08
this O 0 7.679397562299073e-09
correlation O 0 3.04672141737683e-07
is O 0 3.0205239198721756e-08
not O 0 1.4594881747598265e-08
precise O 0 2.503487053218123e-07
and O 0 3.2876531008696475e-07
measured O 0 7.403876224998385e-06
allele O 0 8.496510304212279e-07
length O 0 2.985495939356042e-06
cannot O 0 1.6270598734990926e-07
be O 0 1.1848412029280553e-08
used O 0 3.00788727258805e-08
as O 0 1.6693967097580753e-08
an O 0 2.7615882913778478e-08
accurate O 0 1.95397433344624e-06
predictor O 0 8.780937605479266e-06
of O 0 3.7245460049462054e-08
age O 0 3.4832399364859157e-07
of O 0 1.6971961258605006e-07
onset O 0 0.000283765111817047
. O 0 3.586596221794025e-06

In O 0 3.831647518381942e-06
order O 0 4.35146318977786e-07
to O 0 4.1454367050164365e-08
further O 0 5.888102094786518e-08
characterize O 0 4.949222898176231e-07
the O 0 1.2066260524079553e-07
dynamics O 0 3.585378863135702e-06
of O 0 7.264679311447253e-07
DM B-Disease 1 1.0
CTG O 0 0.0006305730203166604
repeat O 0 6.4277610363205895e-06
somatic O 0 8.718530807527713e-06
instability O 0 9.322906407760456e-06
, O 0 1.7645776040353667e-07
we O 0 2.8149440112201773e-08
have O 0 2.1048000675705225e-08
studied O 0 1.0530223448768083e-07
repeat O 0 9.995136451834696e-07
length O 0 1.226108793161984e-06
changes O 0 9.22247096468709e-08
over O 0 6.617645453843579e-08
time O 0 1.173139310139959e-07
in O 0 5.710895720767439e-07
111 O 0 0.0012756827054545283
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 3.866165934596211e-05
with O 0 1.8098683085554512e-07
varying O 0 4.206891389912926e-06
clinical O 0 3.127653690171428e-05
severity O 0 0.00019860357861034572
and O 0 2.0083489289390855e-06
CTG O 0 3.787176319747232e-05
repeat O 0 1.1812668390120962e-06
size O 0 1.3576442370322184e-07
over O 0 6.1058280209636e-08
time O 0 5.837824801346869e-08
intervals O 0 1.2867052134879486e-07
of O 0 1.4095668632307934e-08
1 O 0 2.1309624287368933e-07
- O 0 4.157344392297091e-06
7 O 0 1.6366492445740732e-06
years O 0 5.323349228092411e-07
. O 0 1.3634288507091696e-06

We O 0 2.0052115360158496e-05
have O 0 4.1926466565200826e-07
found O 0 1.0246715476114332e-07
a O 0 1.3708823587421648e-07
direct O 0 1.5488984672629158e-07
progression O 0 2.2248673303693067e-06
of O 0 1.8951412883438934e-08
the O 0 4.8187530410359614e-08
size O 0 2.6276683229298214e-07
heterogeneity O 0 8.781379392530653e-07
over O 0 8.020359842930702e-08
time O 0 4.205974235560461e-08
related O 0 2.264983578470492e-08
to O 0 3.179872365421943e-08
initial O 0 5.085658472125942e-07
CTG O 0 6.382455467246473e-06
repeat O 0 5.080869414086919e-07
size O 0 2.0393501642956835e-07
and O 0 4.238226480879348e-08
the O 0 3.985540786288766e-08
time O 0 1.2518410130724078e-07
interval O 0 5.929875328547496e-07
and O 0 1.203119381898432e-07
always O 0 9.853062010733993e-08
biased O 0 2.8108939886806183e-07
towards O 0 1.0176035658560068e-07
further O 0 1.3252385144824075e-07
expansion O 0 2.5249710233765654e-06
. O 0 2.104576878991793e-06

Attempts O 0 0.0001207235109177418
to O 0 3.7891422834945843e-06
mathematically O 0 1.2744606465275865e-05
model O 0 2.1181601823627716e-06
the O 0 2.420275677650352e-07
dynamics O 0 9.275981028622482e-06
have O 0 5.990267482047784e-07
proved O 0 5.137897005624836e-06
only O 0 1.2791855397153995e-07
partially O 0 6.813103027525358e-06
successful O 0 3.6075414300285047e-07
suggesting O 0 4.020863002551778e-07
that O 0 1.9404311046855582e-08
individual O 0 1.4683310567420449e-08
specific O 0 2.3188906794757713e-08
genetic O 0 5.425148970061855e-07
and O 0 7.562691735074623e-07
/ O 0 1.5198475921351928e-05
or O 0 4.5615078647642804e-07
environmental O 0 5.293889557833609e-07
factors O 0 6.628977189393481e-08
also O 0 2.1138043848623056e-07
play O 0 4.4649560493326135e-08
a O 0 1.1000904009961232e-07
role O 0 2.4525846242795524e-07
in O 0 4.074915125329426e-07
somatic O 0 2.5175238988595083e-05
mosaicism O 0 0.00018944646581076086
. O 0 1.1900741583303898e-06
. O 0 3.452777036727639e-06

Aspartylglucosaminuria B-Disease 1 0.9997767806053162
among O 0 4.7688237827969715e-05
Palestinian O 0 0.0003035823174286634
Arabs O 0 0.00038098159711807966
. O 0 2.9684490073123015e-05

Aspartylglucosaminuria B-Disease 1 0.9999994039535522
( O 0 0.06973302364349365
AGU B-Disease 1 0.9999996423721313
) O 0 1.2845469427702483e-05
is O 0 5.921257866248197e-07
a O 0 2.1810753878526157e-06
rare O 0 1.646499731577933e-05
disorder B-Disease 0 0.004697255324572325
of I-Disease 0 2.0599212291472213e-07
glycoprotein I-Disease 0 0.00023449014406651258
metabolism I-Disease 0 0.0012462942395359278
caused O 0 1.2562720257847104e-05
by O 0 4.1895691538229585e-07
the O 0 1.4776319403608795e-05
deficiency B-Disease 0 0.00023814811720512807
of I-Disease 0 6.350437331548164e-08
the I-Disease 0 9.932231250786572e-07
lysosomal I-Disease 0 0.0027740506920963526
enzyme I-Disease 0 4.455266025615856e-05
aspartylglucosaminidase I-Disease 0 0.0004505272663664073
( O 0 3.109253839284065e-06
AGA O 0 8.127823093673214e-05
) O 0 3.235832537029637e-06
. O 0 3.83790484193014e-06

AGU B-Disease 1 0.9999995231628418
is O 0 0.00033505322062410414
inherited O 0 0.0006000809371471405
as O 0 2.4081869014480617e-06
an O 0 4.361402716313023e-06
autosomal O 1 0.9991119503974915
recessive O 1 0.9982337951660156
trait O 0 0.002252022735774517
and O 0 4.897345206700265e-06
occurs O 0 2.4534455178581993e-07
with O 0 3.374841384129468e-08
a O 0 1.2408670500008157e-06
high O 0 4.48244099970907e-06
frequency O 0 9.743369446368888e-06
in O 0 1.4821840466083813e-07
Finland O 0 1.9386150597711094e-05
because O 0 5.89255115812648e-08
of O 0 1.9311009680222924e-08
a O 0 4.6973329403954267e-07
founder O 0 9.167572898149956e-06
effect O 0 2.1907189875491895e-06
. O 0 1.567527078805142e-06

While O 0 2.590347321529407e-05
very O 0 1.3265818097352167e-06
few O 0 7.345590233853727e-07
patients O 0 2.722816816458362e-06
with O 0 1.5666618082832429e-06
AGU B-Disease 1 1.0
have O 0 3.0299001991807017e-06
been O 0 1.2292066458030604e-06
reported O 0 7.360287668234378e-07
from O 0 3.30035625495384e-08
non O 0 2.1937911753866501e-07
- O 0 1.3459797628456727e-05
Finnish O 0 1.6188585505005904e-05
origin O 0 2.4132529574671935e-07
, O 0 1.6040726791288762e-07
we O 0 5.256621307125897e-07
diagnosed O 0 0.0013759249122813344
the O 0 1.4006577657710295e-06
disorder O 0 0.0003325037541799247
in O 0 3.3500481322334963e-07
8 O 0 8.160733159456868e-06
patients O 0 9.044451871886849e-07
originating O 0 1.307593606725277e-07
from O 0 5.795554969267869e-08
3 O 0 4.55439192137419e-07
unrelated O 0 7.19603576726513e-07
families O 0 1.7963765230888384e-07
, O 0 2.3443599062034082e-08
all O 0 5.250265555645228e-09
Palestinian O 0 3.4686847811826738e-06
Arabs O 0 2.666630962266936e-06
from O 0 4.090223271191462e-08
the O 0 8.089895686680393e-08
region O 0 4.974942271473992e-07
of O 0 1.4675546822218166e-07
Jerusalem O 0 6.588857650058344e-05
. O 0 7.059436484269099e-06

The O 0 4.95313506689854e-05
clinical O 0 0.0005832543247379363
diagnosis O 0 0.13729065656661987
of O 0 3.2539664971409366e-05
AGU B-Disease 1 1.0
is O 0 1.4574148735846393e-05
often O 0 1.0164624200115213e-06
difficult O 0 6.175858402457379e-07
, O 0 8.211966218141242e-08
in O 0 2.5959748128911997e-08
particular O 0 3.671014781048143e-08
early O 0 1.8371497390035074e-07
in O 0 3.6594588692651087e-08
the O 0 7.682579905576858e-08
course O 0 1.751117650883316e-07
of O 0 1.2165347840209506e-08
the O 0 9.950928188118269e-07
disease O 0 1.0652054697857238e-05
, O 0 1.0404168904187827e-07
and O 0 7.248886646493702e-08
most O 0 5.026521421314101e-09
of O 0 5.5147442168390626e-09
the O 0 3.506624466353969e-07
patients O 0 1.8094349343300564e-06
are O 0 3.3355365758325206e-07
diagnosed O 0 0.0006551665137521923
after O 0 4.0386640876022284e-07
the O 0 8.51559178727257e-08
age O 0 6.273926800304253e-08
of O 0 2.7096829668948885e-08
5 O 0 6.767655236217252e-07
years O 0 6.435057002818212e-07
. O 0 1.6321430393873015e-06

However O 0 6.556828884640709e-05
, O 0 1.184870484394196e-06
since O 0 5.244898488854233e-07
these O 0 6.712364353234079e-08
patients O 0 6.264522198762279e-07
excrete O 0 5.265998765935365e-07
early O 0 1.1924730358714442e-07
large O 0 3.084995725544104e-08
amounts O 0 3.409182625091489e-08
of O 0 1.8968915327377545e-08
aspartylglucosamine O 0 6.112894425314153e-06
in O 0 9.19145790589937e-08
urine O 0 8.140198133332888e-07
, O 0 3.46151587393706e-08
biochemical O 0 7.032712687760068e-07
screening O 0 4.112691556201753e-07
is O 0 5.7658958496631385e-08
easy O 0 2.0910475484470226e-07
by O 0 1.8435207493894268e-07
urine O 0 5.1369270295253955e-06
chromatography O 0 1.4403464774659369e-05
. O 0 6.507658554255613e-07
. O 0 1.7686508044789662e-06

Detection O 0 0.0002447559090796858
of O 0 4.572611032926943e-06
heterozygous O 0 4.529961370280944e-05
carriers O 0 2.2141759927762905e-06
of O 0 1.7229024251719238e-07
the O 0 3.4516240702942014e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 8.304713446705136e-06
ATM O 0 2.8513750294223428e-05
) O 0 4.900541057395458e-07
gene O 0 1.2147376082793926e-06
by O 0 2.657942559380899e-07
G2 O 0 0.0003481290186755359
phase O 0 1.700117536529433e-05
chromosomal O 0 0.0008148615015670657
radiosensitivity O 0 0.00012110215902794152
of O 0 1.0502097893549944e-06
peripheral O 0 0.029469948261976242
blood O 0 0.0015119833406060934
lymphocytes O 0 0.0002782932424452156
. O 0 6.806582860008348e-06

In O 0 0.05011214315891266
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.007310268469154835
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
) O 0 2.732921075221384e-06
patients O 0 1.8778000594465993e-06
, O 0 1.6590699658536323e-07
mutations O 0 7.928292689030059e-07
in O 0 2.2582801406656472e-08
a O 0 1.973983785319433e-07
single O 0 1.8231639842269942e-06
gene O 0 4.253476220128505e-07
, O 0 1.0200481170841158e-07
ATM O 0 2.034429144259775e-06
, O 0 6.623618276080379e-08
result O 0 1.3738677751007344e-07
in O 0 5.22509310485475e-07
an O 0 0.03567303344607353
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 4.879657808487536e-06
embraces O 0 2.878748773582629e-06
a O 0 4.3838358010361844e-07
variety O 0 1.2679798544468213e-07
of O 0 4.711393586376289e-08
clinical O 0 2.7424925974628422e-06
features O 0 1.4138207006908488e-05
and O 0 3.7689640066673746e-06
manifests O 0 7.969934813445434e-06
extreme O 0 1.3379811207414605e-05
radiosensitivity O 0 1.642337338125799e-05
and O 0 1.4012132965035562e-07
a O 0 1.9662185479774053e-07
strong O 0 5.522177843886311e-07
pre O 0 1.3426284567685798e-05
- O 0 0.000136768096126616
disposition O 0 1.8956721760332584e-05
to O 0 1.3358317119127605e-06
malignancy B-Disease 0 0.0015666604740545154
. O 0 6.605465387110598e-06

Heterozygotes O 0 0.000930087873712182
for O 0 1.3222746702012955e-06
the O 0 4.427016904173797e-07
ATM O 0 7.970801561896224e-06
gene O 0 2.6870329747907817e-06
have O 0 3.908364476501447e-07
no O 0 2.123571647416611e-07
clinical O 0 1.004687646855018e-06
expression O 0 2.782401793410827e-07
of O 0 9.201088602139862e-08
A B-Disease 1 0.9999691247940063
- I-Disease 1 0.9999972581863403
T I-Disease 1 1.0
but O 0 1.0788430699903984e-06
may O 0 5.960127509752056e-06
be O 0 6.364776368172897e-07
cancer B-Disease 0 1.4368410120368935e-05
prone O 0 4.08061077905586e-06
with O 0 1.1979739156231517e-07
a O 0 3.8063208194216713e-06
moderate O 0 0.00022681229165755212
increase O 0 9.362038326798938e-07
in O 0 1.1157424495422674e-07
in O 0 3.893201210303232e-07
vitro O 0 6.701947859255597e-05
radiosensitivity O 0 0.00011522087152116
. O 0 4.8818083087098785e-06

We O 0 2.5821043891482987e-05
performed O 0 6.294943432294531e-06
a O 0 1.9603803593781777e-06
blind O 0 2.6911748136626557e-05
chromosomal O 0 0.0001437564642401412
analysis O 0 1.3345913885132177e-06
on O 0 3.719037977134576e-06
G2 O 0 0.0007315758266486228
- O 0 0.00010172437032451853
phase O 0 5.8113223531108815e-06
lymphocytes O 0 1.6108451745822094e-06
from O 0 4.482123472371313e-08
7 O 0 4.853231985180173e-07
unrelated O 0 2.282688683408196e-06
A B-Disease 1 0.999992847442627
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
patients O 0 6.629952167713782e-06
, O 0 5.0675225793384016e-08
13 O 0 1.2705763197118358e-07
obligate O 0 5.986463520457619e-07
A B-Disease 1 0.9998565912246704
- I-Disease 1 0.9999978542327881
T I-Disease 1 1.0
heterozygotes O 0 5.6451397540513426e-05
( O 0 1.8393183154330472e-07
parents O 0 2.7450090200886734e-08
of O 0 9.765143360596085e-09
the O 0 4.2742306050058687e-07
patients O 0 1.6281135231110966e-06
) O 0 5.096339705801256e-08
, O 0 2.0621534702058852e-08
and O 0 7.890761111184474e-08
14 O 0 1.5539096409611375e-07
normal O 0 6.886408954187573e-08
controls O 0 2.1932680738245836e-07
following O 0 1.0073473077909512e-07
X O 0 3.195674798917025e-05
- O 0 4.256151896697702e-06
irradiation O 0 3.040350122773816e-07
with O 0 2.8487503911378553e-08
1 O 0 2.528973652715649e-07
Gy O 0 2.022862645389978e-05
in O 0 2.6981767931033573e-08
order O 0 1.0240987613485686e-08
to O 0 5.9501248372839655e-09
evaluate O 0 5.549684090055962e-08
this O 0 2.0065495931476107e-08
cytogenetic O 0 2.8621323053812375e-06
method O 0 1.9502829218254192e-07
as O 0 5.051214202467236e-08
a O 0 1.1465014182476807e-07
tool O 0 4.16340157016748e-07
for O 0 3.2802738303416845e-08
detection O 0 7.404494226648239e-07
of O 0 1.0067346067899052e-07
ATM O 0 2.4970780941657722e-05
carriers O 0 4.442341378307901e-06
. O 0 2.4529590518795885e-06

Both O 0 0.00023680001322645694
A B-Disease 1 0.9998125433921814
- I-Disease 1 0.999990701675415
T I-Disease 1 0.9999996423721313
homozygotes O 0 0.000508344266563654
and O 0 4.040774001623504e-06
heterozygotes O 0 4.838087625103071e-05
showed O 0 1.0865792319236789e-05
significantly O 0 1.9127905943605583e-06
increased O 0 7.66576022215304e-07
levels O 0 8.144051832914556e-08
of O 0 5.4223150414145493e-08
radiation O 0 0.00040663298568688333
- O 0 0.0007999489898793399
induced O 0 0.07244867086410522
chromatid O 0 0.05209330469369888
damage O 0 3.373658182681538e-05
relative O 0 8.797574082564097e-07
to O 0 5.773445010959222e-08
that O 0 2.800073595210506e-08
of O 0 4.5817678540061024e-08
normal O 0 2.1650125745509285e-06
controls O 0 3.80227793357335e-05
. O 0 6.424114872061182e-06

These O 0 4.109541350771906e-06
results O 0 2.178813247155631e-06
show O 0 8.216044875553052e-07
that O 0 4.3290697249176446e-08
the O 0 1.641300997334838e-07
G2 O 0 0.00020979005785193294
- O 0 3.4742828574962914e-05
phase O 0 3.316449465273763e-06
chromosomal O 0 0.0001102464011637494
radiosensitivity O 0 4.075131073477678e-05
assay O 0 1.7503276467323303e-05
can O 0 2.035778692288659e-07
be O 0 3.371959067521857e-08
used O 0 8.626428638081052e-08
for O 0 2.5135243220120174e-08
the O 0 4.115837626272878e-08
detection O 0 1.0020485206041485e-06
of O 0 2.596708270630188e-07
A B-Disease 1 0.9999327659606934
- I-Disease 1 0.9999784231185913
T I-Disease 1 0.9999932050704956
heterozygotes O 0 0.00011262572661507875
. O 0 6.139131983218249e-06

In O 0 1.4256624126574025e-05
combination O 0 1.9662365957628936e-05
with O 0 3.1555421742268663e-07
molecular O 0 4.153290774411289e-06
genetic O 0 5.116070042276988e-06
analyses O 0 1.1882584658451378e-06
, O 0 7.480332442355575e-08
this O 0 2.536879151193716e-08
test O 0 3.2127260851666506e-07
may O 0 9.66972834248736e-07
be O 0 8.47996162178788e-09
of O 0 4.195516378757702e-09
value O 0 1.6533341806734825e-08
in O 0 1.8984913197073183e-08
studies O 0 2.1688524753926686e-08
of O 0 1.0134406203121671e-08
familial B-Disease 0 6.8043891587876715e-06
and I-Disease 0 1.4369206837727688e-06
sporadic I-Disease 0 0.000900850398465991
cancers I-Disease 0 0.04997723177075386
aimed O 0 2.298092113051098e-06
at O 0 2.9697170589315647e-07
determination O 0 3.116988693818712e-07
of O 0 7.635114762649664e-09
the O 0 3.0000723683087926e-08
potential O 0 4.609633563745774e-08
involvement O 0 6.802909524594725e-08
of O 0 2.2198873850243217e-08
ATM O 0 3.4778953704517335e-05
mutations O 0 1.091919511964079e-05
in O 0 4.980601033821586e-07
tumor B-Disease 0 0.0010892152786254883
risk O 0 2.5799477043619845e-06
or O 0 2.1037328679085476e-07
development O 0 3.191837265603681e-07
. O 0 3.7461555280060566e-07
. O 0 3.351867917444906e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 0.9999997615814209
: O 0 5.498878181242617e-06
identification O 0 1.0457033567945473e-06
and O 0 2.2241727037908277e-07
detection O 0 1.167571440419124e-06
of O 0 9.746799634058334e-08
founder O 0 1.282622542930767e-05
- O 0 8.249904931290075e-05
effect O 0 1.4808490504947258e-06
mutations O 0 6.674682708762703e-07
in O 0 1.4162582218091302e-08
the O 0 5.895147836554315e-08
ATM O 0 3.917266894859495e-06
gene O 0 7.432531674567144e-07
in O 0 1.8407678226139979e-07
ethnic O 0 1.7583246290087118e-06
populations O 0 6.6121460804424714e-06
. O 0 3.4893084830400767e-06

To O 0 7.198567800514866e-06
facilitate O 0 1.859512508417538e-06
the O 0 3.945785636005894e-07
evaluation O 0 4.92076310365519e-07
of O 0 6.382872186350141e-08
ATM O 0 1.1820876352430787e-05
heterozygotes O 0 9.805208719626535e-06
for O 0 1.5221621652017348e-07
susceptibility O 0 1.79506532731466e-05
to O 0 2.693652731977636e-07
other O 0 6.143889095255872e-07
diseases O 0 9.144067917077336e-06
, O 0 3.1318091231469225e-08
such O 0 1.319664821863853e-08
as O 0 2.354284106331761e-06
breast B-Disease 1 0.971737802028656
cancer I-Disease 0 0.0012652615550905466
, O 0 1.8488766784230393e-07
we O 0 1.222883572182809e-08
have O 0 1.359349965923684e-08
attempted O 0 5.875390911569411e-07
to O 0 2.3331987009100885e-08
define O 0 1.4904705381013628e-07
the O 0 5.578561257379988e-08
most O 0 3.780833068844913e-08
common O 0 8.698745546098507e-07
mutations O 0 1.4266769312598626e-06
and O 0 4.3773269453595276e-08
their O 0 7.742110597064311e-08
frequencies O 0 3.446454002187238e-06
in O 0 6.9410943979164585e-06
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999979734420776
telangiectasia I-Disease 1 1.0
( O 0 6.601763743674383e-05
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
) O 0 6.534188514706329e-07
homozygotes O 0 5.295331447996432e-06
from O 0 1.1446768866107959e-07
10 O 0 2.566901287082146e-07
ethnic O 0 1.4251919537855429e-06
populations O 0 6.513714197353693e-06
. O 0 3.2954267226159573e-06

Both O 0 2.4186259906855412e-05
genomic O 0 0.0001249189517693594
mutations O 0 0.0001573217596160248
and O 0 4.971176394974464e-07
their O 0 1.6481210707297578e-07
effects O 0 4.187303147773491e-06
on O 0 5.157535838407057e-07
cDNA O 0 7.312233719858341e-06
were O 0 1.943544702953659e-06
characterized O 0 4.781159441336058e-05
. O 0 3.3367789455951424e-06

Protein O 0 0.00023802735086064786
- O 0 0.00014483393169939518
truncation O 0 4.1832794522633776e-05
testing O 0 1.5211971913231537e-06
of O 0 4.111279139351609e-08
the O 0 6.155794807227721e-08
entire O 0 3.2968588925541553e-07
ATM O 0 2.353054014747613e-06
cDNA O 0 5.80317009735154e-06
detected O 0 3.040065166715067e-06
92 O 0 9.157080285149277e-07
( O 0 1.8370516841059725e-07
66 O 0 3.3354774586769054e-06
% O 0 3.57820113094931e-07
) O 0 1.2378018254821654e-07
truncating O 0 8.811069164949004e-06
mutations O 0 2.2337476366374176e-06
in O 0 7.058070394805327e-08
140 O 0 1.1512954642967088e-06
mutant O 0 3.7189613067312166e-05
alleles O 0 2.2031257685739547e-05
screened O 0 4.789108788827434e-05
. O 0 7.3678970693435986e-06

The O 0 8.542946488887537e-06
haplotyping O 0 7.020324119366705e-05
of O 0 6.379221417773806e-07
patients O 0 2.1884511625103187e-06
with O 0 2.86101396795857e-07
identical O 0 0.0015359969111159444
mutations O 0 4.3539414036786184e-05
indicates O 0 9.34669458274584e-07
that O 0 3.228482015060763e-08
almost O 0 5.0399158624259144e-08
all O 0 2.797547082877827e-09
of O 0 2.7247473166625014e-09
these O 0 6.853412504170819e-09
represent O 0 3.6586214946510154e-08
common O 0 6.575946827069856e-07
ancestry O 0 3.0032067570573417e-06
and O 0 2.430881806958496e-07
that O 0 4.140269282970621e-08
very O 0 7.367606258412707e-08
few O 0 2.185396539289286e-07
spontaneously O 0 2.6212710508843884e-06
recurring O 0 2.2420616005547345e-05
ATM O 0 0.00025257584638893604
mutations O 0 6.869013304822147e-05
exist O 0 2.7363112167222425e-06
. O 0 4.160819571552565e-06

Assays O 0 0.0006268680444918573
requiring O 0 1.645248630666174e-05
minimal O 0 5.280827735987259e-06
amounts O 0 3.195763440544397e-07
of O 0 3.700343498280745e-08
genomic O 0 1.963302565854974e-06
DNA O 0 2.2951944629312493e-06
were O 0 1.1212529216209077e-07
designed O 0 5.486388090503169e-07
to O 0 1.780554725883121e-08
allow O 0 4.082833982010925e-08
rapid O 0 3.2305584340974747e-07
screening O 0 1.5627595928435767e-07
for O 0 4.52818973428748e-08
common O 0 4.894235985375417e-07
ethnic O 0 6.025571565260179e-06
mutations O 0 4.539180372375995e-05
. O 0 4.028518560517114e-06

These O 0 8.34897582535632e-06
rapid O 0 2.2437641746364534e-05
assays O 0 4.046174217364751e-05
detected O 0 1.4433122487389483e-05
mutations O 0 3.814817318925634e-06
in O 0 1.1627405882563835e-07
76 O 0 4.874890237260843e-06
% O 0 1.2921823611122818e-07
of O 0 3.0144462925818516e-08
Costa O 0 1.90802074939711e-06
Rican O 0 1.5807203453732654e-05
patients O 0 1.2517361938080285e-06
( O 0 5.6018908622945673e-08
3 O 0 1.0838348174502244e-07
) O 0 2.8272767238490815e-08
, O 0 1.4854466101610342e-08
50 O 0 2.6896936233811175e-08
% O 0 1.870070853726702e-08
of O 0 8.932893535984476e-09
Norwegian O 0 0.0006979180034250021
patients O 0 2.634154498082353e-06
( O 0 4.232418149285877e-08
1 O 0 6.849429468047674e-08
) O 0 2.3774342494675693e-08
, O 0 1.3967659917568653e-08
25 O 0 7.56996598738624e-08
% O 0 2.872271132048354e-08
of O 0 8.525436356876526e-09
Polish O 0 3.4821470762835816e-05
patients O 0 9.963786169464584e-07
( O 0 4.381069018677408e-08
4 O 0 2.2367696317360242e-07
) O 0 3.485026667249258e-08
, O 0 2.21322871141183e-08
and O 0 4.7247119994153763e-08
14 O 0 2.2571352076283802e-07
% O 0 3.3509934382891515e-08
of O 0 7.805985191566833e-09
Italian O 0 3.3505475585116073e-05
patients O 0 1.4511145991491503e-06
( O 0 8.787062455439809e-08
1 O 0 2.707374449073541e-07
) O 0 4.13217513539621e-08
, O 0 1.2152522543829036e-08
as O 0 2.0670126943400646e-08
well O 0 4.293734434668295e-08
as O 0 4.625513128075909e-08
in O 0 7.425943238104082e-08
patients O 0 1.4571162409993121e-07
of O 0 1.738313315513551e-08
Amish O 0 4.195909059490077e-05
/ O 0 1.2670937394432258e-05
Mennonite O 0 8.299155524582602e-06
and O 0 6.832231633779884e-07
Irish O 0 5.206209607422352e-06
English O 0 2.049056092801038e-06
backgrounds O 0 6.637201749981614e-06
. O 0 2.7799055715149734e-06

Additional O 0 7.422585622407496e-05
mutations O 0 0.00024177849991247058
were O 0 1.4507866126223234e-06
observed O 0 1.0080563015435473e-06
in O 0 9.957785351843995e-08
Japanese O 0 5.074937234894605e-07
, O 0 7.697041581877784e-08
Utah O 0 5.200029136176454e-07
Mormon O 0 5.315845896802784e-07
, O 0 3.08087386713396e-08
and O 0 5.1762693686896455e-08
African O 0 3.9423815678674146e-07
American O 0 1.4412904647542746e-06
patients O 0 6.161484179756371e-06
. O 0 2.0112565835006535e-06

These O 0 5.54427924726042e-06
assays O 0 9.356110240332782e-06
should O 0 2.823106797222863e-07
facilitate O 0 1.0697499419620726e-07
screening O 0 4.743520776173682e-07
for O 0 2.649181567448977e-07
A B-Disease 1 0.9999393224716187
- I-Disease 1 0.9999978542327881
T I-Disease 1 0.9999998807907104
heterozygotes O 0 1.7095131624955684e-05
in O 0 9.644276843800981e-08
the O 0 1.5969808941918018e-07
populations O 0 6.599619837288628e-07
studied O 0 8.089739935712714e-07
. O 0 2.999906882905634e-07
. O 0 1.533572685730178e-06

The O 0 9.49285677052103e-05
von B-Disease 1 0.6923952102661133
Hippel I-Disease 1 0.9822207093238831
- I-Disease 1 0.6697666645050049
Lindau I-Disease 0 0.32582786679267883
tumor I-Disease 0 0.00045223761117085814
suppressor O 0 0.0001478294434491545
gene O 0 2.851017143257195e-06
is O 0 1.6661178392496367e-07
required O 0 8.294246356399526e-08
for O 0 1.0092147562090759e-07
cell O 0 1.6197234799619764e-05
cycle O 0 8.786114449321758e-06
exit O 0 3.3852325032057706e-06
upon O 0 9.21174489576515e-07
serum O 0 2.967532054753974e-05
withdrawal O 0 3.124199065496214e-05
. O 0 5.649161721521523e-06

The O 0 1.5180266927927732e-05
inactivation O 0 6.237020716071129e-05
of O 0 3.079291275298601e-07
the O 0 1.6487953189425752e-06
von B-Disease 1 0.9733028411865234
Hippel I-Disease 1 0.9995418787002563
- I-Disease 1 0.982788622379303
Lindau I-Disease 1 0.9348500967025757
( I-Disease 0 4.733059995487565e-06
VHL I-Disease 0 0.0004932915326207876
) I-Disease 0 2.8848387501057005e-06
tumor I-Disease 0 0.00015646155225113034
suppressor O 0 0.00038538299850188196
gene O 0 1.555593917146325e-05
predisposes O 0 6.17712430539541e-05
affected O 0 2.0791871975234244e-06
individuals O 0 5.501005873043141e-08
to O 0 5.089180632467105e-08
the O 0 1.7121980135925696e-06
human O 0 0.00025518398615531623
VHL B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999940395355225
and O 0 2.9064556201774394e-06
is O 0 2.806640395647264e-07
associated O 0 6.45487261863309e-07
with O 0 3.397483396838652e-06
sporadic B-Disease 1 0.9988871216773987
renal I-Disease 1 0.9999998807907104
cell I-Disease 1 0.999998927116394
carcinomas I-Disease 1 1.0
( O 0 0.00044514454202726483
RCC B-Disease 1 0.8585739731788635
) O 0 3.279059228589176e-06
and O 0 7.796794307068922e-06
brain B-Disease 0 0.0010680585401132703
hemangioblastomas I-Disease 0 0.00046830286737531424
. O 0 5.910238996875705e-06

VHL O 0 0.04765564575791359
- O 0 0.019352586939930916
negative O 0 0.0001298230781685561
786 O 0 0.0002023012493737042
- O 0 0.0070963031612336636
0 O 0 3.24975153489504e-05
RCC B-Disease 0 0.0008845523116178811
cells O 0 3.9599403862666804e-06
are O 0 6.754373060857688e-08
tumorigenic O 0 1.3304941603564657e-05
in O 0 5.712067263630161e-07
nude O 0 0.009169653058052063
mice O 0 0.0019749635830521584
which O 0 6.365341391756374e-07
is O 0 9.056503813553718e-08
suppressed O 0 4.491649008286913e-07
by O 0 2.6677192010993167e-08
the O 0 6.461401369506348e-08
reintroduction O 0 7.853815077396575e-06
of O 0 1.1235623560423846e-06
VHL B-Disease 0 0.0007292565423995256
. O 0 7.419298981403699e-06

Remarkably O 0 0.008991170674562454
, O 0 5.141396286489908e-06
this O 0 1.7872329749479832e-07
occurs O 0 1.7454306089348393e-07
without O 0 4.014103893723586e-08
affecting O 0 6.969457899685949e-08
the O 0 7.124833700800082e-08
growth O 0 2.557284460635856e-06
rate O 0 2.6788454761117464e-06
and O 0 1.4986547114403947e-07
cell O 0 2.437687044221093e-06
cycle O 0 1.5831725477255532e-06
profile O 0 3.5089794891973725e-07
of O 0 2.4696049649719498e-08
these O 0 3.347313892732018e-08
cells O 0 2.68997155217221e-07
in O 0 7.358435283322251e-08
culture O 0 7.703216056142992e-07
. O 0 1.7060791606127168e-06

The O 0 2.1516667402465828e-05
786 O 0 0.00013782130554318428
- O 0 0.0002023232082137838
0 O 0 8.422935934504494e-06
cell O 0 2.4306682462338358e-05
line O 0 1.927574339788407e-05
, O 0 6.095088878055321e-08
like O 0 4.823249710739219e-08
many O 0 6.866826396390024e-08
cancer B-Disease 0 1.3054026567260735e-05
cells O 0 1.0583577250145026e-06
, O 0 6.855376710745986e-08
fails O 0 3.6947864145986387e-07
to O 0 2.227798034937223e-08
exit O 0 5.686467261512007e-07
the O 0 7.9651577777895e-08
cell O 0 7.25934387446614e-06
cycle O 0 4.32487104262691e-06
upon O 0 3.0904089953764924e-07
serum O 0 9.785423571884166e-06
withdrawal O 0 1.9721353964996524e-05
. O 0 4.40079384134151e-06

Here O 0 2.5853520128293894e-05
, O 0 8.503125172865111e-07
it O 0 1.416887016603141e-07
is O 0 1.0322080612468199e-07
shown O 0 2.1384866499829513e-07
that O 0 1.59249378128834e-08
reintroduction O 0 2.4715216113690985e-06
of O 0 2.7829237581045163e-08
the O 0 1.6327115304193285e-07
wild O 0 2.410240995232016e-06
- O 0 0.00010006019874708727
type O 0 6.915042831678875e-06
VHL B-Disease 0 7.512424781452864e-05
gene O 0 2.9574525797215756e-06
restores O 0 3.129300239379518e-05
the O 0 2.578693454324821e-07
ability O 0 3.891278481660265e-07
of O 0 2.414229243186128e-07
VHL O 0 0.0013042320497334003
- O 0 0.35754337906837463
negative O 0 0.0002996317925862968
RCC B-Disease 1 0.6454847455024719
cancer I-Disease 0 0.00011559260747162625
cells O 0 4.536389326403878e-07
to O 0 2.172073365613869e-08
exit O 0 4.2155079427175224e-07
the O 0 7.692990777741215e-08
cell O 0 4.461399839783553e-06
cycle O 0 2.1563148493441986e-06
and O 0 1.48674828892581e-07
enter O 0 4.689759407483507e-07
G0 O 0 6.231056613614783e-05
/ O 0 1.090450314222835e-05
quiescence O 0 1.8664182789507322e-05
in O 0 5.955418487246789e-07
low O 0 4.5916600356576964e-05
serum O 0 0.00011161007569171488
. O 0 3.8229022720770445e-06

Both O 0 6.643787492066622e-05
VHL O 0 0.007274159695953131
- O 0 0.0014460578095167875
positive O 0 7.383090178336715e-06
and O 0 1.0013922064899816e-06
VHL O 0 0.0006914192344993353
- O 0 0.006688382942229509
negative O 0 2.631534698593896e-05
RCC B-Disease 0 0.0005065463483333588
cells O 0 3.0890171274222666e-06
exit O 0 1.208468006552721e-06
the O 0 2.5118595203821314e-07
cell O 0 9.216013495461084e-06
cycle O 0 3.594615691326908e-06
by O 0 1.227368215950264e-07
contact O 0 2.3325817437580554e-06
inhibition O 0 2.185871016990859e-05
. O 0 4.427161911735311e-06

The O 0 4.5404143747873604e-05
cyclin O 0 0.0008260667091235518
- O 0 0.00012266816338524222
dependent O 0 2.190900340792723e-05
kinase O 0 7.569896115455776e-05
inhibitor O 0 2.1994581402395852e-05
, O 0 4.11871241112749e-07
p27 O 0 9.939443771145307e-06
, O 0 1.2090623613403295e-07
accumulates O 0 6.704897828058165e-07
upon O 0 4.194070513108272e-08
serum O 0 1.4015611213835655e-06
withdrawal O 0 2.7840496841236018e-06
, O 0 6.479827163730079e-08
only O 0 1.2424041351266624e-08
in O 0 7.949976676968618e-09
the O 0 1.7087669945681228e-08
presence O 0 6.246285977340449e-08
of O 0 2.9308550253404064e-08
VHL B-Disease 0 3.736515645869076e-05
, O 0 1.892050249807653e-07
as O 0 8.028333553511402e-08
a O 0 2.834507597526681e-07
result O 0 6.422733633826283e-08
of O 0 7.818695912931162e-09
the O 0 5.656088220007405e-08
stabilization O 0 6.764596491848351e-07
of O 0 3.5350975480241686e-08
the O 0 3.707634732563747e-07
protein O 0 2.7040298391511897e-06
. O 0 1.5118196188268485e-06

We O 0 1.3358901924220845e-05
propose O 0 5.831019734614529e-06
that O 0 1.0641819159218358e-07
the O 0 8.967089115685667e-08
loss O 0 8.098338639683789e-07
of O 0 3.762215783353895e-08
wild O 0 3.103687276961864e-06
- O 0 0.005242309998720884
type O 0 5.384226824389771e-06
VHL B-Disease 0 0.00011797925253631547
gene O 0 2.298936124134343e-06
results O 0 6.581229285984591e-07
in O 0 5.118384649449581e-08
a O 0 2.9745527285740536e-07
specific O 0 3.1363825314656424e-07
cellular O 0 1.997649269469548e-05
defect O 0 2.3548482204205357e-05
in O 0 4.7646392431488493e-07
serum O 0 3.407804251764901e-05
- O 0 2.21381415030919e-05
dependent O 0 5.872992687727674e-07
growth O 0 5.681778247890179e-07
control O 0 4.2091045315828524e-07
, O 0 1.4912781409748277e-07
which O 0 3.5152228861079493e-07
may O 0 1.5842661014175974e-06
initiate O 0 7.194730642368086e-06
tumor B-Disease 0 0.00011715549771906808
formation O 0 9.086901627597399e-06
. O 0 4.4450321183830965e-06

This O 0 1.0590792044240516e-05
is O 0 1.385256268804369e-06
corrected O 0 2.1498843125300482e-05
by O 0 6.481607783825893e-08
the O 0 4.054562907640502e-08
reintroduction O 0 3.0627427349827485e-06
of O 0 6.472737368312664e-08
wild O 0 2.6972202249453403e-06
- O 0 0.003489589085802436
type O 0 1.4523962818202563e-05
VHL B-Disease 0 0.0002855552302207798
, O 0 1.0987646419380326e-06
implicating O 0 1.2660151696763933e-05
VHL B-Disease 0 0.00010476272291271016
as O 0 3.30595156583513e-07
the O 0 1.499702761975641e-07
first O 0 1.8421812910673907e-06
tumor B-Disease 0 2.6529574824962765e-05
suppressor O 0 1.5251732293108944e-05
involved O 0 7.953422453965686e-08
in O 0 5.066362973593641e-08
the O 0 1.0658050086931325e-07
regulation O 0 4.5096416556589247e-07
of O 0 2.2143813893649167e-08
cell O 0 1.6888807294890285e-06
cycle O 0 1.5348191482189577e-06
exit O 0 1.0466102366990526e-06
, O 0 9.937502198908987e-08
which O 0 1.290242863660751e-07
is O 0 2.094775553018735e-08
consistent O 0 7.629454756852283e-08
with O 0 2.0087666641188662e-08
its O 0 2.778665475489106e-07
gatekeeper O 0 1.3919006050855387e-05
function O 0 1.657331978321963e-07
in O 0 8.02958908252549e-08
the O 0 8.519276661900221e-07
kidney O 0 6.44801912130788e-05
. O 0 1.0052473271571216e-06
. O 0 2.467534386596526e-06

Piebaldism B-Disease 1 0.9999991655349731
with O 0 0.2940637469291687
deafness B-Disease 1 1.0
: O 0 4.290462129574735e-06
molecular O 0 3.7257439089444233e-06
evidence O 0 2.4034966372710187e-07
for O 0 1.0282387563620432e-07
an O 0 2.248615373900975e-06
expanded O 0 0.026563594117760658
syndrome O 1 0.9998685121536255
. O 0 9.444142051506788e-06

In O 0 5.246707132755546e-06
a O 0 3.7240458823362133e-06
South O 0 1.1959117500737193e-06
African O 0 6.200904749675828e-07
girl O 0 8.946705747803207e-06
of O 0 2.1061659083443374e-07
Xhosa O 0 0.005756025202572346
stock O 0 2.9146049200790003e-06
with O 0 4.7230182076418714e-07
severe O 0 0.0029776019509881735
piebaldism B-Disease 0 0.024169450625777245
and O 0 0.00017917311924975365
profound O 0 0.038459669798612595
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 5.153629172127694e-05
identified O 0 8.784413694229443e-06
a O 0 1.030443058880337e-06
novel O 0 2.6843949854082894e-06
missense O 0 3.4623724332050188e-06
substitution O 0 1.9954210017658625e-07
at O 0 9.002940970503914e-08
a O 0 1.434620031659506e-07
highly O 0 3.7346228509704815e-07
conserved O 0 6.434382271436334e-07
residue O 0 5.461726573230408e-07
in O 0 2.2330647553303606e-08
the O 0 3.4557565697923565e-08
intracellular O 0 6.478294949374686e-07
kinase O 0 2.3232375951920403e-06
domain O 0 1.198499575139067e-07
of O 0 2.1868929778179336e-08
the O 0 1.882338693803831e-07
KIT O 0 8.111748320516199e-05
proto O 0 0.0003833796945400536
- O 0 9.674327884567901e-05
oncogene O 0 0.00010297772678313777
, O 0 1.749831881170394e-06
R796G O 0 3.8489200960611925e-05
. O 0 5.391548711486394e-06

Though O 0 0.00011787085531977937
auditory B-Disease 0 0.001980703556910157
anomalies I-Disease 0 0.010314475744962692
have O 0 4.01035686081741e-06
been O 0 1.1071119843109045e-06
observed O 0 9.767202300281497e-07
in O 0 2.37199046182468e-07
mice O 0 2.749396844592411e-05
with O 0 3.216404991235322e-07
dominant O 0 3.401848880457692e-05
white O 0 3.036813359358348e-05
spotting O 0 9.362609853269532e-05
( O 0 2.9761263249383774e-06
W O 0 0.0851200595498085
) O 0 1.3203249693560792e-07
due O 0 1.1252271292505611e-07
to O 0 3.875856862123328e-07
KIT O 0 0.4040829539299011
mutations O 0 0.00026711024111136794
, O 0 1.3243027751741465e-05
deafness B-Disease 1 1.0
is O 0 2.009140189329628e-06
not O 0 1.74052360080168e-07
typical O 0 1.0021469734056154e-06
in O 0 3.8029500615266443e-07
human O 0 2.0274951566534583e-06
piebaldism B-Disease 0 0.00013570634473580867
. O 0 6.612297511310317e-06

Thus O 0 3.59403456968721e-05
, O 0 5.335216997082171e-07
the O 0 1.4319205376978061e-07
occurrence O 0 3.9973779166757595e-06
of O 0 5.695097115676617e-06
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
in O 0 0.00031684350688010454
this O 0 2.8322156140347943e-06
patient O 0 1.3073138688923791e-05
extends O 0 3.424887836445123e-06
considerably O 0 3.057387857552385e-06
the O 0 9.475434126215987e-08
phenotypic O 0 2.2069827991799684e-06
range O 0 2.432714154565474e-07
of O 0 2.2979241620646462e-08
piebaldism B-Disease 0 9.041597877512686e-06
due O 0 2.887421146624547e-07
to O 0 8.53686330515302e-08
KIT O 0 8.395824261242524e-05
gene O 0 3.5461769130051835e-06
mutation O 0 1.158984787252848e-06
in O 0 5.8733629515472785e-08
humans O 0 1.530070932176386e-07
and O 0 6.534674525937589e-07
tightens O 0 0.010441893711686134
the O 0 4.04119134600478e-07
clinical O 0 1.4088149100643932e-06
similarity O 0 4.5758338274026755e-07
between O 0 4.801578370461357e-07
piebaldism B-Disease 0 8.061186235863715e-05
and O 0 1.7175577227135364e-07
the O 0 2.4898147543694904e-08
various O 0 3.327117070739405e-08
forms O 0 7.603514973197889e-07
of O 0 1.3130314073350746e-05
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999927282333374
. O 0 1.6025205695768818e-06
. O 0 2.5221359010174638e-06

Cycloheximide O 0 0.001721711945720017
facilitates O 0 5.169655923964456e-05
the O 0 1.5128667882891023e-06
identification O 0 9.686822295407183e-07
of O 0 1.0858915544531555e-07
aberrant O 0 1.9742145013879053e-05
transcripts O 0 1.8969978555105627e-05
resulting O 0 7.343863217101898e-06
from O 0 5.6207813514674854e-08
a O 0 2.601819915071246e-07
novel O 0 1.7730823174133548e-06
splice O 0 9.009453788166866e-05
- O 0 9.735787170939147e-05
site O 0 3.4779927773342934e-06
mutation O 0 1.5273869848897448e-06
in O 0 1.340214481615476e-07
COL17A1 O 0 4.149277810938656e-05
in O 0 3.0078876989136916e-07
a O 0 3.8544881135749165e-06
patient O 0 2.2963764422456734e-05
with O 0 4.054404143971624e-06
generalized O 0 0.004750199615955353
atrophic B-Disease 1 0.9999067783355713
benign I-Disease 1 0.9999297857284546
epidermolysis I-Disease 1 0.9998747110366821
bullosa I-Disease 1 0.9983413219451904
. O 0 0.0001527678978163749

Patients O 0 0.02205687388777733
with O 0 7.135202758945525e-05
generalized O 0 0.012121213600039482
atrophic B-Disease 1 0.999915361404419
benign I-Disease 1 0.9999639987945557
epidermolysis I-Disease 1 0.9999045133590698
bullosa I-Disease 1 0.9994612336158752
often O 0 0.0005451955948956311
show O 0 7.429519610013813e-05
decreased O 0 5.25522482348606e-05
expression O 0 9.586540272721322e-07
of O 0 7.590960393599744e-08
type O 0 7.519329301430844e-06
XVII O 0 0.0020289516542106867
collagen O 0 2.9589386031148024e-05
, O 0 3.3944999699997425e-07
a O 0 1.0794050240292563e-06
transmembrane O 0 5.341465566743864e-06
hemidesmosomal O 0 1.4084553185966797e-05
protein O 0 1.2204018275951967e-06
encoded O 0 9.575593367117108e-07
by O 0 8.6594212689306e-07
COL17A1 O 0 0.00043138282489962876
. O 0 6.695774573017843e-06

This O 0 7.580269539175788e-06
report O 0 2.450321971991798e-06
documents O 0 5.163711875866284e-07
a O 0 5.622721346298931e-07
novel O 0 3.7712579796789214e-06
splice O 0 0.0001716716942610219
- O 0 0.0003609676787164062
site O 0 4.794477263203589e-06
mutation O 0 1.3677642982656835e-06
in O 0 7.89173881798888e-08
COL17A1 O 0 4.469454142963514e-05
in O 0 2.2656195142189972e-07
a O 0 3.5612890769698424e-06
patient O 0 1.5001152860349976e-05
with O 0 2.286558128616889e-06
generalized O 0 0.0015813298523426056
atrophic B-Disease 1 0.9999804496765137
benign I-Disease 1 0.9999797344207764
epidermolysis I-Disease 1 0.9999204874038696
bullosa I-Disease 1 0.9954140186309814
, O 0 1.1783002264564857e-05
and O 0 4.1655698623799253e-07
applies O 0 1.849878543680461e-07
a O 0 1.1527396992505601e-07
new O 0 1.1899579277496741e-07
methodology O 0 4.900064709545404e-07
to O 0 3.7743195235862004e-08
define O 0 5.244233420853561e-07
and O 0 3.443873879405146e-07
characterize O 0 1.7201391528942622e-06
the O 0 2.1932639526767161e-07
resulting O 0 1.3661439197676373e-06
mRNA O 0 5.094205334899016e-06
splice O 0 8.436593634542078e-05
variants O 0 3.507188375806436e-05
. O 0 9.125320502789691e-06

Mutational O 0 0.004830817226320505
analysis O 0 3.5911645682062954e-05
of O 0 1.982735511774081e-06
COL17A1 O 0 0.0003878264396917075
identified O 0 9.694376785773784e-06
a O 0 2.954050160042243e-06
maternally O 0 0.00011826986883534119
inherited O 0 0.00011403600365156308
G O 0 0.002084003994241357
- O 0 3.372972787474282e-05
to O 0 2.8223368531143933e-07
- O 0 0.0003858642012346536
T O 0 6.74410694045946e-05
transversion O 0 2.335729277547216e-06
at O 0 3.936111170332879e-08
the O 0 3.788795410741841e-08
- O 0 1.748855765981716e-06
1 O 0 1.5592848967571626e-07
position O 0 1.997117351493216e-07
of O 0 1.0140907136246824e-07
exon O 0 1.8447624825057574e-05
32 O 0 9.738158041727729e-06
. O 0 5.324747689883225e-06

This O 0 5.5865639296825975e-06
acceptor O 0 9.892180059978273e-06
splice O 0 0.0002750115527305752
- O 0 0.0002979848941322416
site O 0 3.383844614290865e-06
mutation O 0 2.4230503186117858e-06
led O 0 2.5052924002011423e-07
to O 0 2.3097886270306844e-08
the O 0 3.5729289749042437e-08
formation O 0 1.1436185332058812e-07
of O 0 1.5064033576095426e-08
aberrant O 0 2.8247086447663605e-06
transcripts O 0 9.415223303221865e-07
present O 0 1.50121820752247e-07
at O 0 1.374192777348071e-07
extremely O 0 9.575903732184088e-07
low O 0 1.663865623413585e-05
levels O 0 1.8480953940525069e-06
. O 0 1.2452983355615288e-06

Based O 0 5.564370803767815e-05
on O 0 3.4855866033467464e-06
our O 0 2.5167682338178565e-07
recent O 0 3.0764823577555944e-07
finding O 0 2.5075107146221853e-07
that O 0 1.1439522751288678e-07
cycloheximide O 0 3.075608765357174e-05
stabilized O 0 7.83248760853894e-05
mutant O 0 1.8122973415302113e-05
COL17A1 O 0 2.3174479792942293e-05
transcripts O 0 1.3313116369317868e-06
in O 0 1.5627118443717336e-07
keratinocytes O 0 2.5367411581100896e-05
homozygous O 0 6.501618372567464e-06
for O 0 3.271513904223866e-08
a O 0 6.9819238888158e-06
frameshift O 0 0.11543593555688858
mutation O 0 6.034001216903562e-06
, O 0 7.136884505598573e-08
the O 0 6.578995481731909e-08
effects O 0 1.6834807183840894e-06
of O 0 2.4770113071781452e-08
the O 0 1.5242206075072318e-07
splice O 0 0.0001113983744289726
- O 0 9.122314804699272e-05
site O 0 2.6579375571600394e-06
mutation O 0 4.70246078521086e-07
on O 0 8.382754401736747e-08
splicing O 0 1.0406962474007742e-06
of O 0 7.717356709235901e-08
COL17A1 O 0 3.200292485416867e-05
transcripts O 0 2.214442019976559e-06
were O 0 1.7904211802033387e-07
determined O 0 1.4294236905243451e-07
using O 0 1.354120513497037e-07
reverse O 0 4.768976396007929e-06
transcriptase O 0 1.1648036888800561e-05
polymerase O 0 4.578475454763975e-06
chain O 0 2.675454879863537e-06
reaction O 0 2.1224823854026909e-07
of O 0 2.355641726126123e-08
total O 0 7.702239912532605e-08
RNA O 0 6.629077802244865e-07
from O 0 6.111805106456814e-08
keratinocytes O 0 4.058303602505475e-06
incubated O 0 3.2062357604445424e-06
for O 0 1.4688484384350886e-07
2 O 0 2.830187668223516e-06
. O 0 2.7269772999716224e-06

5 O 0 0.00016457965830340981
h O 0 0.00010350798402214423
in O 0 2.8401410645528813e-07
the O 0 1.290428741640426e-07
presence O 0 3.092891347478144e-07
or O 0 2.462728616592358e-07
absence O 0 3.241174226786825e-07
of O 0 8.083711122708337e-08
10 O 0 3.5458350566841546e-07
microg O 0 1.6163116015377454e-05
cycloheximide O 0 2.585882248240523e-05
per O 0 2.7214746296522208e-06
ml O 0 4.838447421207093e-05
. O 0 6.0030251916032284e-06

Using O 0 1.0133275281987153e-05
this O 0 3.6354720123199513e-07
approach O 0 1.0842622941709124e-06
, O 0 1.6041461492477538e-07
an O 0 1.8879262597693014e-07
abnormally O 0 4.070870272698812e-05
spliced O 0 0.003149354597553611
transcript O 0 0.006844830699265003
was O 0 0.00011993880616500974
identified O 0 9.213774205818481e-07
that O 0 9.459954597446085e-09
contains O 0 1.4889099730908129e-08
an O 0 1.10669393649232e-08
extra O 0 9.239514753289768e-08
264 O 0 2.612017624414875e-07
bases O 0 1.6283233605918213e-07
upstream O 0 2.8965834530936263e-07
from O 0 2.9046544725019885e-08
exon O 0 9.782164624994039e-07
32 O 0 5.267179403745104e-07
, O 0 4.102826522967007e-08
resulting O 0 1.7739419888584962e-07
in O 0 6.075600111898893e-08
a O 0 9.96910898720671e-07
premature O 0 1.941284972417634e-05
termination O 0 4.243778221280081e-06
codon O 0 2.878210580092855e-06
27 O 0 3.5357488741283305e-06
bp O 0 4.970122972736135e-06
downstream O 0 6.093659408179519e-07
from O 0 4.16653840318304e-08
the O 0 1.632277246699232e-07
cryptic O 0 1.165717276307987e-05
splice O 0 0.00015166829689405859
site O 0 2.519676309020724e-05
. O 0 5.4948104661889374e-06

Three O 0 9.556923032505438e-06
other O 0 7.164269959503144e-07
splice O 0 7.94377556303516e-05
variants O 0 1.2173133654869162e-05
, O 0 4.0651684685144573e-07
including O 0 8.032162668314413e-08
one O 0 8.36759426192657e-08
derived O 0 9.769598818820668e-08
from O 0 1.0878937750646855e-08
the O 0 1.673783778244342e-08
skipping O 0 1.476344948514452e-07
of O 0 2.489928618842896e-08
exon O 0 2.6481106942810584e-06
32 O 0 1.1394938610465033e-06
, O 0 8.557223907246225e-08
were O 0 3.984575869253604e-07
also O 0 1.2928222759001073e-06
identified O 0 6.973765266593546e-06
. O 0 2.4886667233658955e-06

These O 0 5.70071051697596e-06
results O 0 3.926913450413849e-06
indicate O 0 6.731582971042371e-07
the O 0 6.22633820057672e-08
usefulness O 0 9.630643944547046e-07
of O 0 1.1745822803277406e-07
cycloheximide O 0 0.00010548126010689884
treatment O 0 4.376648575998843e-06
in O 0 6.086735737653726e-08
evaluating O 0 2.0512995035915083e-07
the O 0 1.4241508949908166e-07
abnormal O 0 1.564264152875694e-06
processing O 0 9.161826852732702e-08
of O 0 8.953344732276491e-09
mRNA O 0 1.3890910111058474e-07
due O 0 6.796748408532949e-08
to O 0 2.51177514343226e-08
splice O 0 2.2243168132263236e-05
- O 0 8.131388312904164e-05
site O 0 7.08889774614363e-06
mutations O 0 2.6054078716697404e-06
, O 0 6.157015519647757e-08
because O 0 5.807283898207061e-08
( O 0 1.7146477659935044e-07
i O 0 1.5353433013842732e-07
) O 0 6.58050183233172e-08
aberrant O 0 1.135852812694793e-06
splicing O 0 4.0713207454246e-06
often O 0 7.001942208262335e-07
generates O 0 2.345232559264332e-07
a O 0 2.3083403277723846e-07
premature O 0 3.3192875434906455e-06
termination O 0 5.93459299125243e-06
codon O 0 2.7479904929350596e-06
, O 0 1.0682248330340371e-07
( O 0 8.991477784547897e-08
ii O 0 9.834734555624891e-07
) O 0 5.461560093067419e-08
transcripts O 0 2.54518198516962e-07
with O 0 1.0375631376291494e-07
premature O 0 6.08846448812983e-06
termination O 0 2.230982317996677e-06
codons O 0 1.4088820989854867e-06
can O 0 7.799812351549917e-08
occur O 0 7.136326019008266e-08
at O 0 5.725074814222353e-08
low O 0 3.4386368952254998e-06
or O 0 3.212904005067685e-07
undetectable O 0 3.0439468901022337e-06
levels O 0 1.2299366858314897e-07
due O 0 4.98323267095202e-08
to O 0 2.7873328534155917e-08
nonsense O 0 1.235661670762056e-06
- O 0 1.4286565601651091e-06
mediated O 0 2.5406352506252006e-06
mRNA O 0 5.142908321431605e-07
decay O 0 3.501064043121005e-07
, O 0 2.717482772141011e-08
and O 0 8.681956842337968e-08
( O 0 1.290697042577449e-07
iii O 0 4.922410425933776e-06
) O 0 2.680720356806887e-08
the O 0 2.85795334065142e-08
levels O 0 1.8458704786894486e-08
of O 0 2.82256618078236e-09
these O 0 6.349769154923024e-09
transcripts O 0 1.3534621245980816e-07
can O 0 4.089045191335572e-08
be O 0 2.4819058808134287e-08
increased O 0 4.050335746796918e-07
by O 0 1.1658607235176532e-07
cycloheximide O 0 6.034258331055753e-05
. O 0 2.180303908971837e-06

A O 0 0.0003597769245970994
deletion O 0 0.002460557036101818
mutation O 0 0.00016267062164843082
in O 0 1.3072000228930847e-06
COL17A1 O 0 0.00023534754291176796
in O 0 4.622982032742584e-07
five O 0 9.44201929087285e-07
Austrian O 0 6.926079367985949e-05
families O 0 2.0007823877676856e-06
with O 0 2.269034439450479e-06
generalized O 0 0.0014885234413668513
atrophic B-Disease 1 0.9998675584793091
benign I-Disease 1 0.9999678134918213
epidermolysis I-Disease 1 0.999789297580719
bullosa I-Disease 1 0.9689369201660156
represents O 0 2.9860808353987522e-05
propagation O 0 1.3283973203215282e-05
of O 0 1.9084542657310521e-07
an O 0 5.547968839891837e-07
ancestral O 0 5.7682336773723364e-05
allele O 0 0.00013707033940590918
. O 0 7.812750482116826e-06

Patients O 0 0.010356753133237362
with O 0 2.9664848625543527e-05
generalized O 0 0.003941687289625406
atrophic B-Disease 1 0.9999127388000488
benign I-Disease 1 0.9999357461929321
epidermolysis I-Disease 1 0.9999523162841797
bullosa I-Disease 1 0.9990538954734802
, O 0 1.1673904737108387e-05
a O 0 1.7288684830418788e-06
usually O 0 6.642708854087687e-07
nonlethal O 0 6.762468728993554e-06
form O 0 1.5189168607321335e-06
of O 0 1.4066132507650764e-06
junctional B-Disease 1 0.9899663925170898
epidermolysis I-Disease 1 0.9996310472488403
bullosa I-Disease 1 0.9048451781272888
, O 0 2.4815803953970317e-06
have O 0 6.753883781129844e-07
generalized O 0 1.075566433428321e-05
blistering B-Disease 0 0.33112457394599915
, O 0 3.834631570498459e-05
nail B-Disease 1 0.9999959468841553
dystrophy I-Disease 1 0.9999808073043823
, O 0 2.0237888747942634e-05
patchy B-Disease 1 0.9913771152496338
alopecia I-Disease 1 0.9999992847442627
, O 0 1.605505713087041e-05
and O 0 7.3461422289256e-05
dental B-Disease 1 0.8284878134727478
abnormalities I-Disease 1 0.999882698059082
. O 0 1.715766848064959e-05

Skin B-Disease 1 0.9999946355819702
fragility I-Disease 1 0.7150129675865173
in O 0 6.1846262724429835e-06
most O 0 5.180230573387234e-07
cases O 0 2.932455345217022e-07
is O 0 1.3076585503313254e-07
due O 0 2.893298187700566e-07
to O 0 1.6333515873157012e-07
mutations O 0 1.2142627383582294e-06
in O 0 2.190976466920347e-08
the O 0 6.593517554165373e-08
gene O 0 7.038496505629155e-07
encoding O 0 3.3125581921922276e-06
type O 0 4.659159094444476e-05
XVII O 0 0.02756427973508835
collagen O 0 0.0003333534696139395
( O 0 3.679985638882499e-06
COL17A1 O 0 0.0001534918264951557
) O 0 2.3944603526615538e-06
. O 0 2.7952341952186543e-06

Recently O 0 0.0003095849242527038
, O 0 2.4030339318414917e-06
we O 0 1.885353384523114e-07
reported O 0 6.471305482591561e-07
five O 0 2.1736653366133396e-07
Austrian O 0 2.0511133698164485e-05
families O 0 6.909116336828447e-07
with O 0 1.0536466561461566e-06
generalized O 0 0.0006711315945722163
atrophic B-Disease 1 0.9994920492172241
benign I-Disease 1 0.9993159770965576
epidermolysis I-Disease 1 0.9993471503257751
bullosa I-Disease 1 0.9750705361366272
who O 0 0.00013788438809569925
share O 0 3.3287187761743553e-06
the O 0 2.974291533064388e-07
same O 0 2.059883172478294e-06
COL17A1 O 0 0.0010660934494808316
mutation O 0 4.6710683818673715e-05
. O 0 3.534477855282603e-06

Affected O 0 0.00022559889475814998
individuals O 0 1.7165731378554483e-06
in O 0 2.4854833213794336e-07
three O 0 4.2402643884997815e-07
families O 0 4.302383445065061e-07
are O 0 4.4360778161944836e-08
homozygous O 0 2.1833479877386708e-06
for O 0 4.5803961512547176e-08
4003delTC O 0 1.0651720003806986e-05
, O 0 1.480093487771228e-07
whereas O 0 1.0539888961602628e-07
those O 0 8.793865191591976e-09
in O 0 1.992385456617285e-08
two O 0 1.6623118881398113e-07
others O 0 4.771032422468124e-07
are O 0 9.476156748178255e-08
compound O 0 9.321465768152848e-06
heterozygotes O 0 9.345653234049678e-05
. O 0 4.199464001430897e-06

To O 0 5.099391728435876e-06
determine O 0 1.1562644885998452e-06
if O 0 9.474313600321693e-08
the O 0 6.376156136411737e-08
occurrence O 0 5.541908763007086e-07
of O 0 4.291663202593554e-08
4003delTC O 0 8.07950709713623e-06
in O 0 6.906192595579341e-08
these O 0 2.1618767220843438e-08
unrelated O 0 7.826978958291875e-07
families O 0 2.3504092894199857e-07
signifies O 0 6.18362548721052e-07
propagation O 0 2.908985266003583e-07
of O 0 6.434919708198095e-09
an O 0 2.8685043673704058e-08
ancestral O 0 3.4349561701674247e-06
allele O 0 4.134211849304847e-06
or O 0 1.4163047978854593e-07
a O 0 5.546730790229049e-07
mutational O 0 8.042290573939681e-05
hot O 0 4.11425789934583e-05
spot O 0 3.0143024559947662e-05
, O 0 2.3120568926060514e-07
haplotypes O 0 7.608812666148879e-06
were O 0 7.426608590321848e-07
determined O 0 5.592186198555282e-07
for O 0 1.5344869552791351e-07
polymorphisms O 0 6.380912236636505e-05
both O 0 1.5552306820154627e-07
within O 0 1.886301106424071e-07
and O 0 7.995034252417099e-07
flanking O 0 0.0005357401678338647
COL17A1 O 0 0.002033909084275365
. O 0 1.2350734323263168e-05

Five O 0 0.00015964881458785385
intragenic O 0 0.0012219678610563278
polymorphisms O 0 0.009359430521726608
were O 0 3.998765805590665e-06
chosen O 0 4.708743404080451e-07
based O 0 2.9666796308447374e-07
on O 0 8.996046858555928e-07
their O 0 9.262917615160404e-07
informativeness O 0 0.00015667507250327617
. O 0 3.167854629282374e-06

One O 0 5.126942596689332e-06
of O 0 1.4891804767103167e-07
these O 0 3.2731303889477203e-08
, O 0 6.188120238448391e-08
not O 0 2.6160357435855985e-08
previously O 0 8.584063948546827e-07
reported O 0 3.294616135463002e-06
, O 0 6.45470095150813e-08
was O 0 5.147192041476956e-07
2988 O 0 6.605242219848151e-07
A O 0 7.324513262574328e-07
or O 0 4.3607192878880596e-07
C O 0 2.2474382603832055e-06
that O 0 1.1176099157239605e-08
introduces O 0 1.7724100587201974e-07
a O 0 6.999017898579041e-08
new O 0 6.704443933358561e-08
restriction O 0 1.38394739224168e-07
site O 0 2.2680708866573696e-07
for O 0 6.334034452493142e-08
Eco0109 O 0 1.102694841392804e-05
I O 0 3.171579010086134e-06
. O 0 2.0075390239071567e-06

All O 0 2.706486156967003e-06
the O 0 8.622017730886e-07
4003delTC O 0 2.0229204892530106e-05
alleles O 0 5.220961611485109e-06
showed O 0 3.6979065498599084e-06
the O 0 6.000512797754709e-08
same O 0 1.8392709932868456e-07
haplotype O 0 1.1240274034207687e-05
for O 0 6.369190685973081e-08
these O 0 7.316938877011125e-08
five O 0 5.021914830649621e-07
polymorphic O 0 4.720100696431473e-05
markers O 0 9.852435323409736e-05
. O 0 4.751543656311696e-06

Fourteen O 0 0.0003674459003377706
microsatellite O 0 0.00383578147739172
polymorphisms O 0 0.05308680236339569
were O 0 1.2617073480214458e-05
selected O 0 4.432056357472902e-07
based O 0 2.6388082119410683e-07
on O 0 7.635757697244117e-07
their O 0 2.8819025033044454e-07
high O 0 1.0590499186946545e-05
heterozygosity O 0 2.8607257263502106e-05
and O 0 1.893430976451782e-07
their O 0 4.861792746169158e-08
location O 0 5.729012286792567e-07
within O 0 2.2451729364547646e-07
10q23 O 0 4.685048679675674e-06
- O 0 9.669916835264303e-06
q25 O 0 1.3179502275306731e-05
near O 0 9.201839020533953e-06
COL17A1 O 0 0.00014860874216537923
. O 0 6.44403826299822e-06

Three O 0 4.102860111743212e-05
families O 0 9.991847946366761e-06
shared O 0 9.066093298315536e-06
microsatellite O 0 0.0018947968492284417
polymorphisms O 0 0.0012462770100682974
covering O 0 7.447726602549665e-06
at O 0 3.318827168641292e-07
most O 0 7.088561204682264e-08
19 O 0 1.2945693015353754e-06
cM O 0 8.469089152640663e-06
, O 0 7.152296888079945e-08
whereas O 0 6.134427366077944e-08
the O 0 6.231470450757115e-08
others O 0 1.1819074785535122e-07
shared O 0 6.86801868710063e-08
smaller O 0 1.2650231440147763e-07
regions O 0 1.1486880424627088e-07
consistent O 0 1.6573810057707306e-07
with O 0 4.970996059228128e-08
cross O 0 2.2386016098607797e-06
- O 0 5.790245722891996e-06
over O 0 1.0400717087577505e-07
events O 0 1.0017086538027797e-07
during O 0 1.8916279032055172e-07
passage O 0 1.93019943139916e-07
of O 0 1.682932904145673e-08
this O 0 3.009919069540956e-08
mutation O 0 4.900195449408784e-07
through O 0 6.92230770482638e-08
several O 0 3.7355241033765196e-07
generations O 0 3.3860203529911814e-06
. O 0 2.9366744911385467e-06

These O 0 5.9532426348596346e-06
results O 0 4.706804702436784e-06
indicate O 0 1.057531449077942e-06
that O 0 9.532099198850119e-08
4003delTC O 0 1.089465877157636e-05
occurs O 0 1.9873648682278144e-07
on O 0 1.9725084143829008e-07
a O 0 3.899507134974556e-07
single O 0 2.0581746866810136e-06
ancestral O 0 7.949561222631019e-06
allele O 0 9.985427823266946e-06
. O 0 9.069517545867711e-07
. O 0 4.223187715979293e-06

The O 0 3.2810599805088714e-05
haptoglobin O 0 0.0010324799222871661
- O 0 0.0002679764584172517
gene O 0 2.6460294975549914e-05
deletion O 0 4.1444804082857445e-05
responsible O 0 2.82934570350335e-06
for O 0 1.0203326610280783e-06
anhaptoglobinemia B-Disease 0 0.0006284943083301187
. O 0 1.1466711839602794e-05

We O 0 1.14727163236239e-05
have O 0 4.813567784367478e-07
found O 0 1.582098008157118e-07
an O 0 5.1403389988990966e-08
allelic O 0 1.3212385965744033e-05
deletion O 0 6.7527766987041105e-06
of O 0 4.075846860018828e-08
the O 0 4.824279926651798e-07
haptoglobin O 0 8.049257303355262e-05
( O 0 3.152401859551901e-07
Hp O 0 1.3728674730373314e-06
) O 0 4.222226479555502e-08
gene O 0 8.092056447139839e-08
from O 0 1.7490956238930266e-08
an O 0 3.986065166827757e-08
individual O 0 5.672715630566927e-08
with O 0 3.5025834677071543e-07
anhaptoglobinemia B-Disease 0 0.0002142761804861948
. O 0 3.03623482977855e-06

The O 0 1.5132481166801881e-05
Hp O 0 3.75624731532298e-05
gene O 0 3.7991835597495083e-06
cluster O 0 1.8050434391625458e-06
consists O 0 3.980102007972164e-07
of O 0 3.481326515952787e-08
coding O 0 1.1523824468895327e-05
regions O 0 3.3072697647185123e-07
of O 0 4.9954614667058195e-08
the O 0 1.2750359701385605e-07
alpha O 0 4.664611310545297e-07
chain O 0 1.2110431271139532e-06
and O 0 4.209529791410205e-08
beta O 0 7.469881779798015e-08
chain O 0 2.2305835045699496e-07
of O 0 8.00319455152021e-09
the O 0 3.299915718457669e-08
haptoglobin O 0 5.06271999256569e-06
gene O 0 6.768984803784406e-07
( O 0 1.2721100972612476e-07
Hp O 0 1.0930758662652806e-06
) O 0 2.31711787535005e-08
and O 0 1.372302360636013e-08
of O 0 7.56528617529284e-09
the O 0 7.182413241935137e-08
alpha O 0 2.7444707484391984e-07
chain O 0 9.076397304852435e-07
and O 0 6.403956831491087e-08
beta O 0 1.0341076972508745e-07
chain O 0 2.0077446549748856e-07
of O 0 6.310469036208133e-09
the O 0 5.0574225696209396e-08
haptoglobin O 0 1.3118698007019702e-05
- O 0 1.1239170817134436e-05
related O 0 5.659189810103271e-07
gene O 0 1.3381572898651939e-06
( O 0 5.131698799232254e-07
Hpr O 0 2.2418820663006045e-05
) O 0 7.006605073911487e-08
, O 0 1.9087778468929173e-08
in O 0 3.986894014929021e-08
tandem O 0 5.068623067927547e-06
from O 0 3.387578573210703e-08
the O 0 1.1578055136851617e-07
5 O 0 1.1198587799299276e-06
side O 0 8.271721526398323e-06
. O 0 2.5947699668904534e-06

Southern O 0 0.00023748261446598917
blot O 0 0.0005856462521478534
and O 0 4.107766471861396e-06
PCR O 0 4.227473618811928e-05
analyses O 0 3.1737604331283364e-06
have O 0 3.4295774753445585e-07
indicated O 0 1.2849850463680923e-06
that O 0 1.269520844005001e-08
the O 0 1.9088250979848453e-08
individual O 0 1.504112390193768e-08
with O 0 7.020343417707409e-08
anhaptoglobinemia B-Disease 0 3.700269007822499e-05
was O 0 1.7095864677685313e-05
homozygous O 0 1.3887496379538788e-06
for O 0 1.4110650425891436e-08
the O 0 3.808764148516275e-08
gene O 0 1.860887692828328e-07
deletion O 0 1.5215250641631428e-06
and O 0 2.1338601641218702e-07
that O 0 1.9739040624244808e-08
the O 0 5.130045011014772e-08
gene O 0 3.4601896459207637e-07
deletion O 0 2.697883928703959e-06
was O 0 4.943820840708213e-06
included O 0 7.07744263195309e-08
at O 0 4.63224978375365e-08
least O 0 1.9009082308230063e-08
from O 0 1.0651582726950437e-08
the O 0 4.7541817593810265e-08
promoter O 0 1.1738885632439633e-06
region O 0 2.2939441635116964e-07
of O 0 2.9020958081105164e-08
Hp O 0 1.0623562047840096e-06
to O 0 8.713776367130777e-08
Hpr O 0 4.490626452025026e-06
alpha O 0 2.704117889607005e-07
but O 0 3.45751729469157e-08
not O 0 2.516608788027952e-08
to O 0 9.966981906472938e-08
Hpr O 0 3.686771742650308e-05
beta O 0 2.369876938246307e-06
( O 0 5.086988039693097e-07
Hpdel O 0 1.559104748594109e-05
) O 0 6.498535753962642e-07
. O 0 2.0043403310410213e-06

In O 0 7.305653980438365e-06
addition O 0 1.131487238126283e-06
, O 0 2.2498626606193284e-07
we O 0 4.049022095387045e-08
found O 0 6.696737386846507e-08
seven O 0 8.22290644464374e-08
individuals O 0 1.3076830285285723e-08
with O 0 1.9063509881789287e-08
hypohaptoglobinemia B-Disease 0 1.3200346074881963e-05
in O 0 1.3335515802737063e-07
three O 0 3.013705338617001e-07
families O 0 1.5516809526161524e-07
, O 0 3.1772348307868015e-08
and O 0 4.96321810317113e-08
the O 0 5.593445351337323e-08
genotypes O 0 1.0604188673823955e-06
of O 0 1.138859673233128e-08
six O 0 1.3430754108867404e-07
of O 0 7.804154655843831e-09
the O 0 8.753890057278113e-08
seven O 0 4.1958827523558284e-07
individuals O 0 1.0355401869333036e-08
were O 0 3.460182185222038e-08
found O 0 3.058455533277993e-08
to O 0 3.983670993079613e-08
be O 0 2.155211689114367e-07
Hp2 O 0 3.4917604352813214e-05
/ O 0 1.9946493921452202e-05
Hpdel O 0 6.271988240769133e-05
. O 0 4.277331754565239e-06

The O 0 1.9471364794299006e-05
phenotypes O 0 0.0006607518880628049
and O 0 8.797106602287386e-06
genotypes O 0 0.00011448665463831276
in O 0 3.940092767606984e-07
one O 0 5.2937686234599823e-08
of O 0 7.513460964503338e-09
these O 0 2.061146808784997e-08
three O 0 2.500632945157122e-07
families O 0 3.7161166233090626e-07
showed O 0 2.581370381449233e-06
the O 0 1.3810251608958879e-08
father O 0 1.439173615835898e-07
to O 0 3.0221951163866834e-08
be O 0 6.051925538486103e-08
hypohaptoglobinemic B-Disease 0 5.911546395509504e-06
( O 0 1.1919125597614766e-07
Hp2 O 0 2.269049673486734e-06
) O 0 3.1805878819568534e-08
and O 0 4.5323201192104534e-08
Hp2 O 0 7.4260947258153465e-06
/ O 0 4.0662571336724795e-06
Hpdel O 0 3.5453044802125078e-06
, O 0 2.2475546757050324e-08
the O 0 2.8261014861641343e-08
mother O 0 2.890225800911139e-07
to O 0 1.0106186110192539e-08
be O 0 2.720480374307499e-08
Hp2 O 0 1.641933408791374e-06
- O 0 7.129822279239306e-07
1 O 0 8.548725105583799e-08
and O 0 8.615198510142363e-08
Hp1 O 0 6.865294380986597e-06
/ O 0 2.0548720840452006e-06
Hp2 O 0 2.426625542284455e-06
, O 0 1.761593892979363e-08
one O 0 3.5071237025618984e-09
of O 0 2.7861195572853603e-09
the O 0 1.6480825593134796e-08
two O 0 7.600725382417295e-08
children O 0 7.26840880815871e-08
to O 0 1.3708059576345022e-08
be O 0 3.992509789441101e-08
hypohaptoglobinemic B-Disease 0 8.743351827433798e-06
( O 0 9.185430371871917e-08
Hp2 O 0 1.814165784708166e-06
) O 0 4.306710010837378e-08
and O 0 6.832792820432587e-08
Hp2 O 0 1.386138319503516e-05
/ O 0 9.563022103975527e-06
Hpdel O 0 8.831991181068588e-06
, O 0 4.428790489896528e-08
and O 0 2.4561416012147674e-08
the O 0 2.647726304871867e-08
other O 0 1.565775242795553e-08
child O 0 3.7999916457920335e-07
to O 0 2.562800993644032e-08
be O 0 5.1248811416826356e-08
Hp1 O 0 2.227009190391982e-06
and O 0 1.3980405810798402e-07
Hp1 O 0 1.8061169612337835e-05
/ O 0 7.383695447060745e-06
Hpdel O 0 7.869350156397559e-06
, O 0 6.103162064619028e-08
showing O 0 2.0587192750554095e-07
an O 0 3.134970683049687e-08
anomalous O 0 5.868940206710249e-06
inheritance O 0 4.649373749998631e-06
of O 0 1.565339999842763e-07
Hp O 0 7.45625511626713e-05
phenotypes O 0 2.318926817679312e-05
in O 0 1.4307315154837852e-07
the O 0 2.6996087854058715e-07
child O 0 4.6235290938057005e-06
with O 0 1.8962640524478047e-06
Hp1 O 0 0.000541259883902967
. O 0 4.8923784561338834e-06

The O 0 2.1151861801627092e-05
Hp2 O 0 0.0009096147841773927
/ O 0 0.00032806562376208603
Hpdel O 0 0.00014805416867602617
individuals O 0 5.27082761436759e-07
had O 0 9.72235284280032e-07
an O 0 8.795848316367483e-08
extremely O 0 5.54102086880448e-07
low O 0 2.7865971787832677e-06
level O 0 9.457829719394795e-08
of O 0 4.3868972454674804e-08
Hp O 0 8.187088496924844e-06
( O 0 1.6306326244830416e-07
mean O 0 1.8577918581286212e-07
+ O 0 1.5624138995917747e-06
/ O 0 2.1873286186746554e-06
- O 0 5.225359927862883e-06
SD O 0 3.934108462999575e-05
= O 0 5.61028082302073e-06
0 O 0 5.268686322779104e-07
. O 0 8.626592773453012e-08
049 O 0 8.152503141900524e-06
+ O 0 2.901182824643911e-06
/ O 0 2.133346470145625e-06
- O 0 2.3977736418601125e-06
0 O 0 4.795560357706563e-07
. O 0 4.6873985581896704e-08
043 O 0 4.767321115650702e-06
mg O 0 5.150028755451785e-06
/ O 0 1.3344437093110173e-06
ml O 0 2.261626377730863e-06
; O 0 1.991443809856719e-07
n O 0 2.148590510842041e-06
= O 0 3.6815581552218646e-06
6 O 0 4.019225627871492e-07
) O 0 3.800585801627676e-08
, O 0 2.4410100607497043e-08
compared O 0 8.752888192020691e-08
with O 0 9.26990750826917e-09
the O 0 5.5750831506884424e-08
level O 0 9.843989090541072e-08
( O 0 2.3164284712606786e-08
1 O 0 1.813807415373958e-08
. O 0 9.604200101875904e-09
64 O 0 1.558963731440599e-07
+ O 0 3.2505099056834297e-07
/ O 0 5.219744139139948e-07
- O 0 3.950733571400633e-07
1 O 0 9.986811022599795e-08
. O 0 2.281081101784821e-08
07 O 0 7.372349841716641e-07
mg O 0 2.9016366625000956e-06
/ O 0 1.135858155976166e-06
ml O 0 1.5064744047776912e-06
) O 0 3.094737976994111e-08
obtained O 0 3.035679085883203e-08
from O 0 2.7183070017144928e-08
52 O 0 5.71629016121733e-07
healthy O 0 4.963293918081035e-07
volunteers O 0 6.811412731622113e-07
having O 0 4.983480152986886e-07
phenotype O 0 2.2112042643129826e-05
Hp2 O 0 7.293708222277928e-06
, O 0 7.535508217415554e-08
whereas O 0 1.1137077393641448e-07
the O 0 6.780239658610299e-08
serum O 0 5.0901408030767925e-06
Hp O 0 1.945823896676302e-06
level O 0 2.7420997028571037e-08
of O 0 6.536927887879074e-09
an O 0 1.641923397244227e-08
individual O 0 2.0713855519716162e-08
with O 0 1.384472767540501e-07
Hp1 O 0 0.0001339781447313726
/ O 0 2.6477686333237216e-05
Hpdel O 0 4.440010161488317e-05
was O 0 8.902396984922234e-06
0 O 0 4.475999048736412e-06
. O 0 2.238885372207733e-06

50 O 0 0.00010672715143300593
mg O 0 0.00023392317234538496
/ O 0 8.566612814320251e-05
ml O 0 3.8867787225171924e-05
, O 0 2.942405501471512e-07
which O 0 1.3476558535785443e-07
was O 0 4.6553674337701523e-07
approximately O 0 2.052007097574915e-08
half O 0 4.586043189647171e-08
the O 0 1.58874406963605e-08
level O 0 2.567522372487474e-08
of O 0 7.167439086686045e-09
Hp O 0 9.24695996218361e-07
in O 0 4.7826215876511924e-08
control O 0 1.860544898590888e-06
sera O 0 2.103593487845501e-06
from O 0 2.4363259853998898e-08
the O 0 1.625180203745913e-07
Hp1 O 0 0.00011012568575097248
phenotype O 0 4.336802157922648e-05
( O 0 1.231242805488364e-07
1 O 0 1.3674926435669477e-07
. O 0 2.252270725477956e-08
26 O 0 2.751462773176172e-07
+ O 0 6.291147087722493e-07
/ O 0 8.284394539259665e-07
- O 0 8.168146337084181e-07
0 O 0 2.059410491028757e-07
. O 0 1.8433444992638215e-08
33 O 0 2.658992173110164e-07
mg O 0 1.5405382782773813e-06
/ O 0 1.0311096048098989e-06
ml O 0 1.76333048784727e-06
; O 0 1.9102206749721518e-07
n O 0 2.014254732785048e-06
= O 0 3.7436052480188664e-06
9 O 0 5.86444684813614e-07
) O 0 2.8459535172942196e-08
, O 0 1.6964559534926593e-08
showing O 0 1.6080487341696426e-07
a O 0 2.1790907567265094e-07
gene O 0 1.817343445509323e-06
- O 0 1.609031096450053e-05
dosage O 0 1.7712956832838245e-05
effect O 0 3.6492624531092588e-06
. O 0 2.1194211967667798e-06

The O 0 9.7455813374836e-06
other O 0 8.90363764938229e-07
allele O 0 1.4715738871018402e-05
( O 0 6.603082738365629e-07
Hp2 O 0 9.538794074614998e-06
) O 0 6.446383338243322e-08
of O 0 7.753590658410303e-09
individuals O 0 1.2828108353346579e-08
with O 0 3.20710533685542e-08
Hp2 O 0 6.97875366313383e-05
/ O 0 1.9509801859385334e-05
Hpdel O 0 1.5247819646901917e-05
was O 0 2.5301631012553116e-06
found O 0 4.2966348701156676e-08
to O 0 2.384937047850144e-08
have O 0 7.08539786842266e-08
, O 0 3.132400649974443e-08
in O 0 1.6031604488375706e-08
all O 0 1.5716967283196936e-08
exons O 0 3.770855073526036e-06
, O 0 2.5970450678869383e-07
no O 0 2.084994150663988e-07
mutation O 0 8.039302201723331e-07
, O 0 2.4137220222542055e-08
by O 0 6.717731082517275e-08
DNA O 0 2.5035301405296195e-06
sequencing O 0 5.461827640829142e-06
. O 0 3.3783467188186478e-06

On O 0 3.4094748116331175e-05
the O 0 2.2499830265587661e-07
basis O 0 8.193582345938921e-08
of O 0 2.0867798156132267e-08
the O 0 9.927196487069523e-08
present O 0 1.0538622774447504e-07
study O 0 4.3045339737091126e-08
, O 0 1.4398018777228572e-08
the O 0 1.2967841023225901e-08
mechanism O 0 1.031228009651386e-07
of O 0 3.799701531193023e-08
anhaptoglobinemia B-Disease 0 1.0642875167832244e-05
and O 0 1.6399084756812954e-07
the O 0 3.742812282325758e-08
mechanism O 0 2.690074154543254e-07
of O 0 2.6965922828026123e-08
anomalous O 0 4.089633875992149e-06
inheritance O 0 2.517627763154451e-06
of O 0 1.6740719388508296e-07
Hp O 0 7.176322833402082e-05
phenotypes O 0 4.830070975003764e-05
were O 0 1.0454471066623228e-06
well O 0 6.81514222833357e-07
explained O 0 6.397562174242921e-06
. O 0 2.423329988232581e-06

However O 0 3.0392820917768404e-05
, O 0 7.93321703440597e-07
the O 0 1.7944074670595e-07
mechanism O 0 1.3802069815938012e-06
of O 0 6.198162054715795e-07
hypohaptoglobinemia B-Disease 0 0.00045308726839721203
remains O 0 5.581658842856996e-05
unknown O 0 6.45039981463924e-05

ATM O 0 0.006425563711673021
mutations O 0 0.01280796155333519
and O 0 3.0695460736751556e-05
phenotypes O 0 0.01457889098674059
in O 0 0.0005147075280547142
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 5.394169420469552e-05
in O 0 5.214888005866669e-07
the O 0 5.813883490191074e-07
British O 0 2.260359178762883e-05
Isles O 0 8.930279363994487e-06
: O 0 4.475417725302577e-08
expression O 0 4.00720381321662e-08
of O 0 9.548436707973451e-09
mutant O 0 1.299529685638845e-06
ATM O 0 2.554902721385588e-06
and O 0 1.081967653249194e-07
the O 0 1.3780156393750076e-07
risk O 0 1.184449047286762e-06
of O 0 5.497040547197685e-07
leukemia B-Disease 1 0.9865516424179077
, O 0 0.000596147496253252
lymphoma B-Disease 1 1.0
, O 0 8.920958862290718e-06
and O 0 6.200105417519808e-05
breast B-Disease 1 0.9996435642242432
cancer I-Disease 0 0.060210634022951126
. O 0 1.0983143511111848e-05

We O 0 2.1746142010670155e-05
report O 0 1.5149877299336367e-06
the O 0 1.0557574370295697e-07
spectrum O 0 1.12568375243427e-06
of O 0 6.571157484813739e-08
59 O 0 3.867183295369614e-06
ATM O 0 2.9400673156487755e-05
mutations O 0 2.304465124325361e-05
observed O 0 3.0794226404395886e-06
in O 0 1.4585676581191365e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 0.00037965213414281607
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.338140348001616e-06
patients O 0 5.943888368165062e-07
in O 0 4.678689435877459e-08
the O 0 3.6804661363021296e-07
British O 0 1.6340465663233772e-05
Isles O 0 5.495751975104213e-05
. O 0 4.264225026417989e-06

Of O 0 8.955797966336831e-06
51 O 0 4.562241520034149e-05
ATM O 0 0.00018241358338855207
mutations O 0 2.9994660508236848e-05
identified O 0 1.3658910802405444e-06
in O 0 1.6077881070941658e-07
families O 0 4.0579911342319974e-07
native O 0 9.955031998742925e-08
to O 0 3.1952662737921855e-08
the O 0 1.1814150013833569e-07
British O 0 3.411909801798174e-06
Isles O 0 4.9834552555694245e-06
, O 0 8.641644910767354e-08
11 O 0 2.5055601327039767e-07
were O 0 3.1422206347997417e-07
founder O 0 2.2136059669719543e-06
mutations O 0 7.450535690622928e-07
, O 0 1.8420474034996914e-08
and O 0 2.298402002054445e-08
2 O 0 5.697916805047498e-08
of O 0 8.519388750016788e-09
these O 0 1.6341470399083846e-08
11 O 0 1.365629032079596e-07
conferred O 0 3.156077639232535e-07
a O 0 1.016026430988859e-06
milder O 0 0.009967925027012825
clinical O 0 9.039237193064764e-05
phenotype O 0 0.00026495783822610974
with O 0 1.44228167187066e-07
respect O 0 1.1061098348363885e-07
to O 0 2.468800062160881e-07
both O 0 8.292415259347763e-06
cerebellar B-Disease 1 0.9652736186981201
degeneration I-Disease 1 0.995672345161438
and O 0 6.167280844238121e-06
cellular O 0 1.775193595676683e-05
features O 0 5.756913378718309e-05
. O 0 8.653305485495366e-06

We O 0 4.0141250792657956e-05
report O 0 2.4810410650388803e-06
, O 0 9.157074032373202e-08
in O 0 5.486451470915199e-08
two O 0 1.8924989717561402e-06
A B-Disease 1 0.9999959468841553
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
families O 0 3.373046695287485e-07
, O 0 1.2783948122319089e-08
an O 0 2.612924099310021e-08
ATM O 0 1.017130671243649e-05
mutation O 0 2.977591293529258e-06
( O 0 1.0735681144069531e-07
7271T O 0 1.327585437138623e-06
- O 0 9.550946742820088e-06
- O 0 3.126309093204327e-05
> O 0 3.7801266898895847e-06
G O 0 4.3972700950689614e-05
) O 0 4.551543497655075e-08
that O 0 2.3667883652933597e-08
may O 0 1.3406546486294246e-06
be O 0 2.488494921237816e-08
associated O 0 3.0332540035260536e-08
with O 0 1.4659384817150567e-08
an O 0 1.5364315686383634e-07
increased O 0 7.862515303713735e-06
risk O 0 1.2262489690328948e-06
of O 0 4.544703529063554e-07
breast B-Disease 1 0.9946439266204834
cancer I-Disease 0 0.0003384621231816709
in O 0 1.5744699055630917e-07
both O 0 4.37206608694396e-07
homozygotes O 0 3.179970008204691e-05
and O 0 2.6330744731239974e-06
heterozygotes O 0 2.4424631192232482e-05
( O 0 2.181773339771098e-07
relative O 0 6.036432296241401e-07
risk O 0 4.7252618173843075e-07
12 O 0 1.56258977312973e-07
. O 0 2.8437449728357933e-08
7 O 0 3.291850987352518e-07
; O 0 3.9293081499636173e-07
P O 0 7.156197534641251e-05
= O 0 3.7675877138099167e-06
. O 0 6.784509309909481e-08
0025 O 0 3.1656802548241103e-06
) O 0 3.555396688170731e-08
, O 0 1.6735093311126548e-08
although O 0 2.473833760063826e-08
there O 0 6.898396076593372e-09
is O 0 1.4426552397139858e-08
a O 0 2.214821250845489e-07
less O 0 1.0585717973299325e-06
severe O 0 0.009680446237325668
A B-Disease 1 0.9999997615814209
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 0.0012154231080785394
in O 0 6.798551055453572e-08
terms O 0 1.3507232665688207e-07
of O 0 2.023363343539586e-08
the O 0 1.6816598247260117e-07
degree O 0 1.572811584082956e-06
of O 0 3.2158204703591764e-06
cerebellar B-Disease 1 0.9902297854423523
degeneration I-Disease 1 0.9992794394493103
. O 0 2.782908995868638e-05

This O 0 2.013449375226628e-05
mutation O 0 6.418278644559905e-05
( O 0 1.6088847587525379e-06
7271T O 0 1.3103106539347209e-05
- O 0 2.511141065042466e-05
- O 0 8.792144944891334e-05
> O 0 1.044070904754335e-05
G O 0 0.00015877785335760564
) O 0 1.1240494046660388e-07
also O 0 9.736097439372315e-08
allows O 0 5.293021132501963e-08
expression O 0 4.2524213483829953e-08
of O 0 5.2997868316140284e-09
full O 0 1.1669531119196108e-07
- O 0 2.2862921014166204e-06
length O 0 2.7330932539371133e-07
ATM O 0 3.7186191548244096e-07
protein O 0 7.669256518738621e-08
at O 0 1.7111577932382716e-08
a O 0 4.4955573486049616e-08
level O 0 1.093000250307341e-07
comparable O 0 1.7881720282275637e-07
with O 0 2.7569305061092564e-08
that O 0 5.7981534240525434e-08
in O 0 5.442840915748093e-07
unaffected O 0 3.895647751051001e-05
individuals O 0 3.1623383733858645e-07
. O 0 1.0796788956213277e-06

In O 0 5.3864505389356054e-06
addition O 0 7.781815725138586e-07
, O 0 1.8131075307792344e-07
we O 0 3.699157957726129e-08
have O 0 2.6471758118873367e-08
studied O 0 1.5610972070589924e-07
18 O 0 1.1828619790321682e-06
A B-Disease 1 0.9990542531013489
- I-Disease 1 0.999995231628418
T I-Disease 1 1.0
patients O 0 4.2452270463400055e-06
, O 0 3.188052133396013e-08
in O 0 3.044887719738654e-08
15 O 0 1.922193888503898e-07
families O 0 6.307354993850822e-08
, O 0 5.2610545253628516e-08
who O 0 1.4233610272640362e-06
developed O 0 0.00023326124937739223
leukemia B-Disease 1 0.9821822047233582
, O 0 0.00020005961414426565
lymphoma B-Disease 1 1.0
, O 0 2.1741182081314037e-06
preleukemic O 0 0.00018521620950195938
T O 0 0.0001961050438694656
- O 0 9.18048681342043e-06
cell O 0 1.3679802577826194e-05
proliferation O 0 2.9124432785465615e-06
, O 0 8.259214041572704e-07
or O 0 0.00017286553338635713
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.4488688268320402e-06
mostly O 0 2.778633643174544e-07
in O 0 4.876922616858792e-07
childhood O 0 3.296104114269838e-05
. O 0 6.872074209240964e-06

A O 0 4.024354711873457e-05
wide O 0 7.688657206017524e-06
variety O 0 6.493573323496094e-07
of O 0 1.4534050762904371e-07
ATM O 0 5.912554479436949e-05
mutation O 0 7.320383701880928e-06
types O 0 2.0535621558792627e-07
, O 0 5.3542393629868457e-08
including O 0 1.9085599944901332e-07
missense O 0 0.00024569325614720583
mutations O 0 5.3258140724210534e-06
and O 0 2.507324268208322e-07
in O 0 1.6868013119619718e-07
- O 0 0.00011553068907232955
frame O 0 0.009737299755215645
deletions O 0 3.539957106113434e-05
, O 0 3.610852559177147e-07
were O 0 5.012479391552915e-07
seen O 0 8.70104372552305e-07
in O 0 1.5071124437326944e-07
these O 0 2.887983043819986e-07
patients O 0 6.484912319137948e-06
. O 0 3.145070650134585e-06

We O 0 1.2432286894181743e-05
also O 0 2.6852553673961665e-06
show O 0 1.4636092373621068e-06
that O 0 5.200733355081866e-08
25 O 0 1.9016232499780017e-07
% O 0 3.066071840862605e-08
of O 0 4.3510706149163525e-09
all O 0 5.556303861453671e-08
A B-Disease 1 0.9999864101409912
- I-Disease 1 0.9999977350234985
T I-Disease 1 1.0
patients O 0 2.842397861968493e-06
carried O 0 4.408101119679486e-07
in O 0 6.535832852705425e-08
- O 0 8.861621608957648e-06
frame O 0 6.953623233130202e-05
deletions O 0 2.5579192879376933e-05
or O 0 1.6610234752079123e-06
missense O 0 0.00013809769006911665
mutations O 0 1.4229934095055796e-05
, O 0 5.216509535443947e-08
many O 0 4.718063273401185e-09
of O 0 1.9943055207249927e-08
which O 0 1.2549838857012219e-06
were O 0 1.8745867009783979e-06
also O 0 1.1455171033958322e-06
associated O 0 1.2156910145222355e-07
with O 0 3.889912747467861e-08
expression O 0 1.9886464031060314e-07
of O 0 4.218065186023523e-08
mutant O 0 9.624101039662492e-06
ATM O 0 1.0657166058081202e-05
protein O 0 5.347020760382293e-06
. O 0 2.856198761946871e-06

The O 0 2.4699622372281738e-05
DMPK O 0 0.00035923506948165596
gene O 0 3.500018283375539e-05
of O 0 3.7331701605580747e-06
severely O 1 0.9915498495101929
affected O 0 0.1351204365491867
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.524307906627655
is O 0 2.5361157440784154e-06
hypermethylated O 0 9.274443436879665e-05
proximal O 0 9.208305709762499e-05
to O 0 5.017955686525966e-07
the O 0 3.213651780242799e-07
largely O 0 1.785930749065301e-06
expanded O 0 4.768094186147209e-06
CTG O 0 0.00016496804892085493
repeat O 0 2.9887243726989254e-05
. O 0 5.527759640244767e-06

Using O 0 1.7828604541136883e-05
methylation O 0 0.0001068376368493773
- O 0 8.90366718522273e-05
sensitive O 0 3.7651523143722443e-06
restriction O 0 1.15961938718101e-06
enzymes O 0 1.1593218687266926e-06
, O 0 6.228000870578398e-08
we O 0 2.378554597726179e-08
characterized O 0 2.8077326419406745e-07
the O 0 4.319691981891083e-08
methylation O 0 5.885277460038196e-06
pattern O 0 3.0051582143642008e-05
on O 0 1.573138661115081e-06
the O 0 2.58623458648799e-07
5 O 0 7.339889975810365e-07
side O 0 2.717799532092613e-07
of O 0 1.7352459025232747e-08
the O 0 9.287662550150344e-08
CTG O 0 1.3048264918325003e-05
repeat O 0 7.16088209173904e-07
in O 0 4.478765447402111e-08
the O 0 5.5511662822027574e-08
DMPK O 0 5.979781690257369e-06
gene O 0 1.0641332437444362e-07
of O 0 1.2579559616199276e-08
normal O 0 2.3644200553007977e-07
individuals O 0 1.918322034555331e-08
and O 0 6.384564699146722e-08
of O 0 1.3114176056205906e-07
patients O 0 7.935637768241577e-06
affected O 0 1.9078479454037733e-06
with O 0 9.037462587002665e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 5.556612904911162e-06
showing O 0 4.414657269080635e-06
expansions O 0 1.2330411891525728e-06
of O 0 9.072029172330076e-08
the O 0 5.479203650793352e-07
repetitive O 0 7.527849083999172e-05
sequence O 0 7.737821761111263e-06
. O 0 4.063209871674189e-06

The O 0 1.2507574865594506e-05
gene O 0 1.7497117369202897e-05
segment O 0 2.125790524587501e-05
analyzed O 0 5.9667645473382436e-06
corresponds O 0 2.6553127554507228e-06
to O 0 1.7596771328953764e-07
the O 0 3.7450550394169113e-07
genomic O 0 1.7588930859346874e-05
SacI O 0 0.0001756638230290264
- O 0 2.204138581873849e-05
HindIII O 0 1.583479934197385e-05
fragment O 0 4.753011580760358e-06
carrying O 0 7.654444402760419e-07
exons O 0 1.9357648852746934e-05
11 O 0 3.521601911415928e-06
- O 0 3.7373883969848976e-05
15 O 0 5.111475729790982e-06
. O 0 2.545939878473291e-06

There O 0 4.60468663732172e-06
is O 0 4.7402420477737905e-07
constitutive O 0 2.0084237348783063e-06
methylation O 0 3.589977268347866e-06
in O 0 2.0455618710002454e-07
intron O 0 8.8053013314493e-05
12 O 0 1.5891642988208332e-06
at O 0 6.793897000534344e-08
restriction O 0 8.491311831448911e-08
sites O 0 2.0326858418684424e-08
of O 0 1.0348925272296583e-08
SacII O 0 9.673228305473458e-06
and O 0 3.8568600757571403e-07
HhaI O 0 4.313115823606495e-06
, O 0 5.302944572349588e-08
localized O 0 8.558266131331038e-07
1 O 0 2.2073777472542133e-07
, O 0 4.44649721487167e-08
159 O 0 5.179371100894059e-07
- O 0 3.1623824270354817e-06
1 O 0 2.195942840899079e-07
, O 0 5.3981992209628515e-08
232 O 0 3.7932937857476645e-07
bp O 0 1.5050784440973075e-06
upstream O 0 6.061988244709937e-08
of O 0 6.6840248891253395e-09
the O 0 4.7987398943405424e-08
CTG O 0 1.1529805306054186e-05
repeat O 0 1.2547325241030194e-06
, O 0 8.001702411775113e-08
whereas O 0 5.705224737084791e-08
most O 0 1.8019179037764843e-08
, O 0 2.2126251053578017e-08
if O 0 7.372466637178832e-09
not O 0 5.701175087580168e-09
all O 0 2.005855925801825e-09
, O 0 6.209115444022473e-09
of O 0 1.9470143275412966e-09
the O 0 6.748369862918935e-09
other O 0 4.460638081127399e-09
sites O 0 1.4216114507803468e-08
of O 0 8.852344635101872e-09
SacII O 0 3.377699385964661e-06
, O 0 3.240364065959511e-08
HhaI O 0 1.269544668502931e-06
, O 0 1.9282744290194387e-08
and O 0 6.32452099580405e-08
HpaII O 0 2.8500087410066044e-06
in O 0 1.861739207242863e-08
this O 0 1.5143196918643298e-08
region O 0 2.0008860701636877e-07
are O 0 1.780021641195617e-08
unmethylated O 0 3.7437448554555885e-06
, O 0 6.179062239652922e-08
in O 0 2.4076527438410267e-08
normal O 0 1.9533281658823398e-07
individuals O 0 1.5514377338377017e-08
and O 0 4.1602334022172727e-08
most O 0 1.3311165503182565e-08
of O 0 2.9690477632016155e-08
the O 0 1.3484801684171543e-06
patients O 0 6.9795137278561015e-06
. O 0 1.709362436486117e-06

In O 0 3.4453137232048903e-06
a O 0 1.0899477729253704e-06
number O 0 1.254477268730625e-07
of O 0 5.7584440327218545e-08
young O 0 7.351953286161006e-07
and O 0 4.213195097690914e-06
severely O 0 0.057171501219272614
affected O 0 5.9963763305859175e-06
patients O 0 3.376906761332066e-06
, O 0 1.0817757356562652e-07
however O 0 3.796108316578284e-08
, O 0 1.820948192232663e-08
complete O 0 4.860364910541648e-08
methylation O 0 4.2064957028742356e-07
of O 0 1.444582675702577e-08
these O 0 8.91777585110276e-09
restriction O 0 6.413356601342457e-08
sites O 0 3.7112709350139994e-08
was O 0 1.3822184428136097e-06
found O 0 5.574689510012831e-08
in O 0 3.0117281113462013e-08
the O 0 2.1695399254895165e-07
mutated O 0 2.593884346424602e-05
allele O 0 2.244081042590551e-05
. O 0 2.489096459612483e-06

In O 0 7.80726895754924e-06
most O 0 2.740335958151263e-07
of O 0 3.814042059957501e-08
these O 0 1.378754461711651e-07
patients O 0 9.9793635399692e-07
, O 0 3.957527994202792e-08
the O 0 6.306404287670375e-08
onset O 0 2.5684794309199788e-05
of O 0 2.3592889419887797e-07
the O 0 2.739472438406665e-05
disease O 0 0.09913290292024612
was O 0 0.14487633109092712
congenital O 1 0.9999719858169556
. O 0 1.795688694983255e-05

Preliminary O 0 0.00014960812404751778
in O 0 1.3220023902249523e-05
vivo O 0 0.0001184325956273824
footprinting O 0 0.0002417851792415604
data O 0 1.4351608115248382e-06
gave O 0 5.907766080781585e-07
evidence O 0 6.593693768763842e-08
for O 0 1.743819311172956e-08
protein O 0 3.010037232797913e-07
- O 0 1.3664799780599424e-06
DNA O 0 6.982836566749029e-07
contact O 0 1.3429190914848732e-07
in O 0 3.35323768752005e-08
normal O 0 1.7647862193825858e-07
genes O 0 1.1574390157420567e-07
at O 0 3.350194432982789e-08
an O 0 4.4279541810965384e-08
Sp1 O 0 1.2158967365394346e-05
consensus O 0 1.3436057599847118e-07
binding O 0 8.461950784521832e-08
site O 0 1.1472626226805005e-07
upstream O 0 1.1675341937689154e-07
of O 0 8.78245032254199e-09
the O 0 8.646097171549627e-08
CTG O 0 1.2304262781981379e-05
repeat O 0 1.2770794910466066e-06
and O 0 1.0097519265173105e-07
for O 0 1.1131550792242706e-08
a O 0 1.201409673967646e-07
significant O 0 7.843314620004094e-08
reduction O 0 1.3736752180193434e-07
of O 0 5.224980892393205e-09
this O 0 7.193913464931256e-09
interaction O 0 5.1782446774950586e-08
in O 0 4.0288384184350434e-08
cells O 0 2.1445217157634033e-07
with O 0 3.1995902816106536e-08
a O 0 1.6280188219752745e-06
hypermethylated O 0 6.737473449902609e-05
DMPK O 0 7.113869651220739e-05
gene O 0 4.568195436149836e-06
. O 0 6.36695631328621e-07
. O 0 2.0519032659649383e-06

The O 0 0.00021510355873033404
hemochromatosis B-Disease 1 0.9999960660934448
gene O 0 7.690518395975232e-05
product O 0 7.959270988067146e-06
complexes O 0 1.7848036577561288e-06
with O 0 2.5712500928420923e-07
the O 0 7.524434408878733e-07
transferrin O 0 2.6560132027952932e-05
receptor O 0 1.8368201608609525e-06
and O 0 6.271438905969262e-07
lowers O 0 4.208748941891827e-05
its O 0 9.986620597146612e-08
affinity O 0 4.708312246748392e-07
for O 0 5.566444372107071e-08
ligand O 0 3.103249127889285e-06
binding O 0 7.3919250098697376e-06
. O 0 8.026885552681051e-06

We O 0 4.537151107797399e-05
recently O 0 2.796444641717244e-05
reported O 0 4.165484369877959e-06
the O 0 9.099652942268222e-08
positional O 0 3.55540123564424e-06
cloning O 0 7.603928793287196e-07
of O 0 6.460046364509253e-08
a O 0 1.2719635833491338e-06
candidate O 0 1.4269490748120006e-05
gene O 0 2.5406172426301055e-05
for O 0 0.00012866363977082074
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.31369251012802124
HFE O 1 0.9166260957717896
. O 0 4.39232935605105e-05

The O 0 5.541726295632543e-06
gene O 0 4.065221673954511e-06
product O 0 1.2529998230093042e-06
, O 0 5.634585420466465e-08
a O 0 1.3077308835818258e-07
member O 0 1.2349177325177152e-07
of O 0 1.4108847423699444e-08
the O 0 8.062937695285655e-08
major O 0 2.386016149102943e-07
histocompatibility O 0 2.9433813324430957e-06
complex O 0 2.889487120683043e-07
class O 0 3.872649756431201e-07
I O 0 5.852406843587232e-07
- O 0 1.649861701480404e-06
like O 0 7.555930636726771e-08
family O 0 1.8834232662356953e-07
, O 0 6.339485025819158e-08
was O 0 7.372398727056861e-07
found O 0 4.987939661305063e-08
to O 0 1.6133691715936038e-08
have O 0 4.5072596321915626e-08
a O 0 4.228263037475699e-07
mutation O 0 1.5835668136787717e-06
, O 0 5.327132512888966e-08
Cys O 0 2.76543232757831e-05
- O 0 5.273197984934086e-06
282 O 0 2.468706497893436e-06
- O 0 2.9035663828835823e-05
- O 0 7.073350570863113e-05
> O 0 8.034021448111162e-06
Tyr O 0 1.7662136087892577e-05
( O 0 2.2395657595097873e-07
C282Y O 0 1.35392076572316e-06
) O 0 4.3727123255621336e-08
, O 0 1.5816929987977346e-08
in O 0 4.2541326905620735e-08
85 O 0 4.506047446284356e-07
% O 0 1.1672425159758859e-07
of O 0 6.741270652810272e-08
patient O 0 8.847670869727153e-06
chromosomes O 0 6.707131979055703e-05
. O 0 6.111547918408178e-06

This O 0 1.8741609892458655e-05
mutation O 0 2.6723168048192747e-05
eliminates O 0 1.0974892575177364e-05
the O 0 2.246425907515004e-07
ability O 0 3.79081257051439e-07
of O 0 9.079663243483083e-08
HFE O 0 0.00023154089285526425
to O 0 1.565989578011795e-07
associate O 0 3.6565361938301066e-07
with O 0 1.3098477325002023e-07
beta2 O 0 0.00010078316699946299
- O 0 0.00020948522433172911
microglobulin O 0 0.00010218373790849
( O 0 5.697334586329816e-07
beta2m O 0 6.233988642634358e-06
) O 0 1.2886849276583234e-07
and O 0 1.2999271348235197e-07
prevents O 0 5.198452299737255e-07
cell O 0 6.436250259866938e-06
- O 0 2.927672721853014e-05
surface O 0 2.3742026314721443e-05
expression O 0 7.481854026991641e-06
. O 0 3.211438297512359e-06

A O 0 0.0001127152208937332
second O 0 3.222972009098157e-05
mutation O 0 7.74361706135096e-06
that O 0 5.6000217796281504e-08
has O 0 1.2818050265650527e-07
no O 0 5.0173284193988366e-08
effect O 0 1.3431407808184304e-07
on O 0 1.0105204637511633e-06
beta2m O 0 3.8726382626919076e-05
association O 0 8.98191316878183e-08
, O 0 3.839903683910961e-08
H63D O 0 1.1885954336321447e-05
, O 0 8.774618009965707e-08
was O 0 1.4899220559527748e-06
found O 0 4.2887744911013215e-08
in O 0 1.5965387234473383e-08
eight O 0 6.980313571602892e-08
out O 0 3.7116528517344705e-08
of O 0 1.5549867171671394e-08
nine O 0 1.3049319704805384e-06
patients O 0 5.547312866838183e-07
heterozygous O 0 4.262100787855161e-07
for O 0 1.964742857296642e-08
the O 0 2.2035538904674468e-07
C282Y O 0 2.2496817109640688e-05
mutant O 0 3.254062539781444e-05
. O 0 3.7661077385564568e-06

In O 0 1.2596201486303471e-05
this O 0 5.089079309072986e-07
report O 0 6.717416454193881e-07
, O 0 6.25242435603468e-08
we O 0 1.8245081889745052e-08
demonstrate O 0 6.891441728384962e-08
in O 0 4.334423664431597e-08
cultured O 0 4.456101578398375e-06
293 O 0 2.8855954496975755e-06
cells O 0 2.046874669758836e-06
overexpressing O 0 1.064308889908716e-05
wild O 0 5.321273306435614e-07
- O 0 1.1732119673979469e-05
type O 0 7.118775329217897e-07
or O 0 3.0298835440589755e-07
mutant O 0 1.1156408618262503e-05
HFE O 0 9.071273234440014e-05
proteins O 0 1.5543973574949632e-07
that O 0 1.498671409194685e-08
both O 0 1.4696057704099985e-08
the O 0 6.035303101725731e-08
wild O 0 6.071569487176021e-07
- O 0 2.397329626546707e-05
type O 0 6.363465558933967e-07
and O 0 5.064720767222752e-07
H63D O 0 0.00015432407963089645
HFE O 0 0.0001613521162653342
proteins O 0 4.194882308183878e-07
form O 0 2.6410640430185595e-07
stable O 0 2.4683345145604108e-06
complexes O 0 4.212710678075382e-07
with O 0 1.1254095255708307e-07
the O 0 9.639989002607763e-07
transferrin O 0 0.00020132871577516198
receptor O 0 3.7286135921021923e-05
( O 0 2.4628325263620354e-06
TfR O 0 0.0008279478061012924
) O 0 3.1007286906969966e-06
. O 0 3.8860857785039116e-06

The O 0 3.451453085290268e-05
C282Y O 0 0.0004037705366499722
mutation O 0 0.00012063123722327873
nearly O 0 3.3977817111008335e-06
completely O 0 5.113338374940213e-06
prevents O 0 6.17934574620449e-07
the O 0 1.0501761238401741e-07
association O 0 1.1536635469155954e-07
of O 0 1.5390794416703102e-08
the O 0 2.4472060999869427e-07
mutant O 0 3.138024112558924e-05
HFE O 0 0.00015542293840553612
protein O 0 1.5466769127669977e-06
with O 0 1.9189592137536238e-07
the O 0 2.4137004857038846e-06
TfR O 0 0.0029475984629243612
. O 0 7.444878974638414e-06

Studies O 0 4.5720018533756956e-05
on O 0 5.865487764822319e-06
cell O 0 2.1116025891387835e-05
- O 0 1.1826029549411032e-05
associated O 0 7.116114488781022e-07
transferrin O 0 4.395852556626778e-06
at O 0 1.8871449469770596e-07
37 O 0 6.02282113959518e-07
degrees O 0 1.5838854778849054e-06
C O 0 5.7893730627256446e-06
suggest O 0 1.7338008717615594e-07
that O 0 1.97134184531933e-08
the O 0 5.040358175278925e-08
overexpressed O 0 5.389307716541225e-06
wild O 0 9.379804737363884e-07
- O 0 2.3741889890516177e-05
type O 0 2.6831100967683597e-06
HFE O 0 0.00010388728696852922
protein O 0 3.1055349154485157e-06
decreases O 0 9.677662546891952e-07
the O 0 2.6026727439898423e-08
affinity O 0 1.4400495729205431e-07
of O 0 3.339005161251407e-08
the O 0 2.91945752906031e-07
TfR O 0 0.0003270962042734027
for O 0 4.636572157323826e-07
transferrin O 0 0.00013775323168374598
. O 0 5.071959549241001e-06

The O 0 1.3569088878284674e-05
overexpressed O 0 0.00037719716783612967
H63D O 0 0.00028256457881070673
protein O 0 6.558131190104177e-06
does O 0 3.108516466454603e-07
not O 0 4.771942130332718e-08
have O 0 2.6940629282989903e-08
this O 0 9.702742609363213e-09
effect O 0 1.6212142384119943e-07
, O 0 2.2730940685278256e-08
providing O 0 9.616499596631911e-09
the O 0 6.1508864668269325e-09
first O 0 2.558141964925653e-08
direct O 0 1.913366887151824e-08
evidence O 0 1.5546664400289956e-08
for O 0 9.635374276228958e-09
a O 0 2.8480991431933944e-07
functional O 0 7.057147399791575e-07
consequence O 0 3.3147847489090054e-07
of O 0 3.373869361666948e-08
the O 0 9.017761044560757e-07
H63D O 0 0.0016878237947821617
mutation O 0 2.6289459128747694e-05
. O 0 3.6354413168737665e-06

Addition O 0 3.234839459764771e-05
of O 0 1.5170595588642755e-06
soluble O 0 2.053781099675689e-05
wild O 0 4.82645236843382e-06
- O 0 0.00027523451717570424
type O 0 3.6297122278483585e-05
HFE O 0 0.004932655952870846
/ O 0 0.00022131232253741473
beta2m O 0 7.650726183783263e-05
heterodimers O 0 2.2490146875497885e-05
to O 0 3.1426642976839503e-07
cultured O 0 8.26222913019592e-06
cells O 0 2.554773573137936e-06
also O 0 5.250128083389427e-07
decreased O 0 3.381112264833064e-06
the O 0 8.41948022411998e-08
apparent O 0 1.1279092859695083e-06
affinity O 0 2.1296276031534944e-07
of O 0 1.9638736858951233e-08
the O 0 9.77388694423098e-08
TfR O 0 5.165462425793521e-05
for O 0 1.3486169514465018e-08
its O 0 2.662920017826309e-08
ligand O 0 1.6202589847580384e-07
under O 0 1.0248670889723144e-07
steady O 0 5.817588316858746e-06
- O 0 8.229123523051385e-06
state O 0 5.219933640887575e-08
conditions O 0 7.15682688223751e-07
, O 0 2.8312161504118194e-08
both O 0 1.498831281310231e-08
in O 0 1.0181471310488632e-07
293 O 0 1.5856098798394669e-06
cells O 0 5.136487857271277e-07
and O 0 1.738405330797832e-07
in O 0 1.6924907413340406e-06
HeLa O 0 0.0023789044935256243
cells O 0 2.2207541405805387e-05
. O 0 4.594133315549698e-06

Furthermore O 0 0.00012234540190547705
, O 0 2.0379029592731968e-06
at O 0 2.5903221967382706e-07
4 O 0 7.031974860183254e-07
degrees O 0 6.939287231944036e-06
C O 0 4.691858703154139e-05
, O 0 9.253641053419415e-08
the O 0 1.6565435601023637e-07
added O 0 1.6029332527978113e-06
soluble O 0 1.0152360800930182e-06
complex O 0 3.479946144580026e-07
of O 0 2.0703119218978827e-07
HFE O 0 0.004804649390280247
/ O 0 7.101107621565461e-05
beta2m O 0 2.5371913579874672e-05
inhibited O 0 2.7268420126347337e-06
binding O 0 3.401622734600096e-07
of O 0 6.296512822245859e-08
transferrin O 0 6.906824182806304e-06
to O 0 4.006975018455705e-07
HeLa O 0 0.0004983382532373071
cell O 0 2.218360168626532e-05
TfR O 0 0.0001336945715593174
in O 0 1.610799387208317e-07
a O 0 1.6552943407077692e-06
concentration O 0 2.7899639462702908e-05
- O 0 3.603380173444748e-05
dependent O 0 4.139340489928145e-06
manner O 0 1.1177248779858928e-05
. O 0 5.4747192734794226e-06

Scatchard O 0 0.0015246454859152436
plots O 0 2.1578167434199713e-05
of O 0 2.4863132352948014e-07
these O 0 4.837890088538188e-08
data O 0 3.057633648495539e-07
indicate O 0 2.7233883770350076e-07
that O 0 1.4520965763153981e-08
the O 0 1.0147176254804435e-07
added O 0 2.335201315872837e-06
heterodimer O 0 5.084154054202372e-06
substantially O 0 4.726668066723505e-06
reduced O 0 2.388912321293901e-07
the O 0 3.111974677949547e-08
affinity O 0 2.448018676659558e-07
of O 0 5.918085221878755e-08
TfR O 0 0.00018345663556829095
for O 0 6.637611136284249e-07
transferrin O 0 0.00014926557196304202
. O 0 6.180210220918525e-06

These O 0 6.538466550409794e-06
results O 0 2.230635573141626e-06
establish O 0 4.7016311555125867e-07
a O 0 2.926981892414915e-07
molecular O 0 1.7977012021219707e-06
link O 0 4.805811840924434e-06
between O 0 1.9228241399105173e-06
HFE O 0 0.01632978580892086
and O 0 8.491641665386851e-07
a O 0 4.757565079671622e-07
key O 0 9.773957572178915e-07
protein O 0 3.590312189771794e-07
involved O 0 5.429000538015316e-08
in O 0 1.4327919473089423e-07
iron O 0 9.856016549747437e-05
transport O 0 4.741024213217315e-07
, O 0 3.163025752428439e-08
the O 0 7.355095732464179e-08
TfR O 0 0.00014551845379173756
, O 0 7.324297257582657e-08
and O 0 6.66700401552589e-08
raise O 0 7.84139970733122e-08
the O 0 9.324862659809696e-09
possibility O 0 3.372981538518616e-08
that O 0 2.024251166687918e-08
alterations O 0 2.6323511974624125e-06
in O 0 3.386880820244187e-08
this O 0 2.727281156467143e-08
regulatory O 0 4.37146979948011e-07
mechanism O 0 7.812823810127156e-07
may O 0 8.941400437834091e-07
play O 0 3.298197981393969e-08
a O 0 1.5740104686301493e-07
role O 0 2.7799961799246375e-07
in O 0 1.511064482428992e-07
the O 0 1.002384010462265e-06
pathogenesis O 0 0.00012748305744025856
of O 0 0.00012699895887635648
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 6.647493864875287e-05
. O 0 9.48827619140502e-06

Genomic O 0 0.000303528766380623
organization O 0 8.706532753421925e-06
of O 0 4.5558647343568737e-07
the O 0 1.119760554502136e-06
UBE3A O 0 0.00033944478491321206
/ O 0 2.8841712264693342e-05
E6 O 0 8.380410872632638e-05
- O 0 0.00011407831334508955
AP O 0 4.634427750715986e-05
gene O 0 1.8630341855896404e-06
and O 0 5.338138180377427e-07
related O 0 4.26020869781496e-06
pseudogenes O 0 0.00010610652680043131
. O 0 9.35799198487075e-06

The O 0 6.160147313494235e-05
UBE3A O 0 0.0011958264512941241
gene O 0 3.0248389521148056e-05
encodes O 0 1.8343191186431795e-05
the O 0 1.327848849541624e-06
E6 O 0 9.515223791822791e-05
- O 0 0.0001126030765590258
AP O 0 1.3763934475718997e-05
ubiquitin O 0 7.2811499194358476e-06
- O 0 4.741960310639115e-06
protein O 0 4.468828649351053e-07
ligase O 0 7.491325959563255e-07
and O 0 2.09964809982921e-07
has O 0 7.863549171815976e-07
recently O 0 2.6089310267707333e-06
been O 0 5.80673031436163e-07
shown O 0 1.1431430380071106e-07
to O 0 1.6487584630908714e-08
be O 0 1.471640018735343e-07
mutated O 0 0.00018468749476596713
in O 1 0.5125227570533752
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0005539062549360096
who O 0 3.517828872645623e-06
lack O 0 9.75593820840004e-07
15q11 O 0 1.4642341739090625e-05
- O 0 3.324391946080141e-05
q13 O 0 2.0447092538233846e-05
deletions O 0 1.7506730728200637e-05
or O 0 3.243374067096738e-06
chromosome O 0 0.0003576694580260664
15 O 0 5.3031799325253814e-06
paternal O 0 0.0001451627176720649
uniparental B-Disease 0 0.009019316174089909
disomy I-Disease 0 0.0012519943993538618
. O 0 1.3255158592073712e-05

Previous O 0 7.746752089587972e-05
UBE3A O 0 0.0005141848232597113
cDNA O 0 7.35547801014036e-05
analysis O 0 3.6619035199692007e-06
has O 0 1.652374862715078e-06
shown O 0 7.398022034976748e-07
a O 0 4.78842707707372e-07
coding O 0 2.6226356567349285e-05
region O 0 1.1518071687532938e-06
of O 0 1.1875079763967733e-07
approximately O 0 4.795121526512958e-07
2 O 0 2.835599161699065e-06
. O 0 2.6750160486699315e-06

6 O 0 0.0003338740789331496
kb O 0 0.0005386131233535707
and O 0 1.922385990837938e-06
a O 0 2.138187937816838e-06
3 O 0 2.6235538825858384e-05
- O 0 0.0008582706213928759
untranslated O 0 0.00036532312515191734
region O 0 1.0062083674711175e-05
( O 0 6.440158699660969e-07
UTR O 0 3.130416735075414e-05
) O 0 7.875289043113298e-08
of O 0 4.040643375446962e-08
< O 0 2.0277213934605243e-06
50 O 0 2.8092782144995e-07
bp O 0 1.978792852241895e-06
, O 0 2.5621510246764956e-08
whereas O 0 4.796872943302333e-08
Northern O 0 6.639872651703627e-08
analysis O 0 9.319852267708484e-08
has O 0 1.3777030005712732e-07
indicated O 0 1.645507694547632e-07
mRNA O 0 1.6396739965784946e-07
sizes O 0 1.9516448901413241e-07
of O 0 2.522967257334585e-08
5 O 0 4.3629736978800793e-07
- O 0 9.982094525184948e-06
8 O 0 3.4653485272428952e-06
kb O 0 6.75970150041394e-05
. O 0 4.283025646145688e-06

We O 0 1.0877030945266597e-05
have O 0 6.519933322124416e-07
analyzed O 0 6.347082717184094e-07
additional O 0 1.5226413552227314e-07
cDNA O 0 2.6184077341895318e-06
clones O 0 9.825933375395834e-06
and O 0 1.3573321666626725e-07
provide O 0 6.45887539008072e-08
evidence O 0 3.249170532626522e-08
for O 0 1.5198436287278128e-08
an O 0 5.029381711096903e-08
additional O 0 3.439023146256659e-07
0 O 0 2.877634187825606e-06
. O 0 1.759305860105087e-06

5 O 0 0.00010948935960186645
kb O 0 0.00010716239921748638
of O 0 1.1228424909859314e-06
5 O 0 5.784003406006377e-06
- O 0 8.76275880727917e-05
UTR O 0 0.0001347096258541569
and O 0 8.480570272695331e-07
> O 0 2.00743556888483e-06
2 O 0 7.284089633685653e-07
kb O 0 6.693476279906463e-06
of O 0 1.1072328476302573e-07
3 O 0 6.37836046735174e-06
- O 0 0.00012465407780837268
UTR O 0 0.00041722229798324406
. O 0 9.15910550247645e-06

We O 0 1.1971616004302632e-05
have O 0 5.213501026446465e-07
established O 0 1.8372968213498098e-07
the O 0 8.571681320290736e-08
genomic O 0 1.0817772135851556e-06
organization O 0 1.4029129147274944e-07
of O 0 3.442356089067289e-08
UBE3A O 0 3.2658077543601394e-05
and O 0 1.3241458418633556e-07
the O 0 3.171380313915506e-08
sequence O 0 1.2798567183835985e-07
of O 0 6.86901415747343e-08
intron O 0 0.00018139593885280192
- O 0 0.00014078237290959805
exon O 0 5.508901085704565e-05
borders O 0 2.015751124417875e-05
. O 0 6.473493158409838e-06

We O 0 3.492779433145188e-05
have O 0 1.5417052736665937e-06
also O 0 4.357767409146618e-07
mapped O 0 3.5388559354032623e-06
two O 0 1.3844068291746225e-07
highly O 0 3.597986335535097e-07
homologous O 0 1.6918887695283047e-06
processed O 0 1.5412290395033779e-06
pseudogenes O 0 3.751997610379476e-06
, O 0 4.307622134547273e-07
UBE3AP1 O 0 5.033185880165547e-05
and O 0 3.688400340706721e-07
UBE3AP2 O 0 1.771736606315244e-05
, O 0 2.24060787701319e-08
to O 0 1.434675578337874e-08
chromosomes O 0 5.62217451260949e-07
2 O 0 4.820132062377525e-07
and O 0 2.1703759500724118e-07
21 O 0 7.443867389156367e-07
, O 0 3.8699390358942765e-08
respectively O 0 3.768892327116191e-07
, O 0 4.475545622995014e-08
and O 0 6.139250530168283e-08
determined O 0 2.415083599771606e-07
their O 0 7.315152572573425e-08
genomic O 0 4.426469786267262e-06
organization O 0 1.4248984143705457e-06
. O 0 1.8205109881819226e-06

These O 0 5.3385424507723656e-06
results O 0 3.0097010039753513e-06
will O 0 1.235183901826531e-07
form O 0 4.7843094819199905e-08
the O 0 2.536071086467473e-08
basis O 0 4.85139040051763e-08
for O 0 2.6656998386442865e-08
studies O 0 8.687803898510538e-08
of O 0 4.010070853155412e-08
mutation O 0 2.115878714903374e-06
and O 0 1.295484253205359e-07
imprinting O 0 1.0655712685547769e-05
of O 0 4.791675110027427e-07
UBE3A O 0 0.00044338067527860403
. O 0 7.1095259954745416e-06

Mutation O 0 0.011021582409739494
spectrum O 0 0.0004705769824795425
and O 0 1.2886734111816622e-05
genotype O 0 0.0032850089482963085
- O 0 0.09119018167257309
phenotype O 0 0.008275491185486317
analyses O 0 1.4408244169317186e-05
in O 0 7.87832323112525e-06
Cowden B-Disease 1 0.9486429691314697
disease I-Disease 0 0.018111426383256912
and O 0 1.7363439837936312e-05
Bannayan B-Disease 1 0.9511011242866516
- I-Disease 1 0.9999560117721558
Zonana I-Disease 1 0.9999778270721436
syndrome I-Disease 1 0.9999762773513794
, O 0 2.4058315375441452e-06
two O 0 2.0286930521251634e-05
hamartoma B-Disease 1 0.9963667392730713
syndromes I-Disease 1 0.9839836359024048
with O 0 6.782087439205498e-05
germline O 0 0.4360213279724121
PTEN O 0 0.3922220468521118
mutation O 0 0.0011268798261880875
. O 0 2.0925424905726686e-05

The O 0 0.000289186486043036
tumour B-Disease 1 0.9999970197677612
suppressor O 0 0.14616669714450836
gene O 0 0.0002457445370964706
PTEN O 0 0.004707816056907177
, O 0 2.092704335154849e-06
which O 0 4.3506830138539954e-07
maps O 0 4.363549123809207e-06
to O 0 8.595433769187366e-07
10q23 O 0 7.94790466898121e-05
. O 0 4.490202627494e-06

3 O 0 0.0002379549405304715
and O 0 1.899014819173317e-06
encodes O 0 3.4361225971224485e-06
a O 0 1.3930591649113921e-06
403 O 0 2.982516434713034e-06
amino O 0 2.1987186755723087e-06
acid O 0 2.471967036399292e-06
dual O 0 2.5638773877290078e-06
specificity O 0 1.009998049994465e-05
phosphatase O 0 0.041984692215919495
( O 0 6.570768960045825e-07
protein O 0 8.88876456883736e-07
tyrosine O 0 6.6584275373315904e-06
phosphatase O 0 0.0014858368085697293
; O 0 1.185029759653844e-06
PTPase O 0 1.1742125934688374e-05
) O 0 1.0492911428627849e-07
, O 0 4.906031136897582e-08
was O 0 2.2656092824036023e-06
shown O 0 1.659498849448937e-07
recently O 0 2.1201476840815303e-07
to O 0 8.8516696195029e-09
play O 0 3.199523135322124e-08
a O 0 1.9836269871120749e-07
broad O 0 1.353665084025124e-06
role O 0 4.4074789684600546e-07
in O 0 8.289752599921485e-07
human O 0 6.083838343329262e-06
malignancy B-Disease 0 0.0018053168896585703
. O 0 6.814747393946163e-06

Somatic O 0 0.014040873385965824
PTEN O 0 0.09515422582626343
deletions O 0 0.0023422406520694494
and O 0 9.302467515226454e-05
mutations O 0 0.00027289328863844275
were O 0 1.5941978972477955e-06
observed O 0 1.6363371742045274e-06
in O 0 2.82002872609155e-07
sporadic B-Disease 0 0.019718796014785767
breast I-Disease 1 0.9987767338752747
, I-Disease 0 2.7138545192428865e-05
brain I-Disease 0 0.007230038288980722
, I-Disease 0 5.974320629320573e-06
prostate I-Disease 1 0.9082014560699463
and I-Disease 0 0.0004977951757609844
kidney I-Disease 1 0.5283880829811096
cancer I-Disease 0 0.04015745222568512
cell O 0 0.00013565174594987184
lines O 0 5.452039840747602e-05
and O 0 3.6735511343977123e-07
in O 0 1.0298757047166873e-07
several O 0 6.415980919882713e-07
primary O 0 0.00020201480947434902
tumours B-Disease 1 0.9999945163726807
such O 0 3.858073966966913e-07
as O 0 0.00013011913688387722
endometrial B-Disease 1 0.9999805688858032
carcinomas I-Disease 1 1.0
, O 1 0.982337474822998
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9939810633659363
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 5.8528883528197184e-05

In O 0 8.279164831037633e-06
addition O 0 1.4925615232641576e-06
, O 0 1.0466302455824916e-06
PTEN O 0 0.0005050204927101731
was O 0 2.1896074031246826e-05
identified O 0 1.0736496278695995e-06
as O 0 5.110181433565231e-08
the O 0 1.287220641188469e-07
susceptibility O 0 1.024435641738819e-05
gene O 0 1.0906902616625302e-06
for O 0 4.555156465357868e-07
two O 0 0.00037084147334098816
hamartoma B-Disease 1 0.9999963045120239
syndromes I-Disease 1 0.9999985694885254
Cowden B-Disease 1 0.999970555305481
disease I-Disease 1 0.836941123008728
( O 0 3.1738511552248383e-06
CD B-Disease 0 0.00039383344119414687
; O 0 1.5249653188220691e-05
MIM O 0 0.0002595613186713308
158350 O 0 1.4908408957126085e-05
) O 0 2.9180046112742275e-07
and O 0 3.7691401644224243e-07
Bannayan B-Disease 0 0.00010497622861294076
- I-Disease 0 0.0015985766658559442
Zonana I-Disease 0 0.0011263046180829406
( I-Disease 0 1.353128141090565e-06
BZS I-Disease 0 2.0581730495905504e-05
) I-Disease 0 2.6103643335773086e-07
or I-Disease 0 4.1542318740539486e-07
Ruvalcaba I-Disease 0 0.00015258679923135787
- I-Disease 0 0.00021393811039160937
Riley I-Disease 0 0.00015781457477714866
- I-Disease 1 0.935027539730072
Smith I-Disease 1 0.9410168528556824
syndrome I-Disease 1 0.9997926354408264
( O 0 6.537381523230579e-06
MIM O 0 0.0007085546385496855
153480 O 0 8.326115494128317e-05
) O 0 3.9919268601806834e-06
. O 0 4.740255462820642e-06

Constitutive O 0 0.0003295439528301358
DNA O 0 7.50542021705769e-05
from O 0 1.192617901324411e-06
37 O 0 2.8468548407545313e-06
CD B-Disease 0 8.992677066999022e-06
families O 0 3.1421009794030397e-07
and O 0 1.6558973925384635e-07
seven O 0 4.907238349005638e-07
BZS B-Disease 0 3.2145369914360344e-05
families O 0 7.099222329998156e-07
was O 0 3.257223625041661e-06
screened O 0 5.196259280637605e-06
for O 0 1.2667449027503608e-06
germline O 0 0.0009532065014354885
PTEN O 0 0.004514642525464296
mutations O 0 0.00013280948041938245
. O 0 8.578461347497068e-06

PTEN O 1 0.9677085876464844
mutations O 0 0.03362786024808884
were O 0 2.8245116482139565e-05
identified O 0 2.3529394184151897e-06
in O 0 1.1635059848913443e-07
30 O 0 1.1163597690710958e-07
of O 0 1.782219705148691e-08
37 O 0 1.2452176179067465e-06
( O 0 1.517296794872891e-07
81 O 0 1.5203081602521706e-06
% O 0 1.4419460114822868e-07
) O 0 2.4570086409880787e-08
CD B-Disease 0 2.856506625903421e-06
families O 0 7.680205982296684e-08
, O 0 1.454819020807463e-08
including O 0 4.6882568938144686e-08
missense O 0 7.173334324761527e-06
and O 0 3.2140439998329384e-07
nonsense O 0 7.068942068144679e-06
point O 0 2.580306954769185e-06
mutations O 0 2.9473501399479574e-06
, O 0 7.36912397769629e-08
deletions O 0 2.581978378657368e-06
, O 0 1.0454715493324329e-07
insertions O 0 2.4279056560772005e-06
, O 0 8.144797192244368e-08
a O 0 7.947020890242129e-07
deletion O 0 4.752974564325996e-05
/ O 0 1.2115896424802486e-05
insertion O 0 1.1691541658365168e-05
and O 0 2.062005933112232e-06
splice O 0 0.0003879684372805059
site O 0 8.14415470813401e-05
mutations O 0 7.999320951057598e-05
. O 0 7.488506525987759e-06

These O 0 1.911061190185137e-05
mutations O 0 0.00012851538485847414
were O 0 1.1790540384026826e-06
scattered O 0 2.619841552586877e-07
over O 0 2.1015210904806736e-07
the O 0 2.2011698774804245e-07
entire O 0 5.443827149065328e-07
length O 0 4.9652148845780175e-06
of O 0 1.0225083713066851e-07
PTEN O 0 0.00032185815507546067
, O 0 1.843650778710071e-07
with O 0 1.7130941998289018e-08
the O 0 6.7455928842719e-08
exception O 0 7.320987549519486e-08
of O 0 5.849390749546046e-09
the O 0 9.14691540288004e-08
first O 0 6.315540304058231e-07
, O 0 3.293807253612613e-07
fourth O 0 1.4246144019125495e-05
and O 0 1.4647025636804756e-06
last O 0 3.574167067199596e-06
exons O 0 0.0001102672322303988
. O 0 7.655425179109443e-06

A O 0 6.932276301085949e-05
hot O 0 6.43547682557255e-05
spot O 0 4.017096580355428e-05
for O 0 1.2991182529731304e-06
PTEN O 0 0.002815033309161663
mutation O 0 7.222000476758694e-06
in O 0 1.250097909633041e-07
CD B-Disease 0 3.5003253287868574e-05
was O 0 8.423932740697637e-06
identified O 0 3.9846065646997886e-07
in O 0 4.7835158056841465e-08
exon O 0 3.15194984068512e-06
5 O 0 5.385086296882946e-07
that O 0 1.2922606984488993e-08
contains O 0 1.7217978154349112e-08
the O 0 5.5918139452160176e-08
PTPase O 0 6.119164481788175e-06
core O 0 7.816282163730648e-07
motif O 0 5.580837978413911e-07
, O 0 1.3240619267662623e-08
with O 0 1.1324999604767072e-08
13 O 0 6.739651325915474e-08
of O 0 5.198449226639923e-09
30 O 0 1.20200226660927e-07
( O 0 6.035314470409503e-08
43 O 0 7.238040780066513e-07
% O 0 1.7502411253644823e-07
) O 0 3.3345372685289476e-08
CD B-Disease 0 1.8244985767523758e-05
mutations O 0 3.3513915695948526e-06
identified O 0 3.1922755283630977e-07
in O 0 9.708503512229072e-08
this O 0 2.257716431586232e-07
exon O 0 6.08258051215671e-05
. O 0 8.047448318393435e-06

Seven O 0 1.2817214155802503e-05
of O 0 4.30531400752443e-07
30 O 0 9.03957129594346e-07
( O 0 1.4948207649467804e-07
23 O 0 9.74620206761756e-07
% O 0 2.1784300940907997e-07
) O 0 3.414460181261347e-08
were O 0 5.2809703277034714e-08
within O 0 1.0275090112088492e-08
the O 0 3.2654916992669314e-08
core O 0 2.619856559249456e-06
motif O 0 2.751609372353414e-06
, O 0 2.6487768423066882e-08
the O 0 2.5756596855330827e-08
majority O 0 1.4710535367612465e-07
( O 0 3.611372179079808e-08
five O 0 1.0009576278946497e-08
of O 0 5.709554162791619e-09
seven O 0 1.441461989770687e-07
) O 0 2.0201897044103134e-08
of O 0 4.927560581791113e-09
which O 0 2.0550784540773748e-07
were O 0 1.1208097703274689e-06
missense O 0 8.78657228895463e-05
mutations O 0 1.8405622768113972e-06
, O 0 3.336356968475229e-08
possibly O 0 8.932794770544206e-08
pointing O 0 3.0265508144111664e-07
to O 0 2.594623360607784e-08
the O 0 1.4449911134306603e-07
functional O 0 3.5533705045054376e-07
significance O 0 1.0152790252959676e-07
of O 0 2.7916211564615878e-08
this O 0 1.4735093145645806e-07
region O 0 5.235211574472487e-06
. O 0 4.216884917696007e-06

Germline O 1 0.9598044157028198
PTEN O 1 0.972547709941864
mutations O 0 0.057759784162044525
were O 0 1.3081205906928517e-05
identified O 0 2.222064040324767e-06
in O 0 8.30512192351307e-08
four O 0 8.309669397021935e-08
of O 0 2.46687914540189e-08
seven O 0 9.024618066177936e-07
( O 0 3.672500099582976e-07
57 O 0 3.5643572573462734e-06
% O 0 3.7870333358114294e-07
) O 0 1.744199238373767e-07
BZS B-Disease 0 1.55479610839393e-05
families O 0 6.962196152926481e-07
studied O 0 2.0895395209663548e-06
. O 0 2.6857928787649143e-06

Interestingly O 0 0.0008168825297616422
, O 0 7.691750397498254e-06
none O 0 6.054557957213547e-07
of O 0 3.844513329909205e-08
these O 0 1.6195700425214454e-07
mutations O 0 9.28595727600623e-06
was O 0 5.391996182879666e-06
observed O 0 2.2905732066647033e-07
in O 0 7.240043942147167e-08
the O 0 2.9342680818444933e-07
PTPase O 0 4.251370773999952e-05
core O 0 9.070867236005142e-06
motif O 0 3.540730176609941e-05
. O 0 5.313805104378844e-06

It O 0 1.4404934518097434e-05
is O 0 7.617588266839448e-07
also O 0 5.007347567698162e-07
worthy O 0 1.6631523180876684e-07
of O 0 3.9881335567315546e-08
note O 0 6.029907240190369e-07
that O 0 1.7621786696508934e-08
a O 0 2.9260803557917825e-07
single O 0 4.166477538092295e-06
nonsense O 0 5.310801043378888e-06
point O 0 1.451848220312968e-06
mutation O 0 1.1592898090384551e-06
, O 0 4.319963764487511e-08
R233X O 0 1.2009473948637606e-06
, O 0 1.0979898945606692e-07
was O 0 2.72033548753825e-06
observed O 0 1.982983945936212e-07
in O 0 1.3808039156515406e-08
the O 0 7.320861783455257e-08
germline O 0 4.032570359413512e-06
DNA O 0 5.129477358423173e-07
from O 0 3.018065086735078e-08
two O 0 8.035886622792532e-08
unrelated O 0 1.5820692169654649e-06
CD B-Disease 0 4.031303615192883e-05
families O 0 6.5550972294659e-07
and O 0 3.699588830841094e-07
one O 0 4.278128926671343e-07
BZS B-Disease 0 6.656242476310581e-05
family O 0 8.195977898139972e-06
. O 0 4.173711658950197e-06

Genotype O 1 0.9434423446655273
- O 1 0.8987951278686523
phenotype O 0 0.010610939934849739
studies O 0 2.7120929644297576e-06
were O 0 1.204395175591344e-06
not O 0 8.204842316672512e-08
performed O 0 6.212156904439325e-07
on O 0 7.44607518754492e-07
this O 0 2.762257089727882e-08
small O 0 9.484493546096928e-08
group O 0 5.522514925360156e-07
of O 0 2.0616722906652285e-07
BZS B-Disease 0 0.0001021267453324981
families O 0 4.815175088879187e-06
. O 0 3.429198613957851e-06

However O 0 8.005731069715694e-05
, O 0 3.755158104468137e-06
genotype O 0 0.0006233256426639855
- O 0 0.0027773543260991573
phenotype O 0 0.00035372545244172215
analysis O 0 6.331092663458548e-07
inthe O 0 3.278379881521687e-05
group O 0 1.1884397963513038e-06
of O 0 4.1080493673462115e-08
CD B-Disease 0 0.00018416716193314642
families O 0 8.851467896420218e-07
revealed O 0 7.510461159654369e-07
two O 0 2.4830850264834226e-08
possible O 0 5.970976957314633e-08
associations O 0 2.760592821005048e-08
worthy O 0 2.987424352340895e-08
of O 0 9.73189795416829e-09
follow O 0 1.332519161678647e-07
- O 0 3.4362994938419433e-06
up O 0 3.098217007391213e-07
in O 0 1.662825610537766e-07
independent O 0 9.245999308404862e-07
analyses O 0 3.3224198432435514e-06
. O 0 1.6356522110072547e-06

The O 0 5.930225597694516e-06
first O 0 3.76750472241838e-06
was O 0 4.542378064797958e-06
an O 0 1.63714588552466e-07
association O 0 3.5259600394965673e-07
noted O 0 2.3049217645620956e-07
in O 0 4.0908474829848274e-08
the O 0 9.895626362776966e-08
group O 0 1.590448590604865e-07
of O 0 1.6081216358543315e-08
CD B-Disease 0 1.9637500372482464e-05
families O 0 9.137094707512006e-07
with O 0 7.91494494478684e-06
breast B-Disease 1 0.9999710321426392
disease I-Disease 0 0.009443875402212143
. O 0 8.71481461217627e-06

A O 0 4.0164832171285525e-05
correlation O 0 3.990575351053849e-05
was O 0 2.470435902068857e-05
observed O 0 7.392534371319925e-07
between O 0 9.937407696725131e-08
the O 0 8.843859689022793e-08
presence O 0 3.8793106682533107e-07
/ O 0 9.940429663402028e-06
absence O 0 1.6074861264314677e-07
of O 0 3.4795604619830556e-08
a O 0 5.284101916913642e-06
PTEN O 0 0.013926723040640354
mutation O 0 4.544735020317603e-06
and O 0 5.489026122518226e-08
the O 0 6.388268047885504e-08
type O 0 5.525928372662747e-07
of O 0 2.1774580716282799e-07
breast O 0 0.07205788791179657
involvement O 0 1.0059205123980064e-05
( O 0 2.3462150693376316e-06
unaffected O 0 4.1637817048467696e-05
versus O 0 0.00025533876032568514
benign O 0 0.4729331433773041
versus O 0 0.27473947405815125
malignant O 1 0.995812714099884
) O 0 6.333638793876162e-06
. O 0 5.806558419862995e-06

Specifically O 0 3.047844256798271e-05
and O 0 1.3511796623788541e-06
more O 0 4.731367297949873e-08
directly O 0 6.036581368107363e-08
, O 0 2.429495360445344e-08
an O 0 4.862488367507467e-08
association O 0 3.4444585139681294e-07
was O 0 8.665784662298393e-06
also O 0 1.9167330265190685e-06
observed O 0 2.931465417077561e-07
between O 0 1.3535906617789806e-08
the O 0 1.7397097096250036e-08
presence O 0 3.953642391252288e-08
of O 0 2.7286391812708644e-08
a O 0 3.643052195911878e-06
PTEN O 0 0.04146580770611763
mutation O 0 0.000130704342154786
and O 0 0.0001877474715001881
malignant B-Disease 1 0.9999990463256836
breast I-Disease 1 0.9999980926513672
disease I-Disease 0 0.04662351682782173
. O 0 1.695250830380246e-05

Secondly O 0 0.0012949197553098202
, O 0 3.7407039599202108e-06
there O 0 1.907271638401653e-07
appeared O 0 2.3666541437705746e-06
to O 0 5.1413881152484464e-08
be O 0 3.1970341041187567e-08
an O 0 3.116577929063169e-08
interdependent O 0 5.572442205448169e-06
association O 0 2.431470988994988e-07
between O 0 2.8702950771730684e-07
mutations O 0 1.953136006704881e-06
upstream O 0 3.5650265317599406e-07
and O 0 9.913478749012938e-08
within O 0 2.070074422988455e-08
the O 0 4.7356195409520296e-08
PTPase O 0 6.124063020251924e-06
core O 0 1.717116788313433e-06
motif O 0 1.9992660327261547e-06
, O 0 2.3534544979497696e-08
the O 0 2.147119992912394e-08
core O 0 6.12564747370925e-07
motif O 0 4.946811600348155e-07
containing O 0 5.556918480920103e-08
the O 0 3.43847794681551e-08
majority O 0 1.1135951183405268e-07
of O 0 6.815481157218528e-08
missense O 0 0.00015318638179451227
mutations O 0 1.2591181075549684e-05
, O 0 7.900248277792343e-08
and O 0 6.969976595883054e-08
the O 0 5.1758156871528627e-08
involvement O 0 1.1473524352823006e-07
of O 0 1.038489294558076e-08
all O 0 1.7864499213260387e-08
major O 0 1.4684073335047287e-07
organ O 0 8.145865649566986e-06
systems O 0 4.918660579278367e-06
( O 0 2.580159446097241e-07
central O 0 3.6734914488079085e-07
nervous O 0 2.6268066903867293e-06
system O 0 1.5587988855259027e-06
, O 0 1.5446855741174659e-06
thyroid O 0 0.22860121726989746
, O 0 4.073425316164503e-06
breast O 1 0.8429810404777527
, O 0 2.5445673600188456e-05
skin O 1 0.9961850047111511
and O 0 0.008635804988443851
gastrointestinal O 1 0.9997181296348572
tract O 0 0.3504165709018707
) O 0 6.442367066483712e-06
. O 0 5.678832621924812e-06

However O 0 2.556743856985122e-05
, O 0 4.11166780622807e-07
these O 0 1.504823821107948e-08
observations O 0 9.057643524101877e-08
would O 0 4.318950175274949e-08
need O 0 2.022595602113597e-08
to O 0 3.0400073569580854e-08
be O 0 5.3709829472836645e-08
confirmed O 0 1.6824202475618222e-07
by O 0 6.146781750260288e-09
studying O 0 1.0693782748205649e-08
a O 0 2.5547237214595953e-08
larger O 0 2.809151489202577e-08
number O 0 2.0551564006154877e-08
of O 0 3.5011499477377583e-08
CD B-Disease 0 4.3637093767756596e-05
families O 0 1.2820937627111562e-06
. O 0 1.358224722025625e-06

Molecular O 0 0.028054850175976753
defects O 1 0.9963082671165466
leading O 0 1.0543670214246958e-05
to O 0 2.3078558797351434e-07
human O 0 7.431029303006653e-07
complement B-Disease 0 3.6538345739245415e-05
component I-Disease 1 0.6529424786567688
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
in O 0 2.0633895303490135e-07
an O 0 2.1579430153906287e-07
African O 0 6.683937954221619e-07
- O 0 2.3381775463349186e-05
American O 0 2.747306780293002e-06
family O 0 5.216716090217233e-06
. O 0 3.940753231290728e-06

Complement B-Disease 0 0.09780091792345047
component I-Disease 1 0.9992699027061462
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 5.5214921303559095e-05
C6D B-Disease 0 0.010904692113399506
) O 0 6.260177997319261e-06
was O 0 0.0005806675762869418
diagnosed O 0 0.0009804645087569952
in O 0 8.55838280244825e-08
a O 0 7.034510076664446e-07
16 O 0 1.686643372522667e-06
- O 0 1.2623692782653961e-05
year O 0 2.859453900327935e-07
- O 0 2.0035299712617416e-06
old O 0 1.46133572798135e-06
African O 0 1.7814319619446906e-07
- O 0 2.5818283120315755e-06
American O 0 9.201481248055643e-07
male O 0 8.777923540037591e-06
with O 0 2.9913077014498413e-05
meningococcal B-Disease 1 0.9999997615814209
meningitis I-Disease 1 0.9999982118606567
. O 0 4.6142129576765e-05

The O 0 4.812287806998938e-05
patients O 0 0.00010914495214819908
father O 0 4.238596829964081e-06
and O 0 9.56875624069653e-07
two O 0 1.3453485507852747e-06
brothers O 0 9.628017869545147e-05
also O 0 2.1102985101606464e-06
had O 0 7.992572136572562e-06
C6D B-Disease 0 0.00011566284956643358
, O 0 2.347058369878141e-07
but O 0 4.6938669839846625e-08
gave O 0 1.759509444809737e-07
no O 0 3.2700853580536204e-08
history O 0 4.297536193575979e-08
of O 0 4.2049197190863197e-07
meningitis B-Disease 1 0.9992870688438416
or O 0 9.643795237934683e-07
other O 0 6.135089165582031e-07
neisserial B-Disease 0 0.029168756678700447
infection I-Disease 0 0.0004048054979648441
. O 0 6.595802915398963e-06

By O 0 6.012765425111866e-06
using O 0 2.0043764834554167e-06
exon O 0 2.0798397599719465e-05
- O 0 1.2875935681222472e-05
specific O 0 5.225995209912071e-07
polymerase O 0 1.1254507626290433e-05
chain O 0 1.5070900190039538e-05
reaction O 0 9.721259175421437e-07
( O 0 2.2905666696715343e-07
PCR O 0 5.857678388565546e-06
) O 0 7.763966891616292e-08
/ O 0 8.489463994010293e-07
single O 0 5.485807150762412e-07
- O 0 2.155509173462633e-05
strand O 0 2.346818109799642e-05
conformation O 0 2.1933906282356475e-06
polymorphism O 0 1.1810313935711747e-06
as O 0 1.7126204454598337e-08
a O 0 7.282896063998123e-08
screening O 0 2.330744166556542e-07
step O 0 1.448258046821138e-07
and O 0 3.126860903535089e-08
nucleotide O 0 2.536280021558923e-07
sequencing O 0 8.44078513750901e-08
of O 0 8.39172464850435e-09
target O 0 3.282675038462912e-07
exons O 0 2.660108293639496e-06
, O 0 1.369753306335042e-07
we O 0 1.537157956477131e-08
determined O 0 7.435978233161222e-08
that O 0 1.4986198948463425e-08
the O 0 5.0511467009073385e-08
proband O 0 1.3696211681235582e-05
was O 0 1.2411604757289751e-06
a O 0 1.7625609416427324e-07
compound O 0 1.4654264077762491e-06
heterozygote O 0 2.9011498554609716e-06
for O 0 7.805051183140677e-08
two O 0 1.9436649836279685e-06
C6 O 0 0.013162693940103054
gene O 0 5.115846943226643e-05
mutations O 0 5.845558916917071e-05
. O 0 4.93604738949216e-06

The O 0 7.47497915654094e-06
first O 0 1.9516521660989383e-06
, O 0 1.1865672178146269e-07
1195delC O 0 1.2348158406894072e-06
located O 0 1.3884368854633067e-07
in O 0 8.553178076908807e-08
exon O 0 6.608181593037443e-06
7 O 0 4.344979970483109e-06
, O 0 1.3194690495765826e-07
is O 0 3.503120638015389e-08
a O 0 2.592907151210966e-07
novel O 0 7.820002792868763e-06
mutation O 0 2.635149257912417e-06
, O 0 3.641988399749607e-08
while O 0 2.6666098662531112e-08
the O 0 3.73261777042444e-08
second O 0 7.725853947704309e-07
, O 0 6.183684320149041e-08
1936delG O 0 6.483450079031172e-07
in O 0 3.4909344748257354e-08
exon O 0 2.5365800411236705e-06
12 O 0 7.022552495072887e-07
, O 0 1.0430376562453603e-07
has O 0 1.6260700874681788e-07
been O 0 6.405337416026669e-08
described O 0 4.801945010513009e-07
before O 0 6.200301783110262e-08
to O 0 4.281549337292745e-08
cause O 0 1.1496387060105917e-06
C6D B-Disease 0 2.2789497961639427e-05
in O 0 2.7546072089990048e-08
an O 0 4.782758367127826e-08
unrelated O 0 5.447421358439897e-07
African O 0 2.8690743647530326e-07
- O 0 9.165212759398855e-06
American O 0 9.811762993194861e-07
individual O 0 4.6083417259978887e-07
. O 0 2.1237610781099647e-06

Both O 0 0.00012179887562524527
mutations O 0 0.0005070733604952693
result O 0 2.706589384615654e-06
in O 0 2.2938968413654948e-06
premature O 0 0.00023447674175258726
termination O 0 0.00011553597869351506
codons O 0 3.8430007407441735e-05
and O 0 8.651441021356732e-06
C6 O 0 0.02810552343726158
null O 0 0.0005681178881786764
alleles O 0 0.00017653258692007512
. O 0 1.4407118214876391e-05

Allele O 0 0.0015562826301902533
- O 0 0.00012635343591682613
specific O 0 2.0533088900265284e-06
PCR O 0 4.4571319449460134e-05
indicated O 0 2.8627298434003023e-06
that O 0 3.079481558643238e-08
the O 0 4.388763485962954e-08
probands O 0 8.348419214598835e-06
two O 0 7.523559020228276e-07
brothers O 0 0.00018511380767449737
also O 0 1.0819650242410717e-06
inherited O 0 3.3209341836482054e-06
the O 0 1.3574137369687378e-07
1195delC O 0 5.486898317030864e-06
mutation O 0 7.579486123177048e-07
from O 0 2.7482256470534594e-08
their O 0 8.322866307253207e-08
heterozygous O 0 3.1831450542085804e-06
mother O 0 2.312329115738976e-06
and O 0 1.1646761777228676e-07
the O 0 1.1273129985056585e-07
1936delG O 0 4.966105279891053e-06
mutation O 0 5.825155540151172e-07
from O 0 2.966229040168855e-08
their O 0 1.148769115388859e-07
homozygous O 0 9.654419045546092e-06
father O 0 1.1291436976534897e-06
. O 0 2.7946265390710323e-07
. O 0 1.3881192444387125e-06

PAX6 O 0 0.455721914768219
mutations O 0 0.026756389066576958
reviewed O 0 0.0008295496227219701
. O 0 5.441257235361263e-05

Mutations O 0 0.007254977244883776
in O 0 4.435436494532041e-06
PAX6 O 0 0.0005071246414445341
are O 0 3.717654806223436e-07
responsible O 0 4.3986690911879123e-07
for O 0 1.2303144103498198e-07
human O 0 1.8044343050860334e-06
aniridia B-Disease 1 0.9999992847442627
and O 0 1.8714765246841125e-05
have O 0 1.5520702163485112e-06
also O 0 1.5668784953959403e-06
been O 0 5.505445415110444e-07
found O 0 2.038218553934712e-07
in O 0 3.6445044315769337e-07
patients O 0 2.1358891899581067e-06
with O 0 4.525497388385702e-06
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999994039535522
, O 0 3.428038689889945e-05
with O 0 0.010038577951490879
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999988079071045
, O 0 5.834624062117655e-06
with O 0 2.320953171874862e-05
autosomal B-Disease 1 0.9942558407783508
dominant I-Disease 0 0.19258229434490204
keratitis I-Disease 1 0.9596405625343323
, O 0 2.669577497727005e-06
and O 0 1.7643986893745023e-06
with O 0 1.1099262337666005e-05
isolated B-Disease 1 0.706741452217102
foveal I-Disease 1 0.9999998807907104
hypoplasia I-Disease 1 1.0
. O 0 9.2008885985706e-05

No O 0 5.290609260555357e-05
locus O 0 4.001141860499047e-05
other O 0 4.924359586766514e-07
than O 0 3.2504914315723e-07
chromosome O 0 6.22961888439022e-05
11p13 O 0 1.5031125258246902e-05
has O 0 8.161683808793896e-07
been O 0 5.335186301635986e-07
implicated O 0 1.5543187146249693e-06
in O 0 1.1583936156966956e-06
aniridia B-Disease 1 0.9999786615371704
, O 0 8.380426379517303e-07
and O 0 8.61268233620649e-07
PAX6 O 0 4.6401863073697314e-05
is O 0 2.7383842393646773e-07
clearly O 0 2.712889966005605e-07
the O 0 3.3584221625915234e-08
major O 0 1.0552480489423033e-07
, O 0 7.663378198685677e-08
if O 0 2.105530683138568e-08
not O 0 1.3944821297684484e-08
only O 0 1.6359122056996966e-08
, O 0 1.0640540892836725e-07
gene O 0 1.1438773981353734e-06
responsible O 0 2.28977251026663e-06
. O 0 1.912741254272987e-06

Twenty O 0 8.234829147113487e-05
- O 0 8.74592806212604e-05
eight O 0 3.5232646951044444e-06
percent O 0 1.4525545566357323e-06
of O 0 5.346758769064763e-08
identified O 0 2.4752223453106126e-06
PAX6 O 0 0.0001625679578864947
mutations O 0 7.083450782374712e-06
are O 0 1.2101178015200276e-07
C O 0 1.269282802240923e-05
- O 0 6.117646262282506e-05
T O 0 3.0611212423536927e-05
changes O 0 1.6104321787224762e-07
at O 0 5.7438331424464195e-08
CpG O 0 2.307280283275759e-06
dinucleotides O 0 2.1242410639388254e-06
, O 0 3.912637680514308e-08
20 O 0 8.534648543445655e-08
% O 0 3.16604378269858e-08
are O 0 5.022735560800129e-09
splicing O 0 7.400435038107389e-07
errors O 0 1.891196347969526e-06
, O 0 5.7386202456655155e-08
and O 0 3.613591204043587e-08
more O 0 4.002901121680225e-09
than O 0 1.0782733816938617e-08
30 O 0 1.1701403224151363e-07
% O 0 5.803331504239395e-08
are O 0 1.0181273601972407e-08
deletion O 0 2.10786879506486e-06
or O 0 2.9127940592843515e-07
insertion O 0 8.285695002996363e-06
events O 0 3.2062666832644027e-06
. O 0 5.191924628888955e-06

There O 0 5.761054126196541e-06
is O 0 3.976224718371668e-07
a O 0 8.882917086339148e-07
noticeably O 0 0.0005808823043480515
elevated O 0 0.0003658040368463844
level O 0 2.529458527078532e-07
of O 0 4.5480028632027825e-08
mutation O 0 1.4579406979464693e-06
in O 0 2.212165028936397e-08
the O 0 4.801495734341188e-08
paired O 0 2.2446045022661565e-06
domain O 0 2.516052859391493e-07
compared O 0 4.184609565527353e-07
with O 0 2.305000457170081e-08
the O 0 1.2268019133898633e-07
rest O 0 8.690405906008891e-08
of O 0 2.0756727892035087e-08
the O 0 2.3275588034721295e-07
gene O 0 4.255831299815327e-06
. O 0 3.3193985018442618e-06

Increased O 0 0.0006261691451072693
mutation O 0 7.119516521925107e-05
in O 0 3.1398002420246485e-07
the O 0 2.634498343923042e-07
homeodomain O 0 1.577466173330322e-05
is O 0 1.8292824677246244e-07
accounted O 0 3.2016541240409424e-07
for O 0 1.7723584377904444e-08
by O 0 3.056962682990161e-08
the O 0 2.2038145175429236e-07
hypermutable O 0 0.00013651986955665052
CpG O 0 3.666505290311761e-05
dinucleotide O 0 1.8285991245647892e-05
in O 0 5.83696703415626e-07
codon O 0 8.298347893287428e-06
240 O 0 5.34898936166428e-06
. O 0 2.522018121453584e-06

Very O 0 1.4878170077281538e-05
nearly O 0 2.10580151360773e-06
all O 0 2.096342655022454e-07
mutations O 0 3.2954678772512125e-06
appear O 0 8.116694516502321e-07
to O 0 4.2891142015832884e-07
cause O 0 7.133078725019004e-06
loss O 0 1.5780610738147516e-06
of O 0 2.9440945681358244e-08
function O 0 5.614502640582941e-08
of O 0 9.382541854563442e-09
the O 0 1.0963785257445124e-07
mutant O 0 1.843833706516307e-05
allele O 0 1.0192522950092098e-06
, O 0 1.8119955313977698e-08
and O 0 9.77466552143369e-09
more O 0 4.191117231044927e-09
than O 0 1.1475116856729528e-08
80 O 0 9.198561912171499e-08
% O 0 3.220505107037752e-08
of O 0 1.1121385590229238e-08
exonic O 0 8.708583663974423e-06
substitutions O 0 1.4611169945055735e-06
result O 0 3.366625662692968e-07
in O 0 3.625431190812378e-07
nonsense O 0 1.302489181398414e-05
codons O 0 2.554497041273862e-05
. O 0 3.509689804559457e-06

In O 0 4.334062396083027e-06
a O 0 1.5397628203572822e-06
gene O 0 1.2088185030734167e-06
with O 0 7.690393744042012e-08
such O 0 4.754290472419598e-08
extraordinarily O 0 9.710828635434154e-06
high O 0 2.7627372674032813e-06
sequence O 0 3.254896512316918e-07
conservation O 0 1.1038463298973511e-07
throughout O 0 5.1024578340275184e-08
evolution O 0 8.00190065319839e-08
, O 0 3.4895030864845467e-08
there O 0 1.1056791038299707e-08
are O 0 3.5268939768684504e-08
presumed O 0 2.6363952201791108e-05
undiscovered O 0 2.831156234606169e-05
missense O 0 9.676616173237562e-05
mutations O 0 5.563468221225776e-06
, O 0 6.032045973825007e-08
these O 0 1.159577589504579e-08
are O 0 1.659001291898221e-08
hypothesized O 0 8.03956368145009e-07
to O 0 4.959479937838296e-08
exist O 0 3.2501933588946486e-08
in O 0 2.6298085487042044e-08
as O 0 3.809890927186643e-07
- O 0 2.759836206678301e-05
yet O 0 5.833705927216215e-07
unidentified O 0 9.094999768421985e-06
phenotypes O 0 2.542961374274455e-05
. O 0 6.727578352183627e-07
. O 0 3.087815457547549e-06

Genetic O 0 0.0046547940000891685
heterogeneity O 0 0.001791881280951202
and O 0 1.617477391846478e-05
penetrance O 0 0.0001335752895101905
analysis O 0 1.2631173831323395e-06
of O 0 1.6706812289157824e-07
the O 0 1.3702632486456423e-06
BRCA1 O 0 0.00032593481591902673
and O 0 1.0800416021083947e-05
BRCA2 O 0 0.00039723183726891875
genes O 0 7.477617145923432e-06
in O 0 2.4605091311968863e-05
breast B-Disease 1 0.9999502897262573
cancer I-Disease 0 0.17183434963226318
families O 0 1.0158142686123028e-05
. O 0 1.0175983334193006e-05

The O 0 0.0426112599670887
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999997615814209
Linkage O 0 0.010893491096794605
Consortium O 0 0.00026655130204744637
. O 0 1.2537598195194732e-05

The O 0 4.473144599614898e-06
contribution O 0 9.812127927943948e-07
of O 0 2.5620977339713136e-07
BRCA1 O 0 0.00011050996545236558
and O 0 1.6905059965210967e-05
BRCA2 O 0 0.006862945854663849
to O 0 5.574057649937458e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0320461131632328
assessed O 0 9.597108146408573e-06
by O 0 1.2106418978419242e-07
linkage O 0 2.3778984541422687e-05
and O 0 2.322555246792035e-06
mutation O 0 1.887088842522644e-06
analysis O 0 8.433543996488879e-08
in O 0 6.652955164554442e-08
237 O 0 9.368147857458098e-07
families O 0 1.5252661000886292e-07
, O 0 2.2924476539287753e-08
each O 0 5.438304473415201e-09
with O 0 9.402356226928532e-09
at O 0 4.391660723968016e-08
least O 0 1.847670638710497e-08
four O 0 3.9696693932000926e-08
cases O 0 7.522726974684701e-08
of O 0 2.9984823868289823e-07
breast B-Disease 1 0.9989596605300903
cancer I-Disease 0 0.0014978708932176232
, O 0 8.222733782758951e-08
collected O 0 4.634883410403745e-08
by O 0 1.1274269695604744e-07
the O 0 6.116246368037537e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999994039535522
Linkage O 0 0.0005011874600313604
Consortium O 0 1.895196874102112e-05
. O 0 3.859994649246801e-06

Families O 0 0.00013541629596147686
were O 0 3.819378434855025e-06
included O 0 4.554713370907848e-07
without O 0 1.1564504376337936e-07
regard O 0 1.0946922657240066e-07
to O 0 3.4398162540583144e-08
the O 0 9.005706402831493e-08
occurrence O 0 1.1184318964296835e-06
of O 0 8.348621918230492e-07
ovarian B-Disease 1 0.9916728138923645
or I-Disease 0 5.620530828309711e-06
other I-Disease 0 2.435238002362894e-06
cancers I-Disease 0 0.1714642494916916
. O 0 5.6401991059829015e-06

Overall O 0 0.2798178195953369
, O 0 0.00021542827016673982
disease O 0 0.0003746584407053888
was O 0 1.7013289834721945e-05
linked O 0 1.3447454875858966e-05
to O 0 3.281970748503227e-07
BRCA1 O 0 2.0740677427966148e-05
in O 0 5.041655981585791e-08
an O 0 8.607265300497602e-08
estimated O 0 3.4043230812130787e-07
52 O 0 1.3807666618959047e-06
% O 0 2.962361556058113e-08
of O 0 4.099710793070699e-09
families O 0 6.868555857408865e-08
, O 0 2.572193658068045e-08
to O 0 3.8059901896758674e-08
BRCA2 O 0 6.683697392873e-06
in O 0 6.265555896334263e-08
32 O 0 1.0929435347861727e-06
% O 0 5.257552970761026e-08
of O 0 5.452127638250204e-09
families O 0 6.088210113830428e-08
, O 0 3.534854542408539e-08
and O 0 3.5766586137242484e-08
to O 0 2.1567204910866167e-08
neither O 0 1.2679919336733292e-07
gene O 0 9.89100357173811e-08
in O 0 3.401615700227012e-08
16 O 0 3.8287367942757555e-07
% O 0 9.642841547474745e-08
( O 0 2.7786223100179086e-08
95 O 0 2.932528104793164e-07
% O 0 2.687099822651362e-07
confidence O 0 7.366973022726597e-07
interval O 0 2.8542790460051037e-06
[ O 0 9.290493494518159e-07
CI O 0 1.9834351405734196e-05
] O 0 8.171745662366448e-07
6 O 0 4.235244830397278e-07
% O 0 1.7153804776626203e-07
- O 0 3.927894795197062e-06
28 O 0 2.6222335236525396e-06
% O 0 1.3195923997955106e-07
) O 0 2.978991808788578e-08
, O 0 3.356693056844051e-08
suggesting O 0 7.102391350599646e-07
other O 0 2.2641980024218356e-07
predisposition O 0 0.00010304452007403597
genes O 0 1.136204900831217e-05
. O 0 6.262877377594123e-06

The O 0 1.7727963495417498e-05
majority O 0 7.734708560747094e-06
( O 0 1.9608851289376616e-06
81 O 0 5.157809027878102e-06
% O 0 5.413370445239707e-07
) O 0 2.8380229721847172e-08
of O 0 1.9445584698019047e-08
the O 0 1.5769925084896386e-05
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.3765331863833126e-06
were O 0 7.290651069524756e-07
due O 0 2.0980428416805808e-07
to O 0 3.7822471199433494e-07
BRCA1 O 0 5.119175330037251e-05
, O 0 9.425629343695618e-08
with O 0 3.4123246450690203e-08
most O 0 1.0610343537109657e-07
others O 0 3.554807506134239e-07
( O 0 1.0141912554217924e-07
14 O 0 6.83243342791684e-07
% O 0 1.7697480814149458e-07
) O 0 7.724425188371242e-08
due O 0 2.8756485903613793e-07
to O 0 1.1619396218520706e-06
BRCA2 O 0 0.0003287935978733003
. O 0 5.295018127071671e-06

Conversely O 0 0.0008376117912121117
, O 0 1.9257036001363304e-06
the O 0 1.6745988773436693e-07
majority O 0 1.7740738655902533e-07
of O 0 2.605990978565842e-08
families O 0 2.1481201883943868e-07
with O 0 2.2791117260112514e-07
male B-Disease 0 2.1360079699661583e-05
and I-Disease 0 9.69298980635358e-06
female I-Disease 0 0.013524957932531834
breast I-Disease 1 0.9990363121032715
cancer I-Disease 0 0.06663863360881805
were O 0 1.5705677469668444e-06
due O 0 7.614770538566518e-07
to O 0 8.129987918437109e-07
BRCA2 O 0 0.0009173190919682384
( O 0 8.698911528881581e-07
76 O 0 7.2725788413663395e-06
% O 0 7.555180445706355e-07
) O 0 3.782896556003834e-07
. O 0 1.2772391073667677e-06

The O 0 1.2755696843669284e-05
largest O 0 6.11973109698738e-06
proportion O 0 1.586390226293588e-06
( O 0 5.524648258870002e-07
67 O 0 7.894176633271854e-06
% O 0 5.037931600782031e-07
) O 0 1.8037679794247197e-08
of O 0 1.024467977117638e-08
families O 0 1.4353727806337702e-07
due O 0 9.545162527047069e-08
to O 0 3.849554275348055e-08
other O 0 2.7410225200696914e-08
genes O 0 2.072649181172892e-07
was O 0 4.411572263052221e-06
found O 0 6.840747346359421e-08
in O 0 4.593344371528474e-08
families O 0 3.8997111317939925e-08
with O 0 1.2081180500445043e-08
four O 0 1.88752665053471e-07
or O 0 1.1901871488362303e-07
five O 0 6.198787616540358e-08
cases O 0 4.1242063986146604e-08
of O 0 6.48873239583736e-08
female O 0 0.0033596965949982405
breast B-Disease 1 0.999494194984436
cancer I-Disease 0 0.0018963828915730119
only O 0 7.749185328975727e-07
. O 0 4.592202003550483e-06

These O 0 4.989556600776268e-06
estimates O 0 1.8130613170797005e-05
were O 0 8.848573429531825e-07
not O 0 8.834991405137771e-08
substantially O 0 6.0813326854258776e-06
affected O 0 1.4200186626567302e-07
either O 0 3.989997665598821e-08
by O 0 2.345388594449105e-08
changing O 0 1.8333237505885336e-07
the O 0 1.0349936729880937e-07
assumed O 0 1.8613968677527737e-06
penetrance O 0 3.7450802210514667e-06
model O 0 6.61351236885821e-07
for O 0 1.829575637657399e-07
BRCA1 O 0 3.9728543924866244e-05
or O 0 1.964143905297533e-07
by O 0 3.520536395740237e-08
including O 0 8.222608016694721e-08
or O 0 1.1059112239308888e-06
excluding O 0 3.998598185717128e-05
BRCA1 O 0 0.0009723221301101148
mutation O 0 1.7601785657461733e-05
data O 0 3.419894483158714e-06
. O 0 4.289235221222043e-06

Among O 0 2.155410584236961e-05
those O 0 9.905500064633088e-07
families O 0 1.3025297675994807e-06
with O 0 2.4684948130015982e-06
disease O 0 8.547991455998272e-05
due O 0 1.4470335827354575e-06
to O 0 3.0522437555191573e-07
BRCA1 O 0 5.448858792078681e-05
that O 0 4.4064196913495834e-07
were O 0 4.361352694104426e-06
tested O 0 1.27785074255371e-06
by O 0 1.321468268145054e-08
one O 0 1.1916358566566032e-08
of O 0 4.524596253219215e-09
the O 0 2.3872081200693174e-08
standard O 0 3.10749669552024e-07
screening O 0 1.1149361967000004e-07
methods O 0 8.986951627321105e-08
, O 0 8.521766403646325e-08
mutations O 0 4.817669037038286e-07
were O 0 1.355054592977467e-07
detected O 0 2.7536020752449986e-07
in O 0 2.2471773775123438e-08
the O 0 2.914927499375608e-08
coding O 0 2.3772540771460626e-06
sequence O 0 2.0029976610658196e-07
or O 0 4.129212527459458e-08
splice O 0 1.4206676723915734e-06
sites O 0 4.611339576854334e-08
in O 0 1.55239074928204e-08
an O 0 2.417034572488319e-08
estimated O 0 1.666184488158251e-07
63 O 0 7.902205538812268e-07
% O 0 7.321601458443183e-08
( O 0 2.8433113641312957e-08
95 O 0 2.6415023057779763e-07
% O 0 3.0650377880192536e-07
CI O 0 2.2579957658308558e-05
51 O 0 4.66142319055507e-06
% O 0 5.21614140325255e-07
- O 0 9.61396381171653e-06
77 O 0 1.8843732050299877e-06
% O 0 5.137849257152993e-07
) O 0 5.797290327791416e-07
. O 0 2.009270474445657e-06

The O 0 9.267863788409159e-06
estimated O 0 4.607340088114142e-06
sensitivity O 0 1.4809739695920143e-05
was O 0 2.298013214385719e-06
identical O 0 4.886876467935508e-07
for O 0 2.7719048389940326e-08
direct O 0 1.2939038640524814e-07
sequencing O 0 3.7529207475017756e-07
and O 0 9.764661967892607e-08
other O 0 5.769955180312536e-08
techniques O 0 3.600070385800791e-06
. O 0 2.1833104710822226e-06

The O 0 1.9316579709993675e-05
penetrance O 0 0.0001845521474024281
of O 0 3.7731751945102587e-06
BRCA2 O 0 0.001326769939623773
was O 0 1.9992578017991036e-05
estimated O 0 3.566155442058516e-07
by O 0 4.762422278759004e-08
maximizing O 0 7.47595265693235e-07
the O 0 1.8975397608755884e-07
LOD O 0 0.00016682081331964582
score O 0 1.6677408893883694e-06
in O 0 6.4877798422458e-07
BRCA2 O 0 0.000360260863089934
- O 0 0.0049998522736132145
mutation O 0 6.9955267463228665e-06
families O 0 9.985439675119778e-08
, O 0 1.8272489299420158e-08
over O 0 5.4030302010232845e-08
all O 0 3.805140735835266e-08
possible O 0 3.5819911659018544e-07
penetrance O 0 1.9980874640168622e-05
functions O 0 9.647695833336911e-07
. O 0 2.3547579530713847e-06

The O 0 8.561362847103737e-06
estimated O 0 5.919941031606868e-06
cumulative O 0 5.245036390988389e-06
risk O 0 3.0806677386863157e-06
of O 0 3.1228503871716384e-07
breast B-Disease 1 0.8164039254188538
cancer I-Disease 0 0.00030609071836806834
reached O 0 2.2699584860674804e-06
28 O 0 6.933658823982114e-06
% O 0 2.4315798441421066e-07
( O 0 3.7451332701721185e-08
95 O 0 2.0268674916223972e-07
% O 0 1.1477212069621601e-07
CI O 0 6.6365942075208295e-06
9 O 0 9.906746072374517e-07
% O 0 1.198730501528189e-07
- O 0 2.173152324758121e-06
44 O 0 4.2162474755969015e-07
% O 0 4.7424709492815964e-08
) O 0 8.24443358027338e-09
by O 0 5.410937475858191e-09
age O 0 2.2919666164966657e-08
50 O 0 1.9184170696462388e-08
years O 0 1.4225989275473694e-08
and O 0 3.828889560963944e-08
84 O 0 3.562124391010002e-07
% O 0 6.420430764819685e-08
( O 0 1.9488805236278495e-08
95 O 0 1.0970981634272903e-07
% O 0 1.0782572701373283e-07
CI O 0 8.900105967768468e-06
43 O 0 9.250205721400562e-07
% O 0 1.040591470768959e-07
- O 0 6.000890948598681e-07
95 O 0 4.082951647887967e-07
% O 0 8.230281167698195e-08
) O 0 1.269322336128198e-08
by O 0 1.8229290077442784e-08
age O 0 1.2798639659195032e-07
70 O 0 1.6366712429771724e-07
years O 0 3.350533859247662e-07
. O 0 1.002832391350239e-06

The O 0 0.00019624736160039902
corresponding O 1 0.7158836722373962
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0010814041597768664
were O 0 6.312093773885863e-06
0 O 0 8.633779543743003e-06
. O 0 3.914846729458077e-06

4 O 0 0.00019753580272663385
% O 0 6.79997174302116e-06
( O 0 2.9359753739299776e-07
95 O 0 9.602076715964358e-07
% O 0 5.325446750248375e-07
CI O 0 2.1353482225094922e-05
0 O 0 6.197121251716453e-07
% O 0 1.6128237234624976e-07
- O 0 1.5155064829741605e-06
1 O 0 4.4660637854576635e-07
% O 0 8.079733504473552e-08
) O 0 5.183043771950224e-09
by O 0 4.053950064530909e-09
age O 0 4.424712329864633e-08
50 O 0 2.4157625233556246e-08
years O 0 1.518803216526976e-08
and O 0 4.58476634435101e-08
27 O 0 4.879192374573904e-07
% O 0 2.8219270475915437e-08
( O 0 1.3109644925179964e-08
95 O 0 8.27673645176219e-08
% O 0 1.150051645026906e-07
CI O 0 4.6364225454453845e-06
0 O 0 3.2140869166141783e-07
% O 0 9.826842273241709e-08
- O 0 1.722049660202174e-06
47 O 0 4.157491275691427e-06
% O 0 6.556109610755811e-08
) O 0 5.256868718106489e-09
by O 0 1.0311037357269015e-08
age O 0 1.0602292377370759e-07
70 O 0 1.8284069369656208e-07
years O 0 2.790386872675299e-07
. O 0 1.2808594647140126e-06

The O 0 1.678518674452789e-05
lifetime O 0 2.3123106075217947e-05
risk O 0 1.1891441317857243e-05
of O 0 2.393131353528588e-06
breast B-Disease 1 0.999984860420227
cancer I-Disease 0 0.3964056670665741
appears O 0 3.159693051202339e-06
similar O 0 1.0983711007384045e-07
to O 0 5.779581613296614e-08
the O 0 2.58747803627557e-07
risk O 0 6.155037794997043e-07
in O 0 1.5558032373519382e-07
BRCA1 O 0 2.905582732637413e-05
carriers O 0 4.014724481748999e-07
, O 0 4.860309488208259e-08
but O 0 1.921046255404235e-08
there O 0 6.617995929047993e-09
was O 0 4.033882987641846e-07
some O 0 5.090731391987902e-09
suggestion O 0 7.565318327351633e-08
of O 0 1.3977627055794528e-08
a O 0 8.63003037920862e-07
lower O 0 2.5840063244686462e-05
risk O 0 6.435805630644609e-07
in O 0 1.7484060776951083e-07
BRCA2 O 0 2.798285277094692e-05
carriers O 0 6.135767876003229e-07
< O 0 6.110669801273616e-07
50 O 0 6.723819723220004e-08
years O 0 3.4279093341638145e-08
of O 0 4.031313594055064e-08
age O 0 7.375070936177508e-07
. O 0 1.0857057759494637e-06

Eye B-Disease 1 0.9980297684669495
movement I-Disease 0 0.023146919906139374
abnormalities I-Disease 1 0.9887502789497375
correlate O 0 0.00015975463611539453
with O 0 1.1950261978199705e-05
genotype O 0 0.2932005226612091
in O 0 4.020875712740235e-05
autosomal O 1 0.9986374974250793
dominant O 1 0.9248226881027222
cerebellar B-Disease 1 0.9999388456344604
ataxia I-Disease 1 0.9999991655349731
type I-Disease 0 0.0785229280591011
I I-Disease 0 0.0002312278375029564
. O 0 2.5209476007148623e-05

We O 0 3.313311390229501e-05
compared O 0 1.9395158233237453e-05
horizontal O 0 0.001015263726003468
eye O 0 0.03187040612101555
movements O 0 2.7936835977016017e-05
( O 0 1.2565228644234594e-06
visually O 0 3.0847190828353632e-06
guided O 0 2.8200979613757227e-06
saccades O 0 0.0003057095455005765
, O 0 5.49904370927834e-07
antisaccades O 0 1.0093241144204512e-05
, O 0 9.936800893228792e-08
and O 0 1.482233358274243e-07
smooth O 0 6.8838344304822385e-06
pursuit O 0 8.42198005557293e-06
) O 0 9.090337727002407e-08
in O 0 3.3140953092924974e-08
control O 0 5.01674492170423e-07
subjects O 0 2.8298023835304775e-07
( O 0 1.0689340257385993e-07
n O 0 4.361610535852378e-06
= O 0 6.709978151775431e-06
14 O 0 2.276222801356198e-07
) O 0 4.239633710767521e-08
and O 0 1.58024917595867e-07
patients O 0 1.9590854094531096e-07
with O 0 2.307639590526378e-08
three O 0 1.7992158518609358e-07
forms O 0 3.683763338813151e-07
of O 0 7.698397439526161e-07
autosomal O 0 0.11012964695692062
dominant O 0 0.00033115356927737594
cerebellar B-Disease 0 0.011105631478130817
ataxias I-Disease 0 0.0019216026412323117
type I-Disease 0 3.830129207926802e-05
I I-Disease 0 1.7549995391163975e-05
spinocerebellar B-Disease 0 0.0015092137036845088
ataxias I-Disease 0 9.322137339040637e-05
1 I-Disease 0 1.25224607927521e-06
and I-Disease 0 4.599954763762071e-07
2 I-Disease 0 1.4747635077583254e-06
( O 0 1.7324884993286105e-07
SCA1 B-Disease 0 1.0019568435382098e-05
, O 0 1.5827922084099555e-07
n O 0 2.598348373794579e-06
= O 0 2.7474873149913037e-06
11 O 0 2.7145748049406393e-07
; O 0 1.3030226853061322e-07
SCA2 B-Disease 0 6.813882919232128e-06
, O 0 1.7069190505480947e-07
n O 0 2.9425502816593507e-06
= O 0 2.8205981834616978e-06
10 O 0 1.0887681156646067e-07
) O 0 5.5842885871015824e-08
and O 0 2.8526415007945616e-07
SCA3 B-Disease 1 0.9999340772628784
/ O 0 9.747668809723109e-05
Machado B-Disease 0 1.4964874026190955e-05
- I-Disease 0 0.00012166931992396712
Joseph I-Disease 0 0.00010687991016311571
disease I-Disease 0 4.3873977119801566e-05
( O 0 1.01066882507439e-06
MJD B-Disease 1 0.9999324083328247
) O 0 6.063977480152971e-07
( O 0 4.255086878401926e-07
n O 0 9.06917284737574e-06
= O 0 2.0274783310014755e-05
16 O 0 1.0846398481589858e-06
) O 0 8.843807108860346e-07
. O 0 1.8900857412518235e-06

In O 0 3.6178109439788386e-05
SCA1 B-Disease 0 0.00028510886477306485
, O 0 2.519205736462027e-06
saccade O 0 5.133244121680036e-05
amplitude O 0 1.2655418686335906e-05
was O 0 8.71919564815471e-06
significantly O 0 1.0126570487045683e-05
increased O 0 2.6717220862337854e-06
, O 0 1.2046324115999596e-07
resulting O 0 9.099372277887596e-07
in O 0 5.88235423037986e-07
hypermetria B-Disease 0 0.00021056980767752975
. O 0 8.309997610922437e-06

The O 0 1.6203492123167962e-05
smooth O 0 9.610773849999532e-05
pursuit O 0 8.402543608099222e-05
gain O 0 0.0002094552619382739
was O 0 9.346534352516755e-05
decreased O 0 0.00012819227413274348
. O 0 4.773426553583704e-06

In O 0 3.122918133158237e-05
SCA2 B-Disease 0 0.00026164171868003905
, O 0 2.510772674213513e-06
saccade O 0 7.859549805289134e-05
velocity O 0 2.9097782316966914e-05
was O 0 2.768693957477808e-05
markedly O 0 0.0008670014794915915
decreased O 0 0.0001751820818753913
. O 0 5.359457645681687e-06

The O 0 1.0979772014252376e-05
percentage O 0 1.7800437490222976e-05
of O 0 1.931536246502219e-07
errors O 0 3.93081791116856e-06
in O 0 4.3559225559874903e-07
antisaccades O 0 0.00020374823361635208
was O 0 2.089236477331724e-05
greatly O 0 1.014255644804507e-06
increased O 0 4.078414121977403e-07
and O 0 2.884899856780976e-07
was O 0 2.866491968234186e-06
significantly O 0 1.4500576526188524e-06
correlated O 0 9.64886453402869e-07
with O 0 2.408521595498314e-07
age O 0 2.929092033809866e-06
at O 0 4.412056114233565e-06
disease O 0 0.00012243700621183962
onset O 0 0.0004793533880729228
. O 0 1.1126710887765512e-05

In O 0 1.1833430107799359e-05
addition O 0 1.7676205743555329e-06
, O 0 1.1254288523332434e-07
a O 0 1.6603061681053077e-07
correlation O 0 5.235758067101415e-07
between O 0 2.489649091330648e-07
smooth O 0 3.3168744266731665e-05
pursuit O 0 0.0001360879687126726
gain O 0 4.413709757500328e-05
and O 0 1.308536781152725e-07
the O 0 2.2311487768433835e-08
number O 0 1.5286730103980517e-08
of O 0 4.808020648283673e-08
trinucleotide O 0 0.0001560632954351604
repeats O 0 2.6254534532199614e-05
was O 0 8.866119060257915e-06
found O 0 1.8263834817844327e-06
. O 0 3.7782090203108964e-06

In O 0 5.8123576309299096e-05
SCA3 B-Disease 1 0.9998480081558228
, O 0 4.874327714787796e-06
gaze B-Disease 0 5.5288048315560445e-05
- I-Disease 0 0.000172819709405303
evoked I-Disease 0 0.00035263673635199666
nystagmus I-Disease 0 0.16903063654899597
was O 0 5.8637098845792934e-05
often O 0 4.3735633425967535e-07
present O 0 5.560544380500687e-08
as O 0 7.811946289848493e-08
was O 0 1.8563231378720957e-06
saccade O 0 1.6461886843899265e-05
hypometria O 0 1.1549482223927043e-05
and O 0 2.6867769520322327e-07
smooth O 0 6.31900229564053e-06
pursuit O 0 1.4201164049154613e-05
gain O 0 3.4770961065078154e-05
was O 0 5.368951678974554e-05
markedly O 0 0.0004078480997122824
decreased O 0 0.0001265666214749217
. O 0 3.775313416554127e-06

Three O 0 1.4673962141387165e-05
major O 0 2.0103743736399338e-06
criteria O 0 1.9542501377145527e-06
, O 0 4.468185466066643e-07
saccade O 0 1.636740125832148e-05
amplitude O 0 2.764816827038885e-06
, O 0 1.3612392990580702e-07
saccade O 0 9.684314136393368e-06
velocity O 0 2.783359377644956e-06
, O 0 5.719802942394381e-08
and O 0 2.5657893587549552e-08
presence O 0 2.9337073215174314e-08
of O 0 2.3501890211719e-08
gaze B-Disease 0 2.968131775560323e-05
- I-Disease 0 6.27477711532265e-05
evoked I-Disease 0 6.124942592578009e-05
nystagmus I-Disease 0 0.00025293781072832644
, O 0 1.0728025756634452e-07
permitted O 0 3.065341047658876e-08
the O 0 2.629016115918148e-08
correct O 0 1.105293222281034e-06
assignment O 0 1.6681211434388388e-07
of O 0 2.2212891082062924e-08
90 O 0 1.0609595335608901e-07
% O 0 3.609134324733532e-08
of O 0 3.836080342267678e-09
the O 0 5.5666568243850634e-08
SCA1 B-Disease 0 2.3301594410440885e-05
, O 0 6.30472101192936e-08
90 O 0 4.957815491479778e-08
% O 0 1.4522682612039262e-08
of O 0 2.6079287618330227e-09
the O 0 6.46009539195802e-08
SCA2 B-Disease 0 6.545608630403876e-05
, O 0 6.075531189253525e-08
and O 0 8.260050776698336e-08
93 O 0 2.6404899244880653e-07
% O 0 3.924222014006773e-08
of O 0 5.710523609536722e-09
the O 0 1.6366526267574955e-07
patients O 0 6.681159447907703e-07
with O 0 2.6014379272965016e-07
SCA3 B-Disease 1 0.999988317489624
to O 0 9.95957094573896e-08
their O 0 6.841608524155163e-08
genetically O 0 2.4415794541710056e-06
confirmed O 0 2.9682155400223564e-06
patient O 0 1.938030663950485e-06
group O 0 1.161536374638672e-06
and O 0 1.5309758794046502e-07
, O 0 1.2854934539063834e-07
therefore O 0 6.811634989389859e-08
, O 0 5.365392397038704e-08
may O 0 2.4948209897956986e-07
help O 0 1.0966483188212806e-07
orient O 0 5.833889645145973e-06
diagnoses O 0 1.624167271074839e-05
of O 0 8.86255264731517e-08
SCA1 B-Disease 0 0.00010237235255772248
, O 0 2.2054754822420364e-07
SCA2 B-Disease 0 2.731450877035968e-05
, O 0 1.5171535494573618e-07
and O 0 2.623086459152546e-07
SCA3 B-Disease 1 0.9990715980529785
at O 0 2.7017000547857606e-07
early O 0 3.369683554410585e-07
clinical O 0 7.597201943099208e-07
stages O 0 7.319702035601949e-07
of O 0 5.0167159315606114e-08
the O 0 3.151114242427866e-06
diseases O 0 0.00011935273505514488
. O 0 7.687672223255504e-07
. O 0 3.6341762097436003e-06

Genetic O 0 0.00046613794984295964
basis O 0 1.1992227882728912e-05
and O 0 1.513897245786211e-06
molecular O 0 1.804552084649913e-05
mechanism O 0 4.084465035703033e-05
for O 0 7.722058944636956e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
. O 0 0.001075628912076354

Ventricular B-Disease 1 0.9999653100967407
fibrillation I-Disease 1 0.9999942779541016
causes O 0 0.000270243821432814
more O 0 2.2985780390172295e-07
than O 0 6.146209585722318e-08
300 O 0 7.376478805554143e-08
, O 0 3.7135510666530536e-08
000 O 0 1.9671844597723975e-07
sudden O 0 1.4596602113670087e-06
deaths O 0 2.8570786980708363e-06
each O 0 7.195219353661741e-08
year O 0 8.717549349057663e-08
in O 0 9.015106883225599e-08
the O 0 4.148182313201687e-07
USA O 0 1.669139055593405e-05
alone O 0 2.8469389690144453e-06
. O 0 1.923750460264273e-06

In O 0 4.394896677695215e-06
approximately O 0 1.2683973409366445e-06
5 O 0 1.2229510275574285e-06
- O 0 1.5692392480559647e-05
12 O 0 1.6172963341887225e-06
% O 0 6.156957255143425e-08
of O 0 6.509729644221807e-09
these O 0 1.7540635610657773e-08
cases O 0 9.441841797297457e-08
, O 0 3.246475799301152e-08
there O 0 1.566088947413391e-08
are O 0 1.8990528261042527e-08
no O 0 1.7708218535972264e-07
demonstrable O 0 9.37062141019851e-05
cardiac O 0 0.013127792626619339
or O 0 1.3440045449897298e-06
non O 0 3.8131802284624428e-06
- O 0 0.012506996281445026
cardiac O 0 0.11221962422132492
causes O 0 1.613994413673936e-06
to O 0 3.9469668422498216e-08
account O 0 5.039550643459734e-08
for O 0 1.1472819139157764e-08
the O 0 8.744677870708983e-08
episode O 0 2.613475407997612e-05
, O 0 4.3427075979707297e-07
which O 0 9.165619019313453e-08
is O 0 7.324828743549006e-08
therefore O 0 2.8667196261267236e-07
classified O 0 2.7016817512048874e-06
as O 0 4.285791874281131e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.04024360701441765
IVF B-Disease 1 1.0
) O 0 1.7405649487045594e-05
. O 0 6.755133654223755e-06

A O 0 8.866294956533238e-05
distinct O 0 1.555199378344696e-05
group O 0 4.821911261387868e-06
of O 0 5.764283628195699e-07
IVF B-Disease 1 1.0
patients O 0 0.0003426372422836721
has O 0 2.461425765432068e-06
been O 0 2.2737405913630937e-07
found O 0 8.740075685409465e-08
to O 0 1.984231801088754e-08
present O 0 3.791216940385311e-08
with O 0 7.082695674398565e-08
a O 0 3.427913952691597e-06
characteristic O 0 3.28456299030222e-05
electrocardiographic O 0 0.00019866930961143225
pattern O 0 0.00021057702542748302
. O 0 5.845741270604776e-06

Because O 0 1.11408116936218e-05
of O 0 2.2820566414338828e-07
the O 0 9.889060237355807e-08
small O 0 5.7113652474072296e-08
size O 0 8.806121343241102e-08
of O 0 1.4959153915583556e-08
most O 0 4.118782470641236e-08
pedigrees O 0 1.8490367210688419e-06
and O 0 9.216685725732532e-08
the O 0 9.15665552270184e-08
high O 0 5.434580998553429e-06
incidence O 0 0.00023429750581271946
of O 0 8.939289131149053e-08
sudden B-Disease 0 2.6441124646225944e-05
death I-Disease 0 2.4083494281512685e-05
, O 0 1.89982500842234e-07
however O 0 4.205886128261227e-08
, O 0 2.2535642685284074e-08
molecular O 0 3.032340600839234e-07
genetic O 0 4.198536487365345e-07
studies O 0 2.499740681116691e-08
of O 0 2.8717396460820055e-08
IVF B-Disease 1 0.9999998807907104
have O 0 2.094047886203043e-06
not O 0 9.793106414690556e-08
yet O 0 1.2050368525251542e-07
been O 0 5.107223728373356e-07
done O 0 8.48830552513391e-07
. O 0 1.2029762501697405e-06

Because O 0 0.0004003518261015415
IVF B-Disease 1 0.9999995231628418
causes O 0 0.013692684471607208
cardiac O 1 0.994027853012085
rhythm O 1 0.9349564909934998
disturbance O 0 0.0007409256068058312
, O 0 6.563428769368329e-07
we O 0 1.2466179555303825e-07
investigated O 0 8.240347710852802e-07
whether O 0 1.871359387450866e-07
malfunction O 0 1.9423256162554026e-05
of O 0 3.777632429091682e-08
ion O 0 4.027896466141101e-06
channels O 0 2.571777486082283e-06
could O 0 2.487852952981484e-06
cause O 0 1.4865584034851054e-06
the O 0 1.0621758974593831e-06
disorder O 0 0.0002609018702059984
by O 0 4.49601174068448e-08
studying O 0 1.277810071087515e-07
mutations O 0 1.0646036798789282e-06
in O 0 5.7242559137193894e-08
the O 0 4.662289541101927e-07
cardiac O 0 0.000321990461088717
sodium O 0 1.6109241187223233e-05
channel O 0 2.2862330297357403e-05
gene O 0 7.310790351766627e-06
SCN5A O 0 0.00014583795564249158
. O 0 8.29286545922514e-06

We O 0 1.975487612071447e-05
have O 0 7.763750886624621e-07
now O 0 2.1243535286430415e-07
identified O 0 8.226026011470822e-07
a O 0 1.461790247958561e-06
missense O 0 0.0003017678391188383
mutation O 0 7.173292942752596e-06
, O 0 8.453014288534177e-08
a O 0 6.050904630683362e-07
splice O 0 0.0002703283680602908
- O 0 0.0019179225200787187
donor O 0 8.745411832933314e-06
mutation O 0 4.5189462980488315e-06
, O 0 5.3568133040471366e-08
and O 0 1.839835874761775e-07
a O 0 2.9337579690036364e-06
frameshift O 0 0.011922311969101429
mutation O 0 3.2144132546818582e-06
in O 0 6.186539280861325e-08
the O 0 1.848122082037662e-07
coding O 0 1.1053649359382689e-05
region O 0 8.299546152557014e-07
of O 0 5.274467440585795e-08
SCN5A O 0 7.480404747184366e-05
in O 0 5.213694862504781e-07
three O 0 7.897037903603632e-06
IVF B-Disease 1 0.9999997615814209
families O 0 8.096214514807798e-06
. O 0 4.400256329972763e-06

We O 0 2.0737295926664956e-05
show O 0 4.53546908829594e-06
that O 0 1.5021919352875557e-07
sodium O 0 1.1443728453741642e-06
channels O 0 2.9882568242101115e-07
with O 0 3.654987779100338e-08
the O 0 4.888311764261744e-07
missense O 0 0.00016858473827596754
mutation O 0 6.236444733076496e-06
recover O 0 1.8846392322302563e-06
from O 0 7.524879919174055e-08
inactivation O 0 2.981430043291766e-06
more O 0 1.4878085430325427e-08
rapidly O 0 1.2404962035361677e-07
than O 0 1.3913894925110526e-08
normal O 0 9.481870222316502e-08
and O 0 4.697351130289462e-08
that O 0 2.80029244237312e-08
the O 0 2.9305263637979806e-07
frameshift O 0 0.0019492750288918614
mutation O 0 6.369395123329014e-06
causes O 0 3.0701866648996656e-07
the O 0 6.437254285174276e-08
sodium O 0 1.3291145251059788e-06
channel O 0 2.1595046746369917e-06
to O 0 3.0634531356099615e-08
be O 0 5.920060885955536e-08
non O 0 2.657831146279932e-07
- O 0 9.976499313779641e-06
functional O 0 8.223451004596427e-06
. O 0 2.2418789740186185e-06

Our O 0 2.068716275971383e-05
results O 0 1.0485631719348021e-05
indicate O 0 1.6665070461385767e-06
that O 0 1.6108562306271779e-07
mutations O 0 2.5157387426588684e-06
in O 0 1.5899193783752708e-07
cardiac O 0 0.00012398738181218505
ion O 0 1.1697341506078374e-05
- O 0 3.9592043322045356e-05
channel O 0 5.8754753808898386e-06
genes O 0 2.540957382279885e-07
contribute O 0 3.580440122163964e-08
to O 0 1.8866225914848656e-08
the O 0 7.256080181150537e-08
risk O 0 2.3019562434001273e-07
of O 0 4.246901141868875e-08
developing O 0 2.776212340904749e-06
IVF B-Disease 1 0.9999986886978149
. O 0 1.7804005665311706e-06
. O 0 3.434320660744561e-06

Molecular O 0 0.00012035409599775448
heterogeneity O 0 0.00012556744331959635
in O 0 1.9967585558333667e-06
mucopolysaccharidosis B-Disease 0 0.0001633100036997348
IVA I-Disease 0 0.12824709713459015
in O 0 4.665074811782688e-06
Australia O 0 1.0975696795867407e-06
and O 0 3.9422425857083e-07
Northern O 0 1.7900181319419062e-06
Ireland O 0 1.039973881233891e-06
: O 0 9.783753540659745e-08
nine O 0 3.2434621743959724e-07
novel O 0 2.444636038489989e-06
mutations O 0 2.2012318368069828e-06
including O 0 5.592656293629261e-08
T312S O 0 4.855514362134272e-06
, O 0 5.793742374748945e-08
a O 0 2.0139692935572384e-07
common O 0 4.3181847786399885e-07
allele O 0 2.5193521651090123e-06
that O 0 1.880867301906619e-07
confers O 0 5.3062394727021456e-06
a O 0 4.791520768776536e-05
mild O 1 0.9678202271461487
phenotype O 0 0.21387267112731934
. O 0 1.064456046151463e-05

Mucopolysaccharidosis B-Disease 0 0.4484177529811859
IVA I-Disease 1 0.9997308850288391
( O 0 0.045399054884910583
MPS B-Disease 1 0.9999963045120239
IVA I-Disease 1 1.0
) O 0 1.2929375770909246e-05
is O 0 7.98525718437304e-07
an O 0 5.917734142713016e-06
autosomal B-Disease 1 0.9998804330825806
recessive I-Disease 1 0.9999927282333374
lysosomal I-Disease 1 0.9999896287918091
storage I-Disease 1 0.999992847442627
disorder I-Disease 1 0.9999967813491821
caused O 0 0.000479799578897655
by O 0 1.5268539073076681e-06
a O 0 0.0017660451121628284
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999808073043823
in O 0 1.8754467419057619e-06
N O 0 0.00011720968905137852
- O 0 2.30436198762618e-05
acetylgalactosamine O 0 4.2129897337872535e-05
- O 0 3.8707032217644155e-05
6 O 0 7.327962066483451e-06
- O 0 0.0001338254369329661
sulfate O 0 0.00014530147018376738
sulfatase O 0 0.0002665812789928168
( O 0 2.5593485588615295e-06
GALNS O 0 0.00010841863695532084
) O 0 1.955512288986938e-06
. O 0 3.3298806556558702e-06

Previous O 0 7.2728558734525e-05
studies O 0 3.947222467104439e-06
of O 0 3.112913020686392e-07
patients O 0 1.4782484640818438e-06
from O 0 4.675567311096529e-08
a O 0 4.255593921698164e-07
British O 0 4.7719381655042525e-06
- O 0 0.00016745063476264477
Irish O 0 3.9881256270746235e-06
population O 0 2.0052550553373294e-07
showed O 0 5.41654628705146e-07
that O 0 1.0794523497281716e-08
the O 0 4.9422940406884663e-08
I113F O 0 1.6242818674072623e-05
mutation O 0 1.436457523595891e-06
is O 0 1.7539733221383358e-08
the O 0 2.3337728194405827e-08
most O 0 3.246791635547197e-08
common O 0 5.372683062887518e-07
single O 0 9.388823855260853e-06
mutation O 0 1.867921309894882e-05
among O 0 2.2078584152041003e-06
MPS B-Disease 1 0.9999575614929199
IVA I-Disease 1 1.0
patients O 0 0.0026726066134870052
and O 0 1.3951386108601582e-06
produces O 0 2.4241135179181583e-06
a O 0 1.048524154612096e-05
severe O 0 0.40629005432128906
clinical O 0 0.005360757932066917
phenotype O 0 0.32640784978866577
. O 0 1.3232915080152452e-05

We O 0 2.276601480843965e-05
studied O 0 5.575807335844729e-06
mutations O 0 9.490457159699872e-06
in O 0 1.0353885926406292e-07
the O 0 1.4641310031038302e-07
GALNS O 0 1.988590338442009e-05
gene O 0 4.74470596145693e-07
from O 0 7.758667663892993e-08
23 O 0 6.816709401391563e-07
additional O 0 1.4014327689437778e-06
MPS B-Disease 1 0.9999419450759888
IVA I-Disease 1 1.0
patients O 0 0.0003302301629446447
( O 0 2.2465479787570075e-07
15 O 0 1.1672447186583668e-07
from O 0 1.0160807306647257e-08
Australia O 0 5.084794807430626e-08
, O 0 1.237215929705826e-08
8 O 0 5.1956369873096264e-08
from O 0 1.0216950840913341e-08
Northern O 0 1.7616284253563208e-07
Ireland O 0 2.0162025293757324e-07
) O 0 2.217673866766745e-08
, O 0 9.550439550309875e-09
with O 0 8.617528024501553e-09
various O 0 5.0167447085414096e-08
clinical O 0 2.280586886627134e-05
phenotypes O 0 0.0007496785838156939
( O 0 1.284605332330102e-06
severe O 0 0.00011341203207848594
, O 0 2.343287377470915e-07
16 O 0 9.20947854865517e-07
cases O 0 1.1234450170150012e-07
; O 0 3.117993685464171e-07
intermediate O 0 1.6097703792183893e-07
, O 0 2.851343339216328e-08
4 O 0 2.298849750559384e-07
cases O 0 9.180683235854303e-08
; O 0 1.1798954346886603e-06
mild O 0 0.000431932567153126
, O 0 3.347997790115187e-07
3 O 0 1.370494487673568e-06
cases O 0 4.046050605666096e-07
) O 0 6.342248752844171e-07
. O 0 1.5794252021805733e-06

We O 0 8.316902494698297e-06
found O 0 1.092827801585372e-06
two O 0 3.2187833198804583e-07
common O 0 2.5732372250786284e-06
mutations O 0 4.578540938382503e-06
that O 0 3.9201598411864325e-08
together O 0 1.4611489973503922e-07
accounted O 0 3.536598569553462e-07
for O 0 4.8459984469673145e-08
32 O 0 1.052385414368473e-06
% O 0 3.984788321531596e-08
of O 0 3.0456646094023654e-09
the O 0 8.362121661775745e-08
44 O 0 1.1373150528015685e-06
unrelated O 0 1.4035406366019743e-06
alleles O 0 5.571632755163591e-07
in O 0 1.403742686534315e-07
these O 0 5.597009362645622e-07
patients O 0 8.085898116405588e-06
. O 0 2.833755388564896e-06

One O 0 1.0796461538120639e-05
is O 0 4.291286472835054e-07
the O 0 2.4322221747752337e-07
T312S O 0 2.8482852940214798e-05
mutation O 0 4.410511792229954e-06
, O 0 5.4341594335483023e-08
a O 0 2.1821063000970753e-07
novel O 0 4.687605269282358e-06
mutation O 0 2.397757498329156e-06
found O 0 1.2788902381544176e-07
exclusively O 0 3.040065905679512e-07
in O 0 9.92053173831664e-07
milder O 0 0.17537181079387665
patients O 0 5.7836670748656616e-05
. O 0 3.950856807932723e-06

The O 0 3.5533876143745147e-06
other O 0 2.249510941965127e-07
is O 0 1.0708583886298584e-07
the O 0 1.0534622418845174e-07
previously O 0 3.078594318139949e-06
described O 0 4.124185579712503e-06
I113F O 0 8.700730177224614e-06
that O 0 1.3807414234179305e-07
produces O 0 6.05191416980233e-07
a O 0 4.087832166987937e-06
severe O 0 0.14729779958724976
phenotype O 0 0.19387756288051605
. O 0 1.960118424904067e-05

The O 0 1.0415200449642725e-05
I113F O 0 2.870366552087944e-05
and O 0 1.1630528433670406e-06
T312S O 0 2.251583464385476e-05
mutations O 0 3.488037464194349e-06
accounted O 0 5.304856358634424e-07
for O 0 4.638721762262321e-08
8 O 0 1.5025774473542697e-06
( O 0 1.3028500234213425e-07
18 O 0 3.966173380831606e-07
% O 0 8.942596707584016e-08
) O 0 1.7002491858875146e-08
and O 0 6.19183921912736e-08
6 O 0 1.2567865042001358e-06
( O 0 6.445142020083949e-08
14 O 0 2.1458882315528172e-07
% O 0 6.621559123232146e-08
) O 0 8.279875451933094e-09
of O 0 9.068600093087298e-09
44 O 0 4.534754509677441e-07
unrelated O 0 1.9432591216173023e-06
alleles O 0 1.9871972654073033e-06
, O 0 4.7400203584402334e-07
respectively O 0 4.803401679964736e-06
. O 0 3.8274479265965056e-06

The O 0 1.284125664824387e-05
relatively O 0 7.822270163160283e-06
high O 0 2.8717263376165647e-06
residual O 0 1.4018273759575095e-05
GALNS O 0 9.483590838499367e-05
activity O 0 1.592751232237788e-06
seen O 0 4.4580124836102186e-07
when O 0 3.2066161281818495e-08
the O 0 3.0034847497972805e-08
T312S O 0 1.4794317166888504e-06
mutant O 0 1.2027284128635074e-06
cDNA O 0 1.8070845726469997e-06
is O 0 6.197133473051508e-08
overexpressed O 0 1.8191033177572535e-06
in O 0 1.3515298746824556e-07
mutant O 0 1.2461414371500723e-05
cells O 0 8.024809972084768e-07
provides O 0 4.07462650287016e-08
an O 0 1.5160797062208076e-08
explanation O 0 7.150578085202142e-08
for O 0 4.361966432497866e-08
the O 0 1.536452145955991e-06
mild O 1 0.9453089237213135
phenotype O 0 0.348062127828598
in O 0 1.0153589755645953e-06
patients O 0 2.210327693319414e-06
with O 0 2.524250817259599e-07
this O 0 1.0880047511818702e-06
mutation O 0 5.2351020713103935e-05
. O 0 2.431993380014319e-06

The O 0 4.3399809328548145e-06
distribution O 0 2.1556570573011413e-06
and O 0 2.454685841257742e-07
relative O 0 2.3703985618794832e-07
frequencies O 0 1.4850590446258138e-07
of O 0 9.600646500018684e-09
the O 0 6.757762349707264e-08
I113F O 0 4.077218818565598e-06
and O 0 2.1828972762705234e-07
T312S O 0 4.609317784343148e-06
mutations O 0 4.1242779502681515e-07
in O 0 1.6582260897735068e-08
Australia O 0 4.530928521262467e-08
corresponded O 0 8.775538162808516e-08
to O 0 1.4627375755082994e-08
those O 0 1.1198312499516305e-08
observed O 0 7.983089034269142e-08
in O 0 1.3829836831291686e-08
Northern O 0 1.2125964303777437e-06
Ireland O 0 6.15864905739727e-07
and O 0 1.0365781122345652e-07
are O 0 6.283085607350358e-09
unique O 0 1.2175423336202584e-08
to O 0 2.2397703247634126e-08
these O 0 8.31489721520029e-09
two O 0 3.24356683734095e-08
populations O 0 1.1973982338986389e-07
, O 0 1.8129496126562117e-08
suggesting O 0 6.731134050141918e-08
that O 0 1.0453195642412538e-08
both O 0 5.114208434520151e-08
mutations O 0 6.774137659704138e-07
were O 0 1.0788765081315432e-07
probably O 0 7.320944916955341e-08
introduced O 0 1.2961615425410855e-07
to O 0 2.2498921836699992e-08
Australia O 0 4.279671372842131e-08
by O 0 2.727452752537829e-08
Irish O 0 4.5333143816606025e-07
migrants O 0 8.404303031284144e-08
during O 0 6.645979055974749e-08
the O 0 4.757900740059995e-08
19th O 0 2.795543423417257e-06
century O 0 2.875250174838584e-06
. O 0 2.3232219064084347e-06

Haplotype O 0 0.003163587534800172
analysis O 0 1.629911275813356e-05
using O 0 2.583897412478109e-06
6 O 0 4.059557340951869e-06
RFLPs O 0 1.0594469131319784e-05
provides O 0 1.8792570699588396e-07
additional O 0 4.6658122698772786e-08
data O 0 1.2810606619950704e-07
that O 0 1.8253714983984537e-08
the O 0 1.4832869510428282e-07
I113F O 0 1.8426366295898333e-05
mutation O 0 1.4374373904502136e-06
originated O 0 2.2804597676895355e-07
from O 0 3.434113082789736e-08
a O 0 4.6573035206165514e-07
common O 0 1.0837599120350205e-06
ancestor O 0 6.128065251687076e-06
. O 0 3.6617811929318123e-06

The O 0 4.826792974199634e-06
other O 0 5.562696969718672e-07
9 O 0 3.853536327369511e-06
novel O 0 3.493663825793192e-06
mutations O 0 4.3857776290678885e-06
identified O 0 3.3089702355937334e-07
in O 0 6.411472952549957e-08
these O 0 6.620649628530373e-08
23 O 0 4.252350208844291e-06
patients O 0 6.485342396445049e-07
were O 0 1.2612886735041684e-07
each O 0 4.120244057048694e-08
limited O 0 5.19478504656945e-08
to O 0 4.336003200933192e-08
a O 0 4.5876748799855704e-07
single O 0 6.9804787017346825e-06
family O 0 2.131038399966201e-06
. O 0 2.4650553314131685e-06

These O 0 3.5272787499707192e-06
data O 0 9.468557209402206e-07
provide O 0 1.0436625075271877e-07
further O 0 9.261728450837836e-08
evidence O 0 7.634535137412968e-08
for O 0 3.22919646578157e-08
extensive O 0 1.2112880085624056e-06
allelic O 0 5.046931983088143e-05
heterogeneity O 0 9.002574370242655e-05
in O 0 9.033918104250915e-06
MPS B-Disease 1 0.9997372031211853
IVA I-Disease 1 0.9999985694885254
in O 0 1.0590206329652574e-05
British O 0 0.00017693247355055064
- O 0 0.043166324496269226
Irish O 0 5.054493885836564e-05
patients O 0 1.0214075700787362e-06
and O 0 3.958939842618747e-08
provide O 0 3.836528605916101e-08
evidence O 0 2.8538734042626857e-08
for O 0 2.112941110965494e-08
their O 0 5.0531994588709495e-08
transmission O 0 3.933487732865615e-06
to O 0 3.085419564285985e-08
Australia O 0 4.028868971772681e-08
by O 0 1.698272100725262e-08
British O 0 1.2182783848402323e-06
- O 0 1.1375394024071284e-05
Irish O 0 1.2639525266422424e-06
migrants O 0 6.605803264392307e-07
. O 0 2.073340965580428e-07
. O 0 1.7248504491362837e-06

Identification O 0 3.462424865574576e-05
of O 0 1.913724645419279e-06
constitutional O 0 2.9093565899529494e-05
WT1 O 0 0.07419231534004211
mutations O 0 0.0002590495569165796
, O 0 5.50820743683289e-07
in O 0 6.832244707766222e-07
patients O 0 4.179965799266938e-06
with O 0 2.148518660760601e-06
isolated O 0 0.044219400733709335
diffuse B-Disease 1 0.9998812675476074
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 4.5103911361366045e-06
and O 0 2.6326750912630814e-07
analysis O 0 1.9592704347815015e-07
of O 0 3.3475188843112846e-07
genotype O 0 0.14537352323532104
/ O 0 0.015664735808968544
phenotype O 0 0.00046257954090833664
correlations O 0 5.426274583442137e-06
by O 0 5.556706383913479e-08
use O 0 9.079455765004241e-08
of O 0 8.537318763046642e-08
a O 0 3.7886761674599256e-06
computerized O 0 0.00021676610049325973
mutation O 0 2.000997483264655e-05
database O 0 3.5304926768731093e-06
. O 0 4.450308551895432e-06

Constitutional O 0 0.00013657390081789345
mutations O 0 6.981961632845923e-05
of O 0 3.543347020240617e-07
the O 0 6.551229034812422e-07
WT1 O 0 0.00012308056466281414
gene O 0 2.330640427317121e-06
, O 0 1.7737880853019306e-07
encoding O 0 5.497003598975425e-07
a O 0 6.464264060923597e-06
zinc O 0 0.028022022917866707
- O 0 0.00015336908109020442
finger O 0 4.4124470150563866e-05
transcription O 0 1.8297550923307426e-06
factor O 0 5.962988325336482e-07
involved O 0 2.288189193677681e-07
in O 0 9.819017350309878e-07
renal O 0 0.07570335268974304
and O 0 4.405849722388666e-06
gonadal O 0 0.00020874093752354383
development O 0 5.833800287291524e-07
, O 0 1.9989370514394977e-07
are O 0 1.4189621033722233e-08
found O 0 6.594876111876147e-08
in O 0 9.305055925779016e-08
most O 0 1.6673909897235717e-07
patients O 0 1.129251359088812e-06
with O 0 2.121870238624979e-06
Denys B-Disease 1 0.9998509883880615
- I-Disease 1 0.9999970197677612
Drash I-Disease 1 0.9999939203262329
syndrome I-Disease 1 0.9999997615814209
( O 0 2.6362869903095998e-05
DDS B-Disease 1 1.0
) O 0 9.080544259632006e-06
, O 0 1.4946325563869323e-06
or O 0 1.438570052414434e-05
diffuse B-Disease 1 0.9996836185455322
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.00012801686534658074
DMS B-Disease 0 0.005095907021313906
) O 0 3.469997693628102e-07
associated O 0 3.048465089250385e-07
with O 0 4.210614008570701e-07
pseudohermaphroditism B-Disease 1 0.9999958276748657
and O 0 1.6737998521421105e-05
/ O 0 0.0018322188407182693
or O 0 2.4175515136448666e-05
Wilms B-Disease 1 0.767839789390564
tumor I-Disease 0 0.11109794676303864
( O 0 4.711052497441415e-06
WT B-Disease 1 0.9977433681488037
) O 0 3.320687255836674e-06
. O 0 4.355621058493853e-06

Most O 0 7.932216976769269e-05
mutations O 0 0.0007532103336416185
in O 0 2.0643434254452586e-05
DDS B-Disease 1 1.0
patients O 1 0.53240966796875
lie O 0 1.0018985449278262e-05
in O 0 1.401473923579033e-07
exon O 0 8.640788109914865e-06
8 O 0 2.524301862649736e-06
or O 0 2.5402496817150677e-07
exon O 0 4.326133421272971e-06
9 O 0 3.233722509321524e-06
, O 0 9.316831039996032e-08
encoding O 0 1.59556987000542e-06
zinc O 0 0.00032361256307922304
finger O 0 5.5902029998833314e-05
2 O 0 8.104480912152212e-06
or O 0 1.8992068362422287e-06
zinc O 0 0.0009448918281123042
finger O 0 3.806264794548042e-05
3 O 0 1.2931084256706527e-06
, O 0 8.526952655074638e-08
respectively O 0 1.9337775825079007e-07
, O 0 8.331153544816061e-09
with O 0 8.528037831467827e-09
a O 0 6.166289381326351e-07
hot O 0 3.629957791417837e-05
spot O 0 5.346551552065648e-05
( O 0 6.554809601766465e-07
R394W O 0 3.0203220831026556e-06
) O 0 8.428783360159287e-08
in O 0 1.1714065095702608e-07
exon O 0 1.737354432407301e-05
9 O 0 1.1088471183029469e-05
. O 0 3.5348587061889702e-06

We O 0 5.654293090628926e-06
analyzed O 0 3.5563778055802686e-06
a O 0 4.286002592834848e-07
series O 0 3.784985835864063e-07
of O 0 1.0136614747580097e-07
24 O 0 1.0623790331010241e-05
patients O 0 8.244466584983456e-07
, O 0 6.186657230955461e-08
10 O 0 5.91635824775949e-08
with O 0 1.7773830052192352e-07
isolated B-Disease 0 0.0003153891011606902
DMS I-Disease 0 0.2944469749927521
( O 0 8.434700475845602e-07
IDMS B-Disease 0 9.315817442256957e-05
) O 0 1.3037261226145347e-07
, O 0 5.472269393180795e-08
10 O 0 8.630377834606406e-08
with O 0 4.368219492789649e-07
DDS B-Disease 1 1.0
, O 0 1.0124979326064931e-06
and O 0 3.8078786701589706e-07
4 O 0 1.876586452453921e-06
with O 0 3.432644234635518e-06
urogenital B-Disease 1 0.9831255078315735
abnormalities I-Disease 1 0.9999521970748901
and O 0 2.0923847841913812e-05
/ O 0 0.011669349856674671
or O 0 3.6525325413094833e-05
WT B-Disease 1 0.9999922513961792
. O 0 1.1190923032700084e-05

We O 0 2.9709581212955527e-05
report O 0 1.0367247341491748e-05
WT1 O 0 0.0008055008947849274
heterozygous O 0 0.0002417478826828301
mutations O 0 3.6147102946415544e-05
in O 0 4.806838092008547e-07
16 O 0 5.97713005845435e-06
patients O 0 2.016442067542812e-06
, O 0 5.7521319263287296e-08
4 O 0 5.635890261146415e-07
of O 0 8.40528073808855e-08
whom O 0 3.2410243875347078e-06
presented O 0 2.472462256264407e-06
with O 0 6.943954758753534e-06
IDMS B-Disease 0 0.008999137207865715
. O 0 1.1218277904845309e-05

One O 0 3.0531682568835095e-05
male O 0 2.095465788443107e-05
and O 0 5.189021976548247e-07
two O 0 2.14433475775877e-06
female O 0 0.00024499616120010614
IDMS B-Disease 0 0.3822181522846222
patients O 0 4.690928471973166e-05
with O 0 3.7015158795838943e-06
WT1 O 0 0.15079621970653534
mutations O 0 0.00130995805375278
underwent O 0 0.011291437782347202
normal O 0 7.245090819196776e-05
puberty O 0 0.0003557119925972074
. O 0 1.547051579109393e-05

Two O 0 9.35312345973216e-05
mutations O 0 0.0003651136939879507
associated O 0 3.831311460089637e-06
with O 0 1.350529146293411e-06
IDMS B-Disease 0 0.04859568551182747
are O 0 1.1491724194456765e-07
different O 0 4.177049461873139e-08
from O 0 1.0701213426500544e-07
those O 0 9.738474204823433e-08
described O 0 1.0049166121461894e-05
in O 0 8.584558599977754e-06
DDS B-Disease 1 1.0
patients O 0 0.0012857462279498577
. O 0 9.268297617381904e-06

No O 0 0.00018769751477520913
WT1 O 0 0.010602383874356747
mutations O 0 0.0008373188902623951
were O 0 6.893596946611069e-06
detected O 0 2.4719504381209845e-06
in O 0 8.304995446906105e-08
the O 0 1.574933889969543e-07
six O 0 1.5310154140024679e-06
other O 0 9.725310974317836e-07
IDMS B-Disease 0 0.05250658094882965
patients O 0 8.93366177479038e-06
, O 0 2.8768826609848475e-07
suggesting O 0 2.206357748946175e-06
genetic O 0 3.6463716241996735e-06
heterogeneity O 0 7.288166216312675e-06
of O 0 2.399721950041567e-07
this O 0 4.814233761862852e-06
disease O 0 0.00028248055605217814
. O 0 4.9124168981506955e-06

We O 0 4.0589926356915385e-05
analyzed O 0 9.445144678466022e-05
genotype O 0 0.005697246175259352
/ O 0 0.037979286164045334
phenotype O 0 0.004106626845896244
correlations O 0 0.00014273285341914743
, O 0 7.907979693300149e-07
on O 0 1.533713088974764e-06
the O 0 7.007874103237555e-08
basis O 0 8.009428853483769e-08
of O 0 1.15779181797393e-08
the O 0 9.070281947742842e-08
constitution O 0 1.023064442051691e-07
of O 0 1.782012404305533e-08
a O 0 1.0111103847521008e-06
WT1 O 0 0.00011184212053194642
mutation O 0 7.495956992897845e-07
database O 0 5.498351995925077e-08
of O 0 1.952329498067229e-08
84 O 0 8.242791977863817e-07
germ O 0 1.8061566152027808e-05
- O 0 0.00012620277993846685
line O 0 0.0005301442579366267
mutations O 0 2.047321686404757e-06
, O 0 2.018167855055708e-08
to O 0 1.4857214125640894e-08
compare O 0 8.417408992045239e-08
the O 0 2.1229677571454886e-08
distribution O 0 7.796554513106457e-08
and O 0 6.360947679695528e-08
type O 0 1.3201511706029123e-07
of O 0 3.396889169948736e-08
mutations O 0 1.99042733584065e-06
, O 0 4.96761209944907e-08
according O 0 1.523823200955121e-08
to O 0 1.9258814987210826e-08
the O 0 1.434227527852272e-07
different O 0 9.5601353677921e-07
symptoms O 0 0.00014912031474523246
. O 0 2.505390966689447e-06

This O 0 1.07693558675237e-05
demonstrated O 0 2.118585689458996e-05
( O 0 8.658257115712331e-07
1 O 0 6.864586907795456e-07
) O 0 8.370275850211328e-08
the O 0 5.097691158084672e-08
association O 0 1.0344312784127396e-07
between O 0 1.9239509185808856e-07
mutations O 0 1.2910456916870316e-06
in O 0 6.731634272227893e-08
exons O 0 9.950939784175716e-06
8 O 0 2.4752696390351048e-06
and O 0 3.815970899267995e-07
9 O 0 3.839427790808259e-06
and O 0 1.3277461903271615e-06
DMS B-Disease 0 0.0020273313857614994
; O 0 7.092658620422299e-07
( O 0 4.846969403615731e-08
2 O 0 2.786400727927685e-07
) O 0 7.496858245303883e-08
among O 0 6.922149253796306e-08
patients O 0 2.2339428085160762e-07
with O 0 1.6114323386773322e-07
DMS B-Disease 0 0.001018428709357977
, O 0 3.946891524719831e-08
a O 0 8.512716931363684e-08
higher O 0 9.145292523271564e-08
frequency O 0 1.8152269376514596e-07
of O 0 2.3079083533161793e-08
exon O 0 9.028069143823814e-06
8 O 0 3.4100457924068905e-06
mutations O 0 1.909391357912682e-06
among O 0 6.562577681279436e-08
46 O 0 1.2705112339972402e-06
, O 0 2.9769194043183234e-07
XY O 0 0.0008370365248993039
patients O 0 1.0328742519050138e-06
with O 0 1.747309283928189e-07
female O 0 3.5071450838586316e-05
phenotype O 0 0.00011550204362720251
than O 0 4.3872820043588945e-08
among O 0 4.9487173470197376e-08
46 O 0 1.674300051490718e-06
, O 0 2.8628588211176975e-07
XY O 0 0.0006389078916981816
patients O 0 7.201686003099894e-07
with O 0 7.281909830680888e-08
sexual O 0 8.58170665196667e-07
ambiguity O 0 2.0654185846069595e-06
or O 0 1.5684618119848892e-06
male O 0 0.00010506806574994698
phenotype O 0 0.01652761735022068
; O 0 1.4283717746366165e-06
and O 0 3.7522838169934403e-07
( O 0 2.1290061624767986e-07
3 O 0 3.6001901548843307e-07
) O 0 4.452191504356051e-08
statistically O 0 2.54746481687107e-07
significant O 0 3.746412247096487e-08
evidence O 0 5.2787250126584695e-08
that O 0 5.264728386578099e-08
mutations O 0 7.320763302232081e-07
in O 0 4.8016421061447545e-08
exons O 0 1.1507265298860148e-05
8 O 0 2.866956720026792e-06
and O 0 5.907607487642963e-07
9 O 0 1.7167385522043332e-06
preferentially O 0 1.1863403415190987e-06
affect O 0 4.1572755549168505e-07
amino O 0 4.272861247045512e-07
acids O 0 1.2651389624807052e-07
with O 0 1.8985204519594845e-08
different O 0 2.5674342651882398e-08
functions O 0 1.6980493455776013e-07
. O 0 2.3366999357676832e-07
. O 0 1.6823540818222682e-06

The O 0 2.8546348403324373e-05
185delAG O 0 0.000577106315176934
BRCA1 O 0 0.0015718507347628474
mutation O 0 2.9701366656809114e-05
originated O 0 1.0726189429988153e-06
before O 0 1.0464431454693113e-07
the O 0 3.233535394997489e-08
dispersion O 0 1.9261756278865505e-06
of O 0 5.154644000526787e-08
Jews O 0 6.146872237877687e-07
in O 0 5.5982383173613925e-08
the O 0 1.0101565095510523e-07
diaspora O 0 5.969110361547791e-07
and O 0 2.3588570741139847e-07
is O 0 4.3483517231379665e-08
not O 0 1.843618591124141e-08
limited O 0 1.4023109429217584e-07
to O 0 1.7224161297235696e-07
Ashkenazim O 0 5.3751242376165465e-05
. O 0 3.3295884804829257e-06

The O 0 2.0478471924434416e-05
185delAG O 0 0.00012061098823323846
mutation O 0 2.882928129110951e-05
in O 0 6.05543050369306e-07
BRCA1 O 0 9.868251072475687e-05
is O 0 1.091880790227151e-06
detected O 0 2.1217224457359407e-06
in O 0 2.3208693278320425e-07
Ashkenazi O 0 5.2601739298552275e-05
Jews O 0 6.43261557797814e-07
both O 0 1.1102526542572377e-07
in O 0 6.525737603624293e-07
familial B-Disease 0 0.17481908202171326
breast I-Disease 1 0.9999951124191284
and I-Disease 1 0.9996665716171265
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.088149454328232e-06
in O 0 1.0491510948895666e-07
the O 0 1.3302528145686665e-07
general O 0 4.5769246526106144e-07
population O 0 7.976968277034757e-07
. O 0 1.1933176438105875e-06

All O 0 2.152372690034099e-05
tested O 0 6.163602665765211e-05
Ashkenazi O 0 0.0006477422430180013
mutation O 0 5.3996918722987175e-05
carriers O 0 2.733468363658176e-06
share O 0 7.476266432604461e-07
the O 0 1.0986916976207795e-07
same O 0 2.9297663672878116e-07
allelic O 0 1.5876155885052867e-05
pattern O 0 2.5064326109713875e-05
at O 0 3.651615543276421e-07
the O 0 1.208431172017299e-06
BRCA1 O 0 0.00043023418402299285
locus O 0 0.0001630551414564252
. O 0 1.1250902389292605e-05

Our O 0 9.068325198313687e-06
previous O 0 3.936347184207989e-06
study O 0 6.204986675584223e-07
showed O 0 3.118075710517587e-06
that O 0 1.8913207000537113e-08
this O 0 2.4633809658780592e-08
Ashkenazi O 0 0.00016444773063994944
mutation O 0 4.567215455608675e-06
also O 0 5.372160671868187e-07
occurs O 0 4.768403272237265e-08
in O 0 2.234995122307737e-08
Iraqi O 0 5.561811349252821e-07
Jews O 0 1.9367895731647877e-07
with O 0 3.288624839115073e-08
a O 0 4.851011112805281e-07
similar O 0 1.9078843251918443e-06
allelic O 0 0.00012564721691887826
pattern O 0 0.00024719160865060985
. O 0 5.881153356313007e-06

We O 0 1.7586447938811034e-05
extended O 0 6.803318683523685e-06
our O 0 2.3032583840176812e-07
analysis O 0 1.5905425243545324e-07
to O 0 2.0452588955777173e-08
other O 0 1.5372986439388114e-08
non O 0 2.502952156646643e-07
- O 0 4.7273351810872555e-06
Ashkenazi O 0 4.418768185132649e-06
subsets O 0 3.4244399671479187e-07
354 O 0 3.240005810312141e-07
of O 0 1.4347933507963262e-08
Moroccan O 0 6.444173322961433e-06
origin O 0 1.0405418748860029e-07
, O 0 3.102580947711431e-08
200 O 0 7.914092492455893e-08
Yemenites O 0 1.7407489849574631e-06
and O 0 6.224841797575209e-08
150 O 0 2.5194623276547645e-07
Iranian O 0 7.80034611125302e-07
Jews O 0 2.0090999441890744e-06
. O 0 1.8391760931990575e-06

Heteroduplex O 0 0.0014319432666525245
analysis O 0 1.4688075680169277e-05
complemented O 0 1.2324569070187863e-05
by O 0 4.3561303186834266e-07
direct O 0 5.216853082856687e-07
DNA O 0 2.705087354115676e-06
sequencing O 0 1.350536876998376e-06
of O 0 1.1651238196463964e-07
abnormally O 0 2.328819755348377e-05
migrating O 0 4.5697586870119267e-07
bands O 0 1.3845337889506482e-06
were O 0 4.1230197211916675e-07
employed O 0 5.416813110059593e-06
. O 0 1.9754179447772913e-06

Four O 0 9.489552212471608e-06
of O 0 5.726635663449997e-07
Moroccan O 0 4.317732964409515e-05
origin O 0 8.17484021808923e-07
( O 0 2.1113906711889285e-07
1 O 0 1.0031885011585473e-07
. O 0 3.4183635477802454e-08
1 O 0 3.923646545445081e-07
% O 0 1.9342681412126694e-07
) O 0 2.6110459572237232e-08
and O 0 1.5469970549020218e-07
none O 0 4.762694771898168e-08
of O 0 6.440469935142801e-09
the O 0 7.553178704711172e-08
Yemenites O 0 8.47352475830121e-06
or O 0 1.4864873776332388e-07
Iranians O 0 4.383777536531852e-07
was O 0 1.1143572464789031e-06
a O 0 1.1791828313789665e-07
carrier O 0 8.488410685458803e-07
of O 0 3.415737026557508e-08
the O 0 4.1072431145039445e-07
185delAG O 0 3.928094884031452e-05
mutation O 0 1.5247558621922508e-05
. O 0 2.1740395368397003e-06

BRCA1 O 0 0.010851431638002396
allelic O 0 0.0017477633664384484
patterns O 0 0.0004457483591977507
were O 0 4.753066150442464e-06
determined O 0 7.531397727689182e-07
for O 0 2.69893885018746e-08
four O 0 9.790529276187954e-08
of O 0 3.294645622986536e-08
these O 0 1.5159784538809618e-08
individuals O 0 8.90569129552432e-09
and O 0 2.1701849206579027e-08
for O 0 1.4129557079911592e-08
12 O 0 1.0197058486483002e-07
additional O 0 7.374115540415005e-08
non O 0 3.584266892175947e-07
- O 0 1.627311394258868e-05
Ashkenazi O 0 8.30294011393562e-05
185delAG O 0 1.4101111446507275e-05
mutation O 0 3.0677972517878516e-06
carriers O 0 6.425564151868457e-07
who O 0 1.2809193776774919e-06
had O 0 0.0008930187905207276
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 3.5643875889945775e-05

Six O 0 8.262257324531674e-05
non O 0 2.3537575543741696e-05
- O 0 0.0005564886960200965
Ashkenazi O 0 0.0008261780603788793
individuals O 0 1.6894431098535279e-07
shared O 0 1.7823087716806185e-07
the O 0 1.6257352797310887e-07
common O 0 1.1834645192720927e-06
Ashkenazi O 0 0.00025624720728956163
haplotype O 0 0.00010636100341798738
, O 0 3.396938552668871e-07
four O 0 3.6002589354211523e-07
had O 0 1.8674137436391902e-06
a O 0 5.423447078101162e-07
closely O 0 1.2281661838642322e-06
related O 0 5.295960363582708e-07
pattern O 0 2.2590445951209404e-05
, O 0 1.8600751161557127e-07
and O 0 7.957640946187894e-08
the O 0 6.723935541685933e-08
rest O 0 2.2729646786956437e-07
( O 0 1.0630540003830902e-07
n O 0 1.9684166545630433e-06
= O 0 5.284535291139036e-06
6 O 0 4.945721912008594e-07
) O 0 8.014472285822194e-08
displayed O 0 2.9616001029353356e-07
a O 0 7.023918442428112e-07
distinct O 0 7.461916084139375e-06
BRCA1 O 0 0.0002770627324935049
allelic O 0 0.0002989093482028693
pattern O 0 0.000838340783957392
. O 0 1.862732278823387e-05

We O 0 1.4661372915725224e-05
conclude O 0 3.98217844121973e-06
that O 0 1.6449207862478943e-07
the O 0 2.666290299657703e-07
185delAG O 0 0.0001977894571609795
BRCA1 O 0 0.00129057711455971
mutation O 0 1.1919780263269786e-05
occurs O 0 1.460560952182277e-07
in O 0 1.6184051432333035e-08
some O 0 1.9807341544719748e-08
non O 0 2.6379024120615213e-07
- O 0 1.7234824554179795e-05
Ashkenazi O 0 2.066453089355491e-05
populations O 0 2.782988133276376e-07
at O 0 1.1584240411366409e-07
rates O 0 6.23164282842481e-07
comparable O 0 1.4738255060819938e-07
with O 0 2.015452160719633e-08
that O 0 2.4119456654148053e-08
of O 0 2.1238329850348237e-07
Ashkenazim O 0 0.00025454512797296047
. O 0 3.3692190299916547e-06

The O 0 8.377018275496084e-06
majority O 0 2.038814727711724e-06
of O 0 1.2907118218663527e-07
Jewish O 0 2.8721508442686172e-06
185delAG O 0 4.8674646677682176e-05
mutation O 0 6.148277407191927e-06
carriers O 0 3.3899706863849133e-07
have O 0 2.249051256342227e-08
a O 0 1.547031018844791e-07
common O 0 4.339312624779268e-07
allelic O 0 2.4594766728114337e-05
pattern O 0 9.7560667200014e-05
, O 0 8.877389490180576e-08
supporting O 0 1.1113841225096621e-07
the O 0 6.647107397839136e-08
founder O 0 1.0238945833407342e-06
effect O 0 1.0821472073985205e-07
notion O 0 6.982244116215952e-08
, O 0 4.141564602377912e-08
but O 0 2.260564002654064e-08
dating O 0 1.5875541237164725e-07
the O 0 7.033437299241996e-08
mutations O 0 4.896687642030884e-07
origin O 0 1.6513769907078313e-08
to O 0 1.2155489947929254e-08
an O 0 3.2261734617122784e-08
earlier O 0 8.394816291001916e-07
date O 0 5.269515668260283e-07
than O 0 3.917282143106604e-08
currently O 0 1.6923780776778585e-07
estimated O 0 9.876672493192018e-07
. O 0 1.301454403801472e-06

However O 0 3.0650418921140954e-05
, O 0 3.282746945387771e-07
the O 0 6.088372828116917e-08
different O 0 6.984628697637163e-08
allelic O 0 4.8916972446022555e-06
pattern O 0 1.7856713384389877e-05
at O 0 2.287451508209415e-07
the O 0 2.3044252372983465e-07
BRCA1 O 0 4.0306960727320984e-05
locus O 0 7.38783774067997e-06
even O 0 1.9625447578164312e-07
in O 0 3.128644721073215e-08
some O 0 2.547308497469203e-08
Jewish O 0 1.2901693935418734e-06
mutation O 0 1.6405263068008935e-06
carriers O 0 2.1258288995795738e-07
, O 0 4.3858097598103996e-08
might O 0 5.492555388286746e-08
suggest O 0 5.170201333726254e-08
that O 0 1.691893025679292e-08
the O 0 1.9507592696754728e-07
mutation O 0 4.922724656353239e-06
arose O 0 7.221858027151029e-07
independently O 0 9.109514280680742e-07
. O 0 3.7950846376588743e-07
. O 0 2.3718553165963385e-06

Crystal O 0 0.0011053154012188315
structure O 0 1.3563731954491232e-05
of O 0 7.562287578366522e-07
the O 0 5.566116215049988e-06
hemochromatosis B-Disease 1 0.9999998807907104
protein O 0 0.00014676903083454818
HFE O 0 0.00514646153897047
and O 0 6.986479661463818e-07
characterization O 0 2.1280409328028327e-06
of O 0 4.8140222475012706e-08
its O 0 2.0991035398765234e-07
interaction O 0 4.995199560653418e-07
with O 0 5.146558805790846e-07
transferrin O 0 0.00013124187535140663
receptor O 0 2.9606602765852585e-05
. O 0 5.4727565839129966e-06

HFE O 0 0.26398441195487976
is O 0 1.3900977137382142e-05
an O 0 9.161666980617156e-07
MHC O 0 0.00011397361959097907
- O 0 9.614392911316827e-05
related O 0 7.681024385419732e-07
protein O 0 5.504437581294042e-07
that O 0 3.544651150377831e-08
is O 0 6.943306374296299e-08
mutated O 0 1.0630291171764839e-06
in O 0 2.3322606068632012e-07
the O 0 2.4194253001041943e-06
iron B-Disease 1 0.9974863529205322
- I-Disease 1 0.9999924898147583
overload I-Disease 1 0.9999128580093384
disease I-Disease 1 0.9995317459106445
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.0004827381344512105

HFE O 0 0.009298413060605526
binds O 0 0.00017718451272230595
to O 0 6.920776286278851e-06
transferrin O 0 0.00031615857733413577
receptor O 0 5.350892752176151e-05
( O 0 2.5607937459426466e-06
TfR O 0 0.0009340285323560238
) O 0 4.481969995140389e-07
and O 0 1.730559660018116e-07
reduces O 0 1.3984260931465542e-06
its O 0 4.72250434313537e-08
affinity O 0 1.9660666339404997e-07
for O 0 7.062568130322688e-08
iron O 0 7.604915299452841e-05
- O 0 1.8013901353697293e-05
loaded O 0 3.206291012247675e-06
transferrin O 0 1.041812174662482e-05
, O 0 4.1230197211916675e-07
implicating O 0 1.6442651030956767e-05
HFE O 0 0.0008690369431860745
in O 0 3.820977781288093e-06
iron O 0 0.031127922236919403
metabolism O 0 0.00014105314039625227
. O 0 5.663623596774414e-06

The O 0 5.5315580539172515e-05
2 O 0 9.255509212380275e-05
. O 0 1.595330104464665e-05

6 O 0 0.0002231081307400018
A O 0 4.264193194103427e-05
crystal O 0 0.00010755889525171369
structure O 0 2.2835224626760464e-06
of O 0 3.3468037941020157e-07
HFE O 0 0.003345020581036806
reveals O 0 9.459989087190479e-06
the O 0 1.6469803654217685e-07
locations O 0 1.0771765346362372e-06
of O 0 2.9373859433690086e-06
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0008592472295276821
and O 0 5.694623723684344e-07
a O 0 1.6784230183475302e-06
patch O 0 0.2774237096309662
of O 0 3.8408342106777127e-07
histidines O 0 6.050530282664113e-05
that O 0 1.3994092284974613e-07
could O 0 2.5135872760984057e-07
be O 0 2.3293567963378337e-08
involved O 0 2.1740628852739974e-08
in O 0 9.057367833520402e-08
pH O 0 5.290397166390903e-05
- O 0 1.9484961740090512e-05
dependent O 0 1.4543467159455759e-06
interactions O 0 1.8546227238402935e-06
. O 0 2.3834786588849965e-06

We O 0 2.284500442328863e-05
also O 0 3.4531390156189445e-06
demonstrate O 0 1.6322194369422505e-06
that O 0 3.010160583016841e-07
soluble O 0 1.5348075976362452e-05
TfR O 0 0.002465822733938694
and O 0 1.458035171708616e-06
HFE O 0 0.0003765558358281851
bind O 0 3.3758990412025014e-06
tightly O 0 3.307671704533277e-06
at O 0 1.5495308502977423e-07
the O 0 4.409471188182579e-08
basic O 0 2.1024031582328462e-07
pH O 0 3.6231024296284886e-06
of O 0 1.1831295054776092e-08
the O 0 9.336238093737848e-08
cell O 0 5.368511665437836e-06
surface O 0 5.02688772030524e-06
, O 0 1.0857300480893173e-07
but O 0 3.1612525930313495e-08
not O 0 1.478027744639121e-08
at O 0 2.311987934433546e-08
the O 0 1.384171781637633e-07
acidic O 0 2.7773094188887626e-05
pH O 0 3.497883153613657e-05
of O 0 2.432477401725919e-07
intracellular O 0 2.2729676857125014e-05
vesicles O 0 0.00013288648915477097
. O 0 9.053151188709307e-06

TfR O 1 0.98829585313797
HFE O 0 0.08923269063234329
stoichiometry O 0 0.0007599449600093067
( O 0 3.9485494198743254e-05
2 O 0 8.077042366494425e-06
1 O 0 2.614298182379571e-06
) O 0 2.7150019832333783e-07
differs O 0 7.211390311567811e-07
from O 0 2.3160403372912697e-07
TfR O 0 0.0002604882756713778
transferrin O 0 1.576348950038664e-05
stoichiometry O 0 3.1856018267717445e-06
( O 0 1.439741907915959e-07
2 O 0 3.5742658610615763e-07
2 O 0 6.227026574379124e-07
) O 0 4.295176125879152e-08
, O 0 3.9167442622556337e-08
implying O 0 1.1639688324294184e-07
a O 0 2.5387667079712628e-08
different O 0 6.900198634696153e-09
mode O 0 8.235211623741634e-08
of O 0 6.030675514523409e-09
binding O 0 6.991133005840311e-08
for O 0 4.309363887955442e-08
HFE O 0 7.563502731500193e-05
and O 0 2.3957318262546323e-07
transferrin O 0 4.317696493671974e-06
to O 0 7.923004119447796e-08
TfR O 0 0.00010034282604465261
, O 0 6.75887079637505e-08
consistent O 0 2.2872202976031986e-07
with O 0 3.446929142114641e-08
our O 0 8.631037218265192e-08
demonstration O 0 3.403349069230899e-07
that O 0 6.328721013915128e-08
HFE O 0 4.9533478886587545e-05
, O 0 2.565697343470674e-07
transferrin O 0 5.177675120648928e-06
, O 0 1.3095154827169608e-07
and O 0 5.837590606461163e-07
TfR O 0 0.00016054947627708316
form O 0 3.366009480032517e-07
a O 0 6.990865699663118e-07
ternary O 0 7.1568051680515055e-06
complex O 0 1.1149239981023129e-05
. O 0 6.420837962650694e-06

Identification O 0 1.0660195584932808e-05
of O 0 3.7863975421714713e-07
three O 0 6.541713446495123e-07
novel O 0 7.774703590257559e-06
mutations O 0 9.976935871236492e-06
and O 0 1.0747810108568956e-07
a O 0 2.687366418285819e-07
high O 0 7.886636126386293e-07
frequency O 0 8.713075771993317e-07
of O 0 1.1840167069010477e-08
the O 0 1.76722153355513e-07
Arg778Leu O 0 5.850109300808981e-05
mutation O 0 1.4883655694575282e-06
in O 0 1.2023346585010586e-07
Korean O 0 3.832407855952624e-06
patients O 0 3.2748282592365285e-06
with O 0 2.5428507797187194e-06
Wilson B-Disease 0 0.0117729427292943
disease I-Disease 0 0.00024178218154702336
. O 0 4.185973011772148e-06

Four O 0 0.00010065505193779245
mutations O 0 0.0002483581774868071
- O 0 9.393542859470472e-05
- O 0 6.553990533575416e-05
R778L O 0 1.9649060050141998e-05
, O 0 3.0481132284876367e-07
A874V O 0 3.6598926271835808e-06
, O 0 7.160090831348498e-08
L1083F O 0 8.606417054579651e-07
, O 0 2.3054797182453513e-08
and O 0 4.586375368376139e-08
2304delC O 0 2.5580795863788808e-06
- O 0 2.0061221221112646e-05
- O 0 6.7188593675382435e-06
in O 0 4.763021976827986e-08
the O 0 5.970989036541141e-08
copper O 0 6.312678124231752e-06
- O 0 1.9073929706792114e-06
transporting O 0 4.85759869661706e-07
enzyme O 0 4.2902556174340134e-07
, O 0 7.803874524370258e-08
P O 0 1.7753138308762573e-05
- O 0 2.8407528134266613e-06
type O 0 6.676293082819029e-07
ATPase O 0 5.9589224292722065e-06
( O 0 2.1791949222915719e-07
ATP7B O 0 1.3937495168647729e-05
) O 0 6.50291838155681e-08
, O 0 2.8944892704885206e-08
were O 0 5.581105000374009e-08
identified O 0 9.661693667339932e-08
in O 0 6.678675390503486e-08
Korean O 0 3.984465365647338e-06
Patients O 0 1.494502839705092e-06
with O 0 8.768918746682175e-07
Wilson B-Disease 0 0.0010759414872154593
disease I-Disease 0 0.0001859381445683539
. O 0 6.2054818954493385e-06

Arg778Leu O 0 0.0055021303705871105
, O 0 2.4392754767177394e-06
the O 0 1.6383921774831833e-07
most O 0 1.1910206154652769e-07
frequently O 0 1.600064933882095e-06
reported O 0 2.178052909584949e-06
mutation O 0 4.3279720784994424e-07
of O 0 1.0432560593187645e-08
this O 0 2.038299662387999e-08
enzyme O 0 2.137334718099737e-07
, O 0 1.602458041816135e-07
was O 0 5.053670065535698e-06
found O 0 1.0120058391294151e-07
in O 0 3.42741230952015e-08
six O 0 1.2439055296908919e-07
of O 0 2.883413863230544e-08
eight O 0 1.92565221368568e-06
unrelated O 0 1.0087062946695369e-05
patients O 0 1.7095384237109101e-06
studied O 0 9.761087937931734e-08
, O 0 1.6917157452667198e-08
an O 0 2.5332237640895983e-08
allele O 0 7.413941602862906e-07
frequency O 0 4.0904970433075505e-07
of O 0 1.4931850955690606e-07
37 O 0 4.7579596866853535e-06
. O 0 1.6954002148850122e-06

5 O 0 0.0003348453319631517
% O 0 1.4199297766026575e-05
, O 0 2.1175735298584186e-07
which O 0 1.149984782955471e-07
is O 0 6.085563342139721e-08
considerably O 0 3.890802872774657e-06
higher O 0 4.1574381270947924e-07
than O 0 1.776775526707297e-08
those O 0 1.2790484227309662e-08
in O 0 2.834371493065646e-08
other O 0 5.017127691075984e-08
Asian O 0 6.452485195040936e-07
populations O 0 3.1981003303371836e-06
. O 0 2.6159268600167707e-06

The O 0 7.226713023555931e-06
novel O 0 8.600939509051386e-06
single O 0 3.0304581741802394e-06
nucleotide O 0 9.225695976056159e-06
deletion O 0 1.1237189028179273e-05
, O 0 4.1385411009287054e-07
2304delC O 0 9.074242370843422e-06
, O 0 5.404003218245634e-07
was O 0 4.3012696551159024e-06
found O 0 1.7498607007837563e-07
in O 0 1.1994075066468213e-07
one O 0 1.0326998562959488e-06
patient O 0 1.579999843670521e-05
. O 0 2.8845031465607462e-06

Since O 0 4.4928761781193316e-05
a O 0 9.1735464593512e-06
mutation O 0 1.1810318028437905e-05
at O 0 7.326567015297769e-07
cDNA O 0 2.155776383006014e-05
nucleotide O 0 3.1964063964551315e-05
2302 O 0 9.320154640590772e-05
( O 0 8.696256372786593e-07
2302insC O 0 7.213162916741567e-06
) O 0 1.9573299425701407e-07
had O 0 3.1755437248648377e-06
been O 0 9.23635809613188e-07
previously O 0 3.0983344458945794e-06
described O 0 1.793995011212246e-06
, O 0 6.76356464168748e-08
this O 0 9.206122975058406e-09
region O 0 6.194627388822482e-08
of O 0 7.3376478226805375e-09
the O 0 9.739811446252133e-08
ATP7B O 0 7.374089182121679e-05
gene O 0 1.4021627521287883e-06
may O 0 1.3611202120955568e-06
be O 0 8.452482092025093e-08
susceptible O 0 9.600281600796734e-07
to O 0 1.4638965240010293e-07
gene O 0 7.924975761852693e-06
rearrangements O 0 0.0020790020935237408
causing O 0 0.0005993967060931027
Wilson B-Disease 0 0.013044200837612152
disease I-Disease 0 0.00045352106099016964
. O 0 4.751733740704367e-06

Disruption O 0 0.0006111754337325692
of O 0 2.113083837684826e-06
splicing O 0 2.6991789127350785e-05
regulated O 0 2.575405005700304e-06
by O 0 1.275271870326833e-07
a O 0 9.181477480524336e-07
CUG O 0 0.00013898423640057445
- O 0 2.5670589820947498e-05
binding O 0 4.950982201989973e-06
protein O 0 9.313627742812969e-06
in O 0 1.8043403542833403e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 6.053554534446448e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9767729043960571
DM B-Disease 1 1.0
) O 0 4.782637188327499e-05
is O 0 1.2683985914918594e-06
caused O 0 1.025402411869436e-06
by O 0 6.265520369197475e-08
a O 0 1.4138488495518686e-06
CTG O 0 2.3600576241733506e-05
expansion O 0 4.610908774793643e-07
in O 0 7.492583620205551e-08
the O 0 2.889646850690042e-07
3 O 0 1.9761434941756306e-06
untranslated O 0 2.0156818209216e-05
region O 0 1.1745290748876869e-06
of O 0 1.3574900492585584e-07
the O 0 4.451590484677581e-06
DM B-Disease 1 0.9999994039535522
gene O 0 4.886286478722468e-05
. O 0 6.749640760972397e-06

One O 0 1.168988092103973e-05
model O 0 1.0982138519466389e-05
of O 0 1.586630787642207e-06
DM B-Disease 1 0.9999996423721313
pathogenesis O 0 0.00040443678153678775
suggests O 0 4.0564846131019294e-06
that O 0 1.3779171581518312e-07
RNAs O 0 1.18047626074258e-06
from O 0 1.7498397397730514e-08
the O 0 1.3135124099505902e-08
expanded O 0 2.053898953136013e-07
allele O 0 5.610947937384481e-07
create O 0 5.2038885201000085e-08
a O 0 2.198520263618775e-07
gain O 0 3.56702298631717e-06
- O 0 5.112329290568596e-06
of O 0 5.538517200420756e-08
- O 0 1.9187858924851753e-05
function O 0 2.0943005551998795e-07
mutation O 0 1.7654157602464693e-07
by O 0 5.2907171976812606e-09
the O 0 2.4993688896302046e-08
inappropriate O 0 1.2014017158890056e-07
binding O 0 6.627207227438703e-08
of O 0 1.0325502231012251e-08
proteins O 0 3.910212953428527e-08
to O 0 4.131969788545575e-08
the O 0 4.0304453818862385e-07
CUG O 0 0.00014615760301239789
repeats O 0 3.0342369427671656e-05
. O 0 2.664660996742896e-06

Data O 0 5.3596817451762035e-05
presented O 0 1.0424701031297445e-05
here O 0 5.283378641252057e-07
indicate O 0 8.357910132872348e-07
that O 0 4.0892562225280926e-08
the O 0 1.3892977790419536e-07
conserved O 0 1.5459853557331371e-06
heterogeneous O 0 4.8870433602132834e-06
nuclear O 0 3.57383305527037e-06
ribonucleoprotein O 0 6.580296940228436e-06
, O 0 1.0855912790930233e-07
CUG O 0 6.925140041857958e-06
- O 0 2.4275050236610696e-06
binding O 0 5.266174412099645e-07
protein O 0 8.461150287075725e-07
( O 0 1.8699606130212487e-07
CUG O 0 2.4972994651761837e-05
- O 0 0.0005114226951263845
BP O 0 0.00020238554861862212
) O 0 1.1327833959740019e-07
, O 0 4.522743424217879e-08
may O 0 2.749311818206479e-07
mediate O 0 4.189883384242421e-06
the O 0 1.0298340384906624e-06
trans O 0 2.7601994588621892e-05
- O 0 0.000209416524739936
dominant O 0 3.4004754070338095e-06
effect O 0 2.3948842908794177e-07
of O 0 3.6829582938935346e-08
the O 0 3.183811259077629e-07
RNA O 0 9.91393972071819e-06
. O 0 3.1838130780670326e-06

CUG O 0 0.1413375437259674
- O 1 0.636244535446167
BP O 0 0.02853834629058838
was O 0 4.839311259274837e-06
found O 0 6.997803581043627e-08
to O 0 1.9538976658850515e-08
bind O 0 1.63506115313794e-07
to O 0 3.49809958777314e-08
the O 0 1.2902317791940732e-07
human O 0 1.8680478888200014e-06
cardiac O 0 0.02909233048558235
troponin O 0 0.0015797881642356515
T O 0 0.0002678081509657204
( O 0 2.5534143333061365e-07
cTNT O 0 1.1304065310469014e-06
) O 0 8.839458587317495e-08
pre O 0 1.4519063142870436e-06
- O 0 6.016252882545814e-06
messenger O 0 1.954198069142876e-06
RNA O 0 6.442880362556025e-07
and O 0 5.091112953437005e-08
regulate O 0 2.373941185851436e-07
its O 0 1.300182645991299e-07
alternative O 0 1.828279437177116e-06
splicing O 0 3.1016643333714455e-05
. O 0 7.647937309229746e-06

Splicing O 0 0.000299615494441241
of O 0 8.245195203926414e-06
cTNT O 0 0.0002014969359152019
was O 0 5.779455023002811e-05
disrupted O 0 0.0002048328024102375
in O 0 6.007286174281035e-06
DM B-Disease 1 1.0
striated O 1 0.815470814704895
muscle O 0 0.0024601009208709
and O 0 8.72255327521998e-07
in O 0 2.892536485887831e-07
normal O 0 3.913775799446739e-06
cells O 0 2.6499169507587794e-06
expressing O 0 4.176325205662579e-07
transcripts O 0 1.1934098438359797e-06
that O 0 2.6548065079623484e-07
contain O 0 3.3523153888381785e-06
CUG O 0 0.00048005004646256566
repeats O 0 7.722987356828526e-05
. O 0 5.762327873526374e-06

Altered O 0 0.000745329714845866
expression O 0 1.774232259776909e-05
of O 0 7.303336815311923e-07
genes O 0 3.0916341984266182e-06
regulated O 0 1.7408669918950181e-06
posttranscriptionally O 0 1.7822721929405816e-05
by O 0 3.7954791309857683e-07
CUG O 0 0.00032108891173265874
- O 0 0.000581681786570698
BP O 0 0.00010407607624074444
therefore O 0 4.0374854393121495e-07
may O 0 2.4360946326851263e-07
contribute O 0 1.7599658974631893e-07
to O 0 9.776698561836383e-07
DM B-Disease 1 0.9999997615814209
pathogenesis O 0 0.00028136372566223145
. O 0 1.548964974062983e-06
. O 0 4.376026936370181e-06

Identification O 0 1.9252780475653708e-05
of O 0 9.497343285147508e-07
a O 0 2.8873241717519704e-06
novel O 0 1.4190701222105417e-05
nonsense O 0 7.149075827328488e-05
mutation O 0 6.664398824796081e-06
and O 0 2.462578265749471e-07
a O 0 7.827187573639094e-07
missense O 0 8.591995538154151e-06
substitution O 0 4.3483686340550776e-07
in O 0 8.037557108764304e-08
the O 0 1.3822986488776223e-07
vasopressin O 0 1.0175450370297767e-05
- O 0 4.4164000428281724e-05
neurophysin O 0 1.623265961825382e-05
II O 0 6.054551249690121e-06
gene O 0 4.1433349906583317e-07
in O 0 6.52805951517621e-08
two O 0 3.400980688184063e-07
Spanish O 0 4.419463493832154e-06
kindreds O 0 4.0317379898624495e-05
with O 0 5.214120392338373e-06
familial B-Disease 0 0.12056855112314224
neurohypophyseal I-Disease 1 0.9868288636207581
diabetes I-Disease 1 0.9998730421066284
insipidus I-Disease 1 0.9578170776367188
. O 0 6.37424600427039e-05

Familial B-Disease 1 0.9998596906661987
neurohypophyseal I-Disease 1 0.9999657869338989
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999958276748657
( O 0 0.13313835859298706
FNDI B-Disease 1 0.9999998807907104
) O 0 7.265390649990877e-06
is O 0 3.1177737014331797e-07
an O 0 2.5202966753568035e-06
autosomal B-Disease 1 0.9995948672294617
dominant I-Disease 1 0.9981390237808228
disease I-Disease 1 0.9778163433074951
caused O 0 0.0028662618715316057
by O 0 8.899821841623634e-05
deficiency O 0 0.1660938858985901
in O 0 3.458309265624848e-07
the O 0 2.413479478491354e-06
antidiuretic O 0 0.0004658760444726795
hormone O 0 3.456417107372545e-05
arginine O 0 4.7985988203436136e-05
vasopressin O 0 5.3488212870433927e-05
( O 0 9.845657586993184e-07
AVP O 0 1.4395856851479039e-05
) O 0 1.519722445664229e-07
encoded O 0 1.2625812928490632e-07
by O 0 4.050698265700703e-08
the O 0 1.2196356635740813e-07
AVP O 0 6.950255192350596e-05
- O 0 0.00040625716792419553
neurophysin O 0 6.75343835609965e-05
II O 0 1.7961237972485833e-05
( O 0 3.782564590437687e-07
AVP O 0 1.9244631403125823e-05
- O 0 0.00012297464127186686
NPII O 0 6.0493886849144474e-05
) O 0 2.0877516249129258e-07
gene O 0 5.867674985893245e-07
on O 0 3.3917699511221144e-06
chromosome O 0 0.00025205931160598993
20p13 O 0 7.04193371348083e-05
. O 0 5.643916665576398e-06

In O 0 4.1032285480469e-06
this O 0 1.833848557453166e-07
study O 0 1.0228420421753981e-07
, O 0 3.5454554847547115e-08
we O 0 9.921911292565255e-09
analyzed O 0 1.1494255858224278e-07
two O 0 6.815741215859816e-08
families O 0 1.2004350935512775e-07
with O 0 1.3754211636296532e-07
FNDI B-Disease 1 0.997345507144928
using O 0 8.916197913322321e-08
direct O 0 1.0155967089531259e-07
automated O 0 5.61470528737118e-07
fluorescent O 0 3.7085330859554233e-06
, O 0 6.966759968918268e-08
solid O 0 2.1513224623959104e-07
phase O 0 3.949497795474599e-07
, O 0 6.383675810184286e-08
single O 0 6.627952302551421e-07
- O 0 9.4208071459434e-06
stranded O 0 1.065723154169973e-06
DNA O 0 4.5221398181638506e-07
sequencing O 0 2.94658406119197e-07
of O 0 5.158351612521983e-08
PCR O 0 1.3348636457521934e-05
- O 0 1.3722189578402322e-05
amplified O 0 3.7067740777274594e-05
AVP O 0 0.00013539627252612263
- O 0 0.00023240390873979777
NPII O 0 0.00019264880393166095
DNA O 0 4.5797653001500294e-05
. O 0 8.623106623417698e-06

In O 0 7.088613529049326e-06
one O 0 4.3405628957771114e-07
of O 0 3.88994969569012e-08
the O 0 2.261353841959135e-07
families O 0 7.285660217348777e-07
, O 0 1.671969016570074e-07
affected O 0 3.0110621196399734e-07
individuals O 0 2.1940124383945658e-08
presented O 0 1.6819387838040711e-07
a O 0 4.1554918084329984e-07
novel O 0 3.5594757719081827e-06
nonsense O 0 1.0435602234792896e-05
mutation O 0 5.319395768310642e-07
in O 0 2.7593978657591833e-08
exon O 0 2.369440835536807e-06
3 O 0 5.554978770305752e-07
of O 0 1.558876938645426e-08
the O 0 8.970134501851135e-08
gene O 0 1.6371021160921373e-07
, O 0 3.108083390657157e-08
consisting O 0 3.150585925482119e-08
in O 0 1.5860614155371877e-08
a O 0 6.214841050677933e-07
G O 0 6.141846824903041e-05
to O 0 1.4968435380069423e-07
T O 0 1.55355992319528e-05
transition O 0 3.589151447158656e-07
at O 0 5.4593733977981174e-08
nucleotide O 0 1.219617615788593e-06
2101 O 0 3.2843452117958805e-06
, O 0 7.146270064595228e-08
which O 0 2.739611204560788e-08
produces O 0 3.269181192422366e-08
a O 0 3.810668047776744e-08
stop O 0 1.2628125034552795e-07
signal O 0 6.788611699448666e-07
in O 0 8.108912652460276e-08
codon O 0 2.844746177288471e-06
82 O 0 2.1703647234971868e-06
( O 0 8.532367132829677e-07
Glu O 0 0.0001624593569431454
) O 0 3.0712934062648856e-07
of O 0 3.2457489851367427e-07
NPII O 0 0.0002834941551554948
. O 0 6.041907454346074e-06

The O 0 2.616278470668476e-05
premature O 0 0.0001354980340693146
termination O 0 2.8849166483269073e-05
eliminates O 0 1.017641079670284e-05
part O 0 2.88104502033093e-07
of O 0 3.6209318210467245e-08
the O 0 2.573440838204988e-07
C O 0 4.4921307562617585e-05
- O 0 1.6044188669184223e-05
terminal O 0 7.592320230287442e-07
domain O 0 5.6804353221195925e-08
of O 0 1.929274873191389e-08
NPII O 0 2.717801726248581e-05
, O 0 4.486211935272877e-08
including O 0 1.1906157837415776e-08
a O 0 1.5674642384055915e-07
cysteine O 0 2.996046930547891e-07
residue O 0 3.362492861924693e-07
in O 0 3.671476989097755e-08
position O 0 4.639818769192061e-07
85 O 0 2.51352020086415e-07
, O 0 3.358204381243013e-08
which O 0 3.693369876600627e-08
could O 0 7.157428427717605e-08
be O 0 1.7760402926114693e-08
involved O 0 1.2597134002589883e-08
in O 0 2.4955578936669554e-08
the O 0 1.4791875457831338e-07
correct O 0 4.156825070822379e-06
folding O 0 3.9536157601105515e-06
of O 0 9.983020987647251e-08
the O 0 9.657076134317322e-07
prohormone O 0 0.0004851844860240817
. O 0 6.273978669923963e-06

In O 0 6.727271738782292e-06
the O 0 8.419173127549584e-07
second O 0 4.525251370068872e-06
family O 0 5.598674874818244e-07
, O 0 4.1640756620608954e-08
a O 0 7.913504163070684e-08
G279A O 0 6.35702406270866e-07
substitution O 0 7.384812761301873e-08
at O 0 5.058802088342418e-08
position O 0 2.23138783894683e-07
- O 0 2.265840521431528e-06
1 O 0 8.216133551286475e-08
of O 0 7.4066881516898775e-09
the O 0 4.7975134975786204e-08
signal O 0 4.5279666665010154e-06
peptide O 0 2.90384093659668e-07
was O 0 2.2535907362453145e-07
observed O 0 8.083263480784808e-08
in O 0 2.4697367706494333e-08
all O 0 3.512165847041615e-08
affected O 0 7.380601232398476e-07
individuals O 0 4.306274945520272e-07
. O 0 1.1166573585796868e-06

This O 0 3.091408507316373e-05
missense O 0 0.0027339488733559847
mutation O 0 0.00012289411097299308
, O 0 4.6791760155429074e-07
which O 0 4.0679645962882205e-07
replaces O 0 4.469432678888552e-05
Ala O 0 0.0003586866951081902
with O 0 1.1196688092240947e-06
Thr O 0 0.0011451664613559842
, O 0 3.156691832373326e-07
is O 0 9.777802034705019e-08
frequent O 0 1.050047444550728e-06
among O 0 1.915607299451949e-06
FNDI B-Disease 1 0.9999998807907104
patients O 0 3.427201954764314e-05
and O 0 3.992898882643203e-07
is O 0 1.0703907804554547e-07
thought O 0 5.459560981080358e-08
to O 0 1.3434566348280441e-08
reduce O 0 1.7304327570855094e-07
the O 0 2.4744565507717198e-08
efficiency O 0 3.350016299918934e-07
of O 0 2.6105679395982406e-08
cleavage O 0 7.153263140935451e-06
by O 0 1.6429015659014112e-07
signal O 0 8.483494639222044e-06
peptidases O 0 2.2618620278080925e-05
. O 0 4.3072932953691634e-07
. O 0 1.608906359251705e-06

Genetic O 0 0.0008502172422595322
heterogeneity O 0 0.0002852064208127558
of O 0 7.043719961075112e-06
Saethre B-Disease 1 0.9178414344787598
- I-Disease 1 0.9999713897705078
Chotzen I-Disease 1 0.9999659061431885
syndrome I-Disease 1 0.9999983310699463
, O 0 2.3340771804214455e-06
due O 0 6.005591330904281e-07
to O 0 2.821798830154876e-07
TWIST O 0 0.0016018792521208525
and O 0 1.919962596730329e-05
FGFR O 0 0.0062141804955899715
mutations O 0 7.321245357161388e-05
. O 0 4.2728875087050255e-06

Thirty O 0 0.0002485663862898946
- O 0 0.000259439111687243
two O 0 1.2858163245255128e-06
unrelated O 0 1.5049944522615988e-05
patients O 0 4.647201421903446e-06
with O 0 7.277716207454432e-08
features O 0 4.9574928198126145e-06
of O 0 8.830971296447387e-07
Saethre B-Disease 1 0.8551480174064636
- I-Disease 1 0.9998800754547119
Chotzen I-Disease 1 0.9995043277740479
syndrome I-Disease 1 0.9996929168701172
, O 0 3.7770925587210513e-07
a O 0 2.087643224513158e-06
common O 0 3.473693141131662e-05
autosomal B-Disease 1 0.5408927798271179
dominant I-Disease 0 0.04454834386706352
condition I-Disease 0 0.0010142674436792731
of O 0 4.683797669713385e-06
craniosynostosis B-Disease 1 0.993707537651062
and O 0 0.016673529520630836
limb B-Disease 1 0.9262509942054749
anomalies I-Disease 0 0.031142771244049072
, O 0 1.5019757029222092e-06
were O 0 1.0013138762587914e-06
screened O 0 4.807374807569431e-06
for O 0 1.5042820677990676e-07
mutations O 0 2.0656136712204898e-06
in O 0 8.76005259442536e-08
TWIST O 0 0.00010560252849245444
, O 0 8.324611258103687e-07
FGFR2 O 0 3.6822701076744124e-05
, O 0 1.832876392882099e-07
and O 0 4.4123743236923474e-07
FGFR3 O 0 0.00022287786123342812
. O 0 4.977565367880743e-06

Nine O 0 8.91993404366076e-05
novel O 0 7.030592769297073e-06
and O 0 1.0733403996709967e-06
three O 0 6.559098437719513e-07
recurrent O 0 0.04886273667216301
TWIST O 1 0.8479517698287964
mutations O 0 0.0003183611552231014
were O 0 9.927497330863844e-07
found O 0 1.4144568183382944e-07
in O 0 1.8563785886271944e-07
12 O 0 2.17826891457662e-06
families O 0 1.2511479781096568e-06
. O 0 1.8294166466148454e-06

Seven O 0 6.693631439702585e-05
families O 0 4.597192400979111e-06
were O 0 5.569306154029618e-07
found O 0 1.3775768081814022e-07
to O 0 3.779737056675003e-08
have O 0 6.029296883980351e-08
the O 0 1.264228330910555e-07
FGFR3 O 0 9.823102300288156e-05
P250R O 0 1.3705683159059845e-05
mutation O 0 1.5451790886800154e-06
, O 0 3.711391016736343e-08
and O 0 5.404803005149006e-08
one O 0 5.367306599168842e-08
individual O 0 2.5719190333006736e-08
was O 0 1.3751396181760356e-06
found O 0 1.2432225560132792e-07
to O 0 4.916494589224385e-08
have O 0 6.045995348813449e-08
an O 0 1.2088398193554895e-07
FGFR2 O 0 5.2750270697288215e-05
VV269 O 0 9.099771887122188e-06
- O 0 2.10293128475314e-05
270 O 0 6.427062089642277e-06
deletion O 0 6.52861490380019e-05
. O 0 9.28608096728567e-06

To O 0 3.87126465284382e-06
date O 0 3.756354317374644e-06
, O 0 2.0428774405445438e-07
our O 0 5.85533221908463e-08
detection O 0 5.820824071633979e-07
rate O 0 9.663809805715573e-07
for O 0 3.2112186687527355e-08
TWIST O 0 5.362524098018184e-05
or O 0 1.7505628875369439e-06
FGFR O 0 0.0002764105156529695
mutations O 0 3.558148819138296e-06
is O 0 5.570055705561572e-08
68 O 0 1.3048174878349528e-06
% O 0 1.3942884891093854e-07
in O 0 3.553125793587242e-08
our O 0 2.638018088418903e-07
Saethre B-Disease 0 0.0006824726588092744
- I-Disease 1 0.9946280121803284
Chotzen I-Disease 1 0.9979689717292786
syndrome I-Disease 1 0.999805748462677
patients O 0 3.5141340504196705e-06
, O 0 4.598551228696124e-08
including O 0 4.2620026619033524e-08
our O 0 1.532348932187233e-07
five O 0 7.479432611035008e-07
patients O 0 1.3424419194052462e-06
elsewhere O 0 6.264206149353413e-07
reported O 0 6.763706323908991e-07
with O 0 2.6499344585317886e-07
TWIST O 0 0.003737078048288822
mutations O 0 0.00018136913422495127
. O 0 5.49389869775041e-06

More O 0 3.06503648062062e-06
than O 0 3.65144842362497e-07
35 O 0 6.275051873672055e-07
different O 0 1.2515161529336183e-07
TWIST O 0 0.00017015040793921798
mutations O 0 1.8265041944687255e-05
are O 0 5.584011830706004e-08
now O 0 1.093978454491662e-07
known O 0 1.592281932971673e-07
in O 0 8.167322818053435e-08
the O 0 3.486270827579574e-07
literature O 0 1.2520824839157285e-06
. O 0 2.723928446357604e-06

The O 0 8.273915227619e-06
most O 0 3.8110755440357025e-07
common O 0 2.7772085786637035e-07
phenotypic O 0 4.701573288912186e-06
features O 0 7.146962616388919e-06
, O 0 2.6097072236552776e-07
present O 0 3.4721683306315754e-08
in O 0 2.0327748373460963e-08
more O 0 9.291202474059901e-09
than O 0 1.282994332996168e-08
a O 0 1.0544633255449298e-07
third O 0 1.4914218127159984e-06
of O 0 2.282935263053787e-08
our O 0 2.956740274839831e-07
patients O 0 3.716307901413529e-07
with O 0 1.256315158570942e-07
TWIST O 0 0.0420139841735363
mutations O 0 1.9857154256897047e-05
, O 0 3.9412949348616166e-08
are O 0 4.150484400611276e-08
coronal B-Disease 0 6.905766349518672e-05
synostosis I-Disease 0 4.8833000619197264e-05
, O 0 3.041133140868624e-07
brachycephaly B-Disease 0 2.160145595553331e-05
, O 0 5.757318035648495e-07
low B-Disease 0 0.00013440282782539725
frontal I-Disease 1 0.9998722076416016
hairline I-Disease 1 0.9999979734420776
, O 0 1.5502564565395005e-05
facial B-Disease 1 0.6690061688423157
asymmetry I-Disease 0 0.006261650938540697
, O 0 6.484757250291295e-06
ptosis B-Disease 0 0.042681653052568436
, O 0 1.782746949174907e-06
hypertelorism B-Disease 0 0.0001863476209109649
, O 0 1.301908923778683e-06
broad B-Disease 0 1.0009911420638673e-05
great I-Disease 0 2.316198106200318e-06
toes I-Disease 0 0.00017583390581421554
, O 0 3.14702191417382e-07
and O 0 1.2193222573841922e-06
clinodactyly B-Disease 0 0.0001623020216356963
. O 0 5.0202279453515075e-06

Significant O 0 4.00188218918629e-05
intra O 0 0.00011978838301729411
- O 0 0.00019850381067954004
and O 0 2.1667581222573062e-06
interfamilial O 0 6.373401265591383e-05
phenotypic O 0 5.1547940529417247e-05
variability O 0 0.00011663360055536032
is O 0 1.7149061193322268e-07
present O 0 9.430467429183409e-08
for O 0 7.211087904579472e-08
either O 0 9.554995585858705e-07
TWIST O 0 0.04512125998735428
mutations O 0 0.00011265967623330653
or O 0 2.8052161269442877e-06
FGFR O 0 0.003246537409722805
mutations O 0 0.00011210340016987175
. O 0 4.867824372922769e-06

The O 0 7.757305866107345e-06
overlap O 0 8.552003237127792e-06
in O 0 4.937366497870244e-07
clinical O 0 2.9656009701284347e-06
features O 0 5.4671695579600055e-06
and O 0 2.0872510049230186e-06
the O 0 1.491054888447252e-07
presence O 0 2.5398622938155313e-07
, O 0 6.31345713486553e-08
in O 0 1.8735194728947135e-08
the O 0 4.4122394626811e-08
same O 0 6.232112781390242e-08
genes O 0 1.0079393319983865e-07
, O 0 1.7333338320213443e-08
of O 0 7.734506368706207e-09
mutations O 0 2.41494518604668e-07
for O 0 8.041172172568167e-09
more O 0 1.3162511081077355e-08
than O 0 1.106951597051875e-08
one O 0 6.211570280356682e-08
craniosynostotic B-Disease 0 4.3582731450442225e-05
condition I-Disease 0 2.365807858950575e-06
- O 0 2.0081554339412833e-06
such O 0 1.6041209249806343e-08
as O 0 1.2976160235211864e-07
Saethre B-Disease 0 1.564950252941344e-05
- I-Disease 0 1.5086587154655717e-05
Chotzen I-Disease 0 1.3817274520988576e-05
, I-Disease 0 1.48391507082124e-07
Crouzon I-Disease 0 5.659342150465818e-06
, I-Disease 0 1.1785622433535536e-07
and I-Disease 0 9.59468025030219e-07
Pfeiffer I-Disease 0 0.12716040015220642
syndromes I-Disease 0 0.25523459911346436
- O 0 4.6813205699436367e-05
support O 0 3.4907688473140297e-07
the O 0 1.0469082667441398e-07
hypothesis O 0 4.951398864250223e-07
that O 0 3.897197942137609e-08
TWIST O 0 2.8306976673775353e-05
and O 0 1.4571122619599919e-06
FGFRs O 0 1.6613988918834366e-05
are O 0 1.4557238969814534e-08
components O 0 3.701882533846401e-08
of O 0 3.3709093294476133e-09
the O 0 2.521827191515058e-08
same O 0 5.4518292103011845e-08
molecular O 0 2.817179165504058e-07
pathway O 0 2.052575354127839e-07
involved O 0 1.6039404471257512e-08
in O 0 2.4188793190660363e-08
the O 0 7.715119920703728e-08
modulation O 0 2.355741571591352e-06
of O 0 3.353481190515595e-07
craniofacial O 1 0.7162104845046997
and O 0 8.815004548523575e-05
limb O 0 0.004419177770614624
development O 0 3.7280466358424746e-07
in O 0 2.124505442679947e-07
humans O 0 2.999803712100402e-07
. O 0 2.7703359251063375e-07
. O 0 1.678802505011845e-06

Mutation O 0 0.001729481853544712
analysis O 0 4.871829514740966e-05
of O 0 9.962854164768942e-06
UBE3A O 1 0.8799110054969788
in O 1 0.5206509232521057
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.883030354976654
. O 0 4.1993836930487305e-05

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7655258774757385
AS B-Disease 1 0.9992042183876038
) O 0 3.7999009236955317e-06
is O 0 6.593479611183284e-07
caused O 0 2.187407972087385e-06
by O 0 1.799641324851109e-07
chromosome O 0 0.0001099633373087272
15q11 O 0 1.766595960361883e-05
- O 0 4.5849301386624575e-05
q13 O 0 5.495161531143822e-06
deletions O 0 2.3423272068612278e-06
of O 0 1.0239214276452913e-07
maternal O 0 2.602380482130684e-05
origin O 0 4.279712584320805e-07
, O 0 1.0864923893905143e-07
by O 0 1.6792365897799755e-07
paternal O 0 0.0001279579009860754
uniparental B-Disease 0 0.028011830523610115
disomy I-Disease 0 0.007965573109686375
( O 0 1.0484511221875437e-05
UPD B-Disease 1 0.9999879598617554
) O 0 2.702880408378405e-07
15 O 0 1.9613587198819005e-07
, O 0 2.8095586301901676e-08
by O 0 8.889826830227321e-08
imprinting O 0 0.04629911109805107
defects O 1 0.9811657667160034
, O 0 2.3636150103811815e-07
and O 0 1.7808103791594476e-07
by O 0 1.196831931338238e-07
mutations O 0 1.3768021744908765e-06
in O 0 7.412329949829655e-08
the O 0 9.421852382729412e-07
UBE3A O 0 0.0002662076731212437
gene O 0 1.9170352970832027e-05
. O 0 7.496295438613743e-06

UBE3A O 0 0.010418849997222424
encodes O 0 0.00025355303660035133
a O 0 2.8359232601360418e-05
ubiquitin O 0 6.488075450761244e-05
- O 0 5.4359767091227695e-05
protein O 0 7.225520676001906e-06
ligase O 0 5.2084146773268e-06
and O 0 9.519932291368605e-07
shows O 0 1.1636690942395944e-05
brain O 0 0.00010078153718495741
- O 0 3.9123118767747656e-05
specific O 0 3.4447386951796943e-06
imprinting O 0 0.0005281284102238715
. O 0 1.6008501916076057e-05

Here O 0 3.140568878734484e-05
we O 0 3.1519948606728576e-06
describe O 0 5.973106908641057e-06
UBE3A O 0 0.00022067049576435238
coding O 0 0.0002088054025080055
- O 0 0.003907842095941305
region O 0 4.013370562461205e-05
mutations O 0 2.3446391423931345e-05
detected O 0 1.4026134067535168e-06
by O 0 7.450302774714146e-08
SSCP O 0 1.632636849535629e-05
analysis O 0 1.707321217736535e-07
in O 0 1.4086508315358515e-07
13 O 0 3.239507122998475e-06
AS B-Disease 1 0.7048000693321228
individuals O 0 1.6566667682127445e-07
or O 0 3.502459833271132e-07
families O 0 1.125886683439603e-06
. O 0 1.412202095707471e-06

Two O 0 3.710930104716681e-05
identical O 0 3.4001594030996785e-05
de O 0 3.117971937172115e-05
novo O 0 2.5633822588133626e-05
5 O 0 1.450545823900029e-06
- O 0 1.7098229363909923e-05
bp O 0 7.078859198372811e-06
duplications O 0 2.6188722586084623e-06
in O 0 1.591817238022486e-07
exon O 0 1.0664761248335708e-05
16 O 0 4.497865575103788e-06
were O 0 1.324498498433968e-06
found O 0 1.4410541098186513e-06
. O 0 2.4539747300877934e-06

Among O 0 8.681227882334497e-06
the O 0 3.5061628977928194e-07
other O 0 7.226798715009863e-08
11 O 0 3.787900197949057e-07
unique O 0 3.04749733004428e-07
mutations O 0 4.291943241696572e-06
, O 0 8.125370953848687e-08
8 O 0 6.041661322342406e-07
were O 0 1.342703939144485e-07
small O 0 8.13189799941938e-08
deletions O 0 1.8944276689580875e-06
or O 0 2.2336745075790532e-07
insertions O 0 6.995092917350121e-06
predicted O 0 7.692645340284798e-06
to O 0 1.0047089205045268e-07
cause O 0 1.3385734973780927e-06
frameshifts O 0 1.786782013368793e-05
, O 0 5.696558247336725e-08
1 O 0 1.7749337644090701e-07
was O 0 1.2570034186865087e-06
a O 0 3.494526197300729e-07
mutation O 0 3.4587247910167207e-07
to O 0 1.0166429476043959e-08
a O 0 8.323406319732385e-08
stop O 0 2.1274271944093925e-07
codon O 0 4.7038690809131367e-07
, O 0 1.7999187917894233e-08
1 O 0 8.52129460326978e-08
was O 0 5.899809707443637e-07
a O 0 5.507650939762243e-07
missense O 0 3.604631274356507e-05
mutation O 0 9.375852414450492e-07
, O 0 3.138602266972157e-08
and O 0 1.0065061673003584e-07
1 O 0 4.2255300058968714e-07
was O 0 8.758232070249505e-06
predicted O 0 4.185753823549021e-06
to O 0 6.104838234932686e-08
cause O 0 1.7469760393851175e-07
insertion O 0 3.763490212804754e-07
of O 0 2.6389786356162404e-08
an O 0 3.370692809312459e-07
isoleucine O 0 0.001099333050660789
in O 0 8.024230879755123e-08
the O 0 1.7682380359929084e-07
hect O 0 7.342729077208787e-06
domain O 0 8.473078594306571e-08
of O 0 1.350094258611989e-08
the O 0 7.591481931967792e-08
UBE3A O 0 1.027410962706199e-05
protein O 0 2.676904671261582e-07
, O 0 1.9479587720638847e-08
which O 0 1.4238693779589084e-08
functions O 0 1.8116914191068645e-08
in O 0 4.093126548809778e-08
E2 O 0 4.414320301293628e-06
binding O 0 3.8192550277926784e-07
and O 0 1.3048119740233233e-07
ubiquitin O 0 4.297481154935667e-06
transfer O 0 1.7834883010436897e-06
. O 0 6.437048341467744e-06

Eight O 0 2.6283771148882806e-05
of O 0 2.5593064378881536e-07
the O 0 1.854158000469397e-07
cases O 0 2.914772778694896e-07
were O 0 2.4355676941922866e-06
familial O 0 4.001672277809121e-05
, O 0 6.592215981982008e-07
and O 0 5.053989866610209e-07
five O 0 4.7658389235039067e-07
were O 0 8.937087727645121e-07
sporadic O 0 5.875452916370705e-05
. O 0 6.099639904277865e-06

In O 0 1.625144977879245e-05
two O 0 3.936463599529816e-06
familial O 0 0.0004916604957543314
cases O 0 3.971907062805258e-06
and O 0 1.039085645970772e-06
one O 0 3.457623165559198e-07
sporadic O 0 2.6009613065980375e-05
case O 0 1.276148168471991e-06
, O 0 4.212630244637694e-07
mosaicism O 0 3.871493390761316e-05
for O 0 6.275794248722377e-07
UBE3A O 0 0.000487835262902081
mutations O 0 1.5469067875528708e-05
was O 0 3.772484433284262e-06
detected O 0 9.318462730334431e-07
in O 0 4.2747764439354796e-08
the O 0 1.8555731173819368e-07
mother O 0 3.860790002363501e-06
of O 0 4.163646494248496e-08
three O 0 1.7786526314012008e-06
AS B-Disease 1 0.99977046251297
sons O 0 6.526269135065377e-05
, O 0 2.846355151575608e-08
in O 0 1.6553631354554454e-08
the O 0 8.560407849245166e-08
maternal O 0 3.5081270652881358e-06
grandfather O 0 5.561233251683007e-07
of O 0 8.763273662282245e-09
two O 0 2.0209130013881804e-07
AS B-Disease 1 0.9698447585105896
first O 0 9.580397772879223e-07
cousins O 0 5.803424755868036e-06
, O 0 1.741392026133326e-07
and O 0 1.0153060969742e-07
in O 0 3.474785614798748e-08
the O 0 1.967248408618616e-07
mother O 0 3.173957111357595e-06
of O 0 3.4846280527744966e-08
an O 0 5.840007020196936e-07
AS B-Disease 1 0.9855008721351624
daughter O 0 0.007310017012059689
. O 0 7.288228516699746e-06

The O 0 6.449436568800593e-06
frequencies O 0 3.999765340267913e-06
with O 0 1.8224827158519474e-07
which O 0 2.8208731350787275e-07
we O 0 8.41748928337438e-08
detected O 0 1.529919245513156e-06
mutations O 0 1.0880846730287885e-06
were O 0 1.6085029130863404e-07
5 O 0 3.0449871246673865e-07
( O 0 7.319786732296052e-08
14 O 0 2.381578667609574e-07
% O 0 5.950036907620415e-08
) O 0 4.852924284648452e-09
of O 0 3.871996945292722e-09
35 O 0 7.158547532526427e-08
in O 0 1.6049227724579396e-08
sporadic O 0 2.5145973268081434e-06
cases O 0 1.409325420809182e-07
and O 0 2.9695243597416265e-07
8 O 0 1.1323940043439507e-06
( O 0 7.508062793704084e-08
80 O 0 5.18797271809035e-08
% O 0 6.642658689770542e-08
) O 0 6.961351051160136e-09
of O 0 7.493338394226612e-09
10 O 0 9.267100153920182e-08
in O 0 1.5115068663362763e-07
familial O 0 3.3425309084123e-05
cases O 0 9.09114987734938e-07
. O 0 6.035706405782548e-07
. O 0 2.885358753701439e-06

The O 0 0.00021519709844142199
hemochromatosis B-Disease 1 0.9999969005584717
845 O 0 0.0047995769418776035
G O 0 0.2147327959537506
- O 0 0.0003212768933735788
- O 0 3.221620136173442e-05
> O 0 1.0949308943963842e-06
A O 0 2.235387768223518e-07
and O 0 7.497173015735825e-08
187 O 0 9.438913366466295e-07
C O 0 7.5120969995623454e-06
- O 0 1.6203273844439536e-05
- O 0 6.08298068982549e-05
> O 0 2.0370758647914045e-05
G O 0 0.0007931722211651504
mutations O 0 3.145859636788373e-06
: O 0 1.0541295836219433e-07
prevalence O 0 3.1369677344628144e-06
in O 0 2.6006787834376155e-07
non O 0 1.965603360076784e-06
- O 0 0.0002210067759733647
Caucasian O 0 0.00018067336350213736
populations O 0 1.1620810255408287e-05
. O 0 4.130301931581926e-06

Hemochromatosis B-Disease 1 0.9993683695793152
, O 0 0.00010783339530462399
the O 0 0.00020896656496915966
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 7.148278655222384e-06
iron I-Disease 1 0.9371013641357422
metabolism I-Disease 0 0.00010316800035070628
, O 0 3.7997020285729377e-07
leads O 0 1.8589328192319954e-06
, O 0 1.9995700029085128e-07
if O 0 1.4354917254877364e-07
untreated O 0 6.987698725424707e-06
, O 0 5.3153090817659177e-08
to O 0 1.400394324946319e-07
progressive O 0 0.00012491682718973607
iron B-Disease 0 0.06949744373559952
overload I-Disease 0 0.00018044128955807537
and O 0 5.1474607971613295e-06
premature B-Disease 0 4.3825093598570675e-05
death I-Disease 0 2.3343829525401816e-05
. O 0 5.298069481796119e-06

The O 0 0.00019212304323446006
hemochromatosis B-Disease 1 0.9999980926513672
gene O 0 0.00016219094686675817
, O 0 3.889849267579848e-06
HFE O 0 0.0008448218577541411
, O 0 1.5294480135708e-06
recently O 0 3.488536549411947e-06
has O 0 1.0390242550784023e-06
been O 0 8.943379157244635e-07
identified O 0 1.0099279279529583e-06
, O 0 4.4160447743024633e-08
and O 0 3.816989391225434e-08
characterization O 0 1.6369116906389536e-07
of O 0 9.37869515382772e-09
this O 0 3.0550388885330904e-08
gene O 0 2.8801440521419863e-07
has O 0 2.1307823772076517e-06
shown O 0 3.9984740851650713e-07
that O 0 1.1125629306718565e-08
it O 0 1.257317805425373e-08
contains O 0 2.98037825530173e-08
two O 0 1.8208271512776264e-07
mutations O 0 1.894286583592475e-06
that O 0 2.668858911647476e-08
result O 0 1.0838368780241581e-07
in O 0 1.3205391269366373e-07
amino O 0 1.267130301130237e-06
acid O 0 1.0734181614679983e-06
substitutions O 0 7.102310632944864e-07
- O 0 1.0383189419371774e-06
cDNA O 0 3.0146072731440654e-06
nucleotides O 0 1.5865945215409738e-06
845 O 0 4.112716396775795e-06
G O 0 2.826095987984445e-05
- O 0 1.2261051779205445e-05
- O 0 1.229234658239875e-05
> O 0 8.561245863347722e-07
A O 0 4.5907430035185826e-07
( O 0 1.5071023540258466e-07
C282Y O 0 1.1071774679294322e-06
) O 0 4.7020389359886394e-08
and O 0 4.8188173451535476e-08
187 O 0 5.922274226577429e-07
C O 0 3.857893261738354e-06
- O 0 1.5562034604954533e-05
- O 0 5.379067806643434e-05
> O 0 2.4312827008543536e-05
G O 0 0.00017444582772441208
( O 0 1.0079679668706376e-06
H63D O 0 3.270061279181391e-05
) O 0 7.814530249561358e-07
. O 0 2.7604144179349532e-06

Although O 0 0.05220293626189232
hemochromatosis B-Disease 1 1.0
is O 0 9.613295333110727e-06
common O 0 2.8029219265590655e-06
in O 0 7.061995006552024e-07
Caucasians O 0 2.5449458917137235e-05
, O 0 2.2862782600441278e-07
affecting O 0 5.222313461672456e-07
> O 0 2.469262199156219e-06
= O 0 3.335312158014858e-06
1 O 0 4.5571900386676134e-07
/ O 0 3.5429420677246526e-06
300 O 0 5.935754643360269e-08
individuals O 0 4.878724979562321e-09
of O 0 2.9650224497856925e-09
northern O 0 1.4723573826813663e-07
European O 0 8.75746337669625e-08
origin O 0 1.1463024662816679e-07
, O 0 8.460595068982002e-08
it O 0 7.683722458295961e-08
has O 0 3.7105459682607034e-07
not O 0 2.8939151519580264e-08
been O 0 8.305185161816553e-08
recognized O 0 4.7491788279785396e-08
in O 0 6.510029493256297e-08
other O 0 9.553723145927506e-08
populations O 0 2.7262908588454593e-06
. O 0 2.0988682081224397e-06

The O 0 5.574190709012328e-06
present O 0 8.313155603900668e-07
study O 0 1.8358082343183924e-07
used O 0 1.6277769532280217e-07
PCR O 0 1.8852231733035296e-05
and O 0 1.3994973357966956e-07
restriction O 0 3.0623436941823456e-07
- O 0 2.144639438483864e-06
enzyme O 0 2.629736570725072e-07
digestion O 0 3.144049287584494e-07
to O 0 1.5861431279518e-08
analyze O 0 7.174513427798956e-08
the O 0 1.7913325933704982e-08
frequency O 0 2.0676127121532772e-07
of O 0 9.79039427306816e-09
the O 0 6.911634642392528e-08
845 O 0 5.487934231496183e-06
G O 0 7.927573460619897e-05
- O 0 1.4087978343013674e-05
- O 0 8.520711162418593e-06
> O 0 3.8219585007936985e-07
A O 0 8.457110567405834e-08
and O 0 4.490107130550314e-08
187 O 0 3.4599059972606483e-07
C O 0 2.507836370568839e-06
- O 0 6.9372172220028006e-06
- O 0 1.251103458344005e-05
> O 0 5.608739684248576e-06
G O 0 5.624114419333637e-05
mutations O 0 1.1896031537617091e-06
in O 0 1.0529781491186441e-07
HLA O 0 1.2229532330820803e-05
- O 0 1.1377586588423583e-06
typed O 0 6.468898732236994e-07
samples O 0 1.1369741059752414e-07
from O 0 3.19584536612183e-08
non O 0 2.1044031939254637e-07
- O 0 1.5138371054490563e-05
Caucasian O 0 3.612483851611614e-05
populations O 0 6.976978852435423e-07
, O 0 2.8097783655312014e-08
comprising O 0 5.801505054137124e-08
Australian O 0 3.0881167845109303e-07
Aboriginal O 0 4.387457863685995e-07
, O 0 4.730419789211737e-08
Chinese O 0 1.7348057212984713e-08
, O 0 4.104290241002673e-08
and O 0 2.025248306836147e-07
Pacific O 0 2.040129402303137e-06
Islanders O 0 1.9738474293262698e-05
. O 0 3.0071730634517735e-06

Results O 0 0.000598853686824441
showed O 0 7.463213114533573e-05
that O 0 1.2932672177612403e-07
the O 0 1.4149655669370986e-07
845 O 0 1.1089496183558367e-05
G O 0 0.0005527649191208184
- O 0 6.060093073756434e-05
- O 0 4.440644624992274e-05
> O 0 1.811907850424177e-06
A O 0 1.455889901080809e-06
mutation O 0 2.98893451144977e-06
was O 0 1.9581061678763945e-06
present O 0 5.501079414216292e-08
in O 0 4.5845041540815146e-08
these O 0 3.5460573144519e-08
populations O 0 2.995018633100699e-07
( O 0 5.927891066903612e-08
allele O 0 2.1242037462343433e-07
frequency O 0 3.206867233984667e-07
0 O 0 1.6615733500202623e-07
. O 0 1.660435167138985e-08
32 O 0 3.0288086350083177e-07
% O 0 1.0443196174492186e-07
) O 0 1.4427130601291083e-08
, O 0 1.7158114928861323e-08
and O 0 1.4014632654379966e-07
, O 0 7.440120697310704e-08
furthermore O 0 7.540885604839787e-08
, O 0 4.3906556612682834e-08
it O 0 4.734616965151872e-08
was O 0 3.086879132752074e-06
always O 0 9.113618659739586e-08
seen O 0 6.566884991343613e-08
in O 0 1.682133721203627e-08
conjunction O 0 1.7135525354206038e-07
with O 0 2.61045158822526e-07
HLA O 0 0.0002883844717871398
haplotypes O 0 1.8973723854287528e-05
common O 0 3.711399187977804e-07
in O 0 2.8612979008357797e-07
Caucasians O 0 9.374946785101201e-06
, O 0 9.794862876333355e-08
suggesting O 0 2.1759302626378485e-07
that O 0 2.1273006467481537e-08
845 O 0 3.980242126999656e-06
G O 0 0.00020417667110450566
- O 0 3.96539326175116e-05
- O 0 3.506078428472392e-05
> O 0 1.2188909295218764e-06
A O 0 2.3001705358183244e-06
may O 0 2.5971096420107642e-06
have O 0 5.060587682237383e-08
been O 0 4.127346642235352e-08
introduced O 0 1.327468623912864e-07
into O 0 3.137123982810408e-08
these O 0 2.881467509041613e-08
populations O 0 2.317688654329686e-07
by O 0 7.556636916206116e-08
Caucasian O 0 1.9107330444967374e-05
admixture O 0 4.748009814647958e-05
. O 0 6.714042683597654e-06

187 O 0 0.00035176792880520225
C O 0 0.0001656352251302451
- O 0 9.673128079157323e-05
- O 0 7.53701533540152e-05
> O 0 1.7964321159524843e-05
G O 0 0.00013514113379642367
was O 0 6.649402166658547e-07
present O 0 3.833624617755049e-08
at O 0 2.297039003451573e-08
an O 0 4.2544737510752384e-08
allele O 0 9.214688247993763e-07
frequency O 0 4.78369827305869e-07
of O 0 7.735379625728456e-08
2 O 0 5.6538615353929345e-06
. O 0 3.5043083244090667e-06

68 O 0 0.013823566026985645
% O 0 2.6162360882153735e-05
in O 0 1.2527569026588026e-07
the O 0 8.266339079909812e-08
two O 0 2.1398207650236145e-07
populations O 0 6.003266435072874e-07
analyzed O 0 9.001822149912186e-07
( O 0 1.1588383586058626e-07
Australian O 0 4.285054160391155e-07
Aboriginal O 0 6.446512657021231e-07
and O 0 1.201916290938243e-07
Chinese O 0 9.891418528695795e-08
) O 0 3.7198321933828993e-07
. O 0 1.0063043873742572e-06

In O 0 7.857860509830061e-06
the O 0 8.468068131151085e-07
Australian O 0 1.0915892971752328e-06
Aboriginal O 0 9.235424727194186e-07
samples O 0 1.6052173634761857e-07
, O 0 4.7196500929658214e-08
187 O 0 5.821102035952208e-07
C O 0 1.9567380604712525e-06
- O 0 3.7254310427670134e-06
- O 0 9.382952157466207e-06
> O 0 4.07985180572723e-06
G O 0 4.2022918933071196e-05
was O 0 1.5927784033920034e-06
found O 0 6.810114427935332e-08
to O 0 1.64307003558406e-08
be O 0 2.9245615706940953e-08
associated O 0 9.813432200189709e-08
with O 0 4.072467163496185e-07
HLA O 0 0.009005424566566944
haplotypes O 0 2.2971100406721234e-05
common O 0 5.175885462449514e-07
in O 0 3.08877645238681e-07
Caucasians O 0 1.1300505320832599e-05
, O 0 2.487897461378452e-07
suggesting O 0 5.728952032768575e-07
that O 0 2.5457252306182454e-08
it O 0 4.2626776775023245e-08
was O 0 1.601695544195536e-06
introduced O 0 3.2736647881392855e-07
by O 0 6.177106115501374e-08
recent O 0 7.353776254603872e-07
admixture O 0 4.480442657950334e-05
. O 0 6.86532666804851e-06

In O 0 7.538988938904367e-06
the O 0 4.1956704421863833e-07
Chinese O 0 8.241418925081234e-08
samples O 0 7.717518712979654e-08
analyzed O 0 1.9083741165104584e-07
, O 0 2.251403152797593e-08
187 O 0 1.7154556530840637e-07
C O 0 1.193555476675101e-06
- O 0 2.686228299353388e-06
- O 0 1.213457107951399e-05
> O 0 3.6715475744131254e-06
G O 0 5.044449426350184e-05
was O 0 1.9332219380885363e-06
present O 0 6.128591678589146e-08
in O 0 9.6080150058242e-08
association O 0 6.651660555689887e-08
with O 0 2.727728443119304e-08
a O 0 2.7231416765971517e-07
wide O 0 5.772959639216424e-07
variety O 0 7.118151046370258e-08
of O 0 8.118167471593551e-08
HLA O 0 7.173688209149987e-05
haplotypes O 0 5.5198156587721314e-06
, O 0 1.1617009221254193e-07
showing O 0 4.679461653722683e-07
this O 0 2.2445130198889274e-08
mutation O 0 2.2333081517444953e-07
to O 0 2.1533210770030564e-08
be O 0 4.4916831143382296e-08
widespread O 0 1.0203283551390996e-07
and O 0 4.982852601642662e-07
likely O 0 9.777006653166609e-07
to O 0 6.320541956483794e-08
predate O 0 9.158748639492842e-07
the O 0 3.783646462807155e-08
more O 0 2.9218798047736527e-08
genetically O 0 4.920387937090709e-07
restricted O 0 1.9383732308142498e-07
845 O 0 4.800095211976441e-06
G O 0 0.00011388301209080964
- O 0 3.946181095670909e-05
- O 0 3.814287993009202e-05
> O 0 4.36725440522423e-06
A O 0 3.265584382461384e-06
mutation O 0 1.859429175965488e-05
. O 0 3.710277042046073e-06

Genotype O 1 0.9713883996009827
- O 1 0.8658722043037415
phenotype O 0 0.10655070096254349
correlations O 0 0.001620872993953526
in O 0 0.00015661903307773173
attenuated B-Disease 1 0.9996864795684814
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.999997615814209
coli I-Disease 1 0.9999986886978149
. O 0 0.0003921759780496359

Germ O 0 0.02119589038193226
- O 0 0.10212614387273788
line O 0 0.00039575211121700704
mutations O 0 8.926584087021183e-06
of O 0 1.1669107635725595e-07
the O 0 1.1613147989919526e-06
tumor B-Disease 0 0.0007221870473586023
suppressor O 0 0.0006050302181392908
APC O 0 1.8572422050056048e-05
are O 0 2.3473852195365907e-07
implicated O 0 1.5232674741127994e-05
in O 0 3.495578494039364e-05
attenuated B-Disease 1 0.9997509121894836
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999998807907104
coli I-Disease 1 1.0
( O 0 0.012786238454282284
AAPC B-Disease 1 0.9999997615814209
) O 0 3.149269559798995e-06
, O 0 2.409670116776397e-07
a O 0 1.0999367532349424e-06
variant O 0 0.002195222768932581
of O 0 0.00013606174616143107
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 0.0006959218299016356
FAP B-Disease 0 0.0012858721893280745
) O 0 6.82159407006111e-06
. O 0 1.1288980203971732e-05

AAPC B-Disease 1 0.9999932050704956
is O 0 3.567982275853865e-05
recognized O 0 1.9381877791602165e-06
by O 0 1.4819111981978494e-07
the O 0 1.6471970809561753e-07
occurrence O 0 8.406544793615467e-07
of O 0 9.536208978033756e-08
< O 0 7.1929812293092255e-06
100 O 0 3.5578941037783807e-07
colonic B-Disease 0 5.257024531601928e-05
adenomas I-Disease 0 0.0002909539616666734
and O 0 4.241219073719549e-07
a O 0 1.0195400363954832e-06
later O 0 9.498116924078204e-06
onset O 0 0.005107027944177389
of O 0 0.005912842229008675
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.670129899546737e-06
age O 0 9.708760444482323e-07
> O 0 2.213086645497242e-06
40 O 0 6.47946933440835e-07
years O 0 3.3790803399824654e-07
) O 0 4.710980192612624e-07
. O 0 1.4128311249805847e-06

The O 0 8.996768883662298e-06
aim O 0 4.128238742850954e-06
of O 0 8.412995811113433e-08
this O 0 5.239543909851818e-08
study O 0 1.1005079869619294e-07
was O 0 1.2203169035274186e-06
to O 0 1.8280269387105363e-07
assess O 0 6.404533451132011e-06
genotype O 0 0.0008669882081449032
- O 0 0.027152789756655693
phenotype O 0 0.000718090683221817
correlations O 0 5.245756619842723e-05
in O 0 2.149548163288273e-05
AAPC B-Disease 1 0.9999971389770508
families O 0 2.5339870262541808e-05
. O 0 1.1187305062776431e-05

By O 0 7.455201739503536e-06
protein O 0 1.4110851225268561e-05
- O 0 1.6805288396426477e-05
truncation O 0 4.178849485469982e-05
test O 0 3.5649825349537423e-06
( O 0 5.601639259111835e-07
PTT O 0 1.7062744745999225e-06
) O 0 6.85202934391782e-08
assay O 0 1.288264911636361e-06
, O 0 2.419303868350653e-08
the O 0 2.1606606281920904e-08
entire O 0 1.4493826938632992e-07
coding O 0 1.8552825622464297e-06
region O 0 2.0961009283837484e-07
of O 0 1.3633641771093608e-08
the O 0 1.532486351152329e-07
APC B-Disease 0 3.2964549063763116e-06
gene O 0 7.790465588186635e-07
was O 0 3.936824214179069e-06
screened O 0 2.4086371013254393e-06
in O 0 1.3510272367511789e-07
affected O 0 2.145736743841553e-07
individuals O 0 2.478013172435567e-08
from O 0 7.973821425366623e-08
11 O 0 1.0851129445654806e-05
AAPC B-Disease 1 0.999992847442627
kindreds O 0 0.0002189598890254274
, O 0 1.4628191991050699e-07
and O 0 4.60573126304098e-08
their O 0 5.23775547378591e-08
phenotypic O 0 5.909579158469569e-06
differences O 0 3.718945663422346e-06
were O 0 2.003444024012424e-06
examined O 0 2.3195039830170572e-05
. O 0 4.206362063996494e-06

Five O 0 3.371895581949502e-05
novel O 0 2.428944208077155e-05
germ O 0 0.0003328777092974633
- O 0 0.010389509610831738
line O 0 0.0007129546720534563
APC B-Disease 0 3.2347314117942005e-05
mutations O 0 6.43815974399331e-06
were O 0 3.318517087791406e-07
identified O 0 1.0036992534878664e-06
in O 0 2.8750616820616415e-07
seven O 0 4.371930572233396e-06
kindreds O 0 0.000393742200685665
. O 0 7.137045940908138e-06

Mutations O 0 0.05363820120692253
were O 0 5.464631158247357e-06
located O 0 5.477135118781007e-07
in O 0 7.847280159012371e-08
three O 0 1.0555942964174392e-07
different O 0 2.6770059946557012e-08
regions O 0 8.672291329503423e-08
of O 0 1.731737775401143e-08
the O 0 1.5892234728198673e-07
APC B-Disease 0 2.467880221956875e-06
gene O 0 4.474158856737631e-07
( O 0 6.375194772090254e-08
1 O 0 9.968807290761106e-08
) O 0 2.3393035064600554e-08
at O 0 1.120318326996994e-08
the O 0 3.183956565067092e-08
5 O 0 1.1792729281978609e-07
end O 0 2.47638610062495e-07
spanning O 0 5.12510098360508e-07
exons O 0 2.178385329898447e-06
4 O 0 8.408854341723782e-07
and O 0 3.978728102538298e-07
5 O 0 4.969005544808169e-07
, O 0 4.8556302090219106e-08
( O 0 2.754076611211076e-08
2 O 0 7.972848692361367e-08
) O 0 1.7207341329594783e-08
within O 0 1.444935460170882e-08
exon O 0 8.088906042758026e-07
9 O 0 1.0297554808857967e-06
, O 0 3.289164141051515e-08
and O 0 8.331856093946044e-08
( O 0 3.99311161913829e-08
3 O 0 1.0801509375824025e-07
) O 0 1.4845033646793127e-08
at O 0 1.869386068165113e-08
the O 0 5.03174177879373e-08
3 O 0 5.716879059036728e-07
distal O 0 5.280077402858296e-06
end O 0 6.527972118419711e-07
of O 0 5.288601201414167e-08
the O 0 2.801455138978781e-07
gene O 0 5.081061317468993e-06
. O 0 2.9787697712890804e-06

Variability O 0 0.005191303323954344
in O 0 2.2984120278124465e-06
the O 0 4.1882904611156846e-07
number O 0 6.130287601990858e-07
of O 0 3.546485095284879e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.27999189496040344
most O 0 2.832826737630967e-07
apparent O 0 4.3186641960346606e-06
in O 0 2.914533467901492e-07
individuals O 0 2.140524557603385e-08
with O 0 7.321894912593052e-08
mutations O 0 3.0425303521042224e-06
in O 0 1.1832991475557719e-07
region O 0 1.0138495554201654e-06
1 O 0 1.3398570217759698e-06
, O 0 2.300547237155115e-07
and O 0 1.2052844340360025e-06
upper O 0 0.0007846413063816726
- O 1 0.6242993474006653
gastrointestinal O 0 0.12795396149158478
manifestations O 0 8.152051123033743e-06
were O 0 8.184037483260909e-07
more O 0 1.3111900898366002e-07
severe O 0 3.634024324128404e-05
in O 0 3.6150805726720137e-07
them O 0 3.836675546153856e-07
. O 0 3.046626943614683e-06

In O 0 1.2404136214172468e-05
individuals O 0 4.155285751039628e-07
with O 0 3.4050631825266464e-07
mutations O 0 8.069481737038586e-06
in O 0 6.11362409586036e-08
either O 0 4.602320018420869e-07
region O 0 1.1645533959381282e-06
2 O 0 3.29622844219557e-06
or O 0 2.8679141905740835e-07
region O 0 5.361909529710829e-07
3 O 0 6.899186928421841e-07
, O 0 3.504504064721914e-08
the O 0 2.8351553993388734e-08
average O 0 3.570947058051388e-07
number O 0 1.694738571700327e-08
of O 0 1.9378862958774334e-08
adenomas B-Disease 0 1.3652133020514157e-05
tended O 0 1.230162411047786e-06
to O 0 3.199938092279808e-08
be O 0 5.5039340196572084e-08
lower O 0 6.209005505297682e-07
than O 0 1.4552101745834989e-08
those O 0 5.213482978660977e-09
in O 0 1.731338095112278e-08
individuals O 0 1.596124654668074e-08
with O 0 4.8830187893145194e-08
mutations O 0 1.095617108148872e-06
in O 0 2.9545971003130944e-08
region O 0 5.08273956256744e-07
1 O 0 4.124931081150862e-07
, O 0 1.1503127694822979e-07
although O 0 8.126858830337369e-08
age O 0 1.6808837699500145e-07
at O 0 1.6899393529001827e-07
diagnosis O 0 5.660309034283273e-05
was O 0 6.54489213047782e-06
similar O 0 2.9444452138704946e-06
. O 0 4.061877461936092e-06

In O 0 4.869664917350747e-05
all O 0 7.196535534603754e-06
AAPC B-Disease 1 0.99997878074646
kindreds O 0 0.0009068508516065776
, O 0 8.850657877701451e-07
a O 0 8.870295573615294e-07
predominance O 0 2.7560701710171998e-05
of O 0 7.672027777516632e-07
right O 0 0.0040627336129546165
- O 1 0.9997195601463318
sided O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.015675503760576248
rectal B-Disease 1 0.9998352527618408
polyp I-Disease 0 0.18103080987930298
sparing O 0 4.961948070558719e-05
was O 0 3.411146462894976e-05
observed O 0 1.2262512427696493e-05
. O 0 3.818158347712597e-06

No O 0 0.0006659599021077156
desmoid B-Disease 1 0.9723280072212219
tumors I-Disease 1 1.0
were O 0 2.4215549274231307e-05
found O 0 4.496603480674821e-07
in O 0 4.081176427916944e-07
these O 0 5.454282927530585e-07
kindreds O 0 0.0002375636831857264
. O 0 9.196293831337243e-06

Our O 0 1.2360986147541553e-05
data O 0 2.263365786348004e-06
suggest O 0 5.690747570952226e-07
that O 0 4.5075001509076174e-08
, O 0 6.932508256340952e-08
in O 0 9.608726259102696e-07
AAPC B-Disease 1 0.9999997615814209
families O 0 1.761878252182214e-06
, O 0 5.47712524223698e-08
the O 0 2.0613983409134562e-08
location O 0 7.619958353188849e-08
of O 0 1.2720391850962187e-08
the O 0 5.159217835171148e-07
APC B-Disease 0 5.796366531285457e-05
mutation O 0 9.510199561191257e-06
may O 0 1.0744137171059265e-06
partially O 0 7.1582790042157285e-06
predict O 0 1.3250013353172108e-06
specific O 0 3.9861265577201266e-07
phenotypic O 0 2.5310529963462614e-05
expression O 0 1.5249012903950643e-05
. O 0 5.9047624745289795e-06

This O 0 6.4043256315926556e-06
should O 0 5.155858389116474e-07
help O 0 1.0140811212977496e-07
in O 0 3.428962003226843e-08
the O 0 4.351280225023402e-08
design O 0 7.886590651651204e-07
of O 0 3.994223973791122e-08
tailored O 0 0.00013003851927351207
clinical O 0 1.6863936252775602e-05
- O 0 0.000215564708923921
management O 0 6.716616098856321e-07
protocols O 0 2.1414560080756928e-07
in O 0 4.444411416670846e-08
this O 0 3.234991297063061e-08
subset O 0 4.6768158767918067e-07
of O 0 2.924902844370081e-07
FAP B-Disease 0 0.00017686517094261944
patients O 0 6.511931587738218e-06
. O 0 4.2559511825857044e-07
. O 0 3.401072262931848e-06

Wilms B-Disease 1 0.8235601186752319
' I-Disease 0 0.0025966293178498745
tumor I-Disease 0 0.0007284140447154641
1 O 0 4.860921308136312e-06
and O 0 1.8351498738411465e-06
Dax O 0 0.1385350078344345
- O 0 3.7796140532009304e-05
1 O 0 4.127201691517257e-07
modulate O 0 3.0355254239111673e-06
the O 0 1.4449717866682477e-07
orphan O 0 9.877588126983028e-06
nuclear O 0 1.2944211675858242e-06
receptor O 0 3.4005370252998546e-06
SF O 0 0.00020343279174994677
- O 0 5.338409664545907e-06
1 O 0 1.9843837151256594e-07
in O 0 3.896729694474743e-08
sex O 0 3.815483466951264e-07
- O 0 2.081986849589157e-06
specific O 0 3.216512425296969e-07
gene O 0 2.9396164791251067e-06
expression O 0 2.9506770715670427e-06
. O 0 3.0433952815656085e-06

Products O 0 5.1609324145829305e-05
of O 0 1.435794729331974e-06
steroidogenic O 0 9.98035684460774e-05
factor O 0 3.5037069210375194e-06
1 O 0 2.2654776330455206e-06
( O 0 1.1149929832754424e-06
SF O 0 0.0024478421546518803
- O 0 4.137866199016571e-05
1 O 0 1.0755670700746123e-06
) O 0 2.0543416212603915e-07
and O 0 7.514996696045273e-07
Wilms B-Disease 0 0.0017045463901013136
tumor I-Disease 0 6.239375215955079e-05
1 O 0 1.2252203305251896e-06
( O 0 6.238486776055652e-07
WT1 O 0 6.901065353304148e-05
) O 0 2.4988975155793014e-07
genes O 0 1.848725048603228e-07
are O 0 1.4651277524535544e-08
essential O 0 3.699510742194434e-08
for O 0 1.7850263489549434e-08
mammalian O 0 1.357735072815558e-06
gonadogenesis O 0 9.631694410927594e-06
prior O 0 2.935269947101915e-07
to O 0 1.5852907608859823e-07
sexual O 0 1.680750415289367e-06
differentiation O 0 7.933685992611572e-06
. O 0 3.853179805446416e-06

In O 0 1.0153241419175174e-05
males O 0 8.60666659718845e-06
, O 0 8.581395718465501e-07
SF O 0 0.003103850409388542
- O 0 4.452645225683227e-05
1 O 0 5.95646326928545e-07
participates O 0 1.3371338525303145e-07
in O 0 4.52841426579198e-08
sexual O 0 1.3693562550542993e-07
development O 0 1.7589885104030145e-08
by O 0 2.032127532913819e-08
regulating O 0 1.9336354739607486e-07
expression O 0 7.728198170298128e-08
of O 0 1.6589853046866665e-08
the O 0 3.1480695383834245e-07
polypeptide O 0 2.4210607080021873e-05
hormone O 0 1.1344042832206469e-05
Mullerian O 0 9.395880624651909e-05
inhibiting O 0 1.788544795999769e-05
substance O 0 5.234427590039559e-06
( O 0 2.8595729872904485e-06
MIS O 0 0.0005923372227698565
) O 0 2.1336986719688866e-06
. O 0 2.9841608011338394e-06

Here O 0 2.1235759049886838e-05
, O 0 1.265850073650654e-06
we O 0 1.2539702254343865e-07
show O 0 6.113537551755144e-07
that O 0 1.4737382514340425e-07
WT1 O 0 0.0002471176558174193
- O 0 0.00015103761688806117
KTS O 0 0.00022424077906180173
isoforms O 0 4.81581810163334e-06
associate O 0 7.557111416645057e-07
and O 0 2.6645770390132384e-07
synergize O 0 8.503144272253849e-06
with O 0 9.043106388162414e-07
SF O 0 0.35621771216392517
- O 0 5.011666871723719e-05
1 O 0 6.457101449086622e-07
to O 0 2.2742743510661967e-07
promote O 0 3.9239484976860695e-06
MIS O 0 0.0014780316269025207
expression O 0 1.4200570149114355e-05
. O 0 6.160097200336168e-06

In O 0 2.7434227376943454e-05
contrast O 0 6.032181408954784e-05
, O 0 6.126159860286862e-06
WT1 O 0 0.002729442436248064
missense O 0 0.005527487024664879
mutations O 0 0.00015508022624999285
, O 0 5.899871666770196e-07
associated O 0 5.043099235990667e-07
with O 0 4.458790670014423e-07
male B-Disease 0 0.0001900360657600686
pseudohermaphroditism I-Disease 1 0.9999872446060181
in O 0 2.851364297384862e-05
Denys B-Disease 1 0.9993342757225037
- I-Disease 1 0.9999866485595703
Drash I-Disease 1 0.9996292591094971
syndrome I-Disease 1 0.9999759197235107
, O 0 1.611402808521234e-06
fail O 0 1.575973669787345e-06
to O 0 1.8200597651230055e-07
synergize O 0 3.355395165272057e-05
with O 0 1.9027493181056343e-06
SF O 1 0.7583410739898682
- O 0 0.0004804300260730088
1 O 0 7.586069386888994e-06
. O 0 4.1154985410685185e-06

Additionally O 0 0.00016591043095104396
, O 0 2.3096931727195624e-06
the O 0 5.979650836707151e-07
X O 0 0.010386068373918533
- O 0 0.003706942778080702
linked O 0 2.8356149414321408e-05
, O 0 1.7504581251159834e-07
candidate O 0 7.674844937355374e-07
dosage O 0 5.096105269331019e-06
- O 0 7.1853710323921405e-06
sensitive O 0 1.9419696855038637e-06
sex O 0 1.189853946925723e-06
- O 0 1.0122650564881042e-05
reversal O 0 4.849752713198541e-06
gene O 0 8.571449257033237e-07
, O 0 1.722731610698247e-07
Dax O 0 0.036462023854255676
- O 0 2.1156158254598267e-05
1 O 0 5.651094738823303e-07
, O 0 1.1537900235225607e-07
antagonizes O 0 4.233219897287199e-06
synergy O 0 1.3024800864513963e-06
between O 0 4.525439862845815e-07
SF O 0 0.0639534592628479
- O 0 0.0001275854738196358
1 O 0 1.3807376717522857e-06
and O 0 4.871492933489208e-07
WT1 O 0 3.7250771129038185e-05
, O 0 1.5263836417034327e-07
most O 0 3.848174046083841e-08
likely O 0 1.0478272116642984e-07
through O 0 1.2127816972906658e-08
a O 0 5.237216171849468e-08
direct O 0 1.04919308796525e-07
interaction O 0 2.3173525676156714e-07
with O 0 4.848346861763275e-07
SF O 1 0.7760738134384155
- O 0 0.00023916386999189854
1 O 0 4.8804304242366925e-06
. O 0 3.995255610789172e-06

We O 0 1.0968823517032433e-05
propose O 0 1.0025723895523697e-05
that O 0 4.964751951774815e-07
WT1 O 0 7.455033482983708e-05
and O 0 3.7457480175362434e-06
Dax O 1 0.8326836824417114
- O 0 0.00030074676033109426
1 O 0 1.2864380778410123e-06
functionally O 0 1.6748462030591327e-06
oppose O 0 2.0095106378903438e-07
each O 0 2.2300639557215618e-08
other O 0 1.909764613117204e-08
in O 0 1.3672175214196614e-07
testis O 0 8.207342943933327e-06
development O 0 1.5870547542817803e-07
by O 0 1.7105057281696645e-07
modulating O 0 2.3932772819534875e-05
SF O 0 0.053375545889139175
- O 0 9.392162610311061e-05
1 O 0 2.082126002278528e-06
- O 0 2.0730494725285098e-05
mediated O 0 4.5356759073911235e-05
transactivation O 0 6.705270789097995e-05
. O 0 1.0210793561782339e-06
. O 0 2.0047609723405913e-06

A O 0 9.535833669360727e-05
mouse O 0 0.00015290765441022813
model O 0 3.0403372875298373e-05
for O 0 1.9332594092702493e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
imprinting O 0 0.012419591657817364
- O 0 0.21729013323783875
centre O 0 0.0003136562299914658
mutations O 0 0.000213991166674532
. O 0 1.0667731658031698e-05

Imprinting O 0 0.0007982817478477955
in O 0 7.304776318051154e-06
the O 0 9.721156857267488e-07
15q11 O 0 2.702058009163011e-05
- O 0 5.9768513892777264e-05
q13 O 0 8.595634426455945e-06
region O 0 4.941949782732991e-07
involves O 0 1.0361807767367281e-07
an O 0 7.028314286117165e-08
imprinting O 0 6.762758130207658e-05
centre O 0 2.8846552595496178e-05
( O 0 8.977783068075951e-07
IC O 0 8.002181857591495e-06
) O 0 6.034566268908748e-08
, O 0 1.9486723346062718e-08
mapping O 0 1.729837038055848e-07
in O 0 2.5898176048144705e-08
part O 0 4.3647627734344496e-08
to O 0 3.019619398969553e-08
the O 0 9.364827491253891e-08
promoter O 0 3.4351330668869196e-06
and O 0 1.2301784124701953e-07
first O 0 1.7016644449086016e-07
exon O 0 4.293343408789951e-06
of O 0 5.916781447012909e-07
SNRPN O 0 0.0006439242861233652
. O 0 6.047649094398366e-06

Deletion O 0 0.0009555325959809124
of O 0 1.8008171309702448e-06
this O 0 7.988311381268431e-07
IC O 0 4.551321399048902e-05
abolishes O 0 3.988079333794303e-05
local O 0 7.883236889938416e-07
paternally O 0 1.9312177755637094e-05
derived O 0 9.60257011684007e-07
gene O 0 1.1144243217131589e-06
expression O 0 5.547317982745881e-07
and O 0 3.49166100477305e-07
results O 0 5.2802533900830895e-06
in O 0 6.107515946496278e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00041604353464208543
PWS B-Disease 1 0.9999970197677612
) O 0 1.65609635587316e-05
. O 0 1.0807020771608222e-05

We O 0 1.7450260202167556e-05
have O 0 6.762970770068932e-07
created O 0 1.339876121164707e-06
two O 0 3.377578821073257e-07
deletion O 0 0.00012407796748448163
mutations O 0 3.0249399060267024e-05
in O 0 6.508006435979041e-07
mice O 0 8.998171688290313e-05
to O 0 1.5070635299707646e-06
understand O 0 7.916213689895812e-06
PWS B-Disease 1 0.9999990463256836
and O 0 1.5184721178229665e-06
the O 0 1.0452203724753417e-07
mechanism O 0 2.44108974811752e-07
of O 0 3.2779162495444325e-08
this O 0 2.096038826948643e-07
IC O 0 3.906130586983636e-05
. O 0 2.412239155091811e-06

Mice O 0 0.33540403842926025
harbouring O 0 0.0005587516934610903
an O 0 2.585092715889914e-06
intragenic O 0 0.00024806734290905297
deletion O 0 6.228739948710427e-05
in O 0 1.890723865471955e-06
Snrpn O 0 9.761128603713587e-05
are O 0 3.2031564956014336e-07
phenotypically O 0 3.241902231820859e-05
normal O 0 1.5178322883002693e-06
, O 0 1.1675764710616932e-07
suggesting O 0 1.011088215818745e-06
that O 0 4.701222877656619e-08
mutations O 0 8.138676435009984e-07
of O 0 4.801468378445861e-08
SNRPN O 0 0.00010314134851796553
are O 0 4.89542166803858e-08
not O 0 3.764928990790395e-08
sufficient O 0 1.777793272594863e-07
to O 0 6.663368026238459e-07
induce O 0 6.883202149765566e-05
PWS B-Disease 1 0.9999384880065918
. O 0 1.1675351743178908e-05

Mice O 0 0.0337725393474102
with O 0 1.4106594790064264e-06
a O 0 1.422716309207317e-06
larger O 0 1.1506082273626816e-06
deletion O 0 1.1252458534727339e-05
involving O 0 7.332019436034898e-07
both O 0 4.788207661476918e-07
Snrpn O 0 9.235963079845533e-05
and O 0 1.520831574453041e-06
the O 0 1.1981503575952956e-06
putative O 0 0.0014650961384177208
PWS O 1 0.9999988079071045
- O 0 0.19797761738300323
IC O 0 0.00011358454503351822
lack O 0 7.208529950730735e-07
expression O 0 2.0149145996128937e-07
of O 0 2.9101665077746475e-08
the O 0 3.1186718274511804e-07
imprinted O 0 4.8213139962172136e-05
genes O 0 4.2795431909326e-06
Zfp127 O 0 2.9417811674647965e-05
( O 0 3.564781820841745e-07
mouse O 0 7.90723515819991e-06
homologue O 0 1.3194254279369488e-05
of O 0 2.800947527248354e-07
ZNF127 O 0 0.0002061645791400224
) O 0 2.776326368802984e-07
, O 0 1.6557616788759333e-07
Ndn O 0 3.733409903361462e-05
and O 0 1.9253934624430258e-07
Ipw O 0 6.107905846874928e-06
, O 0 2.873296409688919e-07
and O 0 3.0651543170279183e-07
manifest O 0 1.4395486687135417e-06
several O 0 2.65968196799804e-07
phenotypes O 0 5.9093079471495e-05
common O 0 4.7089229155972134e-06
to O 0 3.448413553996943e-05
PWS B-Disease 1 1.0
infants O 0 0.2259228527545929
. O 0 1.2791317203664221e-05

These O 0 3.764606390177505e-06
data O 0 1.3225018165030633e-06
demonstrate O 0 9.59726094151847e-07
that O 0 4.2485055473662214e-08
both O 0 4.026864175443734e-08
the O 0 6.754424219934663e-08
position O 0 5.67474955914804e-07
of O 0 1.5617667159517623e-08
the O 0 1.4064575282191072e-07
IC O 0 6.37060384178767e-06
and O 0 7.097503385011805e-08
its O 0 2.8427960430121857e-08
role O 0 4.753818672043053e-08
in O 0 2.5709772089044236e-08
the O 0 2.0519523857842614e-08
coordinate O 0 2.409771298061969e-07
expression O 0 1.1341042949197799e-07
of O 0 9.183639626542117e-09
genes O 0 9.278932822098795e-08
is O 0 2.3644600943839578e-08
conserved O 0 9.572546844083263e-08
between O 0 6.832115673205408e-08
mouse O 0 1.4557173926732503e-05
and O 0 4.2724127524707e-07
human O 0 5.139093772754677e-08
, O 0 4.811314013863921e-08
and O 0 1.36591026489441e-07
indicate O 0 2.7644401257020945e-07
that O 0 1.5870904590542523e-08
the O 0 4.364255090649749e-08
mouse O 0 1.1722267117875163e-05
is O 0 5.351809306830546e-08
a O 0 4.22309653913544e-08
suitable O 0 1.2552600026083383e-07
model O 0 8.463320568807831e-07
system O 0 2.190446224403786e-07
in O 0 5.618691290010247e-08
which O 0 5.941882719184832e-08
to O 0 9.677773249450183e-09
investigate O 0 6.400073715440158e-08
the O 0 4.0104840337562564e-08
molecular O 0 1.2562659890136274e-07
mechanisms O 0 1.332798831299442e-07
of O 0 1.7358649628818057e-08
imprinting O 0 9.033625246956944e-06
in O 0 2.0273856193853135e-07
this O 0 3.69611115047519e-08
region O 0 1.680954397897949e-07
of O 0 1.6454347218086696e-08
the O 0 1.8669884127575642e-07
genome O 0 2.4365642730117543e-06
. O 0 4.460998468402977e-07
. O 0 2.018073473664117e-06

Mutations O 0 0.0009875406976789236
of O 0 1.2323547480264097e-06
the O 0 3.4745141874736873e-07
ATM O 0 1.1782632100221235e-05
gene O 0 4.0193508539232425e-06
detected O 0 2.3290961053135106e-06
in O 0 4.895664460491389e-07
Japanese O 0 0.0003004318568855524
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0015530644450336695
: O 0 2.9452411354213837e-07
possible O 0 2.656589686012012e-07
preponderance O 0 4.378485755296424e-06
of O 0 3.08700904838588e-08
the O 0 1.1219525219985371e-07
two O 0 1.0111161827808246e-06
founder O 0 3.103522249148227e-05
mutations O 0 7.858047865738627e-06
4612del165 O 0 5.031712589698145e-06
and O 0 7.374226811407425e-07
7883del5 O 0 3.8813446735730395e-05
. O 0 4.479240487853531e-06

The O 0 1.8271766748512164e-05
ATM O 0 0.00012501308810897171
( O 0 1.1799465028161649e-05
A O 1 0.9951609969139099
- O 1 0.9999309778213501
T O 1 0.9999992847442627
, O 0 2.7092755772173405e-07
mutated O 0 2.4545036012568744e-06
) O 0 1.4060631770007603e-07
gene O 0 3.806237600656459e-07
on O 0 1.34684023578302e-06
human O 0 5.326387963577872e-06
chromosome O 0 0.00045860614045523107
11q22 O 0 0.00011175373947480693
. O 0 5.065714049123926e-06

3 O 0 0.00022464113135356456
has O 0 6.807348654547241e-06
recently O 0 6.295255388977239e-06
been O 0 7.095898695297365e-07
identified O 0 2.5102957579292706e-07
as O 0 2.952794275756787e-08
the O 0 3.384265312433854e-08
gene O 0 2.2670890587050962e-07
responsible O 0 8.131929263299753e-08
for O 0 1.3064763493275677e-08
the O 0 1.0718551948230015e-06
human O 0 0.00013687691534869373
recessive B-Disease 1 0.9999933242797852
disease I-Disease 1 0.9998881816864014
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0035849374253302813
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 0.9999998807907104
) O 0 4.092751169082476e-06
. O 0 3.066998715439695e-06

In O 0 8.215589332394302e-06
order O 0 4.2335935290793714e-07
to O 0 5.1295849345933675e-08
define O 0 2.0566390901421983e-07
the O 0 5.933660673917984e-08
types O 0 2.100168785545975e-07
of O 0 5.118999979458749e-07
disease O 0 6.36755139566958e-05
- O 0 0.0001154637211584486
causing O 0 8.183154022844974e-06
ATM O 0 1.8236427422380075e-05
mutations O 0 2.7624789709079778e-06
in O 0 8.811296936528379e-08
Japanese O 0 4.626435838872567e-06
A B-Disease 1 0.9999483823776245
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
patients O 0 2.897787453548517e-06
as O 0 7.127008672114243e-08
well O 0 5.550181825242362e-08
as O 0 3.11882004666586e-08
to O 0 1.1769287766583147e-08
look O 0 6.885332481942896e-08
for O 0 1.9730045153210085e-08
possible O 0 9.995691385711325e-08
mutational O 0 1.1368864761607256e-05
hotspots O 0 4.923922006128123e-06
, O 0 1.9158891007009515e-07
reverse O 0 6.6293328018218745e-06
- O 0 8.589889148424845e-06
transcribed O 0 2.992505415022606e-06
RNA O 0 8.583826343055989e-07
derived O 0 8.874951618054183e-08
from O 0 2.787885833299697e-08
ten O 0 1.7186242473599123e-07
patients O 0 3.438429700963752e-07
belonging O 0 5.475140696376002e-08
to O 0 1.8632739795521047e-08
eight O 0 2.183792418009034e-07
unrelated O 0 9.630432487028884e-07
Japanese O 0 3.837777057924541e-06
A B-Disease 1 0.9978629946708679
- I-Disease 1 0.9997168183326721
T I-Disease 1 0.9999995231628418
families O 0 6.348342367346049e-07
was O 0 1.0636944125508307e-06
analyzed O 0 2.5688751748020877e-07
for O 0 5.404349678883591e-08
mutations O 0 6.96441418313043e-07
by O 0 2.2057987436596704e-08
the O 0 5.7654663265793715e-08
restriction O 0 9.034607160174346e-07
endonuclease O 0 1.453222103009466e-05
fingerprinting O 0 5.552930815611035e-06
method O 0 4.896681730315322e-06
. O 0 4.168647592450725e-06

As O 0 4.2145882616750896e-05
has O 0 3.5897512589144753e-06
been O 0 3.9888038827484706e-07
reported O 0 8.532115884918312e-07
by O 0 3.8714080830004605e-08
others O 0 2.918800703355373e-07
, O 0 1.1182692816191775e-07
mutations O 0 8.287665878015105e-07
that O 0 1.6656786172575266e-08
lead O 0 4.2515296172496164e-07
to O 0 9.100087083879771e-08
exon O 0 1.0103862223331816e-05
skipping O 0 9.314907401858363e-06
or O 0 2.4932230644481024e-06
premature O 0 6.178454441396752e-06
protein O 0 7.912317983027606e-07
truncation O 0 1.6063908333308063e-05
were O 0 3.531859647409874e-06
also O 0 2.1129892502358416e-06
predominant O 0 6.028042662364896e-06
in O 0 3.182876469054463e-07
our O 0 9.387098316437914e-07
mutants O 0 4.7189980250550434e-05
. O 0 3.907189693563851e-06

Six O 0 2.5051685952348635e-05
different O 0 1.5470783409909927e-06
mutations O 0 1.0957543054246344e-05
were O 0 5.171572752260545e-07
identified O 0 4.7497675836893904e-07
on O 0 8.859575473252335e-07
12 O 0 2.290162512963434e-07
of O 0 1.0971961117434148e-08
the O 0 1.7706479127355124e-07
16 O 0 1.5562677617708687e-06
alleles O 0 4.317906132200733e-06
examined O 0 1.0525727702770382e-05
. O 0 4.324665042076958e-06

Four O 0 5.6615077483002096e-05
were O 0 2.9121656552888453e-06
deletions O 0 1.341174720437266e-05
involving O 0 1.1507355566209299e-06
a O 0 1.2237209375598468e-05
loss O 0 2.255882282042876e-05
of O 0 1.0112070469858736e-07
a O 0 1.4385591384780128e-06
single O 0 5.592300112766679e-06
exon O 0 2.3668755602557212e-05
exon O 0 3.5304805351188406e-05
7 O 0 4.833979346585693e-06
, O 0 2.622541330765671e-07
exon O 0 7.101895789674018e-06
16 O 0 1.0348826435802039e-06
, O 0 1.5567263744742377e-07
exon O 0 5.338827577361371e-06
33 O 0 4.949207323079463e-06
or O 0 3.948676692289155e-07
exon O 0 2.5570754587533884e-05
35 O 0 7.415210347971879e-06
. O 0 3.212963974874583e-06

The O 0 1.6280284398817457e-05
others O 0 3.5532250421965728e-06
were O 0 5.66692904158117e-07
minute O 0 1.750335741235176e-06
deletions O 0 4.239437203068519e-06
, O 0 1.1910114494639856e-07
4649delA O 0 2.423436171739013e-06
in O 0 8.746929580638607e-08
exon O 0 5.926245194132207e-06
33 O 0 2.1952257611701498e-06
and O 0 1.560176059456353e-07
7883del5 O 0 3.3624653497099644e-06
in O 0 2.642520087192679e-07
exon O 0 3.0626251827925444e-05
55 O 0 1.2983457963855471e-05
. O 0 3.612541149777826e-06

The O 0 2.7592101105256006e-05
mutations O 0 9.477552521275356e-05
4612del165 O 0 2.7206542654312216e-05
and O 0 9.640502867114265e-07
7883del5 O 0 1.1150994396302849e-05
were O 0 3.7196585367382795e-07
found O 0 5.085852450292805e-08
in O 0 1.383693426504351e-08
more O 0 5.821009896322948e-09
than O 0 7.002861401872451e-09
two O 0 3.668935733003309e-08
unrelated O 0 6.966479872971831e-07
families O 0 2.242087617787547e-07
; O 0 2.7618048648037075e-07
44 O 0 5.955157007520029e-07
% O 0 9.173034243303846e-08
( O 0 1.5910151418552232e-08
7 O 0 6.939532681826677e-08
of O 0 8.81556250220683e-09
16 O 0 5.032683247918612e-07
) O 0 9.340118012346466e-09
of O 0 3.965195283228695e-09
the O 0 4.359022298672244e-08
mutant O 0 6.499089067801833e-06
alleles O 0 6.843160917924251e-07
had O 0 1.7150840676549706e-06
one O 0 1.825963380497342e-08
of O 0 1.0663515404019108e-08
the O 0 1.3472626392285747e-07
two O 0 2.176391944885836e-06
mutations O 0 3.782895873882808e-05
. O 0 2.4607898012618534e-06

The O 0 1.973725011339411e-05
4612del165 O 0 0.0002450230240356177
mutations O 0 3.809805275523104e-05
in O 0 1.3502221918315627e-07
three O 0 7.743646790459024e-08
different O 0 4.4386592179535e-08
families O 0 1.6889435983102885e-07
were O 0 2.4084823735393e-07
all O 0 9.792337607450463e-09
ascribed O 0 5.728908263336052e-07
to O 0 3.19502255763382e-08
the O 0 3.9613645697045285e-08
same O 0 1.4564520256499236e-07
T O 0 1.8696837287279777e-05
- O 0 2.130418806700618e-06
- O 0 1.3388900015343097e-06
> O 0 2.6163058919337345e-07
A O 0 1.0387255144905794e-07
substitution O 0 1.3836307743986254e-07
at O 0 5.9235510718735895e-08
the O 0 8.519945282614572e-08
splice O 0 1.1981379429926164e-05
donor O 0 1.144478687820083e-06
site O 0 1.0519217994442442e-06
in O 0 7.566479212073318e-07
intron O 0 0.0003652231825981289
33 O 0 3.28176720358897e-05
. O 0 5.230096576269716e-06

Microsatellite O 0 0.005447447765618563
genotyping O 0 0.00046324319555424154
around O 0 3.812598606600659e-06
the O 0 7.945989750623994e-07
ATM O 0 1.2600310583366081e-05
locus O 0 2.0707850126200356e-05
also O 0 3.895042482326971e-06
indicated O 0 1.376358454763249e-06
that O 0 3.108207735635915e-08
a O 0 4.614128386037919e-07
common O 0 5.656574558088323e-06
haplotype O 0 0.001322950585745275
was O 0 9.250859875464812e-05
shared O 0 1.5257462848694558e-07
by O 0 3.365880374417429e-08
the O 0 1.3366430096084514e-07
mutant O 0 1.1631654160737526e-05
alleles O 0 1.5376834880953538e-06
in O 0 1.650582674983525e-07
both O 0 1.1257503729211749e-06
mutations O 0 3.860646756947972e-05
. O 0 3.3172591429320164e-06

This O 0 3.933247626264347e-06
suggests O 0 1.3883483234167215e-06
that O 0 5.0065356305140085e-08
these O 0 1.8740269780437302e-08
two O 0 2.0713922310733324e-07
founder O 0 7.822418410796672e-05
mutations O 0 2.5598788852221332e-05
may O 0 2.028419430644135e-06
be O 0 7.979283367376411e-08
predominant O 0 1.068784740709816e-06
among O 0 6.975135846687408e-08
Japanese O 0 4.267322708528809e-07
ATM O 0 6.820917860750342e-06
mutant O 0 3.424582246225327e-05
alleles O 0 2.668796878424473e-05
. O 0 6.342512278934009e-06

W474C O 0 0.002872996497899294
amino O 0 0.00019176158821210265
acid O 0 4.1027116822078824e-05
substitution O 0 8.222424185078125e-06
affects O 0 2.3162688194133807e-06
early O 0 3.5950915844296105e-07
processing O 0 1.05297011998573e-07
of O 0 1.7075549862966e-08
the O 0 2.2908828611889476e-08
alpha O 0 1.7573729849118536e-07
- O 0 1.2704732910151506e-07
subunit O 0 7.625847331382829e-08
of O 0 1.2220464640222417e-08
beta O 0 1.6991023699119978e-07
- O 0 2.022308080995572e-06
hexosaminidase O 0 1.7291174572164891e-06
A O 0 4.4281361510911665e-07
and O 0 2.759288122433645e-07
is O 0 1.638589139929536e-07
associated O 0 6.898740139149595e-07
with O 0 2.5179399472108344e-06
subacute O 1 0.9981720447540283
G B-Disease 1 0.9273591637611389
( I-Disease 0 3.108153805442271e-06
M2 I-Disease 0 0.00028014712734147906
) I-Disease 0 2.3482186861656373e-06
gangliosidosis I-Disease 0 5.5367305321851745e-05
. O 0 5.323219284036895e-06

Mutations O 0 0.0018655325984582305
in O 0 2.697806849027984e-06
the O 0 1.1784864000219386e-06
HEXA O 0 0.000339226535288617
gene O 0 2.0917345864290837e-06
, O 0 8.507004167768173e-08
encoding O 0 2.1487328183411591e-07
the O 0 4.131993591727223e-08
alpha O 0 1.4455672214808146e-07
- O 0 2.196030806089766e-07
subunit O 0 9.355883179296143e-08
of O 0 1.8094432618909195e-08
beta O 0 3.1054321425472153e-07
- O 0 5.277021500660339e-06
hexosaminidase O 0 5.791692728962516e-06
A O 0 1.0121078730662703e-06
( O 0 1.4616688304158743e-07
Hex O 0 5.0817975534300786e-06
A O 0 1.3264414064906305e-06
) O 0 9.185271920841842e-08
, O 0 3.039694362882983e-08
that O 0 1.8867881479422977e-08
abolish O 0 5.783098799838626e-07
Hex O 0 4.957421879225876e-06
A O 0 7.162698807405832e-07
enzyme O 0 2.0339596176199848e-06
activity O 0 5.352663720259443e-06
cause O 0 0.001291657448746264
Tay B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
Sachs I-Disease 1 1.0
disease I-Disease 0 0.07085015624761581
( O 0 2.6805219022207893e-06
TSD B-Disease 0 0.0005016964278183877
) O 0 3.105535597569542e-07
, O 0 7.37079659529627e-08
the O 0 4.5306867946237617e-07
fatal O 0 0.00031048202072270215
infantile B-Disease 0 0.015621527098119259
form I-Disease 0 7.785949946992332e-07
of I-Disease 0 2.7761015530813893e-07
G I-Disease 0 0.1342025250196457
( I-Disease 0 1.0272434565194999e-06
M2 I-Disease 0 7.541105151176453e-05
) I-Disease 0 2.2575333957775e-07
gangliosidosis I-Disease 0 5.932816293352516e-06
, I-Disease 0 1.405441167889876e-07
Type I-Disease 0 5.566295158132561e-07
1 I-Disease 0 1.4985532743594376e-06
. O 0 2.691695726753096e-06

Less O 0 0.0006096592987887561
severe O 1 0.8396499752998352
, O 0 1.539486947876867e-05
subacute O 1 0.9137460589408875
( O 0 2.7517076887306757e-05
juvenile O 0 0.13509756326675415
- O 1 0.8155469298362732
onset O 1 0.5103985667228699
) O 0 2.0377067357912892e-06
and O 0 6.7548953666118905e-06
chronic O 0 0.33447644114494324
( O 0 1.2807703342332388e-06
adult O 0 6.821177976235049e-06
- O 0 0.0073899272829294205
onset O 0 0.0005869200685992837
) O 0 1.5307321632462845e-07
variants O 0 6.205992235663871e-07
are O 0 4.061870129135059e-08
characterized O 0 1.2701476634902065e-06
by O 0 2.591715109190318e-08
a O 0 3.6332258446236665e-07
broad O 0 6.698438028251985e-06
spectrum O 0 4.171089585724985e-06
of O 0 4.7405720238202775e-08
clinical O 0 1.3026018450545962e-06
manifestations O 0 2.5700758214952657e-06
and O 0 4.851233370573027e-07
are O 0 2.566503987111446e-08
associated O 0 1.2267807392163377e-07
with O 0 5.044551443234013e-08
residual O 0 1.0868268873309717e-05
levels O 0 2.4672937115610694e-07
of O 0 3.5812458776263156e-08
Hex O 0 1.790714122762438e-05
A O 0 1.798613425307849e-06
enzyme O 0 4.4545249693328515e-06
activity O 0 2.5459642074565636e-06
. O 0 2.2818983325123554e-06

We O 0 1.65767633006908e-05
identified O 0 5.577184310823213e-06
a O 0 2.0409586340974784e-06
1422 O 0 0.0001265631290152669
G O 0 0.0008628757204860449
- O 0 0.00013186846626922488
- O 0 0.0002569579519331455
> O 0 1.3346039850148372e-05
C O 0 7.597066996822832e-06
( O 0 1.1243153608120338e-07
amino O 0 2.6678722520045994e-07
acid O 0 4.2077437001353246e-07
W474C O 0 3.34414949065831e-07
) O 0 1.0726385113457582e-08
substitution O 0 2.5881288223672527e-08
in O 0 1.3634005924245685e-08
the O 0 3.084137034647938e-08
first O 0 2.1811679573602305e-07
position O 0 1.7639482052800304e-07
of O 0 1.7606465618769107e-08
exon O 0 1.803386567189591e-06
13 O 0 4.3208208921896585e-07
of O 0 3.805707038395667e-08
HEXA O 0 4.761794116348028e-05
of O 0 3.251098590340007e-08
a O 0 4.3644882907756255e-07
non O 0 8.147746939357603e-07
- O 0 2.064961699943524e-05
Jewish O 0 2.9141299364709994e-06
proband O 0 3.107881639152765e-05
who O 0 2.2297697341855383e-06
manifested O 0 4.448259460332338e-06
a O 0 2.545199549786048e-06
subacute O 0 0.011330381035804749
variant O 0 0.00020596300601027906
of O 0 2.576982296886854e-06
G B-Disease 0 0.3056303560733795
( I-Disease 0 2.382006186962826e-06
M2 I-Disease 0 0.00033760489895939827
) I-Disease 0 1.9642352526716422e-06
gangliosidosis I-Disease 0 6.504174962174147e-05
. O 0 5.441530447569676e-06

On O 0 4.725153848994523e-05
the O 0 1.6146979078257573e-06
second O 0 3.165778980473988e-05
maternally O 0 0.00035847764229401946
inherited O 0 0.0001779168815119192
allele O 0 1.5266008631442674e-05
, O 0 2.0380359444516216e-07
we O 0 3.138512383316083e-08
identified O 0 3.820150880073925e-07
the O 0 1.9863794875618623e-07
common O 0 1.4604102943849284e-05
infantile O 1 0.986510694026947
disease O 0 0.000622534251306206
- O 0 0.0002555143437348306
causing O 0 7.843987077649217e-06
4 O 0 2.9700331651838496e-06
- O 0 3.295321585028432e-05
bp O 0 7.499370440200437e-06
insertion O 0 2.212181243521627e-06
, O 0 3.358993012625433e-07
+ O 0 6.046743692422751e-06
TATC O 0 2.4550290618208237e-05
1278 O 0 1.9757137124543078e-05
, O 0 9.743082074464837e-08
in O 0 1.8417424030303664e-07
exon O 0 2.6218503990094177e-05
11 O 0 5.6016197049757466e-06
. O 0 4.77122375741601e-06

Pulse O 0 0.007636381778866053
- O 0 0.0006868711207062006
chase O 0 2.433405097690411e-05
analysis O 0 1.8004565163209918e-06
using O 0 6.621154966524045e-07
proband O 0 2.607090209494345e-05
fibroblasts O 0 6.823794137744699e-06
revealed O 0 2.8835681860073237e-06
that O 0 3.089995814775648e-08
the O 0 3.5960169952886645e-08
W474C O 0 1.8502432794775814e-06
- O 0 7.022136969681014e-07
containing O 0 8.878134849510388e-08
alpha O 0 1.7763223070232925e-07
- O 0 3.11983797018911e-07
subunit O 0 2.3698605389199656e-07
precursor O 0 2.2326308624087687e-07
was O 0 8.900920533960743e-07
normally O 0 7.401649781968445e-08
synthesized O 0 3.1546935019832745e-07
, O 0 2.989550296206289e-08
but O 0 1.2640505531180679e-08
not O 0 8.777760740485974e-09
phosphorylated O 0 1.5208418346901453e-07
or O 0 8.093893200111779e-08
secreted O 0 2.683872821762634e-07
, O 0 4.6859771174467824e-08
and O 0 4.322337332496318e-08
the O 0 8.959840158695442e-08
mature O 0 5.767159905190056e-07
lysosomal O 0 3.8565026443393435e-06
alpha O 0 4.7593167096238176e-07
- O 0 1.0648240049704327e-06
subunit O 0 1.3401062233242556e-06
was O 0 4.255409294273704e-06
not O 0 5.056487566434953e-07
detected O 0 1.1899280252691824e-05
. O 0 4.1011317080119625e-06

When O 0 1.2441382750694174e-05
the O 0 7.714074286013783e-07
W474C O 0 9.03011914488161e-06
- O 0 2.668350589374313e-06
containing O 0 3.412403657421237e-07
alpha O 0 4.3306559405209555e-07
- O 0 5.531380224965687e-07
subunit O 0 5.594714593826211e-07
was O 0 1.0704127362259896e-06
transiently O 0 4.60780574940145e-06
co O 0 3.26942972606048e-06
- O 0 7.582575562992133e-06
expressed O 0 5.8118718726518637e-08
with O 0 1.2394834492113205e-08
the O 0 2.7269324576195686e-08
beta O 0 1.313991475626608e-07
- O 0 1.9906957504645106e-07
subunit O 0 1.206260265007586e-07
to O 0 2.257845110875678e-08
produce O 0 8.385824656897967e-08
Hex O 0 5.762965429312317e-06
A O 0 8.239184126068722e-07
( O 0 1.0884733114835399e-07
alphabeta O 0 1.83858867330855e-06
) O 0 5.183482088000346e-08
in O 0 7.386545064491656e-08
COS O 0 0.00019470485858619213
- O 0 1.9011125914403237e-05
7 O 0 1.2911220892419806e-06
cells O 0 1.2188787934519496e-07
, O 0 7.2137544826489375e-09
the O 0 1.1194766891264862e-08
mature O 0 4.7227295851826057e-08
alpha O 0 5.713435058396499e-08
- O 0 7.534703172495938e-08
subunit O 0 7.049473538245365e-08
was O 0 2.8662958584391163e-07
present O 0 2.9470552220800528e-08
, O 0 1.0877069911430226e-08
but O 0 8.541354290514391e-09
its O 0 1.5671616893087048e-08
level O 0 1.1918294973156662e-07
was O 0 1.2222981240483932e-06
much O 0 2.550060074213434e-08
lower O 0 3.36736405870397e-07
than O 0 7.838645288416046e-09
that O 0 3.6521843327363968e-09
from O 0 5.256758583982446e-09
normal O 0 4.243119988700528e-08
alpha O 0 7.884457176032811e-08
- O 0 1.372569897739595e-07
subunit O 0 1.5123173113806843e-07
transfections O 0 1.0515395842958242e-06
, O 0 3.0293918484858295e-08
although O 0 1.7939242979991832e-08
higher O 0 3.8741415409049296e-08
than O 0 5.9436588983885486e-09
in O 0 1.9034370524195765e-08
those O 0 1.8971158866065707e-08
cells O 0 2.5115531343544717e-07
transfected O 0 2.3422669528372353e-06
with O 0 1.911492120143521e-08
an O 0 5.5010900723573286e-08
alpha O 0 3.069554281864839e-07
- O 0 7.999243507583742e-07
subunit O 0 1.3220401342550758e-06
associated O 0 8.054850582084327e-07
with O 0 2.199569962613168e-06
infantile O 0 0.3799194395542145
TSD B-Disease 0 0.012050656601786613
. O 0 2.190227860410232e-05

Furthermore O 0 0.00011441003152867779
, O 0 1.1001801567545044e-06
the O 0 9.870630890418397e-08
precursor O 0 5.260432658360514e-07
level O 0 1.1943998856622784e-07
of O 0 1.5048067680822896e-08
the O 0 4.7734896924112036e-08
W474C O 0 1.0721781791289686e-06
alpha O 0 2.9739737783529563e-07
- O 0 2.977339761400799e-07
subunit O 0 2.3010738914308604e-07
was O 0 4.799252906195761e-07
found O 0 3.290475802941728e-08
to O 0 1.4761486255565615e-08
accumulate O 0 3.642475121523603e-07
in O 0 1.9551837482367773e-08
comparison O 0 3.897458000778897e-08
to O 0 1.0825348617515829e-08
the O 0 2.070974858270347e-08
normal O 0 1.3710145196910162e-07
alpha O 0 2.1451884890666406e-07
- O 0 5.359767101253965e-07
subunit O 0 1.313480765929853e-06
precursor O 0 2.2590525077248458e-06
levels O 0 1.163574211204832e-06
. O 0 1.5953933143464383e-06

We O 0 1.7930571630131453e-05
conclude O 0 3.519513484206982e-06
that O 0 1.0044886522564411e-07
the O 0 2.0006724810173182e-07
1422 O 0 4.040617204736918e-05
G O 0 0.001076041953638196
- O 0 0.00014025003474671394
- O 0 0.00019575531769078225
> O 0 1.2899853572889697e-05
C O 0 1.8140317479264922e-05
mutation O 0 1.2656821581913391e-06
is O 0 3.961235961469356e-08
the O 0 6.362645876833994e-08
cause O 0 7.801246511007776e-07
of O 0 6.932402385473324e-08
Hex B-Disease 0 0.04175847768783569
A I-Disease 0 0.29420942068099976
enzyme I-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999899864196777
in O 0 4.978122092325066e-07
the O 0 1.3160788512323052e-06
proband O 0 0.00036963875754736364
. O 0 8.091120434983168e-06

The O 0 1.0866383490792941e-05
resulting O 0 1.53376877278788e-05
W474C O 0 2.0464492990868166e-05
substitution O 0 3.588505478546722e-06
clearly O 0 2.212550498370547e-06
interferes O 0 1.668708137003705e-06
with O 0 1.74253997897722e-07
alpha O 0 6.571332846760924e-07
- O 0 5.246174055173469e-07
subunit O 0 1.1659564336241601e-07
processing O 0 9.232238795675585e-08
, O 0 1.9000129469759486e-08
but O 0 8.934819106798386e-09
because O 0 6.341768443718365e-09
the O 0 1.015348338739841e-08
base O 0 1.3557810518705082e-07
substitution O 0 1.563376770263858e-07
falls O 0 6.52613744023256e-06
at O 0 3.712481344564367e-08
the O 0 2.2526274179313077e-08
first O 0 1.5798785568676976e-07
position O 0 2.052847349887088e-07
of O 0 3.222575983841125e-08
exon O 0 3.85296652893885e-06
13 O 0 6.368206868501147e-07
, O 0 6.025434373668759e-08
aberrant O 0 8.022062729651225e-07
splicing O 0 4.720613560493803e-06
may O 0 3.396165539015783e-06
also O 0 2.678978319181624e-07
contribute O 0 3.814529492274232e-08
to O 0 5.096485722333455e-08
Hex B-Disease 0 0.0011660774471238256
A I-Disease 0 0.0010080403881147504
deficiency I-Disease 0 0.00011710367107298225
in O 0 5.6608694620763345e-08
this O 0 1.5896449667707202e-07
proband O 0 4.2316281906096265e-05
. O 0 7.226943239402317e-07
. O 0 2.0756035610247636e-06

Two O 0 0.00012012376100756228
frequent O 0 0.0007733716629445553
missense O 0 0.10881444066762924
mutations O 0 0.06934715062379837
in O 0 0.0016453483840450644
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.870773646980524e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.003502701176330447
an O 0 0.09545702487230301
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9972756505012512
by O 0 2.8552853109431453e-05
early O 0 0.013047178275883198
childhood O 1 0.9980055689811707
deafness B-Disease 1 1.0
and O 1 0.9639602899551392
goiter B-Disease 1 1.0
. O 0 0.0001443404908059165

A O 0 7.64452779549174e-05
century O 0 8.394900760322344e-06
after O 0 7.760686457913835e-07
its O 0 9.651527221876677e-08
recognition O 0 2.0259901134522806e-07
as O 0 7.139089461816184e-07
a O 0 0.000819644657894969
syndrome O 1 0.997768759727478
by O 0 2.3425099016094464e-07
Vaughan O 0 2.350213617319241e-05
Pendred O 0 4.101076410734095e-05
, O 0 1.8387167699529527e-07
the O 0 7.402503570119734e-07
disease O 0 3.703806214616634e-05
gene O 0 2.806516704367823e-06
( O 0 1.184045913760201e-06
PDS O 0 7.082145020831376e-05
) O 0 2.024336822614714e-07
was O 0 1.2409025202941848e-06
mapped O 0 5.596952178166248e-06
to O 0 4.612474526766164e-07
chromosome O 0 5.958822293905541e-05
7q22 O 0 4.5109503844287246e-05
- O 0 8.468125452054664e-05
q31 O 0 5.888769737794064e-05
. O 0 4.662241735786665e-06

1 O 0 0.00010015526640927419
and O 0 3.7712902667408343e-06
, O 0 6.48699995053903e-07
recently O 0 1.9803826489805942e-06
, O 0 1.0126720439984638e-07
found O 0 7.016006264848329e-08
to O 0 2.9536053602896573e-08
encode O 0 8.189307436623494e-07
a O 0 1.8331226101508946e-06
putative O 0 0.00012058063293807209
sulfate O 0 9.222461812896654e-05
transporter O 0 0.00038100959500297904
. O 0 8.062489541771356e-06

We O 0 3.4800556022673845e-05
performed O 0 1.0811772881424986e-05
mutation O 0 7.004839972069021e-06
analysis O 0 2.583503260211728e-07
of O 0 3.829108408126558e-08
the O 0 2.0523815180695237e-07
PDS B-Disease 0 8.116824028547853e-05
gene O 0 1.2652816394620459e-06
in O 0 2.7727122642318136e-07
patients O 0 7.911057195997273e-07
from O 0 3.8633604759752416e-08
14 O 0 7.310354135370289e-07
Pendred B-Disease 0 6.085614131734474e-06
families O 0 8.943329987687321e-08
originating O 0 5.597522445555114e-08
from O 0 1.9497209180485697e-08
seven O 0 3.2882734757322396e-08
countries O 0 8.443551635650692e-09
and O 0 7.813078894969294e-08
identified O 0 1.2873757668785402e-06
all O 0 1.4354479560552136e-07
mutations O 0 1.5458452253369614e-05
. O 0 2.98831878353667e-06

The O 0 2.2335871108225547e-05
mutations O 0 4.326883208705112e-05
include O 0 3.0926199201530835e-07
three O 0 3.291342522970808e-07
single O 0 1.977265128516592e-06
base O 0 2.0017805582028814e-06
deletions O 0 5.758455699833576e-06
, O 0 9.091291275353797e-08
one O 0 9.214981133709443e-08
splice O 0 2.785224023682531e-05
site O 0 6.757092251064023e-06
mutation O 0 6.535835836984916e-06
and O 0 8.556666557524295e-07
10 O 0 3.2716379791963845e-06
missense O 0 0.00029193254886195064
mutations O 0 8.212816464947537e-05
. O 0 5.847492047905689e-06

One O 0 0.0001076475455192849
missense O 0 0.0049385735765099525
mutation O 0 0.00017872964963316917
( O 0 2.5207245926139876e-06
L236P O 0 2.0257892174413428e-05
) O 0 5.142663326296315e-07
was O 0 3.7144905036257114e-06
found O 0 1.0947277928607946e-07
in O 0 4.633690053879036e-08
a O 0 6.131649570306763e-07
homozygous O 0 4.576336323225405e-06
state O 0 1.7703211341313363e-08
in O 0 2.7803928048797388e-08
two O 0 1.8831251225037704e-07
consanguineous O 0 1.9543134840205312e-05
families O 0 3.244489334974787e-07
and O 0 1.363202244419881e-07
in O 0 4.4277935984382566e-08
a O 0 1.006964794214582e-06
heterozygous O 0 1.5481010677831364e-06
state O 0 3.79353153334705e-08
in O 0 5.3580187397983536e-08
five O 0 9.138945955555755e-08
additional O 0 2.798605862608383e-07
non O 0 1.0131112730960012e-06
- O 0 4.542779424809851e-05
consanguineous O 0 8.059633546508849e-05
families O 0 1.8868475990529987e-06
. O 0 3.1483987186220475e-06

Another O 0 0.0001714251993689686
missense O 0 0.005947939120233059
mutation O 0 0.00017187578487209976
( O 0 1.7495248130217078e-06
T416P O 0 2.0779323676833883e-05
) O 0 5.242438305685937e-07
was O 0 3.2082853067549877e-06
found O 0 1.216161678030403e-07
in O 0 5.4163610485602476e-08
a O 0 1.8126075929103536e-06
homozygous O 0 8.853977305989247e-06
state O 0 2.7118286283212e-08
in O 0 2.470768656337441e-08
one O 0 9.95129241232462e-08
family O 0 2.7201022589906643e-07
and O 0 1.1459516002787495e-07
in O 0 2.934810083843331e-08
a O 0 2.7847298156302713e-07
heterozygous O 0 1.0415321867185412e-06
state O 0 4.1286455143563217e-08
in O 0 1.0817736750823315e-07
four O 0 7.247849680425134e-07
families O 0 1.0321564332116395e-06
. O 0 2.7993637559120543e-06

Pendred B-Disease 0 0.291291207075119
patients O 0 0.000597909209318459
in O 0 7.415540039801272e-07
three O 0 6.007435331412125e-07
non O 0 1.160017632173549e-06
- O 0 4.901916327071376e-05
consanguineous O 0 4.892184733762406e-05
families O 0 1.0841537232408882e-06
were O 0 5.144498231857142e-07
shown O 0 1.742390338677069e-07
to O 0 2.0433208902659317e-08
be O 0 3.2530959259702286e-08
compound O 0 1.54592783019325e-06
heterozygotes O 0 3.930922957806615e-06
for O 0 1.6307849648455885e-07
L236P O 0 1.1460741916380357e-05
and O 0 1.0043734164355556e-06
T416P O 0 3.4799955756170675e-05
. O 0 3.50884988620237e-06

In O 0 1.2739041267195717e-05
total O 0 3.028906576219015e-06
, O 0 2.715530058594595e-07
one O 0 7.507991028887773e-08
or O 0 9.806807810264218e-08
both O 0 2.2070571148447016e-08
of O 0 1.7248449779572184e-08
these O 0 7.694882953046545e-08
mutations O 0 1.347068973700516e-06
were O 0 3.422539691655402e-07
found O 0 5.379266809768524e-08
in O 0 3.442677964926588e-08
nine O 0 1.2740355259666103e-07
of O 0 1.7865284362983402e-08
the O 0 1.7316097000730224e-07
14 O 0 1.277329261029081e-06
families O 0 3.2668754101905506e-07
analyzed O 0 3.7535187402681913e-06
. O 0 1.591442355675099e-06

The O 0 4.432510650076438e-06
identification O 0 1.634546606510412e-06
of O 0 1.21057723845297e-07
two O 0 6.169618700369028e-07
frequent O 0 3.266199928475544e-05
PDS B-Disease 0 0.05616212263703346
mutations O 0 1.0199999451288022e-05
will O 0 4.554070187623438e-08
facilitate O 0 1.5184302526449756e-07
the O 0 2.0230437769441778e-07
molecular O 0 1.602898737473879e-05
diagnosis O 0 0.05242481082677841
of O 0 0.0005508945323526859
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.160216874675825e-05

Insertional O 0 0.033121854066848755
mutation O 0 0.00043679712689481676
by O 0 3.0546657399099786e-06
transposable O 0 0.0001446482929168269
element O 0 1.1137763067381456e-05
, O 0 1.1829612276414991e-06
L1 O 0 0.0004303682944737375
, O 0 3.048479868539289e-07
in O 0 1.35850939386728e-07
the O 0 1.8393673144601053e-06
DMD B-Disease 1 0.9999942779541016
gene O 0 7.486036338377744e-06
results O 0 1.252744254998106e-06
in O 0 1.7056414662874886e-06
X B-Disease 1 0.9958569407463074
- I-Disease 1 0.9997853636741638
linked I-Disease 1 0.9716459512710571
dilated I-Disease 1 0.9991439580917358
cardiomyopathy I-Disease 1 1.0
. O 0 8.212119428208098e-05

X B-Disease 1 0.9990507960319519
- I-Disease 1 0.9999535083770752
linked I-Disease 1 0.9971576929092407
dilated I-Disease 1 0.9999713897705078
cardiomyopathy I-Disease 1 1.0
( O 0 0.00023769169638399035
XLDCM B-Disease 0 0.0061094388365745544
) O 0 7.547259315288102e-07
is O 0 1.6596032992310938e-07
a O 0 1.2037061196679133e-06
clinical O 0 4.4640742999035865e-05
phenotype O 0 0.00039501371793448925
of O 0 2.1612959244521335e-07
dystrophinopathy B-Disease 0 0.0018774960190057755
which O 0 1.5359643157353275e-06
is O 0 1.645743026301716e-07
characterized O 0 2.6452835300005972e-06
by O 0 2.6302757305529667e-07
preferential O 0 7.097460638760822e-06
myocardial B-Disease 1 0.8949135541915894
involvement I-Disease 0 3.0395290195883717e-06
without O 0 1.6692638382664882e-07
any O 0 1.1644218034234655e-07
overt O 0 5.851781679666601e-06
clinical O 0 2.7406065782997757e-05
signs O 0 2.787642188195605e-05
of O 0 1.2722966857836582e-05
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0003965353243984282

To O 0 5.658705958921928e-06
date O 0 2.009312538575614e-06
, O 0 1.962971651892076e-07
several O 0 2.086489843122763e-07
mutations O 0 4.810406608157791e-06
in O 0 3.1474002071263385e-07
the O 0 1.2961535503563937e-05
Duchenne B-Disease 1 0.9999936819076538
muscular I-Disease 1 0.9996610879898071
dystrophy I-Disease 1 0.9992027878761292
gene O 0 4.613931741914712e-05
, O 0 1.2478789358283393e-05
DMD O 1 1.0
, O 0 4.52503991255071e-06
have O 0 6.541532684423146e-07
been O 0 6.78869582770858e-07
identified O 0 7.640812782483408e-07
in O 0 2.6025296051557234e-07
patients O 0 3.877320580158994e-07
with O 0 1.7451776557209087e-07
XLDCM B-Disease 0 0.0028253141790628433
, O 0 1.2919014125145623e-07
but O 0 2.1571688435528813e-08
a O 0 7.258267231691207e-08
pathogenic O 0 2.8092190973438846e-07
correlation O 0 1.599613455027793e-07
of O 0 1.7621752945728986e-08
these O 0 8.656888184077616e-08
cardiospecific O 0 0.0003052706306334585
mutations O 0 2.4878741896827705e-05
in O 0 1.553845891066885e-06
DMD O 1 0.9999994039535522
with O 0 1.070699681804399e-06
the O 0 7.050870863167802e-06
XLDCM B-Disease 1 0.5636694431304932
phenotype O 0 0.022007158026099205
has O 0 3.5751286304730456e-06
remained O 0 3.2288505735778017e-06
to O 0 1.4164425010676496e-07
be O 0 3.5662100117406226e-07
elucidated O 0 7.793350232532248e-05
. O 0 5.667216555593768e-06

We O 0 4.573881233227439e-05
report O 0 1.6184258129214868e-06
here O 0 7.32758138610734e-08
the O 0 3.694962202871466e-08
identification O 0 1.056754683759209e-07
of O 0 1.920786019127263e-08
a O 0 5.177070079298574e-07
unique O 0 5.414707402451313e-07
de O 0 5.814305040985346e-06
novo O 0 4.783912572747795e-06
L1 O 0 8.7337593868142e-06
insertion O 0 1.4980131481934222e-06
in O 0 4.981322376806929e-08
the O 0 1.968548843933604e-07
muscle O 0 4.77490175398998e-06
exon O 0 5.166247319721151e-06
1 O 0 1.1922812745979172e-06
in O 0 1.4441302482737228e-06
DMD O 1 0.9999990463256836
in O 0 1.8876179410654004e-06
three O 0 4.553411599772517e-06
XLDCM B-Disease 0 0.2835797965526581
patients O 0 3.541283376762294e-06
from O 0 3.9580562827268295e-08
two O 0 1.9944012308314996e-07
unrelated O 0 4.745819296658738e-06
Japanese O 0 2.771794470390887e-06
families O 0 1.9420567696215585e-06
. O 0 2.4088897134788567e-06

The O 0 1.0654768630047329e-05
insertion O 0 3.057829962926917e-05
was O 0 4.719128810393158e-06
a O 0 4.892313540949544e-07
5 O 0 8.847003982737078e-07
- O 0 3.7167867503740126e-06
truncated O 0 1.6307303667417727e-06
form O 0 8.834165043936082e-08
of O 0 2.313267266629282e-08
human O 0 2.998567936174368e-07
L1 O 0 7.76701926952228e-05
inversely O 0 8.607118616055232e-06
integrated O 0 8.699018962943228e-07
in O 0 9.42960411975946e-08
the O 0 1.59274364364137e-07
5 O 0 1.1761218274841667e-06
- O 0 1.4117661521595437e-05
untranslated O 0 2.086862878059037e-05
region O 0 8.920840173232136e-07
in O 0 8.317740451957434e-08
the O 0 2.055121655075709e-07
muscle O 0 3.8922503335925285e-06
exon O 0 2.5913918761943933e-06
1 O 0 5.128684961164254e-07
, O 0 7.293962056564851e-08
which O 0 8.489092806485132e-08
affected O 0 2.595707293551186e-08
the O 0 2.1612047262919987e-08
transcription O 0 5.556473183787602e-07
or O 0 1.4482276355920476e-07
the O 0 7.140874203059866e-08
stability O 0 4.2505726582930947e-07
of O 0 2.513605856790946e-08
the O 0 3.2302656904903415e-07
muscle O 0 7.730041033937596e-06
form O 0 8.8763229655342e-08
of O 0 3.471777887398275e-08
dystrophin O 0 4.686290594690945e-06
transcripts O 0 1.1948321798627148e-06
but O 0 1.8914531096925202e-07
not O 0 1.823874917761259e-08
that O 0 4.430984912318081e-09
of O 0 1.1701912328021535e-08
the O 0 3.994300641352311e-07
brain O 0 4.624238863470964e-05
or O 0 7.886244475230342e-07
Purkinje O 0 0.0005309701664373279
cell O 0 1.4577387446479406e-05
form O 0 3.5758955618803157e-07
, O 0 3.2293877438860363e-07
probably O 0 3.656152500752796e-07
due O 0 8.486357216952456e-08
to O 0 2.7509791777902137e-08
its O 0 6.788495454657095e-08
unique O 0 9.356971730767327e-08
site O 0 3.144168942981196e-07
of O 0 6.979261968353967e-08
integration O 0 3.2369839573220816e-06
. O 0 4.318466380937025e-06

We O 0 9.975205102819018e-06
speculate O 0 3.0374744710570667e-06
that O 0 4.808965314850866e-08
this O 0 2.444224733721967e-08
insertion O 0 5.112628400638641e-07
of O 0 3.90157843810357e-08
an O 0 8.617926994247682e-08
L1 O 0 0.0001999699743464589
sequence O 0 1.3049841527390527e-06
in O 0 2.024027253355598e-06
DMD O 1 0.9999998807907104
is O 0 1.6595794249951723e-06
responsible O 0 1.0339972078554638e-07
for O 0 1.4847752360935829e-08
some O 0 7.058956530414662e-09
of O 0 4.304301803870203e-09
the O 0 5.1683080926068214e-08
population O 0 2.7800801660760044e-08
of O 0 1.1209210448726026e-08
Japanese O 0 1.1190774102942669e-06
patients O 0 4.0711159954298637e-07
with O 0 1.2396422732763313e-07
XLDCM B-Disease 0 0.00015958913718350232
. O 0 5.713924906558532e-07
. O 0 1.8697732002692646e-06

Severe O 1 0.9842915534973145
early O 0 0.00045239971950650215
- O 1 0.9231056571006775
onset O 1 0.9991023540496826
obesity B-Disease 1 1.0
, O 0 0.04071388021111488
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.001491119503043592
red O 0 0.09130699187517166
hair O 1 0.9996362924575806
pigmentation O 1 0.9959762692451477
caused O 0 0.00015597535821143538
by O 0 1.939724370458862e-06
POMC O 0 0.1796007752418518
mutations O 0 6.336385558824986e-05
in O 0 1.1580754062379128e-06
humans O 0 3.435342705415678e-06
. O 0 3.4913855415652506e-06

Sequential O 0 0.00027913134545087814
cleavage O 0 0.0003628286358434707
of O 0 7.112796538422117e-07
the O 0 2.6843181899494084e-07
precursor O 0 1.1247501561229e-06
protein O 0 5.664443278874387e-07
pre O 0 2.6639570478437236e-06
- O 0 2.4046383259701543e-05
pro O 0 8.541879651602358e-06
- O 0 0.00014192642993293703
opiomelanocortin O 0 0.00014079526590649039
( O 0 1.2470762840166572e-06
POMC O 0 3.925249620806426e-05
) O 0 2.1996380894506729e-07
generates O 0 3.1940786016093625e-07
the O 0 2.20059277467044e-07
melanocortin O 0 6.252591992961243e-05
peptides O 0 1.159132534667151e-05
adrenocorticotrophin O 0 0.00010255624511046335
( O 0 1.0961554153254838e-06
ACTH O 0 6.860443681944162e-05
) O 0 1.581437203412861e-07
, O 0 1.4839660877896677e-07
melanocyte O 0 4.546779746306129e-05
- O 0 4.743890531244688e-05
stimulating O 0 9.20415641303407e-06
hormones O 0 7.190258656919468e-06
( O 0 4.827363682124997e-07
MSH O 0 1.5104942576726899e-05
) O 0 8.996487110835005e-08
alpha O 0 1.48697083091065e-07
, O 0 1.7555798592638894e-08
beta O 0 6.108378869384978e-08
and O 0 2.120110842440681e-08
gamma O 0 1.1307563596574255e-07
as O 0 1.5714268997157887e-08
well O 0 1.8640950116832755e-08
as O 0 2.3178472474683076e-08
the O 0 6.247906014777982e-08
opioid O 0 2.866519025701564e-06
- O 0 2.668974275366054e-06
receptor O 0 2.2858232568978565e-06
ligand O 0 4.066474048158852e-06
beta O 0 6.376742931024637e-06
- O 0 5.570465873461217e-05
endorphin O 0 0.00050894491141662
. O 0 1.0424174433865119e-05

While O 0 1.692406294750981e-05
a O 0 1.765755428095872e-06
few O 0 7.033330007288896e-07
cases O 0 2.144562500916436e-07
of O 0 3.0512137527693994e-07
isolated O 0 0.06090439856052399
ACTH B-Disease 1 0.9999643564224243
deficiency I-Disease 1 0.5412599444389343
have O 0 6.677898340967658e-07
been O 0 1.0007915989262983e-06
reported O 0 1.0106011359312106e-05
( O 0 1.313296593252744e-06
OMIM O 0 0.00042173085967078805
201400 O 0 8.435733434453141e-06
) O 0 7.732710116670205e-08
, O 0 4.625671934377351e-08
an O 0 2.123352942362544e-07
inherited O 0 0.0019951569847762585
POMC O 0 0.3189115822315216
defect O 0 0.00021154095884412527
has O 0 1.2741538739646785e-06
not O 0 6.12112671660725e-08
been O 0 5.05604361933365e-07
described O 0 1.933537305376376e-06
so O 0 1.938193889827744e-07
far O 0 6.030068675499933e-07
. O 0 1.138655193244631e-06

Recent O 0 5.702258931705728e-05
studies O 0 3.3745729979273165e-06
in O 0 2.7609411290541175e-07
animal O 0 1.3462675951814163e-06
models O 0 1.4609972822654527e-06
elucidated O 0 5.0277649279451e-06
a O 0 3.81380260705555e-07
central O 0 1.0093840785430075e-07
role O 0 7.628581499830034e-08
of O 0 4.0805218759487616e-08
alpha O 0 7.458597792719956e-07
- O 0 1.127892937802244e-05
MSH O 0 1.2276143934286665e-05
in O 0 1.7105442395859427e-08
the O 0 2.885152206033581e-08
regulation O 0 2.1049088161362306e-07
of O 0 1.3657690978163828e-08
food O 0 1.1823493650808814e-07
intake O 0 6.673403163404146e-07
by O 0 1.3146001620611969e-08
activation O 0 1.7206167512995307e-07
of O 0 2.2439349933733865e-08
the O 0 2.936389762453473e-07
brain O 0 1.209409128932748e-05
melanocortin O 0 1.712828998279292e-05
- O 0 1.630528458917979e-05
4 O 0 1.5996439515220118e-06
- O 0 5.401759608503198e-06
receptor O 0 2.709859018068528e-06
( O 0 2.6324087798457185e-07
MC4 O 0 2.504862641217187e-05
- O 0 2.1406491214293055e-05
R O 0 8.212675311369821e-05
; O 0 1.7501695026567177e-07
refs O 0 1.004655018732592e-06
3 O 0 9.869949053609162e-07
- O 0 7.3527489803382196e-06
5 O 0 5.261265414446825e-07
) O 0 4.1064826206138605e-08
and O 0 2.779412078268706e-08
the O 0 4.8418041131981226e-08
linkage O 0 1.5720498822702211e-06
of O 0 4.160638056305288e-08
human O 0 4.800795636583643e-07
obesity B-Disease 1 0.9935682415962219
to O 0 4.747625723666715e-07
chromosome O 0 3.33362040692009e-05
2 O 0 3.2567035646025033e-07
in O 0 2.5939604242353198e-08
close O 0 1.1155552215313946e-07
proximity O 0 9.861541627742554e-08
to O 0 4.979166590146633e-08
the O 0 3.4961593087246e-07
POMC O 0 0.00014160849968902767
locus O 0 5.3699404816143215e-06
, O 0 1.2063270560247474e-07
led O 0 1.1228216578729189e-07
to O 0 1.835370078140386e-08
the O 0 4.192134639424694e-08
proposal O 0 1.6325869012234762e-07
of O 0 7.5521375819676e-09
an O 0 3.780674262543471e-08
association O 0 1.276059009569508e-07
of O 0 8.556620656463565e-08
POMC O 0 0.00015389954205602407
with O 0 8.921971925701655e-07
human O 0 1.1679517228913028e-05
obesity B-Disease 1 0.9999874830245972
. O 0 1.3741466318606399e-05

The O 0 3.9805076994525734e-06
dual O 0 6.4621867750247475e-06
role O 0 1.6647502434352646e-06
of O 0 2.0176335624455533e-07
alpha O 0 4.133817128604278e-06
- O 0 6.693745672237128e-05
MSH O 0 5.5329404858639464e-05
in O 0 1.0917126047615966e-07
regulating O 0 3.614611614466412e-07
food O 0 2.616478127492883e-07
intake O 0 1.214719077324844e-06
and O 0 1.667996940568628e-07
influencing O 0 2.568201580288587e-06
hair O 0 0.03871418535709381
pigmentation O 0 0.007697868626564741
predicts O 0 1.8051423467113636e-05
that O 0 4.854657831288023e-08
the O 0 4.799014732270734e-07
phenotype O 0 0.0021688733249902725
associated O 0 2.8458239853534906e-07
with O 0 1.1248172171463011e-07
a O 0 2.0210731236147694e-05
defect O 0 0.00015649573470000178
in O 0 1.1754277693398762e-06
POMC O 0 0.00029253296088427305
function O 0 6.558779546139704e-07
would O 0 3.807914765729947e-07
include O 0 6.592379122594139e-07
obesity B-Disease 1 0.9999823570251465
, O 0 9.078266316464578e-07
alteration O 0 2.0376315660541877e-05
in O 0 5.448343472380657e-06
pigmentation O 1 0.9815424084663391
and O 0 0.06686177849769592
ACTH B-Disease 1 0.9999852180480957
deficiency I-Disease 1 0.8060773015022278
. O 0 7.84257281338796e-06

The O 0 5.4030683713790495e-06
observation O 0 7.122263923520222e-06
of O 0 2.1794897975269123e-07
these O 0 6.155278811093012e-07
symptoms O 0 3.369295154698193e-05
in O 0 6.336438929110955e-08
two O 0 2.802195240292349e-07
probands O 0 3.855900285998359e-05
prompted O 0 6.369707534759073e-07
us O 0 4.125693564560606e-08
to O 0 1.5572990008649867e-08
search O 0 1.2234019663992513e-07
for O 0 1.0866437349932312e-07
mutations O 0 1.7950491155716009e-06
within O 0 1.0153313212413195e-07
their O 0 5.851000537404616e-07
POMC O 0 0.0006750542088411748
genes O 0 1.4248889783630148e-05
. O 0 5.244371095614042e-06

Patient O 0 0.010885335505008698
1 O 0 4.690897185355425e-05
was O 0 7.0549735937674996e-06
found O 0 1.481319173990414e-07
to O 0 2.4911969376262277e-08
be O 0 2.086811612400652e-08
a O 0 1.1785083131599094e-07
compound O 0 1.396019570165663e-06
heterozygote O 0 5.105512627778808e-06
for O 0 3.7156127064008615e-08
two O 0 3.324231272472389e-07
mutations O 0 1.7306368818026385e-06
in O 0 5.1384471788651354e-08
exon O 0 8.126196917146444e-06
3 O 0 3.883970293827588e-06
( O 0 2.480219620792923e-07
G7013T O 0 1.9849944692396093e-06
, O 0 8.563183939713781e-08
C7133delta O 0 1.0083225788548589e-05
) O 0 5.5246751173854136e-08
which O 0 2.6731230562404562e-08
interfere O 0 1.0187862642396794e-07
with O 0 3.024294059628119e-08
appropriate O 0 1.1809813571517225e-07
synthesis O 0 4.808424591828953e-07
of O 0 1.4166451478558884e-07
ACTH O 0 0.00010373345867265016
and O 0 5.170832650946977e-07
alpha O 0 4.241147962602554e-06
- O 0 4.178466770099476e-05
MSH O 0 0.0002916796365752816
. O 0 3.7002346289227717e-06

Patient O 0 0.0034217576030641794
2 O 0 9.811062773223966e-05
was O 0 3.469329385552555e-05
homozygous O 0 7.767225724819582e-06
for O 0 8.097275383533997e-08
a O 0 1.0362574585087714e-06
mutation O 0 3.541715614119312e-06
in O 0 2.235417753126967e-07
exon O 0 2.2747892217012122e-05
2 O 0 1.765679735399317e-05
( O 0 1.0067909670397057e-06
C3804A O 0 1.2460892321541905e-05
) O 0 4.972281431037118e-07
which O 0 1.0924225080088945e-06
abolishes O 0 0.0003014201938640326
POMC O 0 0.0009452488156966865
translation O 0 3.3434458600822836e-05
. O 0 1.2748058907163795e-05

These O 0 4.787641955772415e-06
findings O 0 2.4158330234058667e-06
represent O 0 1.8731412865236052e-07
the O 0 5.2204214284756745e-08
first O 0 2.893618216148752e-07
examples O 0 1.6257507695627282e-07
of O 0 5.939310554481381e-08
a O 0 0.00014394520258065313
genetic B-Disease 1 0.9999994039535522
defect I-Disease 1 0.9995811581611633
within O 0 2.335775235451365e-07
the O 0 4.109601832169574e-07
POMC O 0 0.0002279995969729498
gene O 0 8.053721671785752e-07
and O 0 1.0534261463135408e-07
define O 0 5.690828857041197e-07
a O 0 6.708089017593011e-07
new O 0 1.4770626876270398e-05
monogenic B-Disease 1 0.9022510647773743
endocrine I-Disease 1 0.9489143490791321
disorder I-Disease 0 0.031023291870951653
resulting O 0 5.6886156016844325e-06
in O 0 4.942293685417098e-07
early O 0 1.9796367269009352e-05
- O 1 0.5716258883476257
onset O 1 0.988203227519989
obesity B-Disease 1 1.0
, O 0 0.011986850760877132
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.003548901993781328
red O 0 0.04691936448216438
hair O 1 0.9578870534896851
pigmentation O 0 0.3428710401058197
. O 0 2.6978118512488436e-06
. O 0 5.818998033646494e-06

A O 0 9.375286754220724e-05
European O 0 2.7209347535972483e-05
multicenter O 0 0.0006601117202080786
study O 0 8.086167326837312e-06
of O 0 1.7158814443973824e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.004588388146658e-07
classification O 0 1.3060150649835123e-06
of O 0 8.602194156992482e-08
105 O 0 6.888602456456283e-06
mutations O 0 4.262383299646899e-06
and O 0 8.666900441767211e-08
a O 0 2.1845464459602226e-07
general O 0 1.1550627476708542e-07
system O 0 2.2009410827195097e-07
for O 0 7.342634944507154e-08
genotype O 0 1.824171340558678e-05
- O 0 1.5109639207366854e-05
based O 0 1.3702383512281813e-06
prediction O 0 5.363773198041599e-06
of O 0 6.637123988184612e-07
metabolic O 1 0.5191593766212463
phenotype O 0 0.0065602329559624195
. O 0 1.256081486644689e-05

Phenylketonuria B-Disease 1 0.9997221827507019
( O 0 0.00111684063449502
PKU B-Disease 0 0.05974351987242699
) O 0 9.26697157410672e-06
and O 0 2.4943004973465577e-05
mild B-Disease 1 0.9997410178184509
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.1675887554883957
MHP B-Disease 1 1.0
) O 0 3.186100229868316e-06
are O 0 1.4443975260292063e-06
allelic B-Disease 1 0.5187452435493469
disorders I-Disease 1 0.9997697472572327
caused O 0 4.968770736013539e-05
by O 0 9.023172538036306e-07
mutations O 0 3.7792292459926102e-06
in O 0 1.3971609291729692e-07
the O 0 6.868981472507585e-07
gene O 0 7.430685855069896e-06
encoding O 0 7.717363041592762e-05
phenylalanine O 0 0.02671956643462181
hydroxylase O 1 0.6879453659057617
( O 0 4.396594886202365e-05
PAH O 0 0.003249978646636009
) O 0 3.6686881230707513e-06
. O 0 3.2656935218255967e-06

Previous O 0 0.00014618283603340387
studies O 0 3.3574858662177576e-06
have O 0 2.8725730771839153e-07
suggested O 0 5.112091798764595e-07
that O 0 4.082732729671079e-08
the O 0 8.462741618586733e-08
highly O 0 2.1263895177980885e-06
variable O 0 3.3886099117808044e-05
metabolic O 0 0.1387537121772766
phenotypes O 0 0.0025042349006980658
of O 0 0.00013467147073242813
PAH B-Disease 1 0.9999935626983643
deficiency I-Disease 1 0.8765396475791931
correlate O 0 0.0001871619315352291
with O 0 9.851693903328851e-05
PAH O 1 0.9949299693107605
genotypes O 0 0.004147043451666832
. O 0 3.382952490937896e-05

We O 0 1.934187275764998e-05
identified O 0 8.915209946280811e-06
both O 0 5.431661520560738e-07
causative O 0 6.313207268249243e-05
mutations O 0 5.693906859960407e-05
in O 0 6.387811026797863e-07
686 O 0 0.0002207919314969331
patients O 0 1.0404826753074303e-05
from O 0 1.3275762000830582e-07
seven O 0 2.3548605554424284e-07
European O 0 4.121863810269133e-07
centers O 0 1.982171852432657e-06
. O 0 1.9860549400618766e-06

On O 0 1.9673001588671468e-05
the O 0 2.4072653559414903e-07
basis O 0 1.0957576535020053e-07
of O 0 1.5318779134076976e-08
the O 0 1.1570703861707443e-07
phenotypic O 0 8.953876204031985e-06
characteristics O 0 1.1840177194244461e-06
of O 0 1.2955213435361657e-07
297 O 0 9.461044101044536e-06
functionally O 0 4.228227408020757e-05
hemizygous O 0 0.00020232785027474165
patients O 0 7.192775228759274e-06
, O 0 6.552134124149234e-08
105 O 0 2.2500472596220789e-07
of O 0 1.5643752959704216e-08
the O 0 2.389322446560982e-07
mutations O 0 1.636157662687765e-06
were O 0 1.7346675917906396e-07
assigned O 0 1.0372090031296466e-07
to O 0 3.115383506724356e-08
one O 0 2.036069268740448e-08
of O 0 1.1355323792372474e-08
four O 0 2.350642347437315e-07
arbitrary O 0 3.6164725315757096e-05
phenotype O 0 0.003508469322696328
categories O 0 6.550112630065996e-06
. O 0 4.014983460365329e-06

We O 0 1.4398574421647936e-05
proposed O 0 2.4385496999457246e-06
and O 0 1.1280652643108624e-06
tested O 0 9.772802513907664e-07
a O 0 1.1374642383543687e-07
simple O 0 1.0324718857646076e-07
model O 0 2.680516786313092e-07
for O 0 4.036060374801309e-08
correlation O 0 6.987399387980986e-07
between O 0 3.851060057513678e-07
genotype O 0 2.174547807953786e-05
and O 0 4.458845808130718e-07
phenotypic O 0 1.948724820977077e-05
outcome O 0 1.192530726257246e-05
. O 0 8.79167146194959e-06

The O 0 1.7734626453602687e-05
observed O 0 3.938981535611674e-05
phenotype O 0 0.00039151552482508123
matched O 0 2.098735967592802e-05
the O 0 4.995328026780044e-07
predicted O 0 4.874618389294483e-05
phenotype O 0 7.947661651996896e-05
in O 0 3.2402220995209063e-07
79 O 0 1.1700086361088324e-05
% O 0 1.4839746143024968e-07
of O 0 7.351277808709256e-09
the O 0 7.786315592284154e-08
cases O 0 2.5371170409016486e-07
, O 0 9.277783163952336e-08
and O 0 6.50608242835915e-08
in O 0 1.8916670896373944e-08
only O 0 1.5896898020173467e-08
5 O 0 2.8913111904671496e-08
of O 0 1.0846367359818032e-08
184 O 0 9.506985065854678e-07
patients O 0 5.820119213240105e-07
was O 0 1.2436321412678808e-06
the O 0 1.6982794193154405e-07
observed O 0 2.4601702079962706e-06
phenotype O 0 3.904865025106119e-06
more O 0 5.599516406107341e-09
than O 0 1.3448358870959964e-08
one O 0 2.0934773914405014e-08
category O 0 2.2745170724647323e-07
away O 0 1.1200709337799708e-07
from O 0 2.4554577038315983e-08
that O 0 6.063699231617647e-08
expected O 0 9.878763194137719e-07
. O 0 1.7454517546866555e-06

Among O 0 2.4036684408201836e-05
the O 0 5.94590687796881e-07
seven O 0 3.86868890700498e-07
contributing O 0 2.703947643567517e-07
centers O 0 1.2112101899219851e-07
, O 0 4.153105592763495e-08
the O 0 2.897947481983465e-08
proportion O 0 1.445025503699071e-07
of O 0 3.115764002359356e-08
patients O 0 3.315606988962827e-07
for O 0 4.0537742052038084e-08
whom O 0 4.2477765305193316e-07
the O 0 8.661876194082652e-08
observed O 0 4.155129317950923e-06
phenotype O 0 2.4863917133188806e-05
did O 0 1.8750215247109736e-07
not O 0 4.109146445330225e-08
match O 0 1.5571777112199925e-07
the O 0 1.8896987796779285e-07
predicted O 0 6.755306094419211e-05
phenotype O 0 7.396478031296283e-05
was O 0 1.9829924440273317e-06
4 O 0 8.563703772779263e-07
% O 0 1.6489983067913272e-07
- O 0 5.685893029294675e-06
23 O 0 1.4819255511611118e-06
% O 0 2.1957627893698373e-07
( O 0 1.0160093921740554e-07
P O 0 8.104047083179466e-06
< O 0 8.772648811827821e-07
. O 0 4.402975051220892e-08
0001 O 0 1.8527258589529083e-06
) O 0 3.8517502076729215e-08
, O 0 2.3721616670968615e-08
suggesting O 0 7.327986395466723e-08
that O 0 9.654303134709608e-09
differences O 0 8.271307194718247e-08
in O 0 1.623518919302569e-08
methods O 0 6.589482381968992e-08
used O 0 8.169675425051537e-08
for O 0 5.795576996092677e-08
mutation O 0 1.2371543789413408e-06
detection O 0 2.169143954233732e-06
or O 0 6.942922027519671e-06
phenotype O 0 0.024488577619194984
classification O 0 1.9877636077580974e-05
may O 0 3.304442998341983e-06
account O 0 9.738641182366337e-08
for O 0 2.2314340597517912e-08
a O 0 2.3644514612897183e-07
considerable O 0 2.799507967665704e-07
proportion O 0 3.078994836869242e-07
of O 0 1.5660627639135782e-07
genotype O 0 0.0006899605505168438
- O 0 0.0587952621281147
phenotype O 0 0.001572253997437656
inconsistencies O 0 7.660318806301802e-05
. O 0 1.0196780749538448e-05

Our O 0 1.2266921658010688e-05
data O 0 2.344495214856579e-06
indicate O 0 1.3210017186793266e-06
that O 0 9.693978597624664e-08
the O 0 1.1161600923514925e-06
PAH O 0 0.04977700859308243
- O 0 0.013352283276617527
mutation O 0 4.839993562200107e-05
genotype O 0 9.057141141965985e-06
is O 0 5.218698717612824e-08
the O 0 4.542853204725361e-08
main O 0 6.507125362986699e-07
determinant O 0 2.7268290523352334e-06
of O 0 2.3957798589435697e-07
metabolic O 0 0.33631783723831177
phenotype O 0 0.003439160995185375
in O 0 7.952252190079889e-07
most O 0 4.32457864008029e-06
patients O 0 7.914641901152208e-05
with O 0 0.00012621350469999015
PAH B-Disease 1 0.9999600648880005
deficiency I-Disease 0 0.3158121407032013
. O 0 1.0124997061211616e-05

In O 0 1.1320223165967036e-05
the O 0 5.809377512377978e-07
present O 0 2.7114751333101594e-07
study O 0 1.5606268277679192e-07
, O 0 3.242626789301539e-08
the O 0 3.582502827725875e-08
classification O 0 5.548402555177745e-07
of O 0 1.173392192299616e-07
105 O 0 4.2033101635752246e-05
PAH O 0 0.027314502745866776
mutations O 0 9.210812095261645e-06
may O 0 2.3834599005567725e-07
allow O 0 2.5070367115631598e-08
the O 0 6.630418880604338e-08
prediction O 0 1.613112658560567e-06
of O 0 1.3780624641412942e-08
the O 0 1.846415074169272e-07
biochemical O 0 6.486120400950313e-05
phenotype O 0 8.118760160868987e-05
in O 0 8.986608435179733e-08
> O 0 8.854423185766791e-07
10 O 0 1.0108368542205426e-07
, O 0 6.274321862065335e-08
000 O 0 2.5039119577741076e-07
genotypes O 0 2.09354857361177e-06
, O 0 1.0576519571259269e-07
which O 0 5.219923764343548e-07
may O 0 7.639428645234148e-07
be O 0 1.0540608386122585e-08
useful O 0 1.2416177419538599e-08
for O 0 1.7184644818257766e-08
the O 0 2.0417556356733257e-07
management O 0 4.033175571294123e-07
of O 0 1.846975123953598e-07
hyperphenylalaninemia B-Disease 1 0.9996670484542847
in O 0 5.873822374269366e-06
newborns O 0 0.0002272324200021103
. O 0 3.5815817227558e-06

Somatic O 0 0.001663590082898736
instability O 0 0.00015615155280102044
of O 0 7.100671268744918e-07
the O 0 6.352569812406728e-07
CTG O 0 0.00022406145581044257
repeat O 0 1.1244230336160399e-05
in O 0 6.229581117622729e-07
mice O 0 2.1317873688531108e-05
transgenic O 0 4.211692612443585e-06
for O 0 3.507995813833986e-07
the O 0 7.454848673660308e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.713467958732508e-05
is O 0 4.064025063144072e-07
age O 0 1.7724944711972057e-07
dependent O 0 9.908016096460415e-08
but O 0 5.546795023292361e-08
not O 0 1.2578551533692917e-08
correlated O 0 1.4604940190565685e-07
to O 0 1.5894896066015463e-08
the O 0 5.597715002636505e-08
relative O 0 4.888013904746913e-07
intertissue O 0 6.230215149116702e-06
transcription O 0 1.9299357063573552e-06
levels O 0 5.99618260821444e-07
and O 0 8.454382509626157e-07
proliferative O 0 0.0078115565702319145
capacities O 0 3.7594156310660765e-05
. O 0 4.838213044422446e-06

A O 0 0.00023878585489001125
( O 0 1.727095695969183e-05
CTG O 0 0.00015504266775678843
) O 0 8.024932185435318e-07
nexpansion O 0 1.1361312317603733e-05
in O 0 1.3459526826409274e-07
the O 0 1.6982890826966468e-07
3 O 0 4.943368367094081e-06
- O 0 0.00031851170933805406
untranslated O 0 0.00028545723762363195
region O 0 1.0535830369917676e-05
( O 0 5.007906338505563e-07
UTR O 0 1.630845872568898e-05
) O 0 7.300307913737925e-08
of O 0 2.1233077518445498e-08
the O 0 8.437001497441088e-07
DM O 1 0.9999980926513672
protein O 0 4.953249117534142e-06
kinase O 0 1.0031290003098547e-05
gene O 0 1.8102773537975736e-06
( O 0 2.3514361657817062e-07
DMPK O 0 4.518204877967946e-05
) O 0 1.324607978858694e-07
is O 0 1.0462974131542069e-07
responsible O 0 7.42933593755879e-07
for O 0 4.639244707504986e-06
causing O 0 0.4328169822692871
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.05598720535635948
DM B-Disease 1 1.0
) O 0 1.0884564289881382e-05
. O 0 6.57943701298791e-06

Major O 0 0.00016881026385817677
instability O 0 0.00019593513570725918
, O 0 6.945967925275909e-07
with O 0 1.8212057284472394e-07
very O 0 9.977633652624718e-08
large O 0 3.967156558815077e-08
expansions O 0 1.1057719575546798e-06
between O 0 2.976249504627049e-07
generations O 0 3.102749985828268e-07
and O 0 7.693254389096182e-08
high O 0 2.519366546493984e-07
levels O 0 7.118137546058279e-08
of O 0 2.5791107916006695e-08
somatic O 0 9.36328615352977e-06
mosaicism O 0 0.00011017348151654005
, O 0 1.401056977101689e-07
is O 0 1.1858976023404466e-07
observed O 0 1.2341612318778061e-06
in O 0 9.894660024656332e-07
patients O 0 1.4044730050954968e-05
. O 0 4.479996732698055e-06

There O 0 6.048883733456023e-06
is O 0 4.2729831761789683e-07
a O 0 2.863170323053055e-07
good O 0 2.8169321808491077e-07
correlation O 0 1.006726733976393e-06
between O 0 2.7525913992576534e-07
repeat O 0 4.665297183237271e-06
size O 0 1.7955936755242874e-06
( O 0 1.0601463884540863e-07
at O 0 2.21146905232672e-08
least O 0 1.9169320353285002e-08
in O 0 6.625564452633625e-08
leucocytes O 0 2.0819885321543552e-05
) O 0 9.415568058557255e-08
, O 0 6.246476402793633e-08
clinical O 0 1.4421608511838713e-06
severity O 0 3.380298221600242e-05
and O 0 6.963690566408332e-07
age O 0 2.8917312988596677e-07
of O 0 2.0759269148129533e-07
onset O 0 0.00043185436516068876
. O 0 4.397915290610399e-06

The O 0 7.978857320267707e-05
trinucleotide O 0 0.00310403760522604
repeat O 0 0.0002556639665272087
instability O 0 5.54648540855851e-05
mechanisms O 0 7.225444733194308e-06
involved O 0 8.454092608189967e-07
in O 0 5.487316684593679e-06
DM B-Disease 1 1.0
and O 0 1.0583079529169481e-05
other O 0 8.001921969480463e-07
human O 0 2.3322156266658567e-05
genetic B-Disease 1 0.9999997615814209
diseases I-Disease 1 0.9999951124191284
are O 0 8.742048862586671e-07
unknown O 0 1.0074631973111536e-05
. O 0 3.822114649665309e-06

We O 0 1.6140227671712637e-05
studied O 0 6.789493909309385e-06
somatic O 0 3.4392011002637446e-05
instability O 0 2.239437344542239e-05
by O 0 1.5544328846317512e-07
measuring O 0 3.4019317354250234e-06
the O 0 2.76392341902465e-07
CTG O 0 5.913107088417746e-05
repeat O 0 3.984469003626145e-06
length O 0 1.4474697991317953e-06
at O 0 4.3835768792632734e-08
several O 0 2.465449000510489e-08
ages O 0 1.478409075161835e-07
in O 0 8.849711186087461e-09
various O 0 1.756152556708912e-08
tissues O 0 2.4154635980266903e-07
of O 0 2.2497376406249714e-08
transgenic O 0 1.0590651072561741e-05
mice O 0 1.3295732969709206e-05
carrying O 0 2.3482583344502928e-07
a O 0 6.571871722371725e-07
( O 0 7.502300718442712e-07
CTG O 0 2.427786421321798e-05
) O 0 1.7946847208349936e-07
55expansion O 0 1.8893902051786426e-06
surrounded O 0 6.784961215089425e-07
by O 0 3.0444525123130006e-08
45 O 0 1.0235270053726708e-07
kb O 0 2.231603502877988e-06
of O 0 2.0724565175100906e-08
the O 0 3.157944377107924e-07
human O 0 4.123100097785937e-06
DM B-Disease 1 0.9999998807907104
region O 0 2.8311083042353857e-06
, O 0 4.6382616858409165e-08
using O 0 7.50422586293098e-08
small O 0 1.6480676379160286e-07
- O 0 1.0451397429278586e-05
pool O 0 5.458516170619987e-06
PCR O 0 8.187456842279062e-05
. O 0 4.066450856043957e-06

These O 0 9.33794399315957e-06
mice O 0 0.00021246027608867735
have O 0 7.939892157082795e-07
been O 0 4.908277446702414e-07
shown O 0 4.0214956698036985e-07
to O 0 6.306849087422961e-08
reproduce O 0 1.85015153419954e-06
the O 0 1.012030992342261e-07
intergenerational O 0 6.062299235054525e-06
and O 0 4.4020347900186607e-07
somatic O 0 3.1864101401879452e-06
instability O 0 1.3865090977560612e-06
of O 0 2.7259913437660543e-08
the O 0 1.4261038927543268e-07
55 O 0 9.586000260242145e-07
CTG O 0 7.230986739159562e-06
repeat O 0 1.1523675311764237e-06
suggesting O 0 3.908852761469461e-07
that O 0 2.3787585234913422e-08
surrounding O 0 1.0789340620931398e-07
sequences O 0 4.178412780220242e-07
and O 0 7.352879549671343e-08
the O 0 2.9028710102352306e-08
chromatin O 0 1.0602145721350098e-06
environment O 0 6.357781785482075e-07
are O 0 2.1355942791956295e-08
involved O 0 8.896221714849162e-08
in O 0 1.9903843906377006e-07
instability O 0 2.3763885110383853e-05
mechanisms O 0 2.1319032384781167e-05
. O 0 7.871482011978514e-06

As O 0 1.1828928109025583e-05
observed O 0 3.6383441965881502e-06
in O 0 5.1857561800261465e-08
some O 0 9.367933095916214e-09
of O 0 1.0565607944101885e-08
the O 0 2.3774575197421655e-07
tissues O 0 3.952899533032905e-06
of O 0 7.436764803969709e-07
DM B-Disease 1 1.0
patients O 0 4.852485653827898e-05
, O 0 1.0761348789856129e-07
there O 0 1.047217423888469e-08
is O 0 1.3273364629640128e-08
a O 0 1.4520890090352623e-07
tendency O 0 5.568907681663404e-07
for O 0 3.320004537954446e-08
repeat O 0 2.970132300106343e-06
length O 0 2.909695012931479e-06
and O 0 1.1534787347500242e-07
somatic O 0 1.6459611060781754e-06
mosaicism O 0 7.534216820204165e-06
to O 0 7.03910103538874e-08
increase O 0 2.2373968988631532e-07
with O 0 3.3806589527785036e-08
the O 0 1.428077496257174e-07
age O 0 1.0761903013190022e-07
of O 0 1.574186825337165e-08
the O 0 3.481101202851278e-07
mouse O 0 0.00013219895481597632
. O 0 4.461625394469593e-06

Furthermore O 0 0.00013150996528565884
, O 0 1.3832325294060865e-06
we O 0 1.2573458718634356e-07
observed O 0 2.769538127722626e-07
no O 0 2.934250353803236e-08
correlation O 0 1.6897428167794715e-07
between O 0 8.010911045630564e-08
the O 0 2.1330687616227806e-07
somatic O 0 1.3075617971480824e-05
mutation O 0 6.122077138570603e-06
rate O 0 6.404124178516213e-06
and O 0 7.0011805064496e-07
tissue O 0 3.774117794819176e-05
proliferation O 0 6.131467216619058e-06
capacity O 0 1.9712156245077495e-06
. O 0 2.0603979464794975e-06

The O 0 9.587924978404772e-06
somatic O 0 6.653361197095364e-05
mutation O 0 3.852018926409073e-05
rates O 0 2.2490182800538605e-06
in O 0 4.590120994407698e-08
different O 0 7.486541164780647e-08
tissues O 0 2.22622338696965e-06
were O 0 5.488570309353236e-07
also O 0 6.438065156544326e-07
not O 0 3.1487477514247075e-08
correlated O 0 1.7457035994539183e-07
to O 0 1.934813553816639e-08
the O 0 3.18101243124147e-08
relative O 0 4.795098789145413e-07
inter O 0 3.7793515730299987e-06
- O 0 0.0002523276780266315
tissue O 0 6.530483005917631e-06
difference O 0 9.968237435487026e-08
in O 0 1.287505035918457e-08
transcriptional O 0 4.47378369017315e-07
levels O 0 8.028563058815052e-08
of O 0 5.4123310277987e-09
the O 0 2.636950924284065e-08
three O 0 1.6884992248833441e-07
genes O 0 5.673455802934768e-07
( O 0 1.1954676892855787e-07
DMAHP O 0 6.614316134800902e-06
, O 0 1.319760940532433e-07
DMPK O 0 1.163249726232607e-05
and O 0 2.8562320153469045e-07
59 O 0 9.913816256812424e-07
) O 0 4.962962663057624e-08
surrounding O 0 9.545617274397955e-08
the O 0 1.6563808458158746e-07
repeat O 0 1.7477039364166558e-05
. O 0 7.367352736764587e-07
. O 0 2.3504815089836484e-06

A O 0 0.00020111996855121106
novel O 0 0.00030480005079880357
missense O 0 0.01228934433311224
mutation O 0 0.00012617160973604769
in O 0 1.7399075886714854e-06
patients O 0 5.858169970451854e-06
from O 0 2.0800011668598017e-07
a O 0 3.250458803449874e-06
retinoblastoma B-Disease 0 0.0004829868848901242
pedigree O 0 0.0001168902381323278
showing O 0 3.69754561688751e-05
only O 0 4.141837735005538e-07
mild O 0 0.00014665738854091614
expression O 0 7.756276545478613e-07
of O 0 9.767344977262837e-08
the O 0 6.438141099351924e-06
tumor B-Disease 0 0.0375821478664875
phenotype O 0 0.0013350618537515402
. O 0 9.434409548703115e-06

We O 0 1.2475349649321288e-05
have O 0 3.4132304449485673e-07
used O 0 2.4527389541617595e-07
single O 0 1.075605950973113e-06
strand O 0 4.1629322367953137e-05
conformation O 0 3.899261173501145e-06
polymorphism O 0 1.6924406054386054e-06
analysis O 0 6.836886257133301e-08
to O 0 1.9483303859146872e-08
study O 0 3.1874503036988244e-08
the O 0 4.024337840746739e-08
27 O 0 9.833646572587895e-07
exons O 0 1.239504513250722e-06
of O 0 2.1859298371396108e-08
the O 0 2.929118068095704e-07
RB1 O 0 4.707595144282095e-05
gene O 0 4.1949584783651517e-07
in O 0 5.3435982749761024e-08
individuals O 0 1.672673377584033e-08
from O 0 1.2120231929202419e-08
a O 0 3.9151618125288223e-07
family O 0 2.824727289407747e-06
showing O 0 1.3726573342864867e-05
mild O 0 0.0001144126508734189
expression O 0 2.7804148317045474e-07
of O 0 5.864061236593443e-08
the O 0 2.113999016728485e-06
retinoblastoma B-Disease 0 0.0026988238096237183
phenotype O 0 0.002479779301211238
. O 0 8.091776180663146e-06

In O 0 7.964707947394345e-06
this O 0 5.378998935157142e-07
family O 0 2.7012051759811584e-06
affected O 0 6.686042297587846e-07
individuals O 0 6.655429984903094e-08
developed O 0 4.960760634276085e-06
unilateral B-Disease 0 0.25946569442749023
tumors I-Disease 1 1.0
and O 0 4.658048419514671e-05
, O 0 3.0923544613870035e-07
as O 0 7.366018195398283e-08
a O 0 3.4002866300397727e-07
result O 0 7.150632796992795e-08
of O 0 2.2069560401405397e-08
linkage O 0 4.152324436290655e-06
analysis O 0 6.104111207605456e-07
, O 0 4.2898872720797954e-07
unaffected O 0 1.5367115338449366e-05
mutation O 0 3.4005338420683984e-06
carriers O 0 2.634056386341399e-07
were O 0 2.807427392781392e-07
also O 0 7.144047344809223e-07
identified O 0 7.6030653417547e-07
within O 0 6.253855389104501e-08
the O 0 2.599622064280993e-07
pedigree O 0 2.8250235118321143e-05
. O 0 4.799312137038214e-06

A O 0 0.00011474655184429139
single O 0 2.8064821890438907e-05
band O 0 1.9333407180965878e-05
shift O 0 3.735926611625473e-06
using O 0 7.835021165192302e-07
SSCP O 0 6.956925062695518e-05
was O 0 3.609324721765006e-06
identified O 0 3.1599265071236005e-07
in O 0 4.4279541810965384e-08
exon O 0 7.37118625693256e-06
21 O 0 3.1623551421944285e-06
which O 0 2.446688256441121e-07
resulted O 0 2.87488063577257e-07
in O 0 6.826527254588655e-08
a O 0 2.639563490447472e-06
missense O 0 0.0001348481746390462
mutation O 0 2.693806663955911e-06
converting O 0 5.697530127690698e-07
a O 0 1.5376980400105822e-06
cys O 0 0.0004995134077034891
- O 0 0.00011142313451273367
- O 0 4.8187674110522494e-05
> O 0 3.1134077289607376e-06
arg O 0 3.043476681341417e-06
at O 0 8.733459821996803e-08
nucleotide O 0 8.462158120892127e-07
position O 0 5.697600613530085e-07
28 O 0 6.01747558448551e-07
in O 0 7.126899248532936e-08
the O 0 4.3430139839983894e-07
exon O 0 8.321917994180694e-05
. O 0 9.49856166698737e-06

The O 0 3.552679845597595e-05
mutation O 0 8.493632049066946e-05
destroyed O 0 7.61582577979425e-06
an O 0 7.659825769223971e-07
NdeI O 0 5.0161943363491446e-05
restriction O 0 3.3945821087399963e-06
enzyme O 0 5.604034413408954e-06
site O 0 7.283386366907507e-06
. O 0 4.075617198395776e-06

Analysis O 0 1.6621057511656545e-05
of O 0 3.9405659890690004e-07
all O 0 8.021491737508768e-08
family O 0 3.7531356156250695e-07
members O 0 1.3211965210757626e-07
demonstrated O 0 3.6085771171201486e-07
that O 0 1.820468931157393e-08
the O 0 1.7606055280339206e-07
missense O 0 0.00014796145842410624
mutation O 0 1.0885083611356094e-05
co O 0 5.528993369807722e-06
- O 0 1.9966018953709863e-05
segregated O 0 2.6405327844258863e-06
with O 0 1.338652623417147e-06
patients O 0 1.1101867130491883e-05
with O 0 2.1898664272157475e-05
tumors B-Disease 1 1.0
or O 0 8.49917414598167e-05
who O 0 9.004801540868357e-06
, O 0 8.581397992202255e-08
as O 0 2.112223818073744e-08
a O 0 3.1649753395868174e-07
result O 0 9.935417466522267e-08
of O 0 1.5957168031377478e-08
linkage O 0 2.8269748781895032e-06
analysis O 0 4.047578840982169e-07
had O 0 6.495979050669121e-06
been O 0 7.774887080813642e-07
predicted O 0 2.0672453047154704e-06
to O 0 2.21255334054149e-08
carry O 0 1.4054732844215323e-07
the O 0 4.220242146857345e-07
predisposing O 0 5.473136843647808e-05
mutation O 0 2.2104915842646733e-05
. O 0 2.1804037260153564e-06

These O 0 1.2695239774984657e-06
observations O 0 1.6168769434443675e-06
point O 0 5.896609422961774e-07
to O 0 3.059634323676619e-08
another O 0 1.5076227555255173e-07
region O 0 1.6426885451892304e-07
of O 0 1.0902035718629577e-08
the O 0 2.80726681012311e-07
RB1 O 0 0.00013475689047481865
gene O 0 5.802046985081688e-07
where O 0 2.782844887860847e-07
mutations O 0 8.304122616209497e-07
only O 0 2.125585041312661e-08
modify O 0 1.948962875530924e-07
the O 0 6.413539921368283e-08
function O 0 1.3259775499818716e-08
of O 0 3.3482510097826435e-09
the O 0 2.5360373356875243e-08
gene O 0 1.5388643248570588e-07
and O 0 1.6198418961721472e-07
raise O 0 9.04835388837455e-08
important O 0 9.223682262415878e-09
questions O 0 2.03736689741163e-08
for O 0 2.254901332321424e-08
genetic O 0 6.426128038583556e-07
counseling O 0 2.963068936878699e-07
in O 0 9.300035230808135e-08
families O 0 1.1272506128534587e-07
with O 0 5.0357456871097384e-08
these O 0 9.99855132022276e-08
distinctive O 0 2.0142924768151715e-05
phenotypes O 0 8.499409159412608e-05
. O 0 6.104821750341216e-07
. O 0 2.3696238713455386e-06

Maternal B-Disease 0 0.14387302100658417
disomy I-Disease 0 0.19234152138233185
and O 0 0.002809025812894106
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.3920139685506e-05
with O 0 1.725817810438457e-06
gamete O 0 5.708194294129498e-05
complementation O 0 0.00026449773577041924
in O 0 4.768144208355807e-07
a O 0 7.411212550323398e-07
case O 0 9.009637551571359e-07
of O 0 1.6303683025853388e-07
familial O 0 0.00015441564028151333
translocation O 0 0.0011305398074910045
( O 0 1.203203510158346e-06
3 O 0 1.4590102637157543e-06
; O 0 2.894368833494809e-07
15 O 0 1.9084362179455638e-07
) O 0 8.307704746357558e-08
( O 0 1.0517878479276987e-07
p25 O 0 2.086785343635711e-06
; O 0 1.628531549613399e-07
q11 O 0 2.132567260559881e-06
. O 0 7.242792321449087e-08
2 O 0 5.260853868094273e-07
) O 0 5.958809765616024e-07
. O 0 1.445069869987492e-06

Maternal B-Disease 1 0.5980822443962097
uniparental I-Disease 1 0.9338180422782898
disomy I-Disease 1 0.6096329689025879
( I-Disease 0 0.00039929835475049913
UPD I-Disease 1 0.9999960660934448
) I-Disease 0 2.0314203084126348e-06
for I-Disease 0 2.179988740635963e-07
chromosome I-Disease 0 6.493688852060586e-05
15 I-Disease 0 1.2567205658342573e-06
is O 0 4.9943562174803446e-08
responsible O 0 4.274801312931231e-08
for O 0 8.245660154670986e-09
an O 0 4.531637287641388e-08
estimated O 0 2.1757122681265173e-07
30 O 0 1.363883654903475e-07
% O 0 2.2873594573979972e-08
of O 0 7.92885135325605e-09
cases O 0 3.227602007882524e-07
of O 0 5.4024912969907746e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.000227345124585554
PWS B-Disease 1 0.9999980926513672
) O 0 8.140631507558282e-06
. O 0 7.586177616758505e-06

We O 0 2.3389737179968506e-05
report O 0 1.4201609701558482e-06
on O 0 2.1793070459352748e-07
an O 0 6.540721386727455e-08
unusual O 0 2.1615062451019185e-07
case O 0 2.234040863413611e-07
of O 0 4.0094437991911036e-08
maternal B-Disease 0 1.7244854461750947e-05
disomy I-Disease 0 7.23965567885898e-05
15 I-Disease 0 1.5896251852609566e-06
in O 0 1.0707271940191276e-06
PWS B-Disease 1 0.9999948740005493
that O 0 2.5348435883643106e-07
is O 0 7.204337748589751e-08
most O 0 2.134763477101842e-08
consistent O 0 2.196127155684735e-07
with O 0 3.718788832429709e-08
adjacent O 0 6.975615178816952e-07
- O 0 1.7909258531290106e-05
1 O 0 3.6943916370546503e-07
segregation O 0 3.0614444312959677e-07
of O 0 1.1784629272426628e-08
a O 0 4.6399648567785334e-07
paternal O 0 2.5198540242854506e-05
t O 0 4.474456363823265e-05
( O 0 9.047836613262916e-08
3 O 0 1.6195514263017685e-07
; O 0 1.324532235003062e-07
15 O 0 9.994433014526294e-08
) O 0 3.5095077066671365e-08
( O 0 4.0721637617480155e-08
p25 O 0 9.387053978571203e-07
; O 0 7.4718485620906e-08
q11 O 0 4.772616080117587e-07
. O 0 1.6941955394145225e-08
2 O 0 7.074230268244719e-08
) O 0 1.1599115445903863e-08
with O 0 1.1213530548559447e-08
simultaneous O 0 9.45185718137509e-07
maternal O 0 2.89518302452052e-05
meiotic O 0 0.00012021348084090278
nondisjunction O 0 2.6194886231678538e-05
for O 0 3.716463936598302e-07
chromosome O 0 0.00012068140495102853
15 O 0 3.545669869708945e-06
. O 0 2.346421069887583e-06

The O 0 2.1141961042303592e-05
patient O 0 7.943851232994348e-05
( O 0 2.576240149210207e-06
J O 0 9.920096636051312e-05
. O 0 2.6892072924056265e-07
B O 0 1.4644456314272247e-06
. O 0 3.137417436960277e-08
) O 0 2.1225627477861053e-08
, O 0 8.759279523928853e-09
a O 0 7.744650787344654e-08
17 O 0 3.3413343203392287e-07
- O 0 2.0016811959067127e-06
year O 0 1.5070219205881585e-07
- O 0 4.465553956833901e-06
old O 0 2.4353773824259406e-06
white O 0 6.155446044431301e-06
male O 0 2.554369302742998e-06
with O 0 1.0686318319130805e-06
PWS B-Disease 1 0.9999995231628418
, O 0 1.366043534289929e-06
was O 0 4.81258120998973e-06
found O 0 8.681426066914355e-08
to O 0 3.4173531560099946e-08
have O 0 1.1167409752488311e-07
47 O 0 7.525611067649152e-07
chromosomes O 0 7.918816891105962e-07
with O 0 4.1937262551527965e-08
a O 0 1.997059371205978e-06
supernumerary O 0 0.0027470134664326906
, O 0 1.141466896115162e-06
paternal O 0 3.7339261325541884e-05
der O 0 0.00028949795523658395
( O 0 1.0391337212922735e-07
15 O 0 8.37062756886553e-08
) O 0 1.3536732623720127e-08
consisting O 0 1.1769736296685096e-08
of O 0 1.0285796214759557e-08
the O 0 3.878822099068202e-07
short O 0 2.8031465262756683e-05
arm O 0 0.00014993931108620018
and O 0 1.4965324623972265e-07
the O 0 1.5055681501507934e-07
proximal O 0 5.376083208830096e-05
long O 0 1.3488053809851408e-05
arm O 0 3.1388197385240346e-05
of O 0 4.891846927534971e-08
chromosome O 0 2.5654388082330115e-05
15 O 0 5.354448830985348e-07
, O 0 9.421370350537472e-08
and O 0 6.126838911768573e-07
distal O 0 0.004599723499268293
chromosome O 0 0.007863805629312992
arm O 0 0.0010853186249732971
3p O 0 0.0009103777701966465
. O 0 9.323297490482219e-06

The O 0 2.2079719201428816e-05
t O 0 0.00022086859098635614
( O 0 4.5444866714206e-07
3 O 0 2.964383156722761e-07
; O 0 8.285012853548324e-08
15 O 0 2.0631613040222874e-07
) O 0 4.0121367561596344e-08
was O 0 7.328866331590689e-07
present O 0 1.728879794882232e-08
in O 0 1.2589591591449789e-08
the O 0 3.7726280766037235e-08
balanced O 0 5.649941954288806e-07
state O 0 1.798131066266251e-08
in O 0 4.434588873891698e-08
the O 0 6.707769557579013e-07
patients O 0 1.6238832358794753e-06
father O 0 1.0000588872571825e-06
and O 0 3.0295743158603727e-07
a O 0 2.2264507606450934e-06
sister O 0 0.00010872508573811501
. O 0 4.98096505907597e-06

Fluorescent O 0 0.000875672500114888
in O 0 4.1863327169266995e-06
situ O 0 2.2903403078089468e-05
hybridization O 0 5.04140552948229e-06
analysis O 0 9.998797168009332e-07
demonstrated O 0 1.4817517239862354e-06
that O 0 7.647987132486378e-08
the O 0 1.8485977761883987e-06
PWS B-Disease 1 0.9999994039535522
critical O 0 4.925810117129004e-06
region O 0 3.0060978133406024e-06
resided O 0 1.94793119590031e-06
on O 0 2.43998897531128e-07
the O 0 7.072503649396822e-08
derivative O 0 1.1245539326409926e-06
chromosome O 0 1.218828128912719e-05
3 O 0 1.0482405059519806e-06
and O 0 1.7616937952880107e-07
that O 0 2.5353505961334122e-08
there O 0 2.959046696560108e-08
was O 0 1.6876506379048806e-06
no O 0 4.720802593283224e-08
deletion O 0 7.40705843327305e-07
of O 0 5.852072249012963e-08
the O 0 5.8157966122962534e-06
PWS B-Disease 1 0.9999977350234985
region O 0 3.3352041555190226e-06
on O 0 1.1831248230009805e-06
the O 0 2.1459047161442868e-07
normal O 0 6.414494464479503e-07
pair O 0 7.490097004847485e-07
of O 0 8.135357631999796e-08
15s O 0 2.0875813788734376e-06
present O 0 2.734099666668044e-07
in O 0 7.34647926492471e-07
J O 0 0.0005355507601052523
. O 0 6.752125955244992e-06

B O 0 0.006463658530265093
. O 0 0.0002018170926021412

Methylation O 0 0.000183580705197528
analysis O 0 8.804189747024793e-06
at O 0 7.541172521996486e-07
exon O 0 6.462365945480997e-06
alpha O 0 7.930417496027076e-07
of O 0 3.4094103540383e-08
the O 0 4.351919713485586e-08
small O 0 1.3590107528216322e-07
nuclear O 0 1.6352669263142161e-06
ribonucleoprotein O 0 9.087534635909833e-06
- O 0 7.848573659430258e-06
associated O 0 6.204950295796152e-07
polypeptide O 0 6.0195070545887575e-06
N O 0 5.643739314109553e-06
( O 0 1.325161491649851e-07
SNRPN O 0 5.0210705921927e-06
) O 0 6.193670287757413e-08
gene O 0 1.825173541192271e-07
showed O 0 5.407689513958758e-07
a O 0 3.684810678805661e-07
pattern O 0 3.950974496547133e-05
characteristic O 0 8.969481655185518e-07
of O 0 1.4356884570077e-08
only O 0 2.7463183727149953e-08
the O 0 1.0589782561964967e-07
maternal O 0 1.3211026271164883e-05
chromosome O 0 1.5731471648905426e-05
15 O 0 5.525032520381501e-07
in O 0 7.752697115392948e-07
J O 0 0.00041815199074335396
. O 0 2.6260800041200127e-06

B O 0 0.0041529592126607895
. O 0 0.00020273879636079073

Maternal B-Disease 0 0.06257160753011703
disomy I-Disease 0 0.045457690954208374
was O 0 0.00010943478264380246
confirmed O 0 2.1210548766248394e-06
by O 0 1.3857170699793642e-07
polymerase O 0 4.5037199924991e-06
chain O 0 5.449132913781796e-06
reaction O 0 2.972726349526056e-07
analysis O 0 5.5923152331160964e-08
of O 0 3.4313892172121996e-08
microsatellite O 0 6.0891732573509216e-05
repeats O 0 4.625751898856834e-06
at O 0 7.163082216266048e-08
the O 0 6.91424517640371e-08
gamma O 0 1.4088928992350702e-06
- O 0 8.445827916148119e-06
aminobutyric O 0 1.4553495020663831e-05
acid O 0 5.0445360102457926e-06
receptor O 0 3.0762876122025773e-06
beta3 O 0 1.0329429642297328e-05
subunit O 0 5.655544100591214e-06
( O 0 1.5246974953697645e-06
GABRB3 O 0 6.220619980012998e-05
) O 0 1.916400378831895e-06
locus O 0 5.554202653001994e-05
. O 0 7.837593329895753e-06

A O 0 0.0002625916386023164
niece O 0 0.002902447246015072
( O 0 9.686466000857763e-06
B O 0 6.443276106438134e-06
. O 0 1.650409586773094e-07
B O 0 1.098365487450792e-06
. O 0 2.1570823349748025e-08
) O 0 1.233276680778772e-08
with O 0 1.542447236602129e-08
45 O 0 2.337742870395232e-07
chromosomes O 0 3.7537870412052143e-07
and O 0 5.484233156494156e-08
the O 0 2.640902074801943e-08
derivative O 0 7.164502449086285e-07
3 O 0 5.402699798651156e-07
but O 0 4.490432559123292e-08
without O 0 1.5835826872034886e-08
the O 0 7.938811563690251e-08
der O 0 3.591068525565788e-05
( O 0 4.677065845726247e-08
15 O 0 5.221257737275664e-08
) O 0 3.0848667620375636e-08
demonstrated O 0 1.0829420915570154e-07
a O 0 3.6675930914498167e-07
phenotype O 0 6.774893699912354e-05
consistent O 0 5.802069154015044e-07
with O 0 1.3668746134953835e-07
that O 0 2.3557591077860707e-07
reported O 0 1.4559399232894066e-06
for O 0 5.715386208748896e-08
haploinsufficiency O 0 7.898462172306608e-06
of O 0 1.226745638405191e-07
distal O 0 9.81936464086175e-05
3 O 0 2.044900247710757e-05
p O 0 9.685155237093568e-05
. O 0 4.602934950526105e-06

Uniparental B-Disease 1 0.9999901056289673
disomy I-Disease 1 0.9999796152114868
associated O 0 0.0003306497819721699
with O 0 3.5944924547948176e-06
unbalanced O 0 0.0003730531607288867
segregation O 0 1.8329796148464084e-05
of O 0 9.044195792284881e-08
non O 0 7.248679025906313e-07
- O 0 3.354460932314396e-05
Robertsonian O 0 2.8531407224363647e-05
translocations O 0 7.761200686218217e-05
has O 0 2.0807483451790176e-06
been O 0 2.5380538772878936e-06
reported O 0 2.721326609389507e-06
previously O 0 1.2724525504381745e-06
but O 0 1.567779861488816e-07
has O 0 3.167777435919561e-07
not O 0 1.7653141171081188e-08
, O 0 9.626243802074441e-09
to O 0 7.3504367037458e-09
our O 0 1.3422375211291637e-08
knowledge O 0 1.6042616124423148e-08
, O 0 2.186909853207908e-08
been O 0 3.606725940130673e-08
observed O 0 1.1906480779089179e-07
in O 0 2.1627428736792353e-08
a O 0 2.8982523758713796e-07
case O 0 2.4262251372419996e-06
of O 0 2.35633046941075e-06
PWS B-Disease 1 0.9999920129776001
. O 0 2.0196859622956254e-05

Furthermore O 0 8.382128726225346e-05
, O 0 1.067812831934134e-06
our O 0 3.312547391942644e-07
findings O 0 5.537444849323947e-07
are O 0 4.088023786152917e-08
best O 0 3.053233683658618e-07
interpreted O 0 3.312623277906823e-07
as O 0 9.498540975982905e-08
true O 0 5.970317715764395e-07
gamete O 0 1.0159295015910175e-05
complementation O 0 7.359253504546359e-05
resulting O 0 7.56851795813418e-06
in O 0 1.745458462210081e-06
maternal B-Disease 0 0.014411666430532932
UPD I-Disease 1 0.9999990463256836
15 I-Disease 0 6.627240509260446e-05
and O 0 7.403076597256586e-05
PWS B-Disease 1 0.9999783039093018

Schwartz B-Disease 1 0.9203224778175354
- I-Disease 1 0.9999436140060425
Jampel I-Disease 1 0.9987289309501648
syndrome I-Disease 1 0.9999768733978271
type I-Disease 0 1.5904282918199897e-05
2 I-Disease 0 1.0508696504984982e-05
and O 0 7.014586572040571e-06
Stuve B-Disease 1 0.9231098890304565
- I-Disease 1 0.9999867677688599
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999693632125854
: O 0 7.058488193933954e-08
a O 0 2.1755982970717014e-07
case O 0 3.8942411606512906e-07
for O 0 1.6815636172395898e-07
" O 0 1.2029751133013633e-06
lumping O 0 1.236658681591507e-05
" O 0 4.28150269726757e-06
. O 0 2.471853804308921e-06

Recent O 0 7.485343667212874e-05
studies O 0 1.3952149856777396e-05
demonstrated O 0 4.372505827632267e-06
the O 0 9.148223512056575e-08
existence O 0 1.8569893711628538e-07
of O 0 4.535069919597845e-08
a O 0 1.2817943115805974e-06
genetically O 0 9.556359145790339e-06
distinct O 0 2.872424602173851e-06
, O 0 7.055444939396693e-07
usually O 0 1.9937147044402082e-07
lethal O 0 3.5291424183014897e-07
form O 0 4.834569367062613e-08
of O 0 1.3323103509321754e-08
the O 0 4.7617413656553254e-07
Schwartz B-Disease 0 0.027307964861392975
- I-Disease 1 0.9981369972229004
Jampel I-Disease 1 0.998916506767273
syndrome I-Disease 1 0.9999505281448364
( O 0 5.0145963541581295e-06
SJS B-Disease 0 0.0004201594565529376
) O 0 1.5765283478685888e-07
of O 0 1.7699439069929213e-07
myotonia B-Disease 0 0.41734063625335693
and O 0 9.062956087291241e-05
skeletal B-Disease 1 0.9932767152786255
dysplasia I-Disease 1 0.9999887943267822
, O 0 3.089252686550026e-06
which O 0 5.798180495730776e-07
we O 0 9.386483412754387e-08
called O 0 3.6848987292614765e-06
SJS B-Disease 0 0.0004162592813372612
type I-Disease 0 2.877294036807143e-06
2 I-Disease 0 4.716689545603003e-06
. O 0 4.021126187581103e-06

This O 0 9.394017251906916e-05
disorder O 1 0.7933549284934998
is O 0 1.0291487342328764e-06
reminiscent O 0 2.3667356799705885e-05
of O 0 1.5615083270859031e-07
another O 0 5.210049039305886e-06
rare O 0 1.0936442777165212e-05
condition O 0 2.0155683159828186e-05
, O 0 1.3435339951684e-07
the O 0 8.521893732904573e-07
Stuve B-Disease 1 0.6110556125640869
- I-Disease 1 0.9999533891677856
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999988079071045
( O 0 1.0780392585729714e-05
SWS B-Disease 1 0.6791287660598755
) O 0 7.612867989337246e-07
, O 0 1.557685749276061e-07
which O 0 6.310868627679156e-08
comprises O 0 5.963670446362812e-08
campomelia B-Disease 0 6.096151082601864e-06
at O 0 2.8524974027277494e-07
birth O 0 4.526144948613364e-06
with O 0 2.2398573946702527e-06
skeletal B-Disease 1 0.9360060691833496
dysplasia I-Disease 1 0.9999877214431763
, O 0 2.2141455701785162e-05
contractures B-Disease 0 0.0036100654397159815
, O 0 4.252308087870915e-07
and O 0 2.8056768996975734e-07
early B-Disease 0 1.7313682292297017e-06
death I-Disease 0 2.125747960235458e-05
. O 0 4.107550921617076e-06

To O 0 4.7658299990871456e-06
test O 0 1.4197141808836022e-06
for O 0 7.720154115986588e-08
possible O 0 3.0675522566525615e-07
nosologic O 0 6.526603829115629e-05
identity O 0 3.464625024207635e-06
between O 0 1.2087584764230996e-06
these O 0 1.125383164435334e-06
disorders O 0 0.008040384389460087
, O 0 1.1243625408496882e-07
we O 0 2.0975221559638157e-08
reviewed O 0 5.136144309858537e-08
the O 0 2.2151670719949834e-08
literature O 0 1.6131414426467927e-08
and O 0 1.2427810780479831e-08
obtained O 0 1.3265341713974976e-08
a O 0 4.6832965949761274e-08
follow O 0 8.714042110113951e-08
- O 0 1.702183567431348e-06
up O 0 4.4205194171809126e-08
of O 0 3.074298149385868e-09
the O 0 1.5632121375119823e-08
only O 0 2.3611249844179838e-08
two O 0 1.1489598250591371e-07
surviving O 0 7.18083583706175e-06
patients O 0 2.8734498869198433e-07
, O 0 1.1842131719674853e-08
one O 0 1.3501663786996687e-08
with O 0 7.310745075983505e-08
SJS B-Disease 0 4.801803515874781e-05
type I-Disease 0 1.1640398156487208e-07
2 I-Disease 0 1.8675726209949062e-07
at O 0 5.46361285103103e-08
age O 0 3.994086483771753e-08
10 O 0 2.8841617094599314e-08
years O 0 1.565751439613905e-08
and O 0 1.542461980363896e-08
another O 0 4.3523677106804826e-08
with O 0 1.5445763779098343e-07
SWS B-Disease 0 0.01362211536616087
at O 0 4.261344486167218e-07
age O 0 2.3258590431396442e-07
7 O 0 5.878922024749045e-07
years O 0 3.909139536517614e-07
. O 0 1.4525032838719198e-06

Patients O 0 0.323225200176239
reported O 0 0.00015264908142853528
as O 0 9.964119271899108e-07
having O 0 1.66959307534853e-06
either O 0 7.193516466941219e-06
neonatal O 1 0.9999963045120239
SJS B-Disease 1 0.9989086389541626
or O 0 2.9281392926350236e-05
SWS B-Disease 1 0.7923223972320557
presented O 0 2.18201375901117e-06
a O 0 3.189883841514529e-07
combination O 0 2.226703372798511e-06
of O 0 6.626853377156294e-08
a O 0 6.829327503510285e-06
severe O 0 0.06031879782676697
, O 0 8.00958696345333e-06
prenatal O 1 0.5800337195396423
- O 1 0.9993014335632324
onset O 1 0.9999707937240601
neuromuscular B-Disease 1 0.9999996423721313
disorder I-Disease 1 0.999937891960144
( O 0 1.5610983609803952e-05
with O 0 0.00013483286602422595
congenital B-Disease 1 1.0
joint I-Disease 0 0.10365878790616989
contractures I-Disease 1 0.9999269247055054
, O 0 0.00039852940244600177
respiratory O 1 0.8394824266433716
and O 0 6.912794106028741e-06
feeding O 0 1.8339989765081555e-05
difficulties O 0 3.081637487412081e-06
, O 0 1.170954178064676e-07
tendency O 0 8.753619908929977e-07
to O 0 1.6091011900698504e-07
hyperthermia B-Disease 0 0.13350796699523926
, O 0 3.6302748185335076e-07
and O 0 1.92344074889661e-07
frequent O 0 1.0905113185799564e-06
death O 0 1.468317350372672e-05
in O 0 4.929720489599276e-07
infancy O 0 1.626922130526509e-05
) O 0 2.9763450370978717e-08
with O 0 1.8605714302566412e-08
a O 0 1.1073695986851817e-06
distinct O 0 4.781769348483067e-06
campomelic B-Disease 0 0.0006294316262938082
- I-Disease 0 0.03443685173988342
metaphyseal I-Disease 0 0.0037458334118127823
skeletal I-Disease 0 0.46093282103538513
dysplasia I-Disease 1 0.9998410940170288
. O 0 5.328950283001177e-05

The O 0 4.6291770559037104e-06
similarity O 0 3.3092997000494506e-06
of O 0 7.753948239042074e-08
the O 0 1.9838482501199906e-07
clinical O 0 2.5034537429746706e-06
and O 0 1.20779293411033e-06
radiographic O 0 0.0029899717774242163
findings O 0 3.6405408536666073e-06
is O 0 9.494773678397905e-08
so O 0 1.627493695366411e-08
extensive O 0 1.3231296236426715e-07
that O 0 8.807885620853995e-08
these O 0 2.7628638576970843e-07
disorders O 0 0.012625192292034626
appear O 0 1.2543066532089142e-06
to O 0 6.374684602405978e-08
be O 0 9.864174899121281e-08
a O 0 3.091151654643909e-07
single O 0 5.762284217780689e-06
entity O 0 9.210337339027319e-06
. O 0 3.952115548599977e-06

The O 0 5.4108345466374885e-06
follow O 0 1.1375135500202305e-06
- O 0 6.480584488599561e-06
up O 0 2.2810991140431724e-07
observation O 0 3.9986304045669385e-07
of O 0 1.001626070973316e-08
an O 0 4.6910564321933634e-08
identical O 0 1.0054438462248072e-05
and O 0 6.124233777882182e-07
unique O 0 2.219879462472818e-07
pattern O 0 8.809901373751927e-06
of O 0 3.528038803324307e-07
progressive O 0 0.3806357979774475
bone B-Disease 1 0.9907488226890564
dysplasia I-Disease 1 0.9995366334915161
in O 0 1.7568863768246956e-06
the O 0 1.2396440070006065e-06
two O 0 1.1890136192960199e-05
patients O 0 1.0986160305037629e-05
( O 0 1.1116829767843228e-07
one O 0 3.756135669163996e-08
with O 0 3.5342685578143573e-07
SJS B-Disease 0 0.0006360462284646928
type I-Disease 0 4.2910164665954653e-07
2 I-Disease 0 4.6192093350327923e-07
, O 0 6.263894647418056e-08
one O 0 3.890676936180171e-08
with O 0 3.9781664895599533e-07
SWS B-Disease 1 0.8188142776489258
) O 0 1.7736003599111427e-07
surviving O 0 6.215967118805565e-07
beyond O 0 3.1500277941631794e-07
infancy O 0 1.944946234289091e-06
adds O 0 2.828124650022801e-07
to O 0 1.057157472672543e-08
the O 0 3.575949136802592e-08
evidence O 0 6.100589899915576e-08
in O 0 5.866108665486536e-08
favor O 0 2.2339044392083451e-07
of O 0 1.2903031176847435e-07
identity O 0 9.499004590907134e-06
. O 0 3.4975573726114817e-06

The O 0 2.1211733837844804e-05
hypothesis O 0 2.7838192181661725e-05
that O 0 2.811081230902346e-06
SWS B-Disease 0 0.32053008675575256
and O 0 5.442443580250256e-06
SJS B-Disease 0 0.001072895247489214
type I-Disease 0 1.3265944289742038e-06
2 I-Disease 0 8.866083476277709e-07
are O 0 1.9843225729232472e-08
the O 0 1.6757235243858304e-07
same O 0 4.425136012287112e-06
disorder O 0 0.002280519111081958
should O 0 2.697673266993661e-07
be O 0 5.721647156065046e-08
testable O 0 4.587303124026221e-07
by O 0 3.41494903466355e-08
molecular O 0 6.066302944418567e-07
methods O 0 7.731086952844635e-07
. O 0 5.547900059355015e-07
. O 0 2.2019416974217165e-06

A O 0 0.00010413752170279622
mouse O 0 0.00021835049847140908
model O 0 2.060529550362844e-05
of O 0 7.342512162722414e-06
severe O 1 0.9996634721755981
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.00022191135212779045
defects O 1 0.998767614364624
in O 0 2.262233101646416e-05
hemostasis O 0 0.49876150488853455
and O 0 0.0016185719287022948
thrombosis B-Disease 1 0.8505374193191528
. O 0 3.235453550587408e-05

von B-Disease 1 0.9991768002510071
Willebrand I-Disease 1 0.9991891980171204
factor I-Disease 0 0.0015513350954279304
( I-Disease 0 0.0001436157472198829
vWf I-Disease 0 0.024587010964751244
) I-Disease 0 0.0007251477218233049
deficiency I-Disease 1 0.9966546297073364
causes O 0 0.02343331277370453
severe O 1 0.9999903440475464
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.7774398656911217e-05
humans O 0 9.726602002047002e-06
. O 0 6.120588750491152e-06

We O 0 1.097004769690102e-05
generated O 0 1.6638327906548511e-06
a O 0 2.9795040745739243e-07
mouse O 0 5.066617177362787e-06
model O 0 1.1446468306530733e-06
for O 0 1.2411682348556496e-07
this O 0 4.537302515927877e-07
disease O 0 5.8123755479755346e-06
by O 0 4.987311896798019e-08
using O 0 7.735984013379493e-07
gene O 0 4.457873728824779e-06
targeting O 0 1.133423484134255e-05
. O 0 6.9355496634671e-06

vWf B-Disease 0 0.07072232663631439
- I-Disease 1 0.994458794593811
deficient I-Disease 0 0.22518427670001984
mice O 0 0.0008532330393791199
appeared O 0 2.264352769998368e-05
normal O 0 1.2245754987816326e-06
at O 0 2.4867424031072005e-07
birth O 0 6.167504579934757e-06
; O 0 5.889713179385581e-07
they O 0 6.274956376728369e-08
were O 0 3.417614493628207e-07
viable O 0 1.442173243049183e-06
and O 0 6.34398475085618e-07
fertile O 0 1.3419065908237826e-05
. O 0 2.375024223510991e-06

Neither O 0 0.0022782408632338047
vWf O 0 0.005670615006238222
nor O 0 0.0003487534704618156
vWf O 0 0.0024010350462049246
propolypeptide O 0 0.0030804527923464775
( O 0 2.4432600184809417e-05
von B-Disease 0 0.09390052407979965
Willebrand I-Disease 1 0.9147034287452698
antigen O 0 0.001540982280857861
II O 0 0.0002920597908087075
) O 0 5.38477820555272e-07
were O 0 3.2158652629732387e-07
detectable O 0 9.132861009675253e-07
in O 0 5.6351549204691764e-08
plasma O 0 2.6611689918354386e-06
, O 0 1.7799071372337494e-07
platelets O 0 4.509410246100742e-06
, O 0 8.951095509246443e-08
or O 0 1.3953339816907828e-07
endothelial O 0 5.913925633649342e-06
cells O 0 4.527809949195216e-07
of O 0 3.924476388306175e-08
the O 0 5.574439114752749e-07
homozygous O 0 0.00015630171401426196
mutant O 0 0.00017508439486846328
mice O 0 0.00033066110336221755
. O 0 4.170472948317183e-06

The O 0 5.3416501032188535e-05
mutant O 0 0.004354318603873253
mice O 1 0.9714412689208984
exhibited O 0 0.05007166787981987
defects O 1 0.8413277268409729
in O 0 1.1003836561940261e-06
hemostasis O 0 0.00018914898100774735
with O 0 3.4556518357931054e-07
a O 0 3.280247710790718e-06
highly O 0 1.1101644304289948e-05
prolonged O 0 0.06966978311538696
bleeding O 1 0.7565711140632629
time O 0 6.93183324074198e-07
and O 0 9.219830303663912e-07
spontaneous O 0 6.982283139223e-06
bleeding O 0 0.00010142797691514716
events O 0 8.574313881126727e-08
in O 0 5.734188945893948e-08
approximately O 0 1.835304033193097e-07
10 O 0 1.3792922004540742e-07
% O 0 1.296313456577991e-07
of O 0 1.1694687174212959e-07
neonates O 0 0.00011645280028460547
. O 0 3.1708984806755325e-06

As O 0 8.143263585225213e-06
in O 0 7.670761874578602e-07
the O 0 3.739808676073153e-07
human O 0 1.4049294350115815e-06
disease O 0 8.37315292301355e-06
, O 0 3.8143184610817116e-08
the O 0 4.104884965272504e-08
factor O 0 2.587709957424522e-07
VIII O 0 4.0556074964115396e-05
level O 0 8.461336875598136e-08
in O 0 3.6090725075155206e-08
these O 0 4.473096737456217e-08
mice O 0 1.6932972357608378e-05
was O 0 2.4389287318626884e-06
reduced O 0 4.021936490516964e-07
strongly O 0 1.6659350876579992e-07
as O 0 2.3286105488296016e-08
a O 0 1.2805477922483988e-07
result O 0 6.553484155347178e-08
of O 0 1.0086235846529235e-08
the O 0 1.5689629151438567e-07
lack O 0 1.6385016010644904e-07
of O 0 3.473102339057732e-08
protection O 0 1.6290982784994412e-06
provided O 0 7.178426812970429e-07
by O 0 5.424859068625665e-07
vWf O 0 6.447859050240368e-05
. O 0 5.780028459412279e-06

Defective O 1 0.9901942610740662
thrombosis B-Disease 1 0.9995536208152771
in O 0 2.463737291691359e-05
mutant O 0 0.0028992716688662767
mice O 0 0.12636303901672363
was O 0 8.842214447213337e-05
also O 0 4.208533027849626e-06
evident O 0 8.984257533484197e-07
in O 0 2.4494330119750884e-08
an O 0 3.4733144360643564e-08
in O 0 1.4997385733295232e-07
vivo O 0 4.521506980381673e-06
model O 0 9.530297120363684e-07
of O 0 6.776277245990059e-07
vascular B-Disease 1 0.9834172129631042
injury I-Disease 0 0.3165384531021118
. O 0 1.2767915904987603e-05

In O 0 7.233580618049018e-06
this O 0 2.2555494183507108e-07
model O 0 1.0056970722871483e-06
, O 0 1.63860789825776e-07
the O 0 2.261591163232879e-07
exteriorized O 0 3.835260577034205e-05
mesentery O 0 0.00014629772340413183
was O 0 1.5206810530798975e-05
superfused O 0 2.0389299606904387e-05
with O 0 6.674644623672066e-07
ferric O 0 0.00021237501641735435
chloride O 0 4.03347221435979e-05
and O 0 4.3173773178750707e-07
the O 0 1.6968741078926541e-07
accumulation O 0 9.076483138414915e-07
of O 0 1.1096769014784513e-07
fluorescently O 0 0.0002553575031924993
labeled O 0 5.307366154738702e-05
platelets O 0 6.242439849302173e-05
was O 0 4.083156909473473e-06
observed O 0 6.003243697705329e-07
by O 0 1.31138520487184e-07
intravital O 0 2.1507867131731473e-05
microscopy O 0 1.4798501979385037e-05
. O 0 3.3418264138163067e-06

We O 0 1.999931009777356e-05
conclude O 0 4.502706360653974e-06
that O 0 1.4456830399467435e-07
these O 0 7.403456692145483e-08
mice O 0 2.3376869648927823e-05
very O 0 3.993405357505253e-07
closely O 0 5.7394363466301e-06
mimic O 0 0.00040285332943312824
severe O 0 0.007102108560502529
human O 0 9.190515265800059e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
and O 0 1.653236904530786e-05
will O 0 8.667740871715068e-07
be O 0 9.234440767613705e-08
very O 0 1.8959221748104937e-08
useful O 0 9.36403843354583e-09
for O 0 7.636454135706572e-09
investigating O 0 3.506469781200394e-08
the O 0 1.993255871468591e-08
role O 0 6.667182361752566e-08
of O 0 2.991683700770409e-08
vWf O 0 2.4453938749502413e-06
in O 0 9.443787263307968e-08
normal O 0 6.700979042761901e-07
physiology O 0 7.011644242993498e-07
and O 0 7.48476963963185e-07
in O 0 2.1752630345872603e-06
disease O 0 2.1872743673156947e-05
models O 0 3.1028971534396987e-06
. O 0 4.1969269659603015e-07
. O 0 2.150183263438521e-06

Oral O 0 0.0014615905238315463
contraceptives O 0 0.034320633858442307
and O 0 1.2836345376854297e-05
the O 0 3.332997493998846e-06
risk O 0 4.693250957643613e-05
of O 0 2.303682776982896e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.365638546412811e-05

Hereditary B-Disease 1 0.9999985694885254
Ovarian I-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9997872710227966
Clinical O 0 0.00041886535473167896
Study O 0 1.4979795196268242e-05
Group O 0 2.79073301499011e-05
. O 0 6.5635936152830254e-06

BACKGROUND O 0 0.0004139791417401284
Women O 0 1.0169580491492525e-05
with O 0 7.958184937706392e-07
mutations O 0 7.763145731587429e-06
in O 0 1.0715611864497987e-07
either O 0 1.9814186202893325e-07
the O 0 4.5379687207969255e-07
BRCA1 O 0 6.514100823551416e-05
or O 0 6.63227751829254e-07
the O 0 6.905532359269273e-07
BRCA2 O 0 4.82133254990913e-05
gene O 0 5.025718792239786e-07
have O 0 7.746852759282774e-08
a O 0 6.299509891505295e-07
high O 0 1.7380056306137703e-05
lifetime O 0 8.492544111504685e-06
risk O 0 1.3638158634421416e-05
of O 0 4.85827295051422e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.545261122577358e-05

Oral O 0 0.0017746150260791183
contraceptives O 1 0.6371632814407349
protect O 0 0.0032894175965338945
against O 1 0.7608567476272583
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.12040367841837e-06
general O 0 3.9958857200872444e-07
, O 0 1.3247027652596444e-07
but O 0 2.9302681170406686e-08
it O 0 1.5203596603896585e-08
is O 0 2.40359661063394e-08
not O 0 7.648523592251877e-09
known O 0 4.402563646976887e-08
whether O 0 1.942994032333445e-08
they O 0 2.8752857872405002e-08
also O 0 4.931516741635278e-07
protect O 0 1.0258150950903655e-06
against O 0 2.1708638087147847e-06
hereditary B-Disease 0 0.005134664010256529
forms I-Disease 0 6.755739377695136e-06
of I-Disease 0 0.00015668819833081216
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 2.2949227059143595e-05

METHODS O 0 2.783423951768782e-05
We O 0 1.3332504522622912e-06
enrolled O 0 1.3644928458234062e-06
207 O 0 4.242778686602833e-06
women O 0 2.690928340598475e-06
with O 0 6.949737871764228e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.918023023492424e-06
161 O 0 7.906939458734996e-07
of O 0 3.974495399461375e-08
their O 0 2.0921525845096767e-07
sisters O 0 8.362267180928029e-06
as O 0 1.217018024135541e-07
controls O 0 7.787383538016002e-07
in O 0 4.406016174129945e-08
a O 0 3.3414013955734845e-07
case O 0 1.1808253930212231e-06
- O 0 2.397103344264906e-05
control O 0 2.373756160523044e-06
study O 0 8.761052754380216e-07
. O 0 2.0278548618080094e-06

All O 0 4.576890660246136e-06
the O 0 1.1464941280792118e-06
patients O 0 4.0071186049317475e-06
carried O 0 7.686945764362463e-07
a O 0 5.666674951498862e-07
pathogenic O 0 2.79692744697968e-06
mutation O 0 2.8800639029213926e-06
in O 0 1.5683913545672112e-07
either O 0 1.4036638731340645e-06
BRCA1 O 0 0.0002014083875110373
( O 0 1.1100722758783377e-06
179 O 0 1.4273124406827264e-06
women O 0 1.056407541000226e-06
) O 0 1.9376949467186932e-07
or O 0 9.622665402275743e-07
BRCA2 O 0 0.0003351209743414074
( O 0 6.846574933661032e-07
28 O 0 2.791674887703266e-06
women O 0 1.0809316108861822e-06
) O 0 7.650846214346529e-07
. O 0 1.7545172568134149e-06

The O 0 9.758974556461908e-06
control O 0 1.3076976756565273e-05
women O 0 3.924420070688939e-06
were O 0 3.4945460924973304e-07
enrolled O 0 2.218524883801365e-07
regardless O 0 5.265350822014625e-08
of O 0 7.76950415115607e-09
whether O 0 5.6075354137874456e-08
or O 0 2.7676213676386396e-07
not O 0 6.503179150740834e-08
they O 0 4.9293209514189584e-08
had O 0 3.961881702707615e-06
either O 0 1.250382183570764e-06
mutation O 0 1.502913346485002e-05
. O 0 2.2995345716481097e-06

Lifetime O 0 0.00017807644326239824
histories O 0 2.5364508474012837e-05
of O 0 5.025925133850251e-07
oral O 0 8.223733857448678e-06
- O 0 4.743239333038218e-05
contraceptive O 0 0.0001244158629560843
use O 0 4.2087270912816166e-07
were O 0 5.600394388238783e-07
obtained O 0 3.784714408539003e-08
by O 0 1.5549749932119994e-08
interview O 0 1.462187583456398e-06
or O 0 6.391887552581466e-08
by O 0 2.0108981146904625e-08
written O 0 9.981688009474965e-08
questionnaire O 0 2.459705399360246e-07
and O 0 2.3690515149610292e-07
were O 0 3.0381124815903604e-07
compared O 0 1.2546033758553676e-06
between O 0 2.982949638408172e-07
patients O 0 6.659200266767584e-07
and O 0 4.1649101945040456e-07
control O 0 3.623997372415033e-06
women O 0 1.3881074210075894e-06
, O 0 7.249149547305933e-08
after O 0 1.2352874989574048e-07
adjustment O 0 2.5369692480126105e-07
for O 0 1.6374388067674772e-08
year O 0 7.930170653480673e-08
of O 0 2.3851555397413904e-08
birth O 0 3.5576329082687153e-06
and O 0 5.062836976321705e-07
parity O 0 1.660869747865945e-05
. O 0 3.6641565657191677e-06

RESULTS O 0 0.0001377846347168088
The O 0 2.692979705898324e-06
adjusted O 0 0.00021140709577593952
odds O 0 9.734775085235015e-05
ratio O 0 0.00017869046132545918
for O 0 0.0018667083932086825
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 3.3876158340717666e-06
with O 0 6.704252086819906e-08
any O 0 2.99525808600265e-08
past O 0 6.801326435379451e-08
use O 0 4.3329112742185316e-08
of O 0 8.290830066925992e-08
oral O 0 3.179616442139377e-06
contraceptives O 0 0.0006931603420525789
was O 0 3.634471431723796e-05
0 O 0 5.5663022067165e-06
. O 0 3.5751629638980376e-06

5 O 0 5.044737918069586e-05
( O 0 2.526645175748854e-06
95 O 0 2.3029670046526007e-06
percent O 0 5.960343514743727e-06
confidence O 0 9.900314807964605e-07
interval O 0 5.450897901937424e-07
, O 0 2.1887792911456927e-08
0 O 0 6.303121580231164e-08
. O 0 7.934766621531253e-09
3 O 0 4.88568332457362e-08
to O 0 2.82324066347428e-08
0 O 0 2.4206013904404244e-07
. O 0 5.129624014443834e-08
8 O 0 5.231076443124039e-07
) O 0 3.3230270446438226e-07
. O 0 1.382402956551232e-06

The O 0 2.815687912516296e-05
risk O 0 4.48434948339127e-05
decreased O 0 1.077644537872402e-05
with O 0 7.023731996014249e-08
increasing O 0 2.3487733358251717e-07
duration O 0 4.3967148144474777e-07
of O 0 1.1155887769120909e-08
use O 0 1.1949639144859248e-07
( O 0 2.341446787568202e-07
P O 0 5.0922476475534495e-06
for O 0 3.094767464517645e-08
trend O 0 6.100694918131921e-07
, O 0 2.9114433530708084e-08
< O 0 3.300438891074009e-07
0 O 0 8.60183249073998e-08
. O 0 1.4211505749983644e-08
001 O 0 3.795544216700364e-07
) O 0 1.5666207886511074e-08
; O 0 1.1790654674825873e-08
use O 0 8.258125738791477e-09
for O 0 1.649991787644467e-08
six O 0 1.0058938926249539e-07
or O 0 7.50876409938428e-08
more O 0 2.386780195706706e-08
years O 0 1.4326704445011273e-07
was O 0 8.773042736720527e-07
associated O 0 4.09829787884064e-08
with O 0 1.2338201571537866e-08
a O 0 4.610253654391272e-07
60 O 0 9.871756674328935e-07
percent O 0 8.134835525197559e-07
reduction O 0 1.3611604572361102e-06
in O 0 5.787546228930296e-07
risk O 0 8.666222129249945e-06
. O 0 2.9833583994332002e-06

Oral O 0 0.0011758325854316354
- O 0 0.0008073142962530255
contraceptive O 0 0.0005160506698302925
use O 0 5.331205557013163e-06
protected O 0 0.00019601940584834665
against O 1 0.6031436324119568
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
both O 0 2.5036445094883675e-07
for O 0 3.746940890891892e-08
carriers O 0 9.232221032107191e-08
of O 0 1.2600522403261039e-08
the O 0 6.475466420852172e-07
BRCA1 O 0 0.0004969583242200315
mutation O 0 1.2689850336755626e-05
( O 0 2.2003661115377326e-07
odds O 0 3.5009779821848497e-06
ratio O 0 1.638243702473119e-06
, O 0 6.260705731619964e-08
0 O 0 1.2049771669353504e-07
. O 0 1.68615859053034e-08
5 O 0 4.557059440912781e-08
; O 0 2.8936780083199665e-08
95 O 0 1.4687881844110962e-07
percent O 0 8.357495744348853e-07
confidence O 0 1.3953007282907492e-07
interval O 0 1.453344111723709e-07
, O 0 1.5480265957990014e-08
0 O 0 2.998190495873132e-08
. O 0 8.774312831860698e-09
3 O 0 2.46053524222134e-08
to O 0 1.645720359988445e-08
0 O 0 8.998409128935236e-08
. O 0 2.057329062665758e-08
9 O 0 3.311543252948468e-07
) O 0 1.4546802873383058e-08
and O 0 1.0505604386423784e-08
for O 0 1.212087941127038e-08
carriers O 0 3.221998312596952e-08
of O 0 9.439245829412357e-09
the O 0 5.090045078759431e-07
BRCA2 O 0 0.00040748901665210724
mutation O 0 4.979156074114144e-06
( O 0 1.1388688392344193e-07
odds O 0 1.5569297602269216e-06
ratio O 0 1.0219347359452513e-06
, O 0 6.340331992760184e-08
0 O 0 6.968766541604055e-08
. O 0 7.402959578683976e-09
4 O 0 4.595850100486132e-08
; O 0 2.9126599798701136e-08
95 O 0 2.050896483751785e-07
percent O 0 4.721478035207838e-07
confidence O 0 1.3058341608029878e-07
interval O 0 1.2180885278212372e-07
, O 0 1.2506734314854384e-08
0 O 0 3.9041541555207004e-08
. O 0 6.4903269425542476e-09
2 O 0 3.628260003551986e-08
to O 0 1.3741358273478e-08
1 O 0 1.5527525931702257e-07
. O 0 4.594448199668477e-08
1 O 0 3.9169691490315017e-07
) O 0 4.903772037323506e-07
. O 0 1.0917007102762e-06

CONCLUSIONS O 0 0.00010680533887352794
Oral O 0 7.932375592645258e-05
- O 0 0.00020044416305609047
contraceptive O 0 0.00014770784764550626
use O 0 1.6790697827673284e-06
may O 0 2.7755243081628578e-06
reduce O 0 5.957377879894921e-07
the O 0 2.2629826901265915e-07
risk O 0 3.367503722984111e-06
of O 0 1.7961510820896365e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
in O 0 9.70453925219772e-07
women O 0 1.0090450359712122e-06
with O 0 2.885197147861618e-07
pathogenic O 0 5.4280135373119265e-06
mutations O 0 3.6249859931558603e-06
in O 0 1.1031055180410476e-07
the O 0 1.3625358405988663e-06
BRCA1 O 0 0.0006537463050335646
or O 0 2.7103091269964352e-05
BRCA2 O 0 0.0013059783959761262
gene O 0 0.00025385728804394603

A O 0 0.00013192494225222617
Japanese O 0 3.060000381083228e-05
family O 0 5.265132585918764e-06
with O 0 5.539702669921098e-06
adrenoleukodystrophy B-Disease 1 0.9999992847442627
with O 0 1.4520351214741822e-06
a O 0 3.6902333704347257e-06
codon O 0 1.8251093933940865e-05
291 O 0 4.60930868939613e-06
deletion O 0 1.071750284609152e-05
: O 0 1.184690248123843e-07
a O 0 3.4562782502689515e-07
clinical O 0 6.819525879109278e-06
, O 0 2.192523567146054e-07
biochemical O 0 8.052853445406072e-06
, O 0 2.8527696827040927e-07
pathological O 0 6.233197836991167e-06
, O 0 2.2516742603784223e-07
and O 0 1.5322408444262692e-06
genetic O 0 1.9462118871160783e-05
report O 0 3.9375263440888375e-06
. O 0 3.338787564644008e-06

We O 0 1.573475674376823e-05
report O 0 1.0891664032897097e-06
a O 0 6.19147442648682e-07
Japanese O 0 2.6411798899061978e-06
family O 0 3.923380063497461e-06
with O 0 2.1353585907490924e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.013244404457509518
ALD B-Disease 1 1.0
) O 0 5.644793077408394e-07
with O 0 4.661542263306728e-08
a O 0 6.42685733964754e-07
three O 0 2.7036227834287274e-07
base O 0 1.317800638389599e-06
pair O 0 1.590801366546657e-05
deletion O 0 5.13862214575056e-05
( O 0 4.834486162508256e-07
delGAG O 0 5.870994300494203e-06
291 O 0 8.467761176689237e-07
) O 0 8.881725221954184e-08
in O 0 1.2045107666835975e-07
the O 0 3.8015648442524252e-06
ALD B-Disease 1 0.9999998807907104
gene O 0 4.860636545345187e-05
. O 0 8.552198778488673e-06

A O 0 4.282679219613783e-05
variety O 0 3.2472923976456514e-06
of O 0 6.16113993601175e-07
phenotypes O 0 0.00013084363308735192
were O 0 2.2798253667133395e-06
observed O 0 7.000880373198015e-07
within O 0 6.303493904624702e-08
this O 0 1.0829503338527502e-07
family O 0 2.133767566192546e-06
. O 0 3.87427098758053e-06

While O 0 1.8154179997509345e-05
the O 0 9.463727224101603e-07
proband O 0 5.7769422710407525e-05
( O 0 9.241503562407161e-07
patient O 0 3.867375198751688e-06
1 O 0 1.105831074710295e-06
) O 0 1.899676362882019e-07
was O 0 2.464686303937924e-06
classified O 0 2.5309884676971706e-07
as O 0 2.5540958858982776e-07
having O 0 2.424602882911131e-07
a O 0 3.579259271191404e-07
rare O 0 4.165561904301285e-07
intermediate O 0 3.2458851251249143e-07
type O 0 2.1623681334403955e-07
of O 0 4.617394822048482e-08
adult O 0 8.437889846391045e-06
cerebral O 0 0.00028500636108219624
and O 0 2.227761342510348e-06
cerebello O 0 0.0016151252202689648
- O 0 0.042672596871852875
brain O 0 7.206964073702693e-05
stem O 0 1.9768219772231532e-06
forms O 0 1.2244922231730015e-07
, O 0 7.462191575768884e-08
his O 0 6.474206770690216e-07
younger O 0 3.635420625869301e-06
brother O 0 7.815067874616943e-06
( O 0 1.5912360140646342e-07
patient O 0 9.007997050503036e-07
2 O 0 8.899053227651166e-07
) O 0 9.47012281926618e-08
and O 0 3.1502679576078663e-07
nephew O 0 0.00017670972738415003
( O 0 6.844388167337456e-07
patient O 0 1.4530658063449664e-06
3 O 0 9.339067332803097e-07
) O 0 1.0380105663898576e-07
had O 0 1.8119872038369067e-06
a O 0 6.341665084619308e-06
childhood O 0 0.006887784693390131
ALD B-Disease 1 1.0
type O 0 8.032832556637004e-05
. O 0 7.144638857425889e-06

Another O 0 6.373145151883364e-05
nephew O 0 0.0013494594022631645
( O 0 9.26242137211375e-06
patient O 0 7.423800525430124e-06
4 O 0 2.4268986180686625e-06
) O 0 7.129795420723894e-08
of O 0 3.849458707350095e-08
patient O 0 3.3765074931579875e-06
1 O 0 2.4116893655445892e-06
was O 0 1.4766232197871432e-05
classified O 0 7.845376899240364e-07
as O 0 2.8912899097122136e-07
having O 0 1.4914331813997705e-07
an O 0 1.5981282786015072e-07
adolescent O 0 3.3557662391103804e-05
form O 0 2.9079694741085405e-06
. O 0 3.6085950796405086e-06

The O 0 5.702847374777775e-06
tau O 0 6.506518730020616e-06
level O 0 3.2376459557781345e-07
in O 0 1.0406113659655603e-07
the O 0 5.803397016279632e-07
cerebrospinal O 0 0.0013783533358946443
fluid O 0 0.00048740580677986145
( O 0 5.48118168808287e-06
CSF O 0 0.00505601754412055
) O 0 5.1312973425865493e-08
in O 0 5.847441997275382e-08
patient O 0 1.6847174038048252e-06
1 O 0 1.6040373793657636e-06
was O 0 1.2155222066212445e-05
as O 0 1.904912068084741e-07
high O 0 1.0254923381580738e-06
as O 0 1.1132383548329017e-07
that O 0 2.234082963070705e-08
of O 0 1.0509636894084906e-07
patients O 0 6.567287982761627e-06
with O 0 2.246877738798503e-05
Alzheimers B-Disease 1 0.9999992847442627
disease I-Disease 0 0.008358141407370567
( O 0 7.445684673257347e-07
AD B-Disease 0 1.3172703802410979e-05
) O 0 8.064766348070407e-07
. O 0 2.3162158413470024e-06

His O 0 0.00011797902698162943
brain O 0 0.0005843384424224496
magnetic O 0 2.7241123461863026e-05
resonance O 0 1.9614273696788587e-05
image O 0 0.00015598889149259776
( O 0 2.0272671008569887e-06
MRI O 0 0.0007717832922935486
) O 0 3.931091669073794e-06
showed O 0 0.0014181742444634438
abnormalities B-Disease 0 0.4123033881187439
in I-Disease 0 1.3833522416462074e-07
the I-Disease 0 4.576396293032303e-07
bilateral I-Disease 0 3.311304226372158e-06
cerebellar I-Disease 0 0.17861685156822205
hemispheres I-Disease 0 0.00017233789549209177
and O 0 1.5010010429250542e-05
brain O 0 0.0001583779085194692
stem O 0 4.0403310777037404e-06
, O 0 1.231082080721535e-07
but O 0 4.7198302155493366e-08
not O 0 1.484460909750851e-08
in O 0 3.5128159936448355e-08
the O 0 9.082588121600566e-07
cerebral O 0 0.0011177895357832313
white O 0 3.1396102713188156e-05
matter O 0 1.2965236351192289e-07
, O 0 3.100734957683926e-08
where O 0 3.47494442110019e-08
marked O 0 3.5054139857493283e-07
reductions O 0 2.5705219286464853e-07
of O 0 9.18549680761771e-09
the O 0 4.3044684616688755e-07
cerebral O 0 0.00024712938466109335
blood O 0 4.029517640447011e-06
flow O 0 1.0740531024566735e-06
and O 0 5.228183681538212e-07
oxygen O 0 2.05846527023823e-06
metabolism O 0 1.533844624646008e-06
were O 0 1.4912042445303086e-07
clearly O 0 5.06496689922642e-07
demonstrated O 0 3.491654467779881e-07
by O 0 6.073630487435366e-08
positron O 0 1.4099201507633552e-05
emission O 0 6.4230789575958624e-06
tomography O 0 0.00013178084918763489
( O 0 2.1239372927084332e-06
PET O 0 1.1657817594823427e-05
) O 0 1.3417853779174038e-06
. O 0 1.798673451958166e-06

In O 0 2.9298515073605813e-05
patients O 0 2.6375570087111555e-05
2 O 0 1.7282357021031203e-06
and O 0 5.526645168174582e-07
3 O 0 1.0514704626984894e-06
, O 0 4.696974542639509e-08
the O 0 9.674085532651588e-08
autopsy O 0 0.00010586518328636885
findings O 0 2.247181100756279e-06
showed O 0 3.2741147151682526e-05
massive O 0 1.5964000340318307e-05
demyelination B-Disease 1 0.9999676942825317
of I-Disease 0 4.4776209051633487e-07
the I-Disease 0 5.086636974738212e-06
cerebral I-Disease 0 0.12601274251937866
white I-Disease 0 5.182558743399568e-05
matter I-Disease 0 9.620080021477406e-08
with O 0 3.4560731165811376e-08
sparing O 0 4.2518942677816085e-07
of O 0 3.019233574264035e-08
the O 0 2.559519032274693e-07
U O 0 0.0002206467470386997
- O 0 0.001330151571892202
fibers O 0 2.4087719793897122e-05
, O 0 3.6873654352120866e-08
compatible O 0 1.5403281850012718e-07
with O 0 4.2262474408971684e-08
the O 0 1.4355930488818558e-07
findings O 0 8.472575814266747e-07
of O 0 4.977856633558986e-07
childhood O 0 0.0016999890794977546
ALD B-Disease 1 1.0
. O 0 3.672167440527119e-05

Oleic O 1 0.9976944327354431
and O 0 0.00019230286125093699
erucic O 0 0.43838852643966675
acids O 0 0.0001835602306528017
( O 0 1.3030007721681613e-06
Lorenzos O 0 1.9742859876714647e-05
Oil O 0 3.2726459266996244e-06
) O 0 3.849965324320692e-08
were O 0 2.0377125764525772e-08
administered O 0 6.344650671508134e-08
to O 0 4.3515708370023276e-08
patients O 0 1.9286390795514308e-07
1 O 0 1.2026110596252693e-07
and O 0 1.4824907168531354e-07
4 O 0 6.687017730655498e-07
, O 0 3.119409086593805e-08
but O 0 2.0059985672560288e-08
sufficient O 0 4.894105387620584e-08
effectiveness O 0 3.764262146432884e-07
was O 0 5.34478795088944e-06
not O 0 1.1609013483848685e-07
obtained O 0 6.994640102675476e-07
. O 0 1.872892653409508e-06

The O 0 1.127389714383753e-05
findings O 0 4.2212991502310615e-06
in O 0 2.539344166052615e-07
this O 0 6.196411561631976e-08
family O 0 3.91931592957917e-07
suggest O 0 1.5865931857206306e-07
that O 0 5.403236613688023e-08
delGAG291 O 0 5.045128091296647e-06
is O 0 5.300234562355399e-08
part O 0 2.5449288898471423e-08
of O 0 1.3704949175519232e-08
the O 0 2.4455755465169204e-07
cause O 0 1.2256001582500176e-06
of O 0 1.6349832776541007e-07
Japanese O 0 4.901070496998727e-05
ALD B-Disease 1 0.9999992847442627
with O 0 8.426507065451005e-07
phenotypic O 0 4.2977921111742035e-05
variations O 0 4.932329829898663e-05
. O 0 5.527991561393719e-06

Moreover O 0 7.38576491130516e-05
, O 0 1.0462022146384697e-06
although O 0 8.550551200414702e-08
the O 0 2.2703600777163047e-08
scale O 0 3.2916437930907705e-07
of O 0 8.621078961823514e-09
the O 0 7.148014447011519e-08
study O 0 3.9575052568352476e-08
is O 0 7.845289218266771e-08
limited O 0 6.379513450838203e-08
, O 0 2.9611245011551546e-08
there O 0 6.697769894259409e-09
is O 0 7.284156833264888e-09
a O 0 2.8469523627450144e-08
possibility O 0 5.7771238459736196e-08
that O 0 3.865497788524408e-08
PET O 0 1.2839133205488906e-06
can O 0 1.0514970227859521e-07
detect O 0 1.2467576198105235e-06
an O 0 1.2592646214670822e-07
insidious B-Disease 0 0.0009959841845557094
lesion I-Disease 0 0.43343260884284973
which O 0 8.424514135185746e-07
is O 0 1.8020594438894477e-07
undetectable O 0 1.0350997854402522e-06
by O 0 2.773544416356799e-08
computed O 0 1.5109534388102475e-06
tomogram O 0 2.671949732757639e-05
( O 0 3.6053575058758724e-07
CT O 0 9.679365757619962e-05
) O 0 8.532907003200307e-08
or O 0 7.048586070368401e-08
MRI O 0 5.6400108405796345e-06
analysis O 0 1.492837782279821e-07
, O 0 6.715694667036587e-08
and O 0 7.848956329326029e-08
that O 0 8.637620396712009e-09
the O 0 3.117065716651268e-08
higher O 0 1.9131613271383685e-07
level O 0 1.8933997480985454e-08
of O 0 1.0562504648703452e-08
tau O 0 1.1683662393124905e-07
reflects O 0 6.271546482139456e-08
the O 0 1.7894715043098586e-08
process O 0 1.0233240033130642e-07
of O 0 2.414316497834079e-07
neuronal B-Disease 0 0.011081145144999027
degeneration I-Disease 1 0.9553599953651428
in O 0 0.00021661302889697254
ALD B-Disease 1 1.0
. O 0 6.558730092365295e-05

Lorenzos O 0 0.003937626723200083
Oil O 0 0.0009094414999708533
should O 0 1.7041002138284966e-06
be O 0 5.953715387363445e-08
given O 0 2.6187015222944865e-08
in O 0 2.9405420320927078e-08
the O 0 9.562400293816609e-08
early O 0 1.4124674407867133e-06
stage O 0 8.523693395545706e-06
. O 0 3.4756277500491706e-07
. O 0 1.4482153574135737e-06

Nonsense O 0 0.004605626687407494
mutation O 0 0.00019199961388949305
in O 0 1.2372722721920582e-06
exon O 0 1.9879038518411107e-05
4 O 0 3.631289928307524e-06
of O 0 9.077879070673589e-08
human O 0 5.188437626202358e-07
complement O 0 1.4712738902744604e-06
C9 O 0 7.809919043211266e-05
gene O 0 1.1821018688351614e-06
is O 0 1.1392425847134291e-07
the O 0 9.7900255013883e-08
major O 0 2.889804022743192e-07
cause O 0 1.4986591168053565e-06
of O 0 1.5212160064947966e-07
Japanese O 0 5.02498460264178e-06
complement B-Disease 0 8.697614975972101e-05
C9 I-Disease 1 0.8098023533821106
deficiency I-Disease 0 0.012550656683743
. O 0 5.5718041949148756e-06

Deficiency B-Disease 1 0.9992490410804749
of I-Disease 0 1.8381555264568306e-06
the I-Disease 0 1.1283568710496183e-06
ninth I-Disease 0 3.2850453862920403e-05
component I-Disease 0 4.6068123538134387e-07
of I-Disease 0 1.47595153876523e-08
human I-Disease 0 5.452047702192431e-08
complement I-Disease 0 4.849706556342426e-07
( O 0 3.6288557225816476e-07
C9 O 0 4.7097139031393453e-05
) O 0 5.856739804244171e-08
is O 0 1.5100049211014266e-08
the O 0 3.1422022317428855e-08
most O 0 1.9196731670945155e-07
common O 0 2.9766979423584417e-05
complement B-Disease 1 0.9999923706054688
deficiency I-Disease 1 0.9999972581863403
in O 0 7.197655804702663e-07
Japan O 0 8.67233836743253e-07
but O 0 1.1951621559092018e-07
is O 0 4.9493216636165016e-08
rare O 0 5.343679987390715e-08
in O 0 4.0731890749157174e-08
other O 0 3.516596791541815e-08
countries O 0 8.10914499993487e-08
. O 0 1.6688259165675845e-06

We O 0 8.993508345156442e-06
studied O 0 9.915783039105008e-07
the O 0 9.866809591585479e-08
molecular O 0 5.34260493623151e-07
basis O 0 5.071071313977882e-07
of O 0 2.1689804725610884e-06
C9 B-Disease 1 0.9995104074478149
deficiency I-Disease 0 0.0706356018781662
in O 0 2.412052140243759e-07
four O 0 5.87455019740446e-07
Japanese O 0 1.1133482985314913e-05
C9 B-Disease 0 0.004780659452080727
- I-Disease 0 0.17479035258293152
deficient I-Disease 0 0.0024376772344112396
patients O 0 1.2465431609598454e-05
who O 0 7.860956429794896e-06
had O 0 0.0014000848168507218
suffered O 1 0.8817636966705322
from O 0 0.00012442974548321217
meningococcal B-Disease 1 0.9999998807907104
meningitis I-Disease 1 0.9999992847442627
. O 0 4.677795368479565e-05

Direct O 0 4.559206354315393e-05
sequencing O 0 2.546424002503045e-05
of O 0 1.2931860737808165e-06
amplified O 0 3.4300923289265484e-05
C9 O 0 0.00011025692947441712
cDNA O 0 1.7353988368995488e-05
and O 0 1.269784434043686e-06
DNA O 0 7.212021955638193e-06
revealed O 0 1.3688304534298368e-06
a O 0 3.061055906528054e-07
nonsense O 0 2.2074500520830043e-06
substitution O 0 6.51307914267818e-07
( O 0 1.9587191957270988e-07
CGA O 0 2.1492467567441054e-05
- O 0 9.144104842562228e-05
- O 0 3.968719101976603e-05
> O 0 3.875570655509364e-06
TGA O 0 1.0463504622748587e-05
) O 0 1.0677317874296932e-07
at O 0 4.641394468762883e-08
codon O 0 6.304666726464347e-07
95 O 0 1.2948049743499723e-07
in O 0 4.452293467238633e-08
exon O 0 2.2115402771305526e-06
4 O 0 6.616950258830911e-07
in O 0 7.056509332414862e-08
the O 0 1.5095636740625196e-07
four O 0 1.9558947315090336e-06
C9 B-Disease 0 0.012446939013898373
- I-Disease 0 0.0728592574596405
deficient I-Disease 0 0.0005671845865435898
individuals O 0 1.0013196742875152e-06
. O 0 2.7363219032849884e-06

An O 0 1.59021292347461e-05
allele O 0 6.81063684169203e-05
- O 0 1.5418409020639956e-05
specific O 0 5.540619554267323e-07
polymerase O 0 5.147941919858567e-06
chain O 0 5.5737386901455466e-06
reaction O 0 4.283395469428797e-07
system O 0 2.0209516549130058e-07
designed O 0 1.3887588465877343e-06
to O 0 4.9256836831546025e-08
detect O 0 1.2792846746378927e-06
exclusively O 0 1.4101482292971923e-07
only O 0 1.8147209956964616e-08
one O 0 7.711732585846676e-09
of O 0 4.785556839692617e-09
the O 0 1.9646529736405682e-08
normal O 0 1.6006602265861147e-07
and O 0 1.8862398576402484e-07
mutant O 0 3.970339548686752e-06
alleles O 0 5.680445269717893e-07
indicated O 0 4.14120194136558e-07
that O 0 7.426323112014188e-09
all O 0 2.7965334492563443e-09
the O 0 3.6655855240042e-08
four O 0 9.325885912403464e-07
patients O 0 1.2098679462724249e-06
were O 0 5.816517614221084e-07
homozygous O 0 2.4120138277794467e-06
for O 0 1.4823530847252187e-08
the O 0 5.786420231856937e-08
mutation O 0 3.1714048986941634e-07
in O 0 2.3227819667681615e-08
exon O 0 2.297594619449228e-06
4 O 0 1.837631430134934e-06
and O 0 4.841720624426671e-07
that O 0 2.7536302127373347e-08
the O 0 5.0092101133714095e-08
parents O 0 6.573802835418974e-08
of O 0 2.519923114618905e-08
patient O 0 3.0070498269196833e-06
2 O 0 1.5998331264199805e-06
were O 0 1.5634260535080102e-06
heterozygous O 0 1.316543512075441e-05
. O 0 1.6323938325513154e-06

The O 0 1.2629485354409553e-05
common O 0 4.068398084200453e-06
mutation O 0 4.125853592995554e-06
at O 0 1.666524696020133e-07
codon O 0 1.306610556639498e-06
95 O 0 4.057867215578881e-07
in O 0 9.865114947160691e-08
exon O 0 4.220095888740616e-06
4 O 0 2.841259401975549e-06
might O 0 9.359895898342074e-07
be O 0 5.240583433874235e-08
responsible O 0 6.737414537383302e-08
for O 0 4.662494035301279e-08
most O 0 4.7028734684317897e-07
Japanese O 0 3.245335756218992e-05
C9 B-Disease 0 0.3957878351211548
deficiency I-Disease 0 0.0010219557443633676
. O 0 4.825310497835744e-07
. O 0 3.788174126384547e-06

BRCA1 O 0 0.00571603374555707
required O 0 4.672884642786812e-06
for O 0 2.892028874157404e-07
transcription O 0 9.485951522947289e-06
- O 0 0.00028974757879041135
coupled O 0 0.0002895857614930719
repair O 0 0.00019287779286969453
of O 0 9.58101963988156e-07
oxidative O 0 0.0005422286340035498
DNA O 0 0.00025935054873116314
damage O 0 0.00030030927155166864
. O 0 9.911917004501447e-06

The O 0 0.00012907566269859672
breast B-Disease 1 0.9997614026069641
and I-Disease 1 0.9718092679977417
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.42982274293899536
gene O 0 5.729496115236543e-05
BRCA1 O 0 0.00020647521887440234
encodes O 0 1.6395895727328025e-05
a O 0 4.994319169782102e-05
zinc O 0 0.23898670077323914
finger O 0 0.00015016994439065456
protein O 0 1.183896870315948e-06
of O 0 1.0249589621480482e-07
unknown O 0 2.0266252249712124e-06
function O 0 1.3405791605691775e-06
. O 0 2.6997320219379617e-06

Association O 0 5.3102874517207965e-05
of O 0 6.528682092721283e-07
the O 0 6.501715574813716e-07
BRCA1 O 0 2.751117426669225e-05
protein O 0 6.186793370943633e-07
with O 0 4.9275818980731856e-08
the O 0 2.869588797693723e-07
DNA O 0 6.629572453675792e-06
repair O 0 4.989163426216692e-05
protein O 0 1.6028599247874808e-06
Rad51 O 0 3.2460695365443826e-05
and O 0 1.8214522867765481e-07
changes O 0 1.1856849368996336e-07
in O 0 1.4856079921798937e-08
the O 0 3.4531147719008004e-08
phosphorylation O 0 1.1750427830747867e-07
and O 0 1.1896015905676904e-07
cellular O 0 4.1484594248686335e-07
localization O 0 5.847330157848774e-07
of O 0 1.201348531765234e-08
the O 0 5.539679293065092e-08
protein O 0 2.0350856289041985e-07
after O 0 1.4893906552515546e-07
exposure O 0 2.30406030254926e-07
to O 0 2.2140351774169176e-08
DNA O 0 1.2877061408289592e-06
- O 0 4.580838321999181e-06
damaging O 0 1.0784933692775667e-06
agents O 0 8.655435834725722e-08
are O 0 1.2307152630341989e-08
consistent O 0 1.1285370504765524e-07
with O 0 1.785533676468276e-08
a O 0 1.6555691217945423e-07
role O 0 2.8776867111446336e-07
for O 0 2.1823433371537249e-07
BRCA1 O 0 2.3167185645434074e-05
in O 0 5.879516606910329e-07
DNA O 0 3.700610977830365e-05
repair O 0 0.00026460870867595077
. O 0 7.193762940005399e-06

Here O 0 1.362341754429508e-05
, O 0 6.177089630909904e-07
it O 0 8.049938315934924e-08
is O 0 7.051100681110256e-08
shown O 0 1.8695256187584164e-07
that O 0 8.410363960820177e-08
mouse O 0 6.50374058750458e-05
embryonic O 0 3.8346097426256165e-05
stem O 0 3.1130701245274395e-05
cells O 0 1.4329480109154247e-05
deficient B-Disease 0 2.9059401640552096e-05
in I-Disease 0 3.5919728702538123e-07
BRCA1 I-Disease 0 5.686424265149981e-05
are O 0 1.1493039409060657e-07
defective O 0 9.60252873483114e-06
in O 0 3.045138043944462e-07
the O 0 1.4857319285965787e-07
ability O 0 1.6620677456558042e-07
to O 0 2.2445215464017565e-08
carry O 0 7.529143175588615e-08
out O 0 6.150911957547578e-08
transcription O 0 9.933170304066152e-07
- O 0 1.5110949789232109e-05
coupled O 0 1.8636561435414478e-05
repair O 0 2.2133581296657212e-05
of O 0 7.558251979844499e-08
oxidative O 0 2.492388739483431e-05
DNA O 0 0.000118291522085201
damage O 0 8.007226279005408e-05
, O 0 2.7753790732276684e-07
and O 0 4.562164690469217e-07
are O 0 4.954147669877784e-08
hypersensitive O 0 6.766720161976991e-06
to O 0 9.150707569460792e-07
ionizing O 0 0.00017567722534295171
radiation O 0 6.191437569214031e-05
and O 0 6.434947295019811e-07
hydrogen O 0 8.85714416654082e-06
peroxide O 0 0.00035036212648265064
. O 0 5.780083483841736e-06

These O 0 8.043260095291771e-06
results O 0 5.468812105391407e-06
suggest O 0 1.6418379118476878e-06
that O 0 1.754559519895338e-07
BRCA1 O 0 3.4100990887964144e-05
participates O 0 7.335523264373478e-07
, O 0 1.7671844432243233e-07
directly O 0 1.4409260984393768e-07
or O 0 3.1008005407784367e-07
indirectly O 0 3.2149881690202164e-07
, O 0 1.8228419662591477e-08
in O 0 2.1961811924597896e-08
transcription O 0 2.6714749310485786e-06
- O 0 0.0001962376554729417
coupled O 0 5.889213571208529e-05
repair O 0 3.215833567082882e-05
of O 0 2.399836205313477e-07
oxidative O 0 0.0001243070000782609
DNA O 0 9.721305104903877e-05
damage O 0 0.0001061858783941716
. O 0 1.3312418332134257e-06
. O 0 4.121307483728742e-06

Truncation O 0 0.014305293560028076
mutations O 0 0.0023629574570804834
in O 0 2.528387767597451e-06
the O 0 8.739622785469692e-07
transactivation O 0 6.299514643615112e-05
region O 0 3.306927283119876e-06
of O 0 3.234806627006037e-07
PAX6 O 0 0.0003093079139944166
result O 0 1.4671071539851255e-06
in O 0 4.2366991692688316e-07
dominant O 0 1.990989039768465e-05
- O 0 0.0006595326121896505
negative O 0 1.643630093894899e-05
mutants O 0 8.795458415988833e-05
. O 0 4.076231107319472e-06

PAX6 O 0 0.011347256600856781
is O 0 6.093059255363187e-06
a O 0 2.6365971734776394e-06
transcription O 0 7.911172360763885e-06
factor O 0 7.634869234607322e-07
with O 0 9.097396969082183e-08
two O 0 4.216721833927295e-07
DNA O 0 4.997623818780994e-06
- O 0 1.3783871509076562e-05
binding O 0 8.773962463237694e-07
domains O 0 6.539168566632725e-07
( O 0 1.6347244979897368e-07
paired O 0 1.50437824686378e-06
box O 0 8.677015102875885e-06
and O 0 1.4278964499681024e-06
homeobox O 0 1.9270046323072165e-05
) O 0 1.304907897292651e-07
and O 0 6.681733566438197e-08
a O 0 6.07956565090717e-07
proline O 0 4.681418795371428e-05
- O 0 5.373827298171818e-05
serine O 0 1.5368303138529882e-05
- O 0 2.1454439774970524e-05
threonine O 0 4.395605719764717e-05
( O 0 7.811751174813253e-07
PST O 0 5.703982606064528e-05
) O 0 4.574407057589269e-07
- O 0 1.2646298273466527e-05
rich O 0 1.2627127716768882e-06
transactivation O 0 3.285524871898815e-05
domain O 0 4.048160462843953e-06
. O 0 2.7150379082740983e-06

PAX6 O 0 0.04785488173365593
regulates O 0 0.0006583374924957752
eye O 0 0.001084782648831606
development O 0 1.9759265796892578e-06
in O 0 2.550255260302947e-07
animals O 0 1.7062177448678995e-07
ranging O 0 1.694855740197454e-07
from O 0 3.345788357478341e-08
jellyfish O 0 2.9747340590802196e-07
to O 0 3.893988065328813e-08
Drosophila O 0 5.041363237978658e-07
to O 0 1.134449334472265e-07
humans O 0 6.426403729165031e-07
. O 0 1.9782175968430238e-06

Heterozygous O 0 0.19886615872383118
mutations O 0 0.0016933823935687542
in O 0 1.6767799024819396e-06
the O 0 4.595351299485628e-07
human O 0 1.1885282447110512e-06
PAX6 O 0 0.00035730053787119687
gene O 0 5.058665919932537e-06
result O 0 9.052183713720297e-07
in O 0 1.5701108679877507e-07
various O 0 1.2173175889529375e-07
phenotypes O 0 3.714835474966094e-05
, O 0 3.461417463768157e-07
including O 0 9.00504289802484e-07
aniridia B-Disease 1 0.9999997615814209
, O 0 3.8043377571739256e-05
Peters B-Disease 1 0.9999992847442627
anomaly I-Disease 1 0.9999977350234985
, O 0 2.680141551536508e-05
autosomal B-Disease 0 0.1129671186208725
dominant I-Disease 0 0.003102622926235199
keratitis I-Disease 1 0.814720630645752
, O 0 7.674664630030748e-06
and O 0 2.6819619961315766e-05
familial B-Disease 1 0.6795454621315002
foveal I-Disease 1 0.9958702921867371
dysplasia I-Disease 1 0.999993085861206
. O 0 5.678030720446259e-05

It O 0 1.213601808558451e-05
is O 0 9.775823173185927e-07
believed O 0 6.645256007686839e-07
that O 0 2.5199037523293555e-08
the O 0 9.363881048329858e-08
mutated O 0 9.335415597888641e-06
allele O 0 2.559968606874463e-06
of O 0 7.16018604407509e-08
PAX6 O 0 5.047452214057557e-05
produces O 0 3.035859208466718e-07
an O 0 3.369547840748055e-08
inactive O 0 4.5725181507805246e-07
protein O 0 4.1887503243742685e-07
and O 0 1.0561275303189177e-06
aniridia B-Disease 1 0.9999910593032837
is O 0 1.4289508953879704e-06
caused O 0 1.7327689647572697e-06
due O 0 5.619751277663454e-07
to O 0 5.58593910682248e-07
genetic O 0 4.6781122364336625e-05
haploinsufficiency O 0 0.0002936700184363872
. O 0 5.215333658270538e-06

However O 0 2.5393117539351806e-05
, O 0 4.1034766695702274e-07
several O 0 2.8665635909419507e-07
truncation O 0 0.00010355911945225671
mutations O 0 6.692840543109924e-05
have O 0 4.434470781689015e-07
been O 0 2.3488048839226394e-07
found O 0 1.0993771581979672e-07
to O 0 5.1449980276174756e-08
occur O 0 4.3037289287894964e-08
in O 0 1.6694730931021695e-08
the O 0 1.4063931530472473e-07
C O 0 2.4789671442704275e-05
- O 0 2.12837039725855e-05
terminal O 0 7.822278348612599e-06
half O 0 2.3249675962233596e-07
of O 0 3.032062423358184e-08
PAX6 O 0 2.3465674530598335e-05
in O 0 4.939862492392422e-07
patients O 0 1.515119151918043e-06
with O 0 9.487710599387356e-07
Aniridia B-Disease 1 0.9999982118606567
resulting O 0 9.415562089998275e-06
in O 0 8.785151095480614e-08
mutant O 0 2.114378048645449e-06
proteins O 0 6.108227523782261e-08
that O 0 1.7312753897158473e-08
retain O 0 1.1433328239718321e-07
the O 0 5.894787946658653e-08
DNA O 0 5.710297159566835e-07
- O 0 1.5922681768643088e-06
binding O 0 1.90148710998983e-07
domains O 0 1.4472004750132328e-07
but O 0 8.962575037685383e-08
have O 0 3.1664123412156187e-07
lost O 0 2.859834921764559e-06
most O 0 2.3921717939856535e-08
of O 0 1.4564681016793202e-08
the O 0 3.149360736642848e-07
transactivation O 0 3.782470230362378e-05
domain O 0 5.2230534492991865e-06
. O 0 2.646424263730296e-06

It O 0 7.91005641076481e-06
is O 0 7.526817284997378e-07
not O 0 7.956168701639399e-08
clear O 0 2.2754935002922139e-07
whether O 0 3.6390581215073325e-08
such O 0 2.301920432046245e-08
mutants O 0 2.347722511331085e-05
really O 0 1.0034618753707036e-06
behave O 0 2.5052924002011423e-07
as O 0 6.286984444159316e-08
loss O 0 7.052135515550617e-07
- O 0 2.7719004265236435e-06
of O 0 6.311567091188408e-08
- O 0 1.216264263348421e-05
function O 0 2.0011896140204044e-07
mutants O 0 1.2430155038600788e-06
as O 0 1.2854002306994516e-07
predicted O 0 1.9535830233508023e-06
by O 0 2.287425360236739e-07
haploinsufficiency O 0 5.146566400071606e-05
. O 0 2.1753876353614032e-06

Contrary O 0 6.549405225086957e-05
to O 0 5.957883786322782e-07
this O 0 8.802913953331881e-08
theory O 0 1.4499606493245665e-07
, O 0 4.9433683813049356e-08
our O 0 1.8789663158713665e-08
data O 0 1.5043136158965353e-07
showed O 0 1.4611169945055735e-06
that O 0 1.035802910109851e-08
these O 0 1.1325020921049145e-08
mutants O 0 1.1794926422226126e-06
are O 0 1.8134890922283375e-08
dominant O 0 4.2012280232484045e-07
- O 0 4.548542165139224e-06
negative O 0 4.304222045448114e-07
in O 0 8.71134915314542e-08
transient O 0 5.7034349083551206e-06
transfection O 0 5.775928366347216e-05
assays O 0 9.813356882659718e-06
when O 0 1.6738772501412313e-07
they O 0 3.7936981556185856e-08
are O 0 2.3357053180461662e-08
coexpressed O 0 1.4848312730464386e-06
with O 0 1.0535627126273539e-07
wild O 0 1.8722782897384604e-06
- O 0 0.00012867970508523285
type O 0 1.8531520254327916e-05
PAX6 O 0 0.00029179954435676336
. O 0 7.992236533027608e-06

We O 0 7.5045786616101395e-06
found O 0 4.4517165065371955e-07
that O 0 3.868307985044339e-08
the O 0 9.012424584398104e-08
dominant O 0 4.386861292005051e-06
- O 0 8.249464735854417e-05
negative O 0 2.146683755199774e-06
effects O 0 3.490383278403897e-06
result O 0 1.6564692373322032e-07
from O 0 1.71494125567051e-08
the O 0 2.9430390569018527e-08
enhanced O 0 1.940945821843343e-06
DNA O 0 1.8782586721499683e-06
binding O 0 2.6846970513361157e-07
ability O 0 8.570373211114202e-08
of O 0 2.981845170779707e-08
these O 0 1.6785273260211397e-07
mutants O 0 3.193000520695932e-05
. O 0 2.8038627988280496e-06

Kinetic O 0 0.00018301043019164354
studies O 0 2.0406509975146037e-06
of O 0 7.58877405360181e-08
binding O 0 8.505704158778826e-07
and O 0 8.57950510635419e-07
dissociation O 0 2.8318909244262613e-05
revealed O 0 4.156765953666763e-06
that O 0 2.1166803421124314e-08
various O 0 2.4098627093849245e-08
truncation O 0 7.967214514792431e-06
mutants O 0 8.577340850024484e-06
have O 0 8.767140258214567e-08
3 O 0 3.1120580956667254e-07
- O 0 3.676284904940985e-06
5 O 0 2.8752646130669746e-07
- O 0 1.519010993433767e-06
fold O 0 9.85092697192158e-07
higher O 0 7.831012283077143e-08
affinity O 0 4.131938524665202e-08
to O 0 4.199383063507867e-09
various O 0 6.4300245128379174e-09
DNA O 0 3.2580331321696576e-07
- O 0 3.393936651718832e-07
binding O 0 7.529000356498727e-08
sites O 0 3.9766565151921895e-08
when O 0 2.1770421909650395e-08
compared O 0 7.839141602516975e-08
with O 0 2.2807592259255216e-08
the O 0 1.6765930865858536e-07
wild O 0 3.0043352126085665e-06
- O 0 0.00015994973364286125
type O 0 1.3816892533213831e-05
PAX6 O 0 0.0003525879583321512
. O 0 4.8453234740009066e-06

These O 0 3.7580814478133107e-06
results O 0 1.814318125070713e-06
provide O 0 9.89153150499078e-08
a O 0 3.408734698950866e-07
new O 0 6.706618478347082e-07
insight O 0 4.455768305433594e-07
into O 0 2.3955184502710836e-08
the O 0 2.3396381720885984e-08
role O 0 8.026588460552375e-08
of O 0 7.48948352224943e-08
mutant O 0 2.2178546714712866e-05
PAX6 O 0 8.743002399569377e-05
in O 0 1.3205117284087464e-06
causing O 0 2.4238330297521316e-05
aniridia B-Disease 1 0.999911904335022
. O 0 1.8693077663556323e-06
. O 0 3.996848136011977e-06

Reversal O 0 0.0029737709555774927
of O 0 4.741900920635089e-05
severe O 1 0.9997774958610535
hypertrophic B-Disease 1 0.9999990463256836
cardiomyopathy I-Disease 1 1.0
and O 0 0.0031223525293171406
excellent O 0 5.2787061576964334e-05
neuropsychologic O 0 0.00023050804156810045
outcome O 0 2.8347474199108547e-06
in O 0 3.9247802874342597e-07
very B-Disease 0 5.946507712906168e-07
- I-Disease 0 0.0006379307014867663
long I-Disease 0 3.0831823096377775e-05
- I-Disease 0 4.501577859628014e-05
chain I-Disease 0 9.949913874152116e-06
acyl I-Disease 0 3.7308852824935457e-06
- I-Disease 0 8.361422260350082e-06
coenzyme I-Disease 0 1.6238172975135967e-05
A I-Disease 0 3.7176916521275416e-05
dehydrogenase I-Disease 0 0.10797382891178131
deficiency I-Disease 0 0.18823663890361786
. O 0 1.1207284842384979e-05

Very B-Disease 0 7.558442302979529e-05
- I-Disease 0 0.0009657411719672382
long I-Disease 0 2.9470234949258156e-05
- I-Disease 0 7.841426122467965e-05
chain I-Disease 0 1.254235758096911e-05
acyl I-Disease 0 3.4544927984825335e-06
- I-Disease 0 1.5789447616043617e-06
coenzyme I-Disease 0 8.278289556074014e-07
A I-Disease 0 1.4268946415540995e-06
dehydrogenase I-Disease 0 4.563699258142151e-05
( I-Disease 0 3.637792133304174e-06
VLCAD I-Disease 0 0.18220117688179016
) I-Disease 0 2.920489714597352e-05
deficiency I-Disease 0 0.0006947562796995044
is O 0 1.694820213060666e-07
a O 0 4.6068348638073076e-06
disorder O 0 0.0038610114715993404
of O 0 2.1798348370793974e-07
fatty O 0 3.497803118079901e-05
acid O 0 4.604441073752241e-06
beta O 0 2.5407635462215694e-07
oxidation O 0 3.4010875538115215e-07
that O 0 2.8393927209435788e-08
reportedly O 0 1.6173395351870568e-06
has O 0 2.0665483191351086e-07
high O 0 8.765456982473552e-07
rates O 0 1.1783716900026775e-06
of O 0 1.1442883618428823e-07
morbidity O 0 0.16191424429416656
and O 0 4.403791081131203e-06
mortality O 0 0.0009290581801906228
. O 0 2.7145122203364735e-06

We O 0 9.851284630713053e-06
describe O 0 2.7795397272711853e-06
the O 0 2.3554535744096938e-07
outcome O 0 1.9116785665573843e-07
of O 0 2.1752864398649763e-08
a O 0 3.9187963807307824e-07
5 O 0 1.2572946843647514e-06
- O 0 1.4834506146144122e-05
year O 0 3.1727904570288956e-07
- O 0 5.71714190300554e-06
old O 0 4.646625257009873e-06
girl O 0 3.9668535464443266e-05
with O 0 2.025908906944096e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
who O 0 1.0197783012699801e-05
was O 0 2.6891402740147896e-06
first O 0 2.074126115303443e-07
seen O 0 4.696383371083357e-07
at O 0 3.970600559455306e-08
5 O 0 7.787028266648122e-08
months O 0 6.179993761179503e-08
of O 0 1.3297361434183586e-08
age O 0 3.279758402641164e-07
with O 0 2.159086761821527e-06
severe O 1 0.9845251441001892
hypertrophic B-Disease 1 0.9999926090240479
cardiomyopathy I-Disease 1 1.0
, O 0 0.4531838297843933
hepatomegaly B-Disease 1 1.0
, O 0 0.008553270250558853
encephalopathy B-Disease 1 0.7802779078483582
, O 0 1.615015321476676e-06
and O 0 5.108980531076668e-06
hypotonia B-Disease 1 0.6803780794143677
. O 0 1.159764997282764e-05

Biochemical O 0 0.005501885432749987
studies O 0 0.0007324862526729703
indicated O 1 0.9235889911651611
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0002975876850541681
by O 0 5.061799583927495e-07
a O 0 5.756396149081411e-06
stable O 0 0.00013539704377762973
yet O 0 3.3855228593893116e-06
inactive O 0 1.4564422599505633e-05
enzyme O 0 1.7889031369122677e-05
. O 0 6.36237064099987e-06

Molecular O 0 0.00020145467715337873
genetic O 0 3.409750934224576e-05
analysis O 0 1.3502611864169012e-06
of O 0 2.2920417563909723e-07
her O 0 1.199067264678888e-05
VLCAD O 0 0.015776347368955612
gene O 0 7.665521479793824e-06
revealed O 0 7.329856089199893e-06
a O 0 2.091174110319116e-06
T1372C O 0 5.483585118781775e-05
( O 0 7.971751188051712e-07
F458L O 0 7.540074420830933e-06
) O 0 5.450986009236658e-07
missense O 0 2.328879781998694e-05
mutation O 0 4.054605142300716e-06
and O 0 5.63892228910845e-07
a O 0 9.812327334657311e-06
1668 O 0 0.005946986377239227
ACAG O 0 0.001104576513171196
1669 O 0 0.00010925907554337755
splice O 0 0.0005025058053433895
site O 0 6.378582475008443e-05
mutation O 0 9.19240846997127e-05
. O 0 6.8444019234448206e-06

After O 0 6.460674194386229e-05
initial O 0 1.21130306069972e-05
treatment O 0 5.050721938459901e-06
with O 0 4.5224845734992414e-07
intravenous O 0 9.412829967914149e-05
glucose O 0 0.0009423978044651449
and O 0 1.06287711787445e-06
carnitine O 0 4.765011908602901e-06
, O 0 4.425227118076691e-08
the O 0 5.724496432435444e-08
patient O 0 2.0985080482205376e-06
has O 0 6.679617854388198e-07
thrived O 0 5.697861524822656e-07
on O 0 1.6053459717113583e-07
a O 0 3.036733460248797e-07
low O 0 8.89813691173913e-06
- O 0 1.5254539903253317e-05
fat O 0 2.8187912448629504e-06
diet O 0 3.2499769986316096e-07
supplemented O 0 1.0275897466271999e-07
with O 0 3.085955313508748e-08
medium O 0 1.264269599232648e-06
- O 0 1.954570871021133e-05
chain O 0 5.378048172133276e-06
triglyceride O 0 4.265835286787478e-06
oil O 0 8.340758768099477e-07
and O 0 1.7418288678072713e-07
carnitine O 0 3.4410941225360148e-06
and O 0 1.2985678665700107e-07
avoidance O 0 2.462714746798156e-06
of O 0 6.02106922542589e-07
fasting O 0 0.00027448739274404943
. O 0 5.78225535718957e-06

Her O 0 0.002156658563762903
ventricular O 1 0.9535424709320068
hypertrophy O 1 0.7978065013885498
resolved O 0 5.362401498132385e-05
significantly O 0 1.1145360076625366e-05
over O 0 3.447646577114938e-07
1 O 0 1.4472434486378916e-06
year O 0 4.777871254191268e-07
, O 0 1.3641633245242701e-07
and O 0 8.575660217502445e-07
cognitively O 0 1.722813794913236e-05
, O 0 2.1523976556636626e-07
she O 0 5.982274728921766e-07
is O 0 1.3910127272254158e-08
in O 0 1.4971398343277542e-08
the O 0 8.950189567258349e-08
superior O 0 3.4509730539866723e-06
range O 0 5.131845455252915e-07
for O 0 1.0851793774691032e-07
age O 0 9.118084562942386e-07
. O 0 1.314917085437628e-06

Clinical O 0 0.0005519873229786754
recognition O 0 3.929417653125711e-05
of O 0 0.00020751473493874073
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.07174912247865e-06
important O 0 1.328827607949279e-07
because O 0 1.6003382086182683e-07
it O 0 3.616597510358588e-08
is O 0 2.8372111771091113e-08
one O 0 1.133137317310684e-08
of O 0 7.563381920761003e-09
the O 0 1.0593357302468576e-07
few O 0 4.2518215082054667e-07
directly O 0 2.028185463132104e-06
treatable O 0 0.0001977217907551676
causes O 0 2.3590914679516573e-06
of O 0 1.6070017636593548e-06
cardiomyopathy B-Disease 1 1.0
in O 0 2.593209319456946e-05
children O 0 2.6546884328126907e-05
. O 0 1.0233761713607237e-06
. O 0 3.857643150695367e-06

Cloning O 0 7.788217772031203e-05
of O 0 8.443810770586424e-07
a O 0 1.447750037186779e-06
novel O 0 2.0517115899565397e-06
member O 0 1.1033642977054114e-07
of O 0 2.297998591416217e-08
the O 0 1.317364279884714e-07
low O 0 2.2385020201909356e-05
- O 0 5.812938979943283e-05
density O 0 1.2473696187953465e-05
lipoprotein O 0 0.0002651266404427588
receptor O 0 1.5058429198688827e-05
family O 0 4.981887286703568e-06
. O 0 4.857648946199333e-06

A O 0 3.31285955326166e-05
gene O 0 1.1306089618301485e-05
encoding O 0 3.6659148463513702e-06
a O 0 3.798179932346102e-06
novel O 0 1.0255793313262984e-05
transmembrane O 0 8.260267350124195e-06
protein O 0 9.349413403469953e-07
was O 0 1.8245624460178078e-06
identified O 0 3.373149581875623e-07
by O 0 1.7731631274386928e-08
DNA O 0 4.675763705108693e-07
sequence O 0 9.29547780970097e-08
analysis O 0 5.2508688952457305e-08
within O 0 2.0507197717734016e-08
the O 0 2.110585342052218e-07
insulin B-Disease 0 0.006336390506476164
- I-Disease 1 0.782243013381958
dependent I-Disease 0 0.0529666393995285
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.157217674423009e-05
IDDM B-Disease 0 0.0011271160328760743
) O 0 1.7221548205270665e-06
locus O 0 3.052882675547153e-05
IDDM4 O 0 0.00015085868653841317
on O 0 1.2099316336389165e-05
chromosome O 0 0.000521456531714648
11q13 O 0 8.694837015355006e-05
. O 0 8.99988390301587e-06

Based O 0 2.36598225455964e-05
on O 0 1.1655455409709248e-06
its O 0 2.7799006829809514e-07
chromosomal O 0 0.00014678036677651107
position O 0 4.540463578450726e-06
, O 0 1.0541858586066155e-07
this O 0 1.830405871316998e-08
gene O 0 1.3454599923079513e-07
is O 0 4.407486997592969e-08
a O 0 1.3509989571502956e-07
candidate O 0 6.056371262275206e-07
for O 0 9.720641003241326e-08
conferring O 0 8.177505151252262e-06
susceptibility O 0 0.00026863726088777184
to O 0 1.125365997722838e-05
diabetes B-Disease 1 0.9141069054603577
. O 0 1.7028221918735653e-05

The O 0 5.778788363386411e-06
gene O 0 9.572485396347474e-06
, O 0 4.552911150312866e-07
termed O 0 7.02058287060936e-06
low O 0 2.9306758733582683e-05
- O 0 5.421776222647168e-05
density O 0 9.035253242473118e-06
lipoprotein O 0 0.00012706289999186993
receptor O 0 4.919130333291832e-06
related O 0 4.448193919870391e-07
protein O 0 1.7764116364560323e-06
5 O 0 2.0264917566237273e-06
( O 0 3.6178877849124547e-07
LRP5 O 0 4.73919280921109e-05
) O 0 7.86895242299579e-08
, O 0 1.269520844005001e-08
encodes O 0 9.96734357272544e-08
a O 0 6.620751236141587e-08
protein O 0 1.2340629496065958e-07
of O 0 2.6576582712323216e-08
1615 O 0 1.959484870894812e-05
amino O 0 2.5437213935219916e-07
acids O 0 9.989306448687785e-08
that O 0 4.809486142676178e-09
contains O 0 2.2546304379034154e-08
conserved O 0 1.7543739261327573e-07
modules O 0 6.666323884019221e-07
which O 0 1.1848101166833658e-07
are O 0 8.925348460309124e-09
characteristic O 0 7.541144242395603e-08
of O 0 6.030537402779146e-09
the O 0 7.162617521316861e-08
low O 0 1.3963624041934963e-05
- O 0 6.110660615377128e-05
density O 0 1.815830182749778e-05
lipoprotein O 0 0.0005515029770322144
( O 0 1.6192886960197939e-06
LDL O 0 8.955106750363484e-05
) O 0 6.945570589778072e-07
receptor O 0 3.4966569728567265e-06
family O 0 3.071816763622337e-06
. O 0 2.5134365841950057e-06

These O 0 2.9352186174946837e-06
modules O 0 5.124996732774889e-06
include O 0 4.6888112592569087e-07
a O 0 1.4679832247566083e-06
putative O 0 3.575083610485308e-05
signal O 0 2.6699475711211562e-05
peptide O 0 8.33055196380883e-07
for O 0 2.1149411111309746e-08
protein O 0 1.7528353168927424e-07
export O 0 7.695543757790801e-08
, O 0 3.272668536169476e-08
four O 0 1.0766152769292603e-07
epidermal O 0 7.848783752706368e-06
growth O 0 1.6688227333361283e-06
factor O 0 2.7078340281150304e-07
( O 0 1.315849971206262e-07
EGF O 0 7.061179985612398e-06
) O 0 1.547464734130699e-07
repeats O 0 1.1881031696248101e-06
with O 0 1.307855512777678e-07
associated O 0 5.552902848648955e-07
spacer O 0 3.39625112246722e-05
domains O 0 1.732149371491687e-06
, O 0 1.5111652373889228e-07
three O 0 2.0761328300977766e-07
LDL O 0 3.859792559524067e-05
- O 0 3.456420745351352e-05
receptor O 0 2.7868495635630097e-06
( O 0 2.1217294943198794e-07
LDLR O 0 1.2718964171654079e-05
) O 0 1.4326690234156558e-07
repeats O 0 1.209539163937734e-06
, O 0 3.613866539353694e-08
a O 0 1.4702119699450122e-07
single O 0 2.100670599247678e-06
transmembrane O 0 1.023790105136868e-06
spanning O 0 4.474479169402912e-07
domain O 0 1.0389157267809424e-07
, O 0 2.580833147192152e-08
and O 0 4.9199936569266356e-08
a O 0 3.68255882676749e-07
cytoplasmic O 0 6.942882464500144e-06
domain O 0 4.8876959226618055e-06
. O 0 3.316085667393054e-06

The O 0 5.5658883866271935e-06
encoded O 0 4.249921857990557e-06
protein O 0 2.7651781238091644e-06
has O 0 2.5037687123585783e-07
a O 0 1.5668872777041543e-07
unique O 0 2.2270721444783703e-07
organization O 0 6.653703366055197e-08
of O 0 3.5697340194928984e-08
EGF O 0 1.5041278857097495e-05
and O 0 6.372210350491514e-07
LDLR O 0 0.00010351962555432692
repeats O 0 1.232835347764194e-05
; O 0 2.851034253126272e-07
therefore O 0 4.43682246498156e-08
, O 0 3.756486677275461e-08
LRP5 O 0 1.62426022143336e-05
likely O 0 4.907435027234897e-07
represents O 0 6.062635549142215e-08
a O 0 6.264516372311846e-08
new O 0 1.667178111119938e-07
category O 0 2.1319766574379173e-07
of O 0 2.7218922227234543e-08
the O 0 4.2529728716544923e-07
LDLR O 0 0.0001733694807626307
family O 0 5.146729108673753e-06
. O 0 4.456959686649498e-06

Both O 0 2.0285788195906207e-05
human O 0 2.5467511477472726e-06
and O 0 1.1681461273838067e-06
mouse O 0 7.82121715019457e-05
LRP5 O 0 0.00019610728486441076
cDNAs O 0 1.767870162439067e-05
have O 0 5.81136134769622e-07
been O 0 3.263029952904617e-07
isolated O 0 1.2454183888621628e-06
and O 0 1.4618122179399506e-07
the O 0 4.7542176417891824e-08
encoded O 0 2.0295328795327805e-07
mature O 0 9.23581424672193e-08
proteins O 0 3.3885672934275135e-08
are O 0 8.784409644135849e-09
95 O 0 2.458096730606485e-07
% O 0 1.6001916947061545e-07
identical O 0 8.781077553976502e-07
, O 0 6.848201650200281e-08
indicating O 0 2.8788261374756985e-07
a O 0 2.771699314507714e-07
high O 0 1.6074508266683551e-06
degree O 0 1.6085887466488202e-07
of O 0 1.7528462237237363e-08
evolutionary O 0 1.1723602710844716e-06
conservation O 0 1.1801836308222846e-06
. O 0 3.4637818657756725e-07
. O 0 2.385557081652223e-06

The O 0 3.2002953957999125e-05
APC B-Disease 0 0.00010907577234320343
variants O 0 1.817448173824232e-05
I1307K O 0 2.8982989533687942e-05
and O 0 6.634364808633109e-07
E1317Q O 0 7.504492714360822e-06
are O 0 1.5689150245634664e-07
associated O 0 3.9600763557245955e-06
with O 1 0.5124992728233337
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.069169805618003e-05
but O 0 4.865791538577469e-07
not O 0 1.1024724244634854e-07
always O 0 7.411425428927032e-08
with O 0 2.8479409053261406e-08
a O 0 6.833443535469996e-07
family O 0 1.3017076980759157e-06
history O 0 8.913101510188426e-07
. O 0 2.1597559225483565e-06

Classical O 0 0.07651398330926895
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.9999988079071045
polyposis I-Disease 1 1.0
( O 0 0.07241930067539215
FAP B-Disease 0 0.0038213273510336876
) O 0 2.755858531600097e-06
is O 0 1.8810519009093696e-07
a O 0 1.0042871281257248e-06
high O 0 0.001195269520394504
- O 1 0.9998164772987366
penetrance O 1 0.9981788396835327
autosomal B-Disease 1 0.999554455280304
dominant I-Disease 1 0.8026981353759766
disease I-Disease 0 0.007446603383868933
that O 0 4.1348206991642655e-07
predisposes O 0 8.540470844309311e-06
to O 0 2.2806685251453018e-07
hundreds O 0 2.2821937761818845e-07
or O 0 3.0306031817417534e-07
thousands O 0 2.8909644811392354e-07
of O 0 5.252744449535385e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9950581789016724
carcinoma I-Disease 1 1.0
and O 0 2.3880951630417258e-05
that O 0 2.3807996285540867e-07
results O 0 6.586038807654404e-07
from O 0 1.2688242634339986e-07
truncating O 0 3.023186400241684e-05
mutations O 0 5.4197066674532834e-06
in O 0 9.351297336479547e-08
the O 0 6.671614869446785e-07
APC B-Disease 0 2.814675826812163e-05
gene O 0 1.1152450497320388e-05
. O 0 5.376935860113008e-06

A O 0 0.00011937638191739097
variant O 0 0.0005050132749602199
of O 0 4.148508651269367e-06
FAP B-Disease 0 0.0008908528834581375
is O 0 2.030748873949051e-05
attenuated B-Disease 1 0.9933724403381348
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999997615814209
, O 0 9.790725016500801e-06
which O 0 4.332217429237062e-07
results O 0 1.8519260436278273e-07
from O 0 4.611005266497159e-08
germ O 0 3.4562821383588016e-05
- O 0 0.0034049078822135925
line O 0 0.007390032988041639
mutations O 0 1.2635186976694968e-06
in O 0 2.041821112186426e-08
the O 0 7.944537827597742e-08
5 O 0 7.151361387514044e-07
and O 0 2.43679153300036e-07
3 O 0 5.122745960761677e-07
regions O 0 9.086107866096427e-08
of O 0 1.7874043578558485e-08
the O 0 3.786476838740782e-07
APC B-Disease 0 1.4977223145251628e-05
gene O 0 6.276264230109518e-06
. O 0 4.042755335831316e-06

Attenuated B-Disease 1 0.9999040365219116
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
patients O 1 0.9473297595977783
have O 0 1.3297635632625315e-05
" O 0 9.515216333966237e-06
multiple O 0 0.00018178866594098508
" O 1 0.964827835559845
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.28920573843061e-05
typically O 0 5.122956281411462e-07
fewer O 0 7.331551898914768e-08
than O 0 1.9206870760513084e-08
100 O 0 5.3904930297221654e-08
) O 0 4.3768679347522266e-08
without O 0 4.1885698465193855e-08
the O 0 1.1382238795931698e-07
florid O 0 0.0004896452301181853
phenotype O 0 0.0001391726837027818
of O 0 3.666900738608092e-07
classical O 0 1.008643812383525e-05
FAP B-Disease 0 0.00019186858844477683
. O 0 4.411668669490609e-06

Another O 0 3.706908682943322e-05
group O 0 4.9644099817669485e-06
of O 0 1.8557342684744071e-07
patients O 0 2.7062797016697004e-06
with O 0 2.2042054581561388e-07
multiple O 0 4.865608207182959e-05
adenomas B-Disease 0 0.19724373519420624
has O 0 1.4010348422743846e-05
no O 0 7.429576385220571e-07
mutations O 0 1.5864659417275107e-06
in O 0 5.5092588269189946e-08
the O 0 1.4940297887733323e-07
APC B-Disease 0 3.7993468140484765e-06
gene O 0 4.3652957515405433e-07
, O 0 8.248117211451245e-08
and O 0 1.6277147096843692e-07
their O 0 4.153728525579936e-07
phenotype O 0 0.0004611249314621091
probably O 0 8.326103966282972e-07
results O 0 9.718175419948238e-08
from O 0 1.638357183253447e-08
variation O 0 7.41682697480428e-07
at O 0 6.77609008903346e-08
a O 0 4.322176891946583e-07
locus O 0 7.4660597420006525e-06
, O 0 2.3151702066570579e-07
or O 0 1.6913519118588738e-07
loci O 0 6.132036105555017e-07
, O 0 4.943500542253787e-08
elsewhere O 0 7.142481450728155e-08
in O 0 2.9417988045565835e-08
the O 0 3.807617190432211e-07
genome O 0 7.2149582592828665e-06
. O 0 2.236279897260829e-06

Recently O 0 0.00046799893607385457
, O 0 1.7660299818089698e-06
however O 0 2.899778337450698e-07
, O 0 8.651144156601731e-08
a O 0 4.858103466176544e-07
missense O 0 3.781294071814045e-05
variant O 0 1.8924443793366663e-05
of O 0 2.5539301873322984e-07
APC B-Disease 0 2.0939296518918127e-05
( O 0 2.786148343147943e-07
I1307K O 0 5.484931079990929e-06
) O 0 2.3223061873522965e-07
was O 0 2.555480477894889e-06
described O 0 3.948424591726507e-07
that O 0 3.9001498919333244e-08
confers O 0 3.162694213187933e-07
an O 0 7.599855678108725e-08
increased O 0 1.674946179264225e-05
risk O 0 2.3925265850266442e-05
of O 0 0.007686192635446787
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.399634341709316e-06
including O 0 4.30850548127637e-07
multiple O 0 2.510669219191186e-05
adenomas B-Disease 0 0.01561612170189619
, O 0 6.466764830292959e-07
in O 0 1.4067219353819382e-06
Ashkenazim O 0 0.00021883529552724212
. O 0 4.974248440703377e-06

We O 0 2.2656098735751584e-05
have O 0 6.124233777882182e-07
studied O 0 2.1534491168040404e-07
a O 0 1.3963322942345258e-07
set O 0 2.6418447873766127e-07
of O 0 5.7294773370131225e-08
164 O 0 9.050837434187997e-06
patients O 0 4.202432592137484e-06
with O 0 1.9190192688256502e-06
multiple O 1 0.9916011691093445
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.014063785783946514
/ I-Disease 1 0.7142277956008911
or I-Disease 0 0.003524414263665676
carcinoma I-Disease 1 1.0
and O 0 1.0475406270415988e-05
analyzed O 0 1.605191755515989e-05
codons O 0 2.4498882339685224e-05
1263 O 0 7.418793393298984e-05
- O 0 5.5418855481548235e-05
1377 O 0 6.772955384803936e-05
( O 0 6.941332912901998e-07
exon O 0 1.3773333193967119e-05
15G O 0 2.25302701437613e-05
) O 0 9.222647179285559e-08
of O 0 1.430653284728578e-08
the O 0 9.366042519332041e-08
APC B-Disease 0 2.65878429672739e-06
gene O 0 5.482391998157254e-07
for O 0 1.250568857358303e-07
germ O 0 3.344781725900248e-05
- O 0 5.91165226069279e-05
line O 0 4.7083940444281325e-05
variants O 0 1.876248097687494e-05
. O 0 7.306796760531142e-06

Three O 0 0.0001569311716593802
patients O 0 3.2407057005912066e-05
with O 0 2.424177409920958e-07
the O 0 3.1502861475019017e-07
I1307K O 0 2.8740370908053592e-05
allele O 0 7.669557817280293e-06
were O 0 1.2503178368206136e-06
detected O 0 1.7575852098161704e-06
, O 0 4.803547781762063e-08
each O 0 2.976776691809846e-08
of O 0 1.1798262988804709e-07
Ashkenazi O 0 0.00029696812271140516
descent O 0 0.0001621631090529263
. O 0 7.440683930326486e-06

Four O 0 0.00027455229428596795
patients O 0 0.0002178399736294523
had O 0 5.721047273254953e-06
a O 0 1.3223025234765373e-06
germ O 0 0.00010087336704600602
- O 0 0.0005899243406020105
line O 0 0.00010677967657102272
E1317Q O 0 1.0685976121749263e-05
missense O 0 7.6269971032161266e-06
variant O 0 2.6661632546165492e-06
of O 0 1.1452927139998792e-07
APC O 0 4.99072712045745e-06
that O 0 1.6099269828373508e-07
was O 0 7.555651336588198e-06
not O 0 2.8697739296035252e-08
present O 0 3.3180548086875206e-08
in O 0 5.475819264688653e-08
controls O 0 1.353145853499882e-05
; O 0 4.4763015694115893e-07
one O 0 9.526115896107967e-09
of O 0 2.771337825890896e-09
these O 0 1.139635497082736e-08
individuals O 0 9.52589829239514e-09
had O 0 1.800509892291302e-07
an O 0 2.363026219143194e-08
unusually O 0 2.1366247437981656e-06
large O 0 4.800973485430404e-08
number O 0 2.742779692255226e-08
of O 0 3.123159331153147e-08
metaplastic B-Disease 0 4.57338901469484e-05
polyps I-Disease 0 2.6242669264320284e-05
of I-Disease 0 8.44645455799764e-08
the I-Disease 0 5.242233100943849e-07
colorectum I-Disease 0 0.00011189631186425686
. O 0 3.443135938141495e-06

There O 0 5.5975824579945765e-06
is O 0 3.3891109296746436e-07
increasing O 0 1.6752569820255303e-07
evidence O 0 8.546214047555623e-08
that O 0 4.6637747885824865e-08
there O 0 4.2590610149773056e-08
exist O 0 6.967344745589799e-08
germ O 0 1.2940982742293272e-05
- O 0 7.273639494087547e-05
line O 0 1.4827632185188122e-05
variants O 0 2.7417451065048226e-07
of O 0 1.5213576176620336e-08
the O 0 8.656426331299372e-08
APC B-Disease 0 2.263723899886827e-06
gene O 0 1.945015242199588e-07
that O 0 4.1269370143481865e-08
predispose O 0 4.006042786386388e-07
to O 0 2.0462303851331853e-08
the O 0 3.30979972318346e-08
development O 0 9.196632078101175e-08
of O 0 4.758218494771427e-07
multiple O 1 0.9989527463912964
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9960455298423767
carcinoma I-Disease 1 1.0
, O 0 9.097515430767089e-06
but O 0 1.28209705962945e-07
without O 0 3.248767654895346e-08
the O 0 1.4152543315049115e-07
florid O 0 0.022795766592025757
phenotype O 0 0.00014947009913157672
of O 0 7.540986501908264e-08
classical O 0 1.2700847946689464e-06
FAP B-Disease 0 1.0502904842724092e-05
, O 0 7.386714173662767e-08
and O 0 9.752898932902099e-08
possibly O 0 1.3402886622770893e-07
with O 0 4.7291660365544885e-08
importance O 0 8.703117941877281e-07
for O 0 0.269248366355896
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 1.3490241144609172e-05
in O 0 6.486604320343758e-08
the O 0 9.680545787205119e-08
general O 0 2.9482930585800204e-07
population O 0 2.3061090814735508e-07
. O 0 1.0996897259474281e-07
. O 0 1.3397267366599408e-06

Genomic O 0 0.0005875178030692041
structure O 0 2.3760034309816547e-05
of O 0 1.7263051859117695e-06
the O 0 1.9996639821329154e-05
human O 0 0.006619410589337349
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999985694885254
diarrhea I-Disease 1 1.0
( O 0 0.0007839738391339779
CLD B-Disease 0 0.4548558294773102
) O 0 6.388185738614993e-06
gene O 0 3.4561369830043986e-05
. O 0 1.4897167602612171e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999991655349731
diarrhea I-Disease 1 1.0
( O 0 0.10979790985584259
CLD B-Disease 1 0.9975520968437195
) O 0 1.3259570550872013e-05
is O 0 1.3869508848074474e-06
caused O 0 5.753388904849999e-06
by O 0 3.1630199259780056e-07
mutations O 0 5.513507858267985e-06
in O 0 9.203088779941027e-08
a O 0 9.42562678574177e-07
gene O 0 1.7882418887893436e-06
which O 0 4.195254348360322e-07
encodes O 0 3.3926075957424473e-06
an O 0 3.8097634842415573e-06
intestinal O 0 0.06240132823586464
anion O 0 0.00035251403460279107
transporter O 0 0.0023996741510927677
. O 0 1.8955906853079796e-05

We O 0 1.4994944649515674e-05
report O 0 2.031104486377444e-06
here O 0 8.723986866243649e-08
the O 0 5.834029082052439e-08
complete O 0 2.3687127281846188e-07
genomic O 0 9.609991593606537e-07
organization O 0 4.405890052794348e-08
of O 0 7.831770787447567e-09
the O 0 8.801806217206831e-08
human O 0 6.53612005407922e-07
CLD B-Disease 0 0.00013953517191112041
gene O 0 1.8055237660519197e-06
which O 0 2.511711159058905e-07
spans O 0 2.1748958261014195e-06
approximately O 0 2.8242541816325684e-07
39kb O 0 6.069697974453447e-06
, O 0 1.1478054773306212e-07
and O 0 1.2978449603906483e-07
comprises O 0 4.1187908550455177e-07
21 O 0 2.4409462184848962e-06
exons O 0 5.674469139194116e-05
. O 0 5.045671514380956e-06

All O 0 2.0997849787818268e-05
exon O 0 0.00021797399676870555
/ O 0 0.00016621063696220517
intron O 0 0.00029173141228966415
boundaries O 0 1.0829501661646646e-05
conform O 0 3.403560867809574e-06
to O 0 1.9467188394628465e-07
the O 0 1.183260224024707e-06
GT O 0 0.0003892769746016711
/ O 0 0.0009707248536869884
AG O 0 0.04904431477189064
rule O 0 1.3513056728697848e-05
. O 0 4.69329052066314e-06

An O 0 4.10736311096116e-06
analysis O 0 1.0896619642153382e-06
of O 0 8.732411060918821e-08
the O 0 2.1923480630903214e-07
putative O 0 1.1194701073691249e-05
promoter O 0 1.3711906831304077e-05
region O 0 9.232553566107526e-07
sequence O 0 9.877746833808487e-07
shows O 0 8.132298603413801e-07
a O 0 8.802542197372532e-07
putative O 0 6.236931221792474e-05
TATA O 0 2.772289553831797e-05
box O 0 2.406818339295569e-06
and O 0 3.4816190463971e-07
predicts O 0 3.5063708310190123e-06
multiple O 0 4.7303342398663517e-07
transcription O 0 2.0525415038719075e-06
factor O 0 7.02397244367603e-07
binding O 0 8.935007826949004e-07
sites O 0 1.5650953173462767e-06
. O 0 2.6667887595976936e-06

The O 0 1.1975451343460009e-05
genomic O 0 2.6811258067027666e-05
structure O 0 5.876865088794148e-06
was O 0 4.477997663343558e-06
determined O 0 5.731618557547336e-07
using O 0 2.1023649310336623e-07
DNA O 0 9.46537852541951e-07
from O 0 2.270377308377647e-08
several O 0 1.4110650425891436e-08
sources O 0 1.8194032946894367e-08
including O 0 1.0932438065935912e-08
multiple O 0 1.5653490947897808e-07
large O 0 1.6333594032857945e-07
- O 0 1.0031566489487886e-05
insert O 0 1.7509819372207858e-05
libaries O 0 9.614605914975982e-06
and O 0 1.6056827689681086e-07
genomic O 0 2.5553097202646313e-06
DNA O 0 1.440672008357069e-06
from O 0 2.495930004897673e-07
Finnish O 0 0.00041242915904149413
CLD B-Disease 0 0.341385155916214
patients O 0 2.170023253711406e-05
and O 0 1.983798483706778e-06
controls O 0 6.567141099367291e-05
. O 0 9.147303899226245e-06

Exon O 0 0.0012857711408287287
- O 0 0.00033754820469766855
specific O 0 2.377503506068024e-06
primers O 0 4.324878318584524e-05
developed O 0 4.79237451145309e-06
in O 0 1.0347074663741296e-07
this O 0 2.5890322774557717e-08
study O 0 3.454313457496028e-08
will O 0 2.9447964067230714e-08
facilitate O 0 1.5480803483569616e-07
mutation O 0 6.107972012614482e-07
screening O 0 2.2128725163383933e-07
studies O 0 7.413149916146722e-08
of O 0 6.708217625828183e-08
patients O 0 1.3640947145177051e-06
with O 0 3.02771724136619e-07
the O 0 1.986224924621638e-05
disease O 0 0.00031552472501061857
. O 0 4.5113720261724666e-06

Genomic O 0 0.0003071749524679035
sequencing O 0 3.687798380269669e-05
of O 0 9.194603762807674e-07
a O 0 8.072852324403357e-06
BAC O 0 0.000978256925009191
clone O 0 0.012654215097427368
H O 1 0.9999874830245972
_ O 0 9.547125046083238e-07
RG364P16 O 0 3.94099015466054e-06
revealed O 0 1.3903677427151706e-06
the O 0 4.30075033364119e-08
presence O 0 7.47388639865676e-08
of O 0 1.3936710452355783e-08
another O 0 2.143830641898603e-07
, O 0 4.488540028546595e-08
highly O 0 7.380405264711953e-08
homologous O 0 3.48339938227582e-07
gene O 0 2.2349358630435745e-07
3 O 0 1.8625745212830225e-07
of O 0 2.528864406770026e-08
the O 0 4.5007524818174716e-07
CLD B-Disease 0 0.0006421265425160527
gene O 0 1.2364231452011154e-06
, O 0 6.354532899877086e-08
with O 0 2.233477935931205e-08
a O 0 3.574259039851313e-07
similar O 0 3.4588006769809e-07
genomic O 0 1.5297398476832313e-06
structure O 0 8.724916256142023e-07
, O 0 1.4172033502291015e-07
recently O 0 1.1945370488319895e-06
identified O 0 6.555922027473571e-07
as O 0 3.398490378003771e-07
the O 0 6.039658546797e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.8829599109012634e-05
( O 0 3.4812715057341848e-06
PDS B-Disease 0 0.00016848686209414154
) O 0 5.731722581003851e-07
. O 0 2.8753933634106943e-07
. O 0 2.486415496605332e-06

The O 0 2.44523416768061e-05
APCI1307K O 0 0.0016402729088440537
allele O 0 0.0002413027104921639
and O 0 4.554716724669561e-05
cancer B-Disease 0 0.0015050030779093504
risk O 0 1.357169480797893e-06
in O 0 7.417393277364681e-08
a O 0 7.63960315453005e-07
community O 0 3.1240179509950394e-07
- O 0 1.7890497474581935e-05
based O 0 2.582106617410318e-07
study O 0 1.0002232642136732e-07
of O 0 8.573528731403712e-08
Ashkenazi O 0 0.00016467210662085563
Jews O 0 1.0721449143602513e-05
. O 0 4.883987458015326e-06

Mutations O 0 0.01155149471014738
in O 0 1.40661895784433e-05
APC O 0 8.190745575120673e-05
are O 0 1.702542476778035e-06
classically O 0 0.0034332468640059233
associated O 0 5.175471960683353e-05
with O 0 0.0004160815733484924
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0011437953216955066
FAP B-Disease 0 0.0004955084878019989
) O 0 7.048047905300336e-07
, O 0 1.997869816250386e-07
a O 0 5.504581622517435e-06
highly O 0 0.0008848056895658374
penetrant O 1 0.9997637867927551
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999995231628418
disorder I-Disease 1 1.0
characterized O 0 0.0994027853012085
by O 0 1.236251864611404e-05
multiple O 0 0.07708334177732468
intestinal O 1 0.9997007846832275
polyps B-Disease 1 0.8500947952270508
and O 0 3.306451162643498e-06
, O 0 2.2005865218943654e-07
without O 0 9.660293187607749e-08
surgical O 0 2.728243634919636e-05
intervention O 0 1.2589168818522012e-06
, O 0 4.357467631166401e-08
the O 0 3.668299086712068e-08
development O 0 6.781681349821156e-07
of O 0 0.0007056781905703247
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.0981594793265685e-05
CRC B-Disease 0 0.0007535333861596882
) O 0 2.261169129269547e-06
. O 0 4.194389020995004e-06

APC B-Disease 0 0.001599236624315381
is O 0 1.1311957678117324e-05
a O 0 2.6752795747597702e-05
tumour O 1 0.9999990463256836
- O 0 0.004157826770097017
suppressor O 0 0.0005568329943343997
gene O 0 6.408015906345099e-06
, O 0 3.9798285911274434e-07
and O 0 7.726987973910582e-07
somatic O 0 7.507217378588393e-05
loss O 0 0.00012944072659593076
occurs O 0 7.032785561023047e-06
in O 0 1.2322629117988981e-05
tumours B-Disease 1 0.9999997615814209
. O 0 3.670809019240551e-05

The O 0 2.861688881239388e-05
germline O 0 0.0006393658695742488
T O 0 0.0003151450655423105
- O 0 6.518026566482149e-06
to O 0 1.3156893885479803e-07
- O 0 4.519584308582125e-06
A O 0 8.342079240719613e-07
transversion O 0 5.759208306699293e-06
responsible O 0 1.2388646553063154e-07
for O 0 2.4781691365660663e-08
the O 0 1.2826426143419667e-07
APC O 0 4.200232979201246e-06
I1307K O 0 2.4759708594501717e-06
allele O 0 1.1325040532028652e-06
converts O 0 2.7048633910453646e-07
the O 0 3.119403046980551e-08
wild O 0 1.77876344764627e-07
- O 0 3.127952140857815e-06
type O 0 1.228562780397624e-07
sequence O 0 5.312015005642934e-08
to O 0 2.3466773413360897e-08
a O 0 1.3452946632241947e-06
homopolymer O 0 0.09598527103662491
tract O 0 0.08547092974185944
( O 0 1.6025205695768818e-06
A8 O 0 0.0038821264170110226
) O 0 1.9600160783284082e-07
that O 0 5.327711960489978e-08
is O 0 2.0505913767010497e-07
genetically O 0 8.646780770504847e-06
unstable O 0 0.0010812886757776141
and O 0 1.6025487639126368e-05
prone O 0 4.558118962449953e-05
to O 0 7.290511803148547e-07
somatic O 0 0.00015445523604284972
mutation O 0 6.204740930115804e-05
. O 0 7.4581530498107895e-06

The O 0 2.725318154261913e-05
I1307K O 0 0.00017692656547296792
allele O 0 0.00010532324813539162
was O 0 9.651151231082622e-06
found O 0 4.7646122425248905e-07
in O 0 4.539007534276607e-07
6 O 0 9.673283784650266e-06
. O 0 4.975207048119046e-06

1 O 0 6.330286123557016e-05
% O 0 3.4809991120710038e-06
of O 0 1.6395645729971875e-07
unselected O 0 6.405218300642446e-05
Ashkenazi O 0 0.000948500179219991
Jews O 0 5.1818146857840475e-06
and O 0 3.971597379859304e-07
higher O 0 5.387325927586062e-07
proportions O 0 1.151506126007007e-06
of O 0 5.0690690756027834e-08
Ashkenazim O 0 1.695499668130651e-05
with O 0 2.7399781288295344e-07
family O 0 1.0422336345072836e-06
or O 0 1.5575609779716615e-07
personal O 0 6.267617891353439e-07
histories O 0 8.425028568126436e-07
of O 0 1.3605526305582316e-07
CRC B-Disease 0 0.0001628585741855204
( O 0 3.94694495753356e-07
ref O 0 2.4620603653602302e-05
. O 0 1.8857380723602546e-07
2 O 0 1.0800877134897746e-06
) O 0 8.540142175661458e-07
. O 0 2.239564537376282e-06

To O 0 3.4302750009373995e-06
evaluate O 0 1.6724711713322904e-06
the O 0 1.0360227520322951e-07
role O 0 1.7490897619154566e-07
of O 0 6.317215195394965e-08
I1307K O 0 1.2133784366596956e-05
in O 0 1.2782688827428501e-06
cancer B-Disease 0 3.422090958338231e-05
, O 0 1.607407966730534e-07
we O 0 5.6263374403897615e-08
genotyped O 0 3.673673745652195e-06
5 O 0 3.660562697405112e-07
, O 0 1.7906960181335307e-07
081 O 0 1.1069156244047917e-05
Ashkenazi O 0 9.320612662122585e-06
volunteers O 0 3.2747669820309966e-07
in O 0 4.3121517023791966e-08
a O 0 2.9019614089520473e-07
community O 0 8.119109793369716e-07
survey O 0 3.69939493793936e-06
. O 0 2.230873633379815e-06

Risk O 0 0.0007324593607336283
of O 0 4.425498900673119e-06
developing O 0 0.00012310453166719526
colorectal B-Disease 1 1.0
, I-Disease 0 0.0006650253781117499
breast I-Disease 1 0.9639062285423279
and I-Disease 0 8.35455193737289e-06
other I-Disease 0 1.6454055185022298e-06
cancers I-Disease 0 0.07205802202224731
were O 0 1.2563023119582795e-06
compared O 0 7.888892241680878e-07
between O 0 1.6493348198309832e-07
genotyped O 0 1.994447666220367e-05
I1307K O 0 5.307226274453569e-06
carriers O 0 2.571041477494873e-07
and O 0 4.8037033906211946e-08
non O 0 1.1142750366843757e-07
- O 0 3.830321475106757e-06
carriers O 0 1.0594227006777146e-07
and O 0 2.249750430394215e-08
their O 0 1.2262539428320451e-08
first O 0 2.3149407013534073e-07
- O 0 2.277941348438617e-05
degree O 0 1.6020377415770781e-06
relatives O 0 2.882190528907813e-06
. O 0 3.0381290798686678e-06

Sperm O 0 0.00027005269657820463
DNA O 0 2.685340223251842e-05
analysis O 0 1.5098860330908792e-06
in O 0 4.93744153118314e-07
a O 0 9.890284673019778e-06
Friedreich B-Disease 1 0.9927816987037659
ataxia I-Disease 1 0.9999638795852661
premutation O 0 0.2540642321109772
carrier O 0 0.00014119953266344965
suggests O 0 1.7230862567885197e-06
both O 0 1.3563901291036018e-07
meiotic O 0 3.0505922040902078e-05
and O 0 3.703316622249986e-07
mitotic O 0 9.508449693385046e-06
expansion O 0 1.9431145119597204e-06
in O 0 2.326094374893728e-07
the O 0 9.505843081569765e-07
FRDA B-Disease 0 0.000512863218318671
gene O 0 2.154144567612093e-05
. O 0 5.303822035784833e-06

Friedreich B-Disease 1 0.9999505281448364
ataxia I-Disease 1 0.9999966621398926
is O 0 0.0012992480769753456
usually O 0 8.751435234444216e-05
caused O 0 8.605772563896608e-06
by O 0 3.3045516545371356e-08
an O 0 3.468878517765006e-08
expansion O 0 3.90646420100893e-07
of O 0 6.987239942191081e-08
a O 0 2.125238097505644e-06
GAA O 0 8.047506707953289e-05
trinucleotide O 0 4.6949517127359286e-05
repeat O 0 4.442421413841657e-06
in O 0 1.798327105007047e-07
intron O 0 1.8312341126147658e-05
1 O 0 5.493487265084696e-07
of O 0 3.868492726155637e-08
the O 0 4.583551174164313e-07
FRDA B-Disease 0 0.00018857615941669792
gene O 0 1.6994430552585982e-05
. O 0 4.868102678301511e-06

Occasionally O 0 0.00014458954683505
, O 0 1.6526048511877889e-06
a O 0 5.921144747844664e-07
fully O 0 4.7043803874657897e-07
expanded O 0 9.021193250191573e-07
allele O 0 1.7738315136739402e-06
has O 0 4.5887512101217e-07
been O 0 3.3625249784563493e-07
found O 0 1.0751254819751921e-07
to O 0 3.133757076057009e-08
arise O 0 1.1971607705163478e-07
from O 0 7.020997117024308e-09
a O 0 1.1333820282288798e-07
premutation O 0 3.4294700981263304e-06
of O 0 2.628364370593772e-08
100 O 0 7.81960878271093e-08
or O 0 8.955979069469322e-08
less O 0 4.281141059436777e-07
triplet O 0 0.00027381954714655876
repeats O 0 7.055054447846487e-05
. O 0 3.67200641449017e-06

We O 0 1.6917010725592263e-05
have O 0 7.188018003034813e-07
examined O 0 1.5246799875967554e-06
the O 0 1.5915652795683854e-07
sperm O 0 1.2479353017624817e-06
DNA O 0 9.823729669733439e-07
of O 0 8.332333578664475e-08
a O 0 1.9636884189822013e-06
premutation O 0 0.0002475930959917605
carrier O 0 4.0390532376477495e-05
. O 0 4.78155016025994e-06

This O 0 1.1950101907132193e-05
mans O 0 9.883621532935649e-05
leucocyte O 0 0.00017048983136191964
DNA O 0 2.0739551473525353e-05
showed O 0 3.370199010532815e-06
one O 0 1.021991735683514e-07
normal O 0 4.1323332311549166e-07
allele O 0 1.2385993386487826e-06
and O 0 1.0739818634419862e-07
one O 0 6.677592523374187e-08
allele O 0 5.114686132401403e-07
of O 0 2.7333115326655388e-08
approximately O 0 2.2259000331814605e-07
100 O 0 4.964856543665519e-07
repeats O 0 2.236690306745004e-05
. O 0 4.3762934183178e-06

His O 0 3.675997140817344e-05
sperm O 0 3.3081269066315144e-05
showed O 0 2.8199096959724557e-06
an O 0 8.695894138099902e-08
expanded O 0 9.503105502517428e-07
allele O 0 1.8335264257984818e-06
in O 0 6.132181340490206e-08
a O 0 3.7366214655776275e-07
tight O 0 1.7444835975766182e-05
range O 0 8.246794322985807e-07
centering O 0 8.104179300971737e-07
on O 0 2.3447584851510328e-07
a O 0 7.382798372645993e-08
size O 0 9.833554770466435e-08
of O 0 4.117345042686793e-08
approximately O 0 3.3798150411712413e-07
320 O 0 3.5864661640516715e-06
trinucleotide O 0 0.00011692826228681952
repeats O 0 8.275954314740375e-05
. O 0 8.318521395267453e-06

His O 0 0.00012589438119903207
affected O 0 4.356836143415421e-05
son O 0 7.201138942036778e-05
has O 0 1.4623410606873222e-06
repeat O 0 3.4304321161471307e-06
sizes O 0 2.430994072710746e-06
of O 0 1.9368265213870473e-07
1040 O 0 2.0044351913384162e-05
and O 0 1.0771693723654607e-06
540 O 0 1.4509080756397452e-05
. O 0 3.346706080264994e-06

These O 0 3.874093636113685e-06
data O 0 2.151894022972556e-06
suggest O 0 4.063622043304349e-07
that O 0 1.997861431846104e-08
expansion O 0 3.3522789522066887e-07
occurs O 0 5.728362495460715e-08
in O 0 1.7842911148591156e-08
two O 0 9.924868038524437e-08
stages O 0 2.881813998101279e-06
, O 0 3.310923801791432e-08
the O 0 1.1506480213085979e-08
first O 0 1.2703401353064692e-07
during O 0 2.5219384269803413e-07
meiosis O 0 4.955362555847387e-07
followed O 0 1.478059488135841e-07
by O 0 2.189163517130055e-08
a O 0 1.0907260872272673e-07
second O 0 1.0123878837475786e-06
mitotic O 0 2.245271207357291e-05
expansion O 0 7.3417909334239084e-06
. O 0 5.347765181795694e-06

We O 0 1.563011210237164e-05
also O 0 1.709355956336367e-06
show O 0 5.678549541698885e-07
that O 0 2.5192694153020057e-08
in O 0 3.3186559278419736e-08
all O 0 1.6003374625483957e-08
informative O 0 2.664190787982079e-07
carrier O 0 2.1781527266284684e-06
father O 0 1.265809999040357e-07
to O 0 3.853565289091421e-08
affected O 0 1.5541957054665545e-07
child O 0 1.57449244397867e-06
transmissions O 0 5.932918156759115e-06
, O 0 3.79314109011375e-08
with O 0 1.071560884469136e-08
the O 0 5.997286223191622e-08
notable O 0 1.3885163241411647e-07
exception O 0 5.662219138002911e-08
of O 0 1.2943328187020597e-08
the O 0 1.383174179636626e-07
premutation O 0 2.3668259018450044e-05
carrier O 0 1.7022047131831641e-06
, O 0 3.710074736318347e-08
the O 0 2.8773705196272203e-08
expansion O 0 5.053705649515905e-07
size O 0 9.347568266093731e-07
decreases O 0 3.400932655495126e-06
. O 0 2.314260711955285e-07
. O 0 1.3356328736335854e-06

The O 0 2.006081740546506e-05
R496H O 0 0.00011347173858666793
mutation O 0 1.925671131175477e-05
of O 0 2.8688882025562634e-07
arylsulfatase O 0 3.0224282454582863e-05
A O 0 1.924881689774338e-05
does O 0 2.4647260943311267e-06
not O 0 1.7560003016114933e-06
cause O 0 0.00022312620421871543
metachromatic B-Disease 1 0.9999970197677612
leukodystrophy I-Disease 1 0.9999969005584717
. O 0 2.385288644290995e-05

Deficiency B-Disease 1 0.9996355772018433
of I-Disease 0 8.851858183334116e-06
arylsulfatase I-Disease 0 0.0005881282268092036
A I-Disease 0 6.171329732751474e-05
( O 0 1.306184731220128e-05
ARSA O 0 0.0016430611722171307
) O 0 1.913507503559231e-06
enzyme O 0 1.1103179531346541e-05
activity O 0 2.075419070024509e-05
causes O 0 0.0004614850622601807
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 1.0
( O 0 0.0005504628643393517
MLD B-Disease 1 0.9999960660934448
) O 0 2.5902634661179036e-05
. O 0 1.9921133571187966e-05

A O 0 3.534455026965588e-05
number O 0 3.0323312785185408e-06
of O 0 1.3258229500934249e-06
ARSA O 0 0.009150591678917408
gene O 0 6.961405597394332e-05
mutations O 0 3.731604738277383e-05
responsible O 0 2.1952364477328956e-06
for O 0 1.8400023691356182e-06
MLD B-Disease 1 0.9999998807907104
have O 0 1.0643809218890965e-05
been O 0 7.588797416246962e-06
identified O 0 8.403760148212314e-06
. O 0 2.748758561210707e-06

Recently O 0 0.0003015814581885934
, O 0 1.439383936485683e-06
the O 0 3.031137794096139e-07
R496H O 0 1.2776406038028654e-05
mutation O 0 2.9685777462873375e-06
of O 0 8.28411188535938e-08
ARSA O 0 0.0035838389303535223
was O 0 4.412712769408245e-06
proposed O 0 1.4823761773641309e-07
to O 0 3.431494022265724e-08
be O 0 7.017973757683649e-08
a O 0 6.338281650641875e-07
cause O 0 2.880281044781441e-06
of O 0 4.444877959031146e-07
MLD B-Disease 1 0.9999992847442627
( O 0 1.4276787396738655e-06
Draghia O 0 4.586268187267706e-05
et O 0 3.741361069842242e-05
al O 0 1.1494191312522162e-05
. O 0 1.5858957169712085e-07
, O 0 1.354270295905735e-07
1997 O 0 6.467035973400925e-07
) O 0 8.101189337139658e-07
. O 0 1.4405978845388745e-06

We O 0 8.410751433984842e-06
have O 0 5.104044475956471e-07
investigated O 0 8.306332119900617e-07
the O 0 1.2702649598850257e-07
R496H O 0 2.32587681239238e-05
mutation O 0 2.4312630557687953e-06
and O 0 1.2445605079847155e-07
found O 0 1.1775736652452906e-07
this O 0 3.123117764403105e-08
mutation O 0 4.3393708892836e-07
at O 0 1.8869537043997298e-08
a O 0 1.1390991261350791e-07
relatively O 0 1.1765465046664758e-07
high O 0 4.474611330351763e-07
frequency O 0 5.822467414873245e-07
in O 0 1.6737967456492697e-08
an O 0 2.5356406752052862e-08
African O 0 8.516630600752251e-08
American O 0 7.016353720246116e-08
population O 0 4.007585729937091e-08
( O 0 4.718309298823442e-08
f O 0 1.1007898592652055e-06
= O 0 1.1855757975354209e-06
0 O 0 1.503622399923188e-07
. O 0 2.483231931194041e-08
09 O 0 4.5177986862654507e-07
, O 0 7.532131718335222e-08
n O 0 3.4743295600492274e-06
= O 0 6.3470019995293114e-06
61 O 0 8.787797014520038e-07
subjects O 0 4.213948159303982e-07
) O 0 7.160766131164564e-07
. O 0 1.9565923139452934e-06

The O 0 2.5959483537008055e-05
ARSA O 0 0.0018026635516434908
enzyme O 0 1.732894997985568e-05
activity O 0 3.256720447097905e-06
in O 0 2.70696631332612e-07
subjects O 0 5.37509151854465e-07
with O 0 1.2655830516905553e-07
and O 0 1.0171219173571444e-06
without O 0 3.424674233087899e-08
the O 0 3.600738907039158e-08
R496H O 0 8.015761522983667e-06
mutation O 0 1.175747229353874e-06
was O 0 1.7115743276008288e-06
determined O 0 2.415461324289936e-07
and O 0 9.690540281326321e-08
found O 0 8.42580973881013e-08
to O 0 4.858983970734698e-08
be O 0 2.1512691716907284e-07
normal O 0 1.7482972225479898e-06
. O 0 1.3580330460172263e-06

It O 0 1.7634683899814263e-05
is O 0 5.780749461337109e-07
therefore O 0 2.2597716053951444e-07
concluded O 0 2.5701837103042635e-07
that O 0 1.64100288913005e-08
the O 0 9.721029670117787e-08
R496H O 0 1.2259788491064683e-05
mutation O 0 1.394555965816835e-06
of O 0 8.077591928667971e-08
ARSA O 0 0.0004314403922762722
does O 0 1.5454634194611572e-07
not O 0 2.175639224333281e-08
negatively O 0 1.0733634070447806e-07
influence O 0 3.6422456162199524e-08
the O 0 3.967542383520595e-08
activity O 0 9.811522261315986e-08
of O 0 3.891114630505399e-08
ARSA O 0 0.0006074795383028686
and O 0 1.1607568239924149e-06
is O 0 1.4034374373750325e-07
not O 0 3.8975546345909606e-08
a O 0 9.72165821622184e-07
cause O 0 7.685768650844693e-06
of O 0 3.519983465594123e-06
MLD B-Disease 1 0.9999970197677612

Down O 0 0.001059802481904626
- O 0 0.0003386144817341119
regulation O 0 6.351349384203786e-06
of O 0 9.031643912749132e-07
transmembrane O 0 4.412791895447299e-05
carbonic O 0 0.00013436224253382534
anhydrases O 0 0.0003792530915234238
in O 0 2.9694625482079573e-05
renal B-Disease 1 0.9999943971633911
cell I-Disease 1 0.9999864101409912
carcinoma I-Disease 1 1.0
cell O 0 0.3793417513370514
lines O 0 7.75449734646827e-05
by O 0 1.8472763940735604e-07
wild O 0 2.3341972337220795e-06
- O 0 0.0001613867498235777
type O 0 1.4805277714913245e-05
von B-Disease 0 0.22347493469715118
Hippel I-Disease 1 0.8286657929420471
- I-Disease 0 0.06287557631731033
Lindau I-Disease 0 0.005940370727330446
transgenes O 0 0.0004653689684346318
. O 0 2.235370448033791e-05

To O 0 1.3064113772998098e-05
discover O 0 1.7626882254262455e-05
genes O 0 6.138493517937604e-06
involved O 0 1.3084485317449435e-06
in O 0 1.3339958968572319e-06
von B-Disease 1 0.9953285455703735
Hippel I-Disease 1 0.999970555305481
- I-Disease 1 0.9996262788772583
Lindau I-Disease 1 0.9835537672042847
( O 0 5.473424607771449e-06
VHL B-Disease 0 0.00038759654853492975
) O 0 1.3922078778705327e-06
- O 0 6.95219132467173e-05
mediated O 0 0.00016799695731606334
carcinogenesis O 0 0.0031837106216698885
, O 0 8.299379601339751e-07
we O 0 2.781369801141409e-07
used O 0 6.116287113400176e-05
renal B-Disease 1 0.9999821186065674
cell I-Disease 1 0.9999531507492065
carcinoma I-Disease 1 1.0
cell O 0 0.49400776624679565
lines O 0 0.000501850969158113
stably O 0 0.0001280864526052028
transfected O 0 8.487373997922987e-05
with O 0 4.81274639696494e-07
wild O 0 5.5035216064425185e-06
- O 0 0.0006247357814572752
type O 0 3.496675344649702e-05
VHL O 0 0.00205824407748878
- O 0 0.003098867367953062
expressing O 0 1.4399865904124454e-05
transgenes O 0 0.00021354519412852824
. O 0 1.1854608601424843e-05

Large O 0 1.7231899619218893e-05
- O 0 3.6462330172071233e-05
scale O 0 4.590966909745475e-06
RNA O 0 2.60422530118376e-06
differential O 0 1.8848331819754094e-06
display O 0 6.672792096651392e-07
technology O 0 3.0643712989331107e-07
applied O 0 1.7698391729936702e-07
to O 0 4.9272056656946006e-08
these O 0 2.6313037082559276e-08
cell O 0 3.9164265217550565e-06
lines O 0 4.7269068090827204e-06
identified O 0 2.8912788252455357e-07
several O 0 7.636880638983712e-08
differentially O 0 2.797756906147697e-06
expressed O 0 2.1363199209645245e-07
genes O 0 2.3083447331373463e-07
, O 0 2.5363469546846318e-08
including O 0 2.2718976921964895e-08
an O 0 1.3676309151833266e-07
alpha O 0 5.004544163966784e-06
carbonic O 0 2.2681588234263472e-05
anhydrase O 0 2.150796899513807e-05
gene O 0 3.800542344833957e-06
, O 0 1.0642422694218112e-06
termed O 0 4.795232234755531e-05
CA12 O 0 0.0009822803549468517
. O 0 1.0426261724205688e-05

The O 0 8.48189210955752e-06
deduced O 0 2.2298689145827666e-05
protein O 0 4.278918822819833e-06
sequence O 0 1.3249217545308056e-06
was O 0 2.769817911030259e-06
classified O 0 3.232089795801585e-07
as O 0 1.1173972325195791e-07
a O 0 6.243164989427896e-07
one O 0 6.346913323795889e-07
- O 0 0.00018547494255471975
pass O 0 6.60422483633738e-06
transmembrane O 0 5.881456672796048e-06
CA O 0 1.6804827964733704e-06
possessing O 0 2.8655631467700005e-07
an O 0 1.953866757276046e-07
apparently O 0 1.0297150765836705e-05
intact O 0 9.713038480185787e-07
catalytic O 0 5.872231554349128e-07
domain O 0 1.379717247118606e-07
in O 0 5.4218912026726684e-08
the O 0 1.5293998956167343e-07
extracellular O 0 9.191348908643704e-06
CA O 0 2.0213698007864878e-05
module O 0 9.260956721846014e-05
. O 0 8.047410119615961e-06

Reintroduced O 0 0.001448600902222097
wild O 0 0.00015189219266176224
- O 0 0.001375765074044466
type O 0 2.7933745514019392e-05
VHL B-Disease 0 0.0008427996654063463
strongly O 0 1.250935201824177e-05
inhibited O 0 1.0129294423677493e-05
the O 0 2.9109003207850037e-07
overexpression O 0 3.5878963444702094e-06
of O 0 2.4521161989810025e-08
the O 0 1.679435257528894e-07
CA12 O 0 5.729020631406456e-05
gene O 0 6.345024985421333e-07
in O 0 1.665323594579604e-07
the O 0 2.7724765914172167e-06
parental O 0 0.08860143274068832
renal B-Disease 1 0.9999991655349731
cell I-Disease 1 0.9999945163726807
carcinoma I-Disease 1 1.0
cell O 0 0.4754096567630768
lines O 0 0.0019524818053469062
. O 0 1.1378595445421524e-05

Similar O 0 7.04440608387813e-05
results O 0 2.7516840418684296e-05
were O 0 1.0014408644565265e-06
obtained O 0 3.950258644636051e-07
with O 0 2.9204323936937726e-07
CA9 O 0 0.0009905964834615588
, O 0 1.9097051051630842e-07
encoding O 0 7.488440019187692e-07
another O 0 2.0264396880520508e-06
transmembrane O 0 1.4115064004727174e-05
CA O 0 2.728566869336646e-06
with O 0 5.832126248606073e-08
an O 0 2.4677081000845646e-07
intact O 0 3.297895091236569e-06
catalytic O 0 3.950480277126189e-06
domain O 0 3.199882257831632e-06
. O 0 2.5734041173564037e-06

Although O 0 2.9487808205885813e-05
both O 0 8.368884891751804e-07
domains O 0 6.530674454552354e-07
of O 0 6.57311289842255e-08
the O 0 4.110174245397502e-07
VHL B-Disease 0 0.0001452639262424782
protein O 0 1.1223029332541046e-06
contribute O 0 8.012042229665894e-08
to O 0 3.277934723655562e-08
regulation O 0 2.40772692450264e-07
of O 0 3.614955801367614e-08
CA12 O 0 0.00018867758626583964
expression O 0 3.424289616305032e-07
, O 0 2.3334477461389724e-08
the O 0 2.9240094789884097e-08
elongin O 0 2.827072194122593e-06
binding O 0 2.2289886203452625e-07
domain O 0 3.5184257285436615e-07
alone O 0 5.180432935958379e-07
could O 0 2.4280461730086245e-07
effectively O 0 1.0365479283791501e-06
regulate O 0 4.752558652398875e-06
CA9 O 0 0.0005974691594019532
expression O 0 8.664205779496115e-06
. O 0 5.33143474967801e-06

We O 0 9.064978075912222e-05
mapped O 0 0.0004448697145562619
CA12 O 0 0.001099538872949779
and O 0 7.635220754309557e-06
CA9 O 0 0.0021527912467718124
loci O 0 1.636340493860189e-05
to O 0 7.437395765919064e-07
chromosome O 0 5.6034237786661834e-05
bands O 0 9.87545990938088e-06
15q22 O 0 3.90914901799988e-05
and O 0 2.3993952709133737e-06
17q21 O 0 0.00010088635463034734
. O 0 6.745618520653807e-06

2 O 0 0.00047666692989878356
respectively O 0 4.52492713520769e-05
, O 0 5.046591695645475e-07
regions O 0 9.475512570134015e-07
prone O 0 5.369269729271764e-06
to O 0 2.5649825374784996e-07
amplification O 0 2.9937164072180167e-05
in O 0 2.2736321625416167e-07
some O 0 2.3061311082983593e-07
human O 0 6.374529220920522e-06
cancers B-Disease 0 0.09311490505933762
. O 0 5.433907062979415e-06

Additional O 0 1.900124698295258e-05
experiments O 0 8.657341822981834e-06
are O 0 1.0687995199987199e-07
needed O 0 1.7089436710193695e-07
to O 0 2.8433763787916178e-08
define O 0 2.1420443374609022e-07
the O 0 6.105467065253833e-08
role O 0 1.5096759398147697e-07
of O 0 7.400576862437447e-08
CA O 0 3.127510581180104e-06
IX O 0 4.676711614592932e-05
and O 0 4.14046144214808e-06
CA O 0 5.019103355152765e-06
XII O 0 1.308828177570831e-05
enzymes O 0 1.9553262120552972e-07
in O 0 2.449540481563872e-08
the O 0 6.830968146687155e-08
regulation O 0 3.4308990848330723e-07
of O 0 4.010002285781411e-08
pH O 0 2.7961834348388948e-05
in O 0 3.8041033434410565e-08
the O 0 7.373706978341943e-08
extracellular O 0 9.897397603708669e-07
microenvironment O 0 1.3455985936161596e-05
and O 0 1.4329600617202232e-07
its O 0 8.105820370474248e-08
potential O 0 1.4519960700454249e-07
impact O 0 4.2268518996024795e-07
on O 0 1.7259975720662624e-05
cancer B-Disease 0 0.00012653367593884468
cell O 0 2.4494307581335306e-05
growth O 0 6.771078005840536e-06
. O 0 2.075585825878079e-06

A O 0 5.614661131403409e-05
gene O 0 1.5992069165804423e-05
encoding O 0 6.965391548874322e-06
a O 0 4.850816367252264e-06
transmembrane O 0 1.0458825272507966e-05
protein O 0 1.7390035509379231e-06
is O 0 2.411532307178277e-07
mutated O 0 5.579647677222965e-06
in O 0 2.2185215584613616e-06
patients O 0 6.484586629085243e-05
with O 0 0.010179108008742332
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9868454933166504
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999793767929077
( O 0 0.018208350986242294
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.765619163052179e-05
. O 0 1.1811376680270769e-05

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.004663491155952215
WFS B-Disease 1 0.9171712398529053
; O 0 0.00037842534948140383
OMIM O 0 0.1337936967611313
222300 O 0 0.00017599074635654688
) O 0 1.5235433465932147e-06
is O 0 4.960729143022036e-07
an O 0 3.0380475436686538e-05
autosomal B-Disease 1 0.9999996423721313
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9998325109481812
defined O 0 1.4036279935680795e-05
by O 0 1.0178748652833747e-06
young O 0 3.0783771762799006e-06
- O 0 0.0001774345728335902
onset O 0 0.0005298821488395333
non O 0 1.0968363312713336e-05
- O 0 0.010942874476313591
immune O 0 0.00010714277595980093
insulin B-Disease 0 0.004122965969145298
- I-Disease 1 0.6686115860939026
dependent I-Disease 0 0.02536904253065586
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.14390656352043152
progressive O 1 0.989327073097229
optic B-Disease 1 0.9999910593032837
atrophy I-Disease 0 0.43510672450065613
. O 0 1.6278607290587388e-05

Linkage O 0 0.0005816130433231592
to O 0 4.4261869334150106e-06
markers O 0 6.683707033516839e-05
on O 0 1.1512841410876717e-05
chromosome O 0 0.0011079995892941952
4p O 0 0.04542273283004761
was O 0 5.429402881418355e-05
confirmed O 0 9.699598422230338e-07
in O 0 1.0928125959708268e-07
five O 0 9.743581586008077e-07
families O 0 1.5800654864506214e-06
. O 0 1.8847074443328893e-06

On O 0 1.2605647498276085e-05
the O 0 3.437960458541056e-07
basis O 0 2.4874657356122043e-07
of O 0 1.048031066375188e-07
meiotic O 0 0.0003031040250789374
recombinants O 0 0.0059234886430203915
and O 0 4.536662163445726e-05
disease O 0 0.00011893144983332604
- O 0 0.00010099040082423016
associated O 0 4.754381279781228e-06
haplotypes O 0 4.284325405023992e-05
, O 0 1.804869640409379e-07
the O 0 2.9474554708031064e-07
WFS B-Disease 0 0.00022467543021775782
gene O 0 2.4555081381549826e-06
was O 0 2.0286013295844896e-06
localized O 0 2.803210463753203e-06
to O 0 1.7138695795893e-07
a O 0 5.489085651788628e-06
BAC O 0 0.00028682834818027914
/ O 0 4.0086124499794096e-05
P1 O 0 2.92273562081391e-05
contig O 0 7.572747563244775e-06
of O 0 4.0203257611892695e-08
less O 0 8.991306543748578e-08
than O 0 5.2652602278158156e-08
250 O 0 7.057518018882547e-07
kb O 0 0.0001255590614164248
. O 0 4.0798713598633185e-06

Mutations O 0 0.0032560068648308516
in O 0 1.6454007436550455e-06
a O 0 1.692576347522845e-06
novel O 0 9.244004104402848e-06
gene O 0 9.525203495286405e-06
( O 0 1.0436002639835351e-06
WFS1 O 0 5.6308334023924544e-05
) O 0 1.4003182968735928e-07
encoding O 0 2.909190754962765e-07
a O 0 5.52328913272504e-07
putative O 0 1.637081913941074e-05
transmembrane O 0 2.6675390927266562e-06
protein O 0 4.757773695018841e-07
were O 0 3.151436942516739e-07
found O 0 7.444435823344975e-08
in O 0 4.1260634020545695e-08
all O 0 2.2065689719852344e-08
affected O 0 7.096840448639341e-08
individuals O 0 1.2855640996178863e-08
in O 0 2.9043995652955346e-08
six O 0 1.424706738362147e-06
WFS B-Disease 0 0.00033025629818439484
families O 0 3.462355095962266e-07
, O 0 2.81554015657548e-08
and O 0 9.039211334993524e-08
these O 0 3.5512016438588034e-08
mutations O 0 1.2865227745351149e-06
were O 0 1.7816562092320964e-07
associated O 0 1.5420994259329746e-07
with O 0 2.1391170434981177e-07
the O 0 4.880437336396426e-05
disease O 0 0.08638553321361542
phenotype O 0 0.0019632428884506226
. O 0 5.9080748542328365e-06

WFS1 O 0 0.005389327183365822
appears O 0 6.22237057541497e-05
to O 0 2.6123916541109793e-07
function O 0 2.419901932171342e-07
in O 0 8.403517171018393e-08
survival O 0 7.0056285039754584e-06
of O 0 1.0137561901046865e-07
islet O 0 7.255772652570158e-05
beta O 0 6.075558758311672e-06
- O 0 0.0002481484552845359
cells O 0 3.913742148142774e-06
and O 0 5.27113400039525e-07
neurons O 0 5.864682407263899e-06
. O 0 4.528937154191226e-07
. O 0 1.9592325770645402e-06

Stable O 0 0.0006563708884641528
interaction O 0 7.717143489571754e-06
between O 0 8.827324791127467e-07
the O 0 1.5792669216807553e-07
products O 0 4.1702404018906236e-07
of O 0 4.177232781898965e-08
the O 0 8.962948641055846e-07
BRCA1 O 0 0.00046844439930282533
and O 0 2.553164813434705e-05
BRCA2 O 0 0.00206933356821537
tumor B-Disease 0 0.00013280466373544186
suppressor O 0 0.00010288487101206556
genes O 0 1.491464445280144e-06
in O 0 2.3075830313246115e-07
mitotic O 0 6.950811803108081e-05
and O 0 8.998785233416129e-06
meiotic O 0 0.0021218492183834314
cells O 0 0.00010147788998438045
. O 0 6.648820999544114e-06

BRCA1 O 1 0.7287994027137756
and O 0 0.00025108884437941015
BRCA2 O 0 0.0016573098255321383
account O 0 2.3833467821532395e-06
for O 0 7.032740256818215e-08
most O 0 1.0030029784502403e-07
cases O 0 1.1544327804813292e-07
of O 0 5.720762885630393e-08
familial O 0 4.10149477829691e-05
, O 0 5.805545129078382e-07
early O 0 4.853532573179109e-06
onset O 0 0.012023000977933407
breast B-Disease 1 0.6509554982185364
and I-Disease 0 0.00012853328371420503
/ I-Disease 1 0.9418004155158997
or I-Disease 1 0.9404792785644531
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 6.043182452231122e-07
encode O 0 4.675375464557874e-07
products O 0 3.8647320366180793e-07
that O 0 2.333955428923673e-08
each O 0 2.7557369719488634e-08
interact O 0 1.1954722367590875e-07
with O 0 2.1969191266180133e-07
hRAD51 O 0 3.1573730666423216e-05
. O 0 2.8978759019082645e-06

Results O 0 6.6252367105335e-05
presented O 0 6.719679277011892e-06
here O 0 5.174532589080627e-07
show O 0 3.1765248422743753e-06
that O 0 4.971252565155737e-07
BRCA1 O 0 0.00017796932661440223
and O 0 2.4269114874186926e-05
BRCA2 O 0 0.0038944121915847063
coexist O 0 8.123206498567015e-06
in O 0 1.6623577892005414e-07
a O 0 6.376897658810776e-07
biochemical O 0 5.53157769900281e-06
complex O 0 5.224998744779441e-07
and O 0 9.211270821651851e-07
colocalize O 0 1.7142210708698258e-05
in O 0 1.9633647241334984e-07
subnuclear O 0 2.841299465217162e-05
foci O 0 1.1838881619041786e-05
in O 0 8.507409177127556e-08
somatic O 0 3.7335619254008634e-06
cells O 0 1.1170386642334051e-06
and O 0 7.053387918176668e-08
on O 0 3.09701761125325e-07
the O 0 8.230061609992845e-08
axial O 0 1.071494352800073e-06
elements O 0 2.4460419467686734e-07
of O 0 6.671710650607565e-08
developing O 0 1.0625669801811455e-06
synaptonemal O 0 6.267122080316767e-05
complexes O 0 1.2541509022412356e-05
. O 0 3.240872729293187e-06

Like O 0 9.016630792757496e-05
BRCA1 O 0 0.001322741387411952
and O 0 1.6944764865911566e-05
RAD51 O 0 0.002872592071071267
, O 0 3.651020506367786e-06
BRCA2 O 0 6.780988042009994e-05
relocates O 0 1.558132680656854e-05
to O 0 7.184707442320359e-07
PCNA O 0 0.0001469249982619658
+ O 0 4.669886493502418e-06
replication O 0 2.3178267838375177e-06
sites O 0 1.4221463118246902e-07
following O 0 1.8510539234739554e-07
exposure O 0 6.981391607041587e-07
of O 0 1.0653883464328828e-07
S O 0 0.00012270864681340754
phase O 0 4.072073807037668e-06
cells O 0 1.379881950924755e-06
to O 0 1.672485865356066e-07
hydroxyurea O 0 6.699468212900683e-05
or O 0 3.1902170576358913e-06
UV O 0 0.0003896079433616251
irradiation O 0 2.5978504709200934e-05
. O 0 3.5345722153579118e-06

Thus O 0 4.628483293345198e-05
, O 0 3.093167833867483e-06
BRCA1 O 0 7.287351036211476e-05
and O 0 3.932970230380306e-06
BRCA2 O 0 0.00012234575115144253
participate O 0 1.2489456935327325e-07
, O 0 6.320240686363832e-08
together O 0 7.956578684797933e-08
, O 0 2.7488495035754568e-08
in O 0 1.9939212947406304e-08
a O 0 4.699125213392108e-07
pathway O 0 1.6445206938442425e-06
( O 0 3.0283811724984844e-07
s O 0 2.4417178792646155e-05
) O 0 6.871844959732698e-08
associated O 0 2.341102245395632e-08
with O 0 1.0781231907230904e-08
the O 0 4.6723044988539186e-08
activation O 0 2.0980988324481586e-07
of O 0 2.426948064737644e-08
double O 0 2.1750518499175087e-05
- O 0 0.0003096094005741179
strand O 0 9.480002336204052e-05
break O 0 7.990087397047319e-06
repair O 0 4.503312811721116e-05
and O 0 1.0245402108921553e-06
/ O 0 9.945721103576943e-06
or O 0 7.718172696513648e-07
homologous O 0 1.3498593034455553e-05
recombination O 0 4.088689456693828e-05
. O 0 7.348186500166776e-06

Dysfunction O 1 0.8285084962844849
of O 0 3.4309227885387372e-06
this O 0 9.163624099528533e-07
pathway O 0 1.6191845134017058e-05
may O 0 5.921555839449866e-06
be O 0 2.9111326682595973e-08
a O 0 1.372340818761586e-07
general O 0 1.85542276653905e-07
phenomenon O 0 5.368826236917812e-07
in O 0 3.951832994175675e-08
the O 0 9.397088263085607e-08
majority O 0 9.153110624993133e-08
of O 0 1.953402062326859e-08
cases O 0 1.8720555772233638e-07
of O 0 3.2912765846049297e-07
hereditary B-Disease 1 0.9040238261222839
breast I-Disease 1 0.8384004235267639
and I-Disease 0 0.0003224678512196988
/ I-Disease 1 0.797849178314209
or I-Disease 1 0.5925909280776978
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 2.611584477563156e-06
. O 0 4.712688223662553e-06

A O 0 8.832111052470282e-05
novel O 0 5.8596342569217086e-05
Arg362Ser O 0 0.0008291039266623557
mutation O 0 1.551158493384719e-05
in O 0 9.546636903223771e-08
the O 0 1.52687576360222e-07
sterol O 0 2.7086629415862262e-05
27 O 0 1.2789889296982437e-05
- O 0 3.9684124203631654e-05
hydroxylase O 0 6.0720674809999764e-05
gene O 0 1.8102393823937746e-06
( O 0 3.1450389315068605e-07
CYP27 O 0 3.247974018449895e-05
) O 0 1.1013311507213075e-07
: O 0 1.6762054855234965e-08
its O 0 3.590116293139545e-08
effects O 0 3.625320630362694e-07
on O 0 1.7905952631736e-07
pre O 0 2.826209311024286e-06
- O 0 1.5935123656163341e-06
mRNA O 0 4.2085343920916785e-07
splicing O 0 1.5221025932987686e-06
and O 0 2.1607849021165748e-07
enzyme O 0 1.707635419734288e-06
activity O 0 1.5239603499139776e-06
. O 0 1.5239982076309389e-06

A O 0 8.492352935718372e-05
novel O 0 2.4918492272263393e-05
C O 0 1.896704634418711e-05
to O 0 5.589211582446296e-08
A O 0 1.6951059933489887e-06
mutation O 0 7.27297049252229e-07
in O 0 3.242781332346567e-08
the O 0 1.5140487619191845e-07
sterol O 0 1.6731919458834454e-05
27 O 0 4.615722446033033e-06
- O 0 1.9756987967411987e-05
hydroxylase O 0 4.809402162209153e-05
gene O 0 1.8652351627679309e-06
( O 0 3.915919819519331e-07
CYP27 O 0 5.3051899158162996e-05
) O 0 1.1152105372502774e-07
was O 0 8.043712682592741e-07
identified O 0 2.210293104099037e-07
by O 0 3.332095843688876e-08
sequencing O 0 4.927957775180403e-07
amplified O 0 3.2354932955058757e-06
CYP27 O 0 1.2178463293821551e-05
gene O 0 4.6789395469204464e-07
products O 0 2.1727989008013537e-07
from O 0 6.023618936978892e-08
a O 0 1.0322509069737862e-06
patient O 0 2.358269011892844e-05
with O 0 1.5800933397258632e-05
cerebrotendinous B-Disease 1 0.9999994039535522
xanthomatosis I-Disease 1 0.9999986886978149
( O 0 1.4596278560929932e-05
CTX B-Disease 0 0.0025821514427661896
) O 0 4.04327556680073e-06
. O 0 4.129963599552866e-06

The O 0 2.920450788224116e-05
mutation O 0 7.91197016951628e-05
changed O 0 2.6571317448542686e-06
the O 0 4.2515941345300234e-07
adrenodoxin O 0 1.3771521480521187e-05
cofactor O 0 4.191154403088149e-06
binding O 0 2.400759512966033e-06
residue O 0 5.573962425842183e-06
362Arg O 0 8.935996447689831e-06
to O 0 3.699807393786614e-07
362Ser O 0 2.5060980988200754e-05
( O 0 7.163067721194238e-07
CGT O 0 1.9522010916261934e-05
362Arg O 0 3.2338766686734743e-06
to O 0 2.161741292638908e-07
AGT O 0 2.7534035325516015e-05
362Ser O 0 8.018476364668459e-06
) O 0 1.3679387222964579e-07
, O 0 3.544982263292695e-08
and O 0 1.4023643757354876e-07
was O 0 7.543375886598369e-06
responsible O 0 6.899779236846371e-07
for O 0 7.794330372234981e-07
deficiency O 0 5.665234129992314e-05
in O 0 5.054770468859715e-08
the O 0 1.6092454302452097e-07
sterol O 0 1.7849257346824743e-05
27 O 0 4.437115876498865e-06
- O 0 6.7459272941050585e-06
hydroxylase O 0 9.177089850709308e-06
activity O 0 2.4474070414726157e-07
, O 0 3.350041311023233e-08
as O 0 3.608975873703457e-08
confirmed O 0 2.5019738814080483e-07
by O 0 2.4163247402952948e-08
expression O 0 8.34564559681894e-08
of O 0 1.7890688042143665e-08
mutant O 0 1.0257075473418809e-06
cDNA O 0 1.406882915944152e-06
into O 0 3.5303406775710755e-07
COS O 0 0.00013986555859446526
- O 0 3.0095288821030408e-05
1 O 0 1.829175857892551e-06
cells O 0 4.213978627376491e-06
. O 0 2.1016644495830406e-06

Quantitative O 0 9.405696619069204e-05
analysis O 0 1.249068372999318e-05
showed O 0 2.6037436327897012e-05
that O 0 6.547137587631369e-08
the O 0 9.777447473879874e-08
expression O 0 2.401251322226017e-07
of O 0 3.518817592862433e-08
CYP27 O 0 1.078863897419069e-05
gene O 0 6.497439244412817e-07
mRNA O 0 2.916173968969815e-07
in O 0 5.495206778505235e-08
the O 0 2.168379467093473e-07
patient O 0 5.6754379329504445e-06
represented O 0 1.495706328569213e-06
52 O 0 1.1748409633582924e-05
. O 0 3.652834948297823e-06

5 O 0 0.0003619483904913068
% O 0 5.874399448657641e-06
of O 0 1.1699840740675427e-07
the O 0 2.7917735678784084e-07
normal O 0 4.336977326602209e-06
level O 0 2.042944743152475e-06
. O 0 3.245784455430112e-06

As O 0 8.378272468689829e-06
the O 0 1.2269474609638564e-06
mutation O 0 4.11828978030826e-06
occurred O 0 6.982843387959292e-07
at O 0 5.883577713916566e-08
the O 0 7.905885723857864e-08
penultimate O 0 1.6814634363981895e-05
nucleotide O 0 1.333850832452299e-06
of O 0 4.073065085208327e-08
exon O 0 8.321870154759381e-06
6 O 0 6.461022621806478e-06
( O 0 3.1116309173739864e-07
- O 0 2.393286649748916e-06
2 O 0 2.0653541810133902e-07
position O 0 1.5866369551531534e-07
of O 0 4.0434343873130274e-08
exon O 0 2.268136540806154e-06
6 O 0 1.3481767382472754e-06
- O 0 6.15478893450927e-06
intron O 0 3.094198109465651e-05
6 O 0 1.2477923974074656e-06
splice O 0 8.144591447489802e-06
site O 0 6.225233732948254e-07
) O 0 3.107289003878577e-08
of O 0 6.608737113111829e-09
the O 0 4.004644083011044e-08
gene O 0 4.2524618493189337e-07
, O 0 5.947347858636931e-08
we O 0 1.704619734255175e-08
hypothesized O 0 2.8787053452106193e-07
that O 0 2.6452577017721524e-08
the O 0 3.761721245609806e-07
mutation O 0 1.844786856963765e-05
may O 0 1.8823507161869202e-06
partially O 0 3.01429668070341e-06
affect O 0 6.718153855445053e-08
the O 0 3.968617079408432e-08
normal O 0 1.9442586562945507e-07
splicing O 0 9.48201204664656e-07
efficiency O 0 4.0335294215765316e-07
in O 0 6.54241816278045e-08
exon O 0 3.587875653465744e-06
6 O 0 2.0638217392843217e-06
and O 0 3.9845681953920575e-07
cause O 0 4.421287371769722e-07
alternative O 0 2.1581200826403801e-07
splicing O 0 2.2387339413398877e-06
elsewhere O 0 3.9263039752768236e-07
, O 0 3.594460196154614e-08
which O 0 2.7577035766057634e-08
resulted O 0 1.0020200846838634e-07
in O 0 1.541959733231124e-07
decreased O 0 9.456344741920475e-06
transcript O 0 8.078105565800797e-06
in O 0 1.9276330931461416e-07
the O 0 1.0283853271175758e-06
patient O 0 4.732729939860292e-05
. O 0 3.313581828479073e-06

Transfection O 0 0.004718890879303217
of O 0 6.78161177347647e-06
constructed O 0 6.319754902506247e-05
minigenes O 0 0.00017535540973767638
, O 0 2.435806436551502e-07
with O 0 7.159093939890226e-08
or O 0 4.5230669343254704e-07
without O 0 5.12815674369449e-08
the O 0 1.283222559322894e-07
mutation O 0 9.148133699454775e-07
, O 0 2.3153329919978205e-08
into O 0 9.651931520693324e-08
COS O 0 0.00010212918277829885
- O 0 1.0863036550290417e-05
1 O 0 3.97011660879798e-07
cells O 0 2.7431650551079656e-07
confirmed O 0 6.740088309697967e-08
that O 0 6.184083023441644e-09
the O 0 2.4134873655157207e-08
mutant O 0 6.863087946840096e-06
minigene O 0 2.6499739760765806e-05
was O 0 3.3951130262721563e-06
responsible O 0 1.1749240513836412e-07
for O 0 1.7777077587766144e-08
a O 0 2.2668297106065438e-07
mRNA O 0 7.921332212390553e-07
species O 0 8.598519229963131e-08
alternatively O 0 8.707759207027266e-07
spliced O 0 3.2090756576508284e-05
at O 0 3.751289057163376e-07
an O 0 1.9096523828920908e-07
activated O 0 1.618088390387129e-05
cryptic O 0 7.230145456560422e-06
5 O 0 5.864094418939203e-07
splice O 0 9.464112736168317e-06
site O 0 1.520928776699293e-06
88 O 0 1.403179339831695e-06
bp O 0 4.68592907054699e-06
upstream O 0 3.0470380352198845e-07
from O 0 2.2123465726053837e-08
the O 0 4.867239056238759e-08
3 O 0 1.7203082336436637e-07
end O 0 1.4636256651101576e-07
of O 0 1.1179237446867774e-07
exon O 0 1.705417707853485e-05
6 O 0 1.022875676426338e-05
. O 0 4.9873156058311e-06

Our O 0 7.840642865630798e-06
data O 0 1.582407321620849e-06
suggest O 0 4.023647761641769e-07
that O 0 2.0535928513254476e-08
the O 0 3.706785633994514e-08
C O 0 1.941077243827749e-06
to O 0 2.5805032777270753e-08
A O 0 1.7183290310640587e-06
mutation O 0 7.977241693879478e-07
at O 0 3.2318954623633545e-08
the O 0 4.3239701597030944e-08
penultimate O 0 9.763647540239617e-06
nucleotide O 0 7.062473628138832e-07
of O 0 3.4894764411319557e-08
exon O 0 2.4419241526629776e-06
6 O 0 3.963919823490869e-07
of O 0 1.7166234655974222e-08
the O 0 7.551939518180006e-08
CYP27 O 0 2.4954280888778158e-05
gene O 0 5.044599902248592e-07
not O 0 4.352890670134002e-08
only O 0 1.1458445214884705e-07
causes O 0 2.8163567549199797e-06
the O 0 3.862973699142458e-06
deficiency B-Disease 0 0.0001068805213435553
in I-Disease 0 4.240150985879154e-08
the I-Disease 0 1.8851844174605503e-07
sterol I-Disease 0 2.0325465811765753e-05
27 I-Disease 0 4.808195626537781e-06
- I-Disease 0 5.6857197705539875e-06
hydroxylase I-Disease 0 1.0172412657993846e-05
activity I-Disease 0 2.947320467683312e-07
, O 0 3.979380380769726e-08
but O 0 4.7845194472984076e-08
also O 0 8.321801487909397e-07
partially O 0 9.337116352980956e-06
leads O 0 2.694274314762879e-07
to O 0 1.839421237548322e-08
alternative O 0 1.74960703702709e-07
pre O 0 1.5524698255831026e-06
- O 0 1.6173611356862239e-06
mRNA O 0 4.6219548721637693e-07
splicing O 0 1.1155226502523874e-06
of O 0 4.8988312073561247e-08
the O 0 3.196358022705681e-07
gene O 0 7.737527084827889e-06
. O 0 3.4717891139735e-06

To O 0 2.7777114155469462e-06
our O 0 3.198468050413794e-07
knowledge O 0 1.5191471902653575e-07
, O 0 1.1100811292408252e-07
this O 0 1.2780851044169594e-08
is O 0 2.191452885824674e-08
the O 0 2.4723997071873782e-08
first O 0 5.25677137375169e-07
report O 0 2.0317870053077058e-07
regarding O 0 4.3239701597030944e-08
effects O 0 7.615743129463226e-07
on O 0 5.452629352475924e-07
pre O 0 4.321894266468007e-06
- O 0 3.2462828585266834e-06
mRNA O 0 3.820223923867161e-07
splicing O 0 3.5297347267260193e-07
of O 0 1.867846322056721e-08
a O 0 2.254506341614615e-07
mutation O 0 6.406950205928297e-07
at O 0 3.3770565011082e-08
the O 0 7.252580047634183e-08
- O 0 8.24570633994881e-06
2 O 0 6.804336294408131e-07
position O 0 1.851643531836089e-07
of O 0 2.2617976824790276e-08
a O 0 3.775392656280019e-07
5 O 0 1.00173508599255e-06
splice O 0 3.557178933988325e-05
site O 0 1.056601649906952e-05
. O 0 4.262269158061827e-06

ATM O 0 0.017760613933205605
germline O 0 0.20262537896633148
mutations O 0 0.002868508454412222
in O 0 7.759436812193599e-06
classical O 0 0.0007736956467851996
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.34751707315444946
in O 0 8.104767061922757e-07
the O 0 1.1865021178891766e-06
Dutch O 0 4.935284232487902e-05
population O 0 1.7449093547838856e-06
. O 0 1.8734518789642607e-06

Germline O 1 0.7936511039733887
mutations O 0 0.0013695887755602598
in O 0 8.902746344574552e-07
the O 0 1.5064068747960846e-07
ATM O 0 4.636108769773273e-06
gene O 0 1.2522914403234608e-06
are O 0 4.3541032113125766e-08
responsible O 0 4.872752583651163e-07
for O 0 7.393486498585844e-07
the O 0 0.14420920610427856
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.07194739580154419
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 0.9999998807907104
) O 0 3.429614025662886e-06
. O 0 2.1954876956442604e-06

In O 0 7.687733159400523e-06
our O 0 1.4265422123571625e-06
study O 0 2.3919076852507715e-07
, O 0 1.394432160850556e-07
we O 0 1.731744347921449e-08
have O 0 1.8316455907552154e-08
determined O 0 6.017911857725267e-08
the O 0 5.3155520873815476e-08
ATM O 0 4.479236395127373e-06
mutation O 0 1.6750857412262121e-06
spectrum O 0 6.032984742887493e-07
in O 0 3.0446670962192e-08
19 O 0 4.830955617762811e-07
classical O 0 3.855264196772623e-07
A B-Disease 1 0.9999511241912842
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
patients O 0 5.458797204482835e-06
, O 0 2.343300309348706e-08
including O 0 1.1894332629935889e-08
some O 0 1.1020389045768297e-08
immigrant O 0 2.1610251224046806e-06
populations O 0 3.5868382042281155e-07
, O 0 3.564767325769935e-08
as O 0 2.2675079591749636e-08
well O 0 3.210844923273726e-08
as O 0 3.282946892113614e-08
12 O 0 7.969655513306861e-08
of O 0 1.771696034325032e-08
Dutch O 0 3.2512184588995297e-06
ethnic O 0 9.625473467167467e-07
origin O 0 1.6691187738615554e-06
. O 0 2.382147158641601e-06

Both O 0 1.107908428821247e-05
the O 0 1.0560278269622358e-06
protein O 0 3.5219243272877065e-06
truncation O 0 3.081319300690666e-05
test O 0 4.919491402688436e-06
( O 0 6.780297212571895e-07
PTT O 0 2.273650352435652e-06
) O 0 3.3156823064928176e-08
and O 0 1.1847395064989996e-08
the O 0 3.576672469307596e-08
restriction O 0 3.5953522115050873e-07
endonuclease O 0 5.638107268168824e-06
fingerprinting O 0 2.2304566300590523e-06
( O 0 2.1899241176015494e-07
REF O 0 1.8363232811680064e-05
) O 0 5.089365373578403e-08
method O 0 9.399509082186341e-08
were O 0 8.397941542170884e-08
used O 0 1.1414415013177859e-07
and O 0 2.508950842639024e-07
compared O 0 2.886264667267824e-07
for O 0 7.918498745596025e-09
their O 0 1.8601951978780562e-08
detection O 0 4.1724632637851755e-07
efficiency O 0 3.10787640955823e-07
, O 0 1.658637316381828e-08
identifying O 0 9.303547443550997e-08
76 O 0 4.468390102374542e-07
% O 0 6.692842902111806e-08
and O 0 3.402868031798789e-08
60 O 0 1.056684126865548e-07
% O 0 3.1544942658001673e-08
of O 0 6.4072773753309775e-09
the O 0 2.664912415184517e-07
mutations O 0 4.805674507224467e-06
, O 0 2.3179605079803878e-07
respectively O 0 3.2325353913620347e-06
. O 0 2.1073160496598575e-06

Most O 0 3.501210085232742e-05
patients O 0 6.461635348387063e-05
were O 0 1.1474370467112749e-06
found O 0 1.8270594637215254e-07
to O 0 1.1180815562283897e-07
be O 0 2.814080630741955e-07
compound O 0 1.8067888959194534e-05
heterozygote O 0 0.00024113323888741434
. O 0 6.7765563471766654e-06

Seventeen O 0 0.0007778777508065104
mutations O 0 0.0005855483468621969
were O 0 1.8750193930827663e-06
distinct O 0 7.814768991920573e-07
, O 0 9.14886939540338e-08
of O 0 2.907087548464915e-08
which O 0 3.244037429794844e-07
10 O 0 1.8394673872990097e-07
were O 0 3.456133015333762e-07
not O 0 2.574314805769973e-07
reported O 0 2.730779442572384e-06
previously O 0 4.5511410462495405e-06
. O 0 2.8211227345309453e-06

Mutations O 0 0.009928081184625626
are O 0 1.5397921515614144e-06
small O 0 1.2961222637386527e-06
deletions O 0 4.474337038118392e-05
or O 0 3.3996614092757227e-06
point O 0 2.0836134353885427e-05
mutations O 0 5.718982356484048e-05
frequently O 0 3.640256409198628e-06
affecting O 0 3.6233891478332225e-06
splice O 0 0.00020516412041615695
sites O 0 1.604630051588174e-05
. O 0 1.5402798453578725e-05

Moreover O 0 0.00013617676449939609
, O 0 4.033366167277563e-06
a O 0 3.519513484206982e-06
16 O 0 1.194038395624375e-05
. O 0 6.33199624644476e-06

7 O 0 0.00042413294431753457
- O 0 0.00034438713919371367
kb O 0 0.00019593213801272213
genomic O 0 1.9638830053736456e-05
deletion O 0 1.4012927749718074e-05
of O 0 8.99566359180426e-08
the O 0 2.540639911785547e-07
3 O 0 9.070677151612472e-07
end O 0 2.550970350512216e-07
of O 0 1.0222545476779032e-08
the O 0 3.3631014417778715e-08
gene O 0 1.2758606260376837e-07
, O 0 4.177224965928872e-08
most O 0 2.037903179541445e-08
likely O 0 2.0211193429986452e-07
a O 0 1.5722972079856845e-07
result O 0 8.707760912329832e-08
of O 0 1.774726321457365e-08
recombination O 0 6.025555308042385e-07
between O 0 7.284786107675245e-08
two O 0 3.732059212779859e-07
LINE O 0 0.0007351379608735442
elements O 0 1.4332719047160936e-06
, O 0 5.18035903951386e-07
was O 0 1.3420216419035569e-05
identified O 0 5.223785592534114e-06
. O 0 1.7364562836519326e-06

The O 0 8.536765562894288e-06
most O 0 8.732058063287695e-07
frequently O 0 2.626743935252307e-06
found O 0 1.067943117050163e-06
mutation O 0 4.071114744874649e-06
, O 0 1.1498674012955235e-07
identified O 0 3.9665516737841244e-07
in O 0 4.486228988298535e-08
three O 0 2.8185522182866407e-07
unrelated O 0 1.319405214417202e-06
Turkish O 0 4.308667485020123e-06
A B-Disease 1 0.9993200302124023
- I-Disease 1 0.9999557733535767
T I-Disease 1 0.9999996423721313
individuals O 0 6.324859214146272e-08
, O 0 4.4356632145081676e-08
was O 0 1.27271823657793e-06
previously O 0 1.1600873222050723e-06
described O 0 1.2540626812551636e-06
to O 0 4.358972205409373e-08
be O 0 2.2177291114644504e-08
a O 0 1.8283965630416787e-07
Turkish O 0 2.459405550325755e-06
A B-Disease 1 0.9986934065818787
- I-Disease 1 0.999790608882904
T I-Disease 1 0.9999959468841553
founder O 0 8.574385719839483e-05
mutation O 0 3.644529351731762e-05
. O 0 5.893258730793605e-06

The O 0 6.444523933168966e-06
presence O 0 1.3410957535597845e-06
of O 0 7.800199597340907e-08
a O 0 1.9181775314791594e-06
founder O 0 6.18606063653715e-05
mutation O 0 4.796617304236861e-06
among O 0 3.6684809856524225e-08
relatively O 0 4.6141284570921925e-08
small O 0 3.0298483721935554e-08
ethnic O 0 1.5578075363009702e-07
population O 0 5.136898906243914e-08
groups O 0 1.3855262714912442e-08
in O 0 8.856837041548715e-09
Western O 0 1.0092455227095343e-07
Europe O 0 1.4559132921476703e-07
could O 0 9.942773004922856e-08
indicate O 0 3.5931236652686493e-08
a O 0 9.34922894657575e-08
high O 0 1.1346088513164432e-06
carrier O 0 9.75666466729308e-07
frequency O 0 3.9381768601742806e-07
in O 0 4.222476235327122e-08
such O 0 8.407877771787753e-08
communities O 0 1.332970782641496e-06
. O 0 2.0140512333455263e-06

In O 0 4.3784111767308787e-05
patients O 0 1.637537934584543e-05
of O 0 1.3729024317399308e-07
Dutch O 0 5.906395927013364e-06
ethnic O 0 5.92635331031488e-07
origin O 0 3.157920218654908e-07
, O 0 1.3481468386089546e-07
however O 0 7.84615750148987e-08
, O 0 5.504920963517179e-08
no O 0 3.998721354037116e-08
significant O 0 6.239700667265424e-08
founder O 0 1.2554124850794324e-06
effect O 0 2.8305743171586073e-07
could O 0 2.843377160388627e-07
be O 0 1.5820104692920722e-07
identified O 0 2.8275114800635492e-06
. O 0 2.56838507084467e-06

The O 0 2.6106379664270207e-05
observed O 0 2.1950767404632643e-05
genetic O 0 1.1626042578427587e-05
heterogeneity O 0 2.023904562520329e-05
including O 0 3.450534507010161e-07
the O 0 1.833145546470405e-07
relative O 0 2.2646070192422485e-06
high O 0 2.3284167127712863e-06
percentage O 0 1.7401265495209373e-06
of O 0 3.172069895640561e-08
splice O 0 5.337769471225329e-05
- O 0 0.00030000481638126075
site O 0 1.0620781722536776e-05
mutations O 0 5.271111604088219e-06
had O 0 1.0861936061701272e-06
no O 0 1.4228979239305772e-07
reflection O 0 5.983426945022075e-07
on O 0 1.461523993384617e-06
the O 0 2.6143554805457825e-06
phenotype O 0 0.0010935637401416898
. O 0 6.134052000561496e-06

All O 0 2.8488828320405446e-05
patients O 0 7.367363286903128e-05
manifested O 0 1.622540185053367e-05
classical O 0 4.0940744838735554e-06
A B-Disease 1 0.9992449283599854
- I-Disease 1 0.9998052716255188
T I-Disease 1 0.9999984502792358
and O 0 6.730530230925069e-07
increased O 0 8.63617231061653e-07
cellular O 0 3.2226885195996147e-06
radioresistant O 0 2.3609964046045206e-05
DNA O 0 6.784664947190322e-06
synthesis O 0 1.1506321243359707e-05
. O 0 5.539612629945623e-06

Determination O 0 0.0001628067111596465
of O 0 6.358849304888281e-07
the O 0 2.9095735953887925e-07
genomic O 0 3.0944720492698252e-06
structure O 0 3.599585625124746e-07
of O 0 3.090826794505119e-08
the O 0 1.7987473199809756e-07
COL4A4 O 0 0.00010186753934249282
gene O 0 7.067391720738669e-07
and O 0 9.514914722785761e-08
of O 0 9.534353750950686e-08
novel O 0 0.00022607302526012063
mutations O 0 0.005867368541657925
causing O 0 0.0008600044529885054
autosomal B-Disease 1 0.9999903440475464
recessive I-Disease 1 0.9999996423721313
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.00012984771456103772

Autosomal B-Disease 1 0.9999998807907104
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 3.594487498048693e-05
a O 0 7.772525714244694e-05
progressive O 1 0.5746403932571411
hematuric B-Disease 1 0.9711568355560303
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 0.028554720804095268
by O 0 4.528156750893686e-06
glomerular B-Disease 1 0.9235794544219971
basement I-Disease 1 0.9836713075637817
membrane I-Disease 0 0.23537856340408325
abnormalities I-Disease 1 0.9999147653579712
and O 0 8.262387382274028e-06
associated O 0 2.2591862034460064e-06
with O 0 1.3755172858509468e-06
mutations O 0 1.7687974832369946e-05
in O 0 1.0942038386474451e-07
either O 0 1.924574775102883e-07
the O 0 2.2375100172666862e-07
COL4A3 O 0 0.00017731754633132368
or O 0 1.2417673644904426e-07
the O 0 6.999578516797555e-08
COL4A4 O 0 1.671520476520527e-05
gene O 0 6.004967190165189e-07
, O 0 6.367927340988899e-08
which O 0 3.2636609859082455e-08
encode O 0 1.2825276485273207e-07
the O 0 5.7779281803505e-08
alpha3 O 0 1.0306150215910748e-05
and O 0 6.819153668402578e-07
alpha4 O 0 4.525608164840378e-05
type O 0 4.746457307192031e-06
IV O 0 0.00020722922636196017
collagen O 0 2.6784855435835198e-05
chains O 0 4.6848534111632034e-05
, O 0 5.530378075491171e-07
respectively O 0 3.471315494607552e-06
. O 0 2.4173587007680908e-06

To O 0 6.3137495089904405e-06
date O 0 4.003425146947848e-06
, O 0 3.0270416573330294e-07
mutation O 0 8.767287908995058e-07
screening O 0 2.167637234151698e-07
in O 0 3.213068922036655e-08
the O 0 4.718875956655211e-08
two O 0 1.330378438524349e-07
genes O 0 5.827789664181182e-07
has O 0 2.0020936517539667e-06
been O 0 2.4568644221290015e-06
hampered O 0 0.00015713016910012811
by O 0 1.9481265667309344e-07
the O 0 1.1482828199405049e-07
lack O 0 1.632104442705895e-07
of O 0 3.557112648877592e-08
genomic O 0 1.9308304217702243e-06
structure O 0 7.095086971276032e-07
information O 0 6.032576038705884e-07
. O 0 2.2921474283066345e-06

We O 0 2.0703662812593393e-05
report O 0 2.1090390873723663e-06
here O 0 9.582502968896733e-08
the O 0 3.814616889030731e-08
complete O 0 1.8568920268080547e-07
characterization O 0 8.732790774956811e-07
of O 0 2.854014979902786e-08
the O 0 1.773262141568921e-07
48 O 0 7.857087211959879e-07
exons O 0 1.3786060435450054e-06
of O 0 2.380610553132101e-08
the O 0 1.4744243514996924e-07
COL4A4 O 0 4.581739631248638e-05
gene O 0 2.06211481668106e-07
, O 0 2.060679094029183e-08
a O 0 5.433144067978901e-08
comprehensive O 0 2.9691167924283945e-07
gene O 0 6.582032483493094e-07
screen O 0 1.0644946087268181e-05
, O 0 1.9378852300633298e-07
and O 0 6.39410728808798e-08
the O 0 1.805440774660383e-08
subsequent O 0 6.648286898780498e-08
detection O 0 2.2281257372469554e-07
of O 0 1.3081943528447937e-08
10 O 0 1.4379251922491676e-07
novel O 0 1.2986375850232434e-06
mutations O 0 2.3101688384485897e-06
in O 0 2.3534776971700921e-07
eight O 0 2.2310174244921654e-05
patients O 0 0.0003816224343609065
diagnosed O 1 0.8222770094871521
with O 0 0.002186464611440897
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.00011034779163310304

Furthermore O 0 0.00014226367056835443
, O 0 1.2074450523869018e-06
we O 0 1.0145840434461206e-07
identified O 0 1.8907046239746705e-07
a O 0 1.1387167830889666e-07
glycine O 0 3.5867606129613705e-06
to O 0 7.56702149828925e-08
alanine O 0 1.2416920753821614e-06
substitution O 0 1.8204035256985662e-07
in O 0 3.4021734762745837e-08
the O 0 8.184164101976421e-08
collagenous O 0 1.1398187780287117e-05
domain O 0 1.2504210644692648e-07
that O 0 1.9801221995408014e-08
is O 0 9.66643156630198e-08
apparently O 0 2.036630348811741e-06
silent O 0 7.168234219534497e-07
in O 0 2.8664915774356814e-08
the O 0 1.0128265870434916e-07
heterozygous O 0 1.3249810990600963e-06
carriers O 0 1.9834833153709042e-07
, O 0 5.0022592290588364e-08
in O 0 1.0896739155441537e-07
11 O 0 1.8690101342144771e-06
. O 0 2.3436500669049565e-06

5 O 0 0.0003006662300322205
% O 0 4.233970685163513e-06
of O 0 3.7663010488131476e-08
all O 0 2.5262755443122842e-08
control O 0 2.2506383174913935e-06
individuals O 0 8.621164937494541e-08
, O 0 2.6443396805575503e-08
and O 0 1.183457172260205e-07
in O 0 4.547733922777297e-08
one O 0 4.5164330941815933e-08
control O 0 6.193257604536484e-07
individual O 0 1.1690572421230172e-07
homozygous O 0 1.0594494597171433e-06
for O 0 2.2489441420248113e-08
this O 0 7.814003311068518e-08
glycine O 0 1.2379389772831928e-05
substitution O 0 7.260562142619165e-06
. O 0 4.298460680729477e-06

There O 0 1.3975921319797635e-05
has O 0 2.9092232125549344e-06
been O 0 5.183061944080691e-07
no O 0 8.581954347164356e-08
previous O 0 2.373947864953152e-07
finding O 0 3.981885754456016e-08
of O 0 9.779570042667274e-09
a O 0 1.6934856716943614e-07
glycine O 0 1.4692787999592838e-06
substitution O 0 1.9123640981888457e-07
that O 0 5.493991395155717e-08
is O 0 3.6956738114213294e-08
not O 0 1.916076719510329e-08
associated O 0 6.180335532235404e-08
with O 0 4.3483517231379665e-08
any O 0 1.988619828807714e-07
obvious O 0 5.654109372699168e-06
phenotype O 0 0.00021811496117152274
in O 0 9.29256771087239e-07
homozygous O 0 0.00017755049339029938
individuals O 0 9.220376000484976e-07
. O 0 2.919832695624791e-06

Founder O 0 0.002109222114086151
BRCA1 O 0 0.011101877316832542
and O 0 0.00011013335461029783
BRCA2 O 0 0.00868672039359808
mutations O 0 3.148071118630469e-05
in O 0 7.377856832135876e-07
French O 0 0.00010559829388512298
Canadian O 0 0.002975008450448513
breast B-Disease 1 0.9999716281890869
and I-Disease 1 0.9969732761383057
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 3.434599784668535e-05
. O 0 6.582656624232186e-06

We O 0 1.1367239494575188e-05
have O 0 1.2233475672474015e-06
identified O 0 8.619666687081917e-07
four O 0 3.963254471273103e-07
mutations O 0 2.39157543546753e-06
in O 0 2.179215030650994e-08
each O 0 3.22474029701425e-08
of O 0 5.53312204942813e-08
the O 0 1.2922090718348045e-05
breast B-Disease 1 0.9995373487472534
cancer I-Disease 0 0.21954700350761414
- O 0 0.005222656764090061
susceptibility O 0 0.00017027131980285048
genes O 0 2.666030695763766e-06
, O 0 4.099799753021216e-07
BRCA1 O 0 3.982212001574226e-05
and O 0 3.091009148192825e-06
BRCA2 O 0 6.920453597558662e-05
, O 0 8.849259103271834e-08
in O 0 1.4421523530927516e-07
French O 0 3.813647708739154e-05
Canadian O 0 0.00016362188034690917
breast B-Disease 1 0.9940179586410522
cancer I-Disease 0 0.07130715996026993
and O 0 0.0021562480833381414
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 6.294373179116519e-06
from O 0 1.0562292800386786e-06
Quebec O 0 0.00010584519623080269
. O 0 8.624339898233302e-06

To O 0 1.992322359001264e-05
identify O 0 1.56463538587559e-05
founder O 0 2.0926780052832328e-05
effects O 0 1.892814543680288e-05
, O 0 4.475691071093024e-07
we O 0 8.944814311462324e-08
examined O 0 1.2422026429703692e-06
independently O 0 8.561882509638963e-07
ascertained O 0 3.929708327632397e-06
French O 0 1.575477290316485e-05
Canadian O 0 2.5290310077252798e-05
cancer B-Disease 0 2.8985310564166866e-05
families O 0 1.229118140599894e-07
for O 0 1.3938916687550318e-08
the O 0 1.678300876051253e-08
distribution O 0 4.301882938761992e-08
of O 0 1.2196550436271991e-08
these O 0 5.279349224451835e-08
eight O 0 1.536896093057294e-06
mutations O 0 1.3340466466615908e-05
. O 0 1.1368845207471168e-06

Mutations O 0 0.032484255731105804
were O 0 1.4033897969056852e-05
found O 0 6.496831588265195e-07
in O 0 1.1026847346329305e-07
41 O 0 6.899786058056634e-07
of O 0 5.4191719556229145e-08
97 O 0 2.5078891212615417e-06
families O 0 1.0961208545268164e-06
. O 0 1.6784309764261707e-06

Six O 0 1.9555889593902975e-05
of O 0 4.4909893404110335e-07
eight O 0 1.926247250594315e-06
mutations O 0 8.923469067667611e-06
were O 0 4.4608961502490274e-07
observed O 0 8.114944876069785e-07
at O 0 2.4655673769302666e-07
least O 0 4.1528687688696664e-07
twice O 0 4.763339802593691e-06
. O 0 3.615077503127395e-06

The O 0 3.5621924325823784e-05
BRCA1 O 0 0.0012726075947284698
C4446T O 0 0.0006003687158226967
mutation O 0 0.0001199142134282738
was O 0 4.962242201145273e-06
the O 0 1.064685477558669e-07
most O 0 1.6306574934787932e-07
common O 0 1.7769469877748634e-06
mutation O 0 6.460738859459525e-06
found O 0 3.627465048339218e-07
, O 0 6.56910259522192e-08
followed O 0 2.3478216348848946e-07
by O 0 1.1926640297588165e-07
the O 0 2.013885932683479e-06
BRCA2 O 0 0.0006445228937081993
8765delAG O 0 0.0001521787780802697
mutation O 0 4.7255100071197376e-05
. O 0 5.40065229870379e-06

Together O 0 2.4056475012912415e-05
, O 0 1.1164017905684887e-06
these O 0 9.476572415678675e-08
mutations O 0 2.9437121611408656e-06
were O 0 3.942415673918731e-07
found O 0 6.772291527568086e-08
in O 0 4.854787150065931e-08
28 O 0 4.114652938369545e-07
of O 0 1.3719280822499513e-08
41 O 0 1.3954499991086777e-06
families O 0 5.624706389539824e-08
identified O 0 2.3376202307190397e-07
to O 0 3.816159477310066e-08
have O 0 1.1042212122447381e-07
a O 0 2.867090643121628e-06
mutation O 0 3.305052814539522e-05
. O 0 3.2734292290115263e-06

The O 0 6.876151473989012e-06
odds O 0 1.9867951777996495e-05
of O 0 1.5316666690523562e-07
detection O 0 1.1005894293703022e-06
of O 0 2.9158616854374486e-08
any O 0 2.0035093584169772e-08
of O 0 1.4584252028271294e-08
the O 0 1.5935184194404428e-07
four O 0 4.175037247478031e-06
BRCA1 O 0 0.0008097146637737751
mutations O 0 1.8404238289804198e-05
was O 0 9.236498044629116e-06
18 O 0 3.56623058905825e-06
. O 0 2.6085228910233127e-06

7x O 0 0.0054441289976239204
greater O 0 2.4667018806212582e-05
if O 0 1.2032907079628785e-06
one O 0 1.1427724189161381e-07
or O 0 6.055839207874669e-08
more O 0 4.0024602299126855e-08
cases O 0 2.382614496809765e-07
of O 0 3.0496121325995773e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 0.00013387470971792936
also O 0 2.082809260173235e-06
present O 0 7.290748271771008e-08
in O 0 8.870416223771826e-08
the O 0 4.912712370241934e-07
family O 0 3.916329205821967e-06
. O 0 1.7184618172905175e-06

The O 0 1.0613886843202636e-05
odds O 0 2.1138632291695103e-05
of O 0 1.5154182619880885e-07
detection O 0 9.981808943848591e-07
of O 0 3.512581159270667e-08
any O 0 2.3200190213401584e-08
of O 0 2.7623256571018828e-08
the O 0 3.8140717606438557e-07
four O 0 1.4739036487299018e-05
BRCA2 O 0 0.006129902321845293
mutations O 0 1.7160728020826355e-05
was O 0 6.679517355223652e-06
5 O 0 3.0773173875786597e-06
. O 0 2.0893321561743505e-06

3x O 0 0.0019914403092116117
greater O 0 2.9059818189125508e-05
if O 0 8.537903113392531e-07
there O 0 6.789726114675432e-08
were O 0 8.407621976402879e-08
at O 0 2.4332146963956802e-08
least O 0 2.582950564544717e-08
five O 0 5.144733350448405e-08
cases O 0 8.117439165289397e-08
of O 0 5.838793413204257e-07
breast B-Disease 1 0.998106837272644
cancer I-Disease 0 0.002814715960994363
in O 0 5.118004651194497e-07
the O 0 9.102011517825304e-07
family O 0 5.191414857108612e-06
. O 0 4.0483532757207286e-06

Interestingly O 0 0.0007247953908517957
, O 0 1.7658716160440235e-06
the O 0 1.8341667384902394e-07
presence O 0 1.324896032883771e-07
of O 0 4.104540707317028e-08
a O 0 1.0813195331138559e-05
breast B-Disease 1 0.9977384805679321
cancer I-Disease 0 0.00027954840334132314
case O 0 8.112306773000455e-07
< O 0 1.8243257500216714e-06
36 O 0 3.370583669948246e-07
years O 0 2.6438303990516943e-08
of O 0 1.7863852619370846e-08
age O 0 2.4079199079096725e-07
was O 0 9.170337875730183e-07
strongly O 0 1.0501241121119165e-07
predictive O 0 2.0848948167895287e-07
of O 0 6.384537787340605e-09
the O 0 3.236188561572817e-08
presence O 0 2.5800702019296295e-08
of O 0 4.966094202529803e-09
any O 0 9.892508145981083e-09
of O 0 8.906251736107151e-09
the O 0 1.1408472744278697e-07
eight O 0 2.9771651952614775e-06
mutations O 0 8.157223419402726e-06
screened O 0 1.176793193735648e-05
. O 0 1.8690474234972498e-06

Carriers O 0 6.336603837553412e-05
of O 0 5.573126031777065e-07
the O 0 2.1626320290124568e-07
same O 0 5.473198143590707e-07
mutation O 0 2.206410499638878e-06
, O 0 2.951245825499882e-08
from O 0 1.2978778052286088e-08
different O 0 1.1472272021251229e-08
families O 0 9.346982210445276e-08
, O 0 3.656347402625215e-08
shared O 0 9.502745967893134e-08
similar O 0 2.532176210934267e-07
haplotypes O 0 1.2138541023887228e-05
, O 0 1.5192341606962145e-07
indicating O 0 4.3042467723353184e-07
that O 0 1.3714179125656756e-08
the O 0 2.9181315142068343e-08
mutant O 0 4.827649263461353e-06
alleles O 0 6.057769610379182e-07
were O 0 4.82543043744954e-07
likely O 0 2.9701050152652897e-07
to O 0 2.1314352949275417e-08
be O 0 4.472465064964126e-08
identical O 0 6.986080620663415e-07
by O 0 4.582790325002861e-08
descent O 0 3.7890376916038804e-06
for O 0 3.505981638340927e-08
a O 0 1.8448308765073307e-06
mutation O 0 1.5295297544071218e-06
in O 0 5.283963133706493e-08
the O 0 3.1364126584776386e-07
founder O 0 7.267517958098324e-06
population O 0 1.1993702173640486e-06
. O 0 1.8272579609401873e-06

The O 0 5.762350156146567e-06
identification O 0 2.181476702389773e-06
of O 0 2.2992533388332959e-07
common O 0 5.1774086387013085e-06
BRCA1 O 0 0.001502741128206253
and O 0 7.10009117028676e-05
BRCA2 O 0 0.02380708046257496
mutations O 0 1.3505082279152703e-05
will O 0 8.958797792502082e-08
facilitate O 0 3.1329238936450565e-07
carrier O 0 2.098984396070591e-06
detection O 0 6.540042249980615e-07
in O 0 1.9569007747577416e-07
French O 0 1.9886963855242357e-05
Canadian O 0 0.00010327097697881982
breast B-Disease 1 0.98265141248703
cancer I-Disease 0 0.009936582297086716
and O 0 0.0007008930551819503
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.095437957905233e-05
. O 0 7.345923222601414e-06

Are O 0 2.0596848116838373e-05
Dp71 O 0 0.0005326363607309759
and O 0 1.0543741154833697e-05
Dp140 O 0 0.0005861530662514269
brain O 0 0.0006896437262184918
dystrophin O 0 0.0001363696064800024
isoforms O 0 8.973032890935428e-06
related O 0 3.1021720587887103e-06
to O 0 3.1589011086907703e-06
cognitive B-Disease 0 0.015425457619130611
impairment I-Disease 0 0.35785529017448425
in O 0 0.00027315804618410766
Duchenne B-Disease 1 0.9999991655349731
muscular I-Disease 1 0.9999971389770508
dystrophy I-Disease 1 0.9999936819076538
? O 0 0.0004743563767988235

Molecular O 0 0.00011555558012332767
study O 0 2.5221650048479205e-06
and O 0 2.972295476411091e-07
neuropsychological O 0 7.77313925937051e-06
analysis O 0 5.123571895637724e-07
were O 0 5.00061389629991e-07
performed O 0 3.720350036928721e-07
concurrently O 0 3.4711825946942554e-07
on O 0 2.291332066306495e-06
49 O 0 2.2137508494779468e-05
patients O 0 4.448662366485223e-06
with O 0 1.0043455404229462e-05
Duchenne B-Disease 1 0.9999986886978149
muscular I-Disease 1 0.9999972581863403
dystrophy I-Disease 1 0.9999992847442627
( O 0 0.0016080146888270974
DMD B-Disease 1 1.0
) O 0 2.7946796308242483e-06
in O 0 1.252246875083074e-07
order O 0 1.0700580332922982e-07
to O 0 3.748005639181429e-08
find O 0 7.086303099868019e-08
a O 0 1.0612651379915405e-07
molecular O 0 2.971252399674995e-07
explanation O 0 6.492768278576477e-08
for O 0 1.65844760147138e-08
the O 0 3.4350833288954163e-07
cognitive B-Disease 0 0.00016904350195545703
impairment I-Disease 0 7.51804982428439e-05
observed O 0 2.3611578399140853e-06
in O 0 1.061572334037919e-06
most O 0 1.5665391401853412e-05
DMD B-Disease 1 1.0
patients O 0 0.00048482438432984054
. O 0 7.029010703263339e-06

Complete O 0 1.7274664060096256e-05
analysis O 0 1.2186898175059468e-06
of O 0 9.06424588720256e-08
the O 0 3.40228467621273e-07
dystrophin O 0 4.098390127182938e-05
gene O 0 4.278939286450623e-06
was O 0 3.3221858757315204e-05
performed O 0 8.522917482878256e-07
to O 0 4.9962523007707205e-08
define O 0 4.0429532077723707e-07
the O 0 3.448421992402473e-08
localization O 0 7.585474008919846e-07
of O 0 2.5153275018396926e-08
deletions O 0 5.738106210628757e-06
and O 0 5.572084660343535e-07
duplications O 0 1.6145316976690083e-06
in O 0 5.71429623619224e-08
relation O 0 1.7375782590534072e-07
to O 0 4.7612960685228245e-08
the O 0 4.855843371842639e-07
different O 0 4.7829048526182305e-06
DMD B-Disease 1 0.9999977350234985
promoters O 0 9.457366104470566e-05
. O 0 4.917258593195584e-06

Qualitative O 0 9.805722220335156e-05
analysis O 0 3.969858425989514e-06
of O 0 2.001947336793819e-07
the O 0 2.625048409754527e-07
Dp71 O 0 3.751969416043721e-05
transcript O 0 3.19546161335893e-05
and O 0 4.571990359636402e-07
testing O 0 1.3520235597752617e-07
for O 0 9.703724046516982e-09
the O 0 2.117996977801795e-08
specific O 0 1.72526615216384e-08
first O 0 5.160831761941154e-08
exon O 0 6.834701480329386e-07
of O 0 5.221646048880757e-08
Dp140 O 0 4.303632977098459e-06
were O 0 6.208916829564259e-07
also O 0 8.044640367188549e-07
carried O 0 1.0711776212701807e-06
out O 0 4.770390660269186e-07
. O 0 1.9307531147205736e-06

Neuropsychological O 0 0.0031696998048573732
analysis O 0 3.537338488968089e-05
assessed O 0 2.886416405090131e-05
verbal O 0 3.460206789895892e-05
and O 0 2.387198037467897e-06
visuospatial O 0 5.388175122789107e-05
intelligence O 0 3.263187181801186e-06
, O 0 3.3505978080938803e-07
verbal O 0 3.0989490369393025e-06
memory O 0 2.8917225790792145e-05
, O 0 5.090598733659135e-07
and O 0 7.468498779417132e-07
reading O 0 2.5734605060279137e-06
skills O 0 3.6549222386383917e-06
. O 0 4.504304342844989e-06

Comparison O 0 3.557453601388261e-05
of O 0 9.736818356032018e-07
molecular O 0 5.108688128530048e-06
and O 0 1.3750371863352484e-06
psychometric O 0 2.6150886696996167e-05
findings O 0 3.863025540340459e-06
demonstrated O 0 1.9325050288898638e-06
that O 0 5.409402703548949e-08
deletions O 0 8.857650755089708e-06
and O 0 9.59094791141979e-07
duplications O 0 6.109391961217625e-06
that O 0 1.2196206000680831e-07
were O 0 3.7222807236503286e-07
localized O 0 2.4089861199172447e-06
in O 0 2.1679308304101141e-07
the O 0 5.4229661827776e-07
distal O 0 2.1565927454503253e-05
part O 0 1.3539501253490016e-07
of O 0 1.484073042234968e-08
the O 0 5.2517101778448705e-08
gene O 0 2.7771235977525066e-07
seemed O 0 4.678725247231341e-07
to O 0 2.242168051225235e-08
be O 0 7.747443220296191e-08
preferentially O 0 7.382079729723046e-07
associated O 0 3.056525770261942e-07
with O 0 8.570860927648027e-07
cognitive B-Disease 0 0.0013853241689503193
impairment I-Disease 0 0.00043218093924224377
. O 0 6.579826276720269e-06

Two O 0 2.028983180935029e-05
altered O 0 0.0001017585163936019
Dp71 O 0 0.00010169838060392067
transcripts O 0 5.237333880359074e-06
and O 0 2.559806944191223e-07
two O 0 1.405154250733176e-07
deleted O 0 3.522602810335229e-06
Dp140 O 0 3.924248176190304e-06
DNA O 0 1.4194230288921972e-06
sequences O 0 4.94752839585999e-07
were O 0 2.1916331149895996e-07
found O 0 1.5101841199793853e-07
in O 0 9.108804732704812e-08
four O 0 2.2780129711463815e-06
patients O 0 7.672499123145826e-06
with O 0 7.47885769669665e-06
severe O 1 0.9979084730148315
cerebral B-Disease 1 0.9999426603317261
dysfunction I-Disease 1 0.9939437508583069
. O 0 2.8331282010185532e-05

These O 0 4.432138211996062e-06
findings O 0 3.5128975923726102e-06
suggest O 0 1.1430616950747208e-06
that O 0 2.9552507996299937e-08
some O 0 8.736170897805096e-09
sequences O 0 1.1400445742992815e-07
located O 0 1.1896855767190573e-07
in O 0 3.626163902481494e-08
the O 0 1.2772009938544215e-07
distal O 0 2.1050500436103903e-05
part O 0 1.5524092589203065e-07
of O 0 7.506756993791441e-09
the O 0 4.498233252547834e-08
gene O 0 2.9576767701655626e-07
and O 0 4.539111557733122e-07
, O 0 6.172678013172117e-08
in O 0 2.6986658241412442e-08
particular O 0 3.1707571679362445e-08
, O 0 3.631687306437925e-08
some O 0 5.476999831444118e-08
DMD B-Disease 1 0.9990237951278687
isoforms O 0 1.5739519767521415e-06
expressed O 0 9.801384948104896e-08
in O 0 6.637390015384881e-08
the O 0 2.4356163521588314e-06
brain O 0 0.0016502590151503682
may O 0 4.7562134568579495e-06
be O 0 5.463154195695097e-08
related O 0 5.246874579256655e-08
to O 0 5.692745830288004e-08
the O 0 2.7944452085648663e-06
cognitive B-Disease 0 0.0013771840604022145
impairment I-Disease 0 0.00017293360724579543
associated O 0 4.9568120630283374e-06
with O 0 2.2711867131874897e-05
DMD B-Disease 1 1.0
. O 0 1.4875205124553759e-05
. O 0 9.171472811431158e-06

I1307K O 0 0.003857693634927273
APC O 0 0.0006846817559562624
and O 0 9.346246770292055e-06
hMLH1 O 0 0.00014007296704221517
mutations O 0 1.3805090929963626e-05
in O 0 1.0154397500627965e-07
a O 0 6.263703653530683e-07
non O 0 1.0162841590499738e-06
- O 0 1.2755476745951455e-05
Jewish O 0 1.693348167464137e-06
family O 0 5.364736352930777e-07
with O 0 9.070538453670451e-07
hereditary B-Disease 1 0.619440495967865
non I-Disease 0 0.0033865501172840595
- I-Disease 1 0.9999990463256836
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001081313967006281

We O 0 8.214954505092464e-06
describe O 0 4.454699137568241e-06
a O 0 2.750796284090029e-06
French O 0 6.29705173196271e-05
Canadian O 0 7.573911716463044e-05
hereditary B-Disease 1 0.8453468084335327
non I-Disease 0 0.019117234274744987
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.000782240298576653
HNPCC B-Disease 1 0.9576338529586792
) O 0 3.50333266396774e-06
kindred O 0 2.276950908708386e-05
which O 0 4.5383669089460454e-07
carries O 0 8.650960126033169e-07
a O 0 3.375157575646881e-07
novel O 0 3.8472462620120496e-06
truncating O 0 4.124475162825547e-05
mutation O 0 1.7255399143323302e-05
in O 0 1.0150375828743563e-06
hMLH1 O 0 9.666692494647577e-05
. O 0 6.8760923568333965e-06

Interestingly O 0 0.0007477827602997422
, O 0 3.650226517493138e-06
the O 0 7.981968224157754e-07
I1307K O 0 4.260377318132669e-05
APC O 0 3.033143912034575e-05
polymorphism O 0 3.1361392757389694e-05
, O 0 1.4770476752801187e-07
associated O 0 9.688673685559479e-08
with O 0 2.2854797165905438e-08
an O 0 1.9795507455455663e-07
increased O 0 2.525343734305352e-05
risk O 0 1.5408440958708525e-05
of O 0 0.0004669232585001737
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.232116564002354e-06
is O 0 2.684835465061042e-07
also O 0 4.1821121499197034e-07
present O 0 6.138559172086389e-08
in O 0 5.151429860461576e-08
this O 0 1.0514970227859521e-07
family O 0 1.910218315970269e-06
. O 0 2.1243586161290295e-06

The O 0 2.595017576823011e-05
I1307K O 0 0.00020696441060863435
polymorphism O 0 0.0002644651976879686
has O 0 2.2295189410215244e-06
previously O 0 1.4064750075704069e-06
only O 0 8.176331789400137e-08
been O 0 3.34589742578828e-07
identified O 0 4.24429373424573e-07
in O 0 5.6633961520446974e-08
individuals O 0 2.5133997993975754e-08
of O 0 3.036130991063146e-08
self O 0 1.0662788554327562e-05
- O 0 0.0009790887124836445
reported O 0 1.221653656102717e-05
Ashkenazi O 0 4.338047074270435e-05
Jewish O 0 3.4859358493122272e-06
origins O 0 8.440746569249313e-06
. O 0 3.488975607979228e-06

In O 0 4.886288934358163e-06
addition O 0 5.983918072161032e-07
, O 0 8.113879346183239e-08
in O 0 2.2468430671551687e-08
this O 0 3.46536701556488e-08
family O 0 2.834956376318587e-07
, O 0 7.525884626602419e-08
there O 0 2.4239456664076897e-08
appears O 0 5.390784849623742e-07
to O 0 2.0625584795652685e-08
be O 0 6.715156075642881e-08
no O 0 2.4269759535400226e-08
relationship O 0 3.632629486105543e-08
between O 0 5.7485127769041355e-08
the O 0 6.988533129970165e-08
I1307K O 0 3.653869725894765e-06
polymorphism O 0 3.074430878768908e-06
and O 0 5.9211789249502544e-08
the O 0 4.9701046833661167e-08
presence O 0 1.6818169967791619e-07
or O 0 1.3923245489877445e-07
absence O 0 6.741842639712559e-07
of O 0 6.646688461842132e-07
cancer B-Disease 0 0.00020217456039972603
. O 0 4.868010137215606e-07
. O 0 1.901581072161207e-06

Identification O 0 2.8118909540353343e-05
of O 0 5.957400617262465e-07
a O 0 2.244795041406178e-06
novel O 0 6.5501435528858565e-06
mutation O 0 1.8380540041107452e-06
of O 0 2.3772889434781064e-08
the O 0 3.3610760397095873e-07
CPO O 0 8.445786079391837e-05
gene O 0 5.295768232826958e-07
in O 0 7.990309569549936e-08
a O 0 1.9978326690761605e-06
Japanese O 0 1.0446724445500877e-05
hereditary B-Disease 0 0.0013140948722139
coproporphyria I-Disease 0 0.00038883747765794396
family O 0 1.2189490917080548e-05
. O 0 5.637886260956293e-06

Hereditary B-Disease 1 0.9998430013656616
coproporphyria I-Disease 1 0.5711138844490051
( O 0 0.00012142847117502242
HCP B-Disease 0 0.08730148524045944
) O 0 2.6720915684563806e-06
is O 0 5.337374773262127e-07
an O 0 4.1820030673989095e-06
autosomal B-Disease 1 0.9997196793556213
dominant I-Disease 1 0.9981685876846313
disease I-Disease 1 0.5293054580688477
characterized O 0 0.00011512653873069212
by O 0 2.113710706908023e-06
a O 0 0.0033643764909356833
deficiency B-Disease 0 0.02250443771481514
of I-Disease 0 2.1237255509731767e-07
coproporphyrinogen I-Disease 0 0.0003006845654454082
oxidase I-Disease 0 1.679625165706966e-05
( O 0 6.271725965234509e-07
CPO O 0 8.247843652497977e-05
) O 0 1.682007848557987e-07
caused O 0 2.50716169603038e-07
by O 0 2.3023419615242346e-08
a O 0 6.006490593790659e-07
mutation O 0 2.254367473142338e-06
in O 0 1.0011184059521838e-07
the O 0 7.015095206952537e-07
CPO O 0 0.0002706011582631618
gene O 0 1.527799577161204e-05
. O 0 6.513844709843397e-06

Only O 0 8.693771633261349e-06
11 O 0 6.6811612668971065e-06
mutations O 0 1.4668090670966194e-06
of O 0 1.993818621315313e-08
the O 0 8.070800561199576e-08
gene O 0 8.029954869925859e-07
have O 0 3.808125654813921e-07
been O 0 1.5445043572981376e-06
reported O 0 4.077934136148542e-06
in O 0 1.8222600601802696e-06
HCP B-Disease 0 0.43291571736335754
patients O 0 7.573470793431625e-05
. O 0 6.5750086832849775e-06

We O 0 1.9271534256404266e-05
report O 0 1.8811878135238658e-06
another O 0 9.44902694755001e-07
mutation O 0 3.936441316909622e-06
in O 0 1.0463473643085308e-07
a O 0 7.715125889262708e-07
Japanese O 0 5.52667370357085e-06
family O 0 5.40530527359806e-06
. O 0 2.8332556212262716e-06

Polymerase O 0 0.0009315029019489884
chain O 0 0.0003465306363068521
reaction O 0 1.9241473637521267e-05
- O 0 5.2663170208688825e-05
single O 0 5.248343313724035e-06
strand O 0 5.091162529424764e-05
conformational O 0 4.169904059381224e-06
polymorphism O 0 1.4513134374283254e-05
and O 0 8.536098050626606e-08
direct O 0 8.501845627506555e-08
sequence O 0 3.1253708243639267e-07
analyses O 0 3.8478589203805313e-07
demonstrated O 0 2.0463015459881717e-07
a O 0 1.6360657184577576e-07
C O 0 2.057362280538655e-06
to O 0 6.896333104577934e-08
T O 0 3.3277663078479236e-06
substitution O 0 7.069806429171877e-08
in O 0 3.047473384754085e-08
exon O 0 1.4645992223449866e-06
1 O 0 7.172515381625999e-08
of O 0 1.6315620854356894e-08
the O 0 1.3097078976898047e-07
CPO O 0 7.399937658192357e-06
gene O 0 1.7383074180088443e-07
at O 0 4.244132156827618e-08
nucleotide O 0 5.86896760523814e-07
position O 0 2.8045374733665085e-07
85 O 0 3.080627948293113e-07
, O 0 5.222283405714734e-08
which O 0 1.1840487701419988e-07
lies O 0 1.2128977289194154e-07
in O 0 1.8771679322071577e-08
the O 0 7.143938773879199e-08
putative O 0 1.7637443079365767e-06
presequence O 0 2.184926643167273e-06
for O 0 3.6163143590783875e-08
targeting O 0 5.195067274144094e-07
to O 0 1.620007168412485e-07
mitochondria O 0 1.006449201668147e-05
. O 0 2.6344432626501657e-06

This O 0 5.824761046824278e-06
mutation O 0 1.125701965065673e-05
changes O 0 3.643600621217047e-07
the O 0 8.684970964623062e-08
codon O 0 1.0554226719250437e-06
for O 0 5.519061474501541e-08
glutamine O 0 7.192859357019188e-07
to O 0 3.7849019918212434e-08
a O 0 3.7473807878996013e-07
termination O 0 5.085283646621974e-06
codon O 0 2.767227897493285e-06
at O 0 2.3234603929722653e-07
amino O 0 1.2299301488383207e-06
acid O 0 4.256342435837723e-06
position O 0 1.6904856465771445e-06
29 O 0 8.641150998300873e-06
. O 0 2.4488406324962853e-06

MaeI O 0 0.0014215585542842746
restriction O 0 3.2120151445269585e-05
analysis O 0 3.3115347832790576e-06
showed O 0 4.463663572096266e-06
two O 0 9.649778576203971e-08
other O 0 5.3894030571655094e-08
carriers O 0 3.026547688023129e-07
in O 0 7.281451530616323e-08
the O 0 4.979152095074824e-07
family O 0 2.9225989237602334e-06
. O 0 2.7079265692009358e-06

The O 0 3.0143080948619172e-05
C O 0 0.0007441139896400273
- O 0 0.054651010781526566
T O 0 0.01883317530155182
mutation O 0 2.73681780527113e-06
is O 0 2.7770592936349203e-08
located O 0 4.4797477727342994e-08
within O 0 2.2380620023909614e-08
a O 0 1.7133531571289495e-07
recently O 0 3.7811757920280797e-06
proposed O 0 4.935581614518014e-07
putative O 0 1.9287876966700424e-06
alternative O 0 4.6752285243201186e-07
translation O 0 6.270122980822634e-07
initiation O 0 7.514695425925311e-07
codon O 0 3.1985703117243247e-06
( O 0 3.70736614740963e-07
TIC O 0 4.179208190180361e-06
- O 0 2.2467138478532434e-06
1 O 0 1.8626472808591643e-07
) O 0 3.884211352556122e-08
, O 0 1.5954125132111585e-08
supporting O 0 4.787477081436009e-08
that O 0 5.051233387121101e-08
TIC O 0 4.0953041207103524e-06
- O 0 4.301064564060653e-06
1 O 0 1.724419718129866e-07
is O 0 1.7757827208697563e-08
the O 0 3.907141277181836e-08
real O 0 5.301786245581752e-07
TIC O 0 2.7053763460571645e-06
rather O 0 7.427940573734304e-08
than O 0 7.042767435905262e-08
TIC O 0 3.2231403110927204e-06
- O 0 3.888328592438484e-06
2 O 0 8.607771633251105e-07
. O 0 2.7279529035695305e-07
. O 0 1.7386817035003332e-06

Human B-Disease 0 0.00023272098042070866
complement I-Disease 0 0.0002998787094838917
factor I-Disease 0 0.00883562583476305
H I-Disease 1 1.0
deficiency I-Disease 1 0.9997419714927673
associated O 0 0.00031535362359136343
with O 0 0.053750425577163696
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00029758652090094984

This O 0 3.030325160580105e-06
study O 0 7.780643045407487e-07
reports O 0 2.8331618295851513e-07
on O 0 6.215398116182769e-07
six O 0 1.6547213590456522e-06
cases O 0 5.405404976954742e-07
of O 0 3.4835463793569943e-06
deficiency B-Disease 0 0.0031626790296286345
in I-Disease 0 4.408613563100516e-08
the I-Disease 0 4.9810282121143246e-08
human I-Disease 0 5.500617561438048e-08
complement I-Disease 0 2.1304725805748603e-07
regulatory I-Disease 0 4.2696836999311927e-07
protein I-Disease 0 7.49878097394685e-07
Factor I-Disease 0 2.2006904600857524e-06
H I-Disease 1 0.9999908208847046
( O 0 1.2319668485361035e-06
FH O 0 7.73713254602626e-05
) O 0 5.492639587600934e-08
in O 0 1.0661399763023383e-08
the O 0 1.991295128789261e-08
context O 0 1.3325244196948915e-07
of O 0 1.4350429466958303e-07
an O 0 5.655755740008317e-05
acute B-Disease 1 0.9999996423721313
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.814027124666609e-05

Five O 0 1.7858927094493993e-05
of O 0 1.0610242640041179e-07
the O 0 1.1822659473637032e-07
cases O 0 1.4828329142346774e-07
were O 0 3.5826539601657714e-07
observed O 0 1.8462706918853655e-07
in O 0 8.537904960803644e-08
children O 0 1.1821853149740491e-06
presenting O 0 7.710434147156775e-06
with O 0 0.0008923771092668176
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.004731554072350264
HUS B-Disease 1 0.9999871253967285
) O 0 3.8087411667220294e-05
. O 0 1.606668229214847e-05

Two O 0 5.908232651563594e-06
of O 0 1.6394270119235443e-07
the O 0 2.655652053817903e-07
children O 0 2.8755930543411523e-06
exhibited O 0 2.8827247660956345e-05
a O 0 6.427380139939487e-05
homozygous O 1 0.9974749684333801
deficiency O 0 0.3277570903301239
characterized O 0 1.0410325558041222e-05
by O 0 9.262895162009954e-08
the O 0 1.5393707997191086e-07
absence O 0 2.3578877517138608e-07
of O 0 1.0315600817989434e-08
the O 0 5.221317422865468e-08
150 O 0 1.0837437969257735e-07
- O 0 1.6327425100826076e-06
kD O 0 1.3083812291370123e-06
form O 0 3.339896892384786e-08
of O 0 2.1432127184084493e-08
Factor O 0 9.896397159536718e-07
H O 1 0.9997192025184631
and O 0 1.977473260694751e-07
the O 0 3.7343198755479534e-08
presence O 0 1.1454500281615765e-07
, O 0 2.5883212018129598e-08
upon O 0 2.6506770112177946e-08
immunoblotting O 0 2.375765006945585e-06
, O 0 1.2013760652962446e-08
of O 0 4.244324003366273e-09
the O 0 3.104646850715653e-08
42 O 0 4.4223162376511027e-07
- O 0 2.186206529586343e-06
kD O 0 5.9535832406254485e-06
Factor O 0 9.856968290478108e-07
H O 0 0.24835115671157837
- O 0 2.1013879631937016e-06
like O 0 1.2553665840187023e-07
protein O 0 3.150598502088542e-07
1 O 0 1.6715401329747692e-07
( O 0 9.603781592204541e-08
FHL O 0 5.439864708023379e-06
- O 0 5.122089532960672e-06
1 O 0 3.077151404795586e-07
) O 0 3.1710353454172946e-08
and O 0 2.6678257825096807e-08
other O 0 3.5801804187940434e-08
FH O 0 8.682011684868485e-05
- O 0 1.2221289580338635e-05
related O 0 4.4655271835836174e-07
protein O 0 1.1448530585767003e-06
( O 0 3.187055881426204e-07
FHR O 0 2.5251438273699023e-05
) O 0 2.910223031449277e-07
bands O 0 3.466935140750138e-06
. O 0 1.8267667201143922e-06

Southern O 0 0.00023243451141752303
blot O 0 0.0006784240831620991
and O 0 4.058334070577985e-06
PCR O 0 1.6973959645838477e-05
analysis O 0 2.381478623192379e-07
of O 0 2.8084656378268846e-08
DNA O 0 4.6218093530114857e-07
of O 0 1.944584582247444e-08
one O 0 1.6060396035300073e-07
patient O 0 8.056916158238892e-06
with O 0 1.5554483979940414e-05
homozygous O 1 0.99924635887146
deficiency O 0 0.038009848445653915
ruled O 0 2.5447698135394603e-06
out O 0 7.018107339717972e-08
the O 0 3.371836498899938e-08
presence O 0 2.925705366862985e-08
of O 0 5.0850834654170285e-09
a O 0 5.276792336417202e-08
large O 0 4.356130034466332e-08
deletion O 0 5.303166972225881e-07
of O 0 1.3408429033745506e-08
the O 0 1.121856172403568e-07
FH O 0 0.00012053579121129587
gene O 0 5.650561547554389e-07
as O 0 1.7546685171510035e-07
the O 0 3.338330998303718e-07
underlying O 0 3.477387872408144e-05
defect O 0 3.461814048932865e-05
for O 0 1.039434437188902e-06
the O 0 5.4631775128655136e-05
deficiency O 0 0.01650499925017357
. O 0 3.2796815503388643e-06

The O 0 5.101351234770846e-06
other O 0 2.7709171490641893e-07
four O 0 3.076171424254426e-07
children O 0 7.545632456640305e-07
presented O 0 7.353734190473915e-07
with O 0 7.923161319922656e-06
heterozygous O 1 0.7842592000961304
deficiency O 0 0.008111730217933655
and O 0 8.701267688593362e-07
exhibited O 0 3.073179186685593e-06
a O 0 4.3337877286830917e-07
normal O 0 2.44064813159639e-06
immunoblotting O 0 3.0092131055425853e-05
pattern O 0 3.902237040165346e-06
of O 0 2.1471159072916635e-08
proteins O 0 7.484314323846775e-08
of O 0 2.331067960881228e-08
the O 0 1.048440481099533e-06
FH O 0 0.000910151400603354
family O 0 3.4867769045376917e-06
. O 0 2.0161151041975245e-06

Factor B-Disease 1 0.9836795926094055
H I-Disease 1 1.0
deficiency I-Disease 1 0.9979973435401917
is O 0 5.12797612373106e-07
the O 0 2.851034253126272e-07
only O 0 3.0811995657131774e-06
complement B-Disease 1 0.9999649524688721
deficiency I-Disease 1 0.9999997615814209
associated O 0 7.587263098685071e-06
with O 0 1.2471496120269876e-05
HUS B-Disease 1 0.9999666213989258
. O 0 4.7102530515985563e-05

These O 0 7.785922207403928e-06
observations O 0 7.088985512382351e-06
suggest O 0 8.767045187596523e-07
a O 0 2.1581323039754352e-07
role O 0 3.3327387427561916e-07
for O 0 2.9244398547234596e-07
FH O 0 0.001305017271079123
and O 0 6.1546420511149336e-06
/ O 0 0.00014679001469630748
or O 0 2.8362319426378235e-06
FH O 0 0.00030273289303295314
receptors O 0 2.017757879002602e-06
in O 0 1.6656316859098297e-07
the O 0 6.423738909688836e-07
pathogenesis O 0 6.055026824469678e-05
of O 0 2.1628395643347176e-06
idiopathic O 1 0.999761164188385
HUS B-Disease 1 0.999996542930603
. O 0 1.4834986359346658e-05
. O 0 1.8343944248044863e-05

Further O 0 2.0572957510012202e-05
evidence O 0 1.3554581528296694e-06
for O 0 1.29022694750347e-07
a O 0 4.707535481429659e-07
major O 0 1.2062423593306448e-06
ancient O 0 5.569286258833017e-06
mutation O 0 0.004007101058959961
underlying O 0 0.3350313603878021
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 2.0867297280346975e-05
linkage O 0 0.001967974239960313
disequilibrium O 0 0.020799702033400536
studies O 0 1.1606638281591586e-06
in O 0 1.8776950128085446e-07
the O 0 3.978788924996479e-07
Japanese O 0 2.532212647565757e-06
population O 0 8.761754202168959e-07
. O 0 1.4861360568829696e-06

The O 0 0.02440051920711994
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6817135810852051
DM B-Disease 1 1.0
) O 0 5.990031422697939e-05
mutation O 0 2.0353223590063863e-05
is O 0 1.3331573711639066e-07
an O 0 1.6031397365168232e-07
unstable O 0 0.0012595250736922026
( O 0 1.7416242599210818e-06
CTG O 0 1.9079763660556637e-05
) O 0 1.370751618878785e-07
n O 0 1.6333669918822125e-06
repeat O 0 1.0231830174234346e-06
, O 0 4.327179325969155e-08
present O 0 1.4848771989761644e-08
at O 0 1.0261968164115842e-08
a O 0 2.0393729371903646e-08
copy O 0 8.801134043778802e-08
number O 0 1.56926152072856e-08
of O 0 7.978929517094002e-09
5 O 0 1.6986292905585287e-07
- O 0 2.8574738735187566e-06
37 O 0 5.619355079033994e-07
repeats O 0 5.83770201956213e-07
on O 0 1.1602727312265415e-07
normal O 0 1.5382290996512893e-07
chromosomes O 0 3.215736512629519e-07
but O 0 2.5886469856573058e-08
amplified O 0 3.8014817960174696e-07
to O 0 2.821970035427057e-08
50 O 0 9.938867151504382e-08
- O 0 8.701176739123184e-07
3000 O 0 5.903299324927502e-07
copies O 0 5.711620474357915e-07
on O 0 4.41937936557224e-06
DM B-Disease 1 0.9999856948852539
chromosomes O 0 0.00018689976423047483
. O 0 6.66994401399279e-06

Previous O 0 0.00010355931590311229
findings O 0 9.549607057124376e-06
in O 0 7.127442813725793e-07
Caucasian O 0 8.210043597500771e-05
populations O 0 1.1461246458566166e-06
of O 0 1.1883678752155902e-07
a O 0 2.7992464310955256e-05
DM B-Disease 1 1.0
founder O 0 0.0001372118276776746
chromosome O 0 7.28602462913841e-05
raise O 0 3.377720645403315e-07
a O 0 1.3534956622152094e-07
question O 0 4.035429057580586e-08
about O 0 1.128132076644306e-08
the O 0 1.1692652179817742e-08
molecular O 0 1.038085741811301e-07
events O 0 9.270282674833652e-08
involved O 0 4.087844729383505e-08
in O 0 7.104871713181637e-08
the O 0 3.703316622249986e-07
expansion O 0 9.712875908007845e-06
mutation O 0 2.5603061658330262e-05
. O 0 3.1695046800450655e-06

To O 0 3.6106710012973053e-06
investigate O 0 3.727076546056196e-06
whether O 0 2.754219394773827e-07
a O 0 8.762013408158964e-07
founder O 0 5.630127816402819e-06
chromosome O 0 1.1815499419753905e-05
for O 0 1.7734176083195052e-07
the O 0 6.475938334915554e-06
DM B-Disease 1 1.0
mutation O 0 4.6303903218358755e-05
exists O 0 1.2964729023678956e-07
in O 0 1.947238281729824e-08
the O 0 5.8339733044476816e-08
Japanese O 0 7.53353845084348e-07
population O 0 4.22426467139303e-08
, O 0 2.4587055946767578e-08
we O 0 2.4077630556007534e-08
genotyped O 0 1.7019254983097198e-06
families O 0 7.023088954838386e-08
using O 0 9.018030056040516e-08
polymorphic O 0 2.6123841507796897e-06
markers O 0 3.2614104839012725e-06
near O 0 1.5716644838903449e-06
the O 0 2.843013646725012e-07
( O 0 4.607177004345431e-07
CTG O 0 9.231284820998553e-06
) O 0 1.1852722536787041e-07
n O 0 2.7007465632777894e-06
repeat O 0 3.076258280998445e-06
region O 0 2.0855600268987473e-06
and O 0 8.787260412645992e-07
constructed O 0 3.832292350125499e-05
haplotypes O 0 0.00014823256060481071
. O 0 5.370283815864241e-06

Six O 0 4.9530215619597584e-05
different O 0 2.6014351988123963e-06
haplotypes O 0 9.786237205844373e-05
were O 0 3.008194198628189e-06
found O 0 1.0697688139771344e-06
and O 0 1.8462229490978643e-05
DM B-Disease 1 1.0
alleles O 0 6.704901170451194e-05
were O 0 4.895112851954764e-06
always O 0 2.28284966397041e-06
haplotype O 0 6.501899042632431e-05
A O 0 1.497311041021021e-05
. O 0 9.01988551049726e-06

To O 0 4.809011898032622e-06
find O 0 8.801098942967656e-07
an O 0 5.981076611760727e-08
origin O 0 9.856464089352812e-08
of O 0 1.615459943593578e-08
the O 0 1.5313482037981885e-07
( O 0 6.067841695767129e-07
CTG O 0 2.0931991457473487e-05
) O 0 1.8965918968660844e-07
n O 0 2.6441036879987223e-06
repeat O 0 2.3596855953655904e-06
mutation O 0 7.810573947608646e-07
and O 0 4.4787139330537684e-08
to O 0 2.3450127173418878e-08
investigate O 0 7.821920888773093e-08
the O 0 3.345992638514872e-08
mechanism O 0 6.244212613637501e-08
of O 0 7.923484979244222e-09
the O 0 3.791057778812501e-08
expansion O 0 6.553622142746462e-07
mutation O 0 5.07930906223919e-07
in O 0 1.3393986364462762e-08
the O 0 5.4641652980080835e-08
Japanese O 0 1.6860244045346917e-07
population O 0 3.898350087183644e-08
we O 0 7.954541914045876e-09
have O 0 1.6796940727203946e-08
studied O 0 8.290260211651912e-08
90 O 0 1.1083590578664371e-07
Japanese O 0 7.717782182226074e-07
DM B-Disease 1 0.9999783039093018
families O 0 3.15992053856462e-07
comprising O 0 8.070939117033049e-08
190 O 0 2.4291671252285596e-07
affected O 0 8.55293293966497e-08
and O 0 1.1678037026285892e-07
130 O 0 7.538224622294365e-07
unaffected O 0 6.412001312128268e-06
members O 0 7.748905090920744e-07
. O 0 2.514244670237531e-06

The O 0 1.2620263078133576e-05
results O 0 4.95921403853572e-06
suggest O 0 5.568461460825347e-07
that O 0 2.428346590477304e-08
a O 0 2.993396606143506e-07
few O 0 2.1776615710678016e-07
common O 0 3.0490318181364273e-07
ancestral O 0 6.289590601227246e-06
mutations O 0 5.23590551892994e-06
in O 0 1.5614516257755895e-07
both O 0 6.189142141010961e-07
Caucasian O 0 8.496329246554524e-05
and O 0 4.85728833155008e-07
Japanese O 0 3.4374559731986665e-07
populations O 0 1.9175359966538963e-07
have O 0 4.420553523232229e-08
originated O 0 3.351524213712764e-08
by O 0 3.7020708720802986e-09
expansion O 0 3.725050135017227e-08
of O 0 6.151203102433556e-09
an O 0 2.0793221366943726e-08
ancestral O 0 8.808387406133988e-07
n O 0 9.620145647204481e-06
= O 0 2.809628540489939e-06
5 O 0 2.0457277116747719e-07
repeat O 0 4.065319672008627e-07
to O 0 1.0141429385157608e-07
n O 0 3.719389269463136e-06
= O 0 6.296036190178711e-06
19 O 0 7.198548246378778e-07
- O 0 2.0249908629921265e-06
37 O 0 8.679255643073702e-07
copies O 0 8.763952337176306e-07
. O 0 1.5294552895284141e-06

These O 0 2.228407083748607e-06
data O 0 1.4506676961900666e-06
support O 0 4.87505303681246e-07
multistep O 0 5.741702807426918e-06
models O 0 1.3731581702813855e-06
of O 0 7.867032536523766e-08
triplet O 0 0.00014123159053269774
repeat O 0 4.714796432381263e-06
expansion O 0 7.108477007022884e-07
that O 0 6.404335550769247e-08
have O 0 6.37092867350475e-08
been O 0 4.785714935451324e-08
proposed O 0 8.014196595240719e-08
for O 0 5.24765475518052e-08
both O 0 1.852948571468005e-06
DM B-Disease 1 1.0
and O 0 3.49822330463212e-05
Friedreichs B-Disease 0 0.0022228718735277653
ataxia I-Disease 0 0.4219341278076172
. O 0 1.9061511693507782e-06
. O 0 4.633452135749394e-06

The O 0 1.042558596964227e-05
molecular O 0 1.3166024473321158e-05
basis O 0 5.553481969400309e-06
of O 0 7.228342292364687e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.0740428706412786e-06
the O 0 3.1221594554153853e-07
western O 0 2.5567724151187576e-06
Cape O 0 1.7963240679819137e-05
, O 0 1.4194337438766524e-07
South O 0 4.861116167376167e-07
Africa O 0 1.200996621264494e-06
. O 0 2.0944892185070785e-06

Deficiency B-Disease 1 0.9995317459106445
of I-Disease 0 2.0109976048843237e-06
the I-Disease 0 5.2112488901912e-07
sixth I-Disease 0 1.2385211448417976e-05
component I-Disease 0 4.579251822178776e-07
of I-Disease 0 2.2154628354087436e-08
human I-Disease 0 1.6086946175164485e-07
complement I-Disease 0 1.3213721103966236e-06
( O 0 5.609064146483433e-07
C6 O 0 0.0001621847623027861
) O 0 1.5441655421000178e-07
has O 0 3.2985761322379403e-07
been O 0 3.898499585375248e-07
reported O 0 5.03706189647346e-07
in O 0 1.5429327149263372e-08
a O 0 9.819778767905518e-08
number O 0 3.060206310578906e-08
of O 0 1.3292797085284747e-08
families O 0 7.36712806315154e-08
from O 0 1.0895176316694233e-08
the O 0 3.3894142603685395e-08
western O 0 6.682166144855728e-07
Cape O 0 4.458473085833248e-06
, O 0 8.641497117878316e-08
South O 0 3.1642781550544896e-07
Africa O 0 7.890276947364327e-07
. O 0 1.350286993329064e-06

Meningococcal B-Disease 1 0.9999966621398926
disease I-Disease 1 0.9989535808563232
is O 0 1.104193324863445e-05
endemic O 0 2.5549636575306067e-06
in O 0 4.246286096076801e-07
the O 0 1.1246879694226664e-06
Cape O 0 3.9613762055523694e-05
and O 0 3.2412606287834933e-07
almost O 0 5.439666139750443e-08
all O 0 1.0549417339689171e-08
pedigrees O 0 1.2091112466805498e-06
of O 0 3.1309016890190833e-07
total O 0 0.00249713147059083
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.0388361008372158e-06
C6Q0 O 0 0.000159243936650455
) O 0 1.389724388900504e-07
have O 0 6.604555835565407e-08
been O 0 3.197443447788828e-07
ascertained O 0 3.134763801426743e-06
because O 0 7.684792535656015e-08
of O 0 4.585352542108012e-07
recurrent O 1 0.9856738448143005
disease O 0 0.011339399963617325
. O 0 5.84769259148743e-06

We O 0 2.625994420668576e-05
have O 0 1.1064850014008698e-06
sequenced O 0 1.8937267896035337e-06
the O 0 1.615506874941275e-07
expressed O 0 1.3169521650979732e-07
exons O 0 1.3027782870267401e-06
of O 0 3.4657766434520454e-08
the O 0 2.6190119228886033e-07
C6 O 0 0.0001959369983524084
gene O 0 3.1005225764602073e-07
from O 0 2.9758739472640627e-08
selected O 0 9.215015950303496e-08
cases O 0 6.315516287713763e-08
and O 0 2.688232711989258e-07
have O 0 8.143818064354491e-08
found O 0 7.648483801858674e-08
three O 0 1.2495651446897682e-07
molecular O 0 1.3862031664757524e-05
defects O 0 0.07111761718988419
leading O 0 1.4041189615454641e-06
to O 0 3.1518845844402676e-07
total O 0 6.016206953063374e-06
deficiency O 0 0.00014732059207744896
879delG O 0 9.456416592001915e-06
, O 0 2.8990348255319986e-07
which O 0 8.875883139580765e-08
is O 0 2.3040815477770593e-08
the O 0 4.7045151774227634e-08
common O 0 7.288863912435772e-07
defect O 0 1.1495803846628405e-05
in O 0 1.100692728073227e-07
the O 0 4.966386200067063e-07
Cape O 0 1.561935459903907e-05
and O 0 5.094406105854432e-07
hitherto O 0 2.000520908040926e-06
unreported O 0 2.6530753416409425e-07
, O 0 5.40918634328591e-08
and O 0 5.0714675126073416e-08
1195delC O 0 9.019215099215216e-07
and O 0 1.3420638822481123e-07
1936delG O 0 1.3668828842128278e-06
, O 0 3.683140903376625e-08
which O 0 3.639051371351343e-08
have O 0 2.569320400880315e-08
been O 0 1.3768517703738326e-07
previously O 0 5.90104207276454e-07
reported O 0 7.36858908112481e-07
in O 0 5.158017657436176e-08
African O 0 3.9320372025031247e-07
- O 0 1.9063028958044015e-05
Americans O 0 2.0814470644836547e-06
. O 0 1.8253978169013862e-06

We O 0 3.445993934292346e-05
also O 0 2.6067498311022064e-06
show O 0 9.58949385676533e-07
that O 0 3.438491091856122e-08
the O 0 9.305323089847661e-08
879delG O 0 1.740388870530296e-05
and O 0 4.310722488298779e-06
1195delC O 0 0.001139601692557335
defects O 0 0.06464195251464844
are O 0 5.673689074114918e-08
associated O 0 3.5524217878446507e-07
with O 0 7.024106025710353e-07
characteristic O 0 0.004967667628079653
C6 O 1 0.9937615990638733
/ O 0 0.0034007630310952663
C7 O 0 0.000597418169490993
region O 0 4.2409010347910225e-06
DNA O 0 5.572494956140872e-06
marker O 0 1.8396392988506705e-05
haplotypes O 0 3.834371455013752e-05
, O 0 2.3309131336191058e-07
although O 0 1.1680041467343472e-07
small O 0 1.1418900669468712e-07
variations O 0 5.241935923550045e-06
were O 0 1.4838700508335023e-06
observed O 0 4.403010279929731e-06
. O 0 2.300916776221129e-06

The O 0 1.616089684830513e-05
1936delG O 0 0.00042941878200508654
defect O 0 0.0003846466715913266
was O 0 2.181541276513599e-05
observed O 0 5.729137342314061e-07
only O 0 3.654973568245623e-08
once O 0 8.774115656251524e-08
in O 0 4.613327675428991e-08
the O 0 2.0359010477477568e-07
Cape O 0 7.59247450332623e-06
, O 0 7.430916326711667e-08
but O 0 2.3224538736599243e-08
its O 0 6.359127979749246e-08
associated O 0 6.555897016369272e-07
haplotype O 0 1.966463605640456e-05
could O 0 1.2529915238701506e-06
be O 0 2.9536121814999206e-07
deduced O 0 9.945939382305369e-06
. O 0 3.6359608657221543e-06

The O 0 3.4397519357298734e-06
data O 0 1.4509442962662433e-06
from O 0 1.1356931395312131e-07
the O 0 1.5511660933498206e-07
haplotypes O 0 1.8526625353842974e-05
indicate O 0 8.823739676699915e-07
that O 0 2.916935315511182e-08
these O 0 1.2058688270144557e-08
three O 0 2.02061812615284e-07
molecular O 0 1.9596885977080092e-05
defects O 0 0.020689914003014565
account O 0 2.832680934261589e-07
for O 0 8.647102589520728e-08
the O 0 2.1706919142161496e-06
defects O 0 0.15477655827999115
in O 0 4.491691640851059e-08
all O 0 1.1070339311913813e-08
the O 0 4.591347035898252e-08
38 O 0 6.502466476376867e-07
unrelated O 0 8.141114449244924e-07
C6Q0 O 0 5.069197140983306e-05
individuals O 0 4.363164762821725e-08
we O 0 1.1850221248721482e-08
have O 0 2.188336800656998e-08
studied O 0 8.867134937418086e-08
from O 0 2.5242044898732274e-08
the O 0 2.6492978122405475e-07
Cape O 0 2.074200165225193e-05
. O 0 2.360923645028379e-06

We O 0 2.048970418400131e-05
have O 0 1.1698740536303376e-06
also O 0 4.982924224350427e-07
observed O 0 4.2981099568351055e-07
the O 0 1.346676867797214e-07
879delG O 0 3.2664182072039694e-05
defect O 0 6.3651259551988915e-06
in O 0 2.618497489947913e-07
two O 0 4.396154508867767e-06
Dutch O 1 0.6817421317100525
C6 B-Disease 1 1.0
- I-Disease 1 0.9999170303344727
deficient I-Disease 1 0.9999938011169434
kindreds O 0 0.00020662034512497485
, O 0 2.7512530209605757e-07
but O 0 3.342407950412962e-08
the O 0 5.501876998437183e-08
879delG O 0 9.678534297563601e-06
defect O 0 1.6140589877977618e-06
in O 0 3.312029051016907e-08
the O 0 1.682426642446444e-07
Cape O 0 1.6337005945388228e-05
probably O 0 6.267492835831945e-07
did O 0 7.772338506129017e-08
not O 0 1.683774186744813e-08
come O 0 1.5836249644962663e-08
from O 0 1.305649277583143e-08
The O 0 4.785833596088196e-08
Netherlands O 0 1.2966601161679137e-06
. O 0 2.009905415434332e-07
. O 0 1.153004063780827e-06

Complement B-Disease 1 0.9998376369476318
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.97466805629665e-06
seven O 0 1.6750346958360751e-06
further O 0 1.2940485021317727e-06
molecular O 0 0.00013594530173577368
defects O 1 0.8762966394424438
and O 0 1.3968799521535402e-06
their O 0 6.377293289006047e-07
associated O 0 3.679939936773735e-06
marker O 0 9.408558980794623e-05
haplotypes O 0 0.00037999716005288064
. O 0 1.086048814613605e-05

Seven O 0 3.23180211125873e-05
further O 0 2.000826270887046e-06
molecular O 0 3.8052282889111666e-06
bases O 0 4.064640052092727e-06
of O 0 5.384178803069517e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.5132997077671462e-06
described O 0 2.6056211936520413e-05
. O 0 6.746828148607165e-06

All O 0 2.589200676084147e-06
these O 0 1.879988502651031e-07
new O 0 4.809126039617695e-07
molecular O 0 1.5250729120452888e-05
defects O 0 0.011862825602293015
involve O 0 1.9770924097883835e-07
single O 0 2.7865200991072925e-06
- O 0 3.2127256417879835e-05
nucleotide O 0 1.4877525700285332e-06
events O 0 1.7389209006068995e-07
, O 0 9.235373710225758e-08
deletions O 0 2.1342520994949155e-06
and O 0 3.719988228567672e-07
substitutions O 0 8.98429277640389e-07
, O 0 3.9201001555966286e-08
some O 0 3.258186165311372e-09
of O 0 8.882009794319856e-09
which O 0 1.0737647215819379e-07
alter O 0 2.3240706923388643e-06
splice O 0 1.239985431311652e-05
sites O 0 2.7024111659557093e-07
, O 0 8.674756202253775e-08
and O 0 2.3358889222890866e-07
others O 0 7.122781084945018e-07
codons O 0 1.155564132204745e-05
. O 0 2.7142068574903533e-06

They O 0 7.492864824598655e-06
are O 0 1.9146763463595562e-07
distributed O 0 2.465656621097878e-07
along O 0 2.7995776008538087e-07
the O 0 2.424020237867808e-07
C7 O 0 0.00011489808821352199
gene O 0 7.778083386256185e-07
, O 0 8.504521531449427e-08
but O 0 2.4924089458977505e-08
predominantly O 0 4.730672742425668e-08
towards O 0 5.634509747665106e-08
the O 0 5.7411821074992986e-08
3 O 0 1.612088453839533e-06
end O 0 5.569774657487869e-06
. O 0 3.3366261504852446e-06

All O 0 4.874467322224518e-06
were O 0 1.3596346661870484e-06
found O 0 4.254482064425247e-07
in O 0 2.672986170182412e-07
compound O 0 1.818661803554278e-05
heterozygous O 0 5.761037755291909e-05
individuals O 0 1.4314482541522011e-06
. O 0 2.9046823328826576e-06

The O 0 0.00011453949991846457
C6 O 1 0.8676055073738098
/ O 0 0.032515257596969604
C7 O 0 0.0037437251303344965
marker O 0 0.00011528527102200314
haplotypes O 0 0.00037041588802821934
associated O 0 6.02600812271703e-06
with O 0 2.479891236362164e-06
most O 0 1.2236007023602724e-05
C7 B-Disease 1 0.9993763566017151
defects I-Disease 1 0.9954918026924133
are O 0 6.237987122403865e-07
tabulated O 0 1.8813147107721306e-05
. O 0 5.823005722049857e-07
. O 0 2.681524165382143e-06

A O 0 6.872576341265813e-05
genome O 0 1.5301719031413086e-05
- O 0 1.1846494089695625e-05
wide O 0 1.5350358353316551e-06
search O 0 8.01680869244592e-07
for O 0 1.5835682631859527e-07
chromosomal O 0 0.007657460402697325
loci O 0 2.508278703317046e-05
linked O 0 3.5197805118514225e-05
to O 0 1.0137296158063691e-06
mental O 0 0.015208476223051548
health O 0 1.1112374522781465e-05
wellness O 0 2.6916985007119365e-05
in O 0 3.1715771342533117e-07
relatives O 0 6.428371648325992e-07
at O 0 1.9871183098985057e-07
high O 0 5.815347321913578e-06
risk O 0 1.0541951269260608e-05
for O 0 4.066101610078476e-06
bipolar B-Disease 1 0.9999991655349731
affective I-Disease 1 0.9999904632568359
disorder I-Disease 1 0.983737587928772
among O 0 2.28985683747851e-07
the O 0 1.6622072962491075e-07
Old O 0 1.1747255484806374e-05
Order O 0 1.770914082044328e-06
Amish O 0 0.00012609813711605966
. O 0 5.1960014388896525e-06

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999992847442627
disorder I-Disease 1 0.9999998807907104
( O 0 0.007256945129483938
BPAD B-Disease 1 0.9999998807907104
; O 0 0.20451423525810242
manic B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999979734420776
depressive I-Disease 1 0.9999998807907104
illness I-Disease 1 0.9477455615997314
) O 0 1.2652973282456514e-06
is O 0 2.0489765972797613e-07
characterized O 0 2.0368984223750886e-06
by O 0 8.441654841817581e-08
episodes O 0 3.779261533054523e-06
of O 0 1.952087842482797e-07
mania B-Disease 0 0.0017866783309727907
and O 0 1.930879989231471e-06
/ O 0 8.880239329300821e-05
or O 0 2.3513243831985164e-06
hypomania B-Disease 0 0.0017622370505705476
interspersed O 0 1.7377553376718424e-05
with O 0 1.6200858965476073e-07
periods O 0 2.1881339762330754e-06
of O 0 6.286595066740119e-07
depression B-Disease 0 0.00047503283713012934
. O 0 5.769135441369144e-06

Compelling O 0 0.00020228368521202356
evidence O 0 5.482028882397572e-06
supports O 0 1.579539684826159e-06
a O 0 8.818666401566588e-07
significant O 0 5.757273697781784e-07
genetic O 0 1.8316580963073648e-06
component O 0 1.02560579762212e-06
in O 0 1.0798852656535018e-07
the O 0 6.130006795501686e-07
susceptibility O 0 3.5038552596233785e-05
to O 0 9.901920066113234e-07
develop O 0 1.8100519810104743e-05
BPAD B-Disease 1 0.9999837875366211
. O 0 1.3007846973778214e-05

To O 0 4.144866579736117e-06
date O 0 4.8959909690893255e-06
, O 0 2.246946593231769e-07
however O 0 1.003517695608025e-07
, O 0 2.90800254987289e-08
linkage O 0 1.7304223547398578e-06
studies O 0 7.37273708750763e-08
have O 0 7.794190537424583e-08
attempted O 0 2.64756522483367e-06
only O 0 4.0020630365233956e-08
to O 0 6.652027906284275e-08
identify O 0 1.1067003242715145e-06
chromosomal O 0 0.0003295809729024768
loci O 0 3.7572394830931444e-06
that O 0 1.8867383744236577e-07
cause O 0 2.27257964979799e-06
or O 0 2.7316835371493653e-07
increase O 0 5.486566010404204e-07
the O 0 2.562796623806207e-07
risk O 0 1.1222098237340106e-06
of O 0 2.1039936370925716e-07
developing O 0 8.31660145195201e-06
BPAD B-Disease 1 0.9999688863754272
. O 0 1.4207070307747927e-05

To O 0 2.308525836269837e-06
determine O 0 9.145272201749322e-07
whether O 0 1.241329243839573e-07
there O 0 5.526118940224478e-08
could O 0 5.029305611969903e-07
be O 0 8.766672010551702e-08
protective O 0 9.429641977476422e-06
alleles O 0 5.876606792298844e-07
that O 0 5.3778098418888476e-08
prevent O 0 3.537708437306719e-07
or O 0 3.2399194083154725e-07
reduce O 0 1.2154097248640028e-06
the O 0 2.0535561873202823e-07
risk O 0 1.7595965573491412e-07
of O 0 2.4491248140634525e-08
developing O 0 8.718303661225946e-07
BPAD B-Disease 1 0.9999924898147583
, O 0 1.2949185190791468e-07
similar O 0 3.5490685945660516e-08
to O 0 1.6522024637311006e-08
what O 0 1.4262176328827536e-08
is O 0 3.304538864767892e-08
observed O 0 2.130072260797533e-07
in O 0 1.3594514314263506e-07
other O 0 2.9985790206410456e-06
genetic B-Disease 1 0.9999998807907104
disorders I-Disease 1 1.0
, O 0 8.779369977673923e-07
we O 0 1.323171261446987e-07
used O 0 2.2566669031220954e-06
mental O 0 0.0003595506423152983
health O 0 6.719141310895793e-06
wellness O 0 9.889154171105474e-05
( O 0 5.226937105362595e-07
absence O 0 3.2842811492628243e-07
of O 0 9.717304294554197e-08
any O 0 1.8182985286330222e-06
psychiatric B-Disease 1 0.9799315333366394
disorder I-Disease 1 0.7679324746131897
) O 0 2.306483111169655e-07
as O 0 9.082330620913126e-08
the O 0 4.2465694605198223e-07
phenotype O 0 6.78512078593485e-05
in O 0 1.413517054515978e-07
our O 0 1.834485203744407e-07
genome O 0 1.0159682233279455e-06
- O 0 4.482757503865287e-06
wide O 0 1.996849960050895e-06
linkage O 0 8.688682100910228e-06
scan O 0 1.4299583199317567e-05
of O 0 2.377865016001124e-08
several O 0 2.3908125257321444e-08
large O 0 1.6481712350469024e-07
multigeneration O 0 8.279771464003716e-06
Old O 0 1.5478220802833675e-06
Order O 0 1.966456721902432e-07
Amish O 0 9.738148946780711e-06
pedigrees O 0 6.097686309658457e-06
exhibiting O 0 6.962866905269038e-07
an O 0 1.1203486849353794e-07
extremely O 0 1.8645415593709913e-06
high O 0 1.8398726751911454e-05
incidence O 0 0.013514171354472637
of O 0 3.7816157600900624e-06
BPAD B-Disease 1 0.9999996423721313
. O 0 1.2440860700735357e-05

We O 0 1.929402606037911e-05
have O 0 5.614801921183243e-07
found O 0 2.138054355782515e-07
strong O 0 2.9041956395303714e-07
evidence O 0 7.42938581765884e-08
for O 0 2.6239565187324843e-08
a O 0 6.068165703254635e-07
locus O 0 1.295822312386008e-05
on O 0 4.437238658283604e-06
chromosome O 0 0.00015082175377756357
4p O 0 0.00018821508274413645
at O 0 3.698258694839751e-07
D4S2949 O 0 3.7352426716097398e-06
( O 0 1.2913137936720887e-07
maximum O 0 2.9548405677815026e-07
GENEHUNTER O 0 1.1287914276181255e-05
- O 0 4.731466560770059e-06
PLUS O 0 1.0660717180144275e-06
nonparametric O 0 3.4971305922226747e-06
linkage O 0 4.41382371718646e-06
score O 0 1.4192403341439785e-06
= O 0 1.938006562340888e-06
4 O 0 2.528860250095022e-07
. O 0 3.401829573590476e-08
05 O 0 1.237938022313756e-06
, O 0 1.5528385688412527e-07
P O 0 1.2596297892741859e-05
= O 0 1.1828427659565932e-06
5 O 0 7.548397462642242e-08
. O 0 1.2000934468403557e-08
22 O 0 5.831036276049417e-08
x O 0 3.09358961203543e-06
10 O 0 1.1141390388047512e-07
( O 0 4.762213379194691e-08
- O 0 9.801858595892554e-07
4 O 0 3.299803097434051e-07
) O 0 3.976133200467302e-08
; O 0 1.0271959638430417e-07
SIBPAL O 0 3.5853615827363683e-06
Pempirical O 0 1.210686264130345e-06
value O 0 3.4496785872306646e-08
< O 0 4.0409909729532956e-07
3 O 0 9.221099617207074e-08
x O 0 3.141650040561217e-06
10 O 0 8.921897176605853e-08
( O 0 5.4079997369171906e-08
- O 0 1.8604207525640959e-06
5 O 0 2.143732444892521e-07
) O 0 3.214840305076905e-08
) O 0 1.9413603169482485e-08
and O 0 4.421818289301882e-08
suggestive O 0 2.194261014665244e-06
evidence O 0 3.105973789274685e-08
for O 0 1.598690069215536e-08
a O 0 4.922086986880458e-07
locus O 0 1.2669765965256374e-05
on O 0 1.7119242329499684e-05
chromosome O 0 0.003385333577170968
4q O 0 0.028043026104569435
at O 0 5.252722417026234e-07
D4S397 O 0 3.4982749639311805e-06
( O 0 2.1405006123131898e-07
maximum O 0 5.950274726274074e-07
GENEHUNTER O 0 3.723780901054852e-05
- O 0 8.886612704372965e-06
PLUS O 0 2.570936203483143e-06
nonparametric O 0 7.162458132370375e-06
linkage O 0 6.33485888101859e-06
score O 0 2.015842028413317e-06
= O 0 3.2954205835267203e-06
3 O 0 3.3991290138146724e-07
. O 0 3.280086247059444e-08
29 O 0 2.983723277338868e-07
, O 0 5.774832345650793e-08
P O 0 8.618913852842525e-06
= O 0 7.4437110697545e-07
2 O 0 1.1314920556060315e-07
. O 0 1.6778880507217764e-08
57 O 0 1.6227951959990605e-07
x O 0 3.4510978821344906e-06
10 O 0 1.2314553998749034e-07
( O 0 5.997297591875395e-08
- O 0 1.8772666408040095e-06
3 O 0 3.042287630705687e-07
) O 0 3.545137872151827e-08
; O 0 6.700710741824878e-08
SIBPAL O 0 2.1702778667531675e-06
Pempirical O 0 1.1534208397279144e-06
value O 0 3.169941109604224e-08
< O 0 2.6062303959406563e-07
1 O 0 4.9605112906192517e-08
x O 0 1.4173034514897154e-06
10 O 0 1.1080039286071042e-07
( O 0 4.6612399273726624e-08
- O 0 7.520459917031985e-07
3 O 0 3.893201210303232e-07
) O 0 3.6404117054189555e-08
) O 0 1.642800562251523e-08
that O 0 1.1166787494687469e-08
are O 0 2.625663597655148e-08
linked O 0 4.138460099056829e-06
to O 0 1.664070964579878e-06
mental O 0 0.0026115579530596733
health O 0 1.6943344235187396e-05
wellness O 0 0.0002014085912378505
. O 0 7.898703188402578e-06

These O 0 6.123992534412537e-06
findings O 0 2.0027239315822953e-06
are O 0 9.78963328179816e-08
consistent O 0 5.794637445433182e-07
with O 0 7.33835037181052e-08
the O 0 4.026442184112966e-07
hypothesis O 0 1.2442418437785818e-06
that O 0 2.997452597242045e-08
certain O 0 7.096975451759135e-08
alleles O 0 4.796337975676579e-07
could O 0 5.955088795417396e-07
prevent O 0 3.966022177337436e-07
or O 0 1.160445251002784e-07
modify O 0 9.953016615327215e-07
the O 0 3.2844943120835524e-07
clinical O 0 3.6848739455308532e-06
manifestations O 0 1.1006650311173871e-06
of O 0 3.004825828156754e-07
BPAD B-Disease 1 0.9999996423721313
and O 0 1.8616738088894635e-06
perhaps O 0 2.4632592499074235e-07
other O 0 2.7745079478336265e-07
related O 0 3.103306153207086e-05
affective B-Disease 1 0.9986531734466553
disorders I-Disease 1 0.9952763319015503
. O 0 2.6681835151975974e-05

Segregation O 0 0.020103907212615013
distortion O 1 0.6665972471237183
in O 0 0.0020798163022845984
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 0.0005592745146714151

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9916600584983826
DM B-Disease 1 1.0
) O 0 5.021047400077805e-05
is O 0 1.081222421817074e-06
an O 0 2.135593831553706e-06
autosomal B-Disease 1 0.9335832595825195
dominant I-Disease 1 0.9003400802612305
disease I-Disease 0 0.11266076564788818
which O 0 4.4736862037098035e-06
, O 0 1.823668611677931e-07
in O 0 4.374864559508751e-08
the O 0 2.2782164421641937e-07
typical O 0 3.6769754387933062e-06
pedigree O 0 8.397543751925696e-06
, O 0 7.878804808569839e-08
shows O 0 9.633925657226428e-08
a O 0 1.1272721422983523e-07
three O 0 2.22389914483756e-07
generation O 0 1.8539877828516182e-06
anticipation O 0 2.7962844342255266e-06
cascade O 0 2.7127756766276434e-05
. O 0 4.881845597992651e-06

This O 0 8.152098416758236e-06
results O 0 1.6048474208218977e-05
in O 0 9.492484423390124e-06
infertility B-Disease 1 0.9999837875366211
and O 1 0.9998337030410767
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0011896826326847076
CDM B-Disease 0 0.0019647942390292883
) O 0 4.21057762878263e-07
with O 0 3.88405574369699e-08
the O 0 1.6950787085079355e-07
disappearance O 0 6.001514066156233e-06
of O 0 7.541495961049804e-07
DM B-Disease 1 1.0
in O 0 4.7051257752173115e-06
that O 0 8.683535952513921e-07
pedigree O 0 6.499730079667643e-05
. O 0 5.670768587151542e-06

The O 0 5.632743523165118e-06
concept O 0 2.3013908503344283e-06
of O 0 2.3599797316364857e-07
segregation O 0 2.884391142288223e-05
distortion O 0 0.007415126543492079
, O 0 4.3205739075347083e-07
where O 0 7.127035672738202e-08
there O 0 1.4137940596015142e-08
is O 0 2.5026031025277007e-08
preferential O 0 3.8003179270162946e-07
transmission O 0 5.468738891067915e-06
of O 0 9.557819424799163e-09
the O 0 2.149779554372344e-08
larger O 0 1.3260539333259658e-07
allele O 0 5.957571147519047e-07
at O 0 6.00781930870653e-08
the O 0 5.303981538418157e-07
DM B-Disease 1 0.9999992847442627
locus O 0 2.5824541808106005e-05
, O 0 1.8285255976024928e-07
has O 0 1.5672371489472425e-07
been O 0 8.478300372871672e-08
put O 0 1.2699209150923707e-07
forward O 0 1.5920906548672065e-07
to O 0 3.939776505035297e-08
explain O 0 3.4908885027107317e-07
partially O 0 2.6839086331165163e-06
the O 0 7.011390579236831e-08
maintenance O 0 8.760158607401536e-07
of O 0 1.9986433130725345e-07
DM B-Disease 1 0.9999998807907104
in O 0 6.12183328030369e-07
the O 0 4.1083714563683316e-07
population O 0 1.2408859220158774e-06
. O 0 1.7542345176480012e-06

In O 0 9.03315140021732e-06
a O 0 4.828818418900482e-06
survey O 0 2.0675233827205375e-06
of O 0 2.6887531134889286e-07
DM B-Disease 1 0.9999996423721313
in O 0 2.504413714632392e-06
Northern O 0 8.170013643393759e-06
Ireland O 0 3.998296961071901e-06
, O 0 4.336801850968186e-07
59 O 0 2.2998110580374487e-06
pedigrees O 0 5.913999302720185e-06
were O 0 1.5121050864763674e-06
ascertained O 0 1.6924415831454098e-05
. O 0 3.020515123353107e-06

Sibships O 0 0.0026866523548960686
where O 0 6.858181222924031e-06
the O 0 2.2667084920158231e-07
status O 0 1.7007266706059454e-07
of O 0 2.1884954293227565e-08
all O 0 6.613516401188235e-09
the O 0 5.329012964239155e-08
members O 0 9.822064583886458e-08
had O 0 1.838476350712881e-06
been O 0 1.807098328754364e-07
identified O 0 2.4730746872592135e-07
were O 0 1.0396016136837716e-07
examined O 0 3.199725142621901e-07
to O 0 2.899324158534e-08
determine O 0 4.2493969232282325e-08
the O 0 7.070345731108318e-08
transmission O 0 3.478204916973482e-06
of O 0 2.1881616518726332e-08
the O 0 4.0602981243864633e-07
DM B-Disease 1 0.9999642372131348
expansion O 0 1.7829798935053986e-06
from O 0 1.4777353385397873e-07
affected O 0 1.679569834323047e-07
parents O 0 8.833794851170751e-08
to O 0 5.171039418883083e-08
their O 0 5.487016210281581e-07
offspring O 0 2.508259603928309e-05
. O 0 2.9476930194505258e-06

Where O 0 1.5880972568993457e-05
the O 0 1.9451094885880593e-06
transmitting O 0 6.231971929082647e-05
parent O 0 1.3396638678386807e-05
was O 0 6.124489118519705e-06
male O 0 3.333474069222575e-06
, O 0 5.794908020106959e-07
58 O 0 1.0455375559104141e-05
. O 0 3.477495056358748e-06

3 O 0 0.00025013857521116734
% O 0 4.612140855897451e-06
of O 0 4.9722761019665995e-08
the O 0 1.894149903591824e-07
offspring O 0 1.1246000212850049e-05
were O 0 2.708443162191543e-06
affected O 0 2.0613046558537462e-07
, O 0 6.714707723176616e-08
and O 0 8.716435218047991e-08
in O 0 5.60174129304869e-08
the O 0 4.9741451846330165e-08
case O 0 1.6833863014653616e-07
of O 0 2.694191536534163e-08
a O 0 2.581343323981855e-06
female O 0 3.4507720556575805e-05
transmitting O 0 4.477512266021222e-05
parent O 0 2.6525767680141144e-06
, O 0 2.9079592422931455e-07
68 O 0 6.247398232517298e-06
. O 0 2.832020982168615e-06

7 O 0 0.001916795619763434
% O 0 5.2133662393316627e-05
were O 0 5.279467586660758e-06
affected O 0 1.0128135727427434e-05
. O 0 6.203878001542762e-06

Studies O 0 2.421416502329521e-05
on O 0 3.955776719521964e-06
meiotic O 0 0.00010639699758030474
drive O 0 3.932465551770292e-05
in O 0 6.872769063193118e-06
DM B-Disease 1 0.9999998807907104
have O 0 1.0669235052773729e-05
shown O 0 1.4315725138658308e-06
increased O 0 1.6940072100624093e-06
transmission O 0 5.367370249587111e-06
of O 0 1.4488238164744871e-08
the O 0 2.737339066527511e-08
larger O 0 1.8473944862762437e-07
allele O 0 5.299233976074902e-07
at O 0 6.107563876867061e-08
the O 0 7.888681921031093e-07
DM B-Disease 1 0.9999978542327881
locus O 0 3.358993853908032e-05
in O 0 2.129112772308872e-06
non O 0 1.0337904313928448e-05
- O 0 0.027776535600423813
DM O 1 0.9999967813491821
heterozygotes O 0 8.742910722503439e-05
for O 0 2.16123521568079e-06
CTGn O 0 0.000335680233547464
. O 0 1.1059638381993864e-05

This O 0 4.478851678868523e-06
study O 0 1.494586967965006e-06
provides O 0 5.097020334687841e-07
further O 0 2.25214691340625e-07
evidence O 0 1.8272355362114467e-07
that O 0 1.1325629856173691e-07
the O 0 5.471058557304787e-07
DM B-Disease 1 0.9999972581863403
expansion O 0 9.516268619336188e-06
tends O 0 2.370518814132083e-06
to O 0 1.260531092839301e-07
be O 0 4.1475257717138447e-07
transmitted O 0 1.0080783795274328e-05
preferentially O 0 1.3092951121507213e-05
. O 0 4.894296125712572e-06

Diagnosis O 1 0.9971752166748047
of O 0 0.0004920838982798159
hemochromatosis B-Disease 1 0.9999997615814209
. O 0 0.0003482800384517759

If O 0 0.0003869716892950237
untreated O 0 0.14057624340057373
, O 0 4.004298898507841e-05
hemochromatosis B-Disease 1 1.0
can O 0 6.464360194513574e-05
cause O 0 0.00015001294377725571
serious O 0 0.0004628336173482239
illness O 0 0.010689173825085163
and O 0 2.888610424633953e-06
early B-Disease 0 6.4958676375681534e-06
death I-Disease 0 5.248623710940592e-05
, O 0 2.0170486436654755e-07
but O 0 8.931824169167157e-08
the O 0 9.191921321871632e-07
disease O 0 1.951121521415189e-05
is O 0 1.3475721516442718e-07
still O 0 3.558504602096946e-07
substantially O 0 8.893844096746761e-06
under O 0 3.31407795783889e-06
- O 1 0.7810298204421997
diagnosed O 0 0.2488892823457718
. O 0 4.269425062375376e-06

The O 0 8.472983608953655e-06
cornerstone O 0 6.97794303050614e-06
of O 0 1.4887089605508663e-07
screening O 0 7.691066912229871e-07
and O 0 1.402995764010484e-07
case O 0 2.5662697566986026e-07
detection O 0 2.2948881905904273e-06
is O 0 5.821523885174429e-08
the O 0 2.9980530058537624e-08
measurement O 0 1.1383306173229357e-06
of O 0 7.403937019034856e-08
serum O 0 1.1423247997299768e-05
transferrin O 0 6.939122158655664e-06
saturation O 0 2.7377861897548428e-06
and O 0 1.8424344716549967e-07
the O 0 3.930687455522275e-07
serum O 0 2.2478634491562843e-05
ferritin O 0 5.63273933948949e-05
level O 0 2.6199338662991067e-06
. O 0 2.9703305699513294e-06

Once O 0 0.00017257468425668776
the O 0 4.871817964158254e-06
diagnosis O 0 0.0005816319026052952
is O 0 9.683635653345846e-07
suspected O 0 1.2241609510965645e-05
, O 0 6.254326194721216e-07
physicians O 0 6.950288593543519e-07
must O 0 5.3772353680869855e-08
use O 0 1.9862204680975992e-07
serum O 0 1.9922861611121334e-05
ferritin O 0 4.9069582019001245e-05
levels O 0 7.635640599801263e-07
and O 0 2.2625835072176415e-07
hepatic O 0 0.00017601372383069247
iron O 0 8.756376337260008e-05
stores O 0 4.130262823309749e-06
on O 0 1.9864792193402536e-06
liver O 0 2.2876551156514324e-05
biopsy O 0 4.573898695525713e-05
specimens O 0 1.3685598787560593e-07
to O 0 3.518468716379175e-08
assess O 0 9.530423881187744e-07
patients O 0 4.0813631585479015e-07
for O 0 1.5348376791735063e-08
the O 0 4.03151361183518e-08
presence O 0 1.3507334983842156e-07
of O 0 1.814313179693272e-07
iron B-Disease 0 0.06588773429393768
overload I-Disease 0 0.00026165193412452936
. O 0 5.130689260113286e-06

Liver O 1 0.9990737438201904
biopsy O 1 0.9194313883781433
is O 0 2.9324990009627072e-06
also O 0 6.759514690202195e-07
used O 0 1.1265692734241384e-07
to O 0 3.752955990421469e-08
establish O 0 1.0615768530897185e-07
the O 0 4.3262470938998376e-08
presence O 0 1.2603976529135252e-07
or O 0 1.8368415055647347e-07
absence O 0 3.1453447491003317e-07
of O 0 2.007644894774785e-07
cirrhosis B-Disease 0 0.0018725325353443623
, O 0 4.7415394988092885e-07
which O 0 2.939522119049798e-07
can O 0 3.155358569983946e-07
affect O 0 5.725320988858584e-06
prognosis O 0 0.025852708145976067
and O 0 5.4173297030502e-06
management O 0 6.930789822945371e-06
. O 0 4.053170414408669e-06

A O 0 0.00012088087532902136
DNA O 0 9.995279833674431e-05
- O 0 6.138930621091276e-05
based O 0 4.371649140466616e-07
test O 0 1.492148840043228e-07
for O 0 2.5101945411165616e-08
the O 0 9.101440667791394e-08
HFE O 0 0.00010532505984883755
gene O 0 5.622549679173972e-07
is O 0 5.526024082769254e-08
commercially O 0 1.5054129676173034e-07
available O 0 3.8624541787157796e-08
, O 0 2.6183220924735906e-08
but O 0 8.74083827540062e-09
its O 0 1.1085171891522805e-08
place O 0 5.163440874866865e-08
in O 0 3.1782715126382755e-08
the O 0 4.361409651210124e-07
diagnosis O 0 0.000685403065290302
of O 0 4.439507847564528e-06
hemochromatosis B-Disease 1 1.0
is O 0 5.589847205555998e-06
still O 0 7.114614390957286e-07
being O 0 7.561494612673414e-07
evaluated O 0 6.181200660648756e-06
. O 0 2.1791001927340403e-06

Currently O 0 3.332517735543661e-05
, O 0 5.61470528737118e-07
the O 0 6.790683926283236e-08
most O 0 2.3705968743570338e-08
useful O 0 1.4734566455842923e-08
role O 0 2.6069404412965014e-08
for O 0 1.6254153578643127e-08
this O 0 2.1060529320493515e-08
test O 0 1.0366394320726613e-07
is O 0 2.7846652983498643e-08
in O 0 1.2502798796276693e-08
the O 0 4.1070780554264275e-08
detection O 0 2.478657052051858e-06
of O 0 9.067649671123945e-07
hemochromatosis B-Disease 1 1.0
in O 0 7.134229349503585e-07
the O 0 1.9855310995353648e-07
family O 0 4.6454064772660786e-07
members O 0 3.041323992647449e-08
of O 0 2.012202493517634e-08
patients O 0 1.3171055002203502e-07
with O 0 4.990442548091778e-08
a O 0 2.1113153252372285e-06
proven O 0 3.118658469247748e-06
case O 0 1.3139388954641618e-07
of O 0 1.2163148710442329e-07
the O 0 1.1267276022408623e-05
disease O 0 0.0002469303726684302
. O 0 2.769603952401667e-06

It O 0 1.088218778022565e-05
is O 0 9.330075840807694e-07
crucial O 0 2.403646021775785e-06
to O 0 6.548663350258721e-06
diagnose O 1 0.9999815225601196
hemochromatosis B-Disease 1 1.0
before O 0 0.012836956419050694
hepatic B-Disease 1 0.9999613761901855
cirrhosis I-Disease 1 0.9933479428291321
develops O 0 0.00015041185542941093
because O 0 1.7950525261767325e-06
phlebotomy O 0 0.0010467935353517532
therapy O 0 0.0002189308579545468
can O 0 5.223138032306451e-06
avert O 0 0.20377014577388763
serious O 1 0.7862106561660767
chronic O 1 0.9999997615814209
disease O 1 0.9022396206855774
and O 0 8.224855264415964e-06
can O 0 9.48634465203213e-07
even O 0 2.8972658583370503e-07
lead O 0 3.2096502309286734e-06
to O 0 2.1595405996777117e-07
normal O 0 1.611046286598139e-06
life O 0 7.03119667377905e-07
expectancy O 0 5.1896727200073656e-06
. O 0 3.4499160506129556e-07
. O 0 1.235298668689211e-06

Prevalence O 0 0.0036310201976448298
of O 0 1.2830344076064648e-06
the O 0 8.605899779468018e-07
I1307K O 0 3.0487222829833627e-05
APC B-Disease 0 2.005307214858476e-05
gene O 0 2.5768347313714912e-06
variant O 0 1.025752499117516e-05
in O 0 3.628710487646458e-07
Israeli O 0 2.4029352061916143e-05
Jews O 0 8.013689694053028e-07
of O 0 2.784835295699395e-08
differing O 0 4.42754469531792e-07
ethnic O 0 4.598739735683921e-07
origin O 0 4.4049323832950904e-07
and O 0 2.7902217425435083e-06
risk O 0 4.8725545639172196e-05
for O 0 0.00024825919535942376
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.33786517533008e-05

BACKGROUND O 0 0.0006931590032763779
& O 0 0.00036356804776005447
AIMS O 0 1.3011606824875344e-05
Israeli O 0 7.721987458353397e-06
Jews O 0 7.8743858011876e-07
of O 0 3.500242229392825e-08
European O 0 5.051296056990395e-07
birth O 0 7.699793968640734e-06
, O 0 7.216509345653321e-08
i O 0 6.026215970678095e-08
. O 0 1.2941205440597514e-08
e O 0 5.646828427074979e-08
. O 0 9.492977959268956e-09
, O 0 2.084003369873244e-08
Ashkenazim O 0 2.7012617920263438e-06
, O 0 6.705084132363481e-08
have O 0 6.694387622019349e-08
the O 0 1.2185015521026799e-06
highest O 1 0.9414060711860657
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.02891360968351364
of O 0 6.03425576173322e-08
any O 0 7.560558401564776e-08
Israeli O 0 1.583868288435042e-05
ethnic O 0 9.056933777173981e-06
group O 0 8.491944754496217e-06
. O 0 2.8223416848049965e-06

The O 0 3.7388894270407036e-05
I1307K O 0 0.00023897447681520134
APC B-Disease 0 0.0001311987143708393
gene O 0 1.8577700757305138e-05
variant O 0 0.00013836301513947546
was O 0 3.418734195292927e-05
found O 0 5.387398118728015e-07
in O 0 5.628901931231667e-07
6 O 0 9.570586371410172e-06
. O 0 3.6087878925172845e-06

1 O 0 7.589259621454403e-05
% O 0 3.076390157730202e-06
of O 0 5.625189203328773e-08
American O 0 3.298824537978362e-07
Jews O 0 8.082907356765645e-07
, O 0 1.0495373459207258e-07
28 O 0 7.962132713146275e-07
% O 0 4.595429459186562e-08
of O 0 2.9174580973290176e-08
their O 0 2.1398982426035218e-05
familial O 1 0.9999995231628418
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.328897557570599e-05
, O 0 3.685868534830661e-07
but O 0 4.604975956112867e-08
not O 0 1.5833350630600762e-08
in O 0 5.7380074025559225e-08
non O 0 8.941835289988376e-07
- O 0 3.4836019040085375e-05
Jews O 0 3.8098871755209984e-06
. O 0 1.9136571154376725e-06

We O 0 1.4530515727528837e-05
assessed O 0 6.973366907914169e-06
the O 0 5.362681463338959e-07
I1307K O 0 1.6678486645105295e-05
prevalence O 0 2.0222125385771506e-05
in O 0 1.5426334698531718e-07
Israeli O 0 1.1511413504194934e-05
Jews O 0 6.639548359999026e-07
of O 0 2.3912594571129375e-08
differing O 0 4.403966329391551e-07
ethnic O 0 5.35458696049318e-07
origin O 0 5.330395538294397e-07
and O 0 5.509670700121205e-06
risk O 0 5.123951632413082e-05
for O 0 0.0007628261810168624
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 3.605260280892253e-05

METHODS O 0 4.2200823372695595e-05
DNA O 0 1.3027339264226612e-05
samples O 0 9.235204174729006e-07
from O 0 1.055165483876408e-07
500 O 0 2.011610291674515e-07
unrelated O 0 1.9761480984925583e-07
Jews O 0 2.1475281641869515e-07
of O 0 1.3168738099977872e-08
European O 0 1.4618262866861187e-07
or O 0 1.3260894604627538e-07
non O 0 1.0761882407450685e-07
- O 0 1.4447253988691955e-06
European O 0 5.8858674378825526e-08
origin O 0 2.7797620205660678e-08
, O 0 1.1285710144193217e-08
with O 0 1.1979255809535516e-08
or O 0 9.461599859150738e-08
without O 0 1.6666351854155437e-08
a O 0 3.6821649729290584e-08
personal O 0 2.1936195082616905e-07
and O 0 8.571097964704677e-07
/ O 0 1.8244116290588863e-05
or O 0 1.640011788595075e-07
family O 0 7.661638790068537e-08
history O 0 2.6900375260652254e-08
of O 0 4.0140886170547674e-08
neoplasia B-Disease 0 0.00013973131717648357
, O 0 2.4608269200143695e-07
were O 0 2.7137750180372677e-07
examined O 0 2.2984026770700439e-07
for O 0 2.0354015362045175e-08
the O 0 9.663261124615019e-08
I1307K O 0 3.932414983864874e-06
variant O 0 3.2466666652908316e-06
by O 0 3.9758297987191327e-08
the O 0 1.0153352292263662e-07
allele O 0 1.029803570418153e-06
- O 0 2.5812521471380023e-06
specific O 0 2.3707103480319347e-07
oligonucleotide O 0 4.431198976817541e-05
( O 0 9.073306728168973e-07
ASO O 0 3.6306017136666924e-05
) O 0 3.192026269971393e-07
method O 0 2.158347570002661e-06
. O 0 2.1591217773675453e-06

RESULTS O 0 0.0001498742785770446
In O 0 7.363144618466322e-07
persons O 0 5.511891458809259e-07
at O 0 2.4983995672300807e-07
average O 0 5.8757718761626165e-06
risk O 0 1.605453508091159e-05
for O 0 0.0007246233872137964
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 3.2425391509605106e-06
I1307K O 0 1.1705153156071901e-05
was O 0 6.826169283158379e-06
found O 0 2.657435800301755e-07
in O 0 1.7405866969966155e-07
5 O 0 1.8191555000157678e-06
. O 0 1.921541070259991e-06

0 O 0 0.000146585502079688
% O 0 2.1579071471933275e-06
of O 0 1.1390110898901185e-07
120 O 0 2.165484289662345e-07
European O 0 2.486441132987238e-07
and O 0 4.2036884906337946e-07
1 O 0 3.161670520057669e-06
. O 0 3.7385927953437204e-06

6 O 0 0.0002885976282414049
% O 0 6.121645128587261e-06
of O 0 1.730236220964798e-07
188 O 0 1.1153673540320597e-06
non O 0 5.769525159848854e-07
- O 0 4.73896716357558e-06
European O 0 3.368269858583517e-07
Jews O 0 8.610169288658653e-07
( O 0 4.3512889646990516e-07
P O 0 1.7664089682511985e-05
= O 0 2.7084845442004735e-06
0 O 0 7.18895023510413e-07
. O 0 8.776258653142577e-08
08 O 0 1.8759888007480185e-06
) O 0 6.336511546578549e-07
. O 0 1.0635037597239716e-06

It O 0 1.4719036698807031e-05
occurred O 0 1.142695236922009e-05
in O 0 1.2039552075293614e-06
15 O 0 4.497985628404422e-06
. O 0 3.5283519537188113e-06

4 O 0 0.00011990711936959997
% O 0 6.972795290494105e-06
of O 0 2.614889069718629e-07
52 O 0 8.21221328806132e-06
Ashkenazi O 0 9.088226215681061e-05
Israelis O 0 3.3914282539626583e-05
with O 0 3.7216743749013403e-06
familial O 1 0.6257017254829407
cancer B-Disease 1 0.5390220284461975
( O 0 5.399658220994752e-06
P O 0 0.00027744151884689927
= O 0 8.660224011691753e-06
0 O 0 6.662554596914561e-07
. O 0 9.242387477570446e-08
02 O 0 1.0221939419352566e-06
) O 0 3.650528768162076e-08
and O 0 8.368615311837857e-08
was O 0 3.0621383757534204e-06
not O 0 4.4235559215621834e-08
detected O 0 1.9554380514819059e-07
in O 0 3.246259083766745e-08
51 O 0 4.878429535892792e-07
non O 0 6.896215154483798e-08
- O 0 1.0434461046315846e-06
European O 0 7.874943719343719e-08
Jews O 0 2.0865176963980048e-07
at O 0 2.248614379141145e-07
increased O 0 9.393123036716133e-06
cancer B-Disease 0 0.0001550972374388948
risk O 0 7.498726517951582e-06
. O 0 2.661234930201317e-06

Colorectal B-Disease 1 0.9999847412109375
neoplasia I-Disease 1 0.9952129125595093
occurred O 0 0.0017036224016919732
personally O 0 4.03538033424411e-05
or O 0 7.171393008320592e-07
in O 0 1.1445961689560136e-07
the O 0 1.2354820455584559e-07
families O 0 1.3780498875348712e-07
of O 0 1.9740848955507317e-08
13 O 0 1.478564257695325e-07
of O 0 1.4250756130707032e-08
20 O 0 2.2921641118500702e-07
Ashkenazi O 0 5.026240614824928e-06
I1307K O 0 1.1102988537459169e-06
carriers O 0 1.1560071300209529e-07
, O 0 1.5325062108217935e-08
8 O 0 6.10386052812828e-08
of O 0 1.3614308791431995e-08
whom O 0 6.290246687967738e-07
also O 0 1.1007689408870647e-06
had O 0 1.1053523394366493e-06
a O 0 2.378934027547075e-07
personal O 0 1.9208173398510553e-06
or O 0 4.050150437251432e-07
family O 0 1.285397672745603e-07
history O 0 9.714913318248364e-08
of O 0 2.2761055618047976e-07
noncolonic O 0 0.0006120054749771953
neoplasia B-Disease 0 0.0018896323163062334
. O 0 5.5033533499226905e-06

CONCLUSIONS O 0 8.685745706316084e-05
The O 0 4.5929768930363934e-06
I1307K O 0 6.433162343455479e-05
APC O 0 3.103939525317401e-05
variant O 0 0.00010386293433839455
may O 0 3.972240847360808e-06
represent O 0 9.974418446745403e-08
a O 0 7.909986265985935e-07
susceptibility O 0 0.00010728550114436075
gene O 0 4.145510956732323e-06
for O 0 5.588754447671818e-06
colorectal B-Disease 1 1.0
, I-Disease 0 6.856709660496563e-06
or I-Disease 0 7.741179501863371e-07
other I-Disease 0 1.2076149857875862e-07
, I-Disease 0 1.712970515654888e-06
cancers I-Disease 0 0.0015068562934175134
in O 0 4.283861301246361e-07
Ashkenazi O 0 0.0002689547836780548
Jews O 0 3.68826317753701e-06
, O 0 1.986051927360677e-07
and O 0 3.167843942719628e-07
partially O 0 7.686164281039964e-06
explains O 0 3.014671108303446e-07
the O 0 9.485722785029793e-08
higher O 0 1.4513166206597816e-06
incidence O 0 0.11907295882701874
of O 0 0.0011664500925689936
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.0259644770703744e-06
European O 0 3.101680931649753e-06
Israelis O 0 4.475677269510925e-05
. O 0 7.44383578421548e-06

Systematic O 0 5.965907621430233e-05
analysis O 0 5.203568889555754e-06
of O 0 1.2100780395485344e-06
coproporphyrinogen O 0 0.0005305284867063165
oxidase O 0 0.0001755471166688949
gene O 0 0.0002532585058361292
defects O 1 0.9704392552375793
in O 0 7.975439984875266e-06
hereditary B-Disease 1 0.8832376599311829
coproporphyria I-Disease 0 0.0030337541829794645
and O 0 1.47324608406052e-05
mutation O 0 3.506312350509688e-05
update O 0 7.117785571608692e-05
. O 0 1.0163248589378782e-05

Hereditary B-Disease 1 0.9997394680976868
coproporphyria I-Disease 0 0.4606112837791443
( O 0 8.296687883557752e-05
HC B-Disease 0 0.013130882754921913
) O 0 5.298074029269628e-06
is O 0 5.552584525503335e-07
an O 0 1.155111203843262e-05
acute O 1 0.9999315738677979
hepatic B-Disease 1 0.9999997615814209
porphyria I-Disease 1 0.9999997615814209
with O 0 0.030741089954972267
autosomal O 1 0.9999964237213135
dominant O 1 0.8592306971549988
inheritance O 0 0.2366027534008026
caused O 0 0.0004055993049405515
by O 0 9.203639592669788e-07
deficient B-Disease 0 8.344684465555474e-05
activity I-Disease 0 8.600927685620263e-07
of I-Disease 0 1.7619676384583727e-07
coproporphyrinogen I-Disease 0 0.0005630532396025956
III I-Disease 0 0.0035381063353270292
oxidase I-Disease 0 4.8175177653320134e-05
( O 0 1.611215338925831e-06
CPO O 0 6.40792422927916e-05
) O 0 9.729318435347523e-07
. O 0 2.120533054039697e-06

Clinical O 0 0.0023961036931723356
manifestations O 0 0.00022953603183850646
of O 0 1.8233865830552531e-06
the O 0 2.0069850506843068e-05
disease O 0 0.003477470250800252
are O 0 2.4874799464669195e-07
characterized O 0 2.5572657250449993e-05
by O 0 1.1778155339925434e-06
acute O 0 0.008167033083736897
attacks O 0 0.002869777148589492
of O 0 2.1879459382034838e-05
neurological B-Disease 1 0.9999443292617798
dysfunction I-Disease 1 0.9491569995880127
often O 0 2.210369348176755e-05
precipitated O 0 1.5873052689130418e-05
by O 0 1.1669175137285492e-07
drugs O 0 5.587894520431291e-07
, O 0 1.9177700494310557e-07
fasting O 0 8.926950613385998e-06
, O 0 1.792139698864048e-07
cyclical O 0 1.0387437214376405e-05
hormonal O 0 6.147800013422966e-05
changes O 0 9.83173322310904e-07
, O 0 6.761952136002947e-07
or O 0 8.419442565354984e-06
infectious B-Disease 0 0.0006259391084313393
diseases I-Disease 0 0.0001742192544043064
. O 0 4.7414218897756655e-06

Skin O 1 0.9999954700469971
photosensitivity O 1 0.999721109867096
may O 0 0.004851961974054575
also O 0 4.9944696911552455e-06
be O 0 3.8840229876768717e-07
present O 0 9.771907798494794e-07
. O 0 5.727089956053533e-06

The O 0 8.955601515481248e-06
seven O 0 3.7582967706839554e-06
exons O 0 3.185132663929835e-05
, O 0 3.2804811667119793e-07
the O 0 1.21693673804657e-07
exon O 0 2.0993164071114734e-05
/ O 0 1.71451556525426e-05
intron O 0 6.022565139573999e-05
boundaries O 0 3.99586497223936e-06
and O 0 3.177841563228867e-07
part O 0 6.681886333126386e-08
of O 0 2.3664902926157083e-08
3 O 0 6.481137688751915e-07
noncoding O 0 1.5094411764948745e-06
sequence O 0 6.046433753681413e-08
of O 0 9.506023523897511e-09
the O 0 1.1610364225589365e-07
CPO O 0 2.2675119907944463e-05
gene O 0 2.651901525041467e-07
were O 0 1.0196377786542143e-07
systematically O 0 6.017085638632125e-07
analyzed O 0 9.797721389759317e-08
by O 0 6.035910882218332e-09
an O 0 1.7876566005270433e-08
exon O 0 2.4244002361228922e-06
- O 0 8.816456102067605e-06
by O 0 1.6878198039194103e-07
- O 0 1.189423073810758e-05
exon O 0 3.853724047075957e-05
denaturing O 0 0.0005698625463992357
gradient O 0 0.0007277174154296517
gel O 0 0.0015428020851686597
electrophoresis O 0 0.0007586237625218928
( O 0 2.5529761842335574e-06
DGGE O 0 2.617708196339663e-05
) O 0 1.5277905163202377e-07
strategy O 0 4.5107341861694294e-07
followed O 0 1.4699848804866633e-07
by O 0 1.665662630045972e-08
direct O 0 4.0675992352134926e-08
sequencing O 0 2.482242962287273e-07
in O 0 4.0919164945307784e-08
seven O 0 2.2381759379186406e-07
unrelated O 0 7.64623109716922e-06
heterozygous O 0 4.839121538680047e-05
HC B-Disease 0 0.0013425633078441024
patients O 0 1.387744032399496e-05
from O 0 3.344544836636487e-07
France O 0 6.694746389257489e-06
, O 0 4.337252619279752e-07
Holland O 0 2.9095283480273793e-06
, O 0 7.325219542053674e-08
and O 0 1.3742962323703978e-07
Czech O 0 2.615911625980516e-06
Republic O 0 2.552039177317056e-06
. O 0 2.2703591184836114e-06

Seven O 0 7.889631524449214e-05
novel O 0 7.547479617642239e-05
mutations O 0 6.711995956720784e-05
and O 0 4.304263256926788e-07
two O 0 2.8620183911698405e-07
new O 0 5.224816959525924e-06
polymorphisms O 0 0.002127682790160179
were O 0 5.907162176299607e-06
detected O 0 1.6574615074205212e-05
. O 0 1.9409662854741327e-06

Among O 0 3.081580143771134e-05
these O 0 8.711646728443156e-07
mutations O 0 9.184944246953819e-06
two O 0 2.2491333595553442e-07
are O 0 3.713006151428999e-07
missense O 0 7.94331353972666e-05
( O 0 4.893022378382739e-07
G197W O 0 3.9238962017407175e-06
, O 0 1.1842384850524468e-07
W427R O 0 4.403472303238232e-06
) O 0 7.188594253193514e-08
, O 0 2.6742348779862368e-08
two O 0 2.442737923047389e-08
are O 0 2.9269223489336582e-08
nonsense O 0 1.7663736571194022e-06
( O 0 1.588129521223891e-07
Q306X O 0 1.5291270756279118e-06
, O 0 8.31347435337193e-08
Q385X O 0 9.021416644827696e-07
) O 0 3.5384093877155465e-08
, O 0 1.2180671582484592e-08
two O 0 1.850202480113694e-08
are O 0 1.4286653637896052e-08
small O 0 1.371554674278741e-07
deletions O 0 6.355251116474392e-06
( O 0 1.970536089856978e-07
662de14bp O 0 2.449083694955334e-06
; O 0 1.538264342570983e-07
1168del3bp O 0 9.574863497618935e-07
removing O 0 1.197912382622235e-07
a O 0 1.3273128729451855e-07
glycine O 0 2.2527276541950414e-06
at O 0 8.16187224472742e-08
position O 0 1.9547705676359328e-07
390 O 0 3.027809611921839e-07
) O 0 3.738923481932943e-08
, O 0 1.565796203806258e-08
and O 0 5.187398599559856e-08
one O 0 2.296316203853621e-08
is O 0 3.5052927671586076e-08
a O 0 1.4088443833770725e-07
splicing O 0 1.7315882359980606e-05
mutation O 0 5.912842880206881e-06
( O 0 1.986633435535623e-07
IVS1 O 0 6.677594228676753e-06
- O 0 7.916410140751395e-06
15c O 0 9.291555215895642e-06
- O 0 7.80456048232736e-06
- O 0 2.1789755919598974e-05
> O 0 6.05205741521786e-06
g O 0 2.9337406886043027e-05
) O 0 7.262242007755049e-08
which O 0 4.707611722665206e-08
creates O 0 2.1296294505646074e-07
a O 0 1.504993889511752e-07
new O 0 3.339986562878039e-07
acceptor O 0 1.345956889053923e-06
splice O 0 5.5576041631866246e-05
site O 0 1.493962190579623e-05
. O 0 4.28674047725508e-06

The O 0 1.0276411558152176e-05
pathological O 0 3.464604742475785e-05
significance O 0 1.839825245042448e-06
of O 0 2.8129562679168885e-07
the O 0 4.835223990085069e-07
point O 0 8.267368684755638e-06
mutations O 0 4.4296875785221346e-06
G197W O 0 2.7380656320019625e-06
, O 0 1.5187285384854476e-07
W427R O 0 2.2464096218755003e-06
, O 0 4.893563954055935e-08
and O 0 1.6006611147645344e-08
the O 0 1.3731428438745752e-08
in O 0 8.008481700017e-08
- O 0 1.831041845434811e-05
frame O 0 0.00010810355888679624
deletion O 0 1.542651079944335e-05
390delGly O 0 6.828500318079023e-06
were O 0 4.1825748553492303e-07
assessed O 0 2.8100257054575195e-07
by O 0 1.6527005541888684e-08
their O 0 2.3203908128266448e-08
respective O 0 1.0507772429946272e-07
expression O 0 1.786263368330765e-07
in O 0 2.1412759565464512e-08
a O 0 9.9007991138933e-08
prokaryotic O 0 1.0890235557781125e-07
system O 0 2.2453015446899371e-07
using O 0 1.6431241078862513e-07
site O 0 8.814117791189346e-07
- O 0 1.3161040442355443e-05
directed O 0 5.993008926452603e-06
mutagenesis O 0 4.94657397211995e-05
. O 0 2.6370926207164302e-06

These O 0 1.3692998436454218e-05
mutations O 0 0.00010438040771987289
resulted O 0 3.4349595807725564e-06
in O 0 2.8053023015672807e-07
the O 0 4.619077458301035e-07
absence O 0 2.617853397168801e-06
or O 0 5.679025889548939e-07
a O 0 1.1310502259220812e-06
dramatic O 0 2.4244362066383474e-05
decrease O 0 1.1058637028327212e-05
of O 0 3.178529652814177e-07
CPO O 0 0.00019833960686810315
activity O 0 3.447972858339199e-06
. O 0 2.1441219359985553e-06

The O 0 8.0506106314715e-06
two O 0 5.243441137281479e-06
polymorphisms O 0 0.0022081471979618073
were O 0 2.4380519789701793e-06
localized O 0 1.675096427788958e-05
in O 0 4.755224551900028e-07
noncoding O 0 1.3976695299788844e-05
part O 0 1.5132216901747597e-07
of O 0 1.3979494006832738e-08
the O 0 7.165746751525148e-08
gene O 0 2.198570570044467e-07
1 O 0 9.837982162252956e-08
) O 0 4.6661856600849205e-08
a O 0 2.891874544275197e-07
C O 0 3.47177883668337e-05
/ O 0 3.922674659406766e-05
G O 0 0.0011010870803147554
polymorphism O 0 7.3127080213453155e-06
in O 0 8.648471805372537e-08
the O 0 2.1680899919829244e-07
promotor O 0 3.1458323064725846e-05
region O 0 9.024961968862044e-07
, O 0 1.6553148896036873e-07
142 O 0 6.140527375464444e-07
bp O 0 3.7075819818710443e-06
upstream O 0 2.2934192145385168e-07
from O 0 1.3475268012541619e-08
the O 0 2.58859262913802e-08
transcriptional O 0 6.148895295154944e-07
initiation O 0 2.780908232580259e-07
site O 0 3.314715115720901e-07
( O 0 9.419321855830276e-08
- O 0 1.6885328477656003e-06
142C O 0 6.611553999391617e-06
/ O 0 1.2010747923341114e-05
G O 0 5.735137892770581e-05
) O 0 6.169606336925426e-08
, O 0 1.7857074041671694e-08
and O 0 3.006465121302426e-08
2 O 0 1.452706612781185e-07
) O 0 2.08728536676972e-08
a O 0 1.2024700879464945e-07
6 O 0 2.275016868225066e-06
bp O 0 1.4456555618380662e-05
deletion O 0 5.2832051551376935e-06
polymorphism O 0 4.541749603959033e-06
in O 0 3.252686298083063e-08
the O 0 9.737843242874078e-08
3 O 0 8.179012525033613e-07
noncoding O 0 2.7237881567998556e-06
part O 0 5.326258900595349e-08
of O 0 1.4469541120831764e-08
the O 0 1.0333269528928213e-07
CPO O 0 2.278723695781082e-05
gene O 0 4.2202623262710404e-07
, O 0 7.682711355982974e-08
574 O 0 9.260364777219365e-07
bp O 0 3.226375611120602e-06
downstream O 0 1.1950504585911403e-07
of O 0 9.036226877867648e-09
the O 0 3.688146676950055e-08
last O 0 2.96292768098283e-07
base O 0 1.204051329750655e-07
of O 0 7.553088821055098e-09
the O 0 5.229270527706831e-08
normal O 0 6.867061870252655e-07
termination O 0 2.118903694281471e-06
codon O 0 3.580307975425967e-06
( O 0 6.004886472510407e-07
+ O 0 5.7136044233629946e-06
574 O 0 1.2199317097838502e-05
delATTCTT O 0 2.3668981157243252e-05
) O 0 1.9947428882005624e-06
. O 0 3.021264092240017e-06

Five O 0 2.886243055399973e-05
intragenic O 0 0.00018029820057563484
dimorphisms O 0 0.00013837542792316526
are O 0 2.2359549234352016e-07
now O 0 1.1344265971047207e-07
well O 0 1.356868892798957e-07
characterized O 0 3.350014367242693e-06
and O 0 3.598343312205543e-07
the O 0 7.827294012940911e-08
high O 0 1.0546901876296033e-06
degree O 0 1.728062812844655e-07
of O 0 4.0411983093235904e-08
allelic O 0 1.1344323866069317e-05
heterogeneity O 0 1.6036508895922452e-05
in O 0 1.0001857617680798e-06
HC B-Disease 0 0.007971484214067459
is O 0 3.4011725347227184e-06
demonstrated O 0 6.090614874665334e-07
with O 0 3.116714708539803e-08
seven O 0 1.3930258546679397e-07
new O 0 1.4762493094622187e-07
different O 0 6.705825228436879e-08
mutations O 0 3.1428319857695897e-07
making O 0 1.5937061448312306e-08
a O 0 7.467104268243929e-08
total O 0 2.8046542865922675e-08
of O 0 2.7045299333394723e-08
nineteen O 0 3.891615506290691e-06
CPO O 0 0.00022047093079891056
gene B-Disease 0 1.0062112778541632e-05
defects I-Disease 0 0.06039898842573166
reported O 0 1.0359281077398919e-05
so O 0 1.1365534646756714e-07
far O 0 2.978691497901309e-07
. O 0 2.9972787274346047e-07
. O 0 1.652655441830575e-06

Coincidence O 0 8.514392538927495e-05
of O 0 4.2134900013479637e-07
two O 0 4.840031238018128e-07
novel O 0 3.87444015359506e-06
arylsulfatase O 0 3.6373701732372865e-05
A O 0 3.994280177721521e-06
alleles O 0 5.470491487358231e-06
and O 0 1.2420817938618711e-06
mutation O 0 1.0282706170983147e-05
459 O 0 4.600464308168739e-06
+ O 0 7.949530299811158e-06
1G O 0 0.0002186679921578616
> O 0 2.5473534606135217e-06
A O 0 3.317684900139284e-07
within O 0 4.3979390795811923e-08
a O 0 4.6437145329036866e-07
family O 0 1.931974111357704e-06
with O 0 8.861849892127793e-06
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999969005584717
: O 0 3.800372496698401e-07
molecular O 0 7.48528407257254e-07
basis O 0 3.15482594714922e-07
of O 0 2.7809878133666643e-07
phenotypic O 0 7.748111966066062e-05
heterogeneity O 0 0.00036722770892083645
. O 0 1.037616948451614e-05

In O 0 8.755225280765444e-06
a O 0 4.010173142887652e-06
family O 0 7.388291578536155e-07
with O 0 1.4349170385230536e-07
three O 0 2.258540234834072e-06
siblings O 0 4.713295493274927e-05
, O 0 1.7440679300761985e-07
one O 0 3.743769028119459e-08
developed O 0 4.077566302385094e-07
classical O 0 1.1150334557896713e-06
late O 0 4.5385830162558705e-05
infantile O 1 0.9571460485458374
metachromatic B-Disease 1 0.9999996423721313
leukodystrophy I-Disease 1 0.9999997615814209
( O 0 3.947630466427654e-05
MLD B-Disease 1 0.9999927282333374
) O 0 1.7033610220096307e-06
, O 0 4.486580280627095e-07
fatal O 0 1.9923338186345063e-05
at O 0 3.6852850371360546e-07
age O 0 2.8805948204535525e-07
5 O 0 4.174230525677558e-07
years O 0 6.343706360212309e-08
, O 0 3.1448703197156647e-08
with O 0 1.2231359391989827e-07
deficient O 0 6.32941082585603e-05
arylsulfatase O 0 2.363864223298151e-05
A O 0 6.453866717492929e-06
( O 0 9.168204542220337e-07
ARSA O 0 0.00013374713307712227
) O 0 8.843285570492299e-08
activity O 0 1.5477392878437968e-07
and O 0 1.4551388005656918e-07
increased O 0 3.1953445613908116e-06
galactosylsulfatide O 0 0.00015659483324270695
( O 0 5.116357897350099e-06
GS O 1 0.9999029636383057
) O 0 1.8633505760590197e-06
excretion O 0 1.2180356861790642e-05
. O 0 3.2344257760996697e-06

The O 0 6.3065281210583635e-06
two O 0 6.479833700723248e-07
other O 0 1.0156082907997188e-07
siblings O 0 4.870647444477072e-06
, O 0 2.0291592761623178e-07
apparently O 0 1.3121211850375403e-06
healthy O 0 3.0598212674703973e-07
at O 0 2.685833244697733e-08
12 O 0 9.7941345700292e-08
( O 0 3.018358540884947e-08
1 O 0 9.718582560935829e-08
/ O 0 1.365342768622213e-06
2 O 0 1.9025918618353899e-07
) O 0 2.6701727051658963e-08
and O 0 3.854837160588431e-08
15 O 0 1.0545578987830595e-07
years O 0 2.8632621607016517e-08
, O 0 2.6156117272080337e-08
respectively O 0 1.8745585350643523e-07
, O 0 2.207840310575193e-08
and O 0 2.604296511776738e-08
their O 0 2.3845414531820097e-08
father O 0 5.989325018163072e-07
, O 0 9.637932407713379e-08
apparently O 0 6.939228001101583e-07
healthy O 0 1.2942938099058665e-07
as O 0 3.608707643820708e-08
well O 0 7.371851040716138e-08
, O 0 7.979496530197139e-08
presented O 0 8.049674420362862e-07
ARSA O 0 0.0005624353652819991
and O 0 6.008993295836262e-06
GS O 1 0.999944806098938
values O 0 2.6566249289317057e-07
within O 0 2.4521021657619713e-08
the O 0 4.1099774250596965e-08
range O 0 5.288359261612641e-07
of O 0 1.235547301803308e-06
MLD B-Disease 1 0.9999995231628418
patients O 0 0.00019837611762341112
. O 0 4.142772013437934e-06

Mutation O 0 0.0014542143326252699
screening O 0 4.155530405114405e-05
and O 0 1.136440118898463e-06
sequence O 0 9.876991953206016e-07
analysis O 0 2.476638769621786e-07
disclosed O 0 6.883151968395396e-07
the O 0 4.518457785707142e-08
involvement O 0 1.853836408827192e-07
of O 0 3.027491501939039e-08
three O 0 3.3198278970303363e-07
different O 0 1.0363048659201013e-06
ARSA O 0 0.07222609966993332
mutations O 0 1.4100304724706803e-05
being O 0 1.5857322921419836e-07
the O 0 4.0062484885083904e-08
molecular O 0 3.202600851182069e-07
basis O 0 1.7420215669972094e-07
of O 0 1.2513562808180723e-07
intrafamilial O 0 5.7748933613765985e-05
phenotypic O 0 5.717619205825031e-05
heterogeneity O 0 0.0003348948375787586
. O 0 1.0582776667433791e-05

The O 0 1.5967396393534727e-05
late O 0 0.0001232474751304835
infantile O 1 0.5044166445732117
patient O 0 0.002705230610445142
inherited O 0 0.00023338518803939223
from O 0 5.165539391782659e-07
his O 0 2.3908137336547952e-06
mother O 0 6.990671863604803e-06
the O 0 1.4252582047902251e-07
frequent O 0 1.818121745600365e-06
0 O 0 1.718055273158825e-06
- O 0 2.1183392163948156e-05
type O 0 2.4033022327785147e-06
mutation O 0 3.6258777527109487e-06
459 O 0 3.4573502034618286e-06
+ O 0 5.507684818439884e-06
1G O 0 9.4813403848093e-05
> O 0 2.2393489871319616e-06
A O 0 8.558478157283389e-07
, O 0 1.4784795610012225e-07
and O 0 1.623216263624272e-07
from O 0 5.090384291861483e-08
his O 0 4.930689101456665e-07
father O 0 8.318254458572483e-07
a O 0 2.1510722092443757e-07
novel O 0 7.726634407845268e-07
, O 0 9.064401496061691e-08
single O 0 5.534076308322255e-07
basepair O 0 3.046490519409417e-06
microdeletion O 0 1.1334592500134022e-06
of O 0 2.133326582054451e-08
guanine O 0 7.938423323139432e-07
at O 0 5.260753255242889e-08
nucleotide O 0 7.861494282224157e-07
7 O 0 2.848234998964472e-07
in O 0 7.475839680637364e-08
exon O 0 8.550046004529577e-06
1 O 0 2.2436884137277957e-06
( O 0 9.22190565688652e-07
7delG O 0 1.9738812625291757e-05
) O 0 1.271129235647095e-06
. O 0 2.163578074032557e-06

The O 0 2.0785309970960952e-05
two O 0 1.5121286196517758e-05
clinically O 0 0.014365311712026596
unaffected O 0 0.00023396666802000254
siblings O 0 4.8840265662875026e-05
carried O 0 5.264309493213659e-06
the O 0 4.271956299817248e-07
maternal O 0 5.940519258729182e-05
mutation O 0 1.3285062777868006e-05
459 O 0 4.622806500265142e-06
+ O 0 6.154178208817029e-06
1G O 0 0.00018458855629432946
> O 0 3.5879409097105963e-06
A O 0 9.93525418380159e-07
and O 0 3.006723545695422e-07
, O 0 5.731575569711822e-08
on O 0 2.5211497245436476e-07
their O 0 9.653404475784555e-08
paternal O 0 7.914432899269741e-06
allele O 0 1.4436097899306333e-06
, O 0 4.930740971076375e-08
a O 0 9.194649663868404e-08
novel O 0 5.174740067559469e-07
cytosine O 0 1.2174259609309956e-06
to O 0 4.306422596300763e-08
thymidine O 0 2.7041098746849457e-06
transition O 0 7.562994710497151e-07
at O 0 1.287929194404569e-07
nucleotide O 0 2.472188725732849e-06
2435 O 0 7.555853699159343e-06
in O 0 8.974823373364416e-08
exon O 0 5.791272997157648e-06
8 O 0 2.2075660126574803e-06
, O 0 1.0677317874296932e-07
resulting O 0 1.340232387292417e-07
in O 0 1.9150389718447514e-08
substitution O 0 1.3059685954885936e-07
of O 0 5.425118843049859e-08
alanine O 0 2.2207012079888955e-05
464 O 0 9.149650395556819e-06
by O 0 5.753908567385224e-07
valine O 0 0.0006473383982665837
( O 0 2.384069830441149e-06
A464V O 0 1.7605865650693886e-05
) O 0 1.2500734101195121e-06
. O 0 3.6085261854168493e-06

The O 0 3.166192618664354e-05
fathers O 0 7.17447474016808e-05
genotype O 0 0.0002665627689566463
thus O 0 3.141278739349218e-06
was O 0 5.207570211496204e-06
7delG O 0 7.107415149221197e-05
/ O 0 6.294914055615664e-05
A464V O 0 0.00010309533536201343
. O 0 7.176399776653852e-06

Mutation O 0 0.0032326735090464354
A464V O 0 0.00048105462337844074
was O 0 2.0227198547217995e-05
not O 0 7.774577426289397e-08
found O 0 1.0016474760732308e-07
in O 0 1.786491594657491e-07
18 O 0 8.53018991620047e-06
unrelated O 0 0.00012697133934125304
MLD B-Disease 1 0.9999998807907104
patients O 0 8.073510980466381e-05
and O 0 1.463986109229154e-06
50 O 0 1.028756059895386e-06
controls O 0 1.3105142897984479e-05
. O 0 3.1947413390298607e-06

A464V O 0 0.00188334914855659
, O 0 1.0992394891218282e-05
although O 0 2.065217813651543e-06
clearly O 0 2.132870349669247e-06
modifying O 0 1.0147917237190995e-05
ARSA O 0 0.027386285364627838
and O 0 3.171018761349842e-05
GS O 1 0.9999997615814209
levels O 0 5.647782472806284e-06
, O 0 1.5393766261695419e-07
apparently O 0 1.2506708344517392e-06
bears O 0 4.586331954214984e-07
little O 0 3.073531900099624e-07
significance O 0 1.4948805926451314e-07
for O 0 9.148711654916042e-08
clinical O 0 3.3653941500233486e-06
manifestation O 0 8.671827345096972e-06
of O 0 1.1800339052570052e-06
MLD B-Disease 1 0.999998927116394
, O 0 1.3554802080761874e-06
mimicking O 0 1.2278368558327202e-05
the O 0 1.0362010698372615e-06
frequent O 0 5.7172917877323925e-05
ARSA O 0 0.046759504824876785
pseudodeficiency O 0 0.0007185102440416813
allele O 0 0.00012922074529342353
. O 0 1.1971067578997463e-05

Our O 0 3.0400648029171862e-05
results O 0 7.5151569944864605e-06
demonstrate O 0 9.616463785278029e-07
that O 0 3.860915143150123e-08
in O 0 8.641909232665057e-08
certain O 0 1.9298238385090372e-07
genetic O 0 2.285958362335805e-05
conditions O 0 0.0002703355858102441
MLD B-Disease 1 0.9999996423721313
- O 0 0.007250689901411533
like O 0 2.6332124889449915e-06
ARSA O 0 0.005331800319254398
and O 0 1.053862342814682e-05
GS O 1 0.999976396560669
values O 0 1.4058770148039912e-06
need O 0 7.130190482484977e-08
not O 0 1.1535772337367689e-08
be O 0 2.2642320018917417e-08
paralleled O 0 2.1010632735851686e-06
by O 0 3.5945978993368044e-07
clinical O 0 6.0917463997611776e-05
disease O 0 2.3281070753000677e-05
, O 0 7.944461799525016e-08
a O 0 1.5503734118738066e-07
finding O 0 2.812631691995193e-07
with O 0 6.965430543459661e-07
serious O 0 1.0589236808300484e-05
diagnostic O 0 9.618666808819398e-05
and O 0 7.881967576395255e-06
prognostic O 0 0.0011613486567512155
implications O 0 2.2918566173757426e-05
. O 0 7.778760846122168e-06

Moreover O 0 0.00011848579742945731
, O 0 2.1643045329255983e-06
further O 0 3.7170771065575536e-06
ARSA O 0 0.02383001334965229
alleles O 0 4.30096588388551e-05
functionally O 0 2.270612822030671e-05
similar O 0 5.668312610396242e-07
to O 0 2.9313369509509357e-07
A464V O 0 3.10978211928159e-05
might O 0 8.886281079867331e-07
exist O 0 6.543204733588937e-08
which O 0 6.903874805175292e-08
, O 0 2.013304367665114e-08
together O 0 2.4414804400407775e-08
with O 0 4.4955488220921325e-08
0 O 0 1.2649220479943324e-06
- O 0 4.294772952562198e-05
type O 0 7.225981789815705e-06
mutations O 0 5.5666578191448934e-06
, O 0 2.806287113799044e-07
may O 0 3.1175495678326115e-06
cause O 0 2.303670044057071e-06
pathological O 0 1.8807550077326596e-05
ARSA O 0 0.46761763095855713
and O 0 0.00010781099263112992
GS O 1 0.9999997615814209
levels O 0 2.8826195830333745e-06
, O 0 6.468590640906768e-08
but O 0 2.2735060056788825e-08
not O 0 3.731891595748493e-08
clinical O 0 1.1126370509373373e-06
outbreak O 0 8.504584343427268e-07
of O 0 5.493886234830825e-08
the O 0 4.123992766835727e-06
disease O 0 9.598756878403947e-05
. O 0 4.840723590859852e-07
. O 0 2.775397206278285e-06

Human O 0 0.012887942604720592
MLH1 O 1 0.9998701810836792
deficiency O 1 0.9996858835220337
predisposes O 0 0.006425207015126944
to O 0 9.318617230746895e-05
hematological B-Disease 1 0.9998266100883484
malignancy I-Disease 1 0.9997028708457947
and O 0 0.00014764447405468673
neurofibromatosis B-Disease 1 0.8187288045883179
type I-Disease 0 4.538687062449753e-05
1 I-Disease 0 3.380072666914202e-05
. O 0 1.1090871339547448e-05

Heterozygous O 0 0.0029547137673944235
germ O 0 0.002560748951509595
- O 0 0.10383870452642441
line O 0 0.0014150739880278707
mutations O 0 1.4720328181283548e-05
in O 0 1.467862631443495e-07
the O 0 2.8295002607592323e-07
DNA O 0 1.2050834811816458e-05
mismatch O 0 0.00048291072016581893
repair O 0 0.0004228406469337642
genes O 0 1.006928323477041e-05
lead O 0 7.652930071344599e-05
to O 0 3.493159238132648e-05
hereditary B-Disease 1 0.9999876022338867
nonpolyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001026175741571933

The O 0 7.883803482400253e-05
disease O 0 0.0008683725609444082
susceptibility O 0 0.00015953087131492794
of O 0 7.184419814620924e-07
individuals O 0 8.199240255635232e-07
who O 0 7.102376002876554e-06
constitutionally O 0 7.071462459862232e-05
lack O 0 6.45638749574573e-07
both O 0 8.678429708197655e-08
wild O 0 2.2116962554719066e-06
- O 0 0.00010208624735241756
type O 0 3.2212535643338924e-06
alleles O 0 2.1694934275728883e-06
is O 0 3.248762254770554e-07
unknown O 0 2.5994859242928214e-06
. O 0 2.7355104066373315e-06

We O 0 1.7201527953147888e-05
have O 0 9.993057119572768e-07
identified O 0 1.2108906730645685e-06
three O 0 2.3945736415953434e-07
offspring O 0 3.444761659920914e-06
in O 0 2.8875862767563376e-07
a O 0 4.7541532694594935e-05
hereditary B-Disease 1 0.9999942779541016
nonpolyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.814642670680769e-05
who O 0 1.120588513003895e-05
developed O 0 6.6959677496925e-05
hematological B-Disease 0 0.06601014733314514
malignancy I-Disease 0 0.012740095146000385
at O 0 2.727635717292287e-07
a O 0 2.608517775115615e-07
very O 0 2.0114049448238802e-07
early O 0 8.586380886299594e-07
age O 0 1.7104601113260287e-07
, O 0 1.4824152572145977e-08
and O 0 3.457866526446196e-08
at O 0 3.151938443579638e-08
least O 0 1.2381508263104024e-08
two O 0 8.387212702132274e-09
of O 0 7.308204708067478e-09
them O 0 1.6384008816316964e-08
displayed O 0 5.953124286861566e-07
signs O 0 5.294455149851274e-07
of O 0 1.2032982965592964e-07
neurofibromatosis B-Disease 0 0.0009315157658420503
type I-Disease 0 3.553574060788378e-06
1 I-Disease 0 4.174929927103221e-06
( O 0 1.534447392259608e-06
NF1 B-Disease 0 8.984521991806105e-05
) O 0 1.3670626231032657e-06
. O 0 2.0269344531698152e-06

DNA O 0 5.590325963567011e-05
sequence O 0 4.135938979743514e-06
analysis O 0 9.931976592270075e-07
and O 0 4.7156549953797366e-07
allele O 0 3.7655834148608847e-06
- O 0 4.553637609205907e-06
specific O 0 1.5489487736886076e-07
amplification O 0 6.9842481025261804e-06
in O 0 1.3855267866347276e-07
two O 0 6.477789042946824e-07
siblings O 0 2.9797713068546727e-05
revealed O 0 8.175883522199001e-06
a O 0 1.0388427654106636e-05
homozygous O 0 0.008077052421867847
MLH1 O 0 0.01287606917321682
mutation O 0 1.9511178834363818e-05
( O 0 5.234983859736531e-07
C676T O 0 8.938825885707047e-06
- O 0 0.0001296346599701792
- O 0 0.00020230973314028233
> O 0 1.3853268683305942e-05
Arg226Stop O 0 3.842040678136982e-05
) O 0 1.3420118420981453e-06
. O 0 2.9291898044903064e-06

Thus O 0 8.113960939226672e-05
, O 0 2.1087637378514046e-06
a O 0 2.597231059553451e-06
homozygous O 0 0.00011019386874977499
germ O 0 0.00042375788325443864
- O 0 0.015091050416231155
line O 0 0.005253346636891365
MLH1 O 0 0.010625898838043213
mutation O 0 3.50492809957359e-05
and O 0 2.6555812837614212e-06
consequent O 0 0.008387812413275242
mismatch O 1 0.9997000694274902
repair O 1 0.999996542930603
deficiency O 1 0.9973106384277344
results O 0 3.619337803684175e-06
in O 0 1.0263709100399865e-06
a O 0 7.43590499041602e-05
mutator O 1 0.9992731213569641
phenotype O 1 0.9268266558647156
characterized O 0 0.00017374547314830124
by O 0 5.5306018111878075e-06
leukemia B-Disease 1 0.908416748046875
and O 0 7.418333552777767e-05
/ O 1 0.9438005685806274
or O 1 0.6087101697921753
lymphoma B-Disease 1 1.0
associated O 0 2.6160412744502537e-05
with O 0 5.696422704204451e-06
neurofibromatosis B-Disease 1 0.7366148233413696
type I-Disease 0 8.94652748684166e-06
1 I-Disease 0 3.8067780678829877e-06
. O 0 8.485125135848648e-07
. O 0 2.8303848012001254e-06

Missense O 1 0.9720981121063232
mutations O 0 0.01062304712831974
in O 0 1.980443130378262e-06
the O 0 3.8726864204363665e-07
most O 0 6.85565098024199e-08
ancient O 0 7.83869325005071e-08
residues O 0 3.0098880188234034e-07
of O 0 2.499311690939976e-08
the O 0 2.584498872693075e-07
PAX6 O 0 0.0001612218766240403
paired O 0 1.0375358215242159e-05
domain O 0 8.286456818495935e-07
underlie O 0 3.2450388971483335e-06
a O 0 8.23333266453119e-07
spectrum O 0 1.1922088560822885e-05
of O 0 1.7569014971741126e-06
human O 0 0.0014647305943071842
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999767541885376
malformations I-Disease 1 0.9999526739120483
. O 0 4.858337706536986e-05

Mutations O 0 0.0023195480462163687
of O 0 1.4044082945474656e-06
the O 0 1.075666432370781e-06
human O 0 5.759180567110889e-06
PAX6 O 0 0.0023084438871592283
gene O 0 0.000425525417085737
underlie O 1 0.5264379978179932
aniridia B-Disease 1 1.0
( O 0 0.407964289188385
congenital B-Disease 1 0.9999997615814209
absence I-Disease 0 3.848475535050966e-05
of I-Disease 0 2.4607354021100036e-07
the I-Disease 0 2.7475555270939367e-06
iris I-Disease 0 0.07485219091176987
) O 0 5.528617066374863e-07
, O 0 1.4006295145918557e-07
a O 0 3.242613274778705e-06
rare O 0 2.3656528355786577e-05
dominant O 0 0.002409508917480707
malformation B-Disease 0 0.21475180983543396
of I-Disease 0 3.530111882810161e-07
the I-Disease 0 6.923496130184503e-06
eye I-Disease 0 0.08066336810588837
. O 0 1.4372260920936242e-05

The O 0 8.931403499445878e-06
spectrum O 0 1.767610592651181e-05
of O 0 4.2099796360162145e-07
PAX6 O 0 0.0017990513006225228
mutations O 0 8.305728988489136e-05
in O 0 3.348059863128583e-06
aniridia B-Disease 1 1.0
patients O 0 9.664877143222839e-05
is O 0 2.0312639037456393e-07
highly O 0 1.585324014286016e-07
biased O 0 1.984521304621012e-06
, O 0 6.823337628247828e-08
with O 0 5.507000722104749e-08
92 O 0 1.5588018413836835e-06
% O 0 5.428006488727988e-08
of O 0 7.726868034296785e-09
all O 0 2.8517893824187013e-08
reported O 0 6.920961368450662e-06
mutations O 0 2.69949509856815e-06
leading O 0 2.3148258776473085e-07
to O 0 5.594662155772312e-08
premature O 0 1.3858244756193017e-06
truncation O 0 3.0422113468375755e-06
of O 0 4.1524561567030105e-08
the O 0 3.3186438486154657e-07
protein O 0 1.28476460758975e-06
( O 0 8.662587447361147e-08
nonsense O 0 7.682842237954901e-07
, O 0 3.081408905813987e-08
splicing O 0 7.011857974248414e-07
, O 0 5.868548313969768e-08
insertions O 0 9.274028798245126e-07
and O 0 1.3069977455870685e-07
deletions O 0 3.184948582202196e-06
) O 0 9.639457942967056e-08
and O 0 7.479718533431878e-08
just O 0 1.3631333217745123e-07
2 O 0 6.316172971310152e-07
% O 0 1.9033794274037064e-07
leading O 0 4.002490783250323e-08
to O 0 6.3591980570265605e-09
substitution O 0 3.0601768230553716e-08
of O 0 7.959367387400107e-09
one O 0 7.968227322407984e-08
amino O 0 5.835826186739723e-07
acid O 0 6.026101573297638e-07
by O 0 2.4287448496806974e-08
another O 0 2.2124484644336917e-07
( O 0 9.119179935623833e-07
missense O 0 1.747627175063826e-05
) O 0 8.222135647883988e-07
. O 0 1.8713660665525822e-06

The O 0 6.485431185865309e-06
extraordinary O 0 3.1417760055774124e-06
conservation O 0 7.732855920039583e-07
of O 0 4.1475722412087634e-08
the O 0 1.2972793683729833e-07
PAX6 O 0 3.654465763247572e-05
protein O 0 4.856764803662372e-07
at O 0 5.278684511722531e-08
the O 0 6.762313375929807e-08
amino O 0 7.388024414467509e-07
acid O 0 2.6338479983678553e-06
level O 0 1.667405342686834e-07
amongst O 0 2.2958131751238398e-07
vertebrates O 0 4.723324593669531e-07
predicts O 0 2.64904520008713e-06
that O 0 6.580150113677519e-08
pathological O 0 8.511988198733889e-06
missense O 0 0.0005727550596930087
mutations O 0 2.3410244466504082e-05
should O 0 2.643452887696185e-07
in O 0 7.742923457954021e-08
fact O 0 6.625930382142542e-08
be O 0 5.359684962513711e-08
common O 0 1.1488940288018057e-07
even O 0 1.2696933993083803e-07
though O 0 8.064891687808995e-08
they O 0 4.1334438094509096e-08
are O 0 2.6793813390213472e-08
hardly O 0 3.410555677874072e-07
ever O 0 1.8582136362965684e-07
seen O 0 9.914081147144316e-07
in O 0 9.941850294126198e-07
aniridia B-Disease 1 0.999994158744812
patients O 0 9.851130744209513e-05
. O 0 4.314440502639627e-06

This O 0 6.853356808278477e-06
indicates O 0 6.740178378095152e-06
that O 0 4.5273264248635314e-08
there O 0 2.425055534160947e-08
is O 0 3.200749887355414e-08
a O 0 3.109951762780838e-07
heavy O 0 0.0007617605151608586
ascertainment O 0 0.00026343943318352103
bias O 0 9.309051529271528e-05
in O 0 7.319255956872439e-08
the O 0 3.8903131382994616e-08
selection O 0 1.1121347398557191e-07
of O 0 5.856795581848928e-08
patients O 0 6.458038228629448e-07
for O 0 9.461239613983707e-08
PAX6 O 0 0.00020779232727363706
mutation O 0 3.254649527661968e-06
analysis O 0 7.204983631936557e-08
and O 0 1.2127566151320934e-07
that O 0 4.37893028504277e-08
the O 0 2.4904852580220904e-07
missing O 0 1.7020072846207768e-05
PAX6 O 0 0.0020079489331692457
missense O 0 0.0015909380745142698
mutations O 0 0.0001430167758371681
frequently O 0 2.2075444576330483e-05
may O 0 2.0438905266928487e-05
underlie O 0 0.00011230057862121612
phenotypes O 0 0.0001801767066353932
distinct O 0 7.183794878073968e-06
from O 0 2.452220087434398e-06
textbook O 0 0.0001723066670820117
aniridia B-Disease 1 0.9999663829803467
. O 0 3.155837839585729e-05

Here O 0 1.4520998774969485e-05
we O 0 5.14394344008906e-07
present O 0 2.3096350787454867e-07
four O 0 5.062977379566291e-07
novel O 0 1.6289151972159743e-05
PAX6 O 0 0.0022847468499094248
missense O 0 0.0016480074264109135
mutations O 0 5.5094948038458824e-05
, O 0 1.531326319081927e-07
two O 0 8.475971924326586e-08
in O 0 4.096946497611498e-07
association O 0 1.797315576368419e-07
with O 0 4.009895917533868e-07
atypical O 0 0.0005738709005527198
phenotypes O 0 0.0020648599602282047
ectopia B-Disease 0 0.0017624507891014218
pupillae I-Disease 0 0.0005489055183716118
( O 0 1.3892861261410872e-06
displaced B-Disease 0 2.9979669307067525e-06
pupils I-Disease 0 5.638483798975358e-06
) O 0 2.696654291867162e-06
and O 0 0.0003981652553193271
congenital B-Disease 1 0.9999997615814209
nystagmus I-Disease 1 0.6450217962265015
( O 0 9.526025905870483e-07
searching B-Disease 0 1.1580566479096888e-06
gaze I-Disease 0 3.450219446676783e-05
) O 0 1.7905030347264983e-07
, O 0 3.027711059644389e-08
and O 0 3.927996061747763e-08
two O 0 1.1052916448761607e-07
in O 0 1.5028196287403262e-07
association O 0 6.289107545853767e-08
with O 0 3.865092779165025e-08
more O 0 2.766542195331567e-07
recognizable O 0 8.77555285114795e-05
aniridia B-Disease 1 0.9999194145202637
phenotypes O 0 0.000734861649107188
. O 0 5.931899522693129e-06

Strikingly O 0 0.02278205193579197
, O 0 5.313896508596372e-06
all O 0 7.625396136745621e-08
four O 0 5.271727445688157e-07
mutations O 0 2.9132825147826225e-06
are O 0 1.7339223390422376e-08
located O 0 1.3525149711313134e-07
within O 0 4.5587984942585535e-08
the O 0 2.0448695181585208e-07
PAX6 O 0 3.071859464398585e-05
paired O 0 5.151398909220006e-06
domain O 0 2.532663927468093e-07
and O 0 1.8335860829665762e-07
affect O 0 2.5363624445162714e-07
amino O 0 5.625553285426577e-07
acids O 0 2.9711219440287095e-07
which O 0 3.074246635037525e-08
are O 0 7.58367768582957e-09
highly O 0 3.3036311464229584e-08
conserved O 0 8.172651888571636e-08
in O 0 2.4426494604767868e-08
all O 0 1.290836859624278e-08
known O 0 1.7665611551365146e-07
paired O 0 2.0715733626275323e-06
domain O 0 9.336502557744097e-07
proteins O 0 1.1054092965423479e-06
. O 0 2.3240440896188375e-06

Our O 0 2.6820285711437464e-05
results O 0 2.7558662623050623e-06
support O 0 1.825587787607219e-07
the O 0 9.2752351577019e-08
hypothesis O 0 9.1625230425052e-07
that O 0 1.6472025521352407e-08
the O 0 3.005215276630224e-08
under O 0 8.486583880085163e-08
- O 0 1.6430251434940146e-06
representation O 0 2.0002566714083514e-07
of O 0 1.210901672266118e-07
missense O 0 0.0006045649643056095
mutations O 0 2.4192351702367887e-05
is O 0 2.424630736186373e-07
caused O 0 1.43437682709191e-06
by O 0 2.726605430325435e-07
ascertainment O 0 0.0005593863897956908
bias O 0 0.003540854435414076
and O 0 1.488929228798952e-06
suggest O 0 2.405027998975129e-07
that O 0 1.862378518069363e-08
a O 0 9.548804058567839e-08
substantial O 0 2.6930771923616703e-07
burden O 0 6.271092161114211e-07
of O 0 9.553559010555546e-08
PAX6 B-Disease 0 0.0006488868966698647
- I-Disease 0 0.06985488533973694
related I-Disease 0 1.1870275557157584e-05
disease I-Disease 0 1.8723156244959682e-05
remains O 0 4.3409519889792136e-07
to O 0 8.806944862271848e-08
be O 0 9.368543629761916e-08
uncovered O 0 5.080368737253593e-06
. O 0 7.869085720813018e-07
. O 0 3.2998486858559772e-06

The O 0 1.0030438716057688e-05
chromosomal O 0 0.0003856358234770596
order O 0 7.832011306163622e-07
of O 0 1.1343920647277628e-07
genes O 0 1.4843074040982174e-06
controlling O 0 1.0355450967836077e-06
the O 0 1.4032526962637348e-07
major O 0 6.456165806412173e-07
histocompatibility O 0 1.0325687071599532e-05
complex O 0 2.945926667052845e-07
, O 0 8.853463384639326e-08
properdin O 0 2.646414031914901e-06
factor O 0 4.6811888410047686e-07
B O 0 2.5995850592153147e-06
, O 0 2.7878866148967063e-07
and O 0 6.984174433455337e-06
deficiency B-Disease 0 4.7306726628448814e-05
of I-Disease 0 1.0976838105136721e-08
the I-Disease 0 1.20169389106195e-07
second I-Disease 0 4.653361429518554e-06
component I-Disease 0 6.84506062498258e-07
of I-Disease 0 7.700918303044091e-08
complement I-Disease 0 2.786278173516621e-06
. O 0 2.593228828118299e-06

The O 0 7.4707741077872925e-06
relationship O 0 2.3178554329206236e-06
of O 0 1.1230100938064425e-07
the O 0 7.850513839002815e-08
genes O 0 3.887510047206888e-07
coding O 0 2.709316277105245e-06
for O 0 1.7263300833292305e-07
HLA O 0 2.362234954489395e-05
to O 0 5.235548172777271e-08
those O 0 4.1233413128338725e-08
coding O 0 1.615337168914266e-06
for O 0 5.441990680310482e-08
properdin O 0 6.179332558531314e-06
Factor O 0 4.2390678345327615e-07
B O 0 1.666923481025151e-06
allotypes O 0 3.830902187473839e-06
and O 0 6.261350904424035e-07
for O 0 1.323344463344256e-06
deficiency B-Disease 0 1.8334654669160955e-05
of I-Disease 0 9.053564120620194e-09
the I-Disease 0 6.457126744408015e-08
second I-Disease 0 2.3698837594565703e-06
component I-Disease 0 4.6285137500490237e-07
of I-Disease 0 3.1364418617840784e-08
complement I-Disease 0 6.412103061848029e-07
( O 0 4.397209636408661e-07
C2 O 0 1.8176318917539902e-05
) O 0 8.898172865201559e-08
was O 0 6.007097681504092e-07
studied O 0 1.0242456482956186e-07
in O 0 3.8331055662865765e-08
families O 0 7.033799676037233e-08
of O 0 6.73105660098372e-08
patients O 0 2.1173320874368073e-06
with O 0 3.0477722248178907e-06
connective O 1 0.9973005652427673
tissue O 1 0.9984240531921387
disorders O 1 0.9971578121185303
. O 0 2.3623204469913617e-05

Patients O 0 0.06855932623147964
were O 0 6.082887466618558e-06
selected O 0 3.8177324768184917e-07
because O 0 9.167717252012153e-08
they O 0 6.402649432857288e-08
were O 0 4.3369379909563577e-07
heterozygous O 0 4.914628789265407e-06
or O 0 1.0763931186374975e-06
homozygous O 0 0.00020575358939822763
for O 0 0.00015900829748716205
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 1.2019489986414555e-05

12 O 0 8.252453699242324e-05
families O 0 3.910257419192931e-06
with O 0 2.7190856144443387e-07
15 O 0 1.3149985989002744e-06
matings O 0 2.8123306037741713e-05
informative O 0 2.6462666937732138e-05
for O 0 0.003483942011371255
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 9.040433724294417e-06
found O 0 4.135433755436679e-06
. O 0 4.560612978821155e-06

Of O 0 5.737794253946049e-06
57 O 0 1.0266323442920111e-05
informative O 0 2.1847683910891647e-06
meioses O 0 4.309682117309421e-05
, O 0 1.3603646209503495e-07
two O 0 4.997405511630859e-08
crossovers O 0 7.339809599216096e-06
were O 0 7.160643349379825e-07
noted O 0 2.1735326072302996e-07
between O 0 3.490182791665575e-07
the O 0 0.0012669118586927652
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999927282333374
gene O 0 9.394361768499948e-07
and O 0 1.3274103594085318e-07
the O 0 1.7791670359201817e-07
HLA O 0 6.343060522340238e-05
- O 0 5.830527516081929e-05
B O 0 3.1396255053550703e-06
gene O 0 2.723866430187627e-07
, O 0 3.532003489681301e-08
with O 0 1.3900447015657846e-08
a O 0 1.5348221893418668e-07
recombinant O 0 1.0323100241294014e-06
fraction O 0 2.81985109040761e-07
of O 0 1.3013176669574023e-07
0 O 0 3.6428125440579606e-06
. O 0 2.1549703888013028e-06

035 O 0 0.1466532051563263
. O 0 0.0007442721398547292

A O 0 0.0002334314485779032
lod O 0 0.0011485217837616801
score O 0 5.9342419262975454e-06
of O 0 1.7922148742854915e-07
13 O 0 2.63545348389016e-06
was O 0 2.3403445084113628e-06
calculated O 0 6.272120458561403e-07
for O 0 8.15283272004308e-08
linkage O 0 0.00033651586272753775
between O 0 0.08586379140615463
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
and O 0 2.2517720026371535e-06
HLA O 0 6.308506999630481e-05
- O 0 2.4309789296239614e-05
B O 0 9.503667683929962e-07
at O 0 4.2086064411250845e-08
a O 0 6.695997001315845e-08
maximum O 0 3.7946250586173846e-07
likelihood O 0 1.9059443445712532e-07
value O 0 1.3732030623714309e-08
of O 0 5.062168018099555e-09
the O 0 2.4387949437709722e-08
recombinant O 0 4.368311294911109e-07
fraction O 0 2.2348677930494887e-07
of O 0 8.341460500105313e-08
0 O 0 2.212029357906431e-06
. O 0 1.4478659977612551e-06

04 O 0 0.013606952503323555
. O 0 0.0004348356742411852

18 O 0 0.00037522995262406766
families O 0 5.6776248129608575e-06
with O 0 4.48752160764343e-07
21 O 0 1.2365268275971175e-06
informative O 0 1.1933710766243166e-06
matings O 0 9.353647328680381e-06
for O 0 1.726229612586394e-07
both O 0 3.886646311457298e-07
properdin O 0 1.9670133042382076e-05
Factor O 0 1.5464676152987522e-06
B O 0 1.5120532452783664e-06
allotype O 0 6.466804279625649e-06
and O 0 6.820129669904418e-07
HLA O 0 7.26001599105075e-05
- O 0 3.8307356589939445e-05
B O 0 5.301611963659525e-06
were O 0 3.2984127074087155e-07
found O 0 9.193718710776011e-07
. O 0 2.8455140181904426e-06

Of O 0 6.9787683969479986e-06
72 O 0 1.6868920283741318e-05
informative O 0 2.1394528175733285e-06
meioses O 0 2.2579139113076963e-05
, O 0 2.56884561622428e-07
three O 0 9.939947887005474e-08
recombinants O 0 1.7820191715145484e-05
were O 0 8.734423317946494e-07
found O 0 1.1270205391156196e-07
, O 0 1.3964490008788744e-08
giving O 0 1.414031380875258e-08
a O 0 5.013530568476199e-08
recombinant O 0 3.6630629551837046e-07
fraction O 0 2.1234339442344208e-07
of O 0 7.873786955769901e-08
0 O 0 2.710650051085395e-06
. O 0 1.3506721643352648e-06

042 O 0 0.018778778612613678
. O 0 0.0003489936061669141

A O 0 0.00015572170377708972
lod O 0 0.0009002999868243933
score O 0 2.855901811926742e-06
of O 0 9.324617167294491e-08
16 O 0 6.643735446232313e-07
between O 0 3.5389129493523797e-07
HLA O 0 4.215051012579352e-05
- O 0 3.0182347472873516e-05
B O 0 2.387780796198058e-06
and O 0 1.058566283518303e-07
Factor O 0 4.1370100234416896e-07
B O 0 1.1248681630604551e-06
allotypes O 0 2.093396915370249e-06
was O 0 6.902648692630464e-07
calculated O 0 1.1454740445060452e-07
at O 0 1.734617072202127e-08
a O 0 5.7804413700068835e-08
maximum O 0 1.7555939280100574e-07
likelihood O 0 1.2383000580484804e-07
value O 0 1.0396725258488004e-08
of O 0 5.264956470796278e-09
the O 0 1.698865048638254e-08
recombinant O 0 2.6020231302936736e-07
fraction O 0 2.0982689363790996e-07
of O 0 6.336959046393531e-08
0 O 0 1.6850934798640083e-06
. O 0 1.2375390952001908e-06

04 O 0 0.026324765756726265
. O 0 0.0005208741058595479

A O 0 3.8914520700927824e-05
crossover O 0 4.1517479985486716e-05
was O 0 2.923198371718172e-05
shown O 0 7.442880018970754e-07
to O 0 6.925583306838234e-08
have O 0 3.9559967035529553e-07
occurred O 0 3.800528531883174e-07
between O 0 4.216810012280803e-08
genes O 0 8.680366647695337e-08
for O 0 2.079540450949935e-08
Factor O 0 1.8767855181067716e-07
B O 0 5.94168398038164e-07
and O 0 2.461094652517204e-07
HLA O 0 6.554103310918435e-05
- O 0 0.00012662554217968136
D O 0 0.00011520746920723468
, O 0 3.840548146172296e-08
in O 0 2.5568882122684045e-08
which O 0 2.575827409145859e-07
HLA O 0 2.7440692065283656e-05
- O 0 2.9148968678782694e-05
D O 0 5.727082316298038e-05
segregared O 0 3.82401822207612e-06
with O 0 1.3528284625863307e-07
HLA O 0 3.8353740819729865e-05
- O 0 1.3807552932121325e-05
A O 0 3.415722176214331e-06
and O 0 3.1695831239630934e-06
B O 0 1.1073243513237685e-05
. O 0 2.2402630293072434e-06

These O 0 2.7290534490020946e-06
studies O 0 6.477906140389678e-07
suggest O 0 4.695828010881087e-07
that O 0 2.5425562100167554e-08
the O 0 3.8264293067413746e-08
genes O 0 1.6644472111693176e-07
for O 0 7.037677818289012e-08
Factor O 0 3.567866997400415e-06
B O 0 0.0007660927367396653
and O 0 0.10237178951501846
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 3.8314023953489595e-08
located O 0 5.676416847677501e-08
outside O 0 4.6285759225384027e-08
those O 0 1.0846781250961612e-08
for O 0 2.8862860546041702e-08
HLA O 0 2.1001013010391034e-05
, O 0 4.363214856084596e-08
that O 0 7.940050394950049e-09
the O 0 9.655316546286485e-09
order O 0 2.584078906409104e-08
of O 0 1.592627363322663e-08
genese O 0 5.188574050407624e-06
is O 0 1.8712862015490828e-07
HLA O 0 7.343331162701361e-06
- O 0 1.1545389497769065e-06
A O 0 4.744724151350965e-07
, O 0 9.31839494455744e-08
- O 0 6.0074348766647745e-06
B O 0 9.593206868885318e-07
, O 0 6.47177458290571e-08
- O 0 5.258874807623215e-06
D O 0 2.1122934413142502e-05
, O 0 9.02062851082519e-08
Factor O 0 3.7760409554721264e-07
B O 0 2.653940555319423e-06
allotype O 0 9.681194933364168e-05
, O 0 6.565926014445722e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
, O 0 1.0129289762517146e-07
that O 0 7.409598712371235e-09
the O 0 3.416688443280691e-08
genes O 0 4.774004196406167e-07
coding O 0 4.447909304872155e-05
for O 0 0.00031829983345232904
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
and O 0 5.728181236008822e-07
Factor O 0 2.8681003527708526e-07
B O 0 1.1047042107747984e-06
allotypes O 0 1.8817100908563589e-06
are O 0 1.0437377184757679e-08
approximately O 0 2.26412417703159e-08
3 O 0 6.898135751498558e-08
- O 0 1.4752389461136772e-06
- O 0 3.2210939480137313e-06
5 O 0 1.816137853438704e-07
centimorgans O 0 5.531222200261254e-07
from O 0 1.478321021153306e-08
the O 0 3.519374658367269e-08
HLA O 0 3.5145496894983808e-06
- O 0 1.4722114656251506e-06
A O 0 4.7613414722036396e-07
and O 0 5.609401227957278e-07
HLA O 0 3.0680363124702126e-05
- O 0 2.735853922786191e-05
B O 0 3.891273991030175e-06
loci O 0 4.007494567304093e-07
, O 0 2.208231997258281e-08
and O 0 2.925610509407761e-08
that O 0 8.948752849846642e-09
the O 0 7.33647524953085e-08
apparent O 0 4.863800768362125e-06
lack O 0 1.7847206379428826e-07
of O 0 1.797674897829893e-08
recombinants O 0 7.16364047548268e-06
between O 0 5.831770621966825e-08
the O 0 8.236248305593108e-08
Factor O 0 5.624888217425905e-07
B O 0 2.6486864044272806e-06
gene O 0 5.654562755808001e-06
and O 0 0.004712814465165138
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 2.4396058506681584e-06
suggests O 0 3.80558390133956e-07
that O 0 1.1493122009653689e-08
these O 0 7.274520985589561e-09
two O 0 8.50422949838503e-08
genes O 0 8.002387517080933e-07
lie O 0 9.85112365015084e-07
in O 0 5.192229579620289e-08
close O 0 3.500199454720132e-07
proximity O 0 5.554984454647638e-07
to O 0 1.1071462324707682e-07
one O 0 3.2855095355444064e-07
another O 0 1.5532488077951712e-06
. O 0 3.985750026913593e-06

Distribution O 0 2.5946736059268005e-05
of O 0 8.671131013215927e-07
emerin O 0 7.437522435793653e-05
and O 0 2.9854331842216197e-06
lamins O 0 4.5326061808736995e-05
in O 0 5.076684601590387e-07
the O 0 8.341029342773254e-07
heart O 0 3.270214074291289e-05
and O 0 2.4536933551644324e-07
implications O 0 5.193388119550946e-07
for O 0 4.678796869939106e-07
Emery B-Disease 0 0.07018718868494034
- I-Disease 1 0.9634126424789429
Dreifuss I-Disease 1 0.9991869330406189
muscular I-Disease 1 0.9995682835578918
dystrophy I-Disease 1 0.997653067111969
. O 0 2.7205116566619836e-05

Emerin O 0 0.00819750688970089
is O 0 1.1533510587469209e-05
a O 0 4.264375093043782e-06
nuclear O 0 4.001501110906247e-06
membrane O 0 2.9763843940600054e-06
protein O 0 1.095726929634111e-06
which O 0 3.581003795716242e-07
is O 0 8.961583830568998e-08
missing O 0 1.0126070719707059e-06
or O 0 2.9472752771653177e-07
defective O 0 3.47631357726641e-05
in O 0 4.4892349251313135e-06
Emery B-Disease 1 0.5143183469772339
- I-Disease 1 0.9974725842475891
Dreifuss I-Disease 1 0.9999457597732544
muscular I-Disease 1 0.9999973773956299
dystrophy I-Disease 1 0.9999963045120239
( O 0 0.00015344354324042797
EDMD B-Disease 1 0.9999939203262329
) O 0 1.0149215086130425e-05
. O 0 8.480889846396167e-06

It O 0 1.7461812603869475e-05
is O 0 5.21049344115454e-07
one O 0 6.021907950071181e-08
member O 0 4.6267132347566076e-08
of O 0 1.4616778898357552e-08
a O 0 2.233597626855044e-07
family O 0 3.007193640769401e-07
of O 0 7.092550902143557e-08
lamina O 0 3.930905950255692e-05
- O 0 9.962279727915302e-05
associated O 0 3.8481377373500436e-07
proteins O 0 9.445805204677526e-08
which O 0 6.875254143778875e-08
includes O 0 1.480350562133026e-07
LAP1 O 0 3.726981594809331e-05
, O 0 2.7470997565615107e-07
LAP2 O 0 2.5330717107863165e-05
and O 0 5.605598971669679e-07
lamin O 0 0.00022895396978128701
B O 0 3.72858157788869e-05
receptor O 0 1.97000008483883e-05
( O 0 2.2951878690946614e-06
LBR O 0 0.0001600516407052055
) O 0 2.821095904437243e-06
. O 0 3.5474758988129906e-06

A O 0 6.251656304812059e-05
panel O 0 1.2620081179193221e-05
of O 0 6.57707630580262e-07
16 O 0 3.0252688247855986e-06
monoclonal O 0 2.9808883482473902e-05
antibodies O 0 7.204322173492983e-06
( O 0 3.5915823559662385e-07
mAbs O 0 3.4782115108100697e-06
) O 0 9.895626362776966e-08
has O 0 8.071862822589537e-08
been O 0 1.2339194199739723e-07
mapped O 0 2.4638918603159254e-06
to O 0 2.480438787699768e-08
six O 0 5.2549566476045584e-08
specific O 0 1.7305985977600358e-08
sites O 0 4.041244494601415e-08
throughout O 0 2.5814829385240046e-08
the O 0 3.737155651606372e-08
emerin O 0 1.0402983434687485e-06
molecule O 0 3.136828183869511e-07
using O 0 2.0507164322225435e-07
phage O 0 2.2165886548464186e-06
- O 0 1.4628570852437406e-06
displayed O 0 4.965131097378617e-07
peptide O 0 2.4869771664270957e-07
libraries O 0 2.9701636705681267e-08
and O 0 2.4646592322596916e-08
has O 0 7.183975014868338e-08
been O 0 3.742462695299764e-08
used O 0 5.864273688871435e-08
to O 0 7.756048603368981e-08
localize O 0 7.79248966864543e-06
emerin O 0 7.932580956548918e-06
in O 0 1.0957492690977233e-07
human O 0 2.2327502335883764e-07
and O 0 1.5364066712209024e-06
rabbit O 0 0.0027995076961815357
heart O 0 0.00034792194492183626
. O 0 5.285366569296457e-06

Several O 0 2.9987882953719236e-05
mAbs O 0 0.0002162436576327309
against O 0 2.277144176332513e-06
different O 0 6.753716093044204e-07
emerin O 0 4.8003428673837334e-05
epitopes O 0 9.962251351680607e-05
did O 0 1.8935317029900034e-06
not O 0 1.0215123324996966e-07
recognize O 0 1.8370201360085048e-07
intercalated O 0 1.4226728808353073e-06
discs O 0 1.6083162336144596e-05
in O 0 1.7276772723562317e-07
the O 0 7.088087272677512e-07
heart O 0 3.788386675296351e-05
, O 0 2.525905244965543e-07
though O 0 8.365471870774854e-08
they O 0 2.300480872463595e-08
recognized O 0 6.336825464359208e-08
cardiomyocyte O 0 2.294706519023748e-06
nuclei O 0 1.452866285944765e-06
strongly O 0 2.7588407647272106e-07
, O 0 4.7897326993506795e-08
both O 0 2.3314992603218343e-08
at O 0 2.6115637652424084e-08
the O 0 3.141585125376878e-08
rim O 0 2.284467655044864e-06
and O 0 1.5809999354132742e-07
in O 0 9.429496117263625e-08
intranuclear O 0 1.4006129276822321e-05
spots O 0 7.808154805388767e-06
or O 0 8.038873033910932e-07
channels O 0 4.797733708983287e-06
. O 0 2.645324002514826e-06

A O 0 0.00048428672016598284
polyclonal O 0 0.002689382992684841
rabbit O 0 0.0006401171558536589
antiserum O 0 0.00027822054107673466
against O 0 1.0749511602625716e-05
emerin O 0 0.0003958018496632576
did O 0 3.4472263905627187e-06
recognize O 0 4.335896051088639e-07
both O 0 1.256366601865011e-07
nuclear O 0 9.156189548775728e-07
membrane O 0 7.698316721871379e-07
and O 0 1.2733748633309006e-07
intercalated O 0 2.12064219340391e-06
discs O 0 1.872404754976742e-05
but O 0 9.95924764879419e-08
, O 0 2.4274712018268474e-08
after O 0 4.067568326604487e-08
affinity O 0 6.982350697626316e-08
purification O 0 2.0958469804099877e-07
against O 0 7.201246887689194e-08
a O 0 2.4354440597562643e-07
pure O 0 8.457865874333947e-07
- O 0 1.7684922568150796e-05
emerin O 0 1.1318808901705779e-05
band O 0 3.3347207590850303e-06
on O 0 1.4134508319330052e-07
a O 0 1.877390616300545e-07
western O 0 6.725641128468851e-07
blot O 0 9.884544851956889e-05
, O 0 6.640555625381239e-07
it O 0 1.2012299066554988e-07
stained O 0 6.130038673290983e-05
only O 0 5.616858800294722e-08
the O 0 1.2550589190141181e-07
nuclear O 0 2.5952379019145155e-06
membrane O 0 8.472627996525262e-06
. O 0 3.315522917546332e-06

These O 0 4.0039135456027e-06
results O 0 2.3847678676247597e-06
would O 0 2.0546276857658086e-07
not O 0 4.476057924307497e-08
be O 0 3.4254778569220434e-08
expected O 0 1.0056752586251605e-07
if O 0 2.2990112924503592e-08
immunostaining O 0 1.872549660220102e-06
at O 0 3.3509486740967986e-08
intercalated O 0 3.7786276152473874e-07
discs O 0 7.211134288809262e-06
were O 0 7.727040269855934e-07
due O 0 9.193281869102066e-08
to O 0 1.197189991586356e-08
a O 0 6.968607380031244e-08
product O 0 5.950547432576059e-08
of O 0 5.3152651169341425e-09
the O 0 5.1920114430004105e-08
emerin O 0 8.165885446942411e-06
gene O 0 1.6190357143841538e-07
and O 0 1.9612689072801004e-07
, O 0 9.309280812885845e-08
therefore O 0 7.602537266393483e-08
, O 0 2.315138836195274e-08
cast O 0 2.9079481578264677e-07
some O 0 1.1752799622399834e-08
doubt O 0 5.318391771425013e-08
upon O 0 8.022574604638066e-09
the O 0 3.388082348010357e-08
hypothesis O 0 1.1491760005810647e-06
that O 0 8.227767693824717e-07
cardiac B-Disease 1 0.8427206873893738
defects I-Disease 1 0.9789839386940002
in O 0 1.4208453649189323e-05
EDMD B-Disease 1 1.0
are O 0 1.417535941072856e-06
caused O 0 3.0461419555649627e-06
by O 0 1.072849684646826e-07
absence O 0 5.197530299483333e-07
of O 0 1.0657542048875257e-07
emerin O 0 5.290185799822211e-05
from O 0 2.2081145800711965e-07
intercalated O 0 1.3405496247287374e-05
discs O 0 0.00013104041863698512
. O 0 4.8861256800591946e-06

Although O 0 6.322678382275626e-05
emerin O 0 0.0006030055228620768
was O 0 1.711091863398906e-05
abundant O 0 3.5662708341988036e-07
in O 0 6.846961042583644e-08
the O 0 9.203756690112641e-08
membranes O 0 1.005274157250824e-06
of O 0 7.970035653670493e-08
cardiomyocyte O 0 4.6628087147837505e-05
nuclei O 0 7.646303856745362e-06
, O 0 1.8960078307372896e-07
it O 0 6.964221910266133e-08
was O 0 2.6984448595612776e-06
absent O 0 2.485440688815288e-07
from O 0 1.9852803845310518e-08
many O 0 2.417200484217119e-08
non O 0 2.5731020514285774e-07
- O 0 2.286664857820142e-05
myocyte O 0 0.00019443457131274045
cells O 0 2.02192245524202e-06
in O 0 1.2179178554561076e-07
the O 0 8.063228165156033e-07
heart O 0 7.782967441016808e-05
. O 0 4.642878138838569e-06

This O 0 3.4756583318085177e-06
distribution O 0 1.4777904198126635e-06
of O 0 1.4054519681394595e-07
emerin O 0 8.132164657581598e-05
was O 0 1.0678681974241044e-05
similar O 0 2.001989400923776e-07
to O 0 2.8430129361822765e-08
that O 0 1.7933906804046273e-08
of O 0 2.7792953716243574e-08
lamin O 0 2.752235195657704e-05
A O 0 4.180097221251344e-06
, O 0 8.607068480159796e-08
a O 0 1.7911709448981128e-07
candidate O 0 8.477093729197804e-07
gene O 0 2.3451632102933218e-07
for O 0 5.0440320364941726e-08
an O 0 8.652437486489362e-07
autosomal O 0 0.00026868359418585896
form O 0 2.38745087699499e-06
of O 0 2.709052751015406e-06
EDMD B-Disease 1 0.9999995231628418
. O 0 3.746842048713006e-05

In O 0 1.7773296349332668e-05
contrast O 0 3.013158311659936e-05
, O 0 4.189467745163711e-06
lamin O 0 0.00744098424911499
B1 O 0 0.2274867743253708
was O 0 2.6096622605109587e-05
absent O 0 2.508644911358715e-06
from O 0 1.9756939195758605e-07
cardiomyocyte O 0 2.2103989977040328e-05
nuclei O 0 8.188532774511259e-06
, O 0 1.4161183514715958e-07
showing O 0 8.743557486923237e-07
that O 0 1.0027849128846356e-07
lamin O 0 0.0002745986566878855
B1 O 0 0.001419237582013011
is O 0 9.907505216233403e-08
not O 0 1.1363296970046122e-08
essential O 0 1.8371281385043403e-08
for O 0 1.3617424521328303e-08
localization O 0 6.761474651284516e-07
of O 0 4.7716508078110564e-08
emerin O 0 8.916493243305013e-06
to O 0 6.565695542803951e-08
the O 0 2.8394802598086244e-07
nuclear O 0 7.97628399595851e-06
lamina O 0 0.00013287001638673246
. O 0 3.3054295727197314e-06

Lamin O 1 0.6702141165733337
B1 O 1 0.9612371325492859
is O 0 2.532332655391656e-05
also O 0 2.557938159952755e-06
almost O 0 8.386230092582991e-07
completely O 0 4.88159867018112e-06
absent O 0 9.602089448890183e-06
from O 0 1.3143378509994363e-06
skeletal O 0 0.009170806035399437
muscle O 0 0.0006986543303355575
nuclei O 0 0.00010599306551739573
. O 0 5.824128038511844e-06

In O 0 0.0001469872222514823
EDMD B-Disease 1 0.9999904632568359
, O 0 2.3711586436547805e-06
the O 0 1.2779564428910817e-07
additional O 0 2.3982326524674136e-07
absence O 0 9.543939540890278e-07
of O 0 1.982976414183213e-07
lamin O 0 0.004019277170300484
B1 O 0 0.11236389726400375
from O 0 1.8863761397369672e-06
heart O 0 7.849946996429935e-05
and O 0 3.388536924830987e-06
skeletal O 0 0.016215858981013298
muscle O 0 0.0001821514597395435
nuclei O 0 7.867128260841127e-06
which O 0 3.4442220453456684e-07
already O 0 4.260442665326991e-07
lack O 0 5.439177925836702e-07
emerin O 0 8.214297849917784e-05
may O 0 9.159814453596482e-07
offer O 0 2.0285646940010338e-08
an O 0 1.5539963982291738e-08
alternative O 0 1.4803475778535358e-07
explanation O 0 3.427451389370617e-08
of O 0 1.4556460037340457e-08
why O 0 8.808792273384825e-08
these O 0 2.457200665162418e-08
tissues O 0 7.156717174439109e-07
are O 0 2.8593438727853027e-08
particularly O 0 1.603887511691937e-07
affected O 0 4.4895506334796664e-07
. O 0 2.7759108434111113e-07
. O 0 1.3073234867988504e-06

Genetic O 0 0.0003431496152188629
mapping O 0 4.22451994381845e-05
of O 0 1.0913853429883602e-06
the O 0 1.4837328308203723e-06
copper B-Disease 0 0.000417522678617388
toxicosis I-Disease 0 0.0018441448919475079
locus O 0 3.711847239173949e-05
in O 0 1.2249690826138249e-06
Bedlington O 0 0.00019715400412678719
terriers O 0 9.042952297022566e-05
to O 0 8.172392540473083e-07
dog O 0 8.589712524553761e-05
chromosome O 0 0.00010058970656245947
10 O 0 6.793442821617646e-07
, O 0 5.8620369003392625e-08
in O 0 3.396183245740758e-08
a O 0 3.57573867404426e-07
region O 0 1.3161139804651611e-06
syntenic O 0 9.396796485816594e-06
to O 0 1.0260288973995557e-07
human O 0 4.3612183731056575e-07
chromosome O 0 2.7669966584653594e-05
region O 0 2.95948120765388e-06
2p13 O 0 4.008983523817733e-05
- O 0 8.52535231388174e-05
p16 O 0 6.350668263621628e-05
. O 0 4.715349405159941e-06

Abnormal O 1 0.9988079071044922
hepatic B-Disease 1 0.9998169541358948
copper I-Disease 0 0.021128129214048386
accumulation I-Disease 0 4.554434781312011e-05
is O 0 6.376569103849761e-07
recognized O 0 2.618217820327118e-07
as O 0 8.583278372498171e-07
an O 0 0.00014555219968315214
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 8.759600859775674e-06
man O 0 0.0005082018324173987
, O 0 5.453684934764169e-07
mouse O 0 2.3737247829558328e-05
, O 0 5.246634486866242e-07
rat O 0 3.9371072489302605e-05
and O 0 2.131083192580263e-06
dog O 0 0.00012884128955192864
. O 0 3.860985088977031e-06

The O 0 1.032106956699863e-05
major O 0 4.42373948317254e-06
cause O 0 1.0587399629002903e-05
of O 0 7.629373612871859e-07
hepatic B-Disease 1 0.5951876640319824
copper I-Disease 0 0.01477732602506876
accumulation I-Disease 0 1.108119704440469e-05
in O 0 5.551272010961839e-07
man O 0 1.323523792962078e-05
is O 0 1.929544168888242e-07
a O 0 6.153782123874407e-07
dysfunctional O 0 5.229064845480025e-05
ATP7B O 0 0.000258622138062492
gene O 0 6.71369707561098e-06
, O 0 1.5952077774272766e-06
causing O 0 8.920333493733779e-05
Wilson B-Disease 0 0.007081593852490187
disease I-Disease 0 0.0004293890669941902
( O 0 5.357045665732585e-06
WD B-Disease 0 0.017584821209311485
) O 0 3.918795300705824e-06
. O 0 4.350979907030705e-06

Mutations O 0 0.002678329823538661
in O 0 1.5510167941101827e-06
the O 0 5.505676199391019e-07
ATP7B O 0 0.00010108539572684094
genes O 0 1.4586763654733659e-06
have O 0 3.1583178383698396e-07
also O 0 1.4037709661351983e-06
been O 0 1.0670055416994728e-06
demonstrated O 0 1.0878335388042615e-06
in O 0 2.4570044843130745e-07
mouse O 0 7.172615005401894e-05
and O 0 6.25424763711635e-06
rat O 0 0.0010071905562654138
. O 0 7.472534434782574e-06

The O 0 1.9124319805996493e-05
ATP7B O 0 0.0003135219740215689
gene O 0 1.2668810995819513e-05
has O 0 2.743928916970617e-06
been O 0 5.527103894564789e-07
excluded O 0 4.1013248619492515e-07
in O 0 5.4131803040036175e-08
the O 0 7.268033641594229e-08
much O 0 1.8371778764958435e-07
rarer O 0 5.265810614218935e-06
human O 0 1.0390421039119246e-06
copper B-Disease 0 0.003643652657046914
overload I-Disease 0 0.005830925889313221
disease O 0 1.721874468785245e-05
non B-Disease 0 5.1089779162794e-07
- I-Disease 0 4.056841498822905e-05
Indian I-Disease 0 2.8786773782485398e-06
childhood I-Disease 0 3.810695488937199e-05
cirrhosis I-Disease 0 0.001891853054985404
, O 0 1.4366726190928603e-06
indicating O 0 1.9693519789143465e-05
genetic O 0 4.157433068030514e-05
heterogeneity O 0 0.00038203815347515047
. O 0 9.817109457799233e-06

By O 0 8.900377906684298e-06
investigating O 0 5.6661897360754665e-06
the O 0 2.11740280064987e-06
common O 0 0.00017423968529328704
autosomal O 1 0.9987657070159912
recessive O 1 0.9998630285263062
copper B-Disease 1 0.9710357785224915
toxicosis I-Disease 1 0.9687790274620056
( O 0 6.498593393189367e-06
CT B-Disease 0 0.02601548098027706
) O 0 2.908109024701844e-07
in O 0 1.9006024842838087e-07
Bedlington O 0 6.173749716253951e-05
terriers O 0 9.829548071138561e-05
, O 0 2.8719870215354604e-07
we O 0 3.4972188700521656e-08
have O 0 2.6495348137700603e-08
identified O 0 9.424138625035994e-08
a O 0 6.218078141273509e-08
new O 0 2.590013252756762e-07
locus O 0 8.480654287268408e-06
involved O 0 6.971544621592329e-07
in O 0 1.3925098755862564e-05
progressive O 1 0.9997735619544983
liver B-Disease 1 1.0
disease I-Disease 1 0.9999995231628418
. O 0 2.7041256544180214e-05

We O 0 1.836834599089343e-05
examined O 0 6.102543920860626e-06
whether O 0 5.432723924059246e-07
the O 0 7.363109375546628e-07
WD B-Disease 0 0.001765548367984593
gene O 0 2.326100911886897e-05
ATP7B O 0 0.0009466296178288758
was O 0 1.9292700017103925e-05
also O 0 8.034320444494369e-07
causative O 0 1.448156012884283e-06
for O 0 1.266554932044528e-07
CT B-Disease 0 0.0008760238415561616
by O 0 7.921659062049002e-08
investigating O 0 1.8080913832818624e-07
the O 0 1.4705821627103433e-07
chromosomal O 0 0.0013243297580629587
co O 0 1.6116047845571302e-05
- O 0 1.9572624296415597e-05
localization O 0 2.013680614254554e-06
of O 0 5.5925816866420064e-08
ATP7B O 0 7.861355697968975e-05
and O 0 4.5136602011552895e-07
C04107 O 0 2.5036758870555786e-06
, O 0 2.0687402013663814e-08
using O 0 3.850288265994095e-08
fluorescence O 0 4.6376513296308985e-07
in O 0 6.299912058693735e-08
situ O 0 2.9101086056471104e-06
hybridization O 0 1.8797817347149248e-06
( O 0 3.077526855577162e-07
FISH O 0 7.153456067499064e-07
) O 0 4.40639041698887e-07
. O 0 1.0896380899794167e-06

C04107 O 0 0.001644878531806171
is O 0 7.1322283474728465e-06
an O 0 6.834642931607959e-07
anonymous O 0 4.649054517358309e-06
microsatellite O 0 0.0002835879276972264
marker O 0 7.753433601465076e-05
closely O 0 1.183259428216843e-05
linked O 0 2.947821849375032e-05
to O 0 2.0108461740164785e-06
CT B-Disease 0 0.10374654829502106
. O 0 1.5896002878434956e-05

However O 0 8.97712234291248e-05
, O 0 6.538846719195135e-06
BAC O 0 0.00018061773153021932
clones O 0 2.047770976787433e-05
containing O 0 1.3763150263912394e-06
ATP7B O 0 5.4632713727187365e-05
and O 0 6.004016199767648e-07
C04107 O 0 5.383641109801829e-06
mapped O 0 5.942793904978316e-06
to O 0 7.564828052863959e-08
the O 0 2.0277296641779685e-07
canine O 0 0.00014209678920451552
chromosome O 0 0.00010911957360804081
regions O 0 1.4497866231977241e-06
CFA22q11 O 0 1.9960880308644846e-05
and O 0 3.240469368392951e-07
CFA10q26 O 0 1.851120759965852e-05
, O 0 1.5753711579691299e-07
respectively O 0 2.513443462248688e-07
, O 0 2.7895454834947486e-08
demonstrating O 0 1.7186685852266237e-07
that O 0 7.305086313635911e-08
WD B-Disease 0 0.0003432286612223834
cannot O 0 3.1979129744286183e-07
be O 0 6.594473944687707e-08
homologous O 0 1.7893336234919843e-06
to O 0 6.382896913237346e-07
CT B-Disease 0 0.0038864032831043005
. O 0 9.39242363529047e-06

The O 0 3.319323877803981e-05
copper O 0 7.120589725673199e-05
transport O 0 3.744337163880118e-06
genes O 0 2.8724191452056402e-06
CTR1 O 0 4.877780156675726e-05
and O 0 1.0941845403067418e-06
CTR2 O 0 0.0005740662454627454
were O 0 2.4579564978921553e-06
also O 0 6.226575237633369e-07
excluded O 0 2.306159672116337e-07
as O 0 6.632809146367435e-08
candidate O 0 2.6154776833209326e-07
genes O 0 1.2026237072859658e-07
for O 0 6.272001229490343e-08
CT B-Disease 0 0.0031391391530632973
since O 0 5.037393293605419e-07
they O 0 3.0712637766328044e-08
both O 0 3.272175419510859e-08
mapped O 0 4.326731868786737e-06
to O 0 2.2583495251637942e-07
canine O 0 0.00012136203440604731
chromosome O 0 0.00019810014055110514
region O 0 6.759554253221722e-06
CFA11q22 O 0 0.00014268170343711972
. O 0 4.575197635858785e-06

2 O 0 0.0004810564569197595
- O 0 0.0009117676527239382
22 O 0 4.2522144212853163e-05
. O 0 1.184869779535802e-05

5 O 0 0.0007438895991072059
. O 0 6.901263259351254e-05

A O 0 6.058914368622936e-05
transcribed O 0 4.623348286258988e-05
sequence O 0 4.704493221652228e-06
identified O 0 9.791833690542262e-07
from O 0 3.638051992993496e-08
the O 0 3.408655757652923e-08
C04107 O 0 2.9173916118452325e-06
- O 0 7.146772077248897e-06
containing O 0 8.387197567572002e-07
BAC O 0 2.7152473194291815e-05
was O 0 2.3577958927489817e-06
found O 0 4.493413996442541e-08
to O 0 1.8037749072163933e-08
be O 0 2.2008315170296555e-08
homologous O 0 1.1350196871262597e-07
to O 0 2.344028793288544e-08
a O 0 2.3703894669324654e-07
gene O 0 4.4417001276997325e-07
expressed O 0 4.9024393433683144e-08
from O 0 2.8759222558960573e-08
human O 0 1.408446621553594e-07
chromosome O 0 2.330383904336486e-05
2p13 O 0 7.205051133496454e-06
- O 0 1.8986756913363934e-05
p16 O 0 1.582929598953342e-06
, O 0 4.770568295953126e-08
a O 0 1.2999073817354656e-07
region O 0 9.675272849563044e-07
devoid O 0 4.154889552410168e-07
of O 0 1.8997084794136754e-08
any O 0 8.196364831292158e-08
positional O 0 2.5942530555767007e-05
candidate O 0 2.5251290935557336e-05
genes O 0 1.0116310477314983e-05
. O 0 3.5080668112641433e-06

Molecular O 0 5.326562313712202e-05
analysis O 0 4.258226454112446e-06
of O 0 1.4571857320788695e-07
the O 0 2.2054166493035154e-07
APC B-Disease 0 5.484742814587662e-06
gene O 0 4.747661819237692e-07
in O 0 7.12154601956172e-08
205 O 0 6.550209832312248e-07
families O 0 1.7916612193857873e-07
: O 0 8.444456511824683e-08
extended O 0 1.0463833859830629e-05
genotype O 0 0.0006308145821094513
- O 0 0.0027222041971981525
phenotype O 0 0.00024624273646622896
correlations O 0 1.0464392289577518e-05
in O 0 5.146480361872818e-07
FAP B-Disease 0 7.707787517574616e-06
and O 0 3.473367939932359e-07
evidence O 0 6.15936457393218e-08
for O 0 1.1315002268474927e-08
the O 0 2.561207956830458e-08
role O 0 8.994187794542086e-08
of O 0 9.300460845906855e-08
APC B-Disease 0 7.139496119634714e-06
amino O 0 1.3497436839315924e-06
acid O 0 4.365905624581501e-06
changes O 0 2.609627927085967e-06
in O 0 0.0005949835758656263
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.3270781338214874
. O 0 2.8381551601341926e-05

BACKGROUND O 0 0.001051172730512917
/ O 0 0.0010407570516690612
AIMS O 0 2.8638458388741128e-05
The O 0 4.396974873088766e-07
development O 0 7.04672345364088e-07
of O 0 6.124872743384913e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.57783687832125e-06
a O 0 4.799454131898528e-07
variable O 0 1.3288254194776528e-06
range O 0 4.470180101634469e-07
of O 0 8.24457870862716e-08
extracolonic O 0 9.243981185136363e-05
manifestations O 0 2.436860631860327e-05
in O 0 2.5774057576199993e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 1.0
( O 0 0.0001817673328332603
FAP B-Disease 0 0.000283522269455716
) O 0 8.246432798841852e-07
is O 0 1.0925895566060717e-07
the O 0 6.81273917280123e-08
result O 0 9.882574403263789e-08
of O 0 1.9971222897652297e-08
the O 0 1.1035027682737564e-06
dominant O 0 4.954939868184738e-05
inheritance O 0 6.77159841870889e-05
of O 0 1.892814543680288e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999992847442627
coli I-Disease 1 0.9999996423721313
( O 0 3.5413886507740244e-05
APC B-Disease 0 0.00010616663348628208
) O 0 2.833749931596685e-06
gene O 0 2.673285416676663e-05
mutations O 0 7.352561806328595e-05
. O 0 9.047264029504731e-06

In O 0 7.650373845535796e-06
this O 0 2.3018377248718025e-07
study O 0 1.939876597134571e-07
, O 0 3.535852499680914e-08
direct O 0 7.979055283158232e-08
mutation O 0 5.591380727310025e-07
analysis O 0 4.9391275069865515e-08
of O 0 1.4960381378159582e-08
the O 0 1.1417049705642057e-07
APC B-Disease 0 3.3944559163501253e-06
gene O 0 5.163914238437428e-07
was O 0 4.150451786699705e-06
performed O 0 2.822665408075409e-07
to O 0 3.875161169730745e-08
determine O 0 6.70577378514281e-07
genotype O 0 0.00011615258699748665
- O 0 0.0006137043237686157
phenotype O 0 0.00012464790779631585
correlations O 0 2.1894697965763044e-06
for O 0 1.725502158933523e-07
nine O 0 3.2428299618914025e-06
extracolonic O 0 4.821507536689751e-05
manifestations O 0 1.1335931731082383e-06
and O 0 9.139311174521936e-08
to O 0 3.075889054571235e-08
investigate O 0 1.863979974814356e-07
the O 0 1.3031022660925373e-07
incidence O 0 3.5040389775531366e-05
of O 0 1.0451604737227171e-07
APC B-Disease 0 1.569218329677824e-05
mutations O 0 3.6740593714057468e-06
in O 0 3.318738777124963e-07
non O 0 3.671683953143656e-05
- O 1 0.9994232654571533
FAP O 1 0.9997978806495667
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3652151867281646e-05

METHODS O 0 4.945592809235677e-05
The O 0 2.3776576654199744e-06
APC B-Disease 0 2.344690619793255e-05
gene O 0 3.47234549735731e-06
was O 0 3.451749989835662e-06
analysed O 0 1.3137300811649766e-06
in O 0 1.3332538628674229e-07
190 O 0 5.726417384721572e-07
unrelated O 0 2.9838392947567627e-06
FAP B-Disease 0 1.4319371985038742e-05
and O 0 3.059325308640837e-07
15 O 0 2.1464870769705158e-06
non O 0 1.3501914509106427e-05
- O 1 0.9986274242401123
FAP O 1 0.9998668432235718
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.839599518571049e-05
using O 0 2.0128934465901693e-06
denaturing O 0 0.001369956647977233
gradient O 0 0.0009893802925944328
gel O 0 0.00045565608888864517
electrophoresis O 0 0.00010686095629353076
, O 0 1.3108774510328658e-07
the O 0 5.595974883476629e-08
protein O 0 3.0430072683884646e-07
truncation O 0 2.9724246815021615e-06
test O 0 5.063919275016815e-07
, O 0 5.7175235212980624e-08
and O 0 5.8831513882751096e-08
direct O 0 4.459347735519259e-07
sequencing O 0 3.5102589208690915e-06
. O 0 2.000379936362151e-06

RESULTS O 0 0.00024600548204034567
Chain O 0 6.491614476544783e-05
terminating O 0 1.3038786164543126e-05
signals O 0 8.04843057267135e-06
were O 0 7.651576083844702e-07
only O 0 4.080973070585969e-08
identified O 0 4.6021267507967423e-07
in O 0 3.1229635055751714e-07
patients O 0 1.3456783563015051e-06
belonging O 0 1.552494950374239e-07
to O 0 6.138255059795483e-08
the O 0 4.878657478002424e-07
FAP B-Disease 0 1.9317241822136566e-05
group O 0 8.922771712605027e-07
( O 0 3.9274647178899613e-07
105 O 0 3.7158190480113262e-06
patients O 0 6.085312634240836e-06
) O 0 1.6105947224787087e-06
. O 0 3.0017893095646286e-06

Amino O 0 0.0003372967184986919
acid O 0 8.509782492183149e-05
changes O 0 1.5139795550567214e-06
were O 0 4.355872533778893e-07
identified O 0 3.9046091160344076e-07
in O 0 5.963750027149217e-08
four O 0 1.002717681330978e-06
patients O 0 9.942599490386783e-07
, O 0 4.9862084239293836e-08
three O 0 4.113663365501452e-08
of O 0 4.222822624910805e-08
whom O 0 1.4836338095847168e-06
belonged O 0 6.345352403513971e-07
to O 0 1.9120681926665384e-08
the O 0 8.476020241232618e-08
non O 0 9.440722692488634e-07
- O 0 0.00012021187285427004
FAP O 0 4.238594920025207e-05
group O 0 4.309925316192675e-06
of O 0 2.7396552468417212e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.0014070810284465551
. O 0 1.4870211998641025e-05

Genotype O 1 0.9986164569854736
- O 1 0.9960306286811829
phenotype O 0 0.4094269275665283
correlations O 0 0.00025455825380049646
identified O 0 2.5712042770464905e-05
significant O 0 8.768190582486568e-07
differences O 0 9.311310350312851e-06
in O 0 7.5600382842822e-07
the O 0 2.656412050328072e-07
nature O 0 1.9393993966332346e-07
of O 0 2.292421363847552e-08
certain O 0 9.004812540069906e-08
extracolonic O 0 6.275913619901985e-05
manifestations O 0 3.7014206100138836e-06
in O 0 6.644343670814123e-07
FAP B-Disease 0 6.899144500494003e-05
patients O 0 1.7889514083435643e-06
belonging O 0 4.236101176502416e-07
to O 0 1.4601472742015176e-07
three O 0 1.35483389840374e-06
mutation O 0 3.490425297059119e-05
subgroups O 0 3.497926445561461e-05
. O 0 5.932284238951979e-06

CONCLUSIONS O 0 0.0002374251198489219
Extended O 0 0.00018378981621935964
genotype O 0 0.030821863561868668
- O 0 0.15337178111076355
phenotype O 0 0.0005345033132471144
correlations O 0 1.4372151781572029e-05
made O 0 1.4596574828829034e-06
in O 0 1.763892782946641e-07
this O 0 6.824339493505249e-08
study O 0 1.3028039802520652e-07
may O 0 9.150638220489782e-07
have O 0 2.0524376864727856e-08
the O 0 1.7849172806450042e-08
potential O 0 2.2029396973266557e-08
to O 0 1.2476569999364528e-08
determine O 0 3.602964682158927e-08
the O 0 2.6387420248852322e-08
most O 0 7.37602512401736e-09
appropriate O 0 2.585696279311378e-08
surveillance O 0 4.917174578622507e-07
and O 0 3.316283709864365e-07
prophylactic O 0 7.323909812839702e-06
treatment O 0 4.645141416403931e-06
regimens O 0 8.255148713942617e-06
for O 0 1.5148431486977643e-07
those O 0 2.2628123019785562e-07
patients O 0 8.491358016726736e-07
with O 0 3.4515153402026044e-07
mutations O 0 1.1163698218297213e-05
associated O 0 6.190352337398508e-07
with O 0 4.6767803496550187e-07
life O 0 8.805776815279387e-06
threatening O 0 0.00010847106022993103
conditions O 0 8.627778879599646e-05
. O 0 4.610021278494969e-06

This O 0 3.4027689252980053e-06
study O 0 4.748028459289344e-07
also O 0 4.29964359227597e-07
provided O 0 1.6297107663376664e-07
evidence O 0 5.0005233731553744e-08
for O 0 2.9875383944499845e-08
the O 0 1.386105736855825e-07
pathological O 0 3.094306748607778e-06
nature O 0 2.2499915530715953e-07
of O 0 5.236626776650155e-08
amino O 0 1.312301378675329e-06
acid O 0 1.1693388159983442e-06
changes O 0 7.113197142416539e-08
in O 0 1.3537537313368375e-07
APC O 0 3.5089199172944063e-06
associated O 0 1.5007185538706835e-07
with O 0 3.699313211313893e-08
both O 0 3.3001242627506144e-07
FAP B-Disease 0 1.8738161088549532e-05
and O 0 2.1397097498265794e-06
non O 0 2.5693389034131542e-05
- O 1 0.9987736344337463
FAP O 1 0.999750554561615
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.002355132019147277
. O 0 1.9966328181908466e-06
. O 0 4.575420007313369e-06

Inherited B-Disease 1 0.9999951124191284
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999974966049194
and O 0 0.42677947878837585
cancer B-Disease 1 0.9334805607795715
risk O 0 5.954730568191735e-06
of O 0 1.3057992021003884e-07
the O 0 1.4875809029035736e-06
APC O 0 0.00010560021473793313
I1307K O 0 0.0001484324166085571
polymorphism O 0 0.00015147130761761218
. O 0 7.5948428275296465e-06

Germ O 0 0.0318218357861042
- O 0 0.017469793558120728
line O 0 0.0001337722351308912
and O 0 1.1890111863976927e-06
somatic O 0 1.9040862753172405e-05
truncating O 0 5.6849272368708625e-05
mutations O 0 8.816901754471473e-06
of O 0 4.5240117430012106e-08
the O 0 1.328149892287911e-07
APC B-Disease 0 5.295038590702461e-06
gene O 0 4.697256770214153e-07
are O 0 2.326621739712209e-08
thought O 0 9.694866776044364e-08
to O 0 1.6192765883715765e-07
initiate O 0 0.00018155653378926218
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.34674954414367676
formation O 0 5.071503619547002e-05
in O 0 0.00016757010598666966
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0017135335365310311
sporadic O 1 0.995303750038147
colorectal O 1 1.0
carcinogenesis O 1 0.9990413784980774
, O 0 3.637938789324835e-05
respectively O 0 3.0727911507710814e-05
. O 0 6.745065547875129e-06

Recently O 0 0.0003781644336413592
, O 0 2.490703991497867e-06
an O 0 7.530011885137355e-07
isoleucine O 0 0.0015441293362528086
- O 0 0.0004590177268255502
- O 0 0.0005234346026554704
> O 0 2.059641519736033e-05
lysine O 0 2.7763244361267425e-05
polymorphism O 0 5.619534022116568e-06
at O 0 2.3026765916256409e-07
codon O 0 4.317692400945816e-06
1307 O 0 9.4869828899391e-06
( O 0 2.464030046667176e-07
I1307K O 0 1.8813528868122376e-06
) O 0 4.31340971829286e-08
of O 0 8.708621379582837e-09
the O 0 9.564662661887269e-08
APC B-Disease 0 1.5972476603565156e-06
gene O 0 1.7917295735969674e-07
has O 0 3.1806490596864023e-07
been O 0 1.0829771923681619e-07
identified O 0 8.898665981860177e-08
in O 0 2.1264570548851225e-08
6 O 0 1.416741270077182e-06
% O 0 1.7328932244708994e-07
- O 0 5.626387064694427e-06
7 O 0 1.7463044059695676e-06
% O 0 6.568325972011735e-08
of O 0 6.66068489252325e-09
the O 0 1.1743885863779724e-07
Ashkenazi O 0 2.3865355615271255e-05
Jewish O 0 1.464657884753251e-06
population O 0 8.387806360588002e-07
. O 0 1.2629753882720252e-06

To O 0 4.897307917417493e-06
assess O 0 5.278989647194976e-06
the O 0 7.682980935896921e-07
risk O 0 7.964152359818399e-07
of O 0 2.9302064774583414e-08
this O 0 5.473803810218669e-08
common O 0 1.5612014294674736e-06
APC B-Disease 0 1.3930690329289064e-05
allelic O 0 2.739056981226895e-05
variant O 0 0.0003444484027568251
in O 0 0.00017701835895422846
colorectal O 1 1.0
carcinogenesis O 1 0.9347890615463257
, O 0 2.857261279132217e-06
we O 0 1.0536954420103939e-07
have O 0 3.220849364993228e-08
analyzed O 0 1.3977752644223074e-07
a O 0 7.257090572920788e-08
large O 0 1.1774399411024206e-07
cohort O 0 1.5232731129799504e-06
of O 0 2.710866731092665e-08
unselected O 0 9.52451318880776e-06
Ashkenazi O 0 2.4288863642141223e-05
Jewish O 0 1.5008446325737168e-06
subjects O 0 5.155548592483683e-07
with O 0 7.289371524166199e-07
adenomatous B-Disease 0 0.005568227265030146
polyps I-Disease 0 0.10713692009449005
and O 0 6.515901077364106e-06
. O 0 4.80039261674392e-06
or O 1 0.6029707193374634
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.924782158217567e-07
for O 0 6.145119613165662e-08
the O 0 8.511173064107425e-07
APC O 0 4.3393294617999345e-05
I1307K O 0 5.3850413678446785e-05
polymorphism O 0 6.465710612246767e-05
. O 0 5.716683972423198e-06

The O 0 2.3834993044147268e-05
APC O 0 0.00014968203322496265
I1307K O 0 7.670370541745797e-05
allele O 0 2.654850686667487e-05
was O 0 4.624124812835362e-06
identified O 0 4.987017518942594e-07
in O 0 6.646968131462927e-08
48 O 0 9.984389635064872e-07
( O 0 6.171242006303146e-08
10 O 0 4.6009986931494495e-08
. O 0 1.4088437083614735e-08
1 O 0 1.3747681748554896e-07
% O 0 7.173103711011208e-08
) O 0 1.9755047375724644e-08
of O 0 5.0388873518159016e-08
476 O 0 1.6214124116231687e-05
patients O 0 1.663107286731247e-05
. O 0 3.7330776194721693e-06

Compared O 0 0.00023983338905964047
with O 0 3.6959210092391004e-07
the O 0 1.2080032263384055e-07
frequency O 0 1.4566537629434606e-06
in O 0 5.94068154669003e-08
two O 0 8.586391686549177e-08
separate O 0 2.0472892003908782e-07
population O 0 8.306468401997336e-08
control O 0 5.209743108025577e-07
groups O 0 3.164015183187985e-08
, O 0 2.0522341159789903e-08
the O 0 6.664092211394745e-08
APC O 0 3.2865668799786363e-06
I1307K O 0 4.789043487107847e-06
allele O 0 1.385644623042026e-06
is O 0 5.118745960430715e-08
associated O 0 5.1293600478174994e-08
with O 0 1.6964559534926593e-08
an O 0 8.612224888793207e-08
estimated O 0 7.092590408319666e-07
relative O 0 1.5401960808958393e-06
risk O 0 4.744814532386954e-07
of O 0 3.7088362603299174e-08
1 O 0 2.0929937818436883e-06
. O 0 1.891497731776326e-06

5 O 0 0.00030118064023554325
- O 0 0.0004012527933809906
1 O 0 2.5446497602388263e-05
. O 0 1.18644356916775e-05

7 O 0 0.002419319236651063
for O 0 8.779720519669354e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9918507933616638
( O 0 1.2337126463535242e-05
both O 0 3.30781676893821e-06
P O 0 0.022783856838941574
= O 0 6.384769949363545e-05
. O 0 5.360825525713153e-07
01 O 0 1.9752031221287325e-05
) O 0 1.539852291898569e-06
. O 0 4.214200089336373e-06

Furthermore O 0 0.00017404243408236653
, O 0 2.1183500393817667e-06
compared O 0 1.3280855455377605e-06
with O 0 2.3321449305058195e-07
noncarriers O 0 8.305158553412184e-05
, O 0 3.279348845808272e-07
APC O 0 3.1375125217891764e-06
I1307K O 0 4.5544975364464335e-06
carriers O 0 5.2871138223054e-07
had O 0 1.7913434646743553e-07
increased O 0 1.1788073095431173e-07
numbers O 0 5.6012925853110573e-08
of O 0 4.510389572942586e-08
adenomas B-Disease 0 0.01932300627231598
and O 0 0.00603323383256793
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9911696910858154
per O 0 1.2672230695898179e-05
patient O 0 2.7258405680186115e-05
( O 0 6.810217882957659e-07
P O 0 0.00011742134665837511
= O 0 4.87490433442872e-06
. O 0 4.3894999635085696e-08
03 O 0 6.155407845653826e-07
) O 0 4.1048540566634983e-08
, O 0 2.3578847319072338e-08
as O 0 2.0399410161076048e-08
well O 0 1.8014368663443747e-08
as O 0 2.5664011360504446e-08
a O 0 2.3105162938463764e-07
younger O 0 2.1932398794888286e-06
age O 0 5.128220550432161e-07
at O 0 6.326439461190603e-07
diagnosis O 0 0.0001227700849995017
. O 0 5.019576747145038e-06

We O 0 1.6237367162830196e-05
conclude O 0 6.6523912209959235e-06
that O 0 2.0478475448726385e-07
the O 0 2.744701248502679e-07
APC O 0 1.0311752703273669e-05
I1307K O 0 8.627532224636525e-06
variant O 0 2.3063799744704738e-05
leads O 0 6.428306278394302e-06
to O 0 9.85804945230484e-07
increased O 0 9.663355740485713e-05
adenoma B-Disease 1 0.9999997615814209
formation O 0 4.603163688443601e-06
and O 0 1.4321253161142522e-07
directly O 0 5.12373752314943e-08
contributes O 0 6.702028088056977e-08
to O 0 1.5338367020945043e-08
3 O 0 2.5477561393927317e-07
% O 0 4.916794438258876e-08
- O 0 1.584400592946622e-06
4 O 0 8.90353533122834e-07
% O 0 4.4732754389542606e-08
of O 0 1.0507969605555445e-08
all O 0 1.034377916653284e-07
Ashkenazi O 0 0.023506835103034973
Jewish O 1 0.7182121276855469
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.1101894162711687e-05

The O 0 1.1149239981023129e-05
estimated O 0 4.107926997676259e-06
relative O 0 3.868946805596352e-06
risk O 0 1.9015012640011264e-06
for O 0 1.4375549994838366e-07
carriers O 0 1.0015173756983131e-06
may O 0 2.75614780775868e-07
justify O 0 2.5866341957225814e-07
specific O 0 4.622514282459633e-08
clinical O 0 3.6704273043142166e-07
screening O 0 1.535797338192424e-07
for O 0 1.5991687973837543e-08
the O 0 3.459317809983986e-08
360 O 0 5.8496391375229e-07
, O 0 3.615610921769985e-08
000 O 0 4.8623952864090825e-08
Americans O 0 2.4637710538399915e-08
expected O 0 3.72559760819513e-08
to O 0 2.0587579641073717e-08
harbor O 0 2.066230308628292e-06
this O 0 2.5322430374785654e-08
allele O 0 4.697673432474403e-07
, O 0 3.5236062956300884e-08
and O 0 8.37062756886553e-08
genetic O 0 5.687899147233111e-07
testing O 0 5.385210499753157e-08
in O 0 1.3512457819331303e-08
the O 0 1.4606522213966855e-08
setting O 0 1.1157466417444084e-07
of O 0 1.4318270125102117e-08
long O 0 1.006989691632043e-06
- O 0 1.4610900507250335e-05
term O 0 1.3322362519829767e-06
- O 0 2.7791925276687834e-06
outcome O 0 1.9782919480348937e-07
studies O 0 6.893308324151803e-08
may O 0 2.5535601366755145e-07
impact O 0 3.227201830213744e-07
significantly O 0 0.00014635185652878135
on O 1 0.9984931945800781
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 2.377612872805912e-05
in O 0 3.612950365550205e-07
this O 0 2.503625466943049e-07
population O 0 9.661459898779867e-07
. O 0 2.1001637833251152e-06

Localization O 0 0.0003107032098341733
of O 0 2.618163080114755e-06
human O 0 2.0375960048113484e-06
BRCA1 O 0 0.00012493574467953295
and O 0 2.441602646285901e-06
its O 0 5.216370482230559e-07
loss O 0 3.2526356790185673e-06
in O 0 3.0367974090950156e-07
high O 0 1.8373708371655084e-05
- O 0 0.0015613322611898184
grade O 0 3.88786520488793e-06
, O 0 2.2611899908042687e-07
non B-Disease 0 2.4773999030003324e-06
- I-Disease 0 0.03597798943519592
inherited I-Disease 0 0.19933512806892395
breast I-Disease 1 0.9998935461044312
carcinomas I-Disease 1 0.9999998807907104
. O 0 4.39431460108608e-05

Although O 0 2.568063064245507e-05
the O 0 1.1241110087212292e-06
link O 0 7.146485586417839e-06
between O 0 2.028378958129906e-06
the O 0 5.718712600355502e-06
BRCA1 O 0 0.3579961359500885
tumour B-Disease 1 0.9999996423721313
- O 0 0.011152565479278564
suppressor O 0 0.0010062208166345954
gene O 0 1.628036261536181e-05
and O 0 3.6838613596046343e-05
hereditary B-Disease 1 0.9996007084846497
breast I-Disease 1 0.9999994039535522
and I-Disease 1 0.9998873472213745
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.3570038390753325e-06
established O 0 1.4875253384616371e-07
, O 0 2.7576088967862233e-08
the O 0 2.3996527431791037e-08
role O 0 1.5467240643829427e-07
, O 0 7.70833921137637e-08
if O 0 9.004208045837458e-09
any O 0 7.055564577029827e-09
, O 0 1.732629684170206e-08
of O 0 1.8976443527662923e-08
BRCA1 O 0 9.059741387318354e-06
in O 0 2.7076069386566815e-07
non B-Disease 0 3.4630525078682695e-06
- I-Disease 0 0.19061073660850525
familial I-Disease 0 0.4132896363735199
cancers I-Disease 1 0.9296676516532898
is O 0 2.0559816675813636e-06
unclear O 0 7.030847427813569e-06
. O 0 6.491619387816172e-06

BRCA1 O 1 0.9896091222763062
mutations O 0 0.010863348841667175
are O 0 1.5975248288668809e-06
rare O 0 1.0272335657646181e-06
in O 0 1.4702598036819836e-06
sporadic B-Disease 1 0.721450686454773
cancers I-Disease 1 0.999152421951294
, O 0 1.7527110003356938e-06
but O 0 5.723578055949474e-07
loss O 0 2.317150347153074e-06
of O 0 3.519566575960198e-07
BRCA1 O 0 0.00030159379821270704
resulting O 0 7.647777238162234e-06
from O 0 1.762671928418058e-07
reduced O 0 4.051562882523285e-06
expression O 0 6.467961384259979e-07
or O 0 1.203800934490573e-07
incorrect O 0 1.3123926692060195e-06
subcellular O 0 1.0066383765661158e-05
localization O 0 6.486445727205137e-06
is O 0 1.26733922911626e-07
postulated O 0 9.694465461507207e-07
to O 0 4.5557211336699766e-08
be O 0 3.001377280043016e-08
important O 0 3.021872529984648e-08
in O 0 8.990740241188178e-08
non B-Disease 0 2.0392812984937336e-06
- I-Disease 0 0.007259320002049208
familial I-Disease 0 0.2638035714626312
breast I-Disease 1 0.9999921321868896
and I-Disease 1 0.998552143573761
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 4.250819256412797e-05

Epigenetic O 0 0.0495457760989666
loss O 0 0.040037427097558975
, O 0 3.889063009410165e-06
however O 0 4.921040499539231e-07
, O 0 1.413422552332122e-07
has O 0 3.4600708431753446e-07
not O 0 2.5937030301292907e-08
received O 0 7.253022005215826e-08
general O 0 7.59336415967482e-08
acceptance O 0 4.916292937195976e-07
due O 0 1.7178655298266676e-07
to O 0 4.965282229818513e-08
controversy O 0 3.0448273946603877e-07
regarding O 0 7.045320415954848e-08
the O 0 6.123742224417583e-08
subcellular O 0 3.2555526559008285e-06
localization O 0 2.1642219962814124e-06
of O 0 1.260076771814056e-07
BRCA1 O 0 2.1991334506310523e-05
proteins O 0 1.3041291424542578e-07
, O 0 5.805866720720587e-08
reports O 0 3.3272755217694794e-08
of O 0 1.0703659292232715e-08
which O 0 2.5752231636033684e-07
have O 0 1.0331179822742342e-07
ranged O 0 1.806462478270987e-06
from O 0 1.5701747457796955e-08
exclusively O 0 2.3361865331139597e-08
nuclear O 0 1.415769901313979e-07
, O 0 1.528533033479107e-08
to O 0 8.455380395844259e-09
conditionally O 0 1.4605876685891417e-06
nuclear O 0 2.2468437066436309e-07
, O 0 8.244496640941179e-09
to O 0 7.13294889820304e-09
the O 0 8.733375977953983e-08
ER O 0 9.267246787203476e-05
/ O 0 1.1703088603098877e-05
golgi O 0 1.0057747203973122e-05
, O 0 5.904679056811801e-08
to O 0 3.4673966808895784e-08
cytoplasmic O 0 1.315580675509409e-06
invaginations O 0 3.1409942948812386e-06
into O 0 1.3831399314767623e-07
the O 0 3.5024669386984897e-07
nucleus O 0 6.951707291591447e-06
. O 0 2.4778062197583495e-06

In O 0 5.263104867481161e-06
an O 0 3.313337231247715e-07
attempt O 0 3.233472853025887e-06
to O 0 2.4305899160026456e-07
resolve O 0 3.06616516354552e-06
this O 0 4.925993835058762e-08
issue O 0 3.8898389220776153e-07
, O 0 1.2389993742090155e-07
we O 0 2.5825023897141364e-08
have O 0 9.252247679114589e-08
comprehensively O 0 1.3506525647244416e-05
characterized O 0 8.812607120489702e-06
19 O 0 2.3224199594551465e-06
anti O 0 1.075328418664867e-05
- O 0 0.0010329758515581489
BRCA1 O 0 0.00046771534834988415
antibodies O 0 2.2774482204113156e-05
. O 0 5.110501206218032e-06

These O 0 6.878414296807023e-06
reagents O 0 2.4085467885015532e-05
detect O 0 8.832050298224203e-06
a O 0 7.005622251199384e-07
220 O 0 1.5837600813028985e-06
- O 0 5.5868731578812e-06
kD O 0 9.758407031768002e-06
protein O 0 6.567912009813881e-07
localized O 0 1.9537692423909903e-06
in O 0 1.2817280037324963e-07
discrete O 0 1.1139492244183202e-06
nuclear O 0 1.3698777365789283e-06
foci O 0 7.774644473101944e-06
in O 0 6.102416705289215e-08
all O 0 2.918543628993575e-08
epithelial O 0 8.261693437816575e-06
cell O 0 5.607732236967422e-05
lines O 0 1.4700364772579633e-05
, O 0 2.55292640360949e-08
including O 0 2.2494802465189423e-08
those O 0 5.041021822194125e-08
derived O 0 4.2838530589506263e-07
from O 0 9.244305942956998e-07
breast B-Disease 0 0.10334939509630203
malignancies I-Disease 0 0.004851982928812504
. O 0 7.963142707012594e-06

Immunohistochemical O 0 0.0047163814306259155
staining O 0 0.000736722897272557
of O 0 3.8245211726462e-06
human O 0 7.036267561488785e-06
breast O 0 0.07832887023687363
specimens O 0 1.3140420378476847e-06
also O 0 4.488215836317977e-06
revealed O 0 2.8646649298025295e-05
BRCA1 O 0 0.0002079522528219968
nuclear O 0 9.264762411476113e-06
foci O 0 0.00016415852587670088
in O 0 3.839329110633116e-06
benign O 1 0.8578159809112549
breast O 1 0.9911090135574341
, O 0 1.0156786629522685e-05
invasive B-Disease 0 0.014761817641556263
lobular I-Disease 1 0.999971866607666
cancers I-Disease 1 0.998989999294281
and O 0 1.798972880351357e-05
low B-Disease 0 0.018431270495057106
- I-Disease 1 0.773128867149353
grade I-Disease 0 0.0008695844444446266
ductal I-Disease 1 0.9984287619590759
carcinomas I-Disease 1 1.0
. O 0 0.00016576526104472578

Conversely O 0 0.0006383577128872275
, O 0 9.337348274129909e-06
BRCA1 O 0 0.0002379703801125288
expression O 0 1.237060860148631e-05
was O 0 9.541241524857469e-06
reduced O 0 4.361440005595796e-06
or O 0 6.854774028397514e-07
undetectable O 0 3.675447032946977e-06
in O 0 5.4198647347902806e-08
the O 0 6.628597759572585e-08
majority O 0 7.339834695585523e-08
of O 0 1.3279795929577176e-08
high O 0 5.259612407826353e-06
- O 0 0.0023840214125812054
grade O 0 9.544573003950063e-06
, O 0 8.437354495072213e-07
ductal B-Disease 0 0.14769247174263
carcinomas I-Disease 1 1.0
, O 0 4.557530246529495e-06
suggesting O 0 2.208182877438958e-06
that O 0 4.432119737884932e-08
absence O 0 2.372700862451893e-07
of O 0 1.3279193922244303e-07
BRCA1 O 0 0.00028620552620850503
may O 0 2.5782851480471436e-06
contribute O 0 2.6614323189733113e-08
to O 0 1.842602692647688e-08
the O 0 1.0130023753163186e-07
pathogenesis O 0 1.179307105303451e-06
of O 0 2.2651002851148405e-08
a O 0 2.4182617153201136e-07
significant O 0 1.986713016322028e-07
percentage O 0 2.4956639208539855e-06
of O 0 1.8252256950290757e-07
sporadic B-Disease 0 0.15870511531829834
breast I-Disease 1 0.9999949932098389
cancers I-Disease 1 0.9948458671569824
. O 0 1.931106680785888e-06
. O 0 4.717274805443594e-06

